,STUDYID,USUBJID,SUBJID,SITEID,AGE,AGEU,SEX,RACE,ETHNIC,COUNTRY,DTHFL,INVID,INVNAM,ARM,ARMCD,ACTARM,ACTARMCD,TRT01P,TRT01A,TRT02P,TRT02A,REGION1,STRATA1,STRATA2,BMRKR1,BMRKR2,ITTFL,SAFFL,BMEASIFL,BEP01FL,AEWITHFL,RANDDT,TRTSDTM,TRTEDTM,TRT01SDTM,TRT01EDTM,TRT02SDTM,TRT02EDTM,AP01SDTM,AP01EDTM,AP02SDTM,AP02EDTM,EOSSTT,EOTSTT,EOSDT,EOSDY,DCSREAS,DTHDT,DTHCAUS,DTHCAT,LDDTHELD,LDDTHGR1,LSTALVDT,DTHADY,ADTHAUT,ASEQ,TTESEQ,PARAM,PARAMCD,AVAL,AVALU,ADTM,ADY,CNSR,EVNTDESC,CNSDTDSC,lgTMATRSK
1,AB12345,AB12345-BRA-1-id-105,id-105,BRA-1,38,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,B,S1,4.15691403407286,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-08 05:39:28.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,DISCONTINUED,DISCONTINUED,2022-02-14,709,PROTOCOL VIOLATION,,,,,,2022-03-09,,,2,2,Duration of Confirmed Response,CRSD,119.630116922781,DAYS,2020-05-14 05:39:28.683,67,0,Disease Progression,,
2,AB12345,AB12345-BRA-1-id-105,id-105,BRA-1,38,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,B,S1,4.15691403407286,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-08 05:39:28.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,DISCONTINUED,DISCONTINUED,2022-02-14,709,PROTOCOL VIOLATION,,,,,,2022-03-09,,,1,1,Event Free Survival,EFS,69.8965601169039,DAYS,2020-03-22 05:39:28.683,14,1,Last Tumor Assessment,Completion or Discontinuation,
3,AB12345,AB12345-BRA-1-id-105,id-105,BRA-1,38,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,B,S1,4.15691403407286,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-08 05:39:28.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,DISCONTINUED,DISCONTINUED,2022-02-14,709,PROTOCOL VIOLATION,,,,,,2022-03-09,,,3,3,Overall Survival,OS,402.603616425768,DAYS,2021-11-26 05:39:28.683,628,1,Alive,Alive During Study,
4,AB12345,AB12345-BRA-1-id-105,id-105,BRA-1,38,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,B,S1,4.15691403407286,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-08 05:39:28.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,DISCONTINUED,DISCONTINUED,2022-02-14,709,PROTOCOL VIOLATION,,,,,,2022-03-09,,,4,4,Progression Free Survival,PFS,235.718038515188,DAYS,2022-01-09 05:39:28.683,672,1,Last Tumor Assessment,Completion or Discontinuation,
5,AB12345,AB12345-BRA-1-id-105,id-105,BRA-1,38,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,B,S1,4.15691403407286,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-08 05:39:28.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,2020-03-08 05:39:28.683,2021-02-14 14:58:26.683,2021-02-14 14:58:26.683,2022-02-14 20:58:26.683,DISCONTINUED,DISCONTINUED,2022-02-14,709,PROTOCOL VIOLATION,,,,,,2022-03-09,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.64913543887768
6,AB12345,AB12345-BRA-1-id-134,id-134,BRA-1,47,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S2,6.46299057842479,LOW,Y,Y,Y,N,N,2020-11-03,2020-11-04 04:08:58.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,DISCONTINUED,DISCONTINUED,2022-02-20,473,DEATH,2022-03-16,ADVERSE EVENT,ADVERSE EVENT,24,<=30,2022-03-16,496,Yes,4,4,Duration of Confirmed Response,CRSD,90.0547229440417,DAYS,2021-11-11 04:08:58.683,372,0,Death,,
7,AB12345,AB12345-BRA-1-id-134,id-134,BRA-1,47,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S2,6.46299057842479,LOW,Y,Y,Y,N,N,2020-11-03,2020-11-04 04:08:58.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,DISCONTINUED,DISCONTINUED,2022-02-20,473,DEATH,2022-03-16,ADVERSE EVENT,ADVERSE EVENT,24,<=30,2022-03-16,496,Yes,3,3,Event Free Survival,EFS,90.0547229440417,DAYS,2021-06-07 04:08:58.683,215,0,Death,,
8,AB12345,AB12345-BRA-1-id-134,id-134,BRA-1,47,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S2,6.46299057842479,LOW,Y,Y,Y,N,N,2020-11-03,2020-11-04 04:08:58.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,DISCONTINUED,DISCONTINUED,2022-02-20,473,DEATH,2022-03-16,ADVERSE EVENT,ADVERSE EVENT,24,<=30,2022-03-16,496,Yes,2,2,Overall Survival,OS,90.0547229440417,DAYS,2021-03-31 04:08:58.683,147,0,Death,,
9,AB12345,AB12345-BRA-1-id-134,id-134,BRA-1,47,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S2,6.46299057842479,LOW,Y,Y,Y,N,N,2020-11-03,2020-11-04 04:08:58.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,DISCONTINUED,DISCONTINUED,2022-02-20,473,DEATH,2022-03-16,ADVERSE EVENT,ADVERSE EVENT,24,<=30,2022-03-16,496,Yes,1,1,Progression Free Survival,PFS,90.0547229440417,DAYS,2021-02-07 04:08:58.683,95,0,Death,,
10,AB12345,AB12345-BRA-1-id-134,id-134,BRA-1,47,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S2,6.46299057842479,LOW,Y,Y,Y,N,N,2020-11-03,2020-11-04 04:08:58.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,2020-11-04 04:08:58.683,2021-02-19 21:33:55.683,2021-02-19 21:33:55.683,2022-02-20 03:33:55.683,DISCONTINUED,DISCONTINUED,2022-02-20,473,DEATH,2022-03-16,ADVERSE EVENT,ADVERSE EVENT,24,<=30,2022-03-16,496,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-3.71064226541751
11,AB12345,AB12345-BRA-1-id-141,id-141,BRA-1,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.51607612428241,HIGH,Y,Y,Y,Y,N,2020-07-22,2020-07-25 14:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,COMPLETED,COMPLETED,2023-07-26,1096,,,,,,,2023-08-08,,,1,1,Duration of Confirmed Response,CRSD,123.046159744263,DAYS,2021-02-10 14:26:21.683,200,1,Adverse Event,Preferred Term,
12,AB12345,AB12345-BRA-1-id-141,id-141,BRA-1,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.51607612428241,HIGH,Y,Y,Y,Y,N,2020-07-22,2020-07-25 14:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,COMPLETED,COMPLETED,2023-07-26,1096,,,,,,,2023-08-08,,,3,3,Event Free Survival,EFS,27.976743048057,DAYS,2022-02-25 14:26:21.683,580,1,Last Tumor Assessment,Completion or Discontinuation,
13,AB12345,AB12345-BRA-1-id-141,id-141,BRA-1,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.51607612428241,HIGH,Y,Y,Y,Y,N,2020-07-22,2020-07-25 14:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,COMPLETED,COMPLETED,2023-07-26,1096,,,,,,,2023-08-08,,,2,2,Overall Survival,OS,422.869371809065,DAYS,2021-08-10 14:26:21.683,381,1,Alive,Alive During Study,
14,AB12345,AB12345-BRA-1-id-141,id-141,BRA-1,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.51607612428241,HIGH,Y,Y,Y,Y,N,2020-07-22,2020-07-25 14:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,COMPLETED,COMPLETED,2023-07-26,1096,,,,,,,2023-08-08,,,4,4,Progression Free Survival,PFS,216.298857843503,DAYS,2022-02-28 14:26:21.683,583,1,Adverse Event,Preferred Term,
15,AB12345,AB12345-BRA-1-id-141,id-141,BRA-1,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.51607612428241,HIGH,Y,Y,Y,Y,N,2020-07-22,2020-07-25 14:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,2020-07-25 14:26:21.683,2022-07-26 02:26:21.683,2022-07-26 02:26:21.683,2023-07-26 08:26:21.683,COMPLETED,COMPLETED,2023-07-26,1096,,,,,,,2023-08-08,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-1.57139989326298
16,AB12345,AB12345-BRA-1-id-236,id-236,BRA-1,32,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S2,7.66300121077566,HIGH,Y,Y,Y,Y,N,2021-01-11,2021-01-15 08:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,COMPLETED,COMPLETED,2024-01-16,1096,,,,,,,2024-01-26,,,4,4,Duration of Confirmed Response,CRSD,118.811888806522,DAYS,2023-06-02 08:57:38.683,868,1,Last Tumor Assessment,Completion or Discontinuation,
17,AB12345,AB12345-BRA-1-id-236,id-236,BRA-1,32,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S2,7.66300121077566,HIGH,Y,Y,Y,Y,N,2021-01-11,2021-01-15 08:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,COMPLETED,COMPLETED,2024-01-16,1096,,,,,,,2024-01-26,,,3,3,Event Free Survival,EFS,57.639097730862,DAYS,2022-07-28 08:57:38.683,559,0,Disease Progression,,
18,AB12345,AB12345-BRA-1-id-236,id-236,BRA-1,32,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S2,7.66300121077566,HIGH,Y,Y,Y,Y,N,2021-01-11,2021-01-15 08:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,COMPLETED,COMPLETED,2024-01-16,1096,,,,,,,2024-01-26,,,1,1,Overall Survival,OS,240.771485259756,DAYS,2021-11-24 08:57:38.683,313,0,Death,,
19,AB12345,AB12345-BRA-1-id-236,id-236,BRA-1,32,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S2,7.66300121077566,HIGH,Y,Y,Y,Y,N,2021-01-11,2021-01-15 08:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,COMPLETED,COMPLETED,2024-01-16,1096,,,,,,,2024-01-26,,,2,2,Progression Free Survival,PFS,240.771485259756,DAYS,2022-05-13 08:57:38.683,483,0,Death,,
20,AB12345,AB12345-BRA-1-id-236,id-236,BRA-1,32,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S2,7.66300121077566,HIGH,Y,Y,Y,Y,N,2021-01-11,2021-01-15 08:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,2021-01-15 08:57:38.683,2023-01-15 20:57:38.683,2023-01-15 20:57:38.683,2024-01-16 02:57:38.683,COMPLETED,COMPLETED,2024-01-16,1096,,,,,,,2024-01-26,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.351201204884652
21,AB12345,AB12345-BRA-1-id-265,id-265,BRA-1,25,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,A,S2,10.323346349886,MEDIUM,Y,Y,Y,N,N,2019-10-03,2019-10-07 15:08:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,DISCONTINUED,DISCONTINUED,2022-02-16,863,DEATH,2022-02-26,SUICIDE,OTHER,10,<=30,2022-02-26,872,No,1,1,Duration of Confirmed Response,CRSD,130.892906500958,DAYS,2019-11-02 15:08:39.683,26,0,Death,,
22,AB12345,AB12345-BRA-1-id-265,id-265,BRA-1,25,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,A,S2,10.323346349886,MEDIUM,Y,Y,Y,N,N,2019-10-03,2019-10-07 15:08:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,DISCONTINUED,DISCONTINUED,2022-02-16,863,DEATH,2022-02-26,SUICIDE,OTHER,10,<=30,2022-02-26,872,No,4,4,Event Free Survival,EFS,64.5029839861672,DAYS,2021-12-20 15:08:39.683,805,1,Last Tumor Assessment,Completion or Discontinuation,
23,AB12345,AB12345-BRA-1-id-265,id-265,BRA-1,25,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,A,S2,10.323346349886,MEDIUM,Y,Y,Y,N,N,2019-10-03,2019-10-07 15:08:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,DISCONTINUED,DISCONTINUED,2022-02-16,863,DEATH,2022-02-26,SUICIDE,OTHER,10,<=30,2022-02-26,872,No,2,2,Overall Survival,OS,130.892906500958,DAYS,2020-10-23 15:08:39.683,382,0,Death,,
24,AB12345,AB12345-BRA-1-id-265,id-265,BRA-1,25,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,A,S2,10.323346349886,MEDIUM,Y,Y,Y,N,N,2019-10-03,2019-10-07 15:08:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,DISCONTINUED,DISCONTINUED,2022-02-16,863,DEATH,2022-02-26,SUICIDE,OTHER,10,<=30,2022-02-26,872,No,3,3,Progression Free Survival,PFS,130.892906500958,DAYS,2021-10-08 15:08:39.683,732,0,Death,,
25,AB12345,AB12345-BRA-1-id-265,id-265,BRA-1,25,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,A,S2,10.323346349886,MEDIUM,Y,Y,Y,N,N,2019-10-03,2019-10-07 15:08:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,2019-10-07 15:08:39.683,2021-02-16 08:03:39.683,2021-02-16 08:03:39.683,2022-02-16 14:03:39.683,DISCONTINUED,DISCONTINUED,2022-02-16,863,DEATH,2022-02-26,SUICIDE,OTHER,10,<=30,2022-02-26,872,No,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-1.00822904365202
26,AB12345,AB12345-BRA-1-id-42,id-42,BRA-1,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S1,2.26753940777848,MEDIUM,Y,Y,Y,Y,Y,2019-12-31,2020-01-01 21:17:58.683,,2020-01-01 21:17:58.683,,,,2020-01-01 21:17:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,193.939479230903,DAYS,2021-07-23 21:17:58.683,569,0,Disease Progression,,
27,AB12345,AB12345-BRA-1-id-42,id-42,BRA-1,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S1,2.26753940777848,MEDIUM,Y,Y,Y,Y,Y,2019-12-31,2020-01-01 21:17:58.683,,2020-01-01 21:17:58.683,,,,2020-01-01 21:17:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,55.8820794138592,DAYS,2021-04-06 21:17:58.683,461,0,Disease Progression,,
28,AB12345,AB12345-BRA-1-id-42,id-42,BRA-1,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S1,2.26753940777848,MEDIUM,Y,Y,Y,Y,Y,2019-12-31,2020-01-01 21:17:58.683,,2020-01-01 21:17:58.683,,,,2020-01-01 21:17:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,406.972345942631,DAYS,2020-03-30 21:17:58.683,89,1,Alive,Alive During Study,
29,AB12345,AB12345-BRA-1-id-42,id-42,BRA-1,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S1,2.26753940777848,MEDIUM,Y,Y,Y,Y,Y,2019-12-31,2020-01-01 21:17:58.683,,2020-01-01 21:17:58.683,,,,2020-01-01 21:17:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,204.604054824449,DAYS,2020-07-23 21:17:58.683,204,1,Adverse Event,Preferred Term,
30,AB12345,AB12345-BRA-1-id-42,id-42,BRA-1,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S1,2.26753940777848,MEDIUM,Y,Y,Y,Y,Y,2019-12-31,2020-01-01 21:17:58.683,,2020-01-01 21:17:58.683,,,,2020-01-01 21:17:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.523131863074866
31,AB12345,AB12345-BRA-1-id-65,id-65,BRA-1,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,South America,A,S2,7.34091885189189,MEDIUM,Y,Y,Y,Y,N,2019-07-15,2019-07-15 13:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,COMPLETED,COMPLETED,2022-07-15,1096,,,,,,,2022-08-11,,,2,2,Duration of Confirmed Response,CRSD,190.636546956375,DAYS,2020-10-01 13:00:59.683,444,1,Last Tumor Assessment,Completion or Discontinuation,
32,AB12345,AB12345-BRA-1-id-65,id-65,BRA-1,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,South America,A,S2,7.34091885189189,MEDIUM,Y,Y,Y,Y,N,2019-07-15,2019-07-15 13:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,COMPLETED,COMPLETED,2022-07-15,1096,,,,,,,2022-08-11,,,4,4,Event Free Survival,EFS,52.6261664915364,DAYS,2022-03-20 13:00:59.683,979,0,Disease Progression,,
33,AB12345,AB12345-BRA-1-id-65,id-65,BRA-1,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,South America,A,S2,7.34091885189189,MEDIUM,Y,Y,Y,Y,N,2019-07-15,2019-07-15 13:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,COMPLETED,COMPLETED,2022-07-15,1096,,,,,,,2022-08-11,,,1,1,Overall Survival,OS,332.648223266006,DAYS,2019-11-13 13:00:59.683,121,1,Alive,Alive During Study,
34,AB12345,AB12345-BRA-1-id-65,id-65,BRA-1,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,South America,A,S2,7.34091885189189,MEDIUM,Y,Y,Y,Y,N,2019-07-15,2019-07-15 13:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,COMPLETED,COMPLETED,2022-07-15,1096,,,,,,,2022-08-11,,,3,3,Progression Free Survival,PFS,288.104238174856,DAYS,2021-10-19 13:00:59.683,827,1,Adverse Event,Preferred Term,
35,AB12345,AB12345-BRA-1-id-65,id-65,BRA-1,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-1,Dr. BRA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,South America,A,S2,7.34091885189189,MEDIUM,Y,Y,Y,Y,N,2019-07-15,2019-07-15 13:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,2019-07-15 13:00:59.683,2021-07-15 01:00:59.683,2021-07-15 01:00:59.683,2022-07-15 07:00:59.683,COMPLETED,COMPLETED,2022-07-15,1096,,,,,,,2022-08-11,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-3.4841010964942
36,AB12345,AB12345-BRA-1-id-93,id-93,BRA-1,34,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,South America,A,S1,3.86834617432747,LOW,Y,Y,Y,Y,N,2020-06-17,2020-06-20 06:42:30.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,DISCONTINUED,DISCONTINUED,2022-02-19,610,DEATH,2022-04-09,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-09,657,Yes,4,4,Duration of Confirmed Response,CRSD,140.298720216379,DAYS,2021-05-18 06:42:30.683,332,1,Adverse Event,Preferred Term,
37,AB12345,AB12345-BRA-1-id-93,id-93,BRA-1,34,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,South America,A,S1,3.86834617432747,LOW,Y,Y,Y,Y,N,2020-06-17,2020-06-20 06:42:30.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,DISCONTINUED,DISCONTINUED,2022-02-19,610,DEATH,2022-04-09,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-09,657,Yes,2,2,Event Free Survival,EFS,78.9362150838133,DAYS,2021-01-12 06:42:30.683,206,1,Last Tumor Assessment,Completion or Discontinuation,
38,AB12345,AB12345-BRA-1-id-93,id-93,BRA-1,34,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,South America,A,S1,3.86834617432747,LOW,Y,Y,Y,Y,N,2020-06-17,2020-06-20 06:42:30.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,DISCONTINUED,DISCONTINUED,2022-02-19,610,DEATH,2022-04-09,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-09,657,Yes,3,3,Overall Survival,OS,316.033856384456,DAYS,2021-03-19 06:42:30.683,272,1,Alive,Alive During Study,
39,AB12345,AB12345-BRA-1-id-93,id-93,BRA-1,34,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,South America,A,S1,3.86834617432747,LOW,Y,Y,Y,Y,N,2020-06-17,2020-06-20 06:42:30.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,DISCONTINUED,DISCONTINUED,2022-02-19,610,DEATH,2022-04-09,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-09,657,Yes,1,1,Progression Free Survival,PFS,255.695269349962,DAYS,2020-12-27 06:42:30.683,190,1,Adverse Event,Preferred Term,
40,AB12345,AB12345-BRA-1-id-93,id-93,BRA-1,34,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,Y,INV ID BRA-1,Dr. BRA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,South America,A,S1,3.86834617432747,LOW,Y,Y,Y,Y,N,2020-06-17,2020-06-20 06:42:30.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,2020-06-20 06:42:30.683,2021-02-19 06:31:49.683,2021-02-19 06:31:49.683,2022-02-19 12:31:49.683,DISCONTINUED,DISCONTINUED,2022-02-19,610,DEATH,2022-04-09,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-09,657,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.16894387785949
41,AB12345,AB12345-BRA-11-id-171,id-171,BRA-11,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.70180443401467,HIGH,Y,Y,Y,Y,N,2019-12-01,2019-12-03 03:13:14.683,,2019-12-03 03:13:14.683,,,,2019-12-03 03:13:14.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,192.519256123342,DAYS,2020-11-22 03:13:14.683,355,1,Last Tumor Assessment,Completion or Discontinuation,
42,AB12345,AB12345-BRA-11-id-171,id-171,BRA-11,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.70180443401467,HIGH,Y,Y,Y,Y,N,2019-12-01,2019-12-03 03:13:14.683,,2019-12-03 03:13:14.683,,,,2019-12-03 03:13:14.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,24.9083303520456,DAYS,2020-09-23 03:13:14.683,295,1,Last Tumor Assessment,Completion or Discontinuation,
43,AB12345,AB12345-BRA-11-id-171,id-171,BRA-11,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.70180443401467,HIGH,Y,Y,Y,Y,N,2019-12-01,2019-12-03 03:13:14.683,,2019-12-03 03:13:14.683,,,,2019-12-03 03:13:14.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,287.884424068034,DAYS,2020-06-14 03:13:14.683,194,0,Death,,
44,AB12345,AB12345-BRA-11-id-171,id-171,BRA-11,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.70180443401467,HIGH,Y,Y,Y,Y,N,2019-12-01,2019-12-03 03:13:14.683,,2019-12-03 03:13:14.683,,,,2019-12-03 03:13:14.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,287.884424068034,DAYS,2020-10-18 03:13:14.683,320,0,Death,,
45,AB12345,AB12345-BRA-11-id-171,id-171,BRA-11,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,South America,B,S1,7.70180443401467,HIGH,Y,Y,Y,Y,N,2019-12-01,2019-12-03 03:13:14.683,,2019-12-03 03:13:14.683,,,,2019-12-03 03:13:14.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-0.575176934847988
46,AB12345,AB12345-BRA-11-id-217,id-217,BRA-11,43,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,A,S2,0.405598166037395,MEDIUM,Y,Y,N,Y,N,2019-09-25,2019-09-28 13:03:28.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-03-10,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-10,893,Yes,1,1,Duration of Confirmed Response,CRSD,153.156390134245,DAYS,2020-04-23 13:03:28.683,208,0,Disease Progression,,
47,AB12345,AB12345-BRA-11-id-217,id-217,BRA-11,43,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,A,S2,0.405598166037395,MEDIUM,Y,Y,N,Y,N,2019-09-25,2019-09-28 13:03:28.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-03-10,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-10,893,Yes,2,2,Event Free Survival,EFS,28.8726482866332,DAYS,2021-04-17 13:03:28.683,567,1,Last Tumor Assessment,Completion or Discontinuation,
48,AB12345,AB12345-BRA-11-id-217,id-217,BRA-11,43,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,A,S2,0.405598166037395,MEDIUM,Y,Y,N,Y,N,2019-09-25,2019-09-28 13:03:28.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-03-10,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-10,893,Yes,3,3,Overall Survival,OS,292.979216831736,DAYS,2021-08-31 13:03:28.683,703,0,Death,,
49,AB12345,AB12345-BRA-11-id-217,id-217,BRA-11,43,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,A,S2,0.405598166037395,MEDIUM,Y,Y,N,Y,N,2019-09-25,2019-09-28 13:03:28.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-03-10,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-10,893,Yes,4,4,Progression Free Survival,PFS,292.979216831736,DAYS,2021-09-05 13:03:28.683,708,0,Death,,
50,AB12345,AB12345-BRA-11-id-217,id-217,BRA-11,43,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,South America,A,S2,0.405598166037395,MEDIUM,Y,Y,N,Y,N,2019-09-25,2019-09-28 13:03:28.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,2019-09-28 13:03:28.683,2021-02-14 22:19:26.683,2021-02-14 22:19:26.683,2022-02-15 04:19:26.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-03-10,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-10,893,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-2.71803943678022
51,AB12345,AB12345-BRA-11-id-237,id-237,BRA-11,64,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,South America,B,S2,5.29531239662062,HIGH,Y,Y,Y,N,Y,2020-03-10,2020-03-10 15:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,COMPLETED,COMPLETED,2023-03-11,1096,,,,,,,2023-03-31,,,3,3,Duration of Confirmed Response,CRSD,116.079463087954,DAYS,2021-10-24 15:47:06.683,593,1,Adverse Event,Preferred Term,
52,AB12345,AB12345-BRA-11-id-237,id-237,BRA-11,64,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,South America,B,S2,5.29531239662062,HIGH,Y,Y,Y,N,Y,2020-03-10,2020-03-10 15:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,COMPLETED,COMPLETED,2023-03-11,1096,,,,,,,2023-03-31,,,4,4,Event Free Survival,EFS,42.6858594699297,DAYS,2021-12-15 15:47:06.683,645,1,Last Tumor Assessment,Completion or Discontinuation,
53,AB12345,AB12345-BRA-11-id-237,id-237,BRA-11,64,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,South America,B,S2,5.29531239662062,HIGH,Y,Y,Y,N,Y,2020-03-10,2020-03-10 15:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,COMPLETED,COMPLETED,2023-03-11,1096,,,,,,,2023-03-31,,,2,2,Overall Survival,OS,392.471409728751,DAYS,2021-06-19 15:47:06.683,466,1,Alive,Alive During Study,
54,AB12345,AB12345-BRA-11-id-237,id-237,BRA-11,64,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,South America,B,S2,5.29531239662062,HIGH,Y,Y,Y,N,Y,2020-03-10,2020-03-10 15:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,COMPLETED,COMPLETED,2023-03-11,1096,,,,,,,2023-03-31,,,1,1,Progression Free Survival,PFS,294.970791786909,DAYS,2020-04-30 15:47:06.683,51,0,Disease Progression,,
55,AB12345,AB12345-BRA-11-id-237,id-237,BRA-11,64,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,South America,B,S2,5.29531239662062,HIGH,Y,Y,Y,N,Y,2020-03-10,2020-03-10 15:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,2020-03-10 15:47:06.683,2022-03-11 03:47:06.683,2022-03-11 03:47:06.683,2023-03-11 09:47:06.683,COMPLETED,COMPLETED,2023-03-11,1096,,,,,,,2023-03-31,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.7300631784465
56,AB12345,AB12345-BRA-11-id-321,id-321,BRA-11,33,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,South America,C,S1,1.77524359034867,HIGH,Y,Y,Y,N,N,2020-10-06,2020-10-06 11:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,COMPLETED,COMPLETED,2023-10-07,1096,,,,,,,2023-10-29,,,1,1,Duration of Confirmed Response,CRSD,100.201923260465,DAYS,2020-10-06 11:27:51.683,0,1,Last Tumor Assessment,Completion or Discontinuation,
57,AB12345,AB12345-BRA-11-id-321,id-321,BRA-11,33,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,South America,C,S1,1.77524359034867,HIGH,Y,Y,Y,N,N,2020-10-06,2020-10-06 11:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,COMPLETED,COMPLETED,2023-10-07,1096,,,,,,,2023-10-29,,,3,3,Event Free Survival,EFS,33.7655254232232,DAYS,2022-09-08 11:27:51.683,702,0,Disease Progression,,
58,AB12345,AB12345-BRA-11-id-321,id-321,BRA-11,33,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,South America,C,S1,1.77524359034867,HIGH,Y,Y,Y,N,N,2020-10-06,2020-10-06 11:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,COMPLETED,COMPLETED,2023-10-07,1096,,,,,,,2023-10-29,,,2,2,Overall Survival,OS,380.501184426248,DAYS,2021-01-24 11:27:51.683,110,1,Alive,Alive During Study,
59,AB12345,AB12345-BRA-11-id-321,id-321,BRA-11,33,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,South America,C,S1,1.77524359034867,HIGH,Y,Y,Y,N,N,2020-10-06,2020-10-06 11:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,COMPLETED,COMPLETED,2023-10-07,1096,,,,,,,2023-10-29,,,4,4,Progression Free Survival,PFS,261.919260327704,DAYS,2023-05-13 11:27:51.683,949,0,Disease Progression,,
60,AB12345,AB12345-BRA-11-id-321,id-321,BRA-11,33,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,South America,C,S1,1.77524359034867,HIGH,Y,Y,Y,N,N,2020-10-06,2020-10-06 11:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,2020-10-06 11:27:51.683,2022-10-06 23:27:51.683,2022-10-06 23:27:51.683,2023-10-07 05:27:51.683,COMPLETED,COMPLETED,2023-10-07,1096,,,,,,,2023-10-29,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-1.3910673090019
61,AB12345,AB12345-BRA-11-id-345,id-345,BRA-11,37,YEARS,F,WHITE,NOT REPORTED,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,A,S1,3.451543578335,LOW,Y,Y,Y,Y,N,2020-08-15,2020-08-18 04:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-02,,,4,4,Duration of Confirmed Response,CRSD,150.588198448531,DAYS,2022-12-17 04:51:06.683,851,1,Adverse Event,Preferred Term,
62,AB12345,AB12345-BRA-11-id-345,id-345,BRA-11,37,YEARS,F,WHITE,NOT REPORTED,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,A,S1,3.451543578335,LOW,Y,Y,Y,Y,N,2020-08-15,2020-08-18 04:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-02,,,2,2,Event Free Survival,EFS,91.5027719037607,DAYS,2020-11-30 04:51:06.683,104,1,Last Tumor Assessment,Completion or Discontinuation,
63,AB12345,AB12345-BRA-11-id-345,id-345,BRA-11,37,YEARS,F,WHITE,NOT REPORTED,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,A,S1,3.451543578335,LOW,Y,Y,Y,Y,N,2020-08-15,2020-08-18 04:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-02,,,3,3,Overall Survival,OS,305.497322976589,DAYS,2021-08-27 04:51:06.683,374,1,Alive,Alive During Study,
64,AB12345,AB12345-BRA-11-id-345,id-345,BRA-11,37,YEARS,F,WHITE,NOT REPORTED,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,A,S1,3.451543578335,LOW,Y,Y,Y,Y,N,2020-08-15,2020-08-18 04:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-02,,,1,1,Progression Free Survival,PFS,272.648708103225,DAYS,2020-09-19 04:51:06.683,32,1,Last Tumor Assessment,Completion or Discontinuation,
65,AB12345,AB12345-BRA-11-id-345,id-345,BRA-11,37,YEARS,F,WHITE,NOT REPORTED,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,A,S1,3.451543578335,LOW,Y,Y,Y,Y,N,2020-08-15,2020-08-18 04:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,2020-08-18 04:51:06.683,2022-08-18 16:51:06.683,2022-08-18 16:51:06.683,2023-08-18 22:51:06.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-02,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-0.897502257989867
66,AB12345,AB12345-BRA-11-id-397,id-397,BRA-11,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S2,11.6638901925725,HIGH,Y,Y,Y,Y,N,2020-06-23,2020-06-27 21:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-10,,,1,1,Duration of Confirmed Response,CRSD,138.674466218799,DAYS,2020-10-29 21:54:37.683,124,0,Death,,
67,AB12345,AB12345-BRA-11-id-397,id-397,BRA-11,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S2,11.6638901925725,HIGH,Y,Y,Y,Y,N,2020-06-23,2020-06-27 21:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-10,,,4,4,Event Free Survival,EFS,47.2501231147908,DAYS,2022-11-05 21:54:37.683,861,1,Adverse Event,Preferred Term,
68,AB12345,AB12345-BRA-11-id-397,id-397,BRA-11,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S2,11.6638901925725,HIGH,Y,Y,Y,Y,N,2020-06-23,2020-06-27 21:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-10,,,2,2,Overall Survival,OS,138.674466218799,DAYS,2021-06-23 21:54:37.683,361,0,Death,,
69,AB12345,AB12345-BRA-11-id-397,id-397,BRA-11,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S2,11.6638901925725,HIGH,Y,Y,Y,Y,N,2020-06-23,2020-06-27 21:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-10,,,3,3,Progression Free Survival,PFS,138.674466218799,DAYS,2021-07-15 21:54:37.683,383,0,Death,,
70,AB12345,AB12345-BRA-11-id-397,id-397,BRA-11,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,South America,B,S2,11.6638901925725,HIGH,Y,Y,Y,Y,N,2020-06-23,2020-06-27 21:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,2020-06-27 21:54:37.683,2022-06-28 09:54:37.683,2022-06-28 09:54:37.683,2023-06-28 15:54:37.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-10,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-3.43360475224863
71,AB12345,AB12345-BRA-11-id-50,id-50,BRA-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S1,3.60611622882286,LOW,Y,Y,N,Y,N,2019-04-28,2019-04-28 04:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,2,2,Duration of Confirmed Response,CRSD,136.443185131066,DAYS,2020-05-19 04:49:14.683,387,0,Disease Progression,,
72,AB12345,AB12345-BRA-11-id-50,id-50,BRA-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S1,3.60611622882286,LOW,Y,Y,N,Y,N,2019-04-28,2019-04-28 04:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,4,4,Event Free Survival,EFS,43.7147616490256,DAYS,2021-05-29 04:49:14.683,762,1,Adverse Event,Preferred Term,
73,AB12345,AB12345-BRA-11-id-50,id-50,BRA-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S1,3.60611622882286,LOW,Y,Y,N,Y,N,2019-04-28,2019-04-28 04:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,1,1,Overall Survival,OS,306.582865491509,DAYS,2020-03-30 04:49:14.683,337,1,Alive,Alive During Study,
74,AB12345,AB12345-BRA-11-id-50,id-50,BRA-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S1,3.60611622882286,LOW,Y,Y,N,Y,N,2019-04-28,2019-04-28 04:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,3,3,Progression Free Survival,PFS,263.87559697032,DAYS,2020-07-15 04:49:14.683,444,1,Adverse Event,Preferred Term,
75,AB12345,AB12345-BRA-11-id-50,id-50,BRA-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-11,Dr. BRA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,B,S1,3.60611622882286,LOW,Y,Y,N,Y,N,2019-04-28,2019-04-28 04:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,2019-04-28 04:49:14.683,2021-04-27 16:49:14.683,2021-04-27 16:49:14.683,2022-04-27 22:49:14.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.30234318346721
76,AB12345,AB12345-BRA-11-id-9,id-9,BRA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,7.01629609277248,HIGH,Y,Y,N,Y,N,2019-03-24,2019-03-25 23:40:59.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,DISCONTINUED,DISCONTINUED,2022-02-13,1056,DEATH,2022-03-21,DISEASE PROGRESSION,PROGRESSIVE DISEASE,36,>30,2022-03-21,1091,Yes,1,1,Duration of Confirmed Response,CRSD,181.556417467073,DAYS,2021-03-22 23:40:59.683,728,1,Adverse Event,Preferred Term,
77,AB12345,AB12345-BRA-11-id-9,id-9,BRA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,7.01629609277248,HIGH,Y,Y,N,Y,N,2019-03-24,2019-03-25 23:40:59.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,DISCONTINUED,DISCONTINUED,2022-02-13,1056,DEATH,2022-03-21,DISEASE PROGRESSION,PROGRESSIVE DISEASE,36,>30,2022-03-21,1091,Yes,4,4,Event Free Survival,EFS,74.1763700160664,DAYS,2021-12-31 23:40:59.683,1012,0,Disease Progression,,
78,AB12345,AB12345-BRA-11-id-9,id-9,BRA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,7.01629609277248,HIGH,Y,Y,N,Y,N,2019-03-24,2019-03-25 23:40:59.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,DISCONTINUED,DISCONTINUED,2022-02-13,1056,DEATH,2022-03-21,DISEASE PROGRESSION,PROGRESSIVE DISEASE,36,>30,2022-03-21,1091,Yes,3,3,Overall Survival,OS,322.518525179476,DAYS,2021-12-07 23:40:59.683,988,1,Alive,Alive During Study,
79,AB12345,AB12345-BRA-11-id-9,id-9,BRA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,7.01629609277248,HIGH,Y,Y,N,Y,N,2019-03-24,2019-03-25 23:40:59.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,DISCONTINUED,DISCONTINUED,2022-02-13,1056,DEATH,2022-03-21,DISEASE PROGRESSION,PROGRESSIVE DISEASE,36,>30,2022-03-21,1091,Yes,2,2,Progression Free Survival,PFS,250.742285349406,DAYS,2021-10-15 23:40:59.683,935,1,Last Tumor Assessment,Completion or Discontinuation,
80,AB12345,AB12345-BRA-11-id-9,id-9,BRA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-11,Dr. BRA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,7.01629609277248,HIGH,Y,Y,N,Y,N,2019-03-24,2019-03-25 23:40:59.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,2019-03-25 23:40:59.683,2021-02-12 18:31:35.683,2021-02-12 18:31:35.683,2022-02-13 00:31:35.683,DISCONTINUED,DISCONTINUED,2022-02-13,1056,DEATH,2022-03-21,DISEASE PROGRESSION,PROGRESSIVE DISEASE,36,>30,2022-03-21,1091,Yes,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-0.450873958538682
81,AB12345,AB12345-BRA-12-id-59,id-59,BRA-12,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-12,Dr. BRA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,South America,A,S2,11.1938005148809,HIGH,Y,Y,Y,N,N,2019-11-23,2019-11-25 23:42:12.683,,2019-11-25 23:42:12.683,,,,2019-11-25 23:42:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,141.333895316347,DAYS,2021-07-29 23:42:12.683,612,1,Adverse Event,Preferred Term,
82,AB12345,AB12345-BRA-12-id-59,id-59,BRA-12,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-12,Dr. BRA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,South America,A,S2,11.1938005148809,HIGH,Y,Y,Y,N,N,2019-11-23,2019-11-25 23:42:12.683,,2019-11-25 23:42:12.683,,,,2019-11-25 23:42:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,92.0374805969186,DAYS,2021-05-21 23:42:12.683,543,0,Disease Progression,,
83,AB12345,AB12345-BRA-12-id-59,id-59,BRA-12,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-12,Dr. BRA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,South America,A,S2,11.1938005148809,HIGH,Y,Y,Y,N,N,2019-11-23,2019-11-25 23:42:12.683,,2019-11-25 23:42:12.683,,,,2019-11-25 23:42:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,247.375578782521,DAYS,2021-09-07 23:42:12.683,652,0,Death,,
84,AB12345,AB12345-BRA-12-id-59,id-59,BRA-12,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-12,Dr. BRA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,South America,A,S2,11.1938005148809,HIGH,Y,Y,Y,N,N,2019-11-23,2019-11-25 23:42:12.683,,2019-11-25 23:42:12.683,,,,2019-11-25 23:42:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,247.375578782521,DAYS,2021-06-30 23:42:12.683,583,0,Death,,
85,AB12345,AB12345-BRA-12-id-59,id-59,BRA-12,36,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-12,Dr. BRA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,South America,A,S2,11.1938005148809,HIGH,Y,Y,Y,N,N,2019-11-23,2019-11-25 23:42:12.683,,2019-11-25 23:42:12.683,,,,2019-11-25 23:42:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.1710561748183
86,AB12345,AB12345-BRA-13-id-177,id-177,BRA-13,24,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-13,Dr. BRA-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,12.7192256641392,MEDIUM,Y,Y,N,Y,N,2020-08-27,2020-08-30 08:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,COMPLETED,COMPLETED,2023-08-31,1096,,,,,,,2023-09-21,,,1,1,Duration of Confirmed Response,CRSD,124.187121051364,DAYS,2021-10-10 08:45:46.683,406,1,Last Tumor Assessment,Completion or Discontinuation,
87,AB12345,AB12345-BRA-13-id-177,id-177,BRA-13,24,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-13,Dr. BRA-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,12.7192256641392,MEDIUM,Y,Y,N,Y,N,2020-08-27,2020-08-30 08:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,COMPLETED,COMPLETED,2023-08-31,1096,,,,,,,2023-09-21,,,3,3,Event Free Survival,EFS,75.6657053041272,DAYS,2023-02-26 08:45:46.683,910,0,Disease Progression,,
88,AB12345,AB12345-BRA-13-id-177,id-177,BRA-13,24,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-13,Dr. BRA-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,12.7192256641392,MEDIUM,Y,Y,N,Y,N,2020-08-27,2020-08-30 08:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,COMPLETED,COMPLETED,2023-08-31,1096,,,,,,,2023-09-21,,,2,2,Overall Survival,OS,440.895764296874,DAYS,2023-01-24 08:45:46.683,877,1,Alive,Alive During Study,
89,AB12345,AB12345-BRA-13-id-177,id-177,BRA-13,24,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-13,Dr. BRA-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,12.7192256641392,MEDIUM,Y,Y,N,Y,N,2020-08-27,2020-08-30 08:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,COMPLETED,COMPLETED,2023-08-31,1096,,,,,,,2023-09-21,,,4,4,Progression Free Survival,PFS,229.96406275779,DAYS,2023-04-12 08:45:46.683,955,1,Last Tumor Assessment,Completion or Discontinuation,
90,AB12345,AB12345-BRA-13-id-177,id-177,BRA-13,24,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-13,Dr. BRA-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,12.7192256641392,MEDIUM,Y,Y,N,Y,N,2020-08-27,2020-08-30 08:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,2020-08-30 08:45:46.683,2022-08-30 20:45:46.683,2022-08-30 20:45:46.683,2023-08-31 02:45:46.683,COMPLETED,COMPLETED,2023-08-31,1096,,,,,,,2023-09-21,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.860398814165396
91,AB12345,AB12345-BRA-14-id-120,id-120,BRA-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-14,Dr. BRA-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,C,S2,6.93473565595056,HIGH,Y,Y,Y,N,N,2020-09-17,2020-09-19 09:07:52.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,DISCONTINUED,DISCONTINUED,2022-02-12,512,DEATH,2022-03-20,ADVERSE EVENT,ADVERSE EVENT,36,>30,2022-03-20,546,Yes,1,1,Duration of Confirmed Response,CRSD,101.384034054354,DAYS,2020-12-11 09:07:52.683,83,1,Adverse Event,Preferred Term,
92,AB12345,AB12345-BRA-14-id-120,id-120,BRA-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-14,Dr. BRA-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,C,S2,6.93473565595056,HIGH,Y,Y,Y,N,N,2020-09-17,2020-09-19 09:07:52.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,DISCONTINUED,DISCONTINUED,2022-02-12,512,DEATH,2022-03-20,ADVERSE EVENT,ADVERSE EVENT,36,>30,2022-03-20,546,Yes,2,2,Event Free Survival,EFS,80.5923705839086,DAYS,2020-12-18 09:07:52.683,90,0,Disease Progression,,
93,AB12345,AB12345-BRA-14-id-120,id-120,BRA-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-14,Dr. BRA-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,C,S2,6.93473565595056,HIGH,Y,Y,Y,N,N,2020-09-17,2020-09-19 09:07:52.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,DISCONTINUED,DISCONTINUED,2022-02-12,512,DEATH,2022-03-20,ADVERSE EVENT,ADVERSE EVENT,36,>30,2022-03-20,546,Yes,3,3,Overall Survival,OS,430.49223809503,DAYS,2021-05-04 09:07:52.683,227,1,Alive,Alive During Study,
94,AB12345,AB12345-BRA-14-id-120,id-120,BRA-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-14,Dr. BRA-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,C,S2,6.93473565595056,HIGH,Y,Y,Y,N,N,2020-09-17,2020-09-19 09:07:52.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,DISCONTINUED,DISCONTINUED,2022-02-12,512,DEATH,2022-03-20,ADVERSE EVENT,ADVERSE EVENT,36,>30,2022-03-20,546,Yes,4,4,Progression Free Survival,PFS,255.131395347416,DAYS,2022-01-14 09:07:52.683,482,0,Disease Progression,,
95,AB12345,AB12345-BRA-14-id-120,id-120,BRA-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-14,Dr. BRA-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,C,S2,6.93473565595056,HIGH,Y,Y,Y,N,N,2020-09-17,2020-09-19 09:07:52.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,2020-09-19 09:07:52.683,2021-02-12 16:51:28.683,2021-02-12 16:51:28.683,2022-02-12 22:51:28.683,DISCONTINUED,DISCONTINUED,2022-02-12,512,DEATH,2022-03-20,ADVERSE EVENT,ADVERSE EVENT,36,>30,2022-03-20,546,Yes,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-0.230942852480725
96,AB12345,AB12345-BRA-14-id-23,id-23,BRA-14,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-14,Dr. BRA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,6.20238686469015,MEDIUM,Y,Y,N,N,N,2019-11-03,2019-11-06 10:33:42.683,,2019-11-06 10:33:42.683,,,,2019-11-06 10:33:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,169.039170513861,DAYS,2021-10-25 10:33:42.683,719,0,Death,,
97,AB12345,AB12345-BRA-14-id-23,id-23,BRA-14,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-14,Dr. BRA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,6.20238686469015,MEDIUM,Y,Y,N,N,N,2019-11-03,2019-11-06 10:33:42.683,,2019-11-06 10:33:42.683,,,,2019-11-06 10:33:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,94.1911601833999,DAYS,2020-01-02 10:33:42.683,57,1,Last Tumor Assessment,Completion or Discontinuation,
98,AB12345,AB12345-BRA-14-id-23,id-23,BRA-14,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-14,Dr. BRA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,6.20238686469015,MEDIUM,Y,Y,N,N,N,2019-11-03,2019-11-06 10:33:42.683,,2019-11-06 10:33:42.683,,,,2019-11-06 10:33:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,169.039170513861,DAYS,2020-11-01 10:33:42.683,361,0,Death,,
99,AB12345,AB12345-BRA-14-id-23,id-23,BRA-14,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-14,Dr. BRA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,6.20238686469015,MEDIUM,Y,Y,N,N,N,2019-11-03,2019-11-06 10:33:42.683,,2019-11-06 10:33:42.683,,,,2019-11-06 10:33:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,169.039170513861,DAYS,2019-11-17 10:33:42.683,11,0,Death,,
100,AB12345,AB12345-BRA-14-id-23,id-23,BRA-14,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-14,Dr. BRA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,South America,B,S1,6.20238686469015,MEDIUM,Y,Y,N,N,N,2019-11-03,2019-11-06 10:33:42.683,,2019-11-06 10:33:42.683,,,,2019-11-06 10:33:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.78119455316196
101,AB12345,AB12345-BRA-15-id-36,id-36,BRA-15,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-15,Dr. BRA-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,South America,B,S2,4.40684665421566,HIGH,Y,Y,N,Y,N,2020-01-07,2020-01-08 02:45:36.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,767,DEATH,2022-03-31,DISEASE PROGRESSION,PROGRESSIVE DISEASE,47,>30,2022-03-31,812,Yes,2,2,Duration of Confirmed Response,CRSD,141.103837010451,DAYS,2020-10-25 02:45:36.683,291,0,Disease Progression,,
102,AB12345,AB12345-BRA-15-id-36,id-36,BRA-15,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-15,Dr. BRA-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,South America,B,S2,4.40684665421566,HIGH,Y,Y,N,Y,N,2020-01-07,2020-01-08 02:45:36.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,767,DEATH,2022-03-31,DISEASE PROGRESSION,PROGRESSIVE DISEASE,47,>30,2022-03-31,812,Yes,3,3,Event Free Survival,EFS,36.5702068188693,DAYS,2020-11-29 02:45:36.683,326,1,Last Tumor Assessment,Completion or Discontinuation,
103,AB12345,AB12345-BRA-15-id-36,id-36,BRA-15,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-15,Dr. BRA-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,South America,B,S2,4.40684665421566,HIGH,Y,Y,N,Y,N,2020-01-07,2020-01-08 02:45:36.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,767,DEATH,2022-03-31,DISEASE PROGRESSION,PROGRESSIVE DISEASE,47,>30,2022-03-31,812,Yes,1,1,Overall Survival,OS,326.393311144784,DAYS,2020-08-09 02:45:36.683,214,1,Alive,Alive During Study,
104,AB12345,AB12345-BRA-15-id-36,id-36,BRA-15,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-15,Dr. BRA-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,South America,B,S2,4.40684665421566,HIGH,Y,Y,N,Y,N,2020-01-07,2020-01-08 02:45:36.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,767,DEATH,2022-03-31,DISEASE PROGRESSION,PROGRESSIVE DISEASE,47,>30,2022-03-31,812,Yes,4,4,Progression Free Survival,PFS,212.289111316204,DAYS,2021-07-25 02:45:36.683,564,1,Last Tumor Assessment,Completion or Discontinuation,
105,AB12345,AB12345-BRA-15-id-36,id-36,BRA-15,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,Y,INV ID BRA-15,Dr. BRA-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,South America,B,S2,4.40684665421566,HIGH,Y,Y,N,Y,N,2020-01-07,2020-01-08 02:45:36.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,2020-01-08 02:45:36.683,2021-02-12 12:57:18.683,2021-02-12 12:57:18.683,2022-02-12 18:57:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,767,DEATH,2022-03-31,DISEASE PROGRESSION,PROGRESSIVE DISEASE,47,>30,2022-03-31,812,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.06350711335419
106,AB12345,AB12345-BRA-2-id-101,id-101,BRA-2,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S1,8.18055159716974,MEDIUM,Y,Y,N,N,N,2020-06-24,2020-06-26 00:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,COMPLETED,COMPLETED,2023-06-26,1096,,,,,,,2023-07-22,,,3,3,Duration of Confirmed Response,CRSD,134.642343223095,DAYS,2022-10-27 00:24:28.683,853,0,Disease Progression,,
107,AB12345,AB12345-BRA-2-id-101,id-101,BRA-2,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S1,8.18055159716974,MEDIUM,Y,Y,N,N,N,2020-06-24,2020-06-26 00:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,COMPLETED,COMPLETED,2023-06-26,1096,,,,,,,2023-07-22,,,1,1,Event Free Survival,EFS,69.4100307009649,DAYS,2022-06-14 00:24:28.683,718,0,Disease Progression,,
108,AB12345,AB12345-BRA-2-id-101,id-101,BRA-2,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S1,8.18055159716974,MEDIUM,Y,Y,N,N,N,2020-06-24,2020-06-26 00:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,COMPLETED,COMPLETED,2023-06-26,1096,,,,,,,2023-07-22,,,4,4,Overall Survival,OS,487.881776085123,DAYS,2023-06-06 00:24:28.683,1075,1,Alive,Alive During Study,
109,AB12345,AB12345-BRA-2-id-101,id-101,BRA-2,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S1,8.18055159716974,MEDIUM,Y,Y,N,N,N,2020-06-24,2020-06-26 00:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,COMPLETED,COMPLETED,2023-06-26,1096,,,,,,,2023-07-22,,,2,2,Progression Free Survival,PFS,242.275660461746,DAYS,2022-08-25 00:24:28.683,790,1,Adverse Event,Preferred Term,
110,AB12345,AB12345-BRA-2-id-101,id-101,BRA-2,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,A,S1,8.18055159716974,MEDIUM,Y,Y,N,N,N,2020-06-24,2020-06-26 00:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,2020-06-26 00:24:28.683,2022-06-26 12:24:28.683,2022-06-26 12:24:28.683,2023-06-26 18:24:28.683,COMPLETED,COMPLETED,2023-06-26,1096,,,,,,,2023-07-22,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-2.50653381366752
111,AB12345,AB12345-BRA-2-id-296,id-296,BRA-2,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,C,S1,2.75083194182674,HIGH,Y,Y,Y,Y,N,2021-01-19,2021-01-22 02:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,COMPLETED,COMPLETED,2024-01-22,1096,,,,,,,2024-02-20,,,4,4,Duration of Confirmed Response,CRSD,122.858513100073,DAYS,2023-01-14 02:18:40.683,722,0,Disease Progression,,
112,AB12345,AB12345-BRA-2-id-296,id-296,BRA-2,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,C,S1,2.75083194182674,HIGH,Y,Y,Y,Y,N,2021-01-19,2021-01-22 02:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,COMPLETED,COMPLETED,2024-01-22,1096,,,,,,,2024-02-20,,,3,3,Event Free Survival,EFS,47.6305846264586,DAYS,2022-09-08 02:18:40.683,594,1,Last Tumor Assessment,Completion or Discontinuation,
113,AB12345,AB12345-BRA-2-id-296,id-296,BRA-2,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,C,S1,2.75083194182674,HIGH,Y,Y,Y,Y,N,2021-01-19,2021-01-22 02:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,COMPLETED,COMPLETED,2024-01-22,1096,,,,,,,2024-02-20,,,2,2,Overall Survival,OS,301.971583487466,DAYS,2022-04-01 02:18:40.683,434,1,Alive,Alive During Study,
114,AB12345,AB12345-BRA-2-id-296,id-296,BRA-2,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,C,S1,2.75083194182674,HIGH,Y,Y,Y,Y,N,2021-01-19,2021-01-22 02:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,COMPLETED,COMPLETED,2024-01-22,1096,,,,,,,2024-02-20,,,1,1,Progression Free Survival,PFS,269.027868588455,DAYS,2021-11-19 02:18:40.683,301,0,Disease Progression,,
115,AB12345,AB12345-BRA-2-id-296,id-296,BRA-2,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-2,Dr. BRA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,South America,C,S1,2.75083194182674,HIGH,Y,Y,Y,Y,N,2021-01-19,2021-01-22 02:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,2021-01-22 02:18:40.683,2023-01-22 14:18:40.683,2023-01-22 14:18:40.683,2024-01-22 20:18:40.683,COMPLETED,COMPLETED,2024-01-22,1096,,,,,,,2024-02-20,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.800079550193147
116,AB12345,AB12345-BRA-3-id-13,id-13,BRA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,South America,A,S1,3.88872870072116,LOW,Y,Y,Y,Y,N,2020-04-20,2020-04-24 22:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,COMPLETED,COMPLETED,2023-04-25,1096,,,,,,,2023-05-15,,,4,4,Duration of Confirmed Response,CRSD,179.167459602468,DAYS,2023-04-04 22:49:58.683,1075,0,Disease Progression,,
117,AB12345,AB12345-BRA-3-id-13,id-13,BRA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,South America,A,S1,3.88872870072116,LOW,Y,Y,Y,Y,N,2020-04-20,2020-04-24 22:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,COMPLETED,COMPLETED,2023-04-25,1096,,,,,,,2023-05-15,,,2,2,Event Free Survival,EFS,73.3211260195822,DAYS,2021-12-27 22:49:58.683,612,0,Disease Progression,,
118,AB12345,AB12345-BRA-3-id-13,id-13,BRA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,South America,A,S1,3.88872870072116,LOW,Y,Y,Y,Y,N,2020-04-20,2020-04-24 22:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,COMPLETED,COMPLETED,2023-04-25,1096,,,,,,,2023-05-15,,,1,1,Overall Survival,OS,361.615249793977,DAYS,2020-12-18 22:49:58.683,238,1,Alive,Alive During Study,
119,AB12345,AB12345-BRA-3-id-13,id-13,BRA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,South America,A,S1,3.88872870072116,LOW,Y,Y,Y,Y,N,2020-04-20,2020-04-24 22:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,COMPLETED,COMPLETED,2023-04-25,1096,,,,,,,2023-05-15,,,3,3,Progression Free Survival,PFS,250.749348872341,DAYS,2023-03-17 22:49:58.683,1057,0,Disease Progression,,
120,AB12345,AB12345-BRA-3-id-13,id-13,BRA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,South America,A,S1,3.88872870072116,LOW,Y,Y,Y,Y,N,2020-04-20,2020-04-24 22:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,2020-04-24 22:49:58.683,2022-04-25 10:49:58.683,2022-04-25 10:49:58.683,2023-04-25 16:49:58.683,COMPLETED,COMPLETED,2023-04-25,1096,,,,,,,2023-05-15,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.508567815815457
121,AB12345,AB12345-BRA-3-id-8,id-8,BRA-3,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,B,S2,0.648372001156242,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-12 23:40:59.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,707,ADVERSE EVENT,,,,,,2022-03-10,,,4,4,Duration of Confirmed Response,CRSD,130.471524340101,DAYS,2021-11-17 23:40:59.683,615,0,Death,,
122,AB12345,AB12345-BRA-3-id-8,id-8,BRA-3,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,B,S2,0.648372001156242,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-12 23:40:59.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,707,ADVERSE EVENT,,,,,,2022-03-10,,,2,2,Event Free Survival,EFS,77.663043566281,DAYS,2020-12-14 23:40:59.683,277,1,Adverse Event,Preferred Term,
123,AB12345,AB12345-BRA-3-id-8,id-8,BRA-3,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,B,S2,0.648372001156242,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-12 23:40:59.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,707,ADVERSE EVENT,,,,,,2022-03-10,,,1,1,Overall Survival,OS,130.471524340101,DAYS,2020-11-05 23:40:59.683,238,0,Death,,
124,AB12345,AB12345-BRA-3-id-8,id-8,BRA-3,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,B,S2,0.648372001156242,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-12 23:40:59.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,707,ADVERSE EVENT,,,,,,2022-03-10,,,3,3,Progression Free Survival,PFS,130.471524340101,DAYS,2021-07-13 23:40:59.683,488,0,Death,,
125,AB12345,AB12345-BRA-3-id-8,id-8,BRA-3,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-3,Dr. BRA-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,South America,B,S2,0.648372001156242,MEDIUM,Y,Y,Y,Y,N,2020-03-08,2020-03-12 23:40:59.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,2020-03-12 23:40:59.683,2021-02-16 21:14:20.683,2021-02-16 21:14:20.683,2022-02-17 03:14:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,707,ADVERSE EVENT,,,,,,2022-03-10,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-3.25773431108059
126,AB12345,AB12345-BRA-4-id-368,id-368,BRA-4,46,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,5.20454074217988,MEDIUM,Y,Y,Y,N,N,2020-02-25,2020-02-25 19:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-19,,,1,1,Duration of Confirmed Response,CRSD,111.211363784969,DAYS,2020-08-11 19:46:04.683,168,0,Disease Progression,,
127,AB12345,AB12345-BRA-4-id-368,id-368,BRA-4,46,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,5.20454074217988,MEDIUM,Y,Y,Y,N,N,2020-02-25,2020-02-25 19:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-19,,,2,2,Event Free Survival,EFS,80.8502396498807,DAYS,2022-03-22 19:46:04.683,756,1,Adverse Event,Preferred Term,
128,AB12345,AB12345-BRA-4-id-368,id-368,BRA-4,46,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,5.20454074217988,MEDIUM,Y,Y,Y,N,N,2020-02-25,2020-02-25 19:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-19,,,3,3,Overall Survival,OS,398.200233466923,DAYS,2022-10-25 19:46:04.683,973,1,Alive,Alive During Study,
129,AB12345,AB12345-BRA-4-id-368,id-368,BRA-4,46,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,5.20454074217988,MEDIUM,Y,Y,Y,N,N,2020-02-25,2020-02-25 19:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-19,,,4,4,Progression Free Survival,PFS,279.774369997904,DAYS,2022-10-27 19:46:04.683,975,1,Adverse Event,Preferred Term,
130,AB12345,AB12345-BRA-4-id-368,id-368,BRA-4,46,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,South America,B,S2,5.20454074217988,MEDIUM,Y,Y,Y,N,N,2020-02-25,2020-02-25 19:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,2020-02-25 19:46:04.683,2022-02-25 07:46:04.683,2022-02-25 07:46:04.683,2023-02-25 13:46:04.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-19,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-4.12824699062912
131,AB12345,AB12345-BRA-4-id-383,id-383,BRA-4,30,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,South America,A,S2,4.60353435151615,HIGH,Y,Y,N,Y,N,2020-01-15,2020-01-18 21:44:29.683,,2020-01-18 21:44:29.683,,,,2020-01-18 21:44:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,175.842315494083,DAYS,2020-02-13 21:44:29.683,26,0,Disease Progression,,
132,AB12345,AB12345-BRA-4-id-383,id-383,BRA-4,30,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,South America,A,S2,4.60353435151615,HIGH,Y,Y,N,Y,N,2020-01-15,2020-01-18 21:44:29.683,,2020-01-18 21:44:29.683,,,,2020-01-18 21:44:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,85.7980448578019,DAYS,2020-04-27 21:44:29.683,100,1,Last Tumor Assessment,Completion or Discontinuation,
133,AB12345,AB12345-BRA-4-id-383,id-383,BRA-4,30,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,South America,A,S2,4.60353435151615,HIGH,Y,Y,N,Y,N,2020-01-15,2020-01-18 21:44:29.683,,2020-01-18 21:44:29.683,,,,2020-01-18 21:44:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,355.688002612442,DAYS,2020-10-20 21:44:29.683,276,1,Alive,Alive During Study,
134,AB12345,AB12345-BRA-4-id-383,id-383,BRA-4,30,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,South America,A,S2,4.60353435151615,HIGH,Y,Y,N,Y,N,2020-01-15,2020-01-18 21:44:29.683,,2020-01-18 21:44:29.683,,,,2020-01-18 21:44:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,290.214656083845,DAYS,2020-10-03 21:44:29.683,259,0,Disease Progression,,
135,AB12345,AB12345-BRA-4-id-383,id-383,BRA-4,30,YEARS,F,ASIAN,HISPANIC OR LATINO,BRA,N,INV ID BRA-4,Dr. BRA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,South America,A,S2,4.60353435151615,HIGH,Y,Y,N,Y,N,2020-01-15,2020-01-18 21:44:29.683,,2020-01-18 21:44:29.683,,,,2020-01-18 21:44:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.53365490388698
136,AB12345,AB12345-BRA-5-id-234,id-234,BRA-5,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-5,Dr. BRA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,South America,A,S2,3.86786156938137,MEDIUM,Y,Y,N,Y,N,2019-06-21,2019-06-22 20:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,COMPLETED,COMPLETED,2022-06-22,1096,,,,,,,2022-07-06,,,3,3,Duration of Confirmed Response,CRSD,127.201573573984,DAYS,2020-12-27 20:47:28.683,554,1,Adverse Event,Preferred Term,
137,AB12345,AB12345-BRA-5-id-234,id-234,BRA-5,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-5,Dr. BRA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,South America,A,S2,3.86786156938137,MEDIUM,Y,Y,N,Y,N,2019-06-21,2019-06-22 20:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,COMPLETED,COMPLETED,2022-06-22,1096,,,,,,,2022-07-06,,,4,4,Event Free Survival,EFS,52.8838922339492,DAYS,2021-04-25 20:47:28.683,673,1,Adverse Event,Preferred Term,
138,AB12345,AB12345-BRA-5-id-234,id-234,BRA-5,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-5,Dr. BRA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,South America,A,S2,3.86786156938137,MEDIUM,Y,Y,N,Y,N,2019-06-21,2019-06-22 20:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,COMPLETED,COMPLETED,2022-06-22,1096,,,,,,,2022-07-06,,,1,1,Overall Survival,OS,472.720130765811,DAYS,2020-06-16 20:47:28.683,360,1,Alive,Alive During Study,
139,AB12345,AB12345-BRA-5-id-234,id-234,BRA-5,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-5,Dr. BRA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,South America,A,S2,3.86786156938137,MEDIUM,Y,Y,N,Y,N,2019-06-21,2019-06-22 20:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,COMPLETED,COMPLETED,2022-06-22,1096,,,,,,,2022-07-06,,,2,2,Progression Free Survival,PFS,232.991832564585,DAYS,2020-06-26 20:47:28.683,370,0,Disease Progression,,
140,AB12345,AB12345-BRA-5-id-234,id-234,BRA-5,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-5,Dr. BRA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,South America,A,S2,3.86786156938137,MEDIUM,Y,Y,N,Y,N,2019-06-21,2019-06-22 20:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,2019-06-22 20:47:28.683,2021-06-22 08:47:28.683,2021-06-22 08:47:28.683,2022-06-22 14:47:28.683,COMPLETED,COMPLETED,2022-06-22,1096,,,,,,,2022-07-06,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-1.41259321496722
141,AB12345,AB12345-BRA-6-id-369,id-369,BRA-6,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-6,Dr. BRA-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,South America,A,S1,5.41359344335081,HIGH,Y,Y,N,N,N,2020-08-09,2020-08-13 10:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,COMPLETED,COMPLETED,2023-08-14,1096,,,,,,,2023-08-27,,,1,1,Duration of Confirmed Response,CRSD,140.225689974613,DAYS,2020-10-07 10:27:02.683,55,1,Adverse Event,Preferred Term,
142,AB12345,AB12345-BRA-6-id-369,id-369,BRA-6,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-6,Dr. BRA-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,South America,A,S1,5.41359344335081,HIGH,Y,Y,N,N,N,2020-08-09,2020-08-13 10:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,COMPLETED,COMPLETED,2023-08-14,1096,,,,,,,2023-08-27,,,4,4,Event Free Survival,EFS,24.3379260378424,DAYS,2022-05-03 10:27:02.683,628,1,Adverse Event,Preferred Term,
143,AB12345,AB12345-BRA-6-id-369,id-369,BRA-6,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-6,Dr. BRA-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,South America,A,S1,5.41359344335081,HIGH,Y,Y,N,N,N,2020-08-09,2020-08-13 10:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,COMPLETED,COMPLETED,2023-08-14,1096,,,,,,,2023-08-27,,,2,2,Overall Survival,OS,387.295850971714,DAYS,2021-05-25 10:27:02.683,285,1,Alive,Alive During Study,
144,AB12345,AB12345-BRA-6-id-369,id-369,BRA-6,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-6,Dr. BRA-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,South America,A,S1,5.41359344335081,HIGH,Y,Y,N,N,N,2020-08-09,2020-08-13 10:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,COMPLETED,COMPLETED,2023-08-14,1096,,,,,,,2023-08-27,,,3,3,Progression Free Survival,PFS,240.607509366237,DAYS,2021-10-26 10:27:02.683,439,0,Disease Progression,,
145,AB12345,AB12345-BRA-6-id-369,id-369,BRA-6,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-6,Dr. BRA-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,South America,A,S1,5.41359344335081,HIGH,Y,Y,N,N,N,2020-08-09,2020-08-13 10:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,2020-08-13 10:27:02.683,2022-08-13 22:27:02.683,2022-08-13 22:27:02.683,2023-08-14 04:27:02.683,COMPLETED,COMPLETED,2023-08-14,1096,,,,,,,2023-08-27,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.43915090619103
146,AB12345,AB12345-BRA-7-id-301,id-301,BRA-7,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-7,Dr. BRA-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,B,S2,10.5206103829345,LOW,Y,Y,Y,N,N,2019-07-21,2019-07-25 03:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,COMPLETED,COMPLETED,2022-07-24,1096,,,,,,,2022-08-10,,,2,2,Duration of Confirmed Response,CRSD,126.573020010255,DAYS,2019-09-28 03:32:13.683,65,0,Disease Progression,,
147,AB12345,AB12345-BRA-7-id-301,id-301,BRA-7,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-7,Dr. BRA-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,B,S2,10.5206103829345,LOW,Y,Y,Y,N,N,2019-07-21,2019-07-25 03:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,COMPLETED,COMPLETED,2022-07-24,1096,,,,,,,2022-08-10,,,3,3,Event Free Survival,EFS,30.0450081855524,DAYS,2020-01-25 03:32:13.683,184,1,Adverse Event,Preferred Term,
148,AB12345,AB12345-BRA-7-id-301,id-301,BRA-7,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-7,Dr. BRA-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,B,S2,10.5206103829345,LOW,Y,Y,Y,N,N,2019-07-21,2019-07-25 03:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,COMPLETED,COMPLETED,2022-07-24,1096,,,,,,,2022-08-10,,,4,4,Overall Survival,OS,463.211100967601,DAYS,2022-06-24 03:32:13.683,1065,1,Alive,Alive During Study,
149,AB12345,AB12345-BRA-7-id-301,id-301,BRA-7,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-7,Dr. BRA-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,B,S2,10.5206103829345,LOW,Y,Y,Y,N,N,2019-07-21,2019-07-25 03:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,COMPLETED,COMPLETED,2022-07-24,1096,,,,,,,2022-08-10,,,1,1,Progression Free Survival,PFS,265.95500134863,DAYS,2019-09-20 03:32:13.683,57,0,Disease Progression,,
150,AB12345,AB12345-BRA-7-id-301,id-301,BRA-7,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,BRA,N,INV ID BRA-7,Dr. BRA-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,South America,B,S2,10.5206103829345,LOW,Y,Y,Y,N,N,2019-07-21,2019-07-25 03:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,2019-07-25 03:32:13.683,2021-07-24 15:32:13.683,2021-07-24 15:32:13.683,2022-07-24 21:32:13.683,COMPLETED,COMPLETED,2022-07-24,1096,,,,,,,2022-08-10,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-4.24796225533388
151,AB12345,AB12345-CAN-1-id-18,id-18,CAN-1,41,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-1,Dr. CAN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,A,S2,7.47872491134386,MEDIUM,Y,Y,N,N,N,2020-12-30,2021-01-02 02:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,COMPLETED,COMPLETED,2024-01-02,1096,,,,,,,2024-01-24,,,2,2,Duration of Confirmed Response,CRSD,116.00643042475,DAYS,2021-02-05 02:01:15.683,34,0,Death,,
152,AB12345,AB12345-CAN-1-id-18,id-18,CAN-1,41,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-1,Dr. CAN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,A,S2,7.47872491134386,MEDIUM,Y,Y,N,N,N,2020-12-30,2021-01-02 02:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,COMPLETED,COMPLETED,2024-01-02,1096,,,,,,,2024-01-24,,,4,4,Event Free Survival,EFS,50.8006692980416,DAYS,2023-05-22 02:01:15.683,870,1,Adverse Event,Preferred Term,
153,AB12345,AB12345-CAN-1-id-18,id-18,CAN-1,41,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-1,Dr. CAN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,A,S2,7.47872491134386,MEDIUM,Y,Y,N,N,N,2020-12-30,2021-01-02 02:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,COMPLETED,COMPLETED,2024-01-02,1096,,,,,,,2024-01-24,,,1,1,Overall Survival,OS,116.00643042475,DAYS,2021-01-21 02:01:15.683,19,0,Death,,
154,AB12345,AB12345-CAN-1-id-18,id-18,CAN-1,41,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-1,Dr. CAN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,A,S2,7.47872491134386,MEDIUM,Y,Y,N,N,N,2020-12-30,2021-01-02 02:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,COMPLETED,COMPLETED,2024-01-02,1096,,,,,,,2024-01-24,,,3,3,Progression Free Survival,PFS,116.00643042475,DAYS,2022-08-19 02:01:15.683,594,0,Death,,
155,AB12345,AB12345-CAN-1-id-18,id-18,CAN-1,41,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-1,Dr. CAN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,A,S2,7.47872491134386,MEDIUM,Y,Y,N,N,N,2020-12-30,2021-01-02 02:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,2021-01-02 02:01:15.683,2023-01-02 14:01:15.683,2023-01-02 14:01:15.683,2024-01-02 20:01:15.683,COMPLETED,COMPLETED,2024-01-02,1096,,,,,,,2024-01-24,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.53540810730986
156,AB12345,AB12345-CAN-1-id-341,id-341,CAN-1,43,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,Y,INV ID CAN-1,Dr. CAN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S2,4.64258298409802,MEDIUM,Y,Y,N,Y,N,2019-05-20,2019-05-23 08:24:02.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,DISCONTINUED,DISCONTINUED,2022-02-14,998,DEATH,2022-03-02,SUICIDE,OTHER,16,<=30,2022-03-02,1013,Yes,2,2,Duration of Confirmed Response,CRSD,180.212900834158,DAYS,2021-06-16 08:24:02.683,755,0,Death,,
157,AB12345,AB12345-CAN-1-id-341,id-341,CAN-1,43,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,Y,INV ID CAN-1,Dr. CAN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S2,4.64258298409802,MEDIUM,Y,Y,N,Y,N,2019-05-20,2019-05-23 08:24:02.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,DISCONTINUED,DISCONTINUED,2022-02-14,998,DEATH,2022-03-02,SUICIDE,OTHER,16,<=30,2022-03-02,1013,Yes,3,3,Event Free Survival,EFS,39.5318608195521,DAYS,2021-07-06 08:24:02.683,775,1,Adverse Event,Preferred Term,
158,AB12345,AB12345-CAN-1-id-341,id-341,CAN-1,43,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,Y,INV ID CAN-1,Dr. CAN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S2,4.64258298409802,MEDIUM,Y,Y,N,Y,N,2019-05-20,2019-05-23 08:24:02.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,DISCONTINUED,DISCONTINUED,2022-02-14,998,DEATH,2022-03-02,SUICIDE,OTHER,16,<=30,2022-03-02,1013,Yes,4,4,Overall Survival,OS,180.212900834158,DAYS,2021-08-16 08:24:02.683,816,0,Death,,
159,AB12345,AB12345-CAN-1-id-341,id-341,CAN-1,43,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,Y,INV ID CAN-1,Dr. CAN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S2,4.64258298409802,MEDIUM,Y,Y,N,Y,N,2019-05-20,2019-05-23 08:24:02.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,DISCONTINUED,DISCONTINUED,2022-02-14,998,DEATH,2022-03-02,SUICIDE,OTHER,16,<=30,2022-03-02,1013,Yes,1,1,Progression Free Survival,PFS,180.212900834158,DAYS,2019-06-02 08:24:02.683,10,0,Death,,
160,AB12345,AB12345-CAN-1-id-341,id-341,CAN-1,43,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,Y,INV ID CAN-1,Dr. CAN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S2,4.64258298409802,MEDIUM,Y,Y,N,Y,N,2019-05-20,2019-05-23 08:24:02.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,2019-05-23 08:24:02.683,2021-02-13 22:53:27.683,2021-02-13 22:53:27.683,2022-02-14 04:53:27.683,DISCONTINUED,DISCONTINUED,2022-02-14,998,DEATH,2022-03-02,SUICIDE,OTHER,16,<=30,2022-03-02,1013,Yes,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-2.17211228465267
161,AB12345,AB12345-CAN-11-id-139,id-139,CAN-11,31,YEARS,M,ASIAN,NOT REPORTED,CAN,Y,INV ID CAN-11,Dr. CAN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S2,15.0739114266229,LOW,Y,Y,N,Y,N,2020-09-14,2020-09-15 01:17:01.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,DISCONTINUED,DISCONTINUED,2022-02-15,519,DEATH,2022-04-02,ADVERSE EVENT,ADVERSE EVENT,46,>30,2022-04-02,563,Yes,2,2,Duration of Confirmed Response,CRSD,178.979273512959,DAYS,2021-04-21 01:17:01.683,218,0,Death,,
162,AB12345,AB12345-CAN-11-id-139,id-139,CAN-11,31,YEARS,M,ASIAN,NOT REPORTED,CAN,Y,INV ID CAN-11,Dr. CAN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S2,15.0739114266229,LOW,Y,Y,N,Y,N,2020-09-14,2020-09-15 01:17:01.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,DISCONTINUED,DISCONTINUED,2022-02-15,519,DEATH,2022-04-02,ADVERSE EVENT,ADVERSE EVENT,46,>30,2022-04-02,563,Yes,4,4,Event Free Survival,EFS,28.9608829561621,DAYS,2021-12-02 01:17:01.683,443,1,Last Tumor Assessment,Completion or Discontinuation,
163,AB12345,AB12345-CAN-11-id-139,id-139,CAN-11,31,YEARS,M,ASIAN,NOT REPORTED,CAN,Y,INV ID CAN-11,Dr. CAN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S2,15.0739114266229,LOW,Y,Y,N,Y,N,2020-09-14,2020-09-15 01:17:01.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,DISCONTINUED,DISCONTINUED,2022-02-15,519,DEATH,2022-04-02,ADVERSE EVENT,ADVERSE EVENT,46,>30,2022-04-02,563,Yes,1,1,Overall Survival,OS,178.979273512959,DAYS,2021-04-19 01:17:01.683,216,0,Death,,
164,AB12345,AB12345-CAN-11-id-139,id-139,CAN-11,31,YEARS,M,ASIAN,NOT REPORTED,CAN,Y,INV ID CAN-11,Dr. CAN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S2,15.0739114266229,LOW,Y,Y,N,Y,N,2020-09-14,2020-09-15 01:17:01.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,DISCONTINUED,DISCONTINUED,2022-02-15,519,DEATH,2022-04-02,ADVERSE EVENT,ADVERSE EVENT,46,>30,2022-04-02,563,Yes,3,3,Progression Free Survival,PFS,178.979273512959,DAYS,2021-08-09 01:17:01.683,328,0,Death,,
165,AB12345,AB12345-CAN-11-id-139,id-139,CAN-11,31,YEARS,M,ASIAN,NOT REPORTED,CAN,Y,INV ID CAN-11,Dr. CAN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S2,15.0739114266229,LOW,Y,Y,N,Y,N,2020-09-14,2020-09-15 01:17:01.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,2020-09-15 01:17:01.683,2021-02-15 04:49:27.683,2021-02-15 04:49:27.683,2022-02-15 10:49:27.683,DISCONTINUED,DISCONTINUED,2022-02-15,519,DEATH,2022-04-02,ADVERSE EVENT,ADVERSE EVENT,46,>30,2022-04-02,563,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.273116944730726
166,AB12345,AB12345-CAN-11-id-306,id-306,CAN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-11,Dr. CAN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S1,3.11266800160226,HIGH,Y,Y,N,Y,N,2020-06-04,2020-06-08 23:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,COMPLETED,COMPLETED,2023-06-09,1096,,,,,,,2023-07-05,,,3,3,Duration of Confirmed Response,CRSD,132.003500266001,DAYS,2022-09-25 23:55:30.683,839,0,Death,,
167,AB12345,AB12345-CAN-11-id-306,id-306,CAN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-11,Dr. CAN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S1,3.11266800160226,HIGH,Y,Y,N,Y,N,2020-06-04,2020-06-08 23:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,COMPLETED,COMPLETED,2023-06-09,1096,,,,,,,2023-07-05,,,1,1,Event Free Survival,EFS,59.5582724455744,DAYS,2021-05-29 23:55:30.683,355,1,Last Tumor Assessment,Completion or Discontinuation,
168,AB12345,AB12345-CAN-11-id-306,id-306,CAN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-11,Dr. CAN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S1,3.11266800160226,HIGH,Y,Y,N,Y,N,2020-06-04,2020-06-08 23:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,COMPLETED,COMPLETED,2023-06-09,1096,,,,,,,2023-07-05,,,4,4,Overall Survival,OS,132.003500266001,DAYS,2023-03-12 23:55:30.683,1007,0,Death,,
169,AB12345,AB12345-CAN-11-id-306,id-306,CAN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-11,Dr. CAN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S1,3.11266800160226,HIGH,Y,Y,N,Y,N,2020-06-04,2020-06-08 23:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,COMPLETED,COMPLETED,2023-06-09,1096,,,,,,,2023-07-05,,,2,2,Progression Free Survival,PFS,132.003500266001,DAYS,2022-07-20 23:55:30.683,772,0,Death,,
170,AB12345,AB12345-CAN-11-id-306,id-306,CAN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-11,Dr. CAN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S1,3.11266800160226,HIGH,Y,Y,N,Y,N,2020-06-04,2020-06-08 23:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,2020-06-08 23:55:30.683,2022-06-09 11:55:30.683,2022-06-09 11:55:30.683,2023-06-09 17:55:30.683,COMPLETED,COMPLETED,2023-06-09,1096,,,,,,,2023-07-05,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-3.91909380346614
171,AB12345,AB12345-CAN-14-id-104,id-104,CAN-14,39,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CAN,N,INV ID CAN-14,Dr. CAN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,B,S1,4.66313206160675,HIGH,Y,Y,Y,Y,N,2019-06-26,2019-06-28 02:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,COMPLETED,COMPLETED,2022-06-27,1096,,,,,,,2022-07-21,,,1,1,Duration of Confirmed Response,CRSD,180.18980382476,DAYS,2019-08-28 02:51:57.683,61,1,Adverse Event,Preferred Term,
172,AB12345,AB12345-CAN-14-id-104,id-104,CAN-14,39,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CAN,N,INV ID CAN-14,Dr. CAN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,B,S1,4.66313206160675,HIGH,Y,Y,Y,Y,N,2019-06-26,2019-06-28 02:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,COMPLETED,COMPLETED,2022-06-27,1096,,,,,,,2022-07-21,,,2,2,Event Free Survival,EFS,38.3900524687488,DAYS,2021-04-26 02:51:57.683,668,0,Disease Progression,,
173,AB12345,AB12345-CAN-14-id-104,id-104,CAN-14,39,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CAN,N,INV ID CAN-14,Dr. CAN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,B,S1,4.66313206160675,HIGH,Y,Y,Y,Y,N,2019-06-26,2019-06-28 02:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,COMPLETED,COMPLETED,2022-06-27,1096,,,,,,,2022-07-21,,,4,4,Overall Survival,OS,467.624453315511,DAYS,2022-03-13 02:51:57.683,989,1,Alive,Alive During Study,
174,AB12345,AB12345-CAN-14-id-104,id-104,CAN-14,39,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CAN,N,INV ID CAN-14,Dr. CAN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,B,S1,4.66313206160675,HIGH,Y,Y,Y,Y,N,2019-06-26,2019-06-28 02:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,COMPLETED,COMPLETED,2022-06-27,1096,,,,,,,2022-07-21,,,3,3,Progression Free Survival,PFS,210.402443120256,DAYS,2021-09-11 02:51:57.683,806,1,Adverse Event,Preferred Term,
175,AB12345,AB12345-CAN-14-id-104,id-104,CAN-14,39,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CAN,N,INV ID CAN-14,Dr. CAN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,B,S1,4.66313206160675,HIGH,Y,Y,Y,Y,N,2019-06-26,2019-06-28 02:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,2019-06-28 02:51:57.683,2021-06-27 14:51:57.683,2021-06-27 14:51:57.683,2022-06-27 20:51:57.683,COMPLETED,COMPLETED,2022-06-27,1096,,,,,,,2022-07-21,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Preferred Term,-2.21004307128029
176,AB12345,AB12345-CAN-4-id-324,id-324,CAN-4,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,5.34637388449645,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-17 08:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-03,,,3,3,Duration of Confirmed Response,CRSD,171.756406710483,DAYS,2022-08-12 08:05:15.683,633,0,Disease Progression,,
177,AB12345,AB12345-CAN-4-id-324,id-324,CAN-4,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,5.34637388449645,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-17 08:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-03,,,4,4,Event Free Survival,EFS,21.7373442579992,DAYS,2022-12-26 08:05:15.683,769,1,Adverse Event,Preferred Term,
178,AB12345,AB12345-CAN-4-id-324,id-324,CAN-4,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,5.34637388449645,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-17 08:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-03,,,1,1,Overall Survival,OS,495.711641618982,DAYS,2021-12-24 08:05:15.683,402,1,Alive,Alive During Study,
179,AB12345,AB12345-CAN-4-id-324,id-324,CAN-4,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,5.34637388449645,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-17 08:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-03,,,2,2,Progression Free Survival,PFS,286.461782664992,DAYS,2022-07-30 08:05:15.683,620,0,Disease Progression,,
180,AB12345,AB12345-CAN-4-id-324,id-324,CAN-4,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,5.34637388449645,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-17 08:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,2020-11-17 08:05:15.683,2022-11-17 20:05:15.683,2022-11-17 20:05:15.683,2023-11-18 02:05:15.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-03,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-2.83102881356065
181,AB12345,AB12345-CAN-4-id-331,id-331,CAN-4,34,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,A,S2,3.65637007204122,MEDIUM,Y,Y,Y,N,N,2020-04-30,2020-05-03 04:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,COMPLETED,COMPLETED,2023-05-03,1096,,,,,,,2023-05-15,,,4,4,Duration of Confirmed Response,CRSD,102.486069034785,DAYS,2023-01-10 04:59:48.683,982,1,Last Tumor Assessment,Completion or Discontinuation,
182,AB12345,AB12345-CAN-4-id-331,id-331,CAN-4,34,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,A,S2,3.65637007204122,MEDIUM,Y,Y,Y,N,N,2020-04-30,2020-05-03 04:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,COMPLETED,COMPLETED,2023-05-03,1096,,,,,,,2023-05-15,,,2,2,Event Free Survival,EFS,36.1757276416756,DAYS,2022-01-02 04:59:48.683,609,1,Adverse Event,Preferred Term,
183,AB12345,AB12345-CAN-4-id-331,id-331,CAN-4,34,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,A,S2,3.65637007204122,MEDIUM,Y,Y,Y,N,N,2020-04-30,2020-05-03 04:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,COMPLETED,COMPLETED,2023-05-03,1096,,,,,,,2023-05-15,,,3,3,Overall Survival,OS,324.405099917203,DAYS,2022-10-24 04:59:48.683,904,1,Alive,Alive During Study,
184,AB12345,AB12345-CAN-4-id-331,id-331,CAN-4,34,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,A,S2,3.65637007204122,MEDIUM,Y,Y,Y,N,N,2020-04-30,2020-05-03 04:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,COMPLETED,COMPLETED,2023-05-03,1096,,,,,,,2023-05-15,,,1,1,Progression Free Survival,PFS,222.297823196277,DAYS,2021-02-25 04:59:48.683,298,1,Last Tumor Assessment,Completion or Discontinuation,
185,AB12345,AB12345-CAN-4-id-331,id-331,CAN-4,34,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CAN,N,INV ID CAN-4,Dr. CAN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,A,S2,3.65637007204122,MEDIUM,Y,Y,Y,N,N,2020-04-30,2020-05-03 04:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,2020-05-03 04:59:48.683,2022-05-03 16:59:48.683,2022-05-03 16:59:48.683,2023-05-03 22:59:48.683,COMPLETED,COMPLETED,2023-05-03,1096,,,,,,,2023-05-15,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.566843624523759
186,AB12345,AB12345-CAN-5-id-121,id-121,CAN-5,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CAN,N,INV ID CAN-5,Dr. CAN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S2,8.41726395865851,HIGH,Y,Y,Y,N,N,2019-10-11,2019-10-15 07:06:19.683,,2019-10-15 07:06:19.683,,,,2019-10-15 07:06:19.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,108.433047449216,DAYS,2021-08-01 07:06:19.683,656,0,Disease Progression,,
187,AB12345,AB12345-CAN-5-id-121,id-121,CAN-5,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CAN,N,INV ID CAN-5,Dr. CAN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S2,8.41726395865851,HIGH,Y,Y,Y,N,N,2019-10-11,2019-10-15 07:06:19.683,,2019-10-15 07:06:19.683,,,,2019-10-15 07:06:19.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,47.7453511150088,DAYS,2021-02-19 07:06:19.683,493,1,Last Tumor Assessment,Completion or Discontinuation,
188,AB12345,AB12345-CAN-5-id-121,id-121,CAN-5,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CAN,N,INV ID CAN-5,Dr. CAN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S2,8.41726395865851,HIGH,Y,Y,Y,N,N,2019-10-11,2019-10-15 07:06:19.683,,2019-10-15 07:06:19.683,,,,2019-10-15 07:06:19.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,413.316491758451,DAYS,2020-07-22 07:06:19.683,281,1,Alive,Alive During Study,
189,AB12345,AB12345-CAN-5-id-121,id-121,CAN-5,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CAN,N,INV ID CAN-5,Dr. CAN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S2,8.41726395865851,HIGH,Y,Y,Y,N,N,2019-10-11,2019-10-15 07:06:19.683,,2019-10-15 07:06:19.683,,,,2019-10-15 07:06:19.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,228.258189978078,DAYS,2020-05-18 07:06:19.683,216,1,Adverse Event,Preferred Term,
190,AB12345,AB12345-CAN-5-id-121,id-121,CAN-5,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CAN,N,INV ID CAN-5,Dr. CAN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,North America,A,S2,8.41726395865851,HIGH,Y,Y,Y,N,N,2019-10-11,2019-10-15 07:06:19.683,,2019-10-15 07:06:19.683,,,,2019-10-15 07:06:19.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.116658470639191
191,AB12345,AB12345-CHN-1-id-107,id-107,CHN-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,11.02113720708,HIGH,Y,Y,Y,N,N,2020-07-28,2020-07-31 01:51:06.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,DISCONTINUED,DISCONTINUED,2022-02-19,569,PHYSICIAN DECISION,,,,,,2022-03-13,,,3,3,Duration of Confirmed Response,CRSD,194.347468274646,DAYS,2021-10-17 01:51:06.683,443,0,Death,,
192,AB12345,AB12345-CHN-1-id-107,id-107,CHN-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,11.02113720708,HIGH,Y,Y,Y,N,N,2020-07-28,2020-07-31 01:51:06.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,DISCONTINUED,DISCONTINUED,2022-02-19,569,PHYSICIAN DECISION,,,,,,2022-03-13,,,4,4,Event Free Survival,EFS,42.9260957008228,DAYS,2021-12-27 01:51:06.683,514,0,Disease Progression,,
193,AB12345,AB12345-CHN-1-id-107,id-107,CHN-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,11.02113720708,HIGH,Y,Y,Y,N,N,2020-07-28,2020-07-31 01:51:06.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,DISCONTINUED,DISCONTINUED,2022-02-19,569,PHYSICIAN DECISION,,,,,,2022-03-13,,,2,2,Overall Survival,OS,194.347468274646,DAYS,2021-07-16 01:51:06.683,350,0,Death,,
194,AB12345,AB12345-CHN-1-id-107,id-107,CHN-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,11.02113720708,HIGH,Y,Y,Y,N,N,2020-07-28,2020-07-31 01:51:06.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,DISCONTINUED,DISCONTINUED,2022-02-19,569,PHYSICIAN DECISION,,,,,,2022-03-13,,,1,1,Progression Free Survival,PFS,194.347468274646,DAYS,2021-06-04 01:51:06.683,308,0,Death,,
195,AB12345,AB12345-CHN-1-id-107,id-107,CHN-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,11.02113720708,HIGH,Y,Y,Y,N,N,2020-07-28,2020-07-31 01:51:06.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,2020-07-31 01:51:06.683,2021-02-19 15:20:15.683,2021-02-19 15:20:15.683,2022-02-19 21:20:15.683,DISCONTINUED,DISCONTINUED,2022-02-19,569,PHYSICIAN DECISION,,,,,,2022-03-13,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.86503742630572
196,AB12345,AB12345-CHN-1-id-119,id-119,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,8.61738798040987,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-14 00:58:47.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,764,ADVERSE EVENT,,,,,,2022-03-16,,,1,1,Duration of Confirmed Response,CRSD,195.331561239436,DAYS,2020-08-31 00:58:47.683,230,0,Disease Progression,,
197,AB12345,AB12345-CHN-1-id-119,id-119,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,8.61738798040987,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-14 00:58:47.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,764,ADVERSE EVENT,,,,,,2022-03-16,,,3,3,Event Free Survival,EFS,47.0707986841444,DAYS,2021-12-20 00:58:47.683,706,1,Last Tumor Assessment,Completion or Discontinuation,
198,AB12345,AB12345-CHN-1-id-119,id-119,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,8.61738798040987,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-14 00:58:47.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,764,ADVERSE EVENT,,,,,,2022-03-16,,,4,4,Overall Survival,OS,437.46603121981,DAYS,2022-01-15 00:58:47.683,732,1,Alive,Alive During Study,
199,AB12345,AB12345-CHN-1-id-119,id-119,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,8.61738798040987,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-14 00:58:47.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,764,ADVERSE EVENT,,,,,,2022-03-16,,,2,2,Progression Free Survival,PFS,227.325286762789,DAYS,2020-10-17 00:58:47.683,277,1,Adverse Event,Preferred Term,
200,AB12345,AB12345-CHN-1-id-119,id-119,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,8.61738798040987,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-14 00:58:47.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,2020-01-14 00:58:47.683,2021-02-15 14:00:07.683,2021-02-15 14:00:07.683,2022-02-15 20:00:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,764,ADVERSE EVENT,,,,,,2022-03-16,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.14381188679368
201,AB12345,AB12345-CHN-1-id-12,id-12,CHN-1,42,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,3.24721328575446,LOW,Y,Y,Y,Y,N,2020-12-17,2020-12-20 05:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-17,,,3,3,Duration of Confirmed Response,CRSD,181.021077162586,DAYS,2022-08-29 05:45:02.683,617,1,Adverse Event,Preferred Term,
202,AB12345,AB12345-CHN-1-id-12,id-12,CHN-1,42,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,3.24721328575446,LOW,Y,Y,Y,Y,N,2020-12-17,2020-12-20 05:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-17,,,1,1,Event Free Survival,EFS,26.6443033795804,DAYS,2022-03-24 05:45:02.683,459,0,Disease Progression,,
203,AB12345,AB12345-CHN-1-id-12,id-12,CHN-1,42,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,3.24721328575446,LOW,Y,Y,Y,Y,N,2020-12-17,2020-12-20 05:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-17,,,2,2,Overall Survival,OS,388.480966771021,DAYS,2022-05-27 05:45:02.683,523,1,Alive,Alive During Study,
204,AB12345,AB12345-CHN-1-id-12,id-12,CHN-1,42,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,3.24721328575446,LOW,Y,Y,Y,Y,N,2020-12-17,2020-12-20 05:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-17,,,4,4,Progression Free Survival,PFS,276.260469201952,DAYS,2023-05-15 05:45:02.683,876,1,Last Tumor Assessment,Completion or Discontinuation,
205,AB12345,AB12345-CHN-1-id-12,id-12,CHN-1,42,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,3.24721328575446,LOW,Y,Y,Y,Y,N,2020-12-17,2020-12-20 05:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,2020-12-20 05:45:02.683,2022-12-20 17:45:02.683,2022-12-20 17:45:02.683,2023-12-20 23:45:02.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-17,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.07016901342532
206,AB12345,AB12345-CHN-1-id-123,id-123,CHN-1,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.88609033677913,LOW,Y,Y,Y,Y,N,2020-01-24,2020-01-28 17:26:17.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,DISCONTINUED,DISCONTINUED,2022-02-16,750,DEATH,2022-02-17,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-17,750,Yes,3,3,Duration of Confirmed Response,CRSD,168.045508884825,DAYS,2021-07-07 17:26:17.683,526,0,Disease Progression,,
207,AB12345,AB12345-CHN-1-id-123,id-123,CHN-1,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.88609033677913,LOW,Y,Y,Y,Y,N,2020-01-24,2020-01-28 17:26:17.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,DISCONTINUED,DISCONTINUED,2022-02-16,750,DEATH,2022-02-17,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-17,750,Yes,4,4,Event Free Survival,EFS,53.8174340373371,DAYS,2021-11-11 17:26:17.683,653,1,Last Tumor Assessment,Completion or Discontinuation,
208,AB12345,AB12345-CHN-1-id-123,id-123,CHN-1,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.88609033677913,LOW,Y,Y,Y,Y,N,2020-01-24,2020-01-28 17:26:17.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,DISCONTINUED,DISCONTINUED,2022-02-16,750,DEATH,2022-02-17,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-17,750,Yes,2,2,Overall Survival,OS,207.439790898934,DAYS,2021-05-30 17:26:17.683,488,0,Death,,
209,AB12345,AB12345-CHN-1-id-123,id-123,CHN-1,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.88609033677913,LOW,Y,Y,Y,Y,N,2020-01-24,2020-01-28 17:26:17.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,DISCONTINUED,DISCONTINUED,2022-02-16,750,DEATH,2022-02-17,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-17,750,Yes,1,1,Progression Free Survival,PFS,207.439790898934,DAYS,2020-05-03 17:26:17.683,96,0,Death,,
210,AB12345,AB12345-CHN-1-id-123,id-123,CHN-1,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.88609033677913,LOW,Y,Y,Y,Y,N,2020-01-24,2020-01-28 17:26:17.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,2020-01-28 17:26:17.683,2021-02-16 07:12:24.683,2021-02-16 07:12:24.683,2022-02-16 13:12:24.683,DISCONTINUED,DISCONTINUED,2022-02-16,750,DEATH,2022-02-17,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-17,750,Yes,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-0.97886004030023
211,AB12345,AB12345-CHN-1-id-133,id-133,CHN-1,25,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,9.3171198560196,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-08 03:10:13.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,DISCONTINUED,DISCONTINUED,2022-02-17,559,ADVERSE EVENT,,,,,,2022-03-12,,,1,1,Duration of Confirmed Response,CRSD,178.991411160678,DAYS,2020-12-20 03:10:13.683,134,1,Last Tumor Assessment,Completion or Discontinuation,
212,AB12345,AB12345-CHN-1-id-133,id-133,CHN-1,25,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,9.3171198560196,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-08 03:10:13.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,DISCONTINUED,DISCONTINUED,2022-02-17,559,ADVERSE EVENT,,,,,,2022-03-12,,,3,3,Event Free Survival,EFS,69.9634713795967,DAYS,2021-10-28 03:10:13.683,446,1,Last Tumor Assessment,Completion or Discontinuation,
213,AB12345,AB12345-CHN-1-id-133,id-133,CHN-1,25,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,9.3171198560196,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-08 03:10:13.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,DISCONTINUED,DISCONTINUED,2022-02-17,559,ADVERSE EVENT,,,,,,2022-03-12,,,2,2,Overall Survival,OS,222.331650671549,DAYS,2021-05-02 03:10:13.683,267,0,Death,,
214,AB12345,AB12345-CHN-1-id-133,id-133,CHN-1,25,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,9.3171198560196,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-08 03:10:13.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,DISCONTINUED,DISCONTINUED,2022-02-17,559,ADVERSE EVENT,,,,,,2022-03-12,,,4,4,Progression Free Survival,PFS,222.331650671549,DAYS,2021-12-03 03:10:13.683,482,0,Death,,
215,AB12345,AB12345-CHN-1-id-133,id-133,CHN-1,25,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,9.3171198560196,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-08 03:10:13.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,2020-08-08 03:10:13.683,2021-02-17 11:39:37.683,2021-02-17 11:39:37.683,2022-02-17 17:39:37.683,DISCONTINUED,DISCONTINUED,2022-02-17,559,ADVERSE EVENT,,,,,,2022-03-12,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-0.999213014720778
216,AB12345,AB12345-CHN-1-id-144,id-144,CHN-1,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,5.1085576765559,HIGH,Y,Y,Y,N,N,2020-02-16,2020-02-19 20:29:48.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,DISCONTINUED,DISCONTINUED,2022-02-19,731,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-04,,,4,4,Duration of Confirmed Response,CRSD,138.464836333878,DAYS,2022-02-15 20:29:48.683,727,1,Last Tumor Assessment,Completion or Discontinuation,
217,AB12345,AB12345-CHN-1-id-144,id-144,CHN-1,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,5.1085576765559,HIGH,Y,Y,Y,N,N,2020-02-16,2020-02-19 20:29:48.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,DISCONTINUED,DISCONTINUED,2022-02-19,731,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-04,,,1,1,Event Free Survival,EFS,18.4802391892299,DAYS,2020-10-17 20:29:48.683,241,0,Disease Progression,,
218,AB12345,AB12345-CHN-1-id-144,id-144,CHN-1,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,5.1085576765559,HIGH,Y,Y,Y,N,N,2020-02-16,2020-02-19 20:29:48.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,DISCONTINUED,DISCONTINUED,2022-02-19,731,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-04,,,2,2,Overall Survival,OS,389.273738441989,DAYS,2021-01-28 20:29:48.683,344,1,Alive,Alive During Study,
219,AB12345,AB12345-CHN-1-id-144,id-144,CHN-1,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,5.1085576765559,HIGH,Y,Y,Y,N,N,2020-02-16,2020-02-19 20:29:48.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,DISCONTINUED,DISCONTINUED,2022-02-19,731,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-04,,,3,3,Progression Free Survival,PFS,234.409215394408,DAYS,2021-08-27 20:29:48.683,555,1,Adverse Event,Preferred Term,
220,AB12345,AB12345-CHN-1-id-144,id-144,CHN-1,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,5.1085576765559,HIGH,Y,Y,Y,N,N,2020-02-16,2020-02-19 20:29:48.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,2020-02-19 20:29:48.683,2021-02-19 03:43:45.683,2021-02-19 03:43:45.683,2022-02-19 09:43:45.683,DISCONTINUED,DISCONTINUED,2022-02-19,731,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-04,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-1.38132507293815
221,AB12345,AB12345-CHN-1-id-156,id-156,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,5.72875222479301,MEDIUM,Y,Y,Y,N,N,2020-09-05,2020-09-06 11:11:20.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,DISCONTINUED,DISCONTINUED,2022-02-16,528,DEATH,2022-03-03,SUICIDE,OTHER,15,<=30,2022-03-03,542,No,3,3,Duration of Confirmed Response,CRSD,191.831791540608,DAYS,2021-03-27 11:11:20.683,202,0,Disease Progression,,
222,AB12345,AB12345-CHN-1-id-156,id-156,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,5.72875222479301,MEDIUM,Y,Y,Y,N,N,2020-09-05,2020-09-06 11:11:20.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,DISCONTINUED,DISCONTINUED,2022-02-16,528,DEATH,2022-03-03,SUICIDE,OTHER,15,<=30,2022-03-03,542,No,1,1,Event Free Survival,EFS,47.8808194072917,DAYS,2021-01-20 11:11:20.683,136,0,Disease Progression,,
223,AB12345,AB12345-CHN-1-id-156,id-156,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,5.72875222479301,MEDIUM,Y,Y,Y,N,N,2020-09-05,2020-09-06 11:11:20.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,DISCONTINUED,DISCONTINUED,2022-02-16,528,DEATH,2022-03-03,SUICIDE,OTHER,15,<=30,2022-03-03,542,No,4,4,Overall Survival,OS,217.401754343882,DAYS,2021-10-16 11:11:20.683,405,0,Death,,
224,AB12345,AB12345-CHN-1-id-156,id-156,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,5.72875222479301,MEDIUM,Y,Y,Y,N,N,2020-09-05,2020-09-06 11:11:20.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,DISCONTINUED,DISCONTINUED,2022-02-16,528,DEATH,2022-03-03,SUICIDE,OTHER,15,<=30,2022-03-03,542,No,2,2,Progression Free Survival,PFS,217.401754343882,DAYS,2021-02-10 11:11:20.683,157,0,Death,,
225,AB12345,AB12345-CHN-1-id-156,id-156,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,5.72875222479301,MEDIUM,Y,Y,Y,N,N,2020-09-05,2020-09-06 11:11:20.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,2020-09-06 11:11:20.683,2021-02-16 04:37:51.683,2021-02-16 04:37:51.683,2022-02-16 10:37:51.683,DISCONTINUED,DISCONTINUED,2022-02-16,528,DEATH,2022-03-03,SUICIDE,OTHER,15,<=30,2022-03-03,542,No,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.56727969112569
226,AB12345,AB12345-CHN-1-id-16,id-16,CHN-1,46,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,9.9241913235972,LOW,Y,Y,Y,N,N,2021-01-02,2021-01-03 15:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-01-14,,,4,4,Duration of Confirmed Response,CRSD,161.319922888651,DAYS,2022-12-22 15:31:17.683,718,0,Disease Progression,,
227,AB12345,AB12345-CHN-1-id-16,id-16,CHN-1,46,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,9.9241913235972,LOW,Y,Y,Y,N,N,2021-01-02,2021-01-03 15:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-01-14,,,3,3,Event Free Survival,EFS,27.738997801207,DAYS,2022-04-18 15:31:17.683,470,1,Adverse Event,Preferred Term,
228,AB12345,AB12345-CHN-1-id-16,id-16,CHN-1,46,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,9.9241913235972,LOW,Y,Y,Y,N,N,2021-01-02,2021-01-03 15:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-01-14,,,2,2,Overall Survival,OS,313.222096860409,DAYS,2021-11-22 15:31:17.683,323,1,Alive,Alive During Study,
229,AB12345,AB12345-CHN-1-id-16,id-16,CHN-1,46,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,9.9241913235972,LOW,Y,Y,Y,N,N,2021-01-02,2021-01-03 15:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-01-14,,,1,1,Progression Free Survival,PFS,201.724333199672,DAYS,2021-09-25 15:31:17.683,265,1,Last Tumor Assessment,Completion or Discontinuation,
230,AB12345,AB12345-CHN-1-id-16,id-16,CHN-1,46,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,9.9241913235972,LOW,Y,Y,Y,N,N,2021-01-02,2021-01-03 15:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,2021-01-03 15:31:17.683,2023-01-04 03:31:17.683,2023-01-04 03:31:17.683,2024-01-04 09:31:17.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-01-14,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-3.40698744861799
231,AB12345,AB12345-CHN-1-id-163,id-163,CHN-1,41,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.7636188325885,MEDIUM,Y,Y,Y,N,N,2020-05-27,2020-05-27 03:46:14.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,DISCONTINUED,DISCONTINUED,2022-02-19,634,PROTOCOL VIOLATION,,,,,,2022-03-16,,,1,1,Duration of Confirmed Response,CRSD,193.565612705424,DAYS,2020-08-23 03:46:14.683,88,0,Death,,
232,AB12345,AB12345-CHN-1-id-163,id-163,CHN-1,41,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.7636188325885,MEDIUM,Y,Y,Y,N,N,2020-05-27,2020-05-27 03:46:14.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,DISCONTINUED,DISCONTINUED,2022-02-19,634,PROTOCOL VIOLATION,,,,,,2022-03-16,,,4,4,Event Free Survival,EFS,81.2013185257092,DAYS,2022-01-05 03:46:14.683,588,1,Last Tumor Assessment,Completion or Discontinuation,
233,AB12345,AB12345-CHN-1-id-163,id-163,CHN-1,41,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.7636188325885,MEDIUM,Y,Y,Y,N,N,2020-05-27,2020-05-27 03:46:14.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,DISCONTINUED,DISCONTINUED,2022-02-19,634,PROTOCOL VIOLATION,,,,,,2022-03-16,,,3,3,Overall Survival,OS,193.565612705424,DAYS,2021-10-16 03:46:14.683,507,0,Death,,
234,AB12345,AB12345-CHN-1-id-163,id-163,CHN-1,41,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.7636188325885,MEDIUM,Y,Y,Y,N,N,2020-05-27,2020-05-27 03:46:14.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,DISCONTINUED,DISCONTINUED,2022-02-19,634,PROTOCOL VIOLATION,,,,,,2022-03-16,,,2,2,Progression Free Survival,PFS,193.565612705424,DAYS,2021-03-28 03:46:14.683,305,0,Death,,
235,AB12345,AB12345-CHN-1-id-163,id-163,CHN-1,41,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.7636188325885,MEDIUM,Y,Y,Y,N,N,2020-05-27,2020-05-27 03:46:14.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,2020-05-27 03:46:14.683,2021-02-19 00:19:03.683,2021-02-19 00:19:03.683,2022-02-19 06:19:03.683,DISCONTINUED,DISCONTINUED,2022-02-19,634,PROTOCOL VIOLATION,,,,,,2022-03-16,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.487433597372819
236,AB12345,AB12345-CHN-1-id-181,id-181,CHN-1,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,4.53129659020595,HIGH,Y,Y,N,Y,N,2020-05-03,2020-05-05 04:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-23,,,3,3,Duration of Confirmed Response,CRSD,164.334315690212,DAYS,2021-12-25 04:15:17.683,599,1,Last Tumor Assessment,Completion or Discontinuation,
237,AB12345,AB12345-CHN-1-id-181,id-181,CHN-1,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,4.53129659020595,HIGH,Y,Y,N,Y,N,2020-05-03,2020-05-05 04:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-23,,,2,2,Event Free Survival,EFS,32.6123518624809,DAYS,2021-05-07 04:15:17.683,367,0,Disease Progression,,
238,AB12345,AB12345-CHN-1-id-181,id-181,CHN-1,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,4.53129659020595,HIGH,Y,Y,N,Y,N,2020-05-03,2020-05-05 04:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-23,,,4,4,Overall Survival,OS,233.13795751892,DAYS,2022-05-25 04:15:17.683,750,0,Death,,
239,AB12345,AB12345-CHN-1-id-181,id-181,CHN-1,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,4.53129659020595,HIGH,Y,Y,N,Y,N,2020-05-03,2020-05-05 04:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-23,,,1,1,Progression Free Survival,PFS,233.13795751892,DAYS,2020-06-29 04:15:17.683,55,0,Death,,
240,AB12345,AB12345-CHN-1-id-181,id-181,CHN-1,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,4.53129659020595,HIGH,Y,Y,N,Y,N,2020-05-03,2020-05-05 04:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,2020-05-05 04:15:17.683,2022-05-05 16:15:17.683,2022-05-05 16:15:17.683,2023-05-05 22:15:17.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-23,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Completion or Discontinuation,-1.53933632674568
241,AB12345,AB12345-CHN-1-id-186,id-186,CHN-1,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S2,4.52117872462227,HIGH,Y,Y,Y,N,N,2021-01-30,2021-02-02 19:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-18,,,3,3,Duration of Confirmed Response,CRSD,181.718915700912,DAYS,2022-03-31 19:35:51.683,422,1,Last Tumor Assessment,Completion or Discontinuation,
242,AB12345,AB12345-CHN-1-id-186,id-186,CHN-1,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S2,4.52117872462227,HIGH,Y,Y,Y,N,N,2021-01-30,2021-02-02 19:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-18,,,4,4,Event Free Survival,EFS,96.2108352303039,DAYS,2022-09-01 19:35:51.683,576,1,Last Tumor Assessment,Completion or Discontinuation,
243,AB12345,AB12345-CHN-1-id-186,id-186,CHN-1,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S2,4.52117872462227,HIGH,Y,Y,Y,N,N,2021-01-30,2021-02-02 19:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-18,,,1,1,Overall Survival,OS,344.541195360944,DAYS,2021-03-27 19:35:51.683,53,1,Alive,Alive During Study,
244,AB12345,AB12345-CHN-1-id-186,id-186,CHN-1,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S2,4.52117872462227,HIGH,Y,Y,Y,N,N,2021-01-30,2021-02-02 19:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-18,,,2,2,Progression Free Survival,PFS,274.027614318766,DAYS,2021-09-29 19:35:51.683,239,1,Adverse Event,Preferred Term,
245,AB12345,AB12345-CHN-1-id-186,id-186,CHN-1,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S2,4.52117872462227,HIGH,Y,Y,Y,N,N,2021-01-30,2021-02-02 19:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,2021-02-02 19:35:51.683,2023-02-03 07:35:51.683,2023-02-03 07:35:51.683,2024-02-03 13:35:51.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-18,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Completion or Discontinuation,-1.70208531596605
246,AB12345,AB12345-CHN-1-id-197,id-197,CHN-1,31,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,3.65224687330682,MEDIUM,Y,Y,N,N,N,2020-05-29,2020-06-01 07:02:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,DISCONTINUED,DISCONTINUED,2022-02-12,622,ADVERSE EVENT,,,,,,2022-03-11,,,3,3,Duration of Confirmed Response,CRSD,136.652657925151,DAYS,2021-04-24 07:02:57.683,327,1,Last Tumor Assessment,Completion or Discontinuation,
247,AB12345,AB12345-CHN-1-id-197,id-197,CHN-1,31,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,3.65224687330682,MEDIUM,Y,Y,N,N,N,2020-05-29,2020-06-01 07:02:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,DISCONTINUED,DISCONTINUED,2022-02-12,622,ADVERSE EVENT,,,,,,2022-03-11,,,1,1,Event Free Survival,EFS,18.8866009027697,DAYS,2020-12-28 07:02:57.683,210,0,Disease Progression,,
248,AB12345,AB12345-CHN-1-id-197,id-197,CHN-1,31,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,3.65224687330682,MEDIUM,Y,Y,N,N,N,2020-05-29,2020-06-01 07:02:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,DISCONTINUED,DISCONTINUED,2022-02-12,622,ADVERSE EVENT,,,,,,2022-03-11,,,4,4,Overall Survival,OS,486.701249983162,DAYS,2022-02-06 07:02:57.683,615,1,Alive,Alive During Study,
249,AB12345,AB12345-CHN-1-id-197,id-197,CHN-1,31,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,3.65224687330682,MEDIUM,Y,Y,N,N,N,2020-05-29,2020-06-01 07:02:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,DISCONTINUED,DISCONTINUED,2022-02-12,622,ADVERSE EVENT,,,,,,2022-03-11,,,2,2,Progression Free Survival,PFS,274.139302503318,DAYS,2021-01-10 07:02:57.683,223,1,Last Tumor Assessment,Completion or Discontinuation,
250,AB12345,AB12345-CHN-1-id-197,id-197,CHN-1,31,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,3.65224687330682,MEDIUM,Y,Y,N,N,N,2020-05-29,2020-06-01 07:02:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,2020-06-01 07:02:57.683,2021-02-12 02:33:57.683,2021-02-12 02:33:57.683,2022-02-12 08:33:57.683,DISCONTINUED,DISCONTINUED,2022-02-12,622,ADVERSE EVENT,,,,,,2022-03-11,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,1,,Completion or Discontinuation,-0.0203264537666623
251,AB12345,AB12345-CHN-1-id-199,id-199,CHN-1,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S1,8.85826070674254,LOW,Y,Y,N,Y,N,2020-01-07,2020-01-08 21:47:26.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,DISCONTINUED,DISCONTINUED,2022-02-19,773,DEATH,2022-02-26,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-26,779,Yes,2,2,Duration of Confirmed Response,CRSD,72.222845738288,DAYS,2020-03-03 21:47:26.683,55,0,Death,,
252,AB12345,AB12345-CHN-1-id-199,id-199,CHN-1,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S1,8.85826070674254,LOW,Y,Y,N,Y,N,2020-01-07,2020-01-08 21:47:26.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,DISCONTINUED,DISCONTINUED,2022-02-19,773,DEATH,2022-02-26,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-26,779,Yes,1,1,Event Free Survival,EFS,72.222845738288,DAYS,2020-02-12 21:47:26.683,35,0,Death,,
253,AB12345,AB12345-CHN-1-id-199,id-199,CHN-1,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S1,8.85826070674254,LOW,Y,Y,N,Y,N,2020-01-07,2020-01-08 21:47:26.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,DISCONTINUED,DISCONTINUED,2022-02-19,773,DEATH,2022-02-26,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-26,779,Yes,3,3,Overall Survival,OS,72.222845738288,DAYS,2020-05-12 21:47:26.683,125,0,Death,,
254,AB12345,AB12345-CHN-1-id-199,id-199,CHN-1,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S1,8.85826070674254,LOW,Y,Y,N,Y,N,2020-01-07,2020-01-08 21:47:26.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,DISCONTINUED,DISCONTINUED,2022-02-19,773,DEATH,2022-02-26,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-26,779,Yes,4,4,Progression Free Survival,PFS,72.222845738288,DAYS,2021-06-13 21:47:26.683,522,0,Death,,
255,AB12345,AB12345-CHN-1-id-199,id-199,CHN-1,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S1,8.85826070674254,LOW,Y,Y,N,Y,N,2020-01-07,2020-01-08 21:47:26.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,2020-01-08 21:47:26.683,2021-02-19 15:37:55.683,2021-02-19 15:37:55.683,2022-02-19 21:37:55.683,DISCONTINUED,DISCONTINUED,2022-02-19,773,DEATH,2022-02-26,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-26,779,Yes,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,0.0500919399977027
256,AB12345,AB12345-CHN-1-id-208,id-208,CHN-1,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.51649998881236,MEDIUM,Y,Y,N,N,N,2020-07-27,2020-07-31 15:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-13,,,1,1,Duration of Confirmed Response,CRSD,184.762540785596,DAYS,2020-11-07 15:15:03.683,99,1,Last Tumor Assessment,Completion or Discontinuation,
257,AB12345,AB12345-CHN-1-id-208,id-208,CHN-1,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.51649998881236,MEDIUM,Y,Y,N,N,N,2020-07-27,2020-07-31 15:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-13,,,3,3,Event Free Survival,EFS,74.6153541270178,DAYS,2022-04-28 15:15:03.683,636,0,Disease Progression,,
258,AB12345,AB12345-CHN-1-id-208,id-208,CHN-1,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.51649998881236,MEDIUM,Y,Y,N,N,N,2020-07-27,2020-07-31 15:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-13,,,2,2,Overall Survival,OS,471.761551918462,DAYS,2021-08-26 15:15:03.683,391,1,Alive,Alive During Study,
259,AB12345,AB12345-CHN-1-id-208,id-208,CHN-1,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.51649998881236,MEDIUM,Y,Y,N,N,N,2020-07-27,2020-07-31 15:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-13,,,4,4,Progression Free Survival,PFS,270.61566549819,DAYS,2022-07-20 15:15:03.683,719,1,Last Tumor Assessment,Completion or Discontinuation,
260,AB12345,AB12345-CHN-1-id-208,id-208,CHN-1,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.51649998881236,MEDIUM,Y,Y,N,N,N,2020-07-27,2020-07-31 15:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,2020-07-31 15:15:03.683,2022-08-01 03:15:03.683,2022-08-01 03:15:03.683,2023-08-01 09:15:03.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-13,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Completion or Discontinuation,0.0351472620494867
261,AB12345,AB12345-CHN-1-id-212,id-212,CHN-1,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.12569485541014,MEDIUM,Y,Y,Y,Y,N,2020-12-28,2020-12-30 06:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,COMPLETED,COMPLETED,2023-12-31,1096,,,,,,,2024-01-28,,,4,4,Duration of Confirmed Response,CRSD,167.663499200717,DAYS,2023-09-30 06:40:35.683,1004,0,Disease Progression,,
262,AB12345,AB12345-CHN-1-id-212,id-212,CHN-1,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.12569485541014,MEDIUM,Y,Y,Y,Y,N,2020-12-28,2020-12-30 06:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,COMPLETED,COMPLETED,2023-12-31,1096,,,,,,,2024-01-28,,,2,2,Event Free Survival,EFS,52.8797817451414,DAYS,2021-09-12 06:40:35.683,256,1,Last Tumor Assessment,Completion or Discontinuation,
263,AB12345,AB12345-CHN-1-id-212,id-212,CHN-1,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.12569485541014,MEDIUM,Y,Y,Y,Y,N,2020-12-28,2020-12-30 06:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,COMPLETED,COMPLETED,2023-12-31,1096,,,,,,,2024-01-28,,,3,3,Overall Survival,OS,447.234307043254,DAYS,2022-04-25 06:40:35.683,481,1,Alive,Alive During Study,
264,AB12345,AB12345-CHN-1-id-212,id-212,CHN-1,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.12569485541014,MEDIUM,Y,Y,Y,Y,N,2020-12-28,2020-12-30 06:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,COMPLETED,COMPLETED,2023-12-31,1096,,,,,,,2024-01-28,,,1,1,Progression Free Survival,PFS,212.78247826267,DAYS,2021-02-01 06:40:35.683,33,1,Last Tumor Assessment,Completion or Discontinuation,
265,AB12345,AB12345-CHN-1-id-212,id-212,CHN-1,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.12569485541014,MEDIUM,Y,Y,Y,Y,N,2020-12-28,2020-12-30 06:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,2020-12-30 06:40:35.683,2022-12-30 18:40:35.683,2022-12-30 18:40:35.683,2023-12-31 00:40:35.683,COMPLETED,COMPLETED,2023-12-31,1096,,,,,,,2024-01-28,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.283247037664452
266,AB12345,AB12345-CHN-1-id-216,id-216,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,C,S2,7.43057525706726,LOW,Y,Y,Y,Y,N,2020-09-30,2020-10-04 02:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-17,,,2,2,Duration of Confirmed Response,CRSD,128.08000696823,DAYS,2021-12-15 02:51:15.683,437,0,Death,,
267,AB12345,AB12345-CHN-1-id-216,id-216,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,C,S2,7.43057525706726,LOW,Y,Y,Y,Y,N,2020-09-30,2020-10-04 02:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-17,,,4,4,Event Free Survival,EFS,20.715837610187,DAYS,2023-09-05 02:51:15.683,1066,0,Disease Progression,,
268,AB12345,AB12345-CHN-1-id-216,id-216,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,C,S2,7.43057525706726,LOW,Y,Y,Y,Y,N,2020-09-30,2020-10-04 02:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-17,,,1,1,Overall Survival,OS,128.08000696823,DAYS,2021-01-20 02:51:15.683,108,0,Death,,
269,AB12345,AB12345-CHN-1-id-216,id-216,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,C,S2,7.43057525706726,LOW,Y,Y,Y,Y,N,2020-09-30,2020-10-04 02:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-17,,,3,3,Progression Free Survival,PFS,128.08000696823,DAYS,2023-07-08 02:51:15.683,1007,0,Death,,
270,AB12345,AB12345-CHN-1-id-216,id-216,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,C,S2,7.43057525706726,LOW,Y,Y,Y,Y,N,2020-09-30,2020-10-04 02:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,2020-10-04 02:51:15.683,2022-10-04 14:51:15.683,2022-10-04 14:51:15.683,2023-10-04 20:51:15.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-17,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.76605613629486
271,AB12345,AB12345-CHN-1-id-227,id-227,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,12.1904033912419,LOW,Y,Y,N,N,N,2019-04-07,2019-04-09 23:09:23.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1045,PROTOCOL VIOLATION,,,,,,2022-03-15,,,3,3,Duration of Confirmed Response,CRSD,194.342499715276,DAYS,2020-10-09 23:09:23.683,549,0,Death,,
272,AB12345,AB12345-CHN-1-id-227,id-227,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,12.1904033912419,LOW,Y,Y,N,N,N,2019-04-07,2019-04-09 23:09:23.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1045,PROTOCOL VIOLATION,,,,,,2022-03-15,,,2,2,Event Free Survival,EFS,49.9875031155534,DAYS,2020-03-09 23:09:23.683,335,1,Adverse Event,Preferred Term,
273,AB12345,AB12345-CHN-1-id-227,id-227,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,12.1904033912419,LOW,Y,Y,N,N,N,2019-04-07,2019-04-09 23:09:23.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1045,PROTOCOL VIOLATION,,,,,,2022-03-15,,,4,4,Overall Survival,OS,194.342499715276,DAYS,2021-09-12 23:09:23.683,887,0,Death,,
274,AB12345,AB12345-CHN-1-id-227,id-227,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,12.1904033912419,LOW,Y,Y,N,N,N,2019-04-07,2019-04-09 23:09:23.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1045,PROTOCOL VIOLATION,,,,,,2022-03-15,,,1,1,Progression Free Survival,PFS,194.342499715276,DAYS,2019-06-24 23:09:23.683,76,0,Death,,
275,AB12345,AB12345-CHN-1-id-227,id-227,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,12.1904033912419,LOW,Y,Y,N,N,N,2019-04-07,2019-04-09 23:09:23.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,2019-04-09 23:09:23.683,2021-02-17 08:54:24.683,2021-02-17 08:54:24.683,2022-02-17 14:54:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1045,PROTOCOL VIOLATION,,,,,,2022-03-15,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,0.0608648837646824
276,AB12345,AB12345-CHN-1-id-229,id-229,CHN-1,37,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,9.50694944744561,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 12:03:40.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,495,DEATH,2022-04-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-10,543,Yes,4,4,Duration of Confirmed Response,CRSD,103.886658512056,DAYS,2022-02-13 12:03:40.683,488,1,Last Tumor Assessment,Completion or Discontinuation,
277,AB12345,AB12345-CHN-1-id-229,id-229,CHN-1,37,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,9.50694944744561,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 12:03:40.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,495,DEATH,2022-04-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-10,543,Yes,1,1,Event Free Survival,EFS,98.0741153203417,DAYS,2021-05-09 12:03:40.683,208,1,Adverse Event,Preferred Term,
278,AB12345,AB12345-CHN-1-id-229,id-229,CHN-1,37,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,9.50694944744561,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 12:03:40.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,495,DEATH,2022-04-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-10,543,Yes,3,3,Overall Survival,OS,306.002335436642,DAYS,2022-01-03 12:03:40.683,447,1,Alive,Alive During Study,
279,AB12345,AB12345-CHN-1-id-229,id-229,CHN-1,37,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,9.50694944744561,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 12:03:40.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,495,DEATH,2022-04-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-10,543,Yes,2,2,Progression Free Survival,PFS,258.772777719423,DAYS,2021-06-06 12:03:40.683,236,1,Last Tumor Assessment,Completion or Discontinuation,
280,AB12345,AB12345-CHN-1-id-229,id-229,CHN-1,37,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,9.50694944744561,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 12:03:40.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,2020-10-13 12:03:40.683,2021-02-19 14:39:33.683,2021-02-19 14:39:33.683,2022-02-19 20:39:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,495,DEATH,2022-04-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-10,543,Yes,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Completion or Discontinuation,-0.772018417854013
281,AB12345,AB12345-CHN-1-id-232,id-232,CHN-1,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.17424360370127,MEDIUM,Y,Y,N,N,N,2020-02-24,2020-02-24 14:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,COMPLETED,COMPLETED,2023-02-24,1096,,,,,,,2023-03-16,,,2,2,Duration of Confirmed Response,CRSD,109.822723083198,DAYS,2020-09-21 14:35:03.683,210,0,Disease Progression,,
282,AB12345,AB12345-CHN-1-id-232,id-232,CHN-1,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.17424360370127,MEDIUM,Y,Y,N,N,N,2020-02-24,2020-02-24 14:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,COMPLETED,COMPLETED,2023-02-24,1096,,,,,,,2023-03-16,,,1,1,Event Free Survival,EFS,63.0489027115982,DAYS,2020-03-15 14:35:03.683,20,1,Last Tumor Assessment,Completion or Discontinuation,
283,AB12345,AB12345-CHN-1-id-232,id-232,CHN-1,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.17424360370127,MEDIUM,Y,Y,N,N,N,2020-02-24,2020-02-24 14:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,COMPLETED,COMPLETED,2023-02-24,1096,,,,,,,2023-03-16,,,3,3,Overall Survival,OS,463.700366904959,DAYS,2021-01-25 14:35:03.683,336,1,Alive,Alive During Study,
284,AB12345,AB12345-CHN-1-id-232,id-232,CHN-1,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.17424360370127,MEDIUM,Y,Y,N,N,N,2020-02-24,2020-02-24 14:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,COMPLETED,COMPLETED,2023-02-24,1096,,,,,,,2023-03-16,,,4,4,Progression Free Survival,PFS,263.029078859836,DAYS,2021-04-20 14:35:03.683,421,1,Last Tumor Assessment,Completion or Discontinuation,
285,AB12345,AB12345-CHN-1-id-232,id-232,CHN-1,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.17424360370127,MEDIUM,Y,Y,N,N,N,2020-02-24,2020-02-24 14:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,2020-02-24 14:35:03.683,2022-02-24 02:35:03.683,2022-02-24 02:35:03.683,2023-02-24 08:35:03.683,COMPLETED,COMPLETED,2023-02-24,1096,,,,,,,2023-03-16,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-3.20601473593605
286,AB12345,AB12345-CHN-1-id-233,id-233,CHN-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S1,4.07681840229054,LOW,Y,Y,N,Y,N,2021-02-09,2021-02-11 21:54:30.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,DISCONTINUED,DISCONTINUED,2022-02-15,369,DEATH,2022-03-25,MISSING,OTHER,38,>30,2022-03-25,406,,3,3,Duration of Confirmed Response,CRSD,113.398367492482,DAYS,2021-11-06 21:54:30.683,268,1,Last Tumor Assessment,Completion or Discontinuation,
287,AB12345,AB12345-CHN-1-id-233,id-233,CHN-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S1,4.07681840229054,LOW,Y,Y,N,Y,N,2021-02-09,2021-02-11 21:54:30.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,DISCONTINUED,DISCONTINUED,2022-02-15,369,DEATH,2022-03-25,MISSING,OTHER,38,>30,2022-03-25,406,,2,2,Event Free Survival,EFS,44.7535413585138,DAYS,2021-08-24 21:54:30.683,194,1,Last Tumor Assessment,Completion or Discontinuation,
288,AB12345,AB12345-CHN-1-id-233,id-233,CHN-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S1,4.07681840229054,LOW,Y,Y,N,Y,N,2021-02-09,2021-02-11 21:54:30.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,DISCONTINUED,DISCONTINUED,2022-02-15,369,DEATH,2022-03-25,MISSING,OTHER,38,>30,2022-03-25,406,,1,1,Overall Survival,OS,208.094337838702,DAYS,2021-08-13 21:54:30.683,183,0,Death,,
289,AB12345,AB12345-CHN-1-id-233,id-233,CHN-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S1,4.07681840229054,LOW,Y,Y,N,Y,N,2021-02-09,2021-02-11 21:54:30.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,DISCONTINUED,DISCONTINUED,2022-02-15,369,DEATH,2022-03-25,MISSING,OTHER,38,>30,2022-03-25,406,,4,4,Progression Free Survival,PFS,208.094337838702,DAYS,2022-01-28 21:54:30.683,351,0,Death,,
290,AB12345,AB12345-CHN-1-id-233,id-233,CHN-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S1,4.07681840229054,LOW,Y,Y,N,Y,N,2021-02-09,2021-02-11 21:54:30.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,2021-02-11 21:54:30.683,2021-02-15 13:43:12.683,2021-02-15 13:43:12.683,2022-02-15 19:43:12.683,DISCONTINUED,DISCONTINUED,2022-02-15,369,DEATH,2022-03-25,MISSING,OTHER,38,>30,2022-03-25,406,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-2.51047244995537
291,AB12345,AB12345-CHN-1-id-235,id-235,CHN-1,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,4.7111935626967,HIGH,Y,Y,N,N,N,2019-07-11,2019-07-13 00:37:20.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,DISCONTINUED,DISCONTINUED,2022-02-16,950,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,20,<=30,2022-03-08,968,Yes,3,3,Duration of Confirmed Response,CRSD,199.627178465016,DAYS,2021-02-09 00:37:20.683,577,0,Death,,
292,AB12345,AB12345-CHN-1-id-235,id-235,CHN-1,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,4.7111935626967,HIGH,Y,Y,N,N,N,2019-07-11,2019-07-13 00:37:20.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,DISCONTINUED,DISCONTINUED,2022-02-16,950,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,20,<=30,2022-03-08,968,Yes,2,2,Event Free Survival,EFS,44.7876817150973,DAYS,2019-11-15 00:37:20.683,125,1,Last Tumor Assessment,Completion or Discontinuation,
293,AB12345,AB12345-CHN-1-id-235,id-235,CHN-1,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,4.7111935626967,HIGH,Y,Y,N,N,N,2019-07-11,2019-07-13 00:37:20.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,DISCONTINUED,DISCONTINUED,2022-02-16,950,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,20,<=30,2022-03-08,968,Yes,1,1,Overall Survival,OS,199.627178465016,DAYS,2019-10-10 00:37:20.683,89,0,Death,,
294,AB12345,AB12345-CHN-1-id-235,id-235,CHN-1,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,4.7111935626967,HIGH,Y,Y,N,N,N,2019-07-11,2019-07-13 00:37:20.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,DISCONTINUED,DISCONTINUED,2022-02-16,950,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,20,<=30,2022-03-08,968,Yes,4,4,Progression Free Survival,PFS,199.627178465016,DAYS,2022-02-08 00:37:20.683,941,0,Death,,
295,AB12345,AB12345-CHN-1-id-235,id-235,CHN-1,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,4.7111935626967,HIGH,Y,Y,N,N,N,2019-07-11,2019-07-13 00:37:20.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,2019-07-13 00:37:20.683,2021-02-15 23:56:04.683,2021-02-15 23:56:04.683,2022-02-16 05:56:04.683,DISCONTINUED,DISCONTINUED,2022-02-16,950,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,20,<=30,2022-03-08,968,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.776567056902484
296,AB12345,AB12345-CHN-1-id-25,id-25,CHN-1,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,1.78210217337625,MEDIUM,Y,Y,N,N,N,2020-10-29,2020-11-02 12:51:08.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,DISCONTINUED,DISCONTINUED,2022-02-16,471,PROTOCOL VIOLATION,,,,,,2022-03-09,,,2,2,Duration of Confirmed Response,CRSD,133.589738048613,DAYS,2021-04-08 12:51:08.683,157,1,Adverse Event,Preferred Term,
297,AB12345,AB12345-CHN-1-id-25,id-25,CHN-1,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,1.78210217337625,MEDIUM,Y,Y,N,N,N,2020-10-29,2020-11-02 12:51:08.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,DISCONTINUED,DISCONTINUED,2022-02-16,471,PROTOCOL VIOLATION,,,,,,2022-03-09,,,4,4,Event Free Survival,EFS,60.3023489145562,DAYS,2021-12-28 12:51:08.683,421,1,Last Tumor Assessment,Completion or Discontinuation,
298,AB12345,AB12345-CHN-1-id-25,id-25,CHN-1,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,1.78210217337625,MEDIUM,Y,Y,N,N,N,2020-10-29,2020-11-02 12:51:08.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,DISCONTINUED,DISCONTINUED,2022-02-16,471,PROTOCOL VIOLATION,,,,,,2022-03-09,,,1,1,Overall Survival,OS,376.524412073195,DAYS,2021-01-24 12:51:08.683,83,1,Alive,Alive During Study,
299,AB12345,AB12345-CHN-1-id-25,id-25,CHN-1,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,1.78210217337625,MEDIUM,Y,Y,N,N,N,2020-10-29,2020-11-02 12:51:08.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,DISCONTINUED,DISCONTINUED,2022-02-16,471,PROTOCOL VIOLATION,,,,,,2022-03-09,,,3,3,Progression Free Survival,PFS,231.423464347608,DAYS,2021-06-12 12:51:08.683,222,0,Disease Progression,,
300,AB12345,AB12345-CHN-1-id-25,id-25,CHN-1,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,1.78210217337625,MEDIUM,Y,Y,N,N,N,2020-10-29,2020-11-02 12:51:08.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,2020-11-02 12:51:08.683,2021-02-16 04:48:14.683,2021-02-16 04:48:14.683,2022-02-16 10:48:14.683,DISCONTINUED,DISCONTINUED,2022-02-16,471,PROTOCOL VIOLATION,,,,,,2022-03-09,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.66654207387007
301,AB12345,AB12345-CHN-1-id-253,id-253,CHN-1,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.93548873387263,MEDIUM,Y,Y,N,Y,N,2020-10-25,2020-10-25 12:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,COMPLETED,COMPLETED,2023-10-26,1096,,,,,,,2023-11-21,,,1,1,Duration of Confirmed Response,CRSD,103.653911687434,DAYS,2021-05-06 12:06:16.683,193,1,Adverse Event,Preferred Term,
302,AB12345,AB12345-CHN-1-id-253,id-253,CHN-1,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.93548873387263,MEDIUM,Y,Y,N,Y,N,2020-10-25,2020-10-25 12:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,COMPLETED,COMPLETED,2023-10-26,1096,,,,,,,2023-11-21,,,3,3,Event Free Survival,EFS,16.5764446638059,DAYS,2021-11-14 12:06:16.683,385,1,Adverse Event,Preferred Term,
303,AB12345,AB12345-CHN-1-id-253,id-253,CHN-1,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.93548873387263,MEDIUM,Y,Y,N,Y,N,2020-10-25,2020-10-25 12:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,COMPLETED,COMPLETED,2023-10-26,1096,,,,,,,2023-11-21,,,2,2,Overall Survival,OS,380.412804754451,DAYS,2021-07-10 12:06:16.683,258,1,Alive,Alive During Study,
304,AB12345,AB12345-CHN-1-id-253,id-253,CHN-1,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.93548873387263,MEDIUM,Y,Y,N,Y,N,2020-10-25,2020-10-25 12:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,COMPLETED,COMPLETED,2023-10-26,1096,,,,,,,2023-11-21,,,4,4,Progression Free Survival,PFS,287.851329403929,DAYS,2022-10-10 12:06:16.683,715,0,Disease Progression,,
305,AB12345,AB12345-CHN-1-id-253,id-253,CHN-1,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.93548873387263,MEDIUM,Y,Y,N,Y,N,2020-10-25,2020-10-25 12:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,2020-10-25 12:06:16.683,2022-10-26 00:06:16.683,2022-10-26 00:06:16.683,2023-10-26 06:06:16.683,COMPLETED,COMPLETED,2023-10-26,1096,,,,,,,2023-11-21,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-2.37236572218026
306,AB12345,AB12345-CHN-1-id-26,id-26,CHN-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,1.07407317299888,HIGH,Y,Y,Y,N,Y,2020-07-12,2020-07-16 12:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-08-12,,,1,1,Duration of Confirmed Response,CRSD,140.233651013114,DAYS,2021-07-22 12:27:24.683,371,0,Disease Progression,,
307,AB12345,AB12345-CHN-1-id-26,id-26,CHN-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,1.07407317299888,HIGH,Y,Y,Y,N,Y,2020-07-12,2020-07-16 12:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-08-12,,,3,3,Event Free Survival,EFS,54.8973913060036,DAYS,2023-03-26 12:27:24.683,983,1,Last Tumor Assessment,Completion or Discontinuation,
308,AB12345,AB12345-CHN-1-id-26,id-26,CHN-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,1.07407317299888,HIGH,Y,Y,Y,N,Y,2020-07-12,2020-07-16 12:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-08-12,,,2,2,Overall Survival,OS,379.832893051207,DAYS,2022-01-12 12:27:24.683,545,1,Alive,Alive During Study,
309,AB12345,AB12345-CHN-1-id-26,id-26,CHN-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,1.07407317299888,HIGH,Y,Y,Y,N,Y,2020-07-12,2020-07-16 12:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-08-12,,,4,4,Progression Free Survival,PFS,270.209010248072,DAYS,2023-04-24 12:27:24.683,1012,1,Last Tumor Assessment,Completion or Discontinuation,
310,AB12345,AB12345-CHN-1-id-26,id-26,CHN-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,1.07407317299888,HIGH,Y,Y,Y,N,Y,2020-07-12,2020-07-16 12:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,2020-07-16 12:27:24.683,2022-07-17 00:27:24.683,2022-07-17 00:27:24.683,2023-07-17 06:27:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-08-12,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-3.90636913372105
311,AB12345,AB12345-CHN-1-id-275,id-275,CHN-1,27,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,7.14150820266526,HIGH,Y,Y,N,Y,N,2020-06-01,2020-06-02 23:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,COMPLETED,COMPLETED,2023-06-03,1096,,,,,,,2023-06-22,,,4,4,Duration of Confirmed Response,CRSD,103.697375068441,DAYS,2022-08-18 23:28:44.683,807,1,Last Tumor Assessment,Completion or Discontinuation,
312,AB12345,AB12345-CHN-1-id-275,id-275,CHN-1,27,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,7.14150820266526,HIGH,Y,Y,N,Y,N,2020-06-01,2020-06-02 23:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,COMPLETED,COMPLETED,2023-06-03,1096,,,,,,,2023-06-22,,,3,3,Event Free Survival,EFS,57.6664574304596,DAYS,2022-02-16 23:28:44.683,624,1,Last Tumor Assessment,Completion or Discontinuation,
313,AB12345,AB12345-CHN-1-id-275,id-275,CHN-1,27,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,7.14150820266526,HIGH,Y,Y,N,Y,N,2020-06-01,2020-06-02 23:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,COMPLETED,COMPLETED,2023-06-03,1096,,,,,,,2023-06-22,,,2,2,Overall Survival,OS,492.568396357819,DAYS,2021-05-02 23:28:44.683,334,1,Alive,Alive During Study,
314,AB12345,AB12345-CHN-1-id-275,id-275,CHN-1,27,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,7.14150820266526,HIGH,Y,Y,N,Y,N,2020-06-01,2020-06-02 23:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,COMPLETED,COMPLETED,2023-06-03,1096,,,,,,,2023-06-22,,,1,1,Progression Free Survival,PFS,229.797573480755,DAYS,2021-01-23 23:28:44.683,235,1,Adverse Event,Preferred Term,
315,AB12345,AB12345-CHN-1-id-275,id-275,CHN-1,27,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,7.14150820266526,HIGH,Y,Y,N,Y,N,2020-06-01,2020-06-02 23:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,2020-06-02 23:28:44.683,2022-06-03 11:28:44.683,2022-06-03 11:28:44.683,2023-06-03 17:28:44.683,COMPLETED,COMPLETED,2023-06-03,1096,,,,,,,2023-06-22,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-6.40454975409036
316,AB12345,AB12345-CHN-1-id-276,id-276,CHN-1,50,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,3.68598760623753,LOW,Y,Y,Y,N,N,2020-10-21,2020-10-24 05:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,COMPLETED,COMPLETED,2023-10-24,1096,,,,,,,2023-11-08,,,1,1,Duration of Confirmed Response,CRSD,196.109917736612,DAYS,2021-05-26 05:17:41.683,214,0,Disease Progression,,
317,AB12345,AB12345-CHN-1-id-276,id-276,CHN-1,50,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,3.68598760623753,LOW,Y,Y,Y,N,N,2020-10-21,2020-10-24 05:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,COMPLETED,COMPLETED,2023-10-24,1096,,,,,,,2023-11-08,,,3,3,Event Free Survival,EFS,94.4832368940115,DAYS,2023-05-27 05:17:41.683,945,1,Adverse Event,Preferred Term,
318,AB12345,AB12345-CHN-1-id-276,id-276,CHN-1,50,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,3.68598760623753,LOW,Y,Y,Y,N,N,2020-10-21,2020-10-24 05:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,COMPLETED,COMPLETED,2023-10-24,1096,,,,,,,2023-11-08,,,4,4,Overall Survival,OS,450.955438567325,DAYS,2023-08-26 05:17:41.683,1036,1,Alive,Alive During Study,
319,AB12345,AB12345-CHN-1-id-276,id-276,CHN-1,50,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,3.68598760623753,LOW,Y,Y,Y,N,N,2020-10-21,2020-10-24 05:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,COMPLETED,COMPLETED,2023-10-24,1096,,,,,,,2023-11-08,,,2,2,Progression Free Survival,PFS,279.259536415339,DAYS,2023-05-13 05:17:41.683,931,0,Disease Progression,,
320,AB12345,AB12345-CHN-1-id-276,id-276,CHN-1,50,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,3.68598760623753,LOW,Y,Y,Y,N,N,2020-10-21,2020-10-24 05:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,2020-10-24 05:17:41.683,2022-10-24 17:17:41.683,2022-10-24 17:17:41.683,2023-10-24 23:17:41.683,COMPLETED,COMPLETED,2023-10-24,1096,,,,,,,2023-11-08,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-2.83541383384175
321,AB12345,AB12345-CHN-1-id-277,id-277,CHN-1,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S2,4.07226820149157,LOW,Y,Y,N,N,N,2021-01-13,2021-01-14 17:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-02-04,,,4,4,Duration of Confirmed Response,CRSD,113.550477917306,DAYS,2023-07-23 17:03:48.683,920,1,Last Tumor Assessment,Completion or Discontinuation,
322,AB12345,AB12345-CHN-1-id-277,id-277,CHN-1,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S2,4.07226820149157,LOW,Y,Y,N,N,N,2021-01-13,2021-01-14 17:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-02-04,,,2,2,Event Free Survival,EFS,20.6071635603439,DAYS,2021-11-10 17:03:48.683,300,1,Adverse Event,Preferred Term,
323,AB12345,AB12345-CHN-1-id-277,id-277,CHN-1,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S2,4.07226820149157,LOW,Y,Y,N,N,N,2021-01-13,2021-01-14 17:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-02-04,,,3,3,Overall Survival,OS,452.508772164583,DAYS,2023-04-23 17:03:48.683,829,1,Alive,Alive During Study,
324,AB12345,AB12345-CHN-1-id-277,id-277,CHN-1,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S2,4.07226820149157,LOW,Y,Y,N,N,N,2021-01-13,2021-01-14 17:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-02-04,,,1,1,Progression Free Survival,PFS,212.359937559813,DAYS,2021-06-20 17:03:48.683,157,1,Last Tumor Assessment,Completion or Discontinuation,
325,AB12345,AB12345-CHN-1-id-277,id-277,CHN-1,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S2,4.07226820149157,LOW,Y,Y,N,N,N,2021-01-13,2021-01-14 17:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,2021-01-14 17:03:48.683,2023-01-15 05:03:48.683,2023-01-15 05:03:48.683,2024-01-15 11:03:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-02-04,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Completion or Discontinuation,-0.958323371690888
326,AB12345,AB12345-CHN-1-id-279,id-279,CHN-1,33,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,3.64194318194236,HIGH,Y,Y,Y,Y,N,2020-03-16,2020-03-17 18:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,COMPLETED,COMPLETED,2023-03-18,1096,,,,,,,2023-04-03,,,4,4,Duration of Confirmed Response,CRSD,140.265909023583,DAYS,2023-01-28 18:18:37.683,1047,1,Adverse Event,Preferred Term,
327,AB12345,AB12345-CHN-1-id-279,id-279,CHN-1,33,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,3.64194318194236,HIGH,Y,Y,Y,Y,N,2020-03-16,2020-03-17 18:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,COMPLETED,COMPLETED,2023-03-18,1096,,,,,,,2023-04-03,,,2,2,Event Free Survival,EFS,91.7945858545136,DAYS,2021-07-18 18:18:37.683,488,0,Disease Progression,,
328,AB12345,AB12345-CHN-1-id-279,id-279,CHN-1,33,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,3.64194318194236,HIGH,Y,Y,Y,Y,N,2020-03-16,2020-03-17 18:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,COMPLETED,COMPLETED,2023-03-18,1096,,,,,,,2023-04-03,,,1,1,Overall Survival,OS,374.913043808192,DAYS,2020-09-12 18:18:37.683,179,1,Alive,Alive During Study,
329,AB12345,AB12345-CHN-1-id-279,id-279,CHN-1,33,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,3.64194318194236,HIGH,Y,Y,Y,Y,N,2020-03-16,2020-03-17 18:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,COMPLETED,COMPLETED,2023-03-18,1096,,,,,,,2023-04-03,,,3,3,Progression Free Survival,PFS,218.256300780922,DAYS,2022-02-11 18:18:37.683,696,0,Disease Progression,,
330,AB12345,AB12345-CHN-1-id-279,id-279,CHN-1,33,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,3.64194318194236,HIGH,Y,Y,Y,Y,N,2020-03-16,2020-03-17 18:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,2020-03-17 18:18:37.683,2022-03-18 06:18:37.683,2022-03-18 06:18:37.683,2023-03-18 12:18:37.683,COMPLETED,COMPLETED,2023-03-18,1096,,,,,,,2023-04-03,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.64051259197118
331,AB12345,AB12345-CHN-1-id-287,id-287,CHN-1,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,10.1935196391086,LOW,Y,Y,N,N,N,2019-11-19,2019-11-23 12:45:59.683,,2019-11-23 12:45:59.683,,,,2019-11-23 12:45:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,191.35026789736,DAYS,2021-11-07 12:45:59.683,715,1,Adverse Event,Preferred Term,
332,AB12345,AB12345-CHN-1-id-287,id-287,CHN-1,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,10.1935196391086,LOW,Y,Y,N,N,N,2019-11-19,2019-11-23 12:45:59.683,,2019-11-23 12:45:59.683,,,,2019-11-23 12:45:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,58.0277375713922,DAYS,2020-09-15 12:45:59.683,297,1,Last Tumor Assessment,Completion or Discontinuation,
333,AB12345,AB12345-CHN-1-id-287,id-287,CHN-1,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,10.1935196391086,LOW,Y,Y,N,N,N,2019-11-19,2019-11-23 12:45:59.683,,2019-11-23 12:45:59.683,,,,2019-11-23 12:45:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,321.949104778469,DAYS,2021-09-02 12:45:59.683,649,1,Alive,Alive During Study,
334,AB12345,AB12345-CHN-1-id-287,id-287,CHN-1,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,10.1935196391086,LOW,Y,Y,N,N,N,2019-11-19,2019-11-23 12:45:59.683,,2019-11-23 12:45:59.683,,,,2019-11-23 12:45:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,207.664518104866,DAYS,2020-03-09 12:45:59.683,107,1,Last Tumor Assessment,Completion or Discontinuation,
335,AB12345,AB12345-CHN-1-id-287,id-287,CHN-1,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,10.1935196391086,LOW,Y,Y,N,N,N,2019-11-19,2019-11-23 12:45:59.683,,2019-11-23 12:45:59.683,,,,2019-11-23 12:45:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-2.8991430222112
336,AB12345,AB12345-CHN-1-id-288,id-288,CHN-1,42,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,4.58264176937552,MEDIUM,Y,Y,N,Y,N,2019-12-09,2019-12-11 09:17:03.683,,2019-12-11 09:17:03.683,,,,2019-12-11 09:17:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,130.459877569228,DAYS,2021-03-08 09:17:03.683,453,0,Death,,
337,AB12345,AB12345-CHN-1-id-288,id-288,CHN-1,42,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,4.58264176937552,MEDIUM,Y,Y,N,Y,N,2019-12-09,2019-12-11 09:17:03.683,,2019-12-11 09:17:03.683,,,,2019-12-11 09:17:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,79.1127139108721,DAYS,2020-05-02 09:17:03.683,143,1,Adverse Event,Preferred Term,
338,AB12345,AB12345-CHN-1-id-288,id-288,CHN-1,42,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,4.58264176937552,MEDIUM,Y,Y,N,Y,N,2019-12-09,2019-12-11 09:17:03.683,,2019-12-11 09:17:03.683,,,,2019-12-11 09:17:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,130.459877569228,DAYS,2021-05-29 09:17:03.683,535,0,Death,,
339,AB12345,AB12345-CHN-1-id-288,id-288,CHN-1,42,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,4.58264176937552,MEDIUM,Y,Y,N,Y,N,2019-12-09,2019-12-11 09:17:03.683,,2019-12-11 09:17:03.683,,,,2019-12-11 09:17:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,130.459877569228,DAYS,2021-07-11 09:17:03.683,578,0,Death,,
340,AB12345,AB12345-CHN-1-id-288,id-288,CHN-1,42,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,4.58264176937552,MEDIUM,Y,Y,N,Y,N,2019-12-09,2019-12-11 09:17:03.683,,2019-12-11 09:17:03.683,,,,2019-12-11 09:17:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,0.649362613266234
341,AB12345,AB12345-CHN-1-id-307,id-307,CHN-1,24,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.57499101339464,LOW,Y,Y,Y,N,N,2019-03-08,2019-03-11 08:01:26.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,1076,DEATH,2022-04-06,LOST TO FOLLOW UP,OTHER,47,>30,2022-04-06,1121,,2,2,Duration of Confirmed Response,CRSD,123.233002889901,DAYS,2020-09-24 08:01:26.683,563,1,Last Tumor Assessment,Completion or Discontinuation,
342,AB12345,AB12345-CHN-1-id-307,id-307,CHN-1,24,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.57499101339464,LOW,Y,Y,Y,N,N,2019-03-08,2019-03-11 08:01:26.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,1076,DEATH,2022-04-06,LOST TO FOLLOW UP,OTHER,47,>30,2022-04-06,1121,,4,4,Event Free Survival,EFS,76.5238207986113,DAYS,2021-05-27 08:01:26.683,808,1,Adverse Event,Preferred Term,
343,AB12345,AB12345-CHN-1-id-307,id-307,CHN-1,24,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.57499101339464,LOW,Y,Y,Y,N,N,2019-03-08,2019-03-11 08:01:26.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,1076,DEATH,2022-04-06,LOST TO FOLLOW UP,OTHER,47,>30,2022-04-06,1121,,1,1,Overall Survival,OS,401.575879380107,DAYS,2020-07-13 08:01:26.683,490,1,Alive,Alive During Study,
344,AB12345,AB12345-CHN-1-id-307,id-307,CHN-1,24,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.57499101339464,LOW,Y,Y,Y,N,N,2019-03-08,2019-03-11 08:01:26.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,1076,DEATH,2022-04-06,LOST TO FOLLOW UP,OTHER,47,>30,2022-04-06,1121,,3,3,Progression Free Survival,PFS,239.345886697993,DAYS,2021-01-16 08:01:26.683,677,1,Adverse Event,Preferred Term,
345,AB12345,AB12345-CHN-1-id-307,id-307,CHN-1,24,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.57499101339464,LOW,Y,Y,Y,N,N,2019-03-08,2019-03-11 08:01:26.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,2019-03-11 08:01:26.683,2021-02-18 02:48:40.683,2021-02-18 02:48:40.683,2022-02-18 08:48:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,1076,DEATH,2022-04-06,LOST TO FOLLOW UP,OTHER,47,>30,2022-04-06,1121,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-1.04537734629938
346,AB12345,AB12345-CHN-1-id-312,id-312,CHN-1,34,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,11.4892464962912,HIGH,Y,Y,N,Y,N,2020-02-04,2020-02-07 03:04:22.683,,2020-02-07 03:04:22.683,,,,2020-02-07 03:04:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,105.787517060526,DAYS,2020-03-19 03:04:22.683,41,1,Last Tumor Assessment,Completion or Discontinuation,
347,AB12345,AB12345-CHN-1-id-312,id-312,CHN-1,34,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,11.4892464962912,HIGH,Y,Y,N,Y,N,2020-02-04,2020-02-07 03:04:22.683,,2020-02-07 03:04:22.683,,,,2020-02-07 03:04:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,94.8929335619323,DAYS,2020-08-10 03:04:22.683,185,0,Disease Progression,,
348,AB12345,AB12345-CHN-1-id-312,id-312,CHN-1,34,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,11.4892464962912,HIGH,Y,Y,N,Y,N,2020-02-04,2020-02-07 03:04:22.683,,2020-02-07 03:04:22.683,,,,2020-02-07 03:04:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,348.18480880931,DAYS,2021-08-22 03:04:22.683,562,1,Alive,Alive During Study,
349,AB12345,AB12345-CHN-1-id-312,id-312,CHN-1,34,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,11.4892464962912,HIGH,Y,Y,N,Y,N,2020-02-04,2020-02-07 03:04:22.683,,2020-02-07 03:04:22.683,,,,2020-02-07 03:04:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,230.476570455357,DAYS,2020-12-20 03:04:22.683,317,0,Disease Progression,,
350,AB12345,AB12345-CHN-1-id-312,id-312,CHN-1,34,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,11.4892464962912,HIGH,Y,Y,N,Y,N,2020-02-04,2020-02-07 03:04:22.683,,2020-02-07 03:04:22.683,,,,2020-02-07 03:04:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,8,COUNT,,,1,,Completion or Discontinuation,-2.32187347078422
351,AB12345,AB12345-CHN-1-id-315,id-315,CHN-1,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S1,7.43786961197001,HIGH,Y,Y,Y,Y,N,2019-08-21,2019-08-21 07:30:38.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,911,PHYSICIAN DECISION,,,,,,2022-03-07,,,4,4,Duration of Confirmed Response,CRSD,176.298335567117,DAYS,2022-02-02 07:30:38.683,896,1,Adverse Event,Preferred Term,
352,AB12345,AB12345-CHN-1-id-315,id-315,CHN-1,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S1,7.43786961197001,HIGH,Y,Y,Y,Y,N,2019-08-21,2019-08-21 07:30:38.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,911,PHYSICIAN DECISION,,,,,,2022-03-07,,,1,1,Event Free Survival,EFS,47.7422919822857,DAYS,2019-12-16 07:30:38.683,117,1,Last Tumor Assessment,Completion or Discontinuation,
353,AB12345,AB12345-CHN-1-id-315,id-315,CHN-1,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S1,7.43786961197001,HIGH,Y,Y,Y,Y,N,2019-08-21,2019-08-21 07:30:38.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,911,PHYSICIAN DECISION,,,,,,2022-03-07,,,3,3,Overall Survival,OS,435.822243010625,DAYS,2022-01-31 07:30:38.683,894,1,Alive,Alive During Study,
354,AB12345,AB12345-CHN-1-id-315,id-315,CHN-1,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S1,7.43786961197001,HIGH,Y,Y,Y,Y,N,2019-08-21,2019-08-21 07:30:38.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,911,PHYSICIAN DECISION,,,,,,2022-03-07,,,2,2,Progression Free Survival,PFS,286.464699869975,DAYS,2021-08-31 07:30:38.683,741,0,Disease Progression,,
355,AB12345,AB12345-CHN-1-id-315,id-315,CHN-1,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S1,7.43786961197001,HIGH,Y,Y,Y,Y,N,2019-08-21,2019-08-21 07:30:38.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,2019-08-21 07:30:38.683,2021-02-16 21:44:20.683,2021-02-16 21:44:20.683,2022-02-17 03:44:20.683,DISCONTINUED,DISCONTINUED,2022-02-17,911,PHYSICIAN DECISION,,,,,,2022-03-07,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-1.55596139645721
356,AB12345,AB12345-CHN-1-id-316,id-316,CHN-1,25,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,7.57573666592705,LOW,Y,Y,Y,Y,N,2020-09-12,2020-09-15 10:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-12,,,4,4,Duration of Confirmed Response,CRSD,116.505251941271,DAYS,2022-05-29 10:05:42.683,621,0,Death,,
357,AB12345,AB12345-CHN-1-id-316,id-316,CHN-1,25,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,7.57573666592705,LOW,Y,Y,Y,Y,N,2020-09-12,2020-09-15 10:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-12,,,1,1,Event Free Survival,EFS,72.524829962058,DAYS,2020-10-24 10:05:42.683,39,0,Disease Progression,,
358,AB12345,AB12345-CHN-1-id-316,id-316,CHN-1,25,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,7.57573666592705,LOW,Y,Y,Y,Y,N,2020-09-12,2020-09-15 10:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-12,,,3,3,Overall Survival,OS,116.505251941271,DAYS,2022-01-28 10:05:42.683,500,0,Death,,
359,AB12345,AB12345-CHN-1-id-316,id-316,CHN-1,25,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,7.57573666592705,LOW,Y,Y,Y,Y,N,2020-09-12,2020-09-15 10:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-12,,,2,2,Progression Free Survival,PFS,116.505251941271,DAYS,2021-11-29 10:05:42.683,440,0,Death,,
360,AB12345,AB12345-CHN-1-id-316,id-316,CHN-1,25,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,7.57573666592705,LOW,Y,Y,Y,Y,N,2020-09-12,2020-09-15 10:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,2020-09-15 10:05:42.683,2022-09-15 22:05:42.683,2022-09-15 22:05:42.683,2023-09-16 04:05:42.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-12,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.3996746658765
361,AB12345,AB12345-CHN-1-id-329,id-329,CHN-1,48,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.07280943261989,MEDIUM,Y,Y,N,Y,N,2019-07-03,2019-07-06 20:54:49.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,DISCONTINUED,DISCONTINUED,2022-02-13,954,WITHDRAWAL BY SUBJECT,,,,,,2022-03-06,,,3,3,Duration of Confirmed Response,CRSD,171.199343143962,DAYS,2021-01-01 20:54:49.683,545,0,Disease Progression,,
362,AB12345,AB12345-CHN-1-id-329,id-329,CHN-1,48,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.07280943261989,MEDIUM,Y,Y,N,Y,N,2019-07-03,2019-07-06 20:54:49.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,DISCONTINUED,DISCONTINUED,2022-02-13,954,WITHDRAWAL BY SUBJECT,,,,,,2022-03-06,,,2,2,Event Free Survival,EFS,83.2437314931303,DAYS,2020-07-24 20:54:49.683,384,1,Adverse Event,Preferred Term,
363,AB12345,AB12345-CHN-1-id-329,id-329,CHN-1,48,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.07280943261989,MEDIUM,Y,Y,N,Y,N,2019-07-03,2019-07-06 20:54:49.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,DISCONTINUED,DISCONTINUED,2022-02-13,954,WITHDRAWAL BY SUBJECT,,,,,,2022-03-06,,,4,4,Overall Survival,OS,301.498920982704,DAYS,2021-10-16 20:54:49.683,833,1,Alive,Alive During Study,
364,AB12345,AB12345-CHN-1-id-329,id-329,CHN-1,48,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.07280943261989,MEDIUM,Y,Y,N,Y,N,2019-07-03,2019-07-06 20:54:49.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,DISCONTINUED,DISCONTINUED,2022-02-13,954,WITHDRAWAL BY SUBJECT,,,,,,2022-03-06,,,1,1,Progression Free Survival,PFS,292.870308901183,DAYS,2020-03-10 20:54:49.683,248,1,Adverse Event,Preferred Term,
365,AB12345,AB12345-CHN-1-id-329,id-329,CHN-1,48,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.07280943261989,MEDIUM,Y,Y,N,Y,N,2019-07-03,2019-07-06 20:54:49.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,2019-07-06 20:54:49.683,2021-02-13 15:01:33.683,2021-02-13 15:01:33.683,2022-02-13 21:01:33.683,DISCONTINUED,DISCONTINUED,2022-02-13,954,WITHDRAWAL BY SUBJECT,,,,,,2022-03-06,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-2.88017603820047
366,AB12345,AB12345-CHN-1-id-33,id-33,CHN-1,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,5.68514804050855,MEDIUM,Y,Y,Y,Y,N,2020-12-17,2020-12-19 03:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,COMPLETED,COMPLETED,2023-12-19,1096,,,,,,,2024-01-09,,,2,2,Duration of Confirmed Response,CRSD,136.674568080343,DAYS,2023-10-03 03:04:30.683,1018,0,Death,,
367,AB12345,AB12345-CHN-1-id-33,id-33,CHN-1,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,5.68514804050855,MEDIUM,Y,Y,Y,Y,N,2020-12-17,2020-12-19 03:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,COMPLETED,COMPLETED,2023-12-19,1096,,,,,,,2024-01-09,,,4,4,Event Free Survival,EFS,65.6881905405317,DAYS,2023-12-11 03:04:30.683,1087,1,Last Tumor Assessment,Completion or Discontinuation,
368,AB12345,AB12345-CHN-1-id-33,id-33,CHN-1,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,5.68514804050855,MEDIUM,Y,Y,Y,Y,N,2020-12-17,2020-12-19 03:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,COMPLETED,COMPLETED,2023-12-19,1096,,,,,,,2024-01-09,,,1,1,Overall Survival,OS,136.674568080343,DAYS,2022-12-09 03:04:30.683,720,0,Death,,
369,AB12345,AB12345-CHN-1-id-33,id-33,CHN-1,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,5.68514804050855,MEDIUM,Y,Y,Y,Y,N,2020-12-17,2020-12-19 03:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,COMPLETED,COMPLETED,2023-12-19,1096,,,,,,,2024-01-09,,,3,3,Progression Free Survival,PFS,136.674568080343,DAYS,2023-12-04 03:04:30.683,1080,0,Death,,
370,AB12345,AB12345-CHN-1-id-33,id-33,CHN-1,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,5.68514804050855,MEDIUM,Y,Y,Y,Y,N,2020-12-17,2020-12-19 03:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,2020-12-19 03:04:30.683,2022-12-19 15:04:30.683,2022-12-19 15:04:30.683,2023-12-19 21:04:30.683,COMPLETED,COMPLETED,2023-12-19,1096,,,,,,,2024-01-09,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,0.237369390190926
371,AB12345,AB12345-CHN-1-id-336,id-336,CHN-1,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.82924971680894,HIGH,Y,Y,N,Y,N,2020-08-22,2020-08-24 00:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,COMPLETED,COMPLETED,2023-08-24,1096,,,,,,,2023-09-06,,,4,4,Duration of Confirmed Response,CRSD,176.208739052527,DAYS,2023-03-31 00:07:59.683,949,0,Disease Progression,,
372,AB12345,AB12345-CHN-1-id-336,id-336,CHN-1,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.82924971680894,HIGH,Y,Y,N,Y,N,2020-08-22,2020-08-24 00:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,COMPLETED,COMPLETED,2023-08-24,1096,,,,,,,2023-09-06,,,1,1,Event Free Survival,EFS,78.0672082060482,DAYS,2021-07-21 00:07:59.683,331,0,Disease Progression,,
373,AB12345,AB12345-CHN-1-id-336,id-336,CHN-1,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.82924971680894,HIGH,Y,Y,N,Y,N,2020-08-22,2020-08-24 00:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,COMPLETED,COMPLETED,2023-08-24,1096,,,,,,,2023-09-06,,,2,2,Overall Survival,OS,226.072295918129,DAYS,2022-02-10 00:07:59.683,535,0,Death,,
374,AB12345,AB12345-CHN-1-id-336,id-336,CHN-1,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.82924971680894,HIGH,Y,Y,N,Y,N,2020-08-22,2020-08-24 00:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,COMPLETED,COMPLETED,2023-08-24,1096,,,,,,,2023-09-06,,,3,3,Progression Free Survival,PFS,226.072295918129,DAYS,2022-08-29 00:07:59.683,735,0,Death,,
375,AB12345,AB12345-CHN-1-id-336,id-336,CHN-1,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.82924971680894,HIGH,Y,Y,N,Y,N,2020-08-22,2020-08-24 00:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,2020-08-24 00:07:59.683,2022-08-24 12:07:59.683,2022-08-24 12:07:59.683,2023-08-24 18:07:59.683,COMPLETED,COMPLETED,2023-08-24,1096,,,,,,,2023-09-06,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-0.853675974184912
376,AB12345,AB12345-CHN-1-id-337,id-337,CHN-1,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,2.22759227424312,LOW,Y,Y,Y,N,N,2020-06-03,2020-06-05 23:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,COMPLETED,COMPLETED,2023-06-06,1096,,,,,,,2023-07-03,,,3,3,Duration of Confirmed Response,CRSD,167.884080996737,DAYS,2022-07-01 23:39:55.683,756,1,Last Tumor Assessment,Completion or Discontinuation,
377,AB12345,AB12345-CHN-1-id-337,id-337,CHN-1,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,2.22759227424312,LOW,Y,Y,Y,N,N,2020-06-03,2020-06-05 23:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,COMPLETED,COMPLETED,2023-06-06,1096,,,,,,,2023-07-03,,,1,1,Event Free Survival,EFS,36.6695499152411,DAYS,2022-04-24 23:39:55.683,688,0,Disease Progression,,
378,AB12345,AB12345-CHN-1-id-337,id-337,CHN-1,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,2.22759227424312,LOW,Y,Y,Y,N,N,2020-06-03,2020-06-05 23:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,COMPLETED,COMPLETED,2023-06-06,1096,,,,,,,2023-07-03,,,4,4,Overall Survival,OS,248.548066243529,DAYS,2023-01-27 23:39:55.683,966,0,Death,,
379,AB12345,AB12345-CHN-1-id-337,id-337,CHN-1,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,2.22759227424312,LOW,Y,Y,Y,N,N,2020-06-03,2020-06-05 23:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,COMPLETED,COMPLETED,2023-06-06,1096,,,,,,,2023-07-03,,,2,2,Progression Free Survival,PFS,248.548066243529,DAYS,2022-06-11 23:39:55.683,736,0,Death,,
380,AB12345,AB12345-CHN-1-id-337,id-337,CHN-1,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,2.22759227424312,LOW,Y,Y,Y,N,N,2020-06-03,2020-06-05 23:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,2020-06-05 23:39:55.683,2022-06-06 11:39:55.683,2022-06-06 11:39:55.683,2023-06-06 17:39:55.683,COMPLETED,COMPLETED,2023-06-06,1096,,,,,,,2023-07-03,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-1.34152570673449
381,AB12345,AB12345-CHN-1-id-344,id-344,CHN-1,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.58443329532852,LOW,Y,Y,Y,N,N,2020-11-13,2020-11-16 18:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,COMPLETED,COMPLETED,2023-11-17,1096,,,,,,,2023-12-09,,,4,4,Duration of Confirmed Response,CRSD,105.554798268713,DAYS,2023-11-16 18:51:26.683,1095,1,Last Tumor Assessment,Completion or Discontinuation,
382,AB12345,AB12345-CHN-1-id-344,id-344,CHN-1,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.58443329532852,LOW,Y,Y,Y,N,N,2020-11-13,2020-11-16 18:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,COMPLETED,COMPLETED,2023-11-17,1096,,,,,,,2023-12-09,,,3,3,Event Free Survival,EFS,47.1796850673854,DAYS,2022-12-09 18:51:26.683,753,1,Last Tumor Assessment,Completion or Discontinuation,
383,AB12345,AB12345-CHN-1-id-344,id-344,CHN-1,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.58443329532852,LOW,Y,Y,Y,N,N,2020-11-13,2020-11-16 18:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,COMPLETED,COMPLETED,2023-11-17,1096,,,,,,,2023-12-09,,,2,2,Overall Survival,OS,460.34466275014,DAYS,2022-04-24 18:51:26.683,524,1,Alive,Alive During Study,
384,AB12345,AB12345-CHN-1-id-344,id-344,CHN-1,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.58443329532852,LOW,Y,Y,Y,N,N,2020-11-13,2020-11-16 18:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,COMPLETED,COMPLETED,2023-11-17,1096,,,,,,,2023-12-09,,,1,1,Progression Free Survival,PFS,289.902589842677,DAYS,2021-08-17 18:51:26.683,274,1,Adverse Event,Preferred Term,
385,AB12345,AB12345-CHN-1-id-344,id-344,CHN-1,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S2,2.58443329532852,LOW,Y,Y,Y,N,N,2020-11-13,2020-11-16 18:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,2020-11-16 18:51:26.683,2022-11-17 06:51:26.683,2022-11-17 06:51:26.683,2023-11-17 12:51:26.683,COMPLETED,COMPLETED,2023-11-17,1096,,,,,,,2023-12-09,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.401173749785207
386,AB12345,AB12345-CHN-1-id-346,id-346,CHN-1,21,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,3.08003973208152,LOW,Y,Y,N,N,N,2019-11-20,2019-11-23 18:34:29.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,DISCONTINUED,DISCONTINUED,2022-02-12,812,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-07,834,Yes,2,2,Duration of Confirmed Response,CRSD,103.212875919417,DAYS,2020-06-14 18:34:29.683,204,1,Adverse Event,Preferred Term,
387,AB12345,AB12345-CHN-1-id-346,id-346,CHN-1,21,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,3.08003973208152,LOW,Y,Y,N,N,N,2019-11-20,2019-11-23 18:34:29.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,DISCONTINUED,DISCONTINUED,2022-02-12,812,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-07,834,Yes,1,1,Event Free Survival,EFS,55.8861092559528,DAYS,2019-12-05 18:34:29.683,12,1,Last Tumor Assessment,Completion or Discontinuation,
388,AB12345,AB12345-CHN-1-id-346,id-346,CHN-1,21,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,3.08003973208152,LOW,Y,Y,N,N,N,2019-11-20,2019-11-23 18:34:29.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,DISCONTINUED,DISCONTINUED,2022-02-12,812,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-07,834,Yes,4,4,Overall Survival,OS,374.62025443092,DAYS,2021-05-21 18:34:29.683,545,1,Alive,Alive During Study,
389,AB12345,AB12345-CHN-1-id-346,id-346,CHN-1,21,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,3.08003973208152,LOW,Y,Y,N,N,N,2019-11-20,2019-11-23 18:34:29.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,DISCONTINUED,DISCONTINUED,2022-02-12,812,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-07,834,Yes,3,3,Progression Free Survival,PFS,251.200681226328,DAYS,2020-08-14 18:34:29.683,265,1,Adverse Event,Preferred Term,
390,AB12345,AB12345-CHN-1-id-346,id-346,CHN-1,21,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,3.08003973208152,LOW,Y,Y,N,N,N,2019-11-20,2019-11-23 18:34:29.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,2019-11-23 18:34:29.683,2021-02-12 10:44:55.683,2021-02-12 10:44:55.683,2022-02-12 16:44:55.683,DISCONTINUED,DISCONTINUED,2022-02-12,812,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,23,<=30,2022-03-07,834,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-0.374798192068644
391,AB12345,AB12345-CHN-1-id-347,id-347,CHN-1,33,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S2,1.15630749564302,LOW,Y,Y,Y,N,N,2020-09-25,2020-09-26 15:42:32.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,DISCONTINUED,DISCONTINUED,2022-02-17,509,WITHDRAWAL BY SUBJECT,,,,,,2022-03-16,,,2,2,Duration of Confirmed Response,CRSD,139.926573680714,DAYS,2021-03-19 15:42:32.683,174,0,Disease Progression,,
392,AB12345,AB12345-CHN-1-id-347,id-347,CHN-1,33,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S2,1.15630749564302,LOW,Y,Y,Y,N,N,2020-09-25,2020-09-26 15:42:32.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,DISCONTINUED,DISCONTINUED,2022-02-17,509,WITHDRAWAL BY SUBJECT,,,,,,2022-03-16,,,4,4,Event Free Survival,EFS,57.3785932094324,DAYS,2021-10-11 15:42:32.683,380,1,Adverse Event,Preferred Term,
393,AB12345,AB12345-CHN-1-id-347,id-347,CHN-1,33,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S2,1.15630749564302,LOW,Y,Y,Y,N,N,2020-09-25,2020-09-26 15:42:32.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,DISCONTINUED,DISCONTINUED,2022-02-17,509,WITHDRAWAL BY SUBJECT,,,,,,2022-03-16,,,3,3,Overall Survival,OS,404.857805697247,DAYS,2021-10-06 15:42:32.683,375,1,Alive,Alive During Study,
394,AB12345,AB12345-CHN-1-id-347,id-347,CHN-1,33,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S2,1.15630749564302,LOW,Y,Y,Y,N,N,2020-09-25,2020-09-26 15:42:32.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,DISCONTINUED,DISCONTINUED,2022-02-17,509,WITHDRAWAL BY SUBJECT,,,,,,2022-03-16,,,1,1,Progression Free Survival,PFS,202.094694459811,DAYS,2021-02-15 15:42:32.683,142,1,Last Tumor Assessment,Completion or Discontinuation,
395,AB12345,AB12345-CHN-1-id-347,id-347,CHN-1,33,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,C,S2,1.15630749564302,LOW,Y,Y,Y,N,N,2020-09-25,2020-09-26 15:42:32.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,2020-09-26 15:42:32.683,2021-02-17 05:49:19.683,2021-02-17 05:49:19.683,2022-02-17 11:49:19.683,DISCONTINUED,DISCONTINUED,2022-02-17,509,WITHDRAWAL BY SUBJECT,,,,,,2022-03-16,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-0.337301744846847
396,AB12345,AB12345-CHN-1-id-351,id-351,CHN-1,33,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,6.36685490236971,MEDIUM,Y,Y,Y,N,N,2020-07-29,2020-08-01 17:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,COMPLETED,COMPLETED,2023-08-02,1096,,,,,,,2023-08-23,,,3,3,Duration of Confirmed Response,CRSD,28.633902228903,DAYS,2022-06-26 17:04:14.683,694,0,Death,,
397,AB12345,AB12345-CHN-1-id-351,id-351,CHN-1,33,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,6.36685490236971,MEDIUM,Y,Y,Y,N,N,2020-07-29,2020-08-01 17:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,COMPLETED,COMPLETED,2023-08-02,1096,,,,,,,2023-08-23,,,2,2,Event Free Survival,EFS,28.633902228903,DAYS,2022-06-19 17:04:14.683,687,0,Death,,
398,AB12345,AB12345-CHN-1-id-351,id-351,CHN-1,33,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,6.36685490236971,MEDIUM,Y,Y,Y,N,N,2020-07-29,2020-08-01 17:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,COMPLETED,COMPLETED,2023-08-02,1096,,,,,,,2023-08-23,,,4,4,Overall Survival,OS,28.633902228903,DAYS,2023-04-20 17:04:14.683,992,0,Death,,
399,AB12345,AB12345-CHN-1-id-351,id-351,CHN-1,33,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,6.36685490236971,MEDIUM,Y,Y,Y,N,N,2020-07-29,2020-08-01 17:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,COMPLETED,COMPLETED,2023-08-02,1096,,,,,,,2023-08-23,,,1,1,Progression Free Survival,PFS,28.633902228903,DAYS,2021-03-25 17:04:14.683,236,0,Death,,
400,AB12345,AB12345-CHN-1-id-351,id-351,CHN-1,33,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,6.36685490236971,MEDIUM,Y,Y,Y,N,N,2020-07-29,2020-08-01 17:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,2020-08-01 17:04:14.683,2022-08-02 05:04:14.683,2022-08-02 05:04:14.683,2023-08-02 11:04:14.683,COMPLETED,COMPLETED,2023-08-02,1096,,,,,,,2023-08-23,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-3.76855753849333
401,AB12345,AB12345-CHN-1-id-360,id-360,CHN-1,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,3.84994595960248,LOW,Y,Y,Y,N,N,2020-05-10,2020-05-12 21:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,COMPLETED,COMPLETED,2023-05-13,1096,,,,,,,2023-06-06,,,2,2,Duration of Confirmed Response,CRSD,32.4347099894658,DAYS,2020-11-12 21:14:06.683,184,0,Death,,
402,AB12345,AB12345-CHN-1-id-360,id-360,CHN-1,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,3.84994595960248,LOW,Y,Y,Y,N,N,2020-05-10,2020-05-12 21:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,COMPLETED,COMPLETED,2023-05-13,1096,,,,,,,2023-06-06,,,3,3,Event Free Survival,EFS,32.4347099894658,DAYS,2022-02-13 21:14:06.683,642,0,Death,,
403,AB12345,AB12345-CHN-1-id-360,id-360,CHN-1,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,3.84994595960248,LOW,Y,Y,Y,N,N,2020-05-10,2020-05-12 21:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,COMPLETED,COMPLETED,2023-05-13,1096,,,,,,,2023-06-06,,,1,1,Overall Survival,OS,32.4347099894658,DAYS,2020-09-13 21:14:06.683,124,0,Death,,
404,AB12345,AB12345-CHN-1-id-360,id-360,CHN-1,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,3.84994595960248,LOW,Y,Y,Y,N,N,2020-05-10,2020-05-12 21:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,COMPLETED,COMPLETED,2023-05-13,1096,,,,,,,2023-06-06,,,4,4,Progression Free Survival,PFS,32.4347099894658,DAYS,2022-05-30 21:14:06.683,748,0,Death,,
405,AB12345,AB12345-CHN-1-id-360,id-360,CHN-1,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,3.84994595960248,LOW,Y,Y,Y,N,N,2020-05-10,2020-05-12 21:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,2020-05-12 21:14:06.683,2022-05-13 09:14:06.683,2022-05-13 09:14:06.683,2023-05-13 15:14:06.683,COMPLETED,COMPLETED,2023-05-13,1096,,,,,,,2023-06-06,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.35481653210417
406,AB12345,AB12345-CHN-1-id-371,id-371,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,6.32686260477006,LOW,Y,Y,N,Y,N,2021-02-07,2021-02-09 05:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,COMPLETED,COMPLETED,2024-02-09,1096,,,,,,,2024-02-29,,,4,4,Duration of Confirmed Response,CRSD,196.635487512685,DAYS,2023-12-06 05:50:09.683,1030,0,Disease Progression,,
407,AB12345,AB12345-CHN-1-id-371,id-371,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,6.32686260477006,LOW,Y,Y,N,Y,N,2021-02-07,2021-02-09 05:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,COMPLETED,COMPLETED,2024-02-09,1096,,,,,,,2024-02-29,,,2,2,Event Free Survival,EFS,97.8942708321847,DAYS,2022-09-10 05:50:09.683,578,1,Last Tumor Assessment,Completion or Discontinuation,
408,AB12345,AB12345-CHN-1-id-371,id-371,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,6.32686260477006,LOW,Y,Y,N,Y,N,2021-02-07,2021-02-09 05:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,COMPLETED,COMPLETED,2024-02-09,1096,,,,,,,2024-02-29,,,3,3,Overall Survival,OS,276.007032231428,DAYS,2022-11-16 05:50:09.683,645,0,Death,,
409,AB12345,AB12345-CHN-1-id-371,id-371,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,6.32686260477006,LOW,Y,Y,N,Y,N,2021-02-07,2021-02-09 05:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,COMPLETED,COMPLETED,2024-02-09,1096,,,,,,,2024-02-29,,,1,1,Progression Free Survival,PFS,276.007032231428,DAYS,2021-07-22 05:50:09.683,163,0,Death,,
410,AB12345,AB12345-CHN-1-id-371,id-371,CHN-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,A,S2,6.32686260477006,LOW,Y,Y,N,Y,N,2021-02-07,2021-02-09 05:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,2021-02-09 05:50:09.683,2023-02-09 17:50:09.683,2023-02-09 17:50:09.683,2024-02-09 23:50:09.683,COMPLETED,COMPLETED,2024-02-09,1096,,,,,,,2024-02-29,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.818970481338391
411,AB12345,AB12345-CHN-1-id-376,id-376,CHN-1,41,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S1,21.3933676083323,LOW,Y,Y,Y,Y,N,2019-09-26,2019-09-30 23:42:56.683,,2019-09-30 23:42:56.683,,,,2019-09-30 23:42:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,151.582387601957,DAYS,2020-02-07 23:42:56.683,130,1,Last Tumor Assessment,Completion or Discontinuation,
412,AB12345,AB12345-CHN-1-id-376,id-376,CHN-1,41,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S1,21.3933676083323,LOW,Y,Y,Y,Y,N,2019-09-26,2019-09-30 23:42:56.683,,2019-09-30 23:42:56.683,,,,2019-09-30 23:42:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,21.4914952334948,DAYS,2021-07-02 23:42:56.683,641,1,Last Tumor Assessment,Completion or Discontinuation,
413,AB12345,AB12345-CHN-1-id-376,id-376,CHN-1,41,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S1,21.3933676083323,LOW,Y,Y,Y,Y,N,2019-09-26,2019-09-30 23:42:56.683,,2019-09-30 23:42:56.683,,,,2019-09-30 23:42:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,387.404818180948,DAYS,2020-01-11 23:42:56.683,103,1,Alive,Alive During Study,
414,AB12345,AB12345-CHN-1-id-376,id-376,CHN-1,41,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S1,21.3933676083323,LOW,Y,Y,Y,Y,N,2019-09-26,2019-09-30 23:42:56.683,,2019-09-30 23:42:56.683,,,,2019-09-30 23:42:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,260.030519450083,DAYS,2020-09-07 23:42:56.683,343,1,Adverse Event,Preferred Term,
415,AB12345,AB12345-CHN-1-id-376,id-376,CHN-1,41,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,C,S1,21.3933676083323,LOW,Y,Y,Y,Y,N,2019-09-26,2019-09-30 23:42:56.683,,2019-09-30 23:42:56.683,,,,2019-09-30 23:42:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-2.1055683396467
416,AB12345,AB12345-CHN-1-id-389,id-389,CHN-1,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.82133050184039,LOW,Y,Y,Y,N,N,2020-06-30,2020-07-02 12:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,COMPLETED,COMPLETED,2023-07-03,1096,,,,,,,2023-07-13,,,3,3,Duration of Confirmed Response,CRSD,143.55515181087,DAYS,2021-05-16 12:07:49.683,318,0,Disease Progression,,
417,AB12345,AB12345-CHN-1-id-389,id-389,CHN-1,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.82133050184039,LOW,Y,Y,Y,N,N,2020-06-30,2020-07-02 12:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,COMPLETED,COMPLETED,2023-07-03,1096,,,,,,,2023-07-13,,,1,1,Event Free Survival,EFS,15.1395921991207,DAYS,2020-10-18 12:07:49.683,108,0,Disease Progression,,
418,AB12345,AB12345-CHN-1-id-389,id-389,CHN-1,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.82133050184039,LOW,Y,Y,Y,N,N,2020-06-30,2020-07-02 12:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,COMPLETED,COMPLETED,2023-07-03,1096,,,,,,,2023-07-13,,,4,4,Overall Survival,OS,250.096376892179,DAYS,2022-09-01 12:07:49.683,791,0,Death,,
419,AB12345,AB12345-CHN-1-id-389,id-389,CHN-1,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.82133050184039,LOW,Y,Y,Y,N,N,2020-06-30,2020-07-02 12:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,COMPLETED,COMPLETED,2023-07-03,1096,,,,,,,2023-07-13,,,2,2,Progression Free Survival,PFS,250.096376892179,DAYS,2021-03-28 12:07:49.683,269,0,Death,,
420,AB12345,AB12345-CHN-1-id-389,id-389,CHN-1,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.82133050184039,LOW,Y,Y,Y,N,N,2020-06-30,2020-07-02 12:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,2020-07-02 12:07:49.683,2022-07-03 00:07:49.683,2022-07-03 00:07:49.683,2023-07-03 06:07:49.683,COMPLETED,COMPLETED,2023-07-03,1096,,,,,,,2023-07-13,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-4.29648790602367
421,AB12345,AB12345-CHN-1-id-400,id-400,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,2.77614881299282,MEDIUM,Y,Y,Y,Y,N,2019-09-13,2019-09-16 18:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,COMPLETED,COMPLETED,2022-09-16,1096,,,,,,,2022-09-30,,,2,2,Duration of Confirmed Response,CRSD,169.485710677691,DAYS,2020-08-08 18:27:24.683,327,1,Adverse Event,Preferred Term,
422,AB12345,AB12345-CHN-1-id-400,id-400,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,2.77614881299282,MEDIUM,Y,Y,Y,Y,N,2019-09-13,2019-09-16 18:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,COMPLETED,COMPLETED,2022-09-16,1096,,,,,,,2022-09-30,,,3,3,Event Free Survival,EFS,71.9164000195451,DAYS,2021-04-25 18:27:24.683,587,0,Disease Progression,,
423,AB12345,AB12345-CHN-1-id-400,id-400,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,2.77614881299282,MEDIUM,Y,Y,Y,Y,N,2019-09-13,2019-09-16 18:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,COMPLETED,COMPLETED,2022-09-16,1096,,,,,,,2022-09-30,,,4,4,Overall Survival,OS,327.804569108412,DAYS,2022-06-09 18:27:24.683,997,1,Alive,Alive During Study,
424,AB12345,AB12345-CHN-1-id-400,id-400,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,2.77614881299282,MEDIUM,Y,Y,Y,Y,N,2019-09-13,2019-09-16 18:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,COMPLETED,COMPLETED,2022-09-16,1096,,,,,,,2022-09-30,,,1,1,Progression Free Survival,PFS,278.251031436957,DAYS,2020-04-21 18:27:24.683,218,0,Disease Progression,,
425,AB12345,AB12345-CHN-1-id-400,id-400,CHN-1,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,2.77614881299282,MEDIUM,Y,Y,Y,Y,N,2019-09-13,2019-09-16 18:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,2019-09-16 18:27:24.683,2021-09-16 06:27:24.683,2021-09-16 06:27:24.683,2022-09-16 12:27:24.683,COMPLETED,COMPLETED,2022-09-16,1096,,,,,,,2022-09-30,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-1.75616374568346
426,AB12345,AB12345-CHN-1-id-47,id-47,CHN-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,6.39866078857197,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-19 04:58:38.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,DISCONTINUED,DISCONTINUED,2022-02-17,760,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-01,,,4,4,Duration of Confirmed Response,CRSD,175.954291014932,DAYS,2021-04-16 04:58:38.683,453,0,Disease Progression,,
427,AB12345,AB12345-CHN-1-id-47,id-47,CHN-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,6.39866078857197,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-19 04:58:38.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,DISCONTINUED,DISCONTINUED,2022-02-17,760,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-01,,,1,1,Event Free Survival,EFS,28.875882566208,DAYS,2020-02-13 04:58:38.683,25,1,Last Tumor Assessment,Completion or Discontinuation,
428,AB12345,AB12345-CHN-1-id-47,id-47,CHN-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,6.39866078857197,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-19 04:58:38.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,DISCONTINUED,DISCONTINUED,2022-02-17,760,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-01,,,3,3,Overall Survival,OS,425.933766085654,DAYS,2021-04-02 04:58:38.683,439,1,Alive,Alive During Study,
429,AB12345,AB12345-CHN-1-id-47,id-47,CHN-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,6.39866078857197,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-19 04:58:38.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,DISCONTINUED,DISCONTINUED,2022-02-17,760,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-01,,,2,2,Progression Free Survival,PFS,244.370361743495,DAYS,2020-05-12 04:58:38.683,114,1,Last Tumor Assessment,Completion or Discontinuation,
430,AB12345,AB12345-CHN-1-id-47,id-47,CHN-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,6.39866078857197,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-19 04:58:38.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,2020-01-19 04:58:38.683,2021-02-16 22:06:46.683,2021-02-16 22:06:46.683,2022-02-17 04:06:46.683,DISCONTINUED,DISCONTINUED,2022-02-17,760,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-01,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.327600789462172
431,AB12345,AB12345-CHN-1-id-53,id-53,CHN-1,48,YEARS,M,WHITE,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.90562383077701,MEDIUM,Y,Y,Y,N,N,2019-11-04,2019-11-07 07:28:03.683,,2019-11-07 07:28:03.683,,,,2019-11-07 07:28:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,183.554889727384,DAYS,2020-11-01 07:28:03.683,360,1,Last Tumor Assessment,Completion or Discontinuation,
432,AB12345,AB12345-CHN-1-id-53,id-53,CHN-1,48,YEARS,M,WHITE,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.90562383077701,MEDIUM,Y,Y,Y,N,N,2019-11-04,2019-11-07 07:28:03.683,,2019-11-07 07:28:03.683,,,,2019-11-07 07:28:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,23.8835931255016,DAYS,2020-10-03 07:28:03.683,331,1,Last Tumor Assessment,Completion or Discontinuation,
433,AB12345,AB12345-CHN-1-id-53,id-53,CHN-1,48,YEARS,M,WHITE,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.90562383077701,MEDIUM,Y,Y,Y,N,N,2019-11-04,2019-11-07 07:28:03.683,,2019-11-07 07:28:03.683,,,,2019-11-07 07:28:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,339.903837721795,DAYS,2020-08-12 07:28:03.683,279,1,Alive,Alive During Study,
434,AB12345,AB12345-CHN-1-id-53,id-53,CHN-1,48,YEARS,M,WHITE,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.90562383077701,MEDIUM,Y,Y,Y,N,N,2019-11-04,2019-11-07 07:28:03.683,,2019-11-07 07:28:03.683,,,,2019-11-07 07:28:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,233.394936192781,DAYS,2020-11-25 07:28:03.683,384,1,Last Tumor Assessment,Completion or Discontinuation,
435,AB12345,AB12345-CHN-1-id-53,id-53,CHN-1,48,YEARS,M,WHITE,UNKNOWN,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.90562383077701,MEDIUM,Y,Y,Y,N,N,2019-11-04,2019-11-07 07:28:03.683,,2019-11-07 07:28:03.683,,,,2019-11-07 07:28:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-2.59648594277927
436,AB12345,AB12345-CHN-1-id-62,id-62,CHN-1,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.50974181996973,MEDIUM,Y,Y,N,Y,Y,2020-11-21,2020-11-22 01:52:11.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,DISCONTINUED,DISCONTINUED,2022-02-19,455,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,44,>30,2022-04-04,497,Yes,2,2,Duration of Confirmed Response,CRSD,116.587876272388,DAYS,2021-06-06 01:52:11.683,196,0,Disease Progression,,
437,AB12345,AB12345-CHN-1-id-62,id-62,CHN-1,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.50974181996973,MEDIUM,Y,Y,N,Y,Y,2020-11-21,2020-11-22 01:52:11.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,DISCONTINUED,DISCONTINUED,2022-02-19,455,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,44,>30,2022-04-04,497,Yes,4,4,Event Free Survival,EFS,74.0363654994871,DAYS,2022-01-17 01:52:11.683,421,0,Disease Progression,,
438,AB12345,AB12345-CHN-1-id-62,id-62,CHN-1,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.50974181996973,MEDIUM,Y,Y,N,Y,Y,2020-11-21,2020-11-22 01:52:11.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,DISCONTINUED,DISCONTINUED,2022-02-19,455,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,44,>30,2022-04-04,497,Yes,3,3,Overall Survival,OS,307.647237693891,DAYS,2021-12-24 01:52:11.683,397,1,Alive,Alive During Study,
439,AB12345,AB12345-CHN-1-id-62,id-62,CHN-1,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.50974181996973,MEDIUM,Y,Y,N,Y,Y,2020-11-21,2020-11-22 01:52:11.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,DISCONTINUED,DISCONTINUED,2022-02-19,455,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,44,>30,2022-04-04,497,Yes,1,1,Progression Free Survival,PFS,207.3963903822,DAYS,2021-03-13 01:52:11.683,111,0,Disease Progression,,
440,AB12345,AB12345-CHN-1-id-62,id-62,CHN-1,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.50974181996973,MEDIUM,Y,Y,N,Y,Y,2020-11-21,2020-11-22 01:52:11.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,2020-11-22 01:52:11.683,2021-02-19 08:41:59.683,2021-02-19 08:41:59.683,2022-02-19 14:41:59.683,DISCONTINUED,DISCONTINUED,2022-02-19,455,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,44,>30,2022-04-04,497,Yes,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.70885375591723
441,AB12345,AB12345-CHN-1-id-64,id-64,CHN-1,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S2,3.16062621879917,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-28 02:41:32.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,DISCONTINUED,DISCONTINUED,2022-02-14,1024,PHYSICIAN DECISION,,,,,,2022-03-03,,,1,1,Duration of Confirmed Response,CRSD,137.354819732718,DAYS,2019-07-29 02:41:32.683,92,1,Last Tumor Assessment,Completion or Discontinuation,
442,AB12345,AB12345-CHN-1-id-64,id-64,CHN-1,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S2,3.16062621879917,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-28 02:41:32.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,DISCONTINUED,DISCONTINUED,2022-02-14,1024,PHYSICIAN DECISION,,,,,,2022-03-03,,,2,2,Event Free Survival,EFS,86.9117184099741,DAYS,2019-10-31 02:41:32.683,186,1,Last Tumor Assessment,Completion or Discontinuation,
443,AB12345,AB12345-CHN-1-id-64,id-64,CHN-1,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S2,3.16062621879917,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-28 02:41:32.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,DISCONTINUED,DISCONTINUED,2022-02-14,1024,PHYSICIAN DECISION,,,,,,2022-03-03,,,4,4,Overall Survival,OS,318.06355449371,DAYS,2021-09-25 02:41:32.683,881,1,Alive,Alive During Study,
444,AB12345,AB12345-CHN-1-id-64,id-64,CHN-1,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S2,3.16062621879917,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-28 02:41:32.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,DISCONTINUED,DISCONTINUED,2022-02-14,1024,PHYSICIAN DECISION,,,,,,2022-03-03,,,3,3,Progression Free Survival,PFS,288.07106972672,DAYS,2019-12-28 02:41:32.683,244,1,Adverse Event,Preferred Term,
445,AB12345,AB12345-CHN-1-id-64,id-64,CHN-1,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S2,3.16062621879917,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-28 02:41:32.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,2019-04-28 02:41:32.683,2021-02-14 04:26:53.683,2021-02-14 04:26:53.683,2022-02-14 10:26:53.683,DISCONTINUED,DISCONTINUED,2022-02-14,1024,PHYSICIAN DECISION,,,,,,2022-03-03,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,1,,Completion or Discontinuation,-0.553489404532199
446,AB12345,AB12345-CHN-1-id-69,id-69,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S1,8.54000465346121,LOW,Y,Y,N,Y,N,2020-04-01,2020-04-04 18:42:05.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,DISCONTINUED,DISCONTINUED,2022-02-19,686,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-19,,,2,2,Duration of Confirmed Response,CRSD,175.432273605838,DAYS,2020-12-08 18:42:05.683,248,0,Disease Progression,,
447,AB12345,AB12345-CHN-1-id-69,id-69,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S1,8.54000465346121,LOW,Y,Y,N,Y,N,2020-04-01,2020-04-04 18:42:05.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,DISCONTINUED,DISCONTINUED,2022-02-19,686,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-19,,,4,4,Event Free Survival,EFS,57.1521299530286,DAYS,2021-10-27 18:42:05.683,571,1,Last Tumor Assessment,Completion or Discontinuation,
448,AB12345,AB12345-CHN-1-id-69,id-69,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S1,8.54000465346121,LOW,Y,Y,N,Y,N,2020-04-01,2020-04-04 18:42:05.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,DISCONTINUED,DISCONTINUED,2022-02-19,686,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-19,,,3,3,Overall Survival,OS,260.589081305079,DAYS,2021-09-13 18:42:05.683,527,0,Death,,
449,AB12345,AB12345-CHN-1-id-69,id-69,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S1,8.54000465346121,LOW,Y,Y,N,Y,N,2020-04-01,2020-04-04 18:42:05.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,DISCONTINUED,DISCONTINUED,2022-02-19,686,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-19,,,1,1,Progression Free Survival,PFS,260.589081305079,DAYS,2020-08-10 18:42:05.683,128,0,Death,,
450,AB12345,AB12345-CHN-1-id-69,id-69,CHN-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S1,8.54000465346121,LOW,Y,Y,N,Y,N,2020-04-01,2020-04-04 18:42:05.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,2020-04-04 18:42:05.683,2021-02-19 09:27:41.683,2021-02-19 09:27:41.683,2022-02-19 15:27:41.683,DISCONTINUED,DISCONTINUED,2022-02-19,686,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-19,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.90844032284321
451,AB12345,AB12345-CHN-1-id-71,id-71,CHN-1,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S1,7.7014341766477,MEDIUM,Y,Y,Y,Y,N,2020-12-21,2020-12-24 12:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,COMPLETED,COMPLETED,2023-12-25,1096,,,,,,,2024-01-10,,,3,3,Duration of Confirmed Response,CRSD,191.020668274723,DAYS,2022-05-30 12:35:40.683,522,0,Death,,
452,AB12345,AB12345-CHN-1-id-71,id-71,CHN-1,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S1,7.7014341766477,MEDIUM,Y,Y,Y,Y,N,2020-12-21,2020-12-24 12:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,COMPLETED,COMPLETED,2023-12-25,1096,,,,,,,2024-01-10,,,2,2,Event Free Survival,EFS,59.9150877073407,DAYS,2022-04-21 12:35:40.683,483,0,Disease Progression,,
453,AB12345,AB12345-CHN-1-id-71,id-71,CHN-1,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S1,7.7014341766477,MEDIUM,Y,Y,Y,Y,N,2020-12-21,2020-12-24 12:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,COMPLETED,COMPLETED,2023-12-25,1096,,,,,,,2024-01-10,,,1,1,Overall Survival,OS,191.020668274723,DAYS,2021-03-31 12:35:40.683,97,0,Death,,
454,AB12345,AB12345-CHN-1-id-71,id-71,CHN-1,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S1,7.7014341766477,MEDIUM,Y,Y,Y,Y,N,2020-12-21,2020-12-24 12:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,COMPLETED,COMPLETED,2023-12-25,1096,,,,,,,2024-01-10,,,4,4,Progression Free Survival,PFS,191.020668274723,DAYS,2023-12-03 12:35:40.683,1074,0,Death,,
455,AB12345,AB12345-CHN-1-id-71,id-71,CHN-1,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,A,S1,7.7014341766477,MEDIUM,Y,Y,Y,Y,N,2020-12-21,2020-12-24 12:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,2020-12-24 12:35:40.683,2022-12-25 00:35:40.683,2022-12-25 00:35:40.683,2023-12-25 06:35:40.683,COMPLETED,COMPLETED,2023-12-25,1096,,,,,,,2024-01-10,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.00017715625125
456,AB12345,AB12345-CHN-1-id-74,id-74,CHN-1,23,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,1.80317629354182,LOW,Y,Y,N,Y,N,2020-01-18,2020-01-18 04:01:51.683,,2020-01-18 04:01:51.683,,,,2020-01-18 04:01:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,127.974256197922,DAYS,2021-04-26 04:01:51.683,464,1,Adverse Event,Preferred Term,
457,AB12345,AB12345-CHN-1-id-74,id-74,CHN-1,23,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,1.80317629354182,LOW,Y,Y,N,Y,N,2020-01-18,2020-01-18 04:01:51.683,,2020-01-18 04:01:51.683,,,,2020-01-18 04:01:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,98.7869568320457,DAYS,2020-03-29 04:01:51.683,71,0,Disease Progression,,
458,AB12345,AB12345-CHN-1-id-74,id-74,CHN-1,23,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,1.80317629354182,LOW,Y,Y,N,Y,N,2020-01-18,2020-01-18 04:01:51.683,,2020-01-18 04:01:51.683,,,,2020-01-18 04:01:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,334.875808795914,DAYS,2020-07-26 04:01:51.683,190,1,Alive,Alive During Study,
459,AB12345,AB12345-CHN-1-id-74,id-74,CHN-1,23,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,1.80317629354182,LOW,Y,Y,N,Y,N,2020-01-18,2020-01-18 04:01:51.683,,2020-01-18 04:01:51.683,,,,2020-01-18 04:01:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,212.349169468507,DAYS,2020-06-10 04:01:51.683,144,1,Adverse Event,Preferred Term,
460,AB12345,AB12345-CHN-1-id-74,id-74,CHN-1,23,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,1.80317629354182,LOW,Y,Y,N,Y,N,2020-01-18,2020-01-18 04:01:51.683,,2020-01-18 04:01:51.683,,,,2020-01-18 04:01:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,1,,Preferred Term,-2.98808727421342
461,AB12345,AB12345-CHN-1-id-78,id-78,CHN-1,44,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.74209219952827,HIGH,Y,Y,Y,Y,N,2020-02-17,2020-02-21 16:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,COMPLETED,COMPLETED,2023-02-21,1096,,,,,,,2023-03-06,,,4,4,Duration of Confirmed Response,CRSD,89.9134966544807,DAYS,2022-10-01 16:21:14.683,953,0,Death,,
462,AB12345,AB12345-CHN-1-id-78,id-78,CHN-1,44,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.74209219952827,HIGH,Y,Y,Y,Y,N,2020-02-17,2020-02-21 16:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,COMPLETED,COMPLETED,2023-02-21,1096,,,,,,,2023-03-06,,,3,3,Event Free Survival,EFS,89.9134966544807,DAYS,2021-02-04 16:21:14.683,349,0,Death,,
463,AB12345,AB12345-CHN-1-id-78,id-78,CHN-1,44,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.74209219952827,HIGH,Y,Y,Y,Y,N,2020-02-17,2020-02-21 16:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,COMPLETED,COMPLETED,2023-02-21,1096,,,,,,,2023-03-06,,,2,2,Overall Survival,OS,89.9134966544807,DAYS,2020-10-01 16:21:14.683,223,0,Death,,
464,AB12345,AB12345-CHN-1-id-78,id-78,CHN-1,44,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.74209219952827,HIGH,Y,Y,Y,Y,N,2020-02-17,2020-02-21 16:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,COMPLETED,COMPLETED,2023-02-21,1096,,,,,,,2023-03-06,,,1,1,Progression Free Survival,PFS,89.9134966544807,DAYS,2020-04-18 16:21:14.683,57,0,Death,,
465,AB12345,AB12345-CHN-1-id-78,id-78,CHN-1,44,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.74209219952827,HIGH,Y,Y,Y,Y,N,2020-02-17,2020-02-21 16:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,2020-02-21 16:21:14.683,2022-02-21 04:21:14.683,2022-02-21 04:21:14.683,2023-02-21 10:21:14.683,COMPLETED,COMPLETED,2023-02-21,1096,,,,,,,2023-03-06,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.40445936568719
466,AB12345,AB12345-CHN-1-id-86,id-86,CHN-1,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,3.36363243021838,HIGH,Y,Y,Y,Y,N,2020-05-11,2020-05-15 00:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,COMPLETED,COMPLETED,2023-05-15,1096,,,,,,,2023-05-31,,,2,2,Duration of Confirmed Response,CRSD,129.89689046517,DAYS,2020-06-24 00:18:43.683,40,1,Last Tumor Assessment,Completion or Discontinuation,
467,AB12345,AB12345-CHN-1-id-86,id-86,CHN-1,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,3.36363243021838,HIGH,Y,Y,Y,Y,N,2020-05-11,2020-05-15 00:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,COMPLETED,COMPLETED,2023-05-15,1096,,,,,,,2023-05-31,,,4,4,Event Free Survival,EFS,25.5934031319339,DAYS,2022-01-31 00:18:43.683,626,0,Disease Progression,,
468,AB12345,AB12345-CHN-1-id-86,id-86,CHN-1,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,3.36363243021838,HIGH,Y,Y,Y,Y,N,2020-05-11,2020-05-15 00:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,COMPLETED,COMPLETED,2023-05-15,1096,,,,,,,2023-05-31,,,3,3,Overall Survival,OS,314.521908899769,DAYS,2020-12-16 00:18:43.683,215,1,Alive,Alive During Study,
469,AB12345,AB12345-CHN-1-id-86,id-86,CHN-1,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,3.36363243021838,HIGH,Y,Y,Y,Y,N,2020-05-11,2020-05-15 00:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,COMPLETED,COMPLETED,2023-05-15,1096,,,,,,,2023-05-31,,,1,1,Progression Free Survival,PFS,216.473463992588,DAYS,2020-06-03 00:18:43.683,19,0,Disease Progression,,
470,AB12345,AB12345-CHN-1-id-86,id-86,CHN-1,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,3.36363243021838,HIGH,Y,Y,Y,Y,N,2020-05-11,2020-05-15 00:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,2020-05-15 00:18:43.683,2022-05-15 12:18:43.683,2022-05-15 12:18:43.683,2023-05-15 18:18:43.683,COMPLETED,COMPLETED,2023-05-15,1096,,,,,,,2023-05-31,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-2.15256295097698
471,AB12345,AB12345-CHN-1-id-97,id-97,CHN-1,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,1.49296234968167,HIGH,Y,Y,Y,Y,N,2020-01-20,2020-01-20 08:09:12.683,,2020-01-20 08:09:12.683,,,,2020-01-20 08:09:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,171.666660532355,DAYS,2020-08-14 08:09:12.683,207,0,Death,,
472,AB12345,AB12345-CHN-1-id-97,id-97,CHN-1,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,1.49296234968167,HIGH,Y,Y,Y,Y,N,2020-01-20,2020-01-20 08:09:12.683,,2020-01-20 08:09:12.683,,,,2020-01-20 08:09:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,35.2651884779334,DAYS,2020-09-24 08:09:12.683,248,1,Last Tumor Assessment,Completion or Discontinuation,
473,AB12345,AB12345-CHN-1-id-97,id-97,CHN-1,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,1.49296234968167,HIGH,Y,Y,Y,Y,N,2020-01-20,2020-01-20 08:09:12.683,,2020-01-20 08:09:12.683,,,,2020-01-20 08:09:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,171.666660532355,DAYS,2020-06-17 08:09:12.683,149,0,Death,,
474,AB12345,AB12345-CHN-1-id-97,id-97,CHN-1,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,1.49296234968167,HIGH,Y,Y,Y,Y,N,2020-01-20,2020-01-20 08:09:12.683,,2020-01-20 08:09:12.683,,,,2020-01-20 08:09:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,171.666660532355,DAYS,2020-06-04 08:09:12.683,136,0,Death,,
475,AB12345,AB12345-CHN-1-id-97,id-97,CHN-1,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-1,Dr. CHN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,C,S1,1.49296234968167,HIGH,Y,Y,Y,Y,N,2020-01-20,2020-01-20 08:09:12.683,,2020-01-20 08:09:12.683,,,,2020-01-20 08:09:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.05525793930165
476,AB12345,AB12345-CHN-10-id-380,id-380,CHN-10,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-10,Dr. CHN-10 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,5.37548401171907,HIGH,Y,Y,Y,Y,N,2020-05-05,2020-05-09 18:45:03.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,644,DEATH,2022-02-19,ADVERSE EVENT,ADVERSE EVENT,7,<=30,2022-02-19,650,Yes,3,3,Duration of Confirmed Response,CRSD,107.587496656924,DAYS,2021-01-25 18:45:03.683,261,0,Disease Progression,,
477,AB12345,AB12345-CHN-10-id-380,id-380,CHN-10,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-10,Dr. CHN-10 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,5.37548401171907,HIGH,Y,Y,Y,Y,N,2020-05-05,2020-05-09 18:45:03.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,644,DEATH,2022-02-19,ADVERSE EVENT,ADVERSE EVENT,7,<=30,2022-02-19,650,Yes,1,1,Event Free Survival,EFS,69.8267843027133,DAYS,2020-10-05 18:45:03.683,149,0,Disease Progression,,
478,AB12345,AB12345-CHN-10-id-380,id-380,CHN-10,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-10,Dr. CHN-10 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,5.37548401171907,HIGH,Y,Y,Y,Y,N,2020-05-05,2020-05-09 18:45:03.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,644,DEATH,2022-02-19,ADVERSE EVENT,ADVERSE EVENT,7,<=30,2022-02-19,650,Yes,2,2,Overall Survival,OS,329.134071571752,DAYS,2020-11-02 18:45:03.683,177,1,Alive,Alive During Study,
479,AB12345,AB12345-CHN-10-id-380,id-380,CHN-10,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-10,Dr. CHN-10 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,5.37548401171907,HIGH,Y,Y,Y,Y,N,2020-05-05,2020-05-09 18:45:03.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,644,DEATH,2022-02-19,ADVERSE EVENT,ADVERSE EVENT,7,<=30,2022-02-19,650,Yes,4,4,Progression Free Survival,PFS,217.270892206579,DAYS,2021-11-18 18:45:03.683,558,1,Adverse Event,Preferred Term,
480,AB12345,AB12345-CHN-10-id-380,id-380,CHN-10,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-10,Dr. CHN-10 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,5.37548401171907,HIGH,Y,Y,Y,Y,N,2020-05-05,2020-05-09 18:45:03.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,2020-05-09 18:45:03.683,2021-02-12 09:34:26.683,2021-02-12 09:34:26.683,2022-02-12 15:34:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,644,DEATH,2022-02-19,ADVERSE EVENT,ADVERSE EVENT,7,<=30,2022-02-19,650,Yes,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-2.1887600661953
481,AB12345,AB12345-CHN-11-id-113,id-113,CHN-11,38,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,10.8659105005408,LOW,Y,Y,Y,N,N,2021-01-06,2021-01-10 15:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,COMPLETED,COMPLETED,2024-01-11,1096,,,,,,,2024-02-03,,,1,1,Duration of Confirmed Response,CRSD,123.1745099416,DAYS,2022-01-18 15:51:53.683,373,0,Disease Progression,,
482,AB12345,AB12345-CHN-11-id-113,id-113,CHN-11,38,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,10.8659105005408,LOW,Y,Y,Y,N,N,2021-01-06,2021-01-10 15:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,COMPLETED,COMPLETED,2024-01-11,1096,,,,,,,2024-02-03,,,3,3,Event Free Survival,EFS,48.3116006688215,DAYS,2023-04-14 15:51:53.683,824,0,Disease Progression,,
483,AB12345,AB12345-CHN-11-id-113,id-113,CHN-11,38,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,10.8659105005408,LOW,Y,Y,Y,N,N,2021-01-06,2021-01-10 15:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,COMPLETED,COMPLETED,2024-01-11,1096,,,,,,,2024-02-03,,,2,2,Overall Survival,OS,416.704037319869,DAYS,2022-11-29 15:51:53.683,688,1,Alive,Alive During Study,
484,AB12345,AB12345-CHN-11-id-113,id-113,CHN-11,38,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,10.8659105005408,LOW,Y,Y,Y,N,N,2021-01-06,2021-01-10 15:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,COMPLETED,COMPLETED,2024-01-11,1096,,,,,,,2024-02-03,,,4,4,Progression Free Survival,PFS,256.137982290238,DAYS,2023-11-28 15:51:53.683,1052,0,Disease Progression,,
485,AB12345,AB12345-CHN-11-id-113,id-113,CHN-11,38,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,10.8659105005408,LOW,Y,Y,Y,N,N,2021-01-06,2021-01-10 15:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,2021-01-10 15:51:53.683,2023-01-11 03:51:53.683,2023-01-11 03:51:53.683,2024-01-11 09:51:53.683,COMPLETED,COMPLETED,2024-01-11,1096,,,,,,,2024-02-03,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-2.24617076289933
486,AB12345,AB12345-CHN-11-id-116,id-116,CHN-11,30,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,13.3163290938957,LOW,Y,Y,N,N,N,2020-03-11,2020-03-15 19:01:41.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,DISCONTINUED,DISCONTINUED,2022-02-14,701,PHYSICIAN DECISION,,,,,,2022-03-13,,,1,1,Duration of Confirmed Response,CRSD,115.891654137522,DAYS,2020-06-08 19:01:41.683,85,1,Last Tumor Assessment,Completion or Discontinuation,
487,AB12345,AB12345-CHN-11-id-116,id-116,CHN-11,30,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,13.3163290938957,LOW,Y,Y,N,N,N,2020-03-11,2020-03-15 19:01:41.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,DISCONTINUED,DISCONTINUED,2022-02-14,701,PHYSICIAN DECISION,,,,,,2022-03-13,,,4,4,Event Free Survival,EFS,23.3945437520742,DAYS,2021-10-28 19:01:41.683,592,1,Adverse Event,Preferred Term,
488,AB12345,AB12345-CHN-11-id-116,id-116,CHN-11,30,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,13.3163290938957,LOW,Y,Y,N,N,N,2020-03-11,2020-03-15 19:01:41.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,DISCONTINUED,DISCONTINUED,2022-02-14,701,PHYSICIAN DECISION,,,,,,2022-03-13,,,3,3,Overall Survival,OS,292.206540401094,DAYS,2021-09-10 19:01:41.683,544,0,Death,,
489,AB12345,AB12345-CHN-11-id-116,id-116,CHN-11,30,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,13.3163290938957,LOW,Y,Y,N,N,N,2020-03-11,2020-03-15 19:01:41.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,DISCONTINUED,DISCONTINUED,2022-02-14,701,PHYSICIAN DECISION,,,,,,2022-03-13,,,2,2,Progression Free Survival,PFS,292.206540401094,DAYS,2021-04-08 19:01:41.683,389,0,Death,,
490,AB12345,AB12345-CHN-11-id-116,id-116,CHN-11,30,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,13.3163290938957,LOW,Y,Y,N,N,N,2020-03-11,2020-03-15 19:01:41.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,2020-03-15 19:01:41.683,2021-02-13 23:02:48.683,2021-02-13 23:02:48.683,2022-02-14 05:02:48.683,DISCONTINUED,DISCONTINUED,2022-02-14,701,PHYSICIAN DECISION,,,,,,2022-03-13,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,0.238670334622819
491,AB12345,AB12345-CHN-11-id-124,id-124,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,4.36797929369862,MEDIUM,Y,Y,Y,N,N,2019-07-12,2019-07-14 08:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,COMPLETED,COMPLETED,2022-07-14,1096,,,,,,,2022-08-11,,,3,3,Duration of Confirmed Response,CRSD,190.719875344075,DAYS,2021-01-10 08:51:46.683,546,1,Adverse Event,Preferred Term,
492,AB12345,AB12345-CHN-11-id-124,id-124,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,4.36797929369862,MEDIUM,Y,Y,Y,N,N,2019-07-12,2019-07-14 08:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,COMPLETED,COMPLETED,2022-07-14,1096,,,,,,,2022-08-11,,,1,1,Event Free Survival,EFS,88.0532261217013,DAYS,2020-04-23 08:51:46.683,284,1,Last Tumor Assessment,Completion or Discontinuation,
493,AB12345,AB12345-CHN-11-id-124,id-124,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,4.36797929369862,MEDIUM,Y,Y,Y,N,N,2019-07-12,2019-07-14 08:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,COMPLETED,COMPLETED,2022-07-14,1096,,,,,,,2022-08-11,,,2,2,Overall Survival,OS,307.107846811414,DAYS,2020-12-26 08:51:46.683,531,1,Alive,Alive During Study,
494,AB12345,AB12345-CHN-11-id-124,id-124,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,4.36797929369862,MEDIUM,Y,Y,Y,N,N,2019-07-12,2019-07-14 08:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,COMPLETED,COMPLETED,2022-07-14,1096,,,,,,,2022-08-11,,,4,4,Progression Free Survival,PFS,211.526895640418,DAYS,2021-04-14 08:51:46.683,640,1,Last Tumor Assessment,Completion or Discontinuation,
495,AB12345,AB12345-CHN-11-id-124,id-124,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,4.36797929369862,MEDIUM,Y,Y,Y,N,N,2019-07-12,2019-07-14 08:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,2019-07-14 08:51:46.683,2021-07-13 20:51:46.683,2021-07-13 20:51:46.683,2022-07-14 02:51:46.683,COMPLETED,COMPLETED,2022-07-14,1096,,,,,,,2022-08-11,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.66980819901158
496,AB12345,AB12345-CHN-11-id-132,id-132,CHN-11,30,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,3.94925116357987,HIGH,Y,Y,Y,Y,N,2020-02-25,2020-02-27 13:22:51.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,DISCONTINUED,DISCONTINUED,2022-02-18,723,PROTOCOL VIOLATION,,,,,,2022-03-19,,,1,1,Duration of Confirmed Response,CRSD,131.416826485656,DAYS,2020-03-13 13:22:51.683,15,0,Death,,
497,AB12345,AB12345-CHN-11-id-132,id-132,CHN-11,30,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,3.94925116357987,HIGH,Y,Y,Y,Y,N,2020-02-25,2020-02-27 13:22:51.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,DISCONTINUED,DISCONTINUED,2022-02-18,723,PROTOCOL VIOLATION,,,,,,2022-03-19,,,4,4,Event Free Survival,EFS,64.7891229414381,DAYS,2021-05-11 13:22:51.683,439,1,Last Tumor Assessment,Completion or Discontinuation,
498,AB12345,AB12345-CHN-11-id-132,id-132,CHN-11,30,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,3.94925116357987,HIGH,Y,Y,Y,Y,N,2020-02-25,2020-02-27 13:22:51.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,DISCONTINUED,DISCONTINUED,2022-02-18,723,PROTOCOL VIOLATION,,,,,,2022-03-19,,,2,2,Overall Survival,OS,131.416826485656,DAYS,2020-11-28 13:22:51.683,275,0,Death,,
499,AB12345,AB12345-CHN-11-id-132,id-132,CHN-11,30,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,3.94925116357987,HIGH,Y,Y,Y,Y,N,2020-02-25,2020-02-27 13:22:51.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,DISCONTINUED,DISCONTINUED,2022-02-18,723,PROTOCOL VIOLATION,,,,,,2022-03-19,,,3,3,Progression Free Survival,PFS,131.416826485656,DAYS,2020-11-29 13:22:51.683,276,0,Death,,
500,AB12345,AB12345-CHN-11-id-132,id-132,CHN-11,30,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,3.94925116357987,HIGH,Y,Y,Y,Y,N,2020-02-25,2020-02-27 13:22:51.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,2020-02-27 13:22:51.683,2021-02-18 12:49:35.683,2021-02-18 12:49:35.683,2022-02-18 18:49:35.683,DISCONTINUED,DISCONTINUED,2022-02-18,723,PROTOCOL VIOLATION,,,,,,2022-03-19,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-4.14764050105363
501,AB12345,AB12345-CHN-11-id-146,id-146,CHN-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,9.15901239610695,MEDIUM,Y,Y,Y,N,N,2021-01-05,2021-01-09 20:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,COMPLETED,COMPLETED,2024-01-10,1096,,,,,,,2024-02-07,,,2,2,Duration of Confirmed Response,CRSD,135.449541546404,DAYS,2021-11-21 20:42:25.683,316,0,Disease Progression,,
502,AB12345,AB12345-CHN-11-id-146,id-146,CHN-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,9.15901239610695,MEDIUM,Y,Y,Y,N,N,2021-01-05,2021-01-09 20:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,COMPLETED,COMPLETED,2024-01-10,1096,,,,,,,2024-02-07,,,1,1,Event Free Survival,EFS,62.3355883033946,DAYS,2021-03-23 20:42:25.683,73,1,Last Tumor Assessment,Completion or Discontinuation,
503,AB12345,AB12345-CHN-11-id-146,id-146,CHN-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,9.15901239610695,MEDIUM,Y,Y,Y,N,N,2021-01-05,2021-01-09 20:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,COMPLETED,COMPLETED,2024-01-10,1096,,,,,,,2024-02-07,,,4,4,Overall Survival,OS,214.326831162907,DAYS,2023-06-06 20:42:25.683,878,0,Death,,
504,AB12345,AB12345-CHN-11-id-146,id-146,CHN-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,9.15901239610695,MEDIUM,Y,Y,Y,N,N,2021-01-05,2021-01-09 20:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,COMPLETED,COMPLETED,2024-01-10,1096,,,,,,,2024-02-07,,,3,3,Progression Free Survival,PFS,214.326831162907,DAYS,2023-04-27 20:42:25.683,838,0,Death,,
505,AB12345,AB12345-CHN-11-id-146,id-146,CHN-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,9.15901239610695,MEDIUM,Y,Y,Y,N,N,2021-01-05,2021-01-09 20:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,2021-01-09 20:42:25.683,2023-01-10 08:42:25.683,2023-01-10 08:42:25.683,2024-01-10 14:42:25.683,COMPLETED,COMPLETED,2024-01-10,1096,,,,,,,2024-02-07,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.23949862059448
506,AB12345,AB12345-CHN-11-id-153,id-153,CHN-11,41,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S2,6.79286329979451,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 21:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,COMPLETED,COMPLETED,2023-10-14,1096,,,,,,,2023-11-02,,,4,4,Duration of Confirmed Response,CRSD,133.409865782596,DAYS,2023-07-15 21:15:26.683,1005,0,Death,,
507,AB12345,AB12345-CHN-11-id-153,id-153,CHN-11,41,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S2,6.79286329979451,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 21:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,COMPLETED,COMPLETED,2023-10-14,1096,,,,,,,2023-11-02,,,2,2,Event Free Survival,EFS,63.2065143354703,DAYS,2021-05-24 21:15:26.683,223,1,Last Tumor Assessment,Completion or Discontinuation,
508,AB12345,AB12345-CHN-11-id-153,id-153,CHN-11,41,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S2,6.79286329979451,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 21:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,COMPLETED,COMPLETED,2023-10-14,1096,,,,,,,2023-11-02,,,3,3,Overall Survival,OS,133.409865782596,DAYS,2023-06-16 21:15:26.683,976,0,Death,,
509,AB12345,AB12345-CHN-11-id-153,id-153,CHN-11,41,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S2,6.79286329979451,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 21:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,COMPLETED,COMPLETED,2023-10-14,1096,,,,,,,2023-11-02,,,1,1,Progression Free Survival,PFS,133.409865782596,DAYS,2021-02-01 21:15:26.683,111,0,Death,,
510,AB12345,AB12345-CHN-11-id-153,id-153,CHN-11,41,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S2,6.79286329979451,LOW,Y,Y,N,N,N,2020-10-09,2020-10-13 21:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,2020-10-13 21:15:26.683,2022-10-14 09:15:26.683,2022-10-14 09:15:26.683,2023-10-14 15:15:26.683,COMPLETED,COMPLETED,2023-10-14,1096,,,,,,,2023-11-02,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.771642726802294
511,AB12345,AB12345-CHN-11-id-158,id-158,CHN-11,24,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,2.18134957914347,MEDIUM,Y,Y,N,Y,N,2020-07-17,2020-07-20 00:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-07-31,,,1,1,Duration of Confirmed Response,CRSD,125.585432420485,DAYS,2020-12-12 00:53:04.683,145,0,Death,,
512,AB12345,AB12345-CHN-11-id-158,id-158,CHN-11,24,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,2.18134957914347,MEDIUM,Y,Y,N,Y,N,2020-07-17,2020-07-20 00:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-07-31,,,4,4,Event Free Survival,EFS,25.2341012004763,DAYS,2022-02-02 00:53:04.683,562,1,Last Tumor Assessment,Completion or Discontinuation,
513,AB12345,AB12345-CHN-11-id-158,id-158,CHN-11,24,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,2.18134957914347,MEDIUM,Y,Y,N,Y,N,2020-07-17,2020-07-20 00:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-07-31,,,2,2,Overall Survival,OS,125.585432420485,DAYS,2021-03-10 00:53:04.683,233,0,Death,,
514,AB12345,AB12345-CHN-11-id-158,id-158,CHN-11,24,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,2.18134957914347,MEDIUM,Y,Y,N,Y,N,2020-07-17,2020-07-20 00:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-07-31,,,3,3,Progression Free Survival,PFS,125.585432420485,DAYS,2021-07-25 00:53:04.683,370,0,Death,,
515,AB12345,AB12345-CHN-11-id-158,id-158,CHN-11,24,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,2.18134957914347,MEDIUM,Y,Y,N,Y,N,2020-07-17,2020-07-20 00:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,2020-07-20 00:53:04.683,2022-07-20 12:53:04.683,2022-07-20 12:53:04.683,2023-07-20 18:53:04.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-07-31,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,0.244895863553
516,AB12345,AB12345-CHN-11-id-167,id-167,CHN-11,28,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,11.9626547225851,HIGH,Y,Y,N,N,N,2019-11-07,2019-11-08 14:18:56.683,,2019-11-08 14:18:56.683,,,,2019-11-08 14:18:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,183.13199293334,DAYS,2020-10-11 14:18:56.683,338,1,Adverse Event,Preferred Term,
517,AB12345,AB12345-CHN-11-id-167,id-167,CHN-11,28,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,11.9626547225851,HIGH,Y,Y,N,N,N,2019-11-07,2019-11-08 14:18:56.683,,2019-11-08 14:18:56.683,,,,2019-11-08 14:18:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,45.037751897471,DAYS,2021-07-04 14:18:56.683,604,0,Disease Progression,,
518,AB12345,AB12345-CHN-11-id-167,id-167,CHN-11,28,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,11.9626547225851,HIGH,Y,Y,N,N,N,2019-11-07,2019-11-08 14:18:56.683,,2019-11-08 14:18:56.683,,,,2019-11-08 14:18:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,278.322391654365,DAYS,2020-02-21 14:18:56.683,105,0,Death,,
519,AB12345,AB12345-CHN-11-id-167,id-167,CHN-11,28,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,11.9626547225851,HIGH,Y,Y,N,N,N,2019-11-07,2019-11-08 14:18:56.683,,2019-11-08 14:18:56.683,,,,2019-11-08 14:18:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,278.322391654365,DAYS,2020-07-10 14:18:56.683,245,0,Death,,
520,AB12345,AB12345-CHN-11-id-167,id-167,CHN-11,28,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,11.9626547225851,HIGH,Y,Y,N,N,N,2019-11-07,2019-11-08 14:18:56.683,,2019-11-08 14:18:56.683,,,,2019-11-08 14:18:56.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-6.73238741772085
521,AB12345,AB12345-CHN-11-id-174,id-174,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S2,3.08848153867289,HIGH,Y,Y,Y,Y,N,2020-05-17,2020-05-19 21:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,COMPLETED,COMPLETED,2023-05-20,1096,,,,,,,2023-06-01,,,1,1,Duration of Confirmed Response,CRSD,183.919903170317,DAYS,2020-07-17 21:07:01.683,59,1,Adverse Event,Preferred Term,
522,AB12345,AB12345-CHN-11-id-174,id-174,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S2,3.08848153867289,HIGH,Y,Y,Y,Y,N,2020-05-17,2020-05-19 21:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,COMPLETED,COMPLETED,2023-05-20,1096,,,,,,,2023-06-01,,,4,4,Event Free Survival,EFS,94.9129376281053,DAYS,2022-12-26 21:07:01.683,951,0,Disease Progression,,
523,AB12345,AB12345-CHN-11-id-174,id-174,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S2,3.08848153867289,HIGH,Y,Y,Y,Y,N,2020-05-17,2020-05-19 21:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,COMPLETED,COMPLETED,2023-05-20,1096,,,,,,,2023-06-01,,,3,3,Overall Survival,OS,418.135217018425,DAYS,2022-09-27 21:07:01.683,861,1,Alive,Alive During Study,
524,AB12345,AB12345-CHN-11-id-174,id-174,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S2,3.08848153867289,HIGH,Y,Y,Y,Y,N,2020-05-17,2020-05-19 21:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,COMPLETED,COMPLETED,2023-05-20,1096,,,,,,,2023-06-01,,,2,2,Progression Free Survival,PFS,214.898501918651,DAYS,2022-03-22 21:07:01.683,672,0,Disease Progression,,
525,AB12345,AB12345-CHN-11-id-174,id-174,CHN-11,41,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S2,3.08848153867289,HIGH,Y,Y,Y,Y,N,2020-05-17,2020-05-19 21:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,2020-05-19 21:07:01.683,2022-05-20 09:07:01.683,2022-05-20 09:07:01.683,2023-05-20 15:07:01.683,COMPLETED,COMPLETED,2023-05-20,1096,,,,,,,2023-06-01,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.29247983727184
526,AB12345,AB12345-CHN-11-id-184,id-184,CHN-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,1.63913422461511,LOW,Y,Y,N,Y,N,2019-05-04,2019-05-04 08:19:47.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,1018,DEATH,2022-02-27,DISEASE PROGRESSION,PROGRESSIVE DISEASE,12,<=30,2022-02-27,1029,Yes,2,2,Duration of Confirmed Response,CRSD,163.188536535017,DAYS,2020-10-21 08:19:47.683,536,0,Death,,
527,AB12345,AB12345-CHN-11-id-184,id-184,CHN-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,1.63913422461511,LOW,Y,Y,N,Y,N,2019-05-04,2019-05-04 08:19:47.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,1018,DEATH,2022-02-27,DISEASE PROGRESSION,PROGRESSIVE DISEASE,12,<=30,2022-02-27,1029,Yes,3,3,Event Free Survival,EFS,85.0368210568558,DAYS,2020-12-13 08:19:47.683,589,1,Last Tumor Assessment,Completion or Discontinuation,
528,AB12345,AB12345-CHN-11-id-184,id-184,CHN-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,1.63913422461511,LOW,Y,Y,N,Y,N,2019-05-04,2019-05-04 08:19:47.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,1018,DEATH,2022-02-27,DISEASE PROGRESSION,PROGRESSIVE DISEASE,12,<=30,2022-02-27,1029,Yes,4,4,Overall Survival,OS,163.188536535017,DAYS,2021-05-16 08:19:47.683,743,0,Death,,
529,AB12345,AB12345-CHN-11-id-184,id-184,CHN-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,1.63913422461511,LOW,Y,Y,N,Y,N,2019-05-04,2019-05-04 08:19:47.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,1018,DEATH,2022-02-27,DISEASE PROGRESSION,PROGRESSIVE DISEASE,12,<=30,2022-02-27,1029,Yes,1,1,Progression Free Survival,PFS,163.188536535017,DAYS,2020-06-24 08:19:47.683,417,0,Death,,
530,AB12345,AB12345-CHN-11-id-184,id-184,CHN-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,1.63913422461511,LOW,Y,Y,N,Y,N,2019-05-04,2019-05-04 08:19:47.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,2019-05-04 08:19:47.683,2021-02-14 21:30:55.683,2021-02-14 21:30:55.683,2022-02-15 03:30:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,1018,DEATH,2022-02-27,DISEASE PROGRESSION,PROGRESSIVE DISEASE,12,<=30,2022-02-27,1029,Yes,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.05835914707252
531,AB12345,AB12345-CHN-11-id-192,id-192,CHN-11,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,3.76818679808841,MEDIUM,Y,Y,N,N,N,2019-12-26,2019-12-26 00:43:51.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,784,DEATH,2022-03-13,DISEASE PROGRESSION,PROGRESSIVE DISEASE,25,<=30,2022-03-13,807,Yes,1,1,Duration of Confirmed Response,CRSD,125.874090357684,DAYS,2020-03-24 00:43:51.683,89,0,Death,,
532,AB12345,AB12345-CHN-11-id-192,id-192,CHN-11,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,3.76818679808841,MEDIUM,Y,Y,N,N,N,2019-12-26,2019-12-26 00:43:51.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,784,DEATH,2022-03-13,DISEASE PROGRESSION,PROGRESSIVE DISEASE,25,<=30,2022-03-13,807,Yes,4,4,Event Free Survival,EFS,54.9440467264503,DAYS,2021-11-16 00:43:51.683,691,1,Last Tumor Assessment,Completion or Discontinuation,
533,AB12345,AB12345-CHN-11-id-192,id-192,CHN-11,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,3.76818679808841,MEDIUM,Y,Y,N,N,N,2019-12-26,2019-12-26 00:43:51.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,784,DEATH,2022-03-13,DISEASE PROGRESSION,PROGRESSIVE DISEASE,25,<=30,2022-03-13,807,Yes,3,3,Overall Survival,OS,125.874090357684,DAYS,2020-10-08 00:43:51.683,287,0,Death,,
534,AB12345,AB12345-CHN-11-id-192,id-192,CHN-11,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,3.76818679808841,MEDIUM,Y,Y,N,N,N,2019-12-26,2019-12-26 00:43:51.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,784,DEATH,2022-03-13,DISEASE PROGRESSION,PROGRESSIVE DISEASE,25,<=30,2022-03-13,807,Yes,2,2,Progression Free Survival,PFS,125.874090357684,DAYS,2020-09-04 00:43:51.683,253,0,Death,,
535,AB12345,AB12345-CHN-11-id-192,id-192,CHN-11,35,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,3.76818679808841,MEDIUM,Y,Y,N,N,N,2019-12-26,2019-12-26 00:43:51.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,2019-12-26 00:43:51.683,2021-02-16 11:13:45.683,2021-02-16 11:13:45.683,2022-02-16 17:13:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,784,DEATH,2022-03-13,DISEASE PROGRESSION,PROGRESSIVE DISEASE,25,<=30,2022-03-13,807,Yes,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.20901004413205
536,AB12345,AB12345-CHN-11-id-2,id-2,CHN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,6.0153420934137,LOW,Y,Y,N,N,N,2020-07-09,2020-07-13 04:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,COMPLETED,COMPLETED,2023-07-13,1096,,,,,,,2023-07-25,,,1,1,Duration of Confirmed Response,CRSD,132.880812766962,DAYS,2020-11-22 04:42:18.683,132,0,Death,,
537,AB12345,AB12345-CHN-11-id-2,id-2,CHN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,6.0153420934137,LOW,Y,Y,N,N,N,2020-07-09,2020-07-13 04:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,COMPLETED,COMPLETED,2023-07-13,1096,,,,,,,2023-07-25,,,3,3,Event Free Survival,EFS,17.0893298217561,DAYS,2021-04-17 04:42:18.683,278,1,Last Tumor Assessment,Completion or Discontinuation,
538,AB12345,AB12345-CHN-11-id-2,id-2,CHN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,6.0153420934137,LOW,Y,Y,N,N,N,2020-07-09,2020-07-13 04:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,COMPLETED,COMPLETED,2023-07-13,1096,,,,,,,2023-07-25,,,2,2,Overall Survival,OS,132.880812766962,DAYS,2021-02-20 04:42:18.683,222,0,Death,,
539,AB12345,AB12345-CHN-11-id-2,id-2,CHN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,6.0153420934137,LOW,Y,Y,N,N,N,2020-07-09,2020-07-13 04:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,COMPLETED,COMPLETED,2023-07-13,1096,,,,,,,2023-07-25,,,4,4,Progression Free Survival,PFS,132.880812766962,DAYS,2022-04-12 04:42:18.683,638,0,Death,,
540,AB12345,AB12345-CHN-11-id-2,id-2,CHN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,6.0153420934137,LOW,Y,Y,N,N,N,2020-07-09,2020-07-13 04:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,2020-07-13 04:42:18.683,2022-07-13 16:42:18.683,2022-07-13 16:42:18.683,2023-07-13 22:42:18.683,COMPLETED,COMPLETED,2023-07-13,1096,,,,,,,2023-07-25,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.498711159813285
541,AB12345,AB12345-CHN-11-id-220,id-220,CHN-11,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,10.2627340069523,MEDIUM,Y,Y,Y,Y,N,2019-02-27,2019-03-01 13:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-26,,,3,3,Duration of Confirmed Response,CRSD,187.733183940873,DAYS,2020-12-07 13:33:19.683,647,0,Death,,
542,AB12345,AB12345-CHN-11-id-220,id-220,CHN-11,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,10.2627340069523,MEDIUM,Y,Y,Y,Y,N,2019-02-27,2019-03-01 13:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-26,,,2,2,Event Free Survival,EFS,34.112546176184,DAYS,2020-11-25 13:33:19.683,635,1,Last Tumor Assessment,Completion or Discontinuation,
543,AB12345,AB12345-CHN-11-id-220,id-220,CHN-11,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,10.2627340069523,MEDIUM,Y,Y,Y,Y,N,2019-02-27,2019-03-01 13:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-26,,,1,1,Overall Survival,OS,187.733183940873,DAYS,2019-10-14 13:33:19.683,227,0,Death,,
544,AB12345,AB12345-CHN-11-id-220,id-220,CHN-11,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,10.2627340069523,MEDIUM,Y,Y,Y,Y,N,2019-02-27,2019-03-01 13:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-26,,,4,4,Progression Free Survival,PFS,187.733183940873,DAYS,2022-02-03 13:33:19.683,1070,0,Death,,
545,AB12345,AB12345-CHN-11-id-220,id-220,CHN-11,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,10.2627340069523,MEDIUM,Y,Y,Y,Y,N,2019-02-27,2019-03-01 13:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,2019-03-01 13:33:19.683,2021-03-01 01:33:19.683,2021-03-01 01:33:19.683,2022-03-01 07:33:19.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-26,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.539534999154036
546,AB12345,AB12345-CHN-11-id-222,id-222,CHN-11,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,1.65329211080955,HIGH,Y,Y,N,Y,N,2020-02-22,2020-02-25 06:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-10,,,2,2,Duration of Confirmed Response,CRSD,72.6006070594303,DAYS,2020-08-18 06:30:30.683,175,0,Death,,
547,AB12345,AB12345-CHN-11-id-222,id-222,CHN-11,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,1.65329211080955,HIGH,Y,Y,N,Y,N,2020-02-22,2020-02-25 06:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-10,,,3,3,Event Free Survival,EFS,72.6006070594303,DAYS,2020-11-17 06:30:30.683,266,0,Death,,
548,AB12345,AB12345-CHN-11-id-222,id-222,CHN-11,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,1.65329211080955,HIGH,Y,Y,N,Y,N,2020-02-22,2020-02-25 06:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-10,,,1,1,Overall Survival,OS,72.6006070594303,DAYS,2020-06-08 06:30:30.683,104,0,Death,,
549,AB12345,AB12345-CHN-11-id-222,id-222,CHN-11,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,1.65329211080955,HIGH,Y,Y,N,Y,N,2020-02-22,2020-02-25 06:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-10,,,4,4,Progression Free Survival,PFS,72.6006070594303,DAYS,2022-07-08 06:30:30.683,864,0,Death,,
550,AB12345,AB12345-CHN-11-id-222,id-222,CHN-11,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,1.65329211080955,HIGH,Y,Y,N,Y,N,2020-02-22,2020-02-25 06:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,2020-02-25 06:30:30.683,2022-02-24 18:30:30.683,2022-02-24 18:30:30.683,2023-02-25 00:30:30.683,COMPLETED,COMPLETED,2023-02-25,1096,,,,,,,2023-03-10,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-2.18342421938001
551,AB12345,AB12345-CHN-11-id-24,id-24,CHN-11,46,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,3.98173997589417,MEDIUM,Y,Y,Y,Y,N,2020-10-25,2020-10-29 16:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,COMPLETED,COMPLETED,2023-10-30,1096,,,,,,,2023-11-16,,,1,1,Duration of Confirmed Response,CRSD,155.768666393124,DAYS,2021-01-20 16:45:10.683,83,1,Last Tumor Assessment,Completion or Discontinuation,
552,AB12345,AB12345-CHN-11-id-24,id-24,CHN-11,46,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,3.98173997589417,MEDIUM,Y,Y,Y,Y,N,2020-10-25,2020-10-29 16:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,COMPLETED,COMPLETED,2023-10-30,1096,,,,,,,2023-11-16,,,3,3,Event Free Survival,EFS,59.7043308091816,DAYS,2022-03-13 16:45:10.683,500,1,Last Tumor Assessment,Completion or Discontinuation,
553,AB12345,AB12345-CHN-11-id-24,id-24,CHN-11,46,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,3.98173997589417,MEDIUM,Y,Y,Y,Y,N,2020-10-25,2020-10-29 16:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,COMPLETED,COMPLETED,2023-10-30,1096,,,,,,,2023-11-16,,,2,2,Overall Survival,OS,301.459354162216,DAYS,2021-05-29 16:45:10.683,212,1,Alive,Alive During Study,
554,AB12345,AB12345-CHN-11-id-24,id-24,CHN-11,46,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,3.98173997589417,MEDIUM,Y,Y,Y,Y,N,2020-10-25,2020-10-29 16:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,COMPLETED,COMPLETED,2023-10-30,1096,,,,,,,2023-11-16,,,4,4,Progression Free Survival,PFS,224.747167341411,DAYS,2023-08-22 16:45:10.683,1027,1,Last Tumor Assessment,Completion or Discontinuation,
555,AB12345,AB12345-CHN-11-id-24,id-24,CHN-11,46,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,3.98173997589417,MEDIUM,Y,Y,Y,Y,N,2020-10-25,2020-10-29 16:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,2020-10-29 16:45:10.683,2022-10-30 04:45:10.683,2022-10-30 04:45:10.683,2023-10-30 10:45:10.683,COMPLETED,COMPLETED,2023-10-30,1096,,,,,,,2023-11-16,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.984994715506779
556,AB12345,AB12345-CHN-11-id-244,id-244,CHN-11,26,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,7.26417136095093,HIGH,Y,Y,N,Y,N,2020-07-14,2020-07-17 02:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-07-29,,,4,4,Duration of Confirmed Response,CRSD,171.915013855323,DAYS,2023-05-29 02:53:24.683,1046,0,Death,,
557,AB12345,AB12345-CHN-11-id-244,id-244,CHN-11,26,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,7.26417136095093,HIGH,Y,Y,N,Y,N,2020-07-14,2020-07-17 02:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-07-29,,,2,2,Event Free Survival,EFS,95.6570469890721,DAYS,2022-09-07 02:53:24.683,782,1,Last Tumor Assessment,Completion or Discontinuation,
558,AB12345,AB12345-CHN-11-id-244,id-244,CHN-11,26,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,7.26417136095093,HIGH,Y,Y,N,Y,N,2020-07-14,2020-07-17 02:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-07-29,,,1,1,Overall Survival,OS,171.915013855323,DAYS,2021-04-23 02:53:24.683,280,0,Death,,
559,AB12345,AB12345-CHN-11-id-244,id-244,CHN-11,26,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,7.26417136095093,HIGH,Y,Y,N,Y,N,2020-07-14,2020-07-17 02:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-07-29,,,3,3,Progression Free Survival,PFS,171.915013855323,DAYS,2022-10-07 02:53:24.683,812,0,Death,,
560,AB12345,AB12345-CHN-11-id-244,id-244,CHN-11,26,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,7.26417136095093,HIGH,Y,Y,N,Y,N,2020-07-14,2020-07-17 02:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,2020-07-17 02:53:24.683,2022-07-17 14:53:24.683,2022-07-17 14:53:24.683,2023-07-17 20:53:24.683,COMPLETED,COMPLETED,2023-07-17,1096,,,,,,,2023-07-29,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.00907456195825
561,AB12345,AB12345-CHN-11-id-246,id-246,CHN-11,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S2,3.11333834400481,MEDIUM,Y,Y,Y,N,N,2020-12-18,2020-12-22 05:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-08,,,2,2,Duration of Confirmed Response,CRSD,174.378285603598,DAYS,2021-05-16 05:40:20.683,145,1,Adverse Event,Preferred Term,
562,AB12345,AB12345-CHN-11-id-246,id-246,CHN-11,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S2,3.11333834400481,MEDIUM,Y,Y,Y,N,N,2020-12-18,2020-12-22 05:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-08,,,4,4,Event Free Survival,EFS,38.7425862904638,DAYS,2022-10-23 05:40:20.683,670,1,Last Tumor Assessment,Completion or Discontinuation,
563,AB12345,AB12345-CHN-11-id-246,id-246,CHN-11,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S2,3.11333834400481,MEDIUM,Y,Y,Y,N,N,2020-12-18,2020-12-22 05:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-08,,,1,1,Overall Survival,OS,376.074025034904,DAYS,2021-03-19 05:40:20.683,87,1,Alive,Alive During Study,
564,AB12345,AB12345-CHN-11-id-246,id-246,CHN-11,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S2,3.11333834400481,MEDIUM,Y,Y,Y,N,N,2020-12-18,2020-12-22 05:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-08,,,3,3,Progression Free Survival,PFS,287.0748400921,DAYS,2021-07-07 05:40:20.683,197,1,Last Tumor Assessment,Completion or Discontinuation,
565,AB12345,AB12345-CHN-11-id-246,id-246,CHN-11,31,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S2,3.11333834400481,MEDIUM,Y,Y,Y,N,N,2020-12-18,2020-12-22 05:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,2020-12-22 05:40:20.683,2022-12-22 17:40:20.683,2022-12-22 17:40:20.683,2023-12-22 23:40:20.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-08,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-2.49690360456168
566,AB12345,AB12345-CHN-11-id-247,id-247,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,4.01894836611143,HIGH,Y,Y,Y,N,N,2019-07-27,2019-07-28 23:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-08,,,3,3,Duration of Confirmed Response,CRSD,123.960671038367,DAYS,2020-11-21 23:48:24.683,482,0,Disease Progression,,
567,AB12345,AB12345-CHN-11-id-247,id-247,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,4.01894836611143,HIGH,Y,Y,Y,N,N,2019-07-27,2019-07-28 23:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-08,,,1,1,Event Free Survival,EFS,76.1530388519168,DAYS,2020-05-20 23:48:24.683,297,1,Last Tumor Assessment,Completion or Discontinuation,
568,AB12345,AB12345-CHN-11-id-247,id-247,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,4.01894836611143,HIGH,Y,Y,Y,N,N,2019-07-27,2019-07-28 23:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-08,,,2,2,Overall Survival,OS,495.134152146056,DAYS,2020-08-11 23:48:24.683,380,1,Alive,Alive During Study,
569,AB12345,AB12345-CHN-11-id-247,id-247,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,4.01894836611143,HIGH,Y,Y,Y,N,N,2019-07-27,2019-07-28 23:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-08,,,4,4,Progression Free Survival,PFS,264.776487415656,DAYS,2021-09-14 23:48:24.683,779,0,Disease Progression,,
570,AB12345,AB12345-CHN-11-id-247,id-247,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,4.01894836611143,HIGH,Y,Y,Y,N,N,2019-07-27,2019-07-28 23:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,2019-07-28 23:48:24.683,2021-07-28 11:48:24.683,2021-07-28 11:48:24.683,2022-07-28 17:48:24.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-08,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.60873467578778
571,AB12345,AB12345-CHN-11-id-256,id-256,CHN-11,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,7.65204047263246,LOW,Y,Y,N,Y,Y,2020-03-14,2020-03-17 00:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,COMPLETED,COMPLETED,2023-03-17,1096,,,,,,,2023-03-27,,,3,3,Duration of Confirmed Response,CRSD,146.414412860759,DAYS,2022-01-02 00:36:00.683,656,1,Adverse Event,Preferred Term,
572,AB12345,AB12345-CHN-11-id-256,id-256,CHN-11,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,7.65204047263246,LOW,Y,Y,N,Y,Y,2020-03-14,2020-03-17 00:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,COMPLETED,COMPLETED,2023-03-17,1096,,,,,,,2023-03-27,,,1,1,Event Free Survival,EFS,47.1298986743204,DAYS,2020-08-28 00:36:00.683,164,1,Last Tumor Assessment,Completion or Discontinuation,
573,AB12345,AB12345-CHN-11-id-256,id-256,CHN-11,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,7.65204047263246,LOW,Y,Y,N,Y,Y,2020-03-14,2020-03-17 00:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,COMPLETED,COMPLETED,2023-03-17,1096,,,,,,,2023-03-27,,,2,2,Overall Survival,OS,281.229629577138,DAYS,2021-05-16 00:36:00.683,425,0,Death,,
574,AB12345,AB12345-CHN-11-id-256,id-256,CHN-11,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,7.65204047263246,LOW,Y,Y,N,Y,Y,2020-03-14,2020-03-17 00:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,COMPLETED,COMPLETED,2023-03-17,1096,,,,,,,2023-03-27,,,4,4,Progression Free Survival,PFS,281.229629577138,DAYS,2022-11-17 00:36:00.683,975,0,Death,,
575,AB12345,AB12345-CHN-11-id-256,id-256,CHN-11,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,7.65204047263246,LOW,Y,Y,N,Y,Y,2020-03-14,2020-03-17 00:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,2020-03-17 00:36:00.683,2022-03-17 12:36:00.683,2022-03-17 12:36:00.683,2023-03-17 18:36:00.683,COMPLETED,COMPLETED,2023-03-17,1096,,,,,,,2023-03-27,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-0.484467917005764
576,AB12345,AB12345-CHN-11-id-257,id-257,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.83771299145639,HIGH,Y,Y,N,Y,Y,2020-11-15,2020-11-15 17:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,COMPLETED,COMPLETED,2023-11-16,1096,,,,,,,2023-12-07,,,4,4,Duration of Confirmed Response,CRSD,105.030902265571,DAYS,2023-04-18 17:38:32.683,884,0,Death,,
577,AB12345,AB12345-CHN-11-id-257,id-257,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.83771299145639,HIGH,Y,Y,N,Y,Y,2020-11-15,2020-11-15 17:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,COMPLETED,COMPLETED,2023-11-16,1096,,,,,,,2023-12-07,,,1,1,Event Free Survival,EFS,57.0246896205936,DAYS,2021-03-02 17:38:32.683,107,1,Adverse Event,Preferred Term,
578,AB12345,AB12345-CHN-11-id-257,id-257,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.83771299145639,HIGH,Y,Y,N,Y,Y,2020-11-15,2020-11-15 17:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,COMPLETED,COMPLETED,2023-11-16,1096,,,,,,,2023-12-07,,,3,3,Overall Survival,OS,105.030902265571,DAYS,2023-03-02 17:38:32.683,837,0,Death,,
579,AB12345,AB12345-CHN-11-id-257,id-257,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.83771299145639,HIGH,Y,Y,N,Y,Y,2020-11-15,2020-11-15 17:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,COMPLETED,COMPLETED,2023-11-16,1096,,,,,,,2023-12-07,,,2,2,Progression Free Survival,PFS,105.030902265571,DAYS,2021-03-24 17:38:32.683,129,0,Death,,
580,AB12345,AB12345-CHN-11-id-257,id-257,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.83771299145639,HIGH,Y,Y,N,Y,Y,2020-11-15,2020-11-15 17:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,2020-11-15 17:38:32.683,2022-11-16 05:38:32.683,2022-11-16 05:38:32.683,2023-11-16 11:38:32.683,COMPLETED,COMPLETED,2023-11-16,1096,,,,,,,2023-12-07,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.0442829569366
581,AB12345,AB12345-CHN-11-id-263,id-263,CHN-11,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,6.82822741260757,MEDIUM,Y,Y,N,N,Y,2019-04-03,2019-04-03 21:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,COMPLETED,COMPLETED,2022-04-03,1096,,,,,,,2022-05-01,,,4,4,Duration of Confirmed Response,CRSD,116.14383161068,DAYS,2021-10-25 21:51:08.683,936,0,Death,,
582,AB12345,AB12345-CHN-11-id-263,id-263,CHN-11,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,6.82822741260757,MEDIUM,Y,Y,N,N,Y,2019-04-03,2019-04-03 21:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,COMPLETED,COMPLETED,2022-04-03,1096,,,,,,,2022-05-01,,,1,1,Event Free Survival,EFS,26.102847950533,DAYS,2019-08-19 21:51:08.683,138,0,Disease Progression,,
583,AB12345,AB12345-CHN-11-id-263,id-263,CHN-11,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,6.82822741260757,MEDIUM,Y,Y,N,N,Y,2019-04-03,2019-04-03 21:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,COMPLETED,COMPLETED,2022-04-03,1096,,,,,,,2022-05-01,,,3,3,Overall Survival,OS,116.14383161068,DAYS,2021-01-15 21:51:08.683,653,0,Death,,
584,AB12345,AB12345-CHN-11-id-263,id-263,CHN-11,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,6.82822741260757,MEDIUM,Y,Y,N,N,Y,2019-04-03,2019-04-03 21:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,COMPLETED,COMPLETED,2022-04-03,1096,,,,,,,2022-05-01,,,2,2,Progression Free Survival,PFS,116.14383161068,DAYS,2020-11-11 21:51:08.683,588,0,Death,,
585,AB12345,AB12345-CHN-11-id-263,id-263,CHN-11,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,6.82822741260757,MEDIUM,Y,Y,N,N,Y,2019-04-03,2019-04-03 21:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,2019-04-03 21:51:08.683,2021-04-03 09:51:08.683,2021-04-03 09:51:08.683,2022-04-03 15:51:08.683,COMPLETED,COMPLETED,2022-04-03,1096,,,,,,,2022-05-01,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.544573654654688
586,AB12345,AB12345-CHN-11-id-27,id-27,CHN-11,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,12.8134782273952,HIGH,Y,Y,N,Y,N,2019-11-14,2019-11-18 05:24:03.683,,2019-11-18 05:24:03.683,,,,2019-11-18 05:24:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,140.361408819444,DAYS,2021-08-12 05:24:03.683,633,1,Adverse Event,Preferred Term,
587,AB12345,AB12345-CHN-11-id-27,id-27,CHN-11,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,12.8134782273952,HIGH,Y,Y,N,Y,N,2019-11-14,2019-11-18 05:24:03.683,,2019-11-18 05:24:03.683,,,,2019-11-18 05:24:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,22.6035185856745,DAYS,2021-08-09 05:24:03.683,630,1,Last Tumor Assessment,Completion or Discontinuation,
588,AB12345,AB12345-CHN-11-id-27,id-27,CHN-11,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,12.8134782273952,HIGH,Y,Y,N,Y,N,2019-11-14,2019-11-18 05:24:03.683,,2019-11-18 05:24:03.683,,,,2019-11-18 05:24:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,412.401184486225,DAYS,2020-10-25 05:24:03.683,342,1,Alive,Alive During Study,
589,AB12345,AB12345-CHN-11-id-27,id-27,CHN-11,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,12.8134782273952,HIGH,Y,Y,N,Y,N,2019-11-14,2019-11-18 05:24:03.683,,2019-11-18 05:24:03.683,,,,2019-11-18 05:24:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,206.385986786336,DAYS,2019-12-31 05:24:03.683,43,1,Last Tumor Assessment,Completion or Discontinuation,
590,AB12345,AB12345-CHN-11-id-27,id-27,CHN-11,35,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S2,12.8134782273952,HIGH,Y,Y,N,Y,N,2019-11-14,2019-11-18 05:24:03.683,,2019-11-18 05:24:03.683,,,,2019-11-18 05:24:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-1.54049971097318
591,AB12345,AB12345-CHN-11-id-278,id-278,CHN-11,47,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,2.0798092813724,MEDIUM,Y,Y,N,Y,N,2020-08-23,2020-08-24 06:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,COMPLETED,COMPLETED,2023-08-25,1096,,,,,,,2023-09-07,,,4,4,Duration of Confirmed Response,CRSD,154.06422810629,DAYS,2023-02-13 06:55:10.683,903,0,Disease Progression,,
592,AB12345,AB12345-CHN-11-id-278,id-278,CHN-11,47,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,2.0798092813724,MEDIUM,Y,Y,N,Y,N,2020-08-23,2020-08-24 06:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,COMPLETED,COMPLETED,2023-08-25,1096,,,,,,,2023-09-07,,,1,1,Event Free Survival,EFS,43.6045491765253,DAYS,2021-09-03 06:55:10.683,375,1,Last Tumor Assessment,Completion or Discontinuation,
593,AB12345,AB12345-CHN-11-id-278,id-278,CHN-11,47,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,2.0798092813724,MEDIUM,Y,Y,N,Y,N,2020-08-23,2020-08-24 06:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,COMPLETED,COMPLETED,2023-08-25,1096,,,,,,,2023-09-07,,,2,2,Overall Survival,OS,291.323122195899,DAYS,2021-12-16 06:55:10.683,479,0,Death,,
594,AB12345,AB12345-CHN-11-id-278,id-278,CHN-11,47,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,2.0798092813724,MEDIUM,Y,Y,N,Y,N,2020-08-23,2020-08-24 06:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,COMPLETED,COMPLETED,2023-08-25,1096,,,,,,,2023-09-07,,,3,3,Progression Free Survival,PFS,291.323122195899,DAYS,2022-03-27 06:55:10.683,580,0,Death,,
595,AB12345,AB12345-CHN-11-id-278,id-278,CHN-11,47,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,2.0798092813724,MEDIUM,Y,Y,N,Y,N,2020-08-23,2020-08-24 06:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,2020-08-24 06:55:10.683,2022-08-24 18:55:10.683,2022-08-24 18:55:10.683,2023-08-25 00:55:10.683,COMPLETED,COMPLETED,2023-08-25,1096,,,,,,,2023-09-07,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.94737908601152
596,AB12345,AB12345-CHN-11-id-289,id-289,CHN-11,40,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,13.9118107572001,HIGH,Y,Y,N,N,N,2020-09-26,2020-09-28 19:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,COMPLETED,COMPLETED,2023-09-29,1096,,,,,,,2023-10-28,,,3,3,Duration of Confirmed Response,CRSD,196.026716404594,DAYS,2021-06-26 19:05:36.683,271,1,Adverse Event,Preferred Term,
597,AB12345,AB12345-CHN-11-id-289,id-289,CHN-11,40,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,13.9118107572001,HIGH,Y,Y,N,N,N,2020-09-26,2020-09-28 19:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,COMPLETED,COMPLETED,2023-09-29,1096,,,,,,,2023-10-28,,,1,1,Event Free Survival,EFS,47.8848645277321,DAYS,2020-11-28 19:05:36.683,61,1,Last Tumor Assessment,Completion or Discontinuation,
598,AB12345,AB12345-CHN-11-id-289,id-289,CHN-11,40,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,13.9118107572001,HIGH,Y,Y,N,N,N,2020-09-26,2020-09-28 19:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,COMPLETED,COMPLETED,2023-09-29,1096,,,,,,,2023-10-28,,,2,2,Overall Survival,OS,488.320395862684,DAYS,2021-01-27 19:05:36.683,121,1,Alive,Alive During Study,
599,AB12345,AB12345-CHN-11-id-289,id-289,CHN-11,40,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,13.9118107572001,HIGH,Y,Y,N,N,N,2020-09-26,2020-09-28 19:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,COMPLETED,COMPLETED,2023-09-29,1096,,,,,,,2023-10-28,,,4,4,Progression Free Survival,PFS,238.46865913365,DAYS,2021-12-08 19:05:36.683,436,1,Last Tumor Assessment,Completion or Discontinuation,
600,AB12345,AB12345-CHN-11-id-289,id-289,CHN-11,40,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,13.9118107572001,HIGH,Y,Y,N,N,N,2020-09-26,2020-09-28 19:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,2020-09-28 19:05:36.683,2022-09-29 07:05:36.683,2022-09-29 07:05:36.683,2023-09-29 13:05:36.683,COMPLETED,COMPLETED,2023-09-29,1096,,,,,,,2023-10-28,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,1,,Preferred Term,-3.80744823917172
601,AB12345,AB12345-CHN-11-id-291,id-291,CHN-11,50,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,2.30136374630684,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 14:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-22,,,2,2,Duration of Confirmed Response,CRSD,190.264235367067,DAYS,2021-07-20 14:17:00.683,262,0,Disease Progression,,
602,AB12345,AB12345-CHN-11-id-291,id-291,CHN-11,50,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,2.30136374630684,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 14:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-22,,,3,3,Event Free Survival,EFS,72.8540308587253,DAYS,2022-02-05 14:17:00.683,462,0,Disease Progression,,
603,AB12345,AB12345-CHN-11-id-291,id-291,CHN-11,50,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,2.30136374630684,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 14:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-22,,,1,1,Overall Survival,OS,381.219425890595,DAYS,2021-07-06 14:17:00.683,248,1,Alive,Alive During Study,
604,AB12345,AB12345-CHN-11-id-291,id-291,CHN-11,50,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,2.30136374630684,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 14:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-22,,,4,4,Progression Free Survival,PFS,225.379706569947,DAYS,2023-05-21 14:17:00.683,932,0,Disease Progression,,
605,AB12345,AB12345-CHN-11-id-291,id-291,CHN-11,50,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S1,2.30136374630684,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 14:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,2020-10-31 14:17:00.683,2022-11-01 02:17:00.683,2022-11-01 02:17:00.683,2023-11-01 08:17:00.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-22,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.90508750275848
606,AB12345,AB12345-CHN-11-id-298,id-298,CHN-11,31,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,2.78010633306694,MEDIUM,Y,Y,N,N,N,2020-03-26,2020-03-28 15:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-25,,,3,3,Duration of Confirmed Response,CRSD,16.2111321475822,DAYS,2022-05-23 15:25:00.683,786,0,Death,,
607,AB12345,AB12345-CHN-11-id-298,id-298,CHN-11,31,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,2.78010633306694,MEDIUM,Y,Y,N,N,N,2020-03-26,2020-03-28 15:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-25,,,4,4,Event Free Survival,EFS,16.2111321475822,DAYS,2022-06-25 15:25:00.683,819,0,Death,,
608,AB12345,AB12345-CHN-11-id-298,id-298,CHN-11,31,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,2.78010633306694,MEDIUM,Y,Y,N,N,N,2020-03-26,2020-03-28 15:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-25,,,2,2,Overall Survival,OS,16.2111321475822,DAYS,2021-09-04 15:25:00.683,525,0,Death,,
609,AB12345,AB12345-CHN-11-id-298,id-298,CHN-11,31,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,2.78010633306694,MEDIUM,Y,Y,N,N,N,2020-03-26,2020-03-28 15:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-25,,,1,1,Progression Free Survival,PFS,16.2111321475822,DAYS,2020-07-10 15:25:00.683,104,0,Death,,
610,AB12345,AB12345-CHN-11-id-298,id-298,CHN-11,31,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S2,2.78010633306694,MEDIUM,Y,Y,N,N,N,2020-03-26,2020-03-28 15:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,2020-03-28 15:25:00.683,2022-03-29 03:25:00.683,2022-03-29 03:25:00.683,2023-03-29 09:25:00.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-25,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-1.14862263100808
611,AB12345,AB12345-CHN-11-id-317,id-317,CHN-11,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,2.05702249469993,MEDIUM,Y,Y,Y,Y,N,2020-05-19,2020-05-20 22:42:47.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,DISCONTINUED,DISCONTINUED,2022-02-12,633,DEATH,2022-03-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,26,<=30,2022-03-10,658,Yes,4,4,Duration of Confirmed Response,CRSD,150.153779191896,DAYS,2020-11-03 22:42:47.683,167,1,Adverse Event,Preferred Term,
612,AB12345,AB12345-CHN-11-id-317,id-317,CHN-11,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,2.05702249469993,MEDIUM,Y,Y,Y,Y,N,2020-05-19,2020-05-20 22:42:47.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,DISCONTINUED,DISCONTINUED,2022-02-12,633,DEATH,2022-03-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,26,<=30,2022-03-10,658,Yes,1,1,Event Free Survival,EFS,24.3880625069141,DAYS,2020-08-08 22:42:47.683,80,1,Adverse Event,Preferred Term,
613,AB12345,AB12345-CHN-11-id-317,id-317,CHN-11,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,2.05702249469993,MEDIUM,Y,Y,Y,Y,N,2020-05-19,2020-05-20 22:42:47.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,DISCONTINUED,DISCONTINUED,2022-02-12,633,DEATH,2022-03-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,26,<=30,2022-03-10,658,Yes,2,2,Overall Survival,OS,461.183110857382,DAYS,2020-09-13 22:42:47.683,116,1,Alive,Alive During Study,
614,AB12345,AB12345-CHN-11-id-317,id-317,CHN-11,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,2.05702249469993,MEDIUM,Y,Y,Y,Y,N,2020-05-19,2020-05-20 22:42:47.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,DISCONTINUED,DISCONTINUED,2022-02-12,633,DEATH,2022-03-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,26,<=30,2022-03-10,658,Yes,3,3,Progression Free Survival,PFS,237.152664805762,DAYS,2020-10-10 22:42:47.683,143,1,Adverse Event,Preferred Term,
615,AB12345,AB12345-CHN-11-id-317,id-317,CHN-11,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S2,2.05702249469993,MEDIUM,Y,Y,Y,Y,N,2020-05-19,2020-05-20 22:42:47.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,2020-05-20 22:42:47.683,2021-02-12 13:25:23.683,2021-02-12 13:25:23.683,2022-02-12 19:25:23.683,DISCONTINUED,DISCONTINUED,2022-02-12,633,DEATH,2022-03-10,DISEASE PROGRESSION,PROGRESSIVE DISEASE,26,<=30,2022-03-10,658,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-2.44350921278547
616,AB12345,AB12345-CHN-11-id-318,id-318,CHN-11,42,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,3.39500962721571,LOW,Y,Y,N,N,N,2019-08-24,2019-08-28 09:37:04.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,DISCONTINUED,DISCONTINUED,2022-02-16,904,DEATH,2022-02-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,8,<=30,2022-02-24,910,Yes,4,4,Duration of Confirmed Response,CRSD,183.651205920614,DAYS,2021-12-19 09:37:04.683,844,0,Disease Progression,,
617,AB12345,AB12345-CHN-11-id-318,id-318,CHN-11,42,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,3.39500962721571,LOW,Y,Y,N,N,N,2019-08-24,2019-08-28 09:37:04.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,DISCONTINUED,DISCONTINUED,2022-02-16,904,DEATH,2022-02-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,8,<=30,2022-02-24,910,Yes,1,1,Event Free Survival,EFS,15.6734417029656,DAYS,2019-09-12 09:37:04.683,15,1,Adverse Event,Preferred Term,
618,AB12345,AB12345-CHN-11-id-318,id-318,CHN-11,42,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,3.39500962721571,LOW,Y,Y,N,N,N,2019-08-24,2019-08-28 09:37:04.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,DISCONTINUED,DISCONTINUED,2022-02-16,904,DEATH,2022-02-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,8,<=30,2022-02-24,910,Yes,3,3,Overall Survival,OS,377.049706643447,DAYS,2020-08-29 09:37:04.683,367,1,Alive,Alive During Study,
619,AB12345,AB12345-CHN-11-id-318,id-318,CHN-11,42,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,3.39500962721571,LOW,Y,Y,N,N,N,2019-08-24,2019-08-28 09:37:04.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,DISCONTINUED,DISCONTINUED,2022-02-16,904,DEATH,2022-02-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,8,<=30,2022-02-24,910,Yes,2,2,Progression Free Survival,PFS,237.683917931281,DAYS,2019-12-15 09:37:04.683,109,1,Adverse Event,Preferred Term,
620,AB12345,AB12345-CHN-11-id-318,id-318,CHN-11,42,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,3.39500962721571,LOW,Y,Y,N,N,N,2019-08-24,2019-08-28 09:37:04.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,2019-08-28 09:37:04.683,2021-02-16 08:01:19.683,2021-02-16 08:01:19.683,2022-02-16 14:01:19.683,DISCONTINUED,DISCONTINUED,2022-02-16,904,DEATH,2022-02-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,8,<=30,2022-02-24,910,Yes,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-3.01886248286234
621,AB12345,AB12345-CHN-11-id-349,id-349,CHN-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,4.32397547702939,MEDIUM,Y,Y,Y,N,Y,2020-11-11,2020-11-13 19:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,COMPLETED,COMPLETED,2023-11-14,1096,,,,,,,2023-11-29,,,1,1,Duration of Confirmed Response,CRSD,95.8800989191514,DAYS,2021-03-09 19:38:06.683,116,0,Death,,
622,AB12345,AB12345-CHN-11-id-349,id-349,CHN-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,4.32397547702939,MEDIUM,Y,Y,Y,N,Y,2020-11-11,2020-11-13 19:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,COMPLETED,COMPLETED,2023-11-14,1096,,,,,,,2023-11-29,,,4,4,Event Free Survival,EFS,95.8800989191514,DAYS,2023-03-27 19:38:06.683,864,0,Death,,
623,AB12345,AB12345-CHN-11-id-349,id-349,CHN-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,4.32397547702939,MEDIUM,Y,Y,Y,N,Y,2020-11-11,2020-11-13 19:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,COMPLETED,COMPLETED,2023-11-14,1096,,,,,,,2023-11-29,,,2,2,Overall Survival,OS,95.8800989191514,DAYS,2021-11-13 19:38:06.683,365,0,Death,,
624,AB12345,AB12345-CHN-11-id-349,id-349,CHN-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,4.32397547702939,MEDIUM,Y,Y,Y,N,Y,2020-11-11,2020-11-13 19:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,COMPLETED,COMPLETED,2023-11-14,1096,,,,,,,2023-11-29,,,3,3,Progression Free Survival,PFS,95.8800989191514,DAYS,2021-11-22 19:38:06.683,374,0,Death,,
625,AB12345,AB12345-CHN-11-id-349,id-349,CHN-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,4.32397547702939,MEDIUM,Y,Y,Y,N,Y,2020-11-11,2020-11-13 19:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,2020-11-13 19:38:06.683,2022-11-14 07:38:06.683,2022-11-14 07:38:06.683,2023-11-14 13:38:06.683,COMPLETED,COMPLETED,2023-11-14,1096,,,,,,,2023-11-29,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-1.2232488990145
626,AB12345,AB12345-CHN-11-id-354,id-354,CHN-11,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,5.59137560334452,LOW,Y,Y,N,N,N,2020-02-07,2020-02-10 04:49:15.683,,2020-02-10 04:49:15.683,,,,2020-02-10 04:49:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,155.209379433654,DAYS,2021-03-08 04:49:15.683,392,0,Disease Progression,,
627,AB12345,AB12345-CHN-11-id-354,id-354,CHN-11,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,5.59137560334452,LOW,Y,Y,N,N,N,2020-02-07,2020-02-10 04:49:15.683,,2020-02-10 04:49:15.683,,,,2020-02-10 04:49:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,55.4323103534989,DAYS,2021-08-28 04:49:15.683,565,1,Last Tumor Assessment,Completion or Discontinuation,
628,AB12345,AB12345-CHN-11-id-354,id-354,CHN-11,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,5.59137560334452,LOW,Y,Y,N,N,N,2020-02-07,2020-02-10 04:49:15.683,,2020-02-10 04:49:15.683,,,,2020-02-10 04:49:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,472.687251213938,DAYS,2021-09-14 04:49:15.683,582,1,Alive,Alive During Study,
629,AB12345,AB12345-CHN-11-id-354,id-354,CHN-11,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,5.59137560334452,LOW,Y,Y,N,N,N,2020-02-07,2020-02-10 04:49:15.683,,2020-02-10 04:49:15.683,,,,2020-02-10 04:49:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,293.471632502042,DAYS,2021-09-06 04:49:15.683,574,1,Adverse Event,Preferred Term,
630,AB12345,AB12345-CHN-11-id-354,id-354,CHN-11,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,5.59137560334452,LOW,Y,Y,N,N,N,2020-02-07,2020-02-10 04:49:15.683,,2020-02-10 04:49:15.683,,,,2020-02-10 04:49:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.41953615605626
631,AB12345,AB12345-CHN-11-id-356,id-356,CHN-11,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.24981142891721,LOW,Y,Y,Y,Y,N,2020-03-08,2020-03-12 10:37:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,DISCONTINUED,DISCONTINUED,2022-02-12,703,ADVERSE EVENT,,,,,,2022-02-22,,,3,3,Duration of Confirmed Response,CRSD,168.769983458333,DAYS,2021-02-02 10:37:13.683,327,0,Disease Progression,,
632,AB12345,AB12345-CHN-11-id-356,id-356,CHN-11,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.24981142891721,LOW,Y,Y,Y,Y,N,2020-03-08,2020-03-12 10:37:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,DISCONTINUED,DISCONTINUED,2022-02-12,703,ADVERSE EVENT,,,,,,2022-02-22,,,1,1,Event Free Survival,EFS,37.0927311689593,DAYS,2020-08-16 10:37:13.683,157,1,Last Tumor Assessment,Completion or Discontinuation,
633,AB12345,AB12345-CHN-11-id-356,id-356,CHN-11,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.24981142891721,LOW,Y,Y,Y,Y,N,2020-03-08,2020-03-12 10:37:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,DISCONTINUED,DISCONTINUED,2022-02-12,703,ADVERSE EVENT,,,,,,2022-02-22,,,4,4,Overall Survival,OS,343.603255180642,DAYS,2021-03-29 10:37:13.683,382,1,Alive,Alive During Study,
634,AB12345,AB12345-CHN-11-id-356,id-356,CHN-11,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.24981142891721,LOW,Y,Y,Y,Y,N,2020-03-08,2020-03-12 10:37:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,DISCONTINUED,DISCONTINUED,2022-02-12,703,ADVERSE EVENT,,,,,,2022-02-22,,,2,2,Progression Free Survival,PFS,244.79072461836,DAYS,2020-10-24 10:37:13.683,226,0,Disease Progression,,
635,AB12345,AB12345-CHN-11-id-356,id-356,CHN-11,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.24981142891721,LOW,Y,Y,Y,Y,N,2020-03-08,2020-03-12 10:37:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,2020-03-12 10:37:13.683,2021-02-12 08:59:13.683,2021-02-12 08:59:13.683,2022-02-12 14:59:13.683,DISCONTINUED,DISCONTINUED,2022-02-12,703,ADVERSE EVENT,,,,,,2022-02-22,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.99665500529307
636,AB12345,AB12345-CHN-11-id-358,id-358,CHN-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,1.3900249121342,HIGH,Y,Y,N,Y,N,2020-11-28,2020-12-02 13:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,COMPLETED,COMPLETED,2023-12-03,1096,,,,,,,2023-12-18,,,1,1,Duration of Confirmed Response,CRSD,195.938202529214,DAYS,2021-05-14 13:47:17.683,163,1,Last Tumor Assessment,Completion or Discontinuation,
637,AB12345,AB12345-CHN-11-id-358,id-358,CHN-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,1.3900249121342,HIGH,Y,Y,N,Y,N,2020-11-28,2020-12-02 13:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,COMPLETED,COMPLETED,2023-12-03,1096,,,,,,,2023-12-18,,,4,4,Event Free Survival,EFS,73.3301292802207,DAYS,2023-11-01 13:47:17.683,1064,1,Last Tumor Assessment,Completion or Discontinuation,
638,AB12345,AB12345-CHN-11-id-358,id-358,CHN-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,1.3900249121342,HIGH,Y,Y,N,Y,N,2020-11-28,2020-12-02 13:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,COMPLETED,COMPLETED,2023-12-03,1096,,,,,,,2023-12-18,,,3,3,Overall Survival,OS,393.751998385414,DAYS,2023-04-13 13:47:17.683,862,1,Alive,Alive During Study,
639,AB12345,AB12345-CHN-11-id-358,id-358,CHN-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,1.3900249121342,HIGH,Y,Y,N,Y,N,2020-11-28,2020-12-02 13:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,COMPLETED,COMPLETED,2023-12-03,1096,,,,,,,2023-12-18,,,2,2,Progression Free Survival,PFS,225.940448092297,DAYS,2022-01-04 13:47:17.683,398,1,Adverse Event,Preferred Term,
640,AB12345,AB12345-CHN-11-id-358,id-358,CHN-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,1.3900249121342,HIGH,Y,Y,N,Y,N,2020-11-28,2020-12-02 13:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,2020-12-02 13:47:17.683,2022-12-03 01:47:17.683,2022-12-03 01:47:17.683,2023-12-03 07:47:17.683,COMPLETED,COMPLETED,2023-12-03,1096,,,,,,,2023-12-18,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.842606200261577
641,AB12345,AB12345-CHN-11-id-362,id-362,CHN-11,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,7.60836451558251,LOW,Y,Y,N,Y,N,2020-04-23,2020-04-23 03:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,COMPLETED,COMPLETED,2023-04-23,1096,,,,,,,2023-05-10,,,1,1,Duration of Confirmed Response,CRSD,42.3138623998966,DAYS,2021-12-05 03:00:32.683,591,0,Death,,
642,AB12345,AB12345-CHN-11-id-362,id-362,CHN-11,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,7.60836451558251,LOW,Y,Y,N,Y,N,2020-04-23,2020-04-23 03:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,COMPLETED,COMPLETED,2023-04-23,1096,,,,,,,2023-05-10,,,2,2,Event Free Survival,EFS,42.3138623998966,DAYS,2022-01-25 03:00:32.683,642,0,Death,,
643,AB12345,AB12345-CHN-11-id-362,id-362,CHN-11,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,7.60836451558251,LOW,Y,Y,N,Y,N,2020-04-23,2020-04-23 03:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,COMPLETED,COMPLETED,2023-04-23,1096,,,,,,,2023-05-10,,,3,3,Overall Survival,OS,42.3138623998966,DAYS,2022-08-13 03:00:32.683,842,0,Death,,
644,AB12345,AB12345-CHN-11-id-362,id-362,CHN-11,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,7.60836451558251,LOW,Y,Y,N,Y,N,2020-04-23,2020-04-23 03:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,COMPLETED,COMPLETED,2023-04-23,1096,,,,,,,2023-05-10,,,4,4,Progression Free Survival,PFS,42.3138623998966,DAYS,2022-12-05 03:00:32.683,956,0,Death,,
645,AB12345,AB12345-CHN-11-id-362,id-362,CHN-11,39,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,7.60836451558251,LOW,Y,Y,N,Y,N,2020-04-23,2020-04-23 03:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,2020-04-23 03:00:32.683,2022-04-23 15:00:32.683,2022-04-23 15:00:32.683,2023-04-23 21:00:32.683,COMPLETED,COMPLETED,2023-04-23,1096,,,,,,,2023-05-10,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.27929581533374
646,AB12345,AB12345-CHN-11-id-364,id-364,CHN-11,48,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,1.68838803056054,MEDIUM,Y,Y,Y,N,N,2020-12-20,2020-12-20 05:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-14,,,4,4,Duration of Confirmed Response,CRSD,171.472772536799,DAYS,2023-10-14 05:32:09.683,1028,1,Last Tumor Assessment,Completion or Discontinuation,
647,AB12345,AB12345-CHN-11-id-364,id-364,CHN-11,48,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,1.68838803056054,MEDIUM,Y,Y,Y,N,N,2020-12-20,2020-12-20 05:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-14,,,1,1,Event Free Survival,EFS,28.99463923648,DAYS,2022-04-27 05:32:09.683,493,1,Last Tumor Assessment,Completion or Discontinuation,
648,AB12345,AB12345-CHN-11-id-364,id-364,CHN-11,48,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,1.68838803056054,MEDIUM,Y,Y,Y,N,N,2020-12-20,2020-12-20 05:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-14,,,3,3,Overall Survival,OS,346.942936023697,DAYS,2022-09-06 05:32:09.683,625,1,Alive,Alive During Study,
649,AB12345,AB12345-CHN-11-id-364,id-364,CHN-11,48,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,1.68838803056054,MEDIUM,Y,Y,Y,N,N,2020-12-20,2020-12-20 05:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-14,,,2,2,Progression Free Survival,PFS,252.816575136967,DAYS,2022-08-23 05:32:09.683,611,0,Disease Progression,,
650,AB12345,AB12345-CHN-11-id-364,id-364,CHN-11,48,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,1.68838803056054,MEDIUM,Y,Y,Y,N,N,2020-12-20,2020-12-20 05:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,2020-12-20 05:32:09.683,2022-12-20 17:32:09.683,2022-12-20 17:32:09.683,2023-12-20 23:32:09.683,COMPLETED,COMPLETED,2023-12-20,1096,,,,,,,2024-01-14,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-0.128505140465923
651,AB12345,AB12345-CHN-11-id-377,id-377,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.66603063248351,HIGH,Y,Y,Y,N,N,2020-01-10,2020-01-10 16:28:00.683,,2020-01-10 16:28:00.683,,,,2020-01-10 16:28:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,167.576349619776,DAYS,2020-10-19 16:28:00.683,283,0,Disease Progression,,
652,AB12345,AB12345-CHN-11-id-377,id-377,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.66603063248351,HIGH,Y,Y,Y,N,N,2020-01-10,2020-01-10 16:28:00.683,,2020-01-10 16:28:00.683,,,,2020-01-10 16:28:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,20.4766912281048,DAYS,2020-03-28 16:28:00.683,78,0,Disease Progression,,
653,AB12345,AB12345-CHN-11-id-377,id-377,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.66603063248351,HIGH,Y,Y,Y,N,N,2020-01-10,2020-01-10 16:28:00.683,,2020-01-10 16:28:00.683,,,,2020-01-10 16:28:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,323.094247048721,DAYS,2020-06-19 16:28:00.683,161,1,Alive,Alive During Study,
654,AB12345,AB12345-CHN-11-id-377,id-377,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.66603063248351,HIGH,Y,Y,Y,N,N,2020-01-10,2020-01-10 16:28:00.683,,2020-01-10 16:28:00.683,,,,2020-01-10 16:28:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,280.614536185749,DAYS,2021-12-23 16:28:00.683,713,0,Disease Progression,,
655,AB12345,AB12345-CHN-11-id-377,id-377,CHN-11,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,1.66603063248351,HIGH,Y,Y,Y,N,N,2020-01-10,2020-01-10 16:28:00.683,,2020-01-10 16:28:00.683,,,,2020-01-10 16:28:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,0.359216884744646
656,AB12345,AB12345-CHN-11-id-379,id-379,CHN-11,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,5.84650537132412,LOW,Y,Y,N,N,N,2019-07-29,2019-07-30 00:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-24,,,4,4,Duration of Confirmed Response,CRSD,102.17862285208,DAYS,2020-06-02 00:43:21.683,308,0,Disease Progression,,
657,AB12345,AB12345-CHN-11-id-379,id-379,CHN-11,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,5.84650537132412,LOW,Y,Y,N,N,N,2019-07-29,2019-07-30 00:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-24,,,3,3,Event Free Survival,EFS,73.82122581359,DAYS,2020-03-26 00:43:21.683,240,1,Last Tumor Assessment,Completion or Discontinuation,
658,AB12345,AB12345-CHN-11-id-379,id-379,CHN-11,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,5.84650537132412,LOW,Y,Y,N,N,N,2019-07-29,2019-07-30 00:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-24,,,2,2,Overall Survival,OS,446.456009987742,DAYS,2020-02-12 00:43:21.683,197,1,Alive,Alive During Study,
659,AB12345,AB12345-CHN-11-id-379,id-379,CHN-11,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,5.84650537132412,LOW,Y,Y,N,N,N,2019-07-29,2019-07-30 00:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-24,,,1,1,Progression Free Survival,PFS,236.137670860626,DAYS,2019-12-07 00:43:21.683,130,1,Last Tumor Assessment,Completion or Discontinuation,
660,AB12345,AB12345-CHN-11-id-379,id-379,CHN-11,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,5.84650537132412,LOW,Y,Y,N,N,N,2019-07-29,2019-07-30 00:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,2019-07-30 00:43:21.683,2021-07-29 12:43:21.683,2021-07-29 12:43:21.683,2022-07-29 18:43:21.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-24,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.06390124637693
661,AB12345,AB12345-CHN-11-id-38,id-38,CHN-11,25,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,1.48993037060371,LOW,Y,Y,Y,Y,N,2019-06-13,2019-06-17 00:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,COMPLETED,COMPLETED,2022-06-16,1096,,,,,,,2022-07-08,,,3,3,Duration of Confirmed Response,CRSD,144.715305324644,DAYS,2021-05-22 00:54:30.683,705,0,Death,,
662,AB12345,AB12345-CHN-11-id-38,id-38,CHN-11,25,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,1.48993037060371,LOW,Y,Y,Y,Y,N,2019-06-13,2019-06-17 00:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,COMPLETED,COMPLETED,2022-06-16,1096,,,,,,,2022-07-08,,,2,2,Event Free Survival,EFS,41.572958562756,DAYS,2020-04-23 00:54:30.683,311,0,Disease Progression,,
663,AB12345,AB12345-CHN-11-id-38,id-38,CHN-11,25,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,1.48993037060371,LOW,Y,Y,Y,Y,N,2019-06-13,2019-06-17 00:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,COMPLETED,COMPLETED,2022-06-16,1096,,,,,,,2022-07-08,,,1,1,Overall Survival,OS,144.715305324644,DAYS,2019-09-02 00:54:30.683,77,0,Death,,
664,AB12345,AB12345-CHN-11-id-38,id-38,CHN-11,25,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,1.48993037060371,LOW,Y,Y,Y,Y,N,2019-06-13,2019-06-17 00:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,COMPLETED,COMPLETED,2022-06-16,1096,,,,,,,2022-07-08,,,4,4,Progression Free Survival,PFS,144.715305324644,DAYS,2022-05-03 00:54:30.683,1051,0,Death,,
665,AB12345,AB12345-CHN-11-id-38,id-38,CHN-11,25,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,1.48993037060371,LOW,Y,Y,Y,Y,N,2019-06-13,2019-06-17 00:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,2019-06-17 00:54:30.683,2021-06-16 12:54:30.683,2021-06-16 12:54:30.683,2022-06-16 18:54:30.683,COMPLETED,COMPLETED,2022-06-16,1096,,,,,,,2022-07-08,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-2.52965720034481
666,AB12345,AB12345-CHN-11-id-386,id-386,CHN-11,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,4.56042299102589,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-18 12:55:21.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,DISCONTINUED,DISCONTINUED,2022-02-15,759,DEATH,2022-03-26,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-26,797,Yes,2,2,Duration of Confirmed Response,CRSD,133.179546520114,DAYS,2020-02-17 12:55:21.683,30,0,Disease Progression,,
667,AB12345,AB12345-CHN-11-id-386,id-386,CHN-11,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,4.56042299102589,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-18 12:55:21.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,DISCONTINUED,DISCONTINUED,2022-02-15,759,DEATH,2022-03-26,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-26,797,Yes,1,1,Event Free Survival,EFS,85.1623207819648,DAYS,2020-02-15 12:55:21.683,28,1,Adverse Event,Preferred Term,
668,AB12345,AB12345-CHN-11-id-386,id-386,CHN-11,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,4.56042299102589,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-18 12:55:21.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,DISCONTINUED,DISCONTINUED,2022-02-15,759,DEATH,2022-03-26,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-26,797,Yes,3,3,Overall Survival,OS,360.184150421992,DAYS,2020-07-27 12:55:21.683,191,1,Alive,Alive During Study,
669,AB12345,AB12345-CHN-11-id-386,id-386,CHN-11,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,4.56042299102589,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-18 12:55:21.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,DISCONTINUED,DISCONTINUED,2022-02-15,759,DEATH,2022-03-26,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-26,797,Yes,4,4,Progression Free Survival,PFS,214.402516721748,DAYS,2020-11-29 12:55:21.683,316,1,Adverse Event,Preferred Term,
670,AB12345,AB12345-CHN-11-id-386,id-386,CHN-11,36,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,4.56042299102589,HIGH,Y,Y,Y,Y,N,2020-01-16,2020-01-18 12:55:21.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,2020-01-18 12:55:21.683,2021-02-14 20:38:35.683,2021-02-14 20:38:35.683,2022-02-15 02:38:35.683,DISCONTINUED,DISCONTINUED,2022-02-15,759,DEATH,2022-03-26,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-26,797,Yes,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-4.14049859976176
671,AB12345,AB12345-CHN-11-id-391,id-391,CHN-11,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,6.96759895108784,HIGH,Y,Y,N,Y,N,2020-05-12,2020-05-15 21:08:17.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,645,ADVERSE EVENT,,,,,,2022-03-03,,,4,4,Duration of Confirmed Response,CRSD,183.947157836519,DAYS,2021-11-21 21:08:17.683,555,1,Adverse Event,Preferred Term,
672,AB12345,AB12345-CHN-11-id-391,id-391,CHN-11,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,6.96759895108784,HIGH,Y,Y,N,Y,N,2020-05-12,2020-05-15 21:08:17.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,645,ADVERSE EVENT,,,,,,2022-03-03,,,1,1,Event Free Survival,EFS,28.8211527373642,DAYS,2020-07-24 21:08:17.683,70,1,Last Tumor Assessment,Completion or Discontinuation,
673,AB12345,AB12345-CHN-11-id-391,id-391,CHN-11,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,6.96759895108784,HIGH,Y,Y,N,Y,N,2020-05-12,2020-05-15 21:08:17.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,645,ADVERSE EVENT,,,,,,2022-03-03,,,3,3,Overall Survival,OS,266.43074771855,DAYS,2021-05-04 21:08:17.683,354,0,Death,,
674,AB12345,AB12345-CHN-11-id-391,id-391,CHN-11,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,6.96759895108784,HIGH,Y,Y,N,Y,N,2020-05-12,2020-05-15 21:08:17.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,645,ADVERSE EVENT,,,,,,2022-03-03,,,2,2,Progression Free Survival,PFS,266.43074771855,DAYS,2020-08-20 21:08:17.683,97,0,Death,,
675,AB12345,AB12345-CHN-11-id-391,id-391,CHN-11,35,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,6.96759895108784,HIGH,Y,Y,N,Y,N,2020-05-12,2020-05-15 21:08:17.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,2020-05-15 21:08:17.683,2021-02-19 05:03:33.683,2021-02-19 05:03:33.683,2022-02-19 11:03:33.683,DISCONTINUED,DISCONTINUED,2022-02-19,645,ADVERSE EVENT,,,,,,2022-03-03,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,0.47568204227533
676,AB12345,AB12345-CHN-11-id-392,id-392,CHN-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S1,7.77394837459153,LOW,Y,Y,Y,N,N,2019-09-24,2019-09-28 10:00:27.683,,2019-09-28 10:00:27.683,,,,2019-09-28 10:00:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,132.588181388564,DAYS,2020-05-11 10:00:27.683,226,0,Disease Progression,,
677,AB12345,AB12345-CHN-11-id-392,id-392,CHN-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S1,7.77394837459153,LOW,Y,Y,Y,N,N,2019-09-24,2019-09-28 10:00:27.683,,2019-09-28 10:00:27.683,,,,2019-09-28 10:00:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,26.8037209752947,DAYS,2020-10-04 10:00:27.683,372,1,Adverse Event,Preferred Term,
678,AB12345,AB12345-CHN-11-id-392,id-392,CHN-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S1,7.77394837459153,LOW,Y,Y,Y,N,N,2019-09-24,2019-09-28 10:00:27.683,,2019-09-28 10:00:27.683,,,,2019-09-28 10:00:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,283.1430218881,DAYS,2021-03-27 10:00:27.683,546,0,Death,,
679,AB12345,AB12345-CHN-11-id-392,id-392,CHN-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S1,7.77394837459153,LOW,Y,Y,Y,N,N,2019-09-24,2019-09-28 10:00:27.683,,2019-09-28 10:00:27.683,,,,2019-09-28 10:00:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,283.1430218881,DAYS,2021-02-07 10:00:27.683,498,0,Death,,
680,AB12345,AB12345-CHN-11-id-392,id-392,CHN-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S1,7.77394837459153,LOW,Y,Y,Y,N,N,2019-09-24,2019-09-28 10:00:27.683,,2019-09-28 10:00:27.683,,,,2019-09-28 10:00:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.7839408033571
681,AB12345,AB12345-CHN-11-id-54,id-54,CHN-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,4.81516226582073,LOW,Y,Y,N,N,N,2019-08-17,2019-08-21 06:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,COMPLETED,COMPLETED,2022-08-21,1096,,,,,,,2022-09-01,,,2,2,Duration of Confirmed Response,CRSD,114.93999203667,DAYS,2020-09-21 06:30:41.683,397,1,Adverse Event,Preferred Term,
682,AB12345,AB12345-CHN-11-id-54,id-54,CHN-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,4.81516226582073,LOW,Y,Y,N,N,N,2019-08-17,2019-08-21 06:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,COMPLETED,COMPLETED,2022-08-21,1096,,,,,,,2022-09-01,,,4,4,Event Free Survival,EFS,84.915823872434,DAYS,2022-06-29 06:30:41.683,1043,1,Last Tumor Assessment,Completion or Discontinuation,
683,AB12345,AB12345-CHN-11-id-54,id-54,CHN-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,4.81516226582073,LOW,Y,Y,N,N,N,2019-08-17,2019-08-21 06:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,COMPLETED,COMPLETED,2022-08-21,1096,,,,,,,2022-09-01,,,3,3,Overall Survival,OS,389.036530302837,DAYS,2020-12-30 06:30:41.683,497,1,Alive,Alive During Study,
684,AB12345,AB12345-CHN-11-id-54,id-54,CHN-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,4.81516226582073,LOW,Y,Y,N,N,N,2019-08-17,2019-08-21 06:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,COMPLETED,COMPLETED,2022-08-21,1096,,,,,,,2022-09-01,,,1,1,Progression Free Survival,PFS,242.127968952991,DAYS,2020-09-03 06:30:41.683,379,0,Disease Progression,,
685,AB12345,AB12345-CHN-11-id-54,id-54,CHN-11,26,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S2,4.81516226582073,LOW,Y,Y,N,N,N,2019-08-17,2019-08-21 06:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,2019-08-21 06:30:41.683,2021-08-20 18:30:41.683,2021-08-20 18:30:41.683,2022-08-21 00:30:41.683,COMPLETED,COMPLETED,2022-08-21,1096,,,,,,,2022-09-01,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-0.185378252049539
686,AB12345,AB12345-CHN-11-id-55,id-55,CHN-11,43,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,6.30181207833888,HIGH,Y,Y,Y,Y,N,2020-11-20,2020-11-23 17:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,COMPLETED,COMPLETED,2023-11-24,1096,,,,,,,2023-12-21,,,2,2,Duration of Confirmed Response,CRSD,141.49973266758,DAYS,2022-06-25 17:03:42.683,579,1,Adverse Event,Preferred Term,
687,AB12345,AB12345-CHN-11-id-55,id-55,CHN-11,43,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,6.30181207833888,HIGH,Y,Y,Y,Y,N,2020-11-20,2020-11-23 17:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,COMPLETED,COMPLETED,2023-11-24,1096,,,,,,,2023-12-21,,,3,3,Event Free Survival,EFS,90.1338269410189,DAYS,2022-11-25 17:03:42.683,732,0,Disease Progression,,
688,AB12345,AB12345-CHN-11-id-55,id-55,CHN-11,43,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,6.30181207833888,HIGH,Y,Y,Y,Y,N,2020-11-20,2020-11-23 17:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,COMPLETED,COMPLETED,2023-11-24,1096,,,,,,,2023-12-21,,,4,4,Overall Survival,OS,268.989216187038,DAYS,2023-06-25 17:03:42.683,944,0,Death,,
689,AB12345,AB12345-CHN-11-id-55,id-55,CHN-11,43,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,6.30181207833888,HIGH,Y,Y,Y,Y,N,2020-11-20,2020-11-23 17:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,COMPLETED,COMPLETED,2023-11-24,1096,,,,,,,2023-12-21,,,1,1,Progression Free Survival,PFS,268.989216187038,DAYS,2020-11-26 17:03:42.683,3,0,Death,,
690,AB12345,AB12345-CHN-11-id-55,id-55,CHN-11,43,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,6.30181207833888,HIGH,Y,Y,Y,Y,N,2020-11-20,2020-11-23 17:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,2020-11-23 17:03:42.683,2022-11-24 05:03:42.683,2022-11-24 05:03:42.683,2023-11-24 11:03:42.683,COMPLETED,COMPLETED,2023-11-24,1096,,,,,,,2023-12-21,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-2.8663924944262
691,AB12345,AB12345-CHN-11-id-60,id-60,CHN-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.21027430683958,MEDIUM,Y,Y,N,Y,N,2019-09-09,2019-09-09 10:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,COMPLETED,COMPLETED,2022-09-09,1096,,,,,,,2022-09-22,,,3,3,Duration of Confirmed Response,CRSD,101.237916992977,DAYS,2022-05-24 10:45:02.683,988,1,Last Tumor Assessment,Completion or Discontinuation,
692,AB12345,AB12345-CHN-11-id-60,id-60,CHN-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.21027430683958,MEDIUM,Y,Y,N,Y,N,2019-09-09,2019-09-09 10:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,COMPLETED,COMPLETED,2022-09-09,1096,,,,,,,2022-09-22,,,1,1,Event Free Survival,EFS,75.9382745542098,DAYS,2021-05-11 10:45:02.683,610,1,Adverse Event,Preferred Term,
693,AB12345,AB12345-CHN-11-id-60,id-60,CHN-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.21027430683958,MEDIUM,Y,Y,N,Y,N,2019-09-09,2019-09-09 10:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,COMPLETED,COMPLETED,2022-09-09,1096,,,,,,,2022-09-22,,,2,2,Overall Survival,OS,318.175482843071,DAYS,2022-05-22 10:45:02.683,986,1,Alive,Alive During Study,
694,AB12345,AB12345-CHN-11-id-60,id-60,CHN-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.21027430683958,MEDIUM,Y,Y,N,Y,N,2019-09-09,2019-09-09 10:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,COMPLETED,COMPLETED,2022-09-09,1096,,,,,,,2022-09-22,,,4,4,Progression Free Survival,PFS,203.782944846898,DAYS,2022-07-16 10:45:02.683,1041,0,Disease Progression,,
695,AB12345,AB12345-CHN-11-id-60,id-60,CHN-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,C,S1,4.21027430683958,MEDIUM,Y,Y,N,Y,N,2019-09-09,2019-09-09 10:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,2019-09-09 10:45:02.683,2021-09-08 22:45:02.683,2021-09-08 22:45:02.683,2022-09-09 04:45:02.683,COMPLETED,COMPLETED,2022-09-09,1096,,,,,,,2022-09-22,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-1.64744583055917
696,AB12345,AB12345-CHN-11-id-63,id-63,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,6.80482569008692,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-16 23:12:09.683,,2019-10-16 23:12:09.683,,,,2019-10-16 23:12:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,190.021457592957,DAYS,2021-06-17 23:12:09.683,610,1,Last Tumor Assessment,Completion or Discontinuation,
697,AB12345,AB12345-CHN-11-id-63,id-63,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,6.80482569008692,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-16 23:12:09.683,,2019-10-16 23:12:09.683,,,,2019-10-16 23:12:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,48.9000372320879,DAYS,2021-03-05 23:12:09.683,506,0,Disease Progression,,
698,AB12345,AB12345-CHN-11-id-63,id-63,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,6.80482569008692,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-16 23:12:09.683,,2019-10-16 23:12:09.683,,,,2019-10-16 23:12:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,451.030618418008,DAYS,2021-01-17 23:12:09.683,459,1,Alive,Alive During Study,
699,AB12345,AB12345-CHN-11-id-63,id-63,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,6.80482569008692,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-16 23:12:09.683,,2019-10-16 23:12:09.683,,,,2019-10-16 23:12:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,244.490262842737,DAYS,2020-09-18 23:12:09.683,338,1,Adverse Event,Preferred Term,
700,AB12345,AB12345-CHN-11-id-63,id-63,CHN-11,30,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,6.80482569008692,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-16 23:12:09.683,,2019-10-16 23:12:09.683,,,,2019-10-16 23:12:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-0.102214249676295
701,AB12345,AB12345-CHN-11-id-75,id-75,CHN-11,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,4.61262627591708,HIGH,Y,Y,N,Y,N,2020-03-06,2020-03-09 05:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,3,3,Duration of Confirmed Response,CRSD,116.675635031424,DAYS,2023-02-04 05:22:03.683,1062,0,Death,,
702,AB12345,AB12345-CHN-11-id-75,id-75,CHN-11,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,4.61262627591708,HIGH,Y,Y,N,Y,N,2020-03-06,2020-03-09 05:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,2,2,Event Free Survival,EFS,75.4749703628477,DAYS,2021-07-02 05:22:03.683,480,1,Last Tumor Assessment,Completion or Discontinuation,
703,AB12345,AB12345-CHN-11-id-75,id-75,CHN-11,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,4.61262627591708,HIGH,Y,Y,N,Y,N,2020-03-06,2020-03-09 05:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,4,4,Overall Survival,OS,116.675635031424,DAYS,2023-02-14 05:22:03.683,1072,0,Death,,
704,AB12345,AB12345-CHN-11-id-75,id-75,CHN-11,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,4.61262627591708,HIGH,Y,Y,N,Y,N,2020-03-06,2020-03-09 05:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,1,1,Progression Free Survival,PFS,116.675635031424,DAYS,2021-01-09 05:22:03.683,306,0,Death,,
705,AB12345,AB12345-CHN-11-id-75,id-75,CHN-11,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,4.61262627591708,HIGH,Y,Y,N,Y,N,2020-03-06,2020-03-09 05:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,2020-03-09 05:22:03.683,2022-03-09 17:22:03.683,2022-03-09 17:22:03.683,2023-03-09 23:22:03.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.91939222447416
706,AB12345,AB12345-CHN-11-id-88,id-88,CHN-11,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S1,5.36809375789412,HIGH,Y,Y,Y,N,N,2019-05-22,2019-05-22 23:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,COMPLETED,COMPLETED,2022-05-22,1096,,,,,,,2022-06-14,,,4,4,Duration of Confirmed Response,CRSD,108.918453543447,DAYS,2022-02-10 23:38:16.683,995,0,Disease Progression,,
707,AB12345,AB12345-CHN-11-id-88,id-88,CHN-11,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S1,5.36809375789412,HIGH,Y,Y,Y,N,N,2019-05-22,2019-05-22 23:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,COMPLETED,COMPLETED,2022-05-22,1096,,,,,,,2022-06-14,,,3,3,Event Free Survival,EFS,88.8771030784119,DAYS,2021-06-08 23:38:16.683,748,0,Disease Progression,,
708,AB12345,AB12345-CHN-11-id-88,id-88,CHN-11,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S1,5.36809375789412,HIGH,Y,Y,Y,N,N,2019-05-22,2019-05-22 23:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,COMPLETED,COMPLETED,2022-05-22,1096,,,,,,,2022-06-14,,,1,1,Overall Survival,OS,469.870737660676,DAYS,2020-08-16 23:38:16.683,452,1,Alive,Alive During Study,
709,AB12345,AB12345-CHN-11-id-88,id-88,CHN-11,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S1,5.36809375789412,HIGH,Y,Y,Y,N,N,2019-05-22,2019-05-22 23:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,COMPLETED,COMPLETED,2022-05-22,1096,,,,,,,2022-06-14,,,2,2,Progression Free Survival,PFS,216.301366337575,DAYS,2021-05-25 23:38:16.683,734,1,Adverse Event,Preferred Term,
710,AB12345,AB12345-CHN-11-id-88,id-88,CHN-11,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S1,5.36809375789412,HIGH,Y,Y,Y,N,N,2019-05-22,2019-05-22 23:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,2019-05-22 23:38:16.683,2021-05-22 11:38:16.683,2021-05-22 11:38:16.683,2022-05-22 17:38:16.683,COMPLETED,COMPLETED,2022-05-22,1096,,,,,,,2022-06-14,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-4.4091423738307
711,AB12345,AB12345-CHN-11-id-90,id-90,CHN-11,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,10.2096038738838,HIGH,Y,Y,N,N,N,2019-12-27,2019-12-31 21:28:15.683,,2019-12-31 21:28:15.683,,,,2019-12-31 21:28:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,120.845995098352,DAYS,2020-04-17 21:28:15.683,108,0,Disease Progression,,
712,AB12345,AB12345-CHN-11-id-90,id-90,CHN-11,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,10.2096038738838,HIGH,Y,Y,N,N,N,2019-12-27,2019-12-31 21:28:15.683,,2019-12-31 21:28:15.683,,,,2019-12-31 21:28:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,68.3910790004302,DAYS,2021-11-09 21:28:15.683,679,1,Last Tumor Assessment,Completion or Discontinuation,
713,AB12345,AB12345-CHN-11-id-90,id-90,CHN-11,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,10.2096038738838,HIGH,Y,Y,N,N,N,2019-12-27,2019-12-31 21:28:15.683,,2019-12-31 21:28:15.683,,,,2019-12-31 21:28:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,492.841138178483,DAYS,2021-02-23 21:28:15.683,420,1,Alive,Alive During Study,
714,AB12345,AB12345-CHN-11-id-90,id-90,CHN-11,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,10.2096038738838,HIGH,Y,Y,N,N,N,2019-12-27,2019-12-31 21:28:15.683,,2019-12-31 21:28:15.683,,,,2019-12-31 21:28:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,267.286082683131,DAYS,2020-01-12 21:28:15.683,12,0,Disease Progression,,
715,AB12345,AB12345-CHN-11-id-90,id-90,CHN-11,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-11,Dr. CHN-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,10.2096038738838,HIGH,Y,Y,N,N,N,2019-12-27,2019-12-31 21:28:15.683,,2019-12-31 21:28:15.683,,,,2019-12-31 21:28:15.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-1.07340652785496
716,AB12345,AB12345-CHN-11-id-91,id-91,CHN-11,44,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S2,3.00099516745835,LOW,Y,Y,N,N,Y,2020-05-28,2020-05-29 14:09:52.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,DISCONTINUED,DISCONTINUED,2022-02-13,625,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-04,674,Yes,2,2,Duration of Confirmed Response,CRSD,196.176468697377,DAYS,2020-11-25 14:09:52.683,180,1,Last Tumor Assessment,Completion or Discontinuation,
717,AB12345,AB12345-CHN-11-id-91,id-91,CHN-11,44,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S2,3.00099516745835,LOW,Y,Y,N,N,Y,2020-05-28,2020-05-29 14:09:52.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,DISCONTINUED,DISCONTINUED,2022-02-13,625,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-04,674,Yes,3,3,Event Free Survival,EFS,89.9478024209384,DAYS,2021-04-11 14:09:52.683,317,0,Disease Progression,,
718,AB12345,AB12345-CHN-11-id-91,id-91,CHN-11,44,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S2,3.00099516745835,LOW,Y,Y,N,N,Y,2020-05-28,2020-05-29 14:09:52.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,DISCONTINUED,DISCONTINUED,2022-02-13,625,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-04,674,Yes,4,4,Overall Survival,OS,314.575471449643,DAYS,2021-06-13 14:09:52.683,380,1,Alive,Alive During Study,
719,AB12345,AB12345-CHN-11-id-91,id-91,CHN-11,44,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S2,3.00099516745835,LOW,Y,Y,N,N,Y,2020-05-28,2020-05-29 14:09:52.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,DISCONTINUED,DISCONTINUED,2022-02-13,625,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-04,674,Yes,1,1,Progression Free Survival,PFS,246.46931856405,DAYS,2020-11-17 14:09:52.683,172,1,Adverse Event,Preferred Term,
720,AB12345,AB12345-CHN-11-id-91,id-91,CHN-11,44,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-11,Dr. CHN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S2,3.00099516745835,LOW,Y,Y,N,N,Y,2020-05-28,2020-05-29 14:09:52.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,2020-05-29 14:09:52.683,2021-02-12 21:47:48.683,2021-02-12 21:47:48.683,2022-02-13 03:47:48.683,DISCONTINUED,DISCONTINUED,2022-02-13,625,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-04,674,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-4.06499588907998
721,AB12345,AB12345-CHN-12-id-255,id-255,CHN-12,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S1,1.49031319225898,LOW,Y,Y,N,Y,N,2020-06-16,2020-06-20 19:29:02.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,DISCONTINUED,DISCONTINUED,2022-02-13,603,DEATH,2022-02-14,LOST TO FOLLOW UP,OTHER,1,<=30,2022-02-14,603,,1,1,Duration of Confirmed Response,CRSD,119.887280627154,DAYS,2020-12-12 19:29:02.683,175,0,Death,,
722,AB12345,AB12345-CHN-12-id-255,id-255,CHN-12,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S1,1.49031319225898,LOW,Y,Y,N,Y,N,2020-06-16,2020-06-20 19:29:02.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,DISCONTINUED,DISCONTINUED,2022-02-13,603,DEATH,2022-02-14,LOST TO FOLLOW UP,OTHER,1,<=30,2022-02-14,603,,3,3,Event Free Survival,EFS,89.3162440496963,DAYS,2021-02-10 19:29:02.683,235,1,Last Tumor Assessment,Completion or Discontinuation,
723,AB12345,AB12345-CHN-12-id-255,id-255,CHN-12,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S1,1.49031319225898,LOW,Y,Y,N,Y,N,2020-06-16,2020-06-20 19:29:02.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,DISCONTINUED,DISCONTINUED,2022-02-13,603,DEATH,2022-02-14,LOST TO FOLLOW UP,OTHER,1,<=30,2022-02-14,603,,4,4,Overall Survival,OS,119.887280627154,DAYS,2021-10-28 19:29:02.683,495,0,Death,,
724,AB12345,AB12345-CHN-12-id-255,id-255,CHN-12,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S1,1.49031319225898,LOW,Y,Y,N,Y,N,2020-06-16,2020-06-20 19:29:02.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,DISCONTINUED,DISCONTINUED,2022-02-13,603,DEATH,2022-02-14,LOST TO FOLLOW UP,OTHER,1,<=30,2022-02-14,603,,2,2,Progression Free Survival,PFS,119.887280627154,DAYS,2021-02-07 19:29:02.683,232,0,Death,,
725,AB12345,AB12345-CHN-12-id-255,id-255,CHN-12,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S1,1.49031319225898,LOW,Y,Y,N,Y,N,2020-06-16,2020-06-20 19:29:02.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,2020-06-20 19:29:02.683,2021-02-13 03:22:23.683,2021-02-13 03:22:23.683,2022-02-13 09:22:23.683,DISCONTINUED,DISCONTINUED,2022-02-13,603,DEATH,2022-02-14,LOST TO FOLLOW UP,OTHER,1,<=30,2022-02-14,603,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.48167324620564
726,AB12345,AB12345-CHN-12-id-258,id-258,CHN-12,45,YEARS,M,WHITE,UNKNOWN,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,1.71573265321294,HIGH,Y,Y,N,N,N,2020-03-01,2020-03-01 06:38:54.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,DISCONTINUED,DISCONTINUED,2022-02-19,721,DEATH,2022-03-28,SUICIDE,OTHER,37,>30,2022-03-28,756,No,4,4,Duration of Confirmed Response,CRSD,110.55621909909,DAYS,2022-02-08 06:38:54.683,709,1,Adverse Event,Preferred Term,
727,AB12345,AB12345-CHN-12-id-258,id-258,CHN-12,45,YEARS,M,WHITE,UNKNOWN,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,1.71573265321294,HIGH,Y,Y,N,N,N,2020-03-01,2020-03-01 06:38:54.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,DISCONTINUED,DISCONTINUED,2022-02-19,721,DEATH,2022-03-28,SUICIDE,OTHER,37,>30,2022-03-28,756,No,1,1,Event Free Survival,EFS,60.4401294817217,DAYS,2020-08-15 06:38:54.683,167,1,Adverse Event,Preferred Term,
728,AB12345,AB12345-CHN-12-id-258,id-258,CHN-12,45,YEARS,M,WHITE,UNKNOWN,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,1.71573265321294,HIGH,Y,Y,N,N,N,2020-03-01,2020-03-01 06:38:54.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,DISCONTINUED,DISCONTINUED,2022-02-19,721,DEATH,2022-03-28,SUICIDE,OTHER,37,>30,2022-03-28,756,No,3,3,Overall Survival,OS,238.399501726963,DAYS,2021-10-21 06:38:54.683,599,0,Death,,
729,AB12345,AB12345-CHN-12-id-258,id-258,CHN-12,45,YEARS,M,WHITE,UNKNOWN,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,1.71573265321294,HIGH,Y,Y,N,N,N,2020-03-01,2020-03-01 06:38:54.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,DISCONTINUED,DISCONTINUED,2022-02-19,721,DEATH,2022-03-28,SUICIDE,OTHER,37,>30,2022-03-28,756,No,2,2,Progression Free Survival,PFS,238.399501726963,DAYS,2021-05-18 06:38:54.683,443,0,Death,,
730,AB12345,AB12345-CHN-12-id-258,id-258,CHN-12,45,YEARS,M,WHITE,UNKNOWN,CHN,Y,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,1.71573265321294,HIGH,Y,Y,N,N,N,2020-03-01,2020-03-01 06:38:54.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,2020-03-01 06:38:54.683,2021-02-19 11:46:08.683,2021-02-19 11:46:08.683,2022-02-19 17:46:08.683,DISCONTINUED,DISCONTINUED,2022-02-19,721,DEATH,2022-03-28,SUICIDE,OTHER,37,>30,2022-03-28,756,No,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-2.02950241946577
731,AB12345,AB12345-CHN-12-id-266,id-266,CHN-12,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,11.2914245307449,MEDIUM,Y,Y,N,N,N,2019-10-27,2019-10-29 08:14:32.683,,2019-10-29 08:14:32.683,,,,2019-10-29 08:14:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,78.5550035873894,DAYS,2021-05-13 08:14:32.683,562,0,Death,,
732,AB12345,AB12345-CHN-12-id-266,id-266,CHN-12,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,11.2914245307449,MEDIUM,Y,Y,N,N,N,2019-10-27,2019-10-29 08:14:32.683,,2019-10-29 08:14:32.683,,,,2019-10-29 08:14:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,78.5550035873894,DAYS,2020-04-18 08:14:32.683,172,0,Death,,
733,AB12345,AB12345-CHN-12-id-266,id-266,CHN-12,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,11.2914245307449,MEDIUM,Y,Y,N,N,N,2019-10-27,2019-10-29 08:14:32.683,,2019-10-29 08:14:32.683,,,,2019-10-29 08:14:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,78.5550035873894,DAYS,2020-11-07 08:14:32.683,375,0,Death,,
734,AB12345,AB12345-CHN-12-id-266,id-266,CHN-12,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,11.2914245307449,MEDIUM,Y,Y,N,N,N,2019-10-27,2019-10-29 08:14:32.683,,2019-10-29 08:14:32.683,,,,2019-10-29 08:14:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,78.5550035873894,DAYS,2019-12-10 08:14:32.683,42,0,Death,,
735,AB12345,AB12345-CHN-12-id-266,id-266,CHN-12,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,B,S2,11.2914245307449,MEDIUM,Y,Y,N,N,N,2019-10-27,2019-10-29 08:14:32.683,,2019-10-29 08:14:32.683,,,,2019-10-29 08:14:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-2.44679664763037
736,AB12345,AB12345-CHN-12-id-285,id-285,CHN-12,39,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,4.79676126028263,MEDIUM,Y,Y,N,N,N,2020-09-24,2020-09-27 19:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,COMPLETED,COMPLETED,2023-09-28,1096,,,,,,,2023-10-08,,,4,4,Duration of Confirmed Response,CRSD,109.839177201502,DAYS,2023-09-12 19:18:10.683,1080,0,Death,,
737,AB12345,AB12345-CHN-12-id-285,id-285,CHN-12,39,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,4.79676126028263,MEDIUM,Y,Y,N,N,N,2020-09-24,2020-09-27 19:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,COMPLETED,COMPLETED,2023-09-28,1096,,,,,,,2023-10-08,,,3,3,Event Free Survival,EFS,74.1422348248307,DAYS,2023-04-28 19:18:10.683,943,1,Last Tumor Assessment,Completion or Discontinuation,
738,AB12345,AB12345-CHN-12-id-285,id-285,CHN-12,39,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,4.79676126028263,MEDIUM,Y,Y,N,N,N,2020-09-24,2020-09-27 19:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,COMPLETED,COMPLETED,2023-09-28,1096,,,,,,,2023-10-08,,,2,2,Overall Survival,OS,109.839177201502,DAYS,2022-02-22 19:18:10.683,513,0,Death,,
739,AB12345,AB12345-CHN-12-id-285,id-285,CHN-12,39,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,4.79676126028263,MEDIUM,Y,Y,N,N,N,2020-09-24,2020-09-27 19:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,COMPLETED,COMPLETED,2023-09-28,1096,,,,,,,2023-10-08,,,1,1,Progression Free Survival,PFS,109.839177201502,DAYS,2021-12-05 19:18:10.683,434,0,Death,,
740,AB12345,AB12345-CHN-12-id-285,id-285,CHN-12,39,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S1,4.79676126028263,MEDIUM,Y,Y,N,N,N,2020-09-24,2020-09-27 19:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,2020-09-27 19:18:10.683,2022-09-28 07:18:10.683,2022-09-28 07:18:10.683,2023-09-28 13:18:10.683,COMPLETED,COMPLETED,2023-09-28,1096,,,,,,,2023-10-08,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.21813104038641
741,AB12345,AB12345-CHN-12-id-294,id-294,CHN-12,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S1,6.67350837419567,LOW,Y,Y,Y,Y,N,2020-10-09,2020-10-10 11:00:57.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,DISCONTINUED,DISCONTINUED,2022-02-14,492,ADVERSE EVENT,,,,,,2022-03-09,,,3,3,Duration of Confirmed Response,CRSD,66.98020243668,DAYS,2022-01-03 11:00:57.683,450,0,Death,,
742,AB12345,AB12345-CHN-12-id-294,id-294,CHN-12,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S1,6.67350837419567,LOW,Y,Y,Y,Y,N,2020-10-09,2020-10-10 11:00:57.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,DISCONTINUED,DISCONTINUED,2022-02-14,492,ADVERSE EVENT,,,,,,2022-03-09,,,1,1,Event Free Survival,EFS,66.98020243668,DAYS,2021-05-04 11:00:57.683,206,0,Death,,
743,AB12345,AB12345-CHN-12-id-294,id-294,CHN-12,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S1,6.67350837419567,LOW,Y,Y,Y,Y,N,2020-10-09,2020-10-10 11:00:57.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,DISCONTINUED,DISCONTINUED,2022-02-14,492,ADVERSE EVENT,,,,,,2022-03-09,,,4,4,Overall Survival,OS,66.98020243668,DAYS,2022-01-16 11:00:57.683,463,0,Death,,
744,AB12345,AB12345-CHN-12-id-294,id-294,CHN-12,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S1,6.67350837419567,LOW,Y,Y,Y,Y,N,2020-10-09,2020-10-10 11:00:57.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,DISCONTINUED,DISCONTINUED,2022-02-14,492,ADVERSE EVENT,,,,,,2022-03-09,,,2,2,Progression Free Survival,PFS,66.98020243668,DAYS,2021-06-04 11:00:57.683,237,0,Death,,
745,AB12345,AB12345-CHN-12-id-294,id-294,CHN-12,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S1,6.67350837419567,LOW,Y,Y,Y,Y,N,2020-10-09,2020-10-10 11:00:57.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,2020-10-10 11:00:57.683,2021-02-13 22:54:16.683,2021-02-13 22:54:16.683,2022-02-14 04:54:16.683,DISCONTINUED,DISCONTINUED,2022-02-14,492,ADVERSE EVENT,,,,,,2022-03-09,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,0,,,-2.29841178847471
746,AB12345,AB12345-CHN-12-id-322,id-322,CHN-12,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,4.28898741723264,MEDIUM,Y,Y,Y,Y,N,2019-07-01,2019-07-04 15:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,COMPLETED,COMPLETED,2022-07-04,1096,,,,,,,2022-07-24,,,3,3,Duration of Confirmed Response,CRSD,164.971224917099,DAYS,2021-03-12 15:06:11.683,617,0,Death,,
747,AB12345,AB12345-CHN-12-id-322,id-322,CHN-12,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,4.28898741723264,MEDIUM,Y,Y,Y,Y,N,2019-07-01,2019-07-04 15:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,COMPLETED,COMPLETED,2022-07-04,1096,,,,,,,2022-07-24,,,2,2,Event Free Survival,EFS,16.7786465783138,DAYS,2019-11-17 15:06:11.683,136,0,Disease Progression,,
748,AB12345,AB12345-CHN-12-id-322,id-322,CHN-12,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,4.28898741723264,MEDIUM,Y,Y,Y,Y,N,2019-07-01,2019-07-04 15:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,COMPLETED,COMPLETED,2022-07-04,1096,,,,,,,2022-07-24,,,1,1,Overall Survival,OS,164.971224917099,DAYS,2019-07-04 15:06:11.683,0,0,Death,,
749,AB12345,AB12345-CHN-12-id-322,id-322,CHN-12,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,4.28898741723264,MEDIUM,Y,Y,Y,Y,N,2019-07-01,2019-07-04 15:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,COMPLETED,COMPLETED,2022-07-04,1096,,,,,,,2022-07-24,,,4,4,Progression Free Survival,PFS,164.971224917099,DAYS,2021-09-12 15:06:11.683,801,0,Death,,
750,AB12345,AB12345-CHN-12-id-322,id-322,CHN-12,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S1,4.28898741723264,MEDIUM,Y,Y,Y,Y,N,2019-07-01,2019-07-04 15:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,2019-07-04 15:06:11.683,2021-07-04 03:06:11.683,2021-07-04 03:06:11.683,2022-07-04 09:06:11.683,COMPLETED,COMPLETED,2022-07-04,1096,,,,,,,2022-07-24,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,0.397163348610715
751,AB12345,AB12345-CHN-12-id-396,id-396,CHN-12,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,1.15746129486757,HIGH,Y,Y,Y,Y,N,2019-09-19,2019-09-20 10:35:35.683,,2019-09-20 10:35:35.683,,,,2019-09-20 10:35:35.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,184.250445920043,DAYS,2020-06-16 10:35:35.683,270,1,Last Tumor Assessment,Completion or Discontinuation,
752,AB12345,AB12345-CHN-12-id-396,id-396,CHN-12,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,1.15746129486757,HIGH,Y,Y,Y,Y,N,2019-09-19,2019-09-20 10:35:35.683,,2019-09-20 10:35:35.683,,,,2019-09-20 10:35:35.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,98.1621359742712,DAYS,2020-12-21 10:35:35.683,458,1,Last Tumor Assessment,Completion or Discontinuation,
753,AB12345,AB12345-CHN-12-id-396,id-396,CHN-12,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,1.15746129486757,HIGH,Y,Y,Y,Y,N,2019-09-19,2019-09-20 10:35:35.683,,2019-09-20 10:35:35.683,,,,2019-09-20 10:35:35.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,377.490432513878,DAYS,2021-01-25 10:35:35.683,493,1,Alive,Alive During Study,
754,AB12345,AB12345-CHN-12-id-396,id-396,CHN-12,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,1.15746129486757,HIGH,Y,Y,Y,Y,N,2019-09-19,2019-09-20 10:35:35.683,,2019-09-20 10:35:35.683,,,,2019-09-20 10:35:35.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,284.27858420182,DAYS,2019-11-21 10:35:35.683,62,0,Disease Progression,,
755,AB12345,AB12345-CHN-12-id-396,id-396,CHN-12,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,1.15746129486757,HIGH,Y,Y,Y,Y,N,2019-09-19,2019-09-20 10:35:35.683,,2019-09-20 10:35:35.683,,,,2019-09-20 10:35:35.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.585382730476828
756,AB12345,AB12345-CHN-12-id-57,id-57,CHN-12,45,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.92747821093864,LOW,Y,Y,Y,Y,N,2019-10-10,2019-10-13 01:09:21.683,,2019-10-13 01:09:21.683,,,,2019-10-13 01:09:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,140.619655908085,DAYS,2019-12-22 01:09:21.683,70,0,Death,,
757,AB12345,AB12345-CHN-12-id-57,id-57,CHN-12,45,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.92747821093864,LOW,Y,Y,Y,Y,N,2019-10-10,2019-10-13 01:09:21.683,,2019-10-13 01:09:21.683,,,,2019-10-13 01:09:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,82.4110436800402,DAYS,2020-12-30 01:09:21.683,444,1,Last Tumor Assessment,Completion or Discontinuation,
758,AB12345,AB12345-CHN-12-id-57,id-57,CHN-12,45,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.92747821093864,LOW,Y,Y,Y,Y,N,2019-10-10,2019-10-13 01:09:21.683,,2019-10-13 01:09:21.683,,,,2019-10-13 01:09:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,140.619655908085,DAYS,2019-12-23 01:09:21.683,71,0,Death,,
759,AB12345,AB12345-CHN-12-id-57,id-57,CHN-12,45,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.92747821093864,LOW,Y,Y,Y,Y,N,2019-10-10,2019-10-13 01:09:21.683,,2019-10-13 01:09:21.683,,,,2019-10-13 01:09:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,140.619655908085,DAYS,2020-07-30 01:09:21.683,291,0,Death,,
760,AB12345,AB12345-CHN-12-id-57,id-57,CHN-12,45,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-12,Dr. CHN-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.92747821093864,LOW,Y,Y,Y,Y,N,2019-10-10,2019-10-13 01:09:21.683,,2019-10-13 01:09:21.683,,,,2019-10-13 01:09:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.744389618375095
761,AB12345,AB12345-CHN-13-id-102,id-102,CHN-13,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,6.04894627754598,LOW,Y,Y,Y,N,Y,2019-03-23,2019-03-23 06:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,COMPLETED,COMPLETED,2022-03-23,1096,,,,,,,2022-04-12,,,4,4,Duration of Confirmed Response,CRSD,141.930398903787,DAYS,2021-09-04 06:06:17.683,896,0,Death,,
762,AB12345,AB12345-CHN-13-id-102,id-102,CHN-13,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,6.04894627754598,LOW,Y,Y,Y,N,Y,2019-03-23,2019-03-23 06:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,COMPLETED,COMPLETED,2022-03-23,1096,,,,,,,2022-04-12,,,3,3,Event Free Survival,EFS,36.5346569358371,DAYS,2021-08-09 06:06:17.683,870,0,Disease Progression,,
763,AB12345,AB12345-CHN-13-id-102,id-102,CHN-13,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,6.04894627754598,LOW,Y,Y,Y,N,Y,2019-03-23,2019-03-23 06:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,COMPLETED,COMPLETED,2022-03-23,1096,,,,,,,2022-04-12,,,1,1,Overall Survival,OS,141.930398903787,DAYS,2019-03-25 06:06:17.683,2,0,Death,,
764,AB12345,AB12345-CHN-13-id-102,id-102,CHN-13,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,6.04894627754598,LOW,Y,Y,Y,N,Y,2019-03-23,2019-03-23 06:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,COMPLETED,COMPLETED,2022-03-23,1096,,,,,,,2022-04-12,,,2,2,Progression Free Survival,PFS,141.930398903787,DAYS,2020-06-08 06:06:17.683,443,0,Death,,
765,AB12345,AB12345-CHN-13-id-102,id-102,CHN-13,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,6.04894627754598,LOW,Y,Y,Y,N,Y,2019-03-23,2019-03-23 06:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,2019-03-23 06:06:17.683,2021-03-22 18:06:17.683,2021-03-22 18:06:17.683,2022-03-23 00:06:17.683,COMPLETED,COMPLETED,2022-03-23,1096,,,,,,,2022-04-12,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-0.356506165516596
766,AB12345,AB12345-CHN-13-id-166,id-166,CHN-13,43,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,10.5796468303894,LOW,Y,Y,Y,N,N,2020-06-30,2020-06-30 22:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,COMPLETED,COMPLETED,2023-07-01,1096,,,,,,,2023-07-21,,,2,2,Duration of Confirmed Response,CRSD,57.1174602967221,DAYS,2022-04-10 22:40:23.683,649,0,Death,,
767,AB12345,AB12345-CHN-13-id-166,id-166,CHN-13,43,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,10.5796468303894,LOW,Y,Y,Y,N,N,2020-06-30,2020-06-30 22:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,COMPLETED,COMPLETED,2023-07-01,1096,,,,,,,2023-07-21,,,3,3,Event Free Survival,EFS,57.1174602967221,DAYS,2022-04-28 22:40:23.683,667,0,Death,,
768,AB12345,AB12345-CHN-13-id-166,id-166,CHN-13,43,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,10.5796468303894,LOW,Y,Y,Y,N,N,2020-06-30,2020-06-30 22:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,COMPLETED,COMPLETED,2023-07-01,1096,,,,,,,2023-07-21,,,1,1,Overall Survival,OS,57.1174602967221,DAYS,2021-09-04 22:40:23.683,431,0,Death,,
769,AB12345,AB12345-CHN-13-id-166,id-166,CHN-13,43,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,10.5796468303894,LOW,Y,Y,Y,N,N,2020-06-30,2020-06-30 22:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,COMPLETED,COMPLETED,2023-07-01,1096,,,,,,,2023-07-21,,,4,4,Progression Free Survival,PFS,57.1174602967221,DAYS,2023-03-24 22:40:23.683,997,0,Death,,
770,AB12345,AB12345-CHN-13-id-166,id-166,CHN-13,43,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,10.5796468303894,LOW,Y,Y,Y,N,N,2020-06-30,2020-06-30 22:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,2020-06-30 22:40:23.683,2022-07-01 10:40:23.683,2022-07-01 10:40:23.683,2023-07-01 16:40:23.683,COMPLETED,COMPLETED,2023-07-01,1096,,,,,,,2023-07-21,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,0.250399625345352
771,AB12345,AB12345-CHN-13-id-19,id-19,CHN-13,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.95167299036211,MEDIUM,Y,Y,N,Y,N,2019-10-10,2019-10-13 05:40:12.683,,2019-10-13 05:40:12.683,,,,2019-10-13 05:40:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,173.226485354826,DAYS,2020-04-16 05:40:12.683,186,1,Adverse Event,Preferred Term,
772,AB12345,AB12345-CHN-13-id-19,id-19,CHN-13,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.95167299036211,MEDIUM,Y,Y,N,Y,N,2019-10-10,2019-10-13 05:40:12.683,,2019-10-13 05:40:12.683,,,,2019-10-13 05:40:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,87.9509063402656,DAYS,2021-09-15 05:40:12.683,703,1,Adverse Event,Preferred Term,
773,AB12345,AB12345-CHN-13-id-19,id-19,CHN-13,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.95167299036211,MEDIUM,Y,Y,N,Y,N,2019-10-10,2019-10-13 05:40:12.683,,2019-10-13 05:40:12.683,,,,2019-10-13 05:40:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,320.010981941596,DAYS,2020-10-30 05:40:12.683,383,1,Alive,Alive During Study,
774,AB12345,AB12345-CHN-13-id-19,id-19,CHN-13,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.95167299036211,MEDIUM,Y,Y,N,Y,N,2019-10-10,2019-10-13 05:40:12.683,,2019-10-13 05:40:12.683,,,,2019-10-13 05:40:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,297.442849050276,DAYS,2020-01-23 05:40:12.683,102,1,Last Tumor Assessment,Completion or Discontinuation,
775,AB12345,AB12345-CHN-13-id-19,id-19,CHN-13,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,C,S2,5.95167299036211,MEDIUM,Y,Y,N,Y,N,2019-10-10,2019-10-13 05:40:12.683,,2019-10-13 05:40:12.683,,,,2019-10-13 05:40:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.40168387931644
776,AB12345,AB12345-CHN-13-id-239,id-239,CHN-13,58,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S1,5.44251713947204,HIGH,Y,Y,N,Y,N,2020-11-05,2020-11-06 22:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,COMPLETED,COMPLETED,2023-11-07,1096,,,,,,,2023-12-01,,,3,3,Duration of Confirmed Response,CRSD,145.055417786352,DAYS,2022-05-31 22:37:43.683,571,1,Adverse Event,Preferred Term,
777,AB12345,AB12345-CHN-13-id-239,id-239,CHN-13,58,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S1,5.44251713947204,HIGH,Y,Y,N,Y,N,2020-11-05,2020-11-06 22:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,COMPLETED,COMPLETED,2023-11-07,1096,,,,,,,2023-12-01,,,2,2,Event Free Survival,EFS,85.7702211476862,DAYS,2022-03-18 22:37:43.683,497,1,Last Tumor Assessment,Completion or Discontinuation,
778,AB12345,AB12345-CHN-13-id-239,id-239,CHN-13,58,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S1,5.44251713947204,HIGH,Y,Y,N,Y,N,2020-11-05,2020-11-06 22:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,COMPLETED,COMPLETED,2023-11-07,1096,,,,,,,2023-12-01,,,4,4,Overall Survival,OS,285.045913583599,DAYS,2022-08-22 22:37:43.683,654,0,Death,,
779,AB12345,AB12345-CHN-13-id-239,id-239,CHN-13,58,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S1,5.44251713947204,HIGH,Y,Y,N,Y,N,2020-11-05,2020-11-06 22:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,COMPLETED,COMPLETED,2023-11-07,1096,,,,,,,2023-12-01,,,1,1,Progression Free Survival,PFS,285.045913583599,DAYS,2021-02-07 22:37:43.683,93,0,Death,,
780,AB12345,AB12345-CHN-13-id-239,id-239,CHN-13,58,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,B,S1,5.44251713947204,HIGH,Y,Y,N,Y,N,2020-11-05,2020-11-06 22:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,2020-11-06 22:37:43.683,2022-11-07 10:37:43.683,2022-11-07 10:37:43.683,2023-11-07 16:37:43.683,COMPLETED,COMPLETED,2023-11-07,1096,,,,,,,2023-12-01,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Preferred Term,-2.83489436524497
781,AB12345,AB12345-CHN-13-id-240,id-240,CHN-13,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,C,S1,3.49928530945447,LOW,Y,Y,Y,Y,N,2019-04-06,2019-04-08 12:56:28.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,DISCONTINUED,DISCONTINUED,2022-02-15,1044,DEATH,2022-03-30,ADVERSE EVENT,ADVERSE EVENT,43,>30,2022-03-30,1086,Yes,2,2,Duration of Confirmed Response,CRSD,63.4288812137675,DAYS,2020-11-01 12:56:28.683,573,0,Death,,
782,AB12345,AB12345-CHN-13-id-240,id-240,CHN-13,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,C,S1,3.49928530945447,LOW,Y,Y,Y,Y,N,2019-04-06,2019-04-08 12:56:28.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,DISCONTINUED,DISCONTINUED,2022-02-15,1044,DEATH,2022-03-30,ADVERSE EVENT,ADVERSE EVENT,43,>30,2022-03-30,1086,Yes,4,4,Event Free Survival,EFS,63.4288812137675,DAYS,2021-03-21 12:56:28.683,713,0,Death,,
783,AB12345,AB12345-CHN-13-id-240,id-240,CHN-13,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,C,S1,3.49928530945447,LOW,Y,Y,Y,Y,N,2019-04-06,2019-04-08 12:56:28.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,DISCONTINUED,DISCONTINUED,2022-02-15,1044,DEATH,2022-03-30,ADVERSE EVENT,ADVERSE EVENT,43,>30,2022-03-30,1086,Yes,1,1,Overall Survival,OS,63.4288812137675,DAYS,2020-02-11 12:56:28.683,309,0,Death,,
784,AB12345,AB12345-CHN-13-id-240,id-240,CHN-13,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,C,S1,3.49928530945447,LOW,Y,Y,Y,Y,N,2019-04-06,2019-04-08 12:56:28.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,DISCONTINUED,DISCONTINUED,2022-02-15,1044,DEATH,2022-03-30,ADVERSE EVENT,ADVERSE EVENT,43,>30,2022-03-30,1086,Yes,3,3,Progression Free Survival,PFS,63.4288812137675,DAYS,2021-01-14 12:56:28.683,647,0,Death,,
785,AB12345,AB12345-CHN-13-id-240,id-240,CHN-13,42,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,C,S1,3.49928530945447,LOW,Y,Y,Y,Y,N,2019-04-06,2019-04-08 12:56:28.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,2019-04-08 12:56:28.683,2021-02-14 20:29:03.683,2021-02-14 20:29:03.683,2022-02-15 02:29:03.683,DISCONTINUED,DISCONTINUED,2022-02-15,1044,DEATH,2022-03-30,ADVERSE EVENT,ADVERSE EVENT,43,>30,2022-03-30,1086,Yes,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.374368898871337
786,AB12345,AB12345-CHN-13-id-249,id-249,CHN-13,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,A,S2,2.78004443182689,HIGH,Y,Y,Y,N,N,2020-02-24,2020-02-25 05:30:37.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,719,PHYSICIAN DECISION,,,,,,2022-03-10,,,3,3,Duration of Confirmed Response,CRSD,96.7311136831995,DAYS,2021-05-02 05:30:37.683,432,0,Death,,
787,AB12345,AB12345-CHN-13-id-249,id-249,CHN-13,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,A,S2,2.78004443182689,HIGH,Y,Y,Y,N,N,2020-02-24,2020-02-25 05:30:37.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,719,PHYSICIAN DECISION,,,,,,2022-03-10,,,2,2,Event Free Survival,EFS,96.7311136831995,DAYS,2020-09-16 05:30:37.683,204,0,Death,,
788,AB12345,AB12345-CHN-13-id-249,id-249,CHN-13,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,A,S2,2.78004443182689,HIGH,Y,Y,Y,N,N,2020-02-24,2020-02-25 05:30:37.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,719,PHYSICIAN DECISION,,,,,,2022-03-10,,,4,4,Overall Survival,OS,96.7311136831995,DAYS,2021-12-14 05:30:37.683,658,0,Death,,
789,AB12345,AB12345-CHN-13-id-249,id-249,CHN-13,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,A,S2,2.78004443182689,HIGH,Y,Y,Y,N,N,2020-02-24,2020-02-25 05:30:37.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,719,PHYSICIAN DECISION,,,,,,2022-03-10,,,1,1,Progression Free Survival,PFS,96.7311136831995,DAYS,2020-06-24 05:30:37.683,120,0,Death,,
790,AB12345,AB12345-CHN-13-id-249,id-249,CHN-13,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,A,S2,2.78004443182689,HIGH,Y,Y,Y,N,N,2020-02-24,2020-02-25 05:30:37.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,2020-02-25 05:30:37.683,2021-02-12 15:27:18.683,2021-02-12 15:27:18.683,2022-02-12 21:27:18.683,DISCONTINUED,DISCONTINUED,2022-02-12,719,PHYSICIAN DECISION,,,,,,2022-03-10,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-1.44386995755543
791,AB12345,AB12345-CHN-13-id-270,id-270,CHN-13,39,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,15.1115606011746,MEDIUM,Y,Y,N,Y,N,2019-08-13,2019-08-17 15:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,COMPLETED,COMPLETED,2022-08-17,1096,,,,,,,2022-09-02,,,2,2,Duration of Confirmed Response,CRSD,128.37795088999,DAYS,2021-11-13 15:09:21.683,819,1,Last Tumor Assessment,Completion or Discontinuation,
792,AB12345,AB12345-CHN-13-id-270,id-270,CHN-13,39,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,15.1115606011746,MEDIUM,Y,Y,N,Y,N,2019-08-13,2019-08-17 15:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,COMPLETED,COMPLETED,2022-08-17,1096,,,,,,,2022-09-02,,,4,4,Event Free Survival,EFS,96.1538123828359,DAYS,2022-08-07 15:09:21.683,1086,1,Last Tumor Assessment,Completion or Discontinuation,
793,AB12345,AB12345-CHN-13-id-270,id-270,CHN-13,39,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,15.1115606011746,MEDIUM,Y,Y,N,Y,N,2019-08-13,2019-08-17 15:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,COMPLETED,COMPLETED,2022-08-17,1096,,,,,,,2022-09-02,,,3,3,Overall Survival,OS,314.148515136912,DAYS,2022-06-04 15:09:21.683,1022,1,Alive,Alive During Study,
794,AB12345,AB12345-CHN-13-id-270,id-270,CHN-13,39,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,15.1115606011746,MEDIUM,Y,Y,N,Y,N,2019-08-13,2019-08-17 15:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,COMPLETED,COMPLETED,2022-08-17,1096,,,,,,,2022-09-02,,,1,1,Progression Free Survival,PFS,273.960649780929,DAYS,2021-02-06 15:09:21.683,539,1,Adverse Event,Preferred Term,
795,AB12345,AB12345-CHN-13-id-270,id-270,CHN-13,39,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,15.1115606011746,MEDIUM,Y,Y,N,Y,N,2019-08-13,2019-08-17 15:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,2019-08-17 15:09:21.683,2021-08-17 03:09:21.683,2021-08-17 03:09:21.683,2022-08-17 09:09:21.683,COMPLETED,COMPLETED,2022-08-17,1096,,,,,,,2022-09-02,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-0.830921449717942
796,AB12345,AB12345-CHN-13-id-304,id-304,CHN-13,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,8.79002861269654,MEDIUM,Y,Y,N,Y,N,2020-02-21,2020-02-23 10:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,COMPLETED,COMPLETED,2023-02-23,1096,,,,,,,2023-03-24,,,2,2,Duration of Confirmed Response,CRSD,113.342057261616,DAYS,2021-04-27 10:47:53.683,429,0,Disease Progression,,
797,AB12345,AB12345-CHN-13-id-304,id-304,CHN-13,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,8.79002861269654,MEDIUM,Y,Y,N,Y,N,2020-02-21,2020-02-23 10:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,COMPLETED,COMPLETED,2023-02-23,1096,,,,,,,2023-03-24,,,3,3,Event Free Survival,EFS,91.5101614780724,DAYS,2021-12-30 10:47:53.683,676,1,Adverse Event,Preferred Term,
798,AB12345,AB12345-CHN-13-id-304,id-304,CHN-13,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,8.79002861269654,MEDIUM,Y,Y,N,Y,N,2020-02-21,2020-02-23 10:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,COMPLETED,COMPLETED,2023-02-23,1096,,,,,,,2023-03-24,,,4,4,Overall Survival,OS,420.081606507301,DAYS,2022-04-22 10:47:53.683,789,1,Alive,Alive During Study,
799,AB12345,AB12345-CHN-13-id-304,id-304,CHN-13,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,8.79002861269654,MEDIUM,Y,Y,N,Y,N,2020-02-21,2020-02-23 10:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,COMPLETED,COMPLETED,2023-02-23,1096,,,,,,,2023-03-24,,,1,1,Progression Free Survival,PFS,255.588607769459,DAYS,2020-09-25 10:47:53.683,215,0,Disease Progression,,
800,AB12345,AB12345-CHN-13-id-304,id-304,CHN-13,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-13,Dr. CHN-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,8.79002861269654,MEDIUM,Y,Y,N,Y,N,2020-02-21,2020-02-23 10:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,2020-02-23 10:47:53.683,2022-02-22 22:47:53.683,2022-02-22 22:47:53.683,2023-02-23 04:47:53.683,COMPLETED,COMPLETED,2023-02-23,1096,,,,,,,2023-03-24,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.873394918319519
801,AB12345,AB12345-CHN-14-id-1,id-1,CHN-14,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S1,7.72251119475055,HIGH,Y,Y,Y,Y,N,2019-05-06,2019-05-07 11:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,COMPLETED,COMPLETED,2022-05-07,1096,,,,,,,2022-05-20,,,2,2,Duration of Confirmed Response,CRSD,150.931233726442,DAYS,2021-06-04 11:59:24.683,759,1,Last Tumor Assessment,Completion or Discontinuation,
802,AB12345,AB12345-CHN-14-id-1,id-1,CHN-14,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S1,7.72251119475055,HIGH,Y,Y,Y,Y,N,2019-05-06,2019-05-07 11:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,COMPLETED,COMPLETED,2022-05-07,1096,,,,,,,2022-05-20,,,4,4,Event Free Survival,EFS,26.3016883120872,DAYS,2022-02-23 11:59:24.683,1023,1,Last Tumor Assessment,Completion or Discontinuation,
803,AB12345,AB12345-CHN-14-id-1,id-1,CHN-14,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S1,7.72251119475055,HIGH,Y,Y,Y,Y,N,2019-05-06,2019-05-07 11:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,COMPLETED,COMPLETED,2022-05-07,1096,,,,,,,2022-05-20,,,1,1,Overall Survival,OS,300.660909479484,DAYS,2020-01-12 11:59:24.683,250,1,Alive,Alive During Study,
804,AB12345,AB12345-CHN-14-id-1,id-1,CHN-14,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S1,7.72251119475055,HIGH,Y,Y,Y,Y,N,2019-05-06,2019-05-07 11:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,COMPLETED,COMPLETED,2022-05-07,1096,,,,,,,2022-05-20,,,3,3,Progression Free Survival,PFS,236.704990756698,DAYS,2022-01-04 11:59:24.683,973,1,Adverse Event,Preferred Term,
805,AB12345,AB12345-CHN-14-id-1,id-1,CHN-14,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S1,7.72251119475055,HIGH,Y,Y,Y,Y,N,2019-05-06,2019-05-07 11:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,2019-05-07 11:59:24.683,2021-05-06 23:59:24.683,2021-05-06 23:59:24.683,2022-05-07 05:59:24.683,COMPLETED,COMPLETED,2022-05-07,1096,,,,,,,2022-05-20,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-0.22892591994619
806,AB12345,AB12345-CHN-14-id-103,id-103,CHN-14,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S2,5.74779949162614,LOW,Y,Y,Y,Y,N,2019-10-30,2019-11-03 00:05:39.683,,2019-11-03 00:05:39.683,,,,2019-11-03 00:05:39.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,188.204845017754,DAYS,2020-04-02 00:05:39.683,151,1,Last Tumor Assessment,Completion or Discontinuation,
807,AB12345,AB12345-CHN-14-id-103,id-103,CHN-14,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S2,5.74779949162614,LOW,Y,Y,Y,Y,N,2019-10-30,2019-11-03 00:05:39.683,,2019-11-03 00:05:39.683,,,,2019-11-03 00:05:39.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,19.0782881283667,DAYS,2020-12-05 00:05:39.683,398,0,Disease Progression,,
808,AB12345,AB12345-CHN-14-id-103,id-103,CHN-14,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S2,5.74779949162614,LOW,Y,Y,Y,Y,N,2019-10-30,2019-11-03 00:05:39.683,,2019-11-03 00:05:39.683,,,,2019-11-03 00:05:39.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,382.606180198491,DAYS,2021-10-10 00:05:39.683,707,1,Alive,Alive During Study,
809,AB12345,AB12345-CHN-14-id-103,id-103,CHN-14,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S2,5.74779949162614,LOW,Y,Y,Y,Y,N,2019-10-30,2019-11-03 00:05:39.683,,2019-11-03 00:05:39.683,,,,2019-11-03 00:05:39.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,282.351704011671,DAYS,2020-11-29 00:05:39.683,392,1,Last Tumor Assessment,Completion or Discontinuation,
810,AB12345,AB12345-CHN-14-id-103,id-103,CHN-14,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,B,S2,5.74779949162614,LOW,Y,Y,Y,Y,N,2019-10-30,2019-11-03 00:05:39.683,,2019-11-03 00:05:39.683,,,,2019-11-03 00:05:39.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-2.2195462723016
811,AB12345,AB12345-CHN-14-id-143,id-143,CHN-14,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,2.17717102673091,LOW,Y,Y,N,Y,N,2020-08-06,2020-08-07 11:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,COMPLETED,COMPLETED,2023-08-08,1096,,,,,,,2023-08-29,,,1,1,Duration of Confirmed Response,CRSD,147.740293340757,DAYS,2021-03-18 11:36:40.683,223,0,Disease Progression,,
812,AB12345,AB12345-CHN-14-id-143,id-143,CHN-14,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,2.17717102673091,LOW,Y,Y,N,Y,N,2020-08-06,2020-08-07 11:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,COMPLETED,COMPLETED,2023-08-08,1096,,,,,,,2023-08-29,,,3,3,Event Free Survival,EFS,93.3473235310521,DAYS,2023-01-04 11:36:40.683,880,1,Last Tumor Assessment,Completion or Discontinuation,
813,AB12345,AB12345-CHN-14-id-143,id-143,CHN-14,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,2.17717102673091,LOW,Y,Y,N,Y,N,2020-08-06,2020-08-07 11:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,COMPLETED,COMPLETED,2023-08-08,1096,,,,,,,2023-08-29,,,4,4,Overall Survival,OS,431.567213404924,DAYS,2023-02-01 11:36:40.683,908,1,Alive,Alive During Study,
814,AB12345,AB12345-CHN-14-id-143,id-143,CHN-14,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,2.17717102673091,LOW,Y,Y,N,Y,N,2020-08-06,2020-08-07 11:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,COMPLETED,COMPLETED,2023-08-08,1096,,,,,,,2023-08-29,,,2,2,Progression Free Survival,PFS,247.499442356639,DAYS,2021-10-20 11:36:40.683,439,0,Disease Progression,,
815,AB12345,AB12345-CHN-14-id-143,id-143,CHN-14,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,2.17717102673091,LOW,Y,Y,N,Y,N,2020-08-06,2020-08-07 11:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,2020-08-07 11:36:40.683,2022-08-07 23:36:40.683,2022-08-07 23:36:40.683,2023-08-08 05:36:40.683,COMPLETED,COMPLETED,2023-08-08,1096,,,,,,,2023-08-29,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,0,,,-1.44081520140092
816,AB12345,AB12345-CHN-14-id-161,id-161,CHN-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,3.56375144538875,HIGH,Y,Y,Y,N,N,2019-09-09,2019-09-12 02:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-09-23,,,3,3,Duration of Confirmed Response,CRSD,109.519437118433,DAYS,2020-11-17 02:39:34.683,432,1,Adverse Event,Preferred Term,
817,AB12345,AB12345-CHN-14-id-161,id-161,CHN-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,3.56375144538875,HIGH,Y,Y,Y,N,N,2019-09-09,2019-09-12 02:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-09-23,,,4,4,Event Free Survival,EFS,28.8822385761887,DAYS,2021-01-07 02:39:34.683,483,1,Last Tumor Assessment,Completion or Discontinuation,
818,AB12345,AB12345-CHN-14-id-161,id-161,CHN-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,3.56375144538875,HIGH,Y,Y,Y,N,N,2019-09-09,2019-09-12 02:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-09-23,,,2,2,Overall Survival,OS,347.975833946839,DAYS,2020-02-07 02:39:34.683,148,1,Alive,Alive During Study,
819,AB12345,AB12345-CHN-14-id-161,id-161,CHN-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,3.56375144538875,HIGH,Y,Y,Y,N,N,2019-09-09,2019-09-12 02:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-09-23,,,1,1,Progression Free Survival,PFS,286.151479231194,DAYS,2019-10-15 02:39:34.683,33,1,Adverse Event,Preferred Term,
820,AB12345,AB12345-CHN-14-id-161,id-161,CHN-14,33,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,3.56375144538875,HIGH,Y,Y,Y,N,N,2019-09-09,2019-09-12 02:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,2019-09-12 02:39:34.683,2021-09-11 14:39:34.683,2021-09-11 14:39:34.683,2022-09-11 20:39:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-09-23,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-1.83320409052952
821,AB12345,AB12345-CHN-14-id-168,id-168,CHN-14,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,2.75487433343803,HIGH,Y,Y,N,N,N,2019-05-25,2019-05-29 13:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,COMPLETED,COMPLETED,2022-05-29,1096,,,,,,,2022-06-08,,,1,1,Duration of Confirmed Response,CRSD,184.940659510903,DAYS,2019-08-05 13:19:29.683,68,1,Adverse Event,Preferred Term,
822,AB12345,AB12345-CHN-14-id-168,id-168,CHN-14,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,2.75487433343803,HIGH,Y,Y,N,N,N,2019-05-25,2019-05-29 13:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,COMPLETED,COMPLETED,2022-05-29,1096,,,,,,,2022-06-08,,,3,3,Event Free Survival,EFS,62.2093512199353,DAYS,2021-06-09 13:19:29.683,742,1,Adverse Event,Preferred Term,
823,AB12345,AB12345-CHN-14-id-168,id-168,CHN-14,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,2.75487433343803,HIGH,Y,Y,N,N,N,2019-05-25,2019-05-29 13:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,COMPLETED,COMPLETED,2022-05-29,1096,,,,,,,2022-06-08,,,2,2,Overall Survival,OS,234.964758064598,DAYS,2019-09-30 13:19:29.683,124,0,Death,,
824,AB12345,AB12345-CHN-14-id-168,id-168,CHN-14,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,2.75487433343803,HIGH,Y,Y,N,N,N,2019-05-25,2019-05-29 13:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,COMPLETED,COMPLETED,2022-05-29,1096,,,,,,,2022-06-08,,,4,4,Progression Free Survival,PFS,234.964758064598,DAYS,2022-05-26 13:19:29.683,1093,0,Death,,
825,AB12345,AB12345-CHN-14-id-168,id-168,CHN-14,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S2,2.75487433343803,HIGH,Y,Y,N,N,N,2019-05-25,2019-05-29 13:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,2019-05-29 13:19:29.683,2021-05-29 01:19:29.683,2021-05-29 01:19:29.683,2022-05-29 07:19:29.683,COMPLETED,COMPLETED,2022-05-29,1096,,,,,,,2022-06-08,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-2.36782321163465
826,AB12345,AB12345-CHN-14-id-228,id-228,CHN-14,30,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,6.31115193614196,LOW,Y,Y,N,Y,N,2019-10-14,2019-10-18 12:42:48.683,,2019-10-18 12:42:48.683,,,,2019-10-18 12:42:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,186.940553016029,DAYS,2019-11-05 12:42:48.683,18,1,Last Tumor Assessment,Completion or Discontinuation,
827,AB12345,AB12345-CHN-14-id-228,id-228,CHN-14,30,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,6.31115193614196,LOW,Y,Y,N,Y,N,2019-10-14,2019-10-18 12:42:48.683,,2019-10-18 12:42:48.683,,,,2019-10-18 12:42:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,97.9377805953845,DAYS,2021-01-16 12:42:48.683,456,1,Last Tumor Assessment,Completion or Discontinuation,
828,AB12345,AB12345-CHN-14-id-228,id-228,CHN-14,30,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,6.31115193614196,LOW,Y,Y,N,Y,N,2019-10-14,2019-10-18 12:42:48.683,,2019-10-18 12:42:48.683,,,,2019-10-18 12:42:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,275.412405095994,DAYS,2020-03-03 12:42:48.683,137,0,Death,,
829,AB12345,AB12345-CHN-14-id-228,id-228,CHN-14,30,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,6.31115193614196,LOW,Y,Y,N,Y,N,2019-10-14,2019-10-18 12:42:48.683,,2019-10-18 12:42:48.683,,,,2019-10-18 12:42:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,275.412405095994,DAYS,2019-12-07 12:42:48.683,50,0,Death,,
830,AB12345,AB12345-CHN-14-id-228,id-228,CHN-14,30,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,6.31115193614196,LOW,Y,Y,N,Y,N,2019-10-14,2019-10-18 12:42:48.683,,2019-10-18 12:42:48.683,,,,2019-10-18 12:42:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,8,COUNT,,,1,,Completion or Discontinuation,-2.97819953183321
831,AB12345,AB12345-CHN-14-id-305,id-305,CHN-14,28,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,7.83616522068024,MEDIUM,Y,Y,N,N,N,2021-01-20,2021-01-23 21:47:21.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,DISCONTINUED,DISCONTINUED,2022-02-18,391,DEATH,2022-03-06,Post-study reporting of death,OTHER,16,<=30,2022-03-06,406,No,4,4,Duration of Confirmed Response,CRSD,176.9816465443,DAYS,2021-12-15 21:47:21.683,326,1,Last Tumor Assessment,Completion or Discontinuation,
832,AB12345,AB12345-CHN-14-id-305,id-305,CHN-14,28,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,7.83616522068024,MEDIUM,Y,Y,N,N,N,2021-01-20,2021-01-23 21:47:21.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,DISCONTINUED,DISCONTINUED,2022-02-18,391,DEATH,2022-03-06,Post-study reporting of death,OTHER,16,<=30,2022-03-06,406,No,3,3,Event Free Survival,EFS,34.0122407022864,DAYS,2021-12-01 21:47:21.683,312,1,Adverse Event,Preferred Term,
833,AB12345,AB12345-CHN-14-id-305,id-305,CHN-14,28,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,7.83616522068024,MEDIUM,Y,Y,N,N,N,2021-01-20,2021-01-23 21:47:21.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,DISCONTINUED,DISCONTINUED,2022-02-18,391,DEATH,2022-03-06,Post-study reporting of death,OTHER,16,<=30,2022-03-06,406,No,1,1,Overall Survival,OS,287.471358431503,DAYS,2021-05-12 21:47:21.683,109,0,Death,,
834,AB12345,AB12345-CHN-14-id-305,id-305,CHN-14,28,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,7.83616522068024,MEDIUM,Y,Y,N,N,N,2021-01-20,2021-01-23 21:47:21.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,DISCONTINUED,DISCONTINUED,2022-02-18,391,DEATH,2022-03-06,Post-study reporting of death,OTHER,16,<=30,2022-03-06,406,No,2,2,Progression Free Survival,PFS,287.471358431503,DAYS,2021-11-02 21:47:21.683,283,0,Death,,
835,AB12345,AB12345-CHN-14-id-305,id-305,CHN-14,28,YEARS,F,ASIAN,NOT REPORTED,CHN,Y,INV ID CHN-14,Dr. CHN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,B,S1,7.83616522068024,MEDIUM,Y,Y,N,N,N,2021-01-20,2021-01-23 21:47:21.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,2021-01-23 21:47:21.683,2021-02-18 11:51:42.683,2021-02-18 11:51:42.683,2022-02-18 17:51:42.683,DISCONTINUED,DISCONTINUED,2022-02-18,391,DEATH,2022-03-06,Post-study reporting of death,OTHER,16,<=30,2022-03-06,406,No,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Completion or Discontinuation,-2.25289708004623
836,AB12345,AB12345-CHN-14-id-375,id-375,CHN-14,32,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,4.09911613678018,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-27 06:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,COMPLETED,COMPLETED,2023-03-28,1096,,,,,,,2023-04-22,,,4,4,Duration of Confirmed Response,CRSD,119.976070709527,DAYS,2023-02-10 06:46:31.683,1050,1,Adverse Event,Preferred Term,
837,AB12345,AB12345-CHN-14-id-375,id-375,CHN-14,32,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,4.09911613678018,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-27 06:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,COMPLETED,COMPLETED,2023-03-28,1096,,,,,,,2023-04-22,,,3,3,Event Free Survival,EFS,18.7224141869228,DAYS,2022-03-01 06:46:31.683,704,0,Disease Progression,,
838,AB12345,AB12345-CHN-14-id-375,id-375,CHN-14,32,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,4.09911613678018,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-27 06:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,COMPLETED,COMPLETED,2023-03-28,1096,,,,,,,2023-04-22,,,1,1,Overall Survival,OS,285.374235827476,DAYS,2021-07-12 06:46:31.683,472,0,Death,,
839,AB12345,AB12345-CHN-14-id-375,id-375,CHN-14,32,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,4.09911613678018,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-27 06:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,COMPLETED,COMPLETED,2023-03-28,1096,,,,,,,2023-04-22,,,2,2,Progression Free Survival,PFS,285.374235827476,DAYS,2021-11-05 06:46:31.683,588,0,Death,,
840,AB12345,AB12345-CHN-14-id-375,id-375,CHN-14,32,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S1,4.09911613678018,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-27 06:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,2020-03-27 06:46:31.683,2022-03-27 18:46:31.683,2022-03-27 18:46:31.683,2023-03-28 00:46:31.683,COMPLETED,COMPLETED,2023-03-28,1096,,,,,,,2023-04-22,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-3.36249426919063
841,AB12345,AB12345-CHN-14-id-56,id-56,CHN-14,25,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,3.51562966781123,MEDIUM,Y,Y,N,N,N,2019-10-07,2019-10-10 18:04:36.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,DISCONTINUED,DISCONTINUED,2022-02-13,858,LACK OF EFFICACY,,,,,,2022-03-03,,,1,1,Duration of Confirmed Response,CRSD,186.933201923966,DAYS,2020-03-07 18:04:36.683,149,1,Last Tumor Assessment,Completion or Discontinuation,
842,AB12345,AB12345-CHN-14-id-56,id-56,CHN-14,25,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,3.51562966781123,MEDIUM,Y,Y,N,N,N,2019-10-07,2019-10-10 18:04:36.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,DISCONTINUED,DISCONTINUED,2022-02-13,858,LACK OF EFFICACY,,,,,,2022-03-03,,,4,4,Event Free Survival,EFS,70.4416009108536,DAYS,2021-06-21 18:04:36.683,620,1,Last Tumor Assessment,Completion or Discontinuation,
843,AB12345,AB12345-CHN-14-id-56,id-56,CHN-14,25,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,3.51562966781123,MEDIUM,Y,Y,N,N,N,2019-10-07,2019-10-10 18:04:36.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,DISCONTINUED,DISCONTINUED,2022-02-13,858,LACK OF EFFICACY,,,,,,2022-03-03,,,3,3,Overall Survival,OS,372.289527580142,DAYS,2020-09-06 18:04:36.683,332,1,Alive,Alive During Study,
844,AB12345,AB12345-CHN-14-id-56,id-56,CHN-14,25,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,3.51562966781123,MEDIUM,Y,Y,N,N,N,2019-10-07,2019-10-10 18:04:36.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,DISCONTINUED,DISCONTINUED,2022-02-13,858,LACK OF EFFICACY,,,,,,2022-03-03,,,2,2,Progression Free Survival,PFS,281.363658746704,DAYS,2020-07-10 18:04:36.683,274,1,Last Tumor Assessment,Completion or Discontinuation,
845,AB12345,AB12345-CHN-14-id-56,id-56,CHN-14,25,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-14,Dr. CHN-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,3.51562966781123,MEDIUM,Y,Y,N,N,N,2019-10-07,2019-10-10 18:04:36.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,2019-10-10 18:04:36.683,2021-02-13 16:24:30.683,2021-02-13 16:24:30.683,2022-02-13 22:24:30.683,DISCONTINUED,DISCONTINUED,2022-02-13,858,LACK OF EFFICACY,,,,,,2022-03-03,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-2.71097530894382
846,AB12345,AB12345-CHN-15-id-14,id-14,CHN-15,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,3.02691971931521,LOW,Y,Y,N,Y,N,2019-09-29,2019-09-29 11:34:20.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-04-06,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-06,919,Yes,2,2,Duration of Confirmed Response,CRSD,157.465529046021,DAYS,2020-05-27 11:34:20.683,241,0,Disease Progression,,
847,AB12345,AB12345-CHN-15-id-14,id-14,CHN-15,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,3.02691971931521,LOW,Y,Y,N,Y,N,2019-09-29,2019-09-29 11:34:20.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-04-06,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-06,919,Yes,1,1,Event Free Survival,EFS,22.7261469117366,DAYS,2019-11-15 11:34:20.683,47,1,Last Tumor Assessment,Completion or Discontinuation,
848,AB12345,AB12345-CHN-15-id-14,id-14,CHN-15,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,3.02691971931521,LOW,Y,Y,N,Y,N,2019-09-29,2019-09-29 11:34:20.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-04-06,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-06,919,Yes,3,3,Overall Survival,OS,464.440955268219,DAYS,2020-07-10 11:34:20.683,285,1,Alive,Alive During Study,
849,AB12345,AB12345-CHN-15-id-14,id-14,CHN-15,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,3.02691971931521,LOW,Y,Y,N,Y,N,2019-09-29,2019-09-29 11:34:20.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-04-06,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-06,919,Yes,4,4,Progression Free Survival,PFS,265.473041357473,DAYS,2021-06-12 11:34:20.683,622,0,Disease Progression,,
850,AB12345,AB12345-CHN-15-id-14,id-14,CHN-15,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,3.02691971931521,LOW,Y,Y,N,Y,N,2019-09-29,2019-09-29 11:34:20.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,2019-09-29 11:34:20.683,2021-02-15 07:58:07.683,2021-02-15 07:58:07.683,2022-02-15 13:58:07.683,DISCONTINUED,DISCONTINUED,2022-02-15,871,DEATH,2022-04-06,DISEASE PROGRESSION,PROGRESSIVE DISEASE,50,>30,2022-04-06,919,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-3.5487614462394
851,AB12345,AB12345-CHN-15-id-201,id-201,CHN-15,49,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S2,6.9067988141075,MEDIUM,Y,Y,Y,N,N,2019-03-05,2019-03-05 15:24:07.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,DISCONTINUED,DISCONTINUED,2022-02-19,1082,DEATH,2022-02-22,ADVERSE EVENT,ADVERSE EVENT,3,<=30,2022-02-22,1084,Yes,1,1,Duration of Confirmed Response,CRSD,53.7239187792875,DAYS,2020-09-21 15:24:07.683,566,0,Death,,
852,AB12345,AB12345-CHN-15-id-201,id-201,CHN-15,49,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S2,6.9067988141075,MEDIUM,Y,Y,Y,N,N,2019-03-05,2019-03-05 15:24:07.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,DISCONTINUED,DISCONTINUED,2022-02-19,1082,DEATH,2022-02-22,ADVERSE EVENT,ADVERSE EVENT,3,<=30,2022-02-22,1084,Yes,3,3,Event Free Survival,EFS,53.7239187792875,DAYS,2020-12-14 15:24:07.683,650,0,Death,,
853,AB12345,AB12345-CHN-15-id-201,id-201,CHN-15,49,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S2,6.9067988141075,MEDIUM,Y,Y,Y,N,N,2019-03-05,2019-03-05 15:24:07.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,DISCONTINUED,DISCONTINUED,2022-02-19,1082,DEATH,2022-02-22,ADVERSE EVENT,ADVERSE EVENT,3,<=30,2022-02-22,1084,Yes,2,2,Overall Survival,OS,53.7239187792875,DAYS,2020-10-01 15:24:07.683,576,0,Death,,
854,AB12345,AB12345-CHN-15-id-201,id-201,CHN-15,49,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S2,6.9067988141075,MEDIUM,Y,Y,Y,N,N,2019-03-05,2019-03-05 15:24:07.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,DISCONTINUED,DISCONTINUED,2022-02-19,1082,DEATH,2022-02-22,ADVERSE EVENT,ADVERSE EVENT,3,<=30,2022-02-22,1084,Yes,4,4,Progression Free Survival,PFS,53.7239187792875,DAYS,2021-09-21 15:24:07.683,931,0,Death,,
855,AB12345,AB12345-CHN-15-id-201,id-201,CHN-15,49,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S2,6.9067988141075,MEDIUM,Y,Y,Y,N,N,2019-03-05,2019-03-05 15:24:07.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,2019-03-05 15:24:07.683,2021-02-18 22:06:48.683,2021-02-18 22:06:48.683,2022-02-19 04:06:48.683,DISCONTINUED,DISCONTINUED,2022-02-19,1082,DEATH,2022-02-22,ADVERSE EVENT,ADVERSE EVENT,3,<=30,2022-02-22,1084,Yes,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-1.53904803786824
856,AB12345,AB12345-CHN-15-id-245,id-245,CHN-15,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,3.68284941334409,LOW,Y,Y,N,Y,N,2019-03-25,2019-03-29 02:27:00.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,DISCONTINUED,DISCONTINUED,2022-02-17,1057,DEATH,2022-02-18,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-18,1056,Yes,4,4,Duration of Confirmed Response,CRSD,175.039837812074,DAYS,2021-06-25 02:27:00.683,819,0,Death,,
857,AB12345,AB12345-CHN-15-id-245,id-245,CHN-15,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,3.68284941334409,LOW,Y,Y,N,Y,N,2019-03-25,2019-03-29 02:27:00.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,DISCONTINUED,DISCONTINUED,2022-02-17,1057,DEATH,2022-02-18,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-18,1056,Yes,2,2,Event Free Survival,EFS,98.6679563613143,DAYS,2019-07-24 02:27:00.683,117,1,Last Tumor Assessment,Completion or Discontinuation,
858,AB12345,AB12345-CHN-15-id-245,id-245,CHN-15,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,3.68284941334409,LOW,Y,Y,N,Y,N,2019-03-25,2019-03-29 02:27:00.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,DISCONTINUED,DISCONTINUED,2022-02-17,1057,DEATH,2022-02-18,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-18,1056,Yes,3,3,Overall Survival,OS,175.039837812074,DAYS,2021-04-11 02:27:00.683,744,0,Death,,
859,AB12345,AB12345-CHN-15-id-245,id-245,CHN-15,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,3.68284941334409,LOW,Y,Y,N,Y,N,2019-03-25,2019-03-29 02:27:00.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,DISCONTINUED,DISCONTINUED,2022-02-17,1057,DEATH,2022-02-18,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-18,1056,Yes,1,1,Progression Free Survival,PFS,175.039837812074,DAYS,2019-06-03 02:27:00.683,66,0,Death,,
860,AB12345,AB12345-CHN-15-id-245,id-245,CHN-15,34,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,3.68284941334409,LOW,Y,Y,N,Y,N,2019-03-25,2019-03-29 02:27:00.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,2019-03-29 02:27:00.683,2021-02-16 22:42:51.683,2021-02-16 22:42:51.683,2022-02-17 04:42:51.683,DISCONTINUED,DISCONTINUED,2022-02-17,1057,DEATH,2022-02-18,DISEASE PROGRESSION,PROGRESSIVE DISEASE,1,<=30,2022-02-18,1056,Yes,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-3.1586578901018
861,AB12345,AB12345-CHN-15-id-262,id-262,CHN-15,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,4.05546277230382,LOW,Y,Y,N,N,Y,2019-02-26,2019-02-26 09:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,COMPLETED,COMPLETED,2022-02-26,1096,,,,,,,2022-03-17,,,3,3,Duration of Confirmed Response,CRSD,26.3522333977744,DAYS,2021-07-01 09:05:10.683,856,0,Death,,
862,AB12345,AB12345-CHN-15-id-262,id-262,CHN-15,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,4.05546277230382,LOW,Y,Y,N,N,Y,2019-02-26,2019-02-26 09:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,COMPLETED,COMPLETED,2022-02-26,1096,,,,,,,2022-03-17,,,1,1,Event Free Survival,EFS,26.3522333977744,DAYS,2019-04-20 09:05:10.683,53,0,Death,,
863,AB12345,AB12345-CHN-15-id-262,id-262,CHN-15,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,4.05546277230382,LOW,Y,Y,N,N,Y,2019-02-26,2019-02-26 09:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,COMPLETED,COMPLETED,2022-02-26,1096,,,,,,,2022-03-17,,,2,2,Overall Survival,OS,26.3522333977744,DAYS,2020-10-23 09:05:10.683,605,0,Death,,
864,AB12345,AB12345-CHN-15-id-262,id-262,CHN-15,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,4.05546277230382,LOW,Y,Y,N,N,Y,2019-02-26,2019-02-26 09:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,COMPLETED,COMPLETED,2022-02-26,1096,,,,,,,2022-03-17,,,4,4,Progression Free Survival,PFS,26.3522333977744,DAYS,2021-07-04 09:05:10.683,859,0,Death,,
865,AB12345,AB12345-CHN-15-id-262,id-262,CHN-15,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,4.05546277230382,LOW,Y,Y,N,N,Y,2019-02-26,2019-02-26 09:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,2019-02-26 09:05:10.683,2021-02-25 21:05:10.683,2021-02-25 21:05:10.683,2022-02-26 03:05:10.683,COMPLETED,COMPLETED,2022-02-26,1096,,,,,,,2022-03-17,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-1.08773359312538
866,AB12345,AB12345-CHN-15-id-297,id-297,CHN-15,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,11.9349060488111,MEDIUM,Y,Y,Y,Y,N,2019-09-20,2019-09-20 10:24:34.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,DISCONTINUED,DISCONTINUED,2022-02-17,882,PROTOCOL VIOLATION,,,,,,2022-03-07,,,1,1,Duration of Confirmed Response,CRSD,184.837953769602,DAYS,2020-03-22 10:24:34.683,184,0,Disease Progression,,
867,AB12345,AB12345-CHN-15-id-297,id-297,CHN-15,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,11.9349060488111,MEDIUM,Y,Y,Y,Y,N,2019-09-20,2019-09-20 10:24:34.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,DISCONTINUED,DISCONTINUED,2022-02-17,882,PROTOCOL VIOLATION,,,,,,2022-03-07,,,4,4,Event Free Survival,EFS,33.2897485792637,DAYS,2021-10-12 10:24:34.683,753,0,Disease Progression,,
868,AB12345,AB12345-CHN-15-id-297,id-297,CHN-15,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,11.9349060488111,MEDIUM,Y,Y,Y,Y,N,2019-09-20,2019-09-20 10:24:34.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,DISCONTINUED,DISCONTINUED,2022-02-17,882,PROTOCOL VIOLATION,,,,,,2022-03-07,,,3,3,Overall Survival,OS,246.534118545242,DAYS,2021-05-05 10:24:34.683,593,0,Death,,
869,AB12345,AB12345-CHN-15-id-297,id-297,CHN-15,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,11.9349060488111,MEDIUM,Y,Y,Y,Y,N,2019-09-20,2019-09-20 10:24:34.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,DISCONTINUED,DISCONTINUED,2022-02-17,882,PROTOCOL VIOLATION,,,,,,2022-03-07,,,2,2,Progression Free Survival,PFS,246.534118545242,DAYS,2020-04-09 10:24:34.683,202,0,Death,,
870,AB12345,AB12345-CHN-15-id-297,id-297,CHN-15,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S1,11.9349060488111,MEDIUM,Y,Y,Y,Y,N,2019-09-20,2019-09-20 10:24:34.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,2019-09-20 10:24:34.683,2021-02-17 14:34:12.683,2021-02-17 14:34:12.683,2022-02-17 20:34:12.683,DISCONTINUED,DISCONTINUED,2022-02-17,882,PROTOCOL VIOLATION,,,,,,2022-03-07,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.903589512541927
871,AB12345,AB12345-CHN-15-id-399,id-399,CHN-15,33,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,0.991825317502802,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-15 09:24:21.683,,2019-10-15 09:24:21.683,,,,2019-10-15 09:24:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,191.655773832463,DAYS,2021-02-07 09:24:21.683,481,1,Last Tumor Assessment,Completion or Discontinuation,
872,AB12345,AB12345-CHN-15-id-399,id-399,CHN-15,33,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,0.991825317502802,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-15 09:24:21.683,,2019-10-15 09:24:21.683,,,,2019-10-15 09:24:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,92.8402621741407,DAYS,2020-09-03 09:24:21.683,324,1,Last Tumor Assessment,Completion or Discontinuation,
873,AB12345,AB12345-CHN-15-id-399,id-399,CHN-15,33,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,0.991825317502802,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-15 09:24:21.683,,2019-10-15 09:24:21.683,,,,2019-10-15 09:24:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,413.380231522024,DAYS,2020-06-21 09:24:21.683,250,1,Alive,Alive During Study,
874,AB12345,AB12345-CHN-15-id-399,id-399,CHN-15,33,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,0.991825317502802,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-15 09:24:21.683,,2019-10-15 09:24:21.683,,,,2019-10-15 09:24:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,281.985458382405,DAYS,2019-12-10 09:24:21.683,56,1,Last Tumor Assessment,Completion or Discontinuation,
875,AB12345,AB12345-CHN-15-id-399,id-399,CHN-15,33,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-15,Dr. CHN-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,0.991825317502802,LOW,Y,Y,N,Y,N,2019-10-13,2019-10-15 09:24:21.683,,2019-10-15 09:24:21.683,,,,2019-10-15 09:24:21.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,1,,Completion or Discontinuation,-5.76815611313789
876,AB12345,AB12345-CHN-16-id-154,id-154,CHN-16,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,7.17154632805943,MEDIUM,Y,Y,N,Y,N,2019-12-12,2019-12-15 09:30:03.683,,2019-12-15 09:30:03.683,,,,2019-12-15 09:30:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,67.3155587061774,DAYS,2020-08-25 09:30:03.683,254,0,Death,,
877,AB12345,AB12345-CHN-16-id-154,id-154,CHN-16,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,7.17154632805943,MEDIUM,Y,Y,N,Y,N,2019-12-12,2019-12-15 09:30:03.683,,2019-12-15 09:30:03.683,,,,2019-12-15 09:30:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,67.3155587061774,DAYS,2021-07-26 09:30:03.683,589,0,Death,,
878,AB12345,AB12345-CHN-16-id-154,id-154,CHN-16,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,7.17154632805943,MEDIUM,Y,Y,N,Y,N,2019-12-12,2019-12-15 09:30:03.683,,2019-12-15 09:30:03.683,,,,2019-12-15 09:30:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,67.3155587061774,DAYS,2021-09-05 09:30:03.683,630,0,Death,,
879,AB12345,AB12345-CHN-16-id-154,id-154,CHN-16,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,7.17154632805943,MEDIUM,Y,Y,N,Y,N,2019-12-12,2019-12-15 09:30:03.683,,2019-12-15 09:30:03.683,,,,2019-12-15 09:30:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,67.3155587061774,DAYS,2020-01-22 09:30:03.683,38,0,Death,,
880,AB12345,AB12345-CHN-16-id-154,id-154,CHN-16,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,7.17154632805943,MEDIUM,Y,Y,N,Y,N,2019-12-12,2019-12-15 09:30:03.683,,2019-12-15 09:30:03.683,,,,2019-12-15 09:30:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-2.80108668379431
881,AB12345,AB12345-CHN-16-id-241,id-241,CHN-16,41,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S1,2.53578727074981,LOW,Y,Y,Y,N,N,2019-11-16,2019-11-19 07:12:54.683,,2019-11-19 07:12:54.683,,,,2019-11-19 07:12:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,143.969654850662,DAYS,2021-09-13 07:12:54.683,664,0,Death,,
882,AB12345,AB12345-CHN-16-id-241,id-241,CHN-16,41,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S1,2.53578727074981,LOW,Y,Y,Y,N,N,2019-11-16,2019-11-19 07:12:54.683,,2019-11-19 07:12:54.683,,,,2019-11-19 07:12:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,82.5580246420577,DAYS,2020-12-29 07:12:54.683,406,0,Disease Progression,,
883,AB12345,AB12345-CHN-16-id-241,id-241,CHN-16,41,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S1,2.53578727074981,LOW,Y,Y,Y,N,N,2019-11-16,2019-11-19 07:12:54.683,,2019-11-19 07:12:54.683,,,,2019-11-19 07:12:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,143.969654850662,DAYS,2020-12-21 07:12:54.683,398,0,Death,,
884,AB12345,AB12345-CHN-16-id-241,id-241,CHN-16,41,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S1,2.53578727074981,LOW,Y,Y,Y,N,N,2019-11-16,2019-11-19 07:12:54.683,,2019-11-19 07:12:54.683,,,,2019-11-19 07:12:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,143.969654850662,DAYS,2021-05-27 07:12:54.683,555,0,Death,,
885,AB12345,AB12345-CHN-16-id-241,id-241,CHN-16,41,YEARS,F,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S1,2.53578727074981,LOW,Y,Y,Y,N,N,2019-11-16,2019-11-19 07:12:54.683,,2019-11-19 07:12:54.683,,,,2019-11-19 07:12:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,0.164156681390331
886,AB12345,AB12345-CHN-16-id-302,id-302,CHN-16,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,3.79833660784226,MEDIUM,Y,Y,Y,N,N,2020-11-06,2020-11-09 15:41:39.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-12,461,DEATH,2022-03-15,MISSING,OTHER,31,>30,2022-03-15,490,,1,1,Duration of Confirmed Response,CRSD,156.54852851294,DAYS,2021-04-17 15:41:39.683,159,0,Disease Progression,,
887,AB12345,AB12345-CHN-16-id-302,id-302,CHN-16,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,3.79833660784226,MEDIUM,Y,Y,Y,N,N,2020-11-06,2020-11-09 15:41:39.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-12,461,DEATH,2022-03-15,MISSING,OTHER,31,>30,2022-03-15,490,,2,2,Event Free Survival,EFS,50.0699165172409,DAYS,2021-06-16 15:41:39.683,219,1,Last Tumor Assessment,Completion or Discontinuation,
888,AB12345,AB12345-CHN-16-id-302,id-302,CHN-16,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,3.79833660784226,MEDIUM,Y,Y,Y,N,N,2020-11-06,2020-11-09 15:41:39.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-12,461,DEATH,2022-03-15,MISSING,OTHER,31,>30,2022-03-15,490,,4,4,Overall Survival,OS,215.16478320118,DAYS,2022-01-20 15:41:39.683,437,0,Death,,
889,AB12345,AB12345-CHN-16-id-302,id-302,CHN-16,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,3.79833660784226,MEDIUM,Y,Y,Y,N,N,2020-11-06,2020-11-09 15:41:39.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-12,461,DEATH,2022-03-15,MISSING,OTHER,31,>30,2022-03-15,490,,3,3,Progression Free Survival,PFS,215.16478320118,DAYS,2021-07-28 15:41:39.683,261,0,Death,,
890,AB12345,AB12345-CHN-16-id-302,id-302,CHN-16,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S1,3.79833660784226,MEDIUM,Y,Y,Y,N,N,2020-11-06,2020-11-09 15:41:39.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,2020-11-09 15:41:39.683,2021-02-12 17:22:15.683,2021-02-12 17:22:15.683,2022-02-12 23:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-12,461,DEATH,2022-03-15,MISSING,OTHER,31,>30,2022-03-15,490,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.817931003943783
891,AB12345,AB12345-CHN-16-id-323,id-323,CHN-16,51,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,13.94448939385,HIGH,Y,Y,N,Y,N,2019-12-25,2019-12-25 20:10:27.683,,2019-12-25 20:10:27.683,,,,2019-12-25 20:10:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,149.564136634581,DAYS,2020-03-11 20:10:27.683,77,0,Disease Progression,,
892,AB12345,AB12345-CHN-16-id-323,id-323,CHN-16,51,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,13.94448939385,HIGH,Y,Y,N,Y,N,2019-12-25,2019-12-25 20:10:27.683,,2019-12-25 20:10:27.683,,,,2019-12-25 20:10:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,83.6341718630865,DAYS,2020-07-02 20:10:27.683,190,0,Disease Progression,,
893,AB12345,AB12345-CHN-16-id-323,id-323,CHN-16,51,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,13.94448939385,HIGH,Y,Y,N,Y,N,2019-12-25,2019-12-25 20:10:27.683,,2019-12-25 20:10:27.683,,,,2019-12-25 20:10:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,322.057855827734,DAYS,2020-05-05 20:10:27.683,132,1,Alive,Alive During Study,
894,AB12345,AB12345-CHN-16-id-323,id-323,CHN-16,51,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,13.94448939385,HIGH,Y,Y,N,Y,N,2019-12-25,2019-12-25 20:10:27.683,,2019-12-25 20:10:27.683,,,,2019-12-25 20:10:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,214.050918305293,DAYS,2020-06-27 20:10:27.683,185,1,Adverse Event,Preferred Term,
895,AB12345,AB12345-CHN-16-id-323,id-323,CHN-16,51,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,13.94448939385,HIGH,Y,Y,N,Y,N,2019-12-25,2019-12-25 20:10:27.683,,2019-12-25 20:10:27.683,,,,2019-12-25 20:10:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-0.513865567214895
896,AB12345,AB12345-CHN-16-id-352,id-352,CHN-16,28,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,4.21681217663587,MEDIUM,Y,Y,N,Y,N,2021-01-30,2021-02-02 09:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-14,,,4,4,Duration of Confirmed Response,CRSD,100.471427943558,DAYS,2023-07-01 09:25:56.683,879,0,Death,,
897,AB12345,AB12345-CHN-16-id-352,id-352,CHN-16,28,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,4.21681217663587,MEDIUM,Y,Y,N,Y,N,2021-01-30,2021-02-02 09:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-14,,,3,3,Event Free Survival,EFS,24.4172403891571,DAYS,2022-09-07 09:25:56.683,582,1,Adverse Event,Preferred Term,
898,AB12345,AB12345-CHN-16-id-352,id-352,CHN-16,28,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,4.21681217663587,MEDIUM,Y,Y,N,Y,N,2021-01-30,2021-02-02 09:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-14,,,1,1,Overall Survival,OS,100.471427943558,DAYS,2021-08-15 09:25:56.683,194,0,Death,,
899,AB12345,AB12345-CHN-16-id-352,id-352,CHN-16,28,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,4.21681217663587,MEDIUM,Y,Y,N,Y,N,2021-01-30,2021-02-02 09:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-14,,,2,2,Progression Free Survival,PFS,100.471427943558,DAYS,2022-07-12 09:25:56.683,525,0,Death,,
900,AB12345,AB12345-CHN-16-id-352,id-352,CHN-16,28,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S2,4.21681217663587,MEDIUM,Y,Y,N,Y,N,2021-01-30,2021-02-02 09:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,2021-02-02 09:25:56.683,2023-02-02 21:25:56.683,2023-02-02 21:25:56.683,2024-02-03 03:25:56.683,COMPLETED,COMPLETED,2024-02-03,1096,,,,,,,2024-02-14,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.38237192697814
901,AB12345,AB12345-CHN-16-id-381,id-381,CHN-16,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,4.62925089804287,HIGH,Y,Y,N,Y,N,2020-02-14,2020-02-15 07:36:20.683,,2020-02-15 07:36:20.683,,,,2020-02-15 07:36:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,187.882287916727,DAYS,2021-10-01 07:36:20.683,594,1,Last Tumor Assessment,Completion or Discontinuation,
902,AB12345,AB12345-CHN-16-id-381,id-381,CHN-16,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,4.62925089804287,HIGH,Y,Y,N,Y,N,2020-02-14,2020-02-15 07:36:20.683,,2020-02-15 07:36:20.683,,,,2020-02-15 07:36:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,35.2643701958004,DAYS,2020-11-30 07:36:20.683,289,0,Disease Progression,,
903,AB12345,AB12345-CHN-16-id-381,id-381,CHN-16,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,4.62925089804287,HIGH,Y,Y,N,Y,N,2020-02-14,2020-02-15 07:36:20.683,,2020-02-15 07:36:20.683,,,,2020-02-15 07:36:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,327.707712026313,DAYS,2020-06-20 07:36:20.683,126,1,Alive,Alive During Study,
904,AB12345,AB12345-CHN-16-id-381,id-381,CHN-16,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,4.62925089804287,HIGH,Y,Y,N,Y,N,2020-02-14,2020-02-15 07:36:20.683,,2020-02-15 07:36:20.683,,,,2020-02-15 07:36:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,207.721865735948,DAYS,2022-01-02 07:36:20.683,687,0,Disease Progression,,
905,AB12345,AB12345-CHN-16-id-381,id-381,CHN-16,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-16,Dr. CHN-16 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,4.62925089804287,HIGH,Y,Y,N,Y,N,2020-02-14,2020-02-15 07:36:20.683,,2020-02-15 07:36:20.683,,,,2020-02-15 07:36:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-1.94126622123365
906,AB12345,AB12345-CHN-17-id-10,id-10,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S1,4.58057722907235,HIGH,Y,Y,Y,N,N,2020-12-17,2020-12-17 01:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,3,3,Duration of Confirmed Response,CRSD,19.0395888674539,DAYS,2023-01-28 01:03:47.683,772,0,Death,,
907,AB12345,AB12345-CHN-17-id-10,id-10,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S1,4.58057722907235,HIGH,Y,Y,Y,N,N,2020-12-17,2020-12-17 01:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,1,1,Event Free Survival,EFS,19.0395888674539,DAYS,2022-01-09 01:03:47.683,388,0,Death,,
908,AB12345,AB12345-CHN-17-id-10,id-10,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S1,4.58057722907235,HIGH,Y,Y,Y,N,N,2020-12-17,2020-12-17 01:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,2,2,Overall Survival,OS,19.0395888674539,DAYS,2022-03-30 01:03:47.683,468,0,Death,,
909,AB12345,AB12345-CHN-17-id-10,id-10,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S1,4.58057722907235,HIGH,Y,Y,Y,N,N,2020-12-17,2020-12-17 01:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,4,4,Progression Free Survival,PFS,19.0395888674539,DAYS,2023-11-02 01:03:47.683,1050,0,Death,,
910,AB12345,AB12345-CHN-17-id-10,id-10,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,A,S1,4.58057722907235,HIGH,Y,Y,Y,N,N,2020-12-17,2020-12-17 01:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,2020-12-17 01:03:47.683,2022-12-17 13:03:47.683,2022-12-17 13:03:47.683,2023-12-17 19:03:47.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.447727012859557
911,AB12345,AB12345-CHN-17-id-129,id-129,CHN-17,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,3.12912176260979,HIGH,Y,Y,Y,N,N,2020-11-08,2020-11-11 01:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,COMPLETED,COMPLETED,2023-11-11,1096,,,,,,,2023-11-22,,,3,3,Duration of Confirmed Response,CRSD,191.608901834115,DAYS,2023-04-21 01:20:00.683,891,0,Disease Progression,,
912,AB12345,AB12345-CHN-17-id-129,id-129,CHN-17,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,3.12912176260979,HIGH,Y,Y,Y,N,N,2020-11-08,2020-11-11 01:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,COMPLETED,COMPLETED,2023-11-11,1096,,,,,,,2023-11-22,,,1,1,Event Free Survival,EFS,17.8831042395905,DAYS,2021-04-08 01:20:00.683,148,1,Adverse Event,Preferred Term,
913,AB12345,AB12345-CHN-17-id-129,id-129,CHN-17,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,3.12912176260979,HIGH,Y,Y,Y,N,N,2020-11-08,2020-11-11 01:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,COMPLETED,COMPLETED,2023-11-11,1096,,,,,,,2023-11-22,,,4,4,Overall Survival,OS,284.020039392635,DAYS,2023-08-02 01:20:00.683,994,0,Death,,
914,AB12345,AB12345-CHN-17-id-129,id-129,CHN-17,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,3.12912176260979,HIGH,Y,Y,Y,N,N,2020-11-08,2020-11-11 01:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,COMPLETED,COMPLETED,2023-11-11,1096,,,,,,,2023-11-22,,,2,2,Progression Free Survival,PFS,284.020039392635,DAYS,2023-04-13 01:20:00.683,883,0,Death,,
915,AB12345,AB12345-CHN-17-id-129,id-129,CHN-17,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,3.12912176260979,HIGH,Y,Y,Y,N,N,2020-11-08,2020-11-11 01:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,2020-11-11 01:20:00.683,2022-11-11 13:20:00.683,2022-11-11 13:20:00.683,2023-11-11 19:20:00.683,COMPLETED,COMPLETED,2023-11-11,1096,,,,,,,2023-11-22,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.80076898882655
916,AB12345,AB12345-CHN-17-id-182,id-182,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,5.65524232179195,HIGH,Y,Y,N,Y,N,2019-09-17,2019-09-18 07:56:08.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,DISCONTINUED,DISCONTINUED,2022-02-12,879,DEATH,2022-03-09,LOST TO FOLLOW UP,OTHER,25,<=30,2022-03-09,902,,2,2,Duration of Confirmed Response,CRSD,149.526794510894,DAYS,2020-10-24 07:56:08.683,402,1,Adverse Event,Preferred Term,
917,AB12345,AB12345-CHN-17-id-182,id-182,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,5.65524232179195,HIGH,Y,Y,N,Y,N,2019-09-17,2019-09-18 07:56:08.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,DISCONTINUED,DISCONTINUED,2022-02-12,879,DEATH,2022-03-09,LOST TO FOLLOW UP,OTHER,25,<=30,2022-03-09,902,,3,3,Event Free Survival,EFS,30.204070401378,DAYS,2021-05-27 07:56:08.683,617,1,Last Tumor Assessment,Completion or Discontinuation,
918,AB12345,AB12345-CHN-17-id-182,id-182,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,5.65524232179195,HIGH,Y,Y,N,Y,N,2019-09-17,2019-09-18 07:56:08.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,DISCONTINUED,DISCONTINUED,2022-02-12,879,DEATH,2022-03-09,LOST TO FOLLOW UP,OTHER,25,<=30,2022-03-09,902,,4,4,Overall Survival,OS,354.875392373651,DAYS,2021-06-20 07:56:08.683,641,1,Alive,Alive During Study,
919,AB12345,AB12345-CHN-17-id-182,id-182,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,5.65524232179195,HIGH,Y,Y,N,Y,N,2019-09-17,2019-09-18 07:56:08.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,DISCONTINUED,DISCONTINUED,2022-02-12,879,DEATH,2022-03-09,LOST TO FOLLOW UP,OTHER,25,<=30,2022-03-09,902,,1,1,Progression Free Survival,PFS,230.69585270714,DAYS,2019-11-28 07:56:08.683,71,0,Disease Progression,,
920,AB12345,AB12345-CHN-17-id-182,id-182,CHN-17,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S2,5.65524232179195,HIGH,Y,Y,N,Y,N,2019-09-17,2019-09-18 07:56:08.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,2019-09-18 07:56:08.683,2021-02-12 03:08:24.683,2021-02-12 03:08:24.683,2022-02-12 09:08:24.683,DISCONTINUED,DISCONTINUED,2022-02-12,879,DEATH,2022-03-09,LOST TO FOLLOW UP,OTHER,25,<=30,2022-03-09,902,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-4.03858144225231
921,AB12345,AB12345-CHN-17-id-209,id-209,CHN-17,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,C,S2,1.6401105632946,LOW,Y,Y,N,Y,N,2020-12-14,2020-12-16 11:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,1,1,Duration of Confirmed Response,CRSD,142.938191327266,DAYS,2021-01-24 11:13:33.683,39,1,Last Tumor Assessment,Completion or Discontinuation,
922,AB12345,AB12345-CHN-17-id-209,id-209,CHN-17,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,C,S2,1.6401105632946,LOW,Y,Y,N,Y,N,2020-12-14,2020-12-16 11:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,4,4,Event Free Survival,EFS,25.9007277118508,DAYS,2023-10-04 11:13:33.683,1022,0,Disease Progression,,
923,AB12345,AB12345-CHN-17-id-209,id-209,CHN-17,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,C,S2,1.6401105632946,LOW,Y,Y,N,Y,N,2020-12-14,2020-12-16 11:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,3,3,Overall Survival,OS,367.012143693864,DAYS,2022-02-23 11:13:33.683,434,1,Alive,Alive During Study,
924,AB12345,AB12345-CHN-17-id-209,id-209,CHN-17,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,C,S2,1.6401105632946,LOW,Y,Y,N,Y,N,2020-12-14,2020-12-16 11:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,2,2,Progression Free Survival,PFS,269.594496372156,DAYS,2021-04-12 11:13:33.683,117,1,Adverse Event,Preferred Term,
925,AB12345,AB12345-CHN-17-id-209,id-209,CHN-17,31,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,C,S2,1.6401105632946,LOW,Y,Y,N,Y,N,2020-12-14,2020-12-16 11:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,2020-12-16 11:13:33.683,2022-12-16 23:13:33.683,2022-12-16 23:13:33.683,2023-12-17 05:13:33.683,COMPLETED,COMPLETED,2023-12-17,1096,,,,,,,2024-01-07,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.535854498805449
926,AB12345,AB12345-CHN-17-id-309,id-309,CHN-17,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.34396243617971,LOW,Y,Y,Y,Y,N,2019-04-27,2019-04-27 14:58:13.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1028,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-08,,,1,1,Duration of Confirmed Response,CRSD,184.053491475061,DAYS,2019-08-21 14:58:13.683,116,1,Adverse Event,Preferred Term,
927,AB12345,AB12345-CHN-17-id-309,id-309,CHN-17,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.34396243617971,LOW,Y,Y,Y,Y,N,2019-04-27,2019-04-27 14:58:13.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1028,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-08,,,2,2,Event Free Survival,EFS,74.605946841184,DAYS,2019-09-30 14:58:13.683,156,1,Last Tumor Assessment,Completion or Discontinuation,
928,AB12345,AB12345-CHN-17-id-309,id-309,CHN-17,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.34396243617971,LOW,Y,Y,Y,Y,N,2019-04-27,2019-04-27 14:58:13.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1028,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-08,,,4,4,Overall Survival,OS,453.317870013416,DAYS,2020-12-13 14:58:13.683,596,1,Alive,Alive During Study,
929,AB12345,AB12345-CHN-17-id-309,id-309,CHN-17,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.34396243617971,LOW,Y,Y,Y,Y,N,2019-04-27,2019-04-27 14:58:13.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1028,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-08,,,3,3,Progression Free Survival,PFS,288.263200665824,DAYS,2020-02-14 14:58:13.683,293,1,Adverse Event,Preferred Term,
930,AB12345,AB12345-CHN-17-id-309,id-309,CHN-17,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,7.34396243617971,LOW,Y,Y,Y,Y,N,2019-04-27,2019-04-27 14:58:13.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,2019-04-27 14:58:13.683,2021-02-17 12:04:24.683,2021-02-17 12:04:24.683,2022-02-17 18:04:24.683,DISCONTINUED,DISCONTINUED,2022-02-17,1028,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-08,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Preferred Term,-1.30947534237171
931,AB12345,AB12345-CHN-17-id-31,id-31,CHN-17,35,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,2.47905027793051,MEDIUM,Y,Y,Y,Y,Y,2019-11-15,2019-11-17 06:57:47.683,,2019-11-17 06:57:47.683,,,,2019-11-17 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,104.211700777523,DAYS,2020-11-11 06:57:47.683,360,1,Last Tumor Assessment,Completion or Discontinuation,
932,AB12345,AB12345-CHN-17-id-31,id-31,CHN-17,35,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,2.47905027793051,MEDIUM,Y,Y,Y,Y,Y,2019-11-15,2019-11-17 06:57:47.683,,2019-11-17 06:57:47.683,,,,2019-11-17 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,42.3723483469803,DAYS,2020-02-28 06:57:47.683,103,0,Disease Progression,,
933,AB12345,AB12345-CHN-17-id-31,id-31,CHN-17,35,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,2.47905027793051,MEDIUM,Y,Y,Y,Y,Y,2019-11-15,2019-11-17 06:57:47.683,,2019-11-17 06:57:47.683,,,,2019-11-17 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,289.27099222783,DAYS,2020-09-09 06:57:47.683,297,0,Death,,
934,AB12345,AB12345-CHN-17-id-31,id-31,CHN-17,35,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,2.47905027793051,MEDIUM,Y,Y,Y,Y,Y,2019-11-15,2019-11-17 06:57:47.683,,2019-11-17 06:57:47.683,,,,2019-11-17 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,289.27099222783,DAYS,2020-08-06 06:57:47.683,263,0,Death,,
935,AB12345,AB12345-CHN-17-id-31,id-31,CHN-17,35,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,2.47905027793051,MEDIUM,Y,Y,Y,Y,Y,2019-11-15,2019-11-17 06:57:47.683,,2019-11-17 06:57:47.683,,,,2019-11-17 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-5.49080012636791
936,AB12345,AB12345-CHN-17-id-48,id-48,CHN-17,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S1,7.25469059215116,MEDIUM,Y,Y,Y,Y,N,2019-04-29,2019-05-03 06:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-21,,,2,2,Duration of Confirmed Response,CRSD,155.449311621487,DAYS,2020-08-11 06:19:35.683,466,1,Adverse Event,Preferred Term,
937,AB12345,AB12345-CHN-17-id-48,id-48,CHN-17,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S1,7.25469059215116,MEDIUM,Y,Y,Y,Y,N,2019-04-29,2019-05-03 06:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-21,,,1,1,Event Free Survival,EFS,69.2389373411424,DAYS,2020-03-06 06:19:35.683,308,1,Last Tumor Assessment,Completion or Discontinuation,
938,AB12345,AB12345-CHN-17-id-48,id-48,CHN-17,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S1,7.25469059215116,MEDIUM,Y,Y,Y,Y,N,2019-04-29,2019-05-03 06:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-21,,,4,4,Overall Survival,OS,276.632994809188,DAYS,2021-10-27 06:19:35.683,908,0,Death,,
939,AB12345,AB12345-CHN-17-id-48,id-48,CHN-17,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S1,7.25469059215116,MEDIUM,Y,Y,Y,Y,N,2019-04-29,2019-05-03 06:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-21,,,3,3,Progression Free Survival,PFS,276.632994809188,DAYS,2020-09-21 06:19:35.683,507,0,Death,,
940,AB12345,AB12345-CHN-17-id-48,id-48,CHN-17,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S1,7.25469059215116,MEDIUM,Y,Y,Y,Y,N,2019-04-29,2019-05-03 06:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,2019-05-03 06:19:35.683,2021-05-02 18:19:35.683,2021-05-02 18:19:35.683,2022-05-03 00:19:35.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-21,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Preferred Term,-3.7202153812514
941,AB12345,AB12345-CHN-17-id-5,id-5,CHN-17,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,1.86288125680077,LOW,Y,Y,N,Y,N,2021-01-04,2021-01-07 03:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-30,,,3,3,Duration of Confirmed Response,CRSD,174.80164875742,DAYS,2022-05-02 03:52:51.683,480,1,Adverse Event,Preferred Term,
942,AB12345,AB12345-CHN-17-id-5,id-5,CHN-17,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,1.86288125680077,LOW,Y,Y,N,Y,N,2021-01-04,2021-01-07 03:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-30,,,2,2,Event Free Survival,EFS,23.2332100300118,DAYS,2022-02-04 03:52:51.683,393,1,Last Tumor Assessment,Completion or Discontinuation,
943,AB12345,AB12345-CHN-17-id-5,id-5,CHN-17,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,1.86288125680077,LOW,Y,Y,N,Y,N,2021-01-04,2021-01-07 03:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-30,,,4,4,Overall Survival,OS,301.533719105646,DAYS,2023-12-03 03:52:51.683,1060,1,Alive,Alive During Study,
944,AB12345,AB12345-CHN-17-id-5,id-5,CHN-17,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,1.86288125680077,LOW,Y,Y,N,Y,N,2021-01-04,2021-01-07 03:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-30,,,1,1,Progression Free Survival,PFS,287.521798769012,DAYS,2021-01-14 03:52:51.683,7,0,Disease Progression,,
945,AB12345,AB12345-CHN-17-id-5,id-5,CHN-17,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,B,S2,1.86288125680077,LOW,Y,Y,N,Y,N,2021-01-04,2021-01-07 03:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,2021-01-07 03:52:51.683,2023-01-07 15:52:51.683,2023-01-07 15:52:51.683,2024-01-07 21:52:51.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-30,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Preferred Term,-2.79210875184452
946,AB12345,AB12345-CHN-17-id-66,id-66,CHN-17,36,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.83802264904978,LOW,Y,Y,Y,N,N,2019-06-27,2019-06-29 23:27:28.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,DISCONTINUED,DISCONTINUED,2022-02-12,959,ADVERSE EVENT,,,,,,2022-03-11,,,1,1,Duration of Confirmed Response,CRSD,140.696565806866,DAYS,2019-07-26 23:27:28.683,27,0,Disease Progression,,
947,AB12345,AB12345-CHN-17-id-66,id-66,CHN-17,36,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.83802264904978,LOW,Y,Y,Y,N,N,2019-06-27,2019-06-29 23:27:28.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,DISCONTINUED,DISCONTINUED,2022-02-12,959,ADVERSE EVENT,,,,,,2022-03-11,,,2,2,Event Free Survival,EFS,94.4679437635932,DAYS,2020-05-17 23:27:28.683,323,1,Last Tumor Assessment,Completion or Discontinuation,
948,AB12345,AB12345-CHN-17-id-66,id-66,CHN-17,36,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.83802264904978,LOW,Y,Y,Y,N,N,2019-06-27,2019-06-29 23:27:28.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,DISCONTINUED,DISCONTINUED,2022-02-12,959,ADVERSE EVENT,,,,,,2022-03-11,,,4,4,Overall Survival,OS,495.225524902344,DAYS,2021-03-04 23:27:28.683,614,1,Alive,Alive During Study,
949,AB12345,AB12345-CHN-17-id-66,id-66,CHN-17,36,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.83802264904978,LOW,Y,Y,Y,N,N,2019-06-27,2019-06-29 23:27:28.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,DISCONTINUED,DISCONTINUED,2022-02-12,959,ADVERSE EVENT,,,,,,2022-03-11,,,3,3,Progression Free Survival,PFS,278.876338968985,DAYS,2020-06-04 23:27:28.683,341,0,Disease Progression,,
950,AB12345,AB12345-CHN-17-id-66,id-66,CHN-17,36,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,B,S1,6.83802264904978,LOW,Y,Y,Y,N,N,2019-06-27,2019-06-29 23:27:28.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,2019-06-29 23:27:28.683,2021-02-12 09:00:42.683,2021-02-12 09:00:42.683,2022-02-12 15:00:42.683,DISCONTINUED,DISCONTINUED,2022-02-12,959,ADVERSE EVENT,,,,,,2022-03-11,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,0,,,-1.14475449486871
951,AB12345,AB12345-CHN-17-id-84,id-84,CHN-17,40,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,6.61366727233138,LOW,Y,Y,N,N,N,2019-03-23,2019-03-24 10:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,COMPLETED,COMPLETED,2022-03-24,1096,,,,,,,2022-04-21,,,4,4,Duration of Confirmed Response,CRSD,178.721482097171,DAYS,2022-03-05 10:21:04.683,1077,1,Last Tumor Assessment,Completion or Discontinuation,
952,AB12345,AB12345-CHN-17-id-84,id-84,CHN-17,40,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,6.61366727233138,LOW,Y,Y,N,N,N,2019-03-23,2019-03-24 10:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,COMPLETED,COMPLETED,2022-03-24,1096,,,,,,,2022-04-21,,,3,3,Event Free Survival,EFS,43.3392164006364,DAYS,2020-02-01 10:21:04.683,314,0,Disease Progression,,
953,AB12345,AB12345-CHN-17-id-84,id-84,CHN-17,40,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,6.61366727233138,LOW,Y,Y,N,N,N,2019-03-23,2019-03-24 10:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,COMPLETED,COMPLETED,2022-03-24,1096,,,,,,,2022-04-21,,,2,2,Overall Survival,OS,308.739980403334,DAYS,2019-08-11 10:21:04.683,140,1,Alive,Alive During Study,
954,AB12345,AB12345-CHN-17-id-84,id-84,CHN-17,40,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,6.61366727233138,LOW,Y,Y,N,N,N,2019-03-23,2019-03-24 10:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,COMPLETED,COMPLETED,2022-03-24,1096,,,,,,,2022-04-21,,,1,1,Progression Free Survival,PFS,208.936091605574,DAYS,2019-06-22 10:21:04.683,90,1,Adverse Event,Preferred Term,
955,AB12345,AB12345-CHN-17-id-84,id-84,CHN-17,40,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-17,Dr. CHN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,6.61366727233138,LOW,Y,Y,N,N,N,2019-03-23,2019-03-24 10:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,2019-03-24 10:21:04.683,2021-03-23 22:21:04.683,2021-03-23 22:21:04.683,2022-03-24 04:21:04.683,COMPLETED,COMPLETED,2022-03-24,1096,,,,,,,2022-04-21,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-2.91253727237873
956,AB12345,AB12345-CHN-17-id-92,id-92,CHN-17,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,4.85079653417938,LOW,Y,Y,N,Y,N,2020-02-28,2020-03-01 23:06:08.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,DISCONTINUED,DISCONTINUED,2022-02-19,720,DEATH,2022-02-21,LOST TO FOLLOW UP,OTHER,2,<=30,2022-02-21,721,,1,1,Duration of Confirmed Response,CRSD,104.808932752348,DAYS,2020-08-01 23:06:08.683,153,1,Last Tumor Assessment,Completion or Discontinuation,
957,AB12345,AB12345-CHN-17-id-92,id-92,CHN-17,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,4.85079653417938,LOW,Y,Y,N,Y,N,2020-02-28,2020-03-01 23:06:08.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,DISCONTINUED,DISCONTINUED,2022-02-19,720,DEATH,2022-02-21,LOST TO FOLLOW UP,OTHER,2,<=30,2022-02-21,721,,2,2,Event Free Survival,EFS,58.7693677435163,DAYS,2020-09-06 23:06:08.683,189,1,Last Tumor Assessment,Completion or Discontinuation,
958,AB12345,AB12345-CHN-17-id-92,id-92,CHN-17,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,4.85079653417938,LOW,Y,Y,N,Y,N,2020-02-28,2020-03-01 23:06:08.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,DISCONTINUED,DISCONTINUED,2022-02-19,720,DEATH,2022-02-21,LOST TO FOLLOW UP,OTHER,2,<=30,2022-02-21,721,,3,3,Overall Survival,OS,437.665104307234,DAYS,2020-11-04 23:06:08.683,248,1,Alive,Alive During Study,
959,AB12345,AB12345-CHN-17-id-92,id-92,CHN-17,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,4.85079653417938,LOW,Y,Y,N,Y,N,2020-02-28,2020-03-01 23:06:08.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,DISCONTINUED,DISCONTINUED,2022-02-19,720,DEATH,2022-02-21,LOST TO FOLLOW UP,OTHER,2,<=30,2022-02-21,721,,4,4,Progression Free Survival,PFS,208.919612760656,DAYS,2022-01-11 23:06:08.683,681,1,Last Tumor Assessment,Completion or Discontinuation,
960,AB12345,AB12345-CHN-17-id-92,id-92,CHN-17,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-17,Dr. CHN-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S1,4.85079653417938,LOW,Y,Y,N,Y,N,2020-02-28,2020-03-01 23:06:08.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,2020-03-01 23:06:08.683,2021-02-18 19:48:21.683,2021-02-18 19:48:21.683,2022-02-19 01:48:21.683,DISCONTINUED,DISCONTINUED,2022-02-19,720,DEATH,2022-02-21,LOST TO FOLLOW UP,OTHER,2,<=30,2022-02-21,721,,,,Total Number of Exacerbations,TNE,0,COUNT,,,1,,Completion or Discontinuation,-3.30870679109193
961,AB12345,AB12345-CHN-18-id-106,id-106,CHN-18,30,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,4.04955899326059,MEDIUM,Y,Y,N,Y,N,2020-12-08,2020-12-11 02:07:06.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,432,ADVERSE EVENT,,,,,,2022-03-12,,,4,4,Duration of Confirmed Response,CRSD,143.091092444956,DAYS,2021-07-30 02:07:06.683,231,1,Last Tumor Assessment,Completion or Discontinuation,
962,AB12345,AB12345-CHN-18-id-106,id-106,CHN-18,30,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,4.04955899326059,MEDIUM,Y,Y,N,Y,N,2020-12-08,2020-12-11 02:07:06.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,432,ADVERSE EVENT,,,,,,2022-03-12,,,2,2,Event Free Survival,EFS,17.9612753668334,DAYS,2021-06-03 02:07:06.683,174,0,Disease Progression,,
963,AB12345,AB12345-CHN-18-id-106,id-106,CHN-18,30,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,4.04955899326059,MEDIUM,Y,Y,N,Y,N,2020-12-08,2020-12-11 02:07:06.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,432,ADVERSE EVENT,,,,,,2022-03-12,,,3,3,Overall Survival,OS,466.359390923753,DAYS,2021-06-03 02:07:06.683,174,1,Alive,Alive During Study,
964,AB12345,AB12345-CHN-18-id-106,id-106,CHN-18,30,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,4.04955899326059,MEDIUM,Y,Y,N,Y,N,2020-12-08,2020-12-11 02:07:06.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,432,ADVERSE EVENT,,,,,,2022-03-12,,,1,1,Progression Free Survival,PFS,275.929405121133,DAYS,2021-04-08 02:07:06.683,118,0,Disease Progression,,
965,AB12345,AB12345-CHN-18-id-106,id-106,CHN-18,30,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S2,4.04955899326059,MEDIUM,Y,Y,N,Y,N,2020-12-08,2020-12-11 02:07:06.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,2020-12-11 02:07:06.683,2021-02-15 15:00:47.683,2021-02-15 15:00:47.683,2022-02-15 21:00:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,432,ADVERSE EVENT,,,,,,2022-03-12,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-1.42796720947031
966,AB12345,AB12345-CHN-18-id-170,id-170,CHN-18,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,12.9419733005453,MEDIUM,Y,Y,Y,N,N,2020-01-17,2020-01-20 08:35:44.683,,2020-01-20 08:35:44.683,,,,2020-01-20 08:35:44.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,47.5093139358796,DAYS,2020-09-11 08:35:44.683,235,0,Death,,
967,AB12345,AB12345-CHN-18-id-170,id-170,CHN-18,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,12.9419733005453,MEDIUM,Y,Y,Y,N,N,2020-01-17,2020-01-20 08:35:44.683,,2020-01-20 08:35:44.683,,,,2020-01-20 08:35:44.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,47.5093139358796,DAYS,2020-12-02 08:35:44.683,317,0,Death,,
968,AB12345,AB12345-CHN-18-id-170,id-170,CHN-18,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,12.9419733005453,MEDIUM,Y,Y,Y,N,N,2020-01-17,2020-01-20 08:35:44.683,,2020-01-20 08:35:44.683,,,,2020-01-20 08:35:44.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,47.5093139358796,DAYS,2021-12-30 08:35:44.683,710,0,Death,,
969,AB12345,AB12345-CHN-18-id-170,id-170,CHN-18,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,12.9419733005453,MEDIUM,Y,Y,Y,N,N,2020-01-17,2020-01-20 08:35:44.683,,2020-01-20 08:35:44.683,,,,2020-01-20 08:35:44.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,47.5093139358796,DAYS,2020-01-22 08:35:44.683,2,0,Death,,
970,AB12345,AB12345-CHN-18-id-170,id-170,CHN-18,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-18,Dr. CHN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,12.9419733005453,MEDIUM,Y,Y,Y,N,N,2020-01-17,2020-01-20 08:35:44.683,,2020-01-20 08:35:44.683,,,,2020-01-20 08:35:44.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.03233832126911
971,AB12345,AB12345-CHN-18-id-51,id-51,CHN-18,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,6.9528927864748,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:29:04.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,DISCONTINUED,DISCONTINUED,2022-02-14,874,DEATH,2022-03-12,ADVERSE EVENT,ADVERSE EVENT,26,<=30,2022-03-12,898,Yes,2,2,Duration of Confirmed Response,CRSD,134.498665039428,DAYS,2021-01-15 15:29:04.683,478,1,Adverse Event,Preferred Term,
972,AB12345,AB12345-CHN-18-id-51,id-51,CHN-18,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,6.9528927864748,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:29:04.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,DISCONTINUED,DISCONTINUED,2022-02-14,874,DEATH,2022-03-12,ADVERSE EVENT,ADVERSE EVENT,26,<=30,2022-03-12,898,Yes,1,1,Event Free Survival,EFS,67.3221596051008,DAYS,2020-01-01 15:29:04.683,98,0,Disease Progression,,
973,AB12345,AB12345-CHN-18-id-51,id-51,CHN-18,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,6.9528927864748,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:29:04.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,DISCONTINUED,DISCONTINUED,2022-02-14,874,DEATH,2022-03-12,ADVERSE EVENT,ADVERSE EVENT,26,<=30,2022-03-12,898,Yes,3,3,Overall Survival,OS,352.001821389422,DAYS,2021-10-17 15:29:04.683,753,1,Alive,Alive During Study,
974,AB12345,AB12345-CHN-18-id-51,id-51,CHN-18,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,6.9528927864748,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:29:04.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,DISCONTINUED,DISCONTINUED,2022-02-14,874,DEATH,2022-03-12,ADVERSE EVENT,ADVERSE EVENT,26,<=30,2022-03-12,898,Yes,4,4,Progression Free Survival,PFS,253.227877407335,DAYS,2021-10-25 15:29:04.683,761,1,Adverse Event,Preferred Term,
975,AB12345,AB12345-CHN-18-id-51,id-51,CHN-18,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-18,Dr. CHN-18 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,C,S2,6.9528927864748,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:29:04.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,2019-09-25 15:29:04.683,2021-02-14 16:05:51.683,2021-02-14 16:05:51.683,2022-02-14 22:05:51.683,DISCONTINUED,DISCONTINUED,2022-02-14,874,DEATH,2022-03-12,ADVERSE EVENT,ADVERSE EVENT,26,<=30,2022-03-12,898,Yes,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-0.347843967002562
976,AB12345,AB12345-CHN-2-id-118,id-118,CHN-2,36,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,3.22229283609412,HIGH,Y,Y,N,N,N,2020-04-07,2020-04-09 11:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,COMPLETED,COMPLETED,2023-04-10,1096,,,,,,,2023-04-20,,,1,1,Duration of Confirmed Response,CRSD,190.584667841904,DAYS,2020-04-10 11:48:53.683,1,1,Adverse Event,Preferred Term,
977,AB12345,AB12345-CHN-2-id-118,id-118,CHN-2,36,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,3.22229283609412,HIGH,Y,Y,N,N,N,2020-04-07,2020-04-09 11:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,COMPLETED,COMPLETED,2023-04-10,1096,,,,,,,2023-04-20,,,3,3,Event Free Survival,EFS,63.6931528965943,DAYS,2022-02-07 11:48:53.683,669,0,Disease Progression,,
978,AB12345,AB12345-CHN-2-id-118,id-118,CHN-2,36,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,3.22229283609412,HIGH,Y,Y,N,N,N,2020-04-07,2020-04-09 11:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,COMPLETED,COMPLETED,2023-04-10,1096,,,,,,,2023-04-20,,,4,4,Overall Survival,OS,311.297363555059,DAYS,2022-11-19 11:48:53.683,954,1,Alive,Alive During Study,
979,AB12345,AB12345-CHN-2-id-118,id-118,CHN-2,36,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,3.22229283609412,HIGH,Y,Y,N,N,N,2020-04-07,2020-04-09 11:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,COMPLETED,COMPLETED,2023-04-10,1096,,,,,,,2023-04-20,,,2,2,Progression Free Survival,PFS,256.602187850513,DAYS,2021-03-30 11:48:53.683,355,0,Disease Progression,,
980,AB12345,AB12345-CHN-2-id-118,id-118,CHN-2,36,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S1,3.22229283609412,HIGH,Y,Y,N,N,N,2020-04-07,2020-04-09 11:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,2020-04-09 11:48:53.683,2022-04-09 23:48:53.683,2022-04-09 23:48:53.683,2023-04-10 05:48:53.683,COMPLETED,COMPLETED,2023-04-10,1096,,,,,,,2023-04-20,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Preferred Term,-1.91072490938763
981,AB12345,AB12345-CHN-2-id-149,id-149,CHN-2,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,9.64073555273795,LOW,Y,Y,N,N,N,2020-01-03,2020-01-07 08:26:42.683,,2020-01-07 08:26:42.683,,,,2020-01-07 08:26:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,132.834185590036,DAYS,2021-10-28 08:26:42.683,660,1,Last Tumor Assessment,Completion or Discontinuation,
982,AB12345,AB12345-CHN-2-id-149,id-149,CHN-2,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,9.64073555273795,LOW,Y,Y,N,N,N,2020-01-03,2020-01-07 08:26:42.683,,2020-01-07 08:26:42.683,,,,2020-01-07 08:26:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,23.6796683596913,DAYS,2021-01-10 08:26:42.683,369,1,Last Tumor Assessment,Completion or Discontinuation,
983,AB12345,AB12345-CHN-2-id-149,id-149,CHN-2,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,9.64073555273795,LOW,Y,Y,N,N,N,2020-01-03,2020-01-07 08:26:42.683,,2020-01-07 08:26:42.683,,,,2020-01-07 08:26:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,442.873067874461,DAYS,2020-08-23 08:26:42.683,229,1,Alive,Alive During Study,
984,AB12345,AB12345-CHN-2-id-149,id-149,CHN-2,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,9.64073555273795,LOW,Y,Y,N,N,N,2020-01-03,2020-01-07 08:26:42.683,,2020-01-07 08:26:42.683,,,,2020-01-07 08:26:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,299.060050724074,DAYS,2021-12-27 08:26:42.683,720,1,Last Tumor Assessment,Completion or Discontinuation,
985,AB12345,AB12345-CHN-2-id-149,id-149,CHN-2,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,9.64073555273795,LOW,Y,Y,N,N,N,2020-01-03,2020-01-07 08:26:42.683,,2020-01-07 08:26:42.683,,,,2020-01-07 08:26:42.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-3.03567040136146
986,AB12345,AB12345-CHN-2-id-22,id-22,CHN-2,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S2,3.6901569722877,HIGH,Y,Y,N,N,N,2021-01-14,2021-01-15 23:38:01.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,393,DEATH,2022-03-01,MISSING,OTHER,17,<=30,2022-03-01,409,,2,2,Duration of Confirmed Response,CRSD,161.421644943766,DAYS,2021-06-25 23:38:01.683,161,1,Last Tumor Assessment,Completion or Discontinuation,
987,AB12345,AB12345-CHN-2-id-22,id-22,CHN-2,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S2,3.6901569722877,HIGH,Y,Y,N,N,N,2021-01-14,2021-01-15 23:38:01.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,393,DEATH,2022-03-01,MISSING,OTHER,17,<=30,2022-03-01,409,,1,1,Event Free Survival,EFS,21.7128056299407,DAYS,2021-01-20 23:38:01.683,5,1,Last Tumor Assessment,Completion or Discontinuation,
988,AB12345,AB12345-CHN-2-id-22,id-22,CHN-2,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S2,3.6901569722877,HIGH,Y,Y,N,N,N,2021-01-14,2021-01-15 23:38:01.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,393,DEATH,2022-03-01,MISSING,OTHER,17,<=30,2022-03-01,409,,4,4,Overall Survival,OS,353.819530969486,DAYS,2022-01-24 23:38:01.683,374,1,Alive,Alive During Study,
989,AB12345,AB12345-CHN-2-id-22,id-22,CHN-2,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S2,3.6901569722877,HIGH,Y,Y,N,N,N,2021-01-14,2021-01-15 23:38:01.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,393,DEATH,2022-03-01,MISSING,OTHER,17,<=30,2022-03-01,409,,3,3,Progression Free Survival,PFS,249.323367280886,DAYS,2021-11-15 23:38:01.683,304,1,Last Tumor Assessment,Completion or Discontinuation,
990,AB12345,AB12345-CHN-2-id-22,id-22,CHN-2,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,A,S2,3.6901569722877,HIGH,Y,Y,N,N,N,2021-01-14,2021-01-15 23:38:01.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,2021-01-15 23:38:01.683,2021-02-12 12:33:26.683,2021-02-12 12:33:26.683,2022-02-12 18:33:26.683,DISCONTINUED,DISCONTINUED,2022-02-12,393,DEATH,2022-03-01,MISSING,OTHER,17,<=30,2022-03-01,409,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-3.17098949497912
991,AB12345,AB12345-CHN-2-id-223,id-223,CHN-2,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S2,4.62507543507525,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-18 10:22:36.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,DISCONTINUED,DISCONTINUED,2022-02-13,453,DEATH,2022-03-02,DISEASE PROGRESSION,PROGRESSIVE DISEASE,17,<=30,2022-03-02,468,Yes,1,1,Duration of Confirmed Response,CRSD,147.527830023319,DAYS,2021-07-09 10:22:36.683,233,1,Last Tumor Assessment,Completion or Discontinuation,
992,AB12345,AB12345-CHN-2-id-223,id-223,CHN-2,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S2,4.62507543507525,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-18 10:22:36.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,DISCONTINUED,DISCONTINUED,2022-02-13,453,DEATH,2022-03-02,DISEASE PROGRESSION,PROGRESSIVE DISEASE,17,<=30,2022-03-02,468,Yes,2,2,Event Free Survival,EFS,39.9144233413972,DAYS,2021-10-12 10:22:36.683,328,1,Last Tumor Assessment,Completion or Discontinuation,
993,AB12345,AB12345-CHN-2-id-223,id-223,CHN-2,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S2,4.62507543507525,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-18 10:22:36.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,DISCONTINUED,DISCONTINUED,2022-02-13,453,DEATH,2022-03-02,DISEASE PROGRESSION,PROGRESSIVE DISEASE,17,<=30,2022-03-02,468,Yes,4,4,Overall Survival,OS,384.726420417428,DAYS,2021-12-07 10:22:36.683,384,1,Alive,Alive During Study,
994,AB12345,AB12345-CHN-2-id-223,id-223,CHN-2,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S2,4.62507543507525,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-18 10:22:36.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,DISCONTINUED,DISCONTINUED,2022-02-13,453,DEATH,2022-03-02,DISEASE PROGRESSION,PROGRESSIVE DISEASE,17,<=30,2022-03-02,468,Yes,3,3,Progression Free Survival,PFS,296.407854626887,DAYS,2021-10-15 10:22:36.683,331,1,Adverse Event,Preferred Term,
995,AB12345,AB12345-CHN-2-id-223,id-223,CHN-2,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,C,S2,4.62507543507525,MEDIUM,Y,Y,Y,Y,N,2020-11-15,2020-11-18 10:22:36.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,2020-11-18 10:22:36.683,2021-02-13 10:30:19.683,2021-02-13 10:30:19.683,2022-02-13 16:30:19.683,DISCONTINUED,DISCONTINUED,2022-02-13,453,DEATH,2022-03-02,DISEASE PROGRESSION,PROGRESSIVE DISEASE,17,<=30,2022-03-02,468,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-1.20376435309455
996,AB12345,AB12345-CHN-2-id-272,id-272,CHN-2,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,7.17022926183863,MEDIUM,Y,Y,Y,Y,N,2020-01-08,2020-01-11 03:34:36.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,DISCONTINUED,DISCONTINUED,2022-02-16,768,DEATH,2022-02-23,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-23,773,Yes,3,3,Duration of Confirmed Response,CRSD,195.382735133171,DAYS,2021-07-17 03:34:36.683,553,0,Disease Progression,,
997,AB12345,AB12345-CHN-2-id-272,id-272,CHN-2,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,7.17022926183863,MEDIUM,Y,Y,Y,Y,N,2020-01-08,2020-01-11 03:34:36.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,DISCONTINUED,DISCONTINUED,2022-02-16,768,DEATH,2022-02-23,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-23,773,Yes,4,4,Event Free Survival,EFS,86.7482531408314,DAYS,2021-09-29 03:34:36.683,627,1,Adverse Event,Preferred Term,
998,AB12345,AB12345-CHN-2-id-272,id-272,CHN-2,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,7.17022926183863,MEDIUM,Y,Y,Y,Y,N,2020-01-08,2020-01-11 03:34:36.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,DISCONTINUED,DISCONTINUED,2022-02-16,768,DEATH,2022-02-23,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-23,773,Yes,1,1,Overall Survival,OS,228.647352475673,DAYS,2020-12-11 03:34:36.683,335,0,Death,,
999,AB12345,AB12345-CHN-2-id-272,id-272,CHN-2,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,7.17022926183863,MEDIUM,Y,Y,Y,Y,N,2020-01-08,2020-01-11 03:34:36.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,DISCONTINUED,DISCONTINUED,2022-02-16,768,DEATH,2022-02-23,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-23,773,Yes,2,2,Progression Free Survival,PFS,228.647352475673,DAYS,2020-12-14 03:34:36.683,338,0,Death,,
1000,AB12345,AB12345-CHN-2-id-272,id-272,CHN-2,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S1,7.17022926183863,MEDIUM,Y,Y,Y,Y,N,2020-01-08,2020-01-11 03:34:36.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,2020-01-11 03:34:36.683,2021-02-16 17:45:28.683,2021-02-16 17:45:28.683,2022-02-16 23:45:28.683,DISCONTINUED,DISCONTINUED,2022-02-16,768,DEATH,2022-02-23,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-23,773,Yes,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.028950823305202
1001,AB12345,AB12345-CHN-2-id-274,id-274,CHN-2,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,B,S2,2.58527532415263,HIGH,Y,Y,N,N,N,2019-10-10,2019-10-14 16:57:27.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,860,DEATH,2022-03-23,SUICIDE,OTHER,32,>30,2022-03-23,890,No,2,2,Duration of Confirmed Response,CRSD,158.137831790373,DAYS,2020-09-08 16:57:27.683,330,1,Adverse Event,Preferred Term,
1002,AB12345,AB12345-CHN-2-id-274,id-274,CHN-2,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,B,S2,2.58527532415263,HIGH,Y,Y,N,N,N,2019-10-10,2019-10-14 16:57:27.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,860,DEATH,2022-03-23,SUICIDE,OTHER,32,>30,2022-03-23,890,No,4,4,Event Free Survival,EFS,60.9721988206729,DAYS,2021-10-01 16:57:27.683,718,1,Last Tumor Assessment,Completion or Discontinuation,
1003,AB12345,AB12345-CHN-2-id-274,id-274,CHN-2,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,B,S2,2.58527532415263,HIGH,Y,Y,N,N,N,2019-10-10,2019-10-14 16:57:27.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,860,DEATH,2022-03-23,SUICIDE,OTHER,32,>30,2022-03-23,890,No,1,1,Overall Survival,OS,475.616793660447,DAYS,2019-12-19 16:57:27.683,66,1,Alive,Alive During Study,
1004,AB12345,AB12345-CHN-2-id-274,id-274,CHN-2,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,B,S2,2.58527532415263,HIGH,Y,Y,N,N,N,2019-10-10,2019-10-14 16:57:27.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,860,DEATH,2022-03-23,SUICIDE,OTHER,32,>30,2022-03-23,890,No,3,3,Progression Free Survival,PFS,225.628689443693,DAYS,2021-05-15 16:57:27.683,579,1,Adverse Event,Preferred Term,
1005,AB12345,AB12345-CHN-2-id-274,id-274,CHN-2,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,B,S2,2.58527532415263,HIGH,Y,Y,N,N,N,2019-10-10,2019-10-14 16:57:27.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,2019-10-14 16:57:27.683,2021-02-19 15:03:11.683,2021-02-19 15:03:11.683,2022-02-19 21:03:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,860,DEATH,2022-03-23,SUICIDE,OTHER,32,>30,2022-03-23,890,No,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-3.34162020679885
1006,AB12345,AB12345-CHN-2-id-284,id-284,CHN-2,36,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S2,8.02224737240688,MEDIUM,Y,Y,N,N,N,2020-09-13,2020-09-13 23:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,COMPLETED,COMPLETED,2023-09-14,1096,,,,,,,2023-10-08,,,1,1,Duration of Confirmed Response,CRSD,198.733468470164,DAYS,2020-09-30 23:33:11.683,17,1,Adverse Event,Preferred Term,
1007,AB12345,AB12345-CHN-2-id-284,id-284,CHN-2,36,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S2,8.02224737240688,MEDIUM,Y,Y,N,N,N,2020-09-13,2020-09-13 23:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,COMPLETED,COMPLETED,2023-09-14,1096,,,,,,,2023-10-08,,,4,4,Event Free Survival,EFS,89.9957029474899,DAYS,2023-03-10 23:33:11.683,908,1,Adverse Event,Preferred Term,
1008,AB12345,AB12345-CHN-2-id-284,id-284,CHN-2,36,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S2,8.02224737240688,MEDIUM,Y,Y,N,N,N,2020-09-13,2020-09-13 23:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,COMPLETED,COMPLETED,2023-09-14,1096,,,,,,,2023-10-08,,,3,3,Overall Survival,OS,423.755000438541,DAYS,2022-03-05 23:33:11.683,538,1,Alive,Alive During Study,
1009,AB12345,AB12345-CHN-2-id-284,id-284,CHN-2,36,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S2,8.02224737240688,MEDIUM,Y,Y,N,N,N,2020-09-13,2020-09-13 23:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,COMPLETED,COMPLETED,2023-09-14,1096,,,,,,,2023-10-08,,,2,2,Progression Free Survival,PFS,210.162090114318,DAYS,2021-01-14 23:33:11.683,123,1,Adverse Event,Preferred Term,
1010,AB12345,AB12345-CHN-2-id-284,id-284,CHN-2,36,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S2,8.02224737240688,MEDIUM,Y,Y,N,N,N,2020-09-13,2020-09-13 23:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,2020-09-13 23:33:11.683,2022-09-14 11:33:11.683,2022-09-14 11:33:11.683,2023-09-14 17:33:11.683,COMPLETED,COMPLETED,2023-09-14,1096,,,,,,,2023-10-08,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.77518759982475
1011,AB12345,AB12345-CHN-2-id-286,id-286,CHN-2,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,2.63471964500237,LOW,Y,Y,Y,Y,N,2019-05-16,2019-05-16 15:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,COMPLETED,COMPLETED,2022-05-16,1096,,,,,,,2022-05-31,,,2,2,Duration of Confirmed Response,CRSD,114.858843083493,DAYS,2021-03-10 15:23:23.683,664,0,Death,,
1012,AB12345,AB12345-CHN-2-id-286,id-286,CHN-2,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,2.63471964500237,LOW,Y,Y,Y,Y,N,2019-05-16,2019-05-16 15:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,COMPLETED,COMPLETED,2022-05-16,1096,,,,,,,2022-05-31,,,3,3,Event Free Survival,EFS,74.9023704393767,DAYS,2021-06-02 15:23:23.683,748,0,Disease Progression,,
1013,AB12345,AB12345-CHN-2-id-286,id-286,CHN-2,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,2.63471964500237,LOW,Y,Y,Y,Y,N,2019-05-16,2019-05-16 15:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,COMPLETED,COMPLETED,2022-05-16,1096,,,,,,,2022-05-31,,,1,1,Overall Survival,OS,114.858843083493,DAYS,2020-04-17 15:23:23.683,337,0,Death,,
1014,AB12345,AB12345-CHN-2-id-286,id-286,CHN-2,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,2.63471964500237,LOW,Y,Y,Y,Y,N,2019-05-16,2019-05-16 15:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,COMPLETED,COMPLETED,2022-05-16,1096,,,,,,,2022-05-31,,,4,4,Progression Free Survival,PFS,114.858843083493,DAYS,2022-01-23 15:23:23.683,983,0,Death,,
1015,AB12345,AB12345-CHN-2-id-286,id-286,CHN-2,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S1,2.63471964500237,LOW,Y,Y,Y,Y,N,2019-05-16,2019-05-16 15:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,2019-05-16 15:23:23.683,2021-05-16 03:23:23.683,2021-05-16 03:23:23.683,2022-05-16 09:23:23.683,COMPLETED,COMPLETED,2022-05-16,1096,,,,,,,2022-05-31,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-2.63168426450384
1016,AB12345,AB12345-CHN-2-id-292,id-292,CHN-2,32,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,7.87128283076546,MEDIUM,Y,Y,N,Y,N,2020-07-07,2020-07-10 08:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,COMPLETED,COMPLETED,2023-07-11,1096,,,,,,,2023-07-24,,,4,4,Duration of Confirmed Response,CRSD,116.267030010931,DAYS,2022-09-24 08:44:25.683,806,0,Disease Progression,,
1017,AB12345,AB12345-CHN-2-id-292,id-292,CHN-2,32,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,7.87128283076546,MEDIUM,Y,Y,N,Y,N,2020-07-07,2020-07-10 08:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,COMPLETED,COMPLETED,2023-07-11,1096,,,,,,,2023-07-24,,,2,2,Event Free Survival,EFS,90.7189002889208,DAYS,2022-02-24 08:44:25.683,594,1,Last Tumor Assessment,Completion or Discontinuation,
1018,AB12345,AB12345-CHN-2-id-292,id-292,CHN-2,32,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,7.87128283076546,MEDIUM,Y,Y,N,Y,N,2020-07-07,2020-07-10 08:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,COMPLETED,COMPLETED,2023-07-11,1096,,,,,,,2023-07-24,,,3,3,Overall Survival,OS,212.186646950431,DAYS,2022-07-27 08:44:25.683,747,0,Death,,
1019,AB12345,AB12345-CHN-2-id-292,id-292,CHN-2,32,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,7.87128283076546,MEDIUM,Y,Y,N,Y,N,2020-07-07,2020-07-10 08:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,COMPLETED,COMPLETED,2023-07-11,1096,,,,,,,2023-07-24,,,1,1,Progression Free Survival,PFS,212.186646950431,DAYS,2020-12-28 08:44:25.683,171,0,Death,,
1020,AB12345,AB12345-CHN-2-id-292,id-292,CHN-2,32,YEARS,F,ASIAN,NOT REPORTED,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,B,S2,7.87128283076546,MEDIUM,Y,Y,N,Y,N,2020-07-07,2020-07-10 08:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,2020-07-10 08:44:25.683,2022-07-10 20:44:25.683,2022-07-10 20:44:25.683,2023-07-11 02:44:25.683,COMPLETED,COMPLETED,2023-07-11,1096,,,,,,,2023-07-24,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-1.66267212350059
1021,AB12345,AB12345-CHN-2-id-332,id-332,CHN-2,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,4.21852991899993,LOW,Y,Y,N,N,N,2019-10-08,2019-10-08 07:50:23.683,,2019-10-08 07:50:23.683,,,,2019-10-08 07:50:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,162.71102654282,DAYS,2020-07-01 07:50:23.683,267,0,Disease Progression,,
1022,AB12345,AB12345-CHN-2-id-332,id-332,CHN-2,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,4.21852991899993,LOW,Y,Y,N,N,N,2019-10-08,2019-10-08 07:50:23.683,,2019-10-08 07:50:23.683,,,,2019-10-08 07:50:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,98.0923328688368,DAYS,2021-07-11 07:50:23.683,642,1,Last Tumor Assessment,Completion or Discontinuation,
1023,AB12345,AB12345-CHN-2-id-332,id-332,CHN-2,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,4.21852991899993,LOW,Y,Y,N,N,N,2019-10-08,2019-10-08 07:50:23.683,,2019-10-08 07:50:23.683,,,,2019-10-08 07:50:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,465.832828916609,DAYS,2020-10-21 07:50:23.683,379,1,Alive,Alive During Study,
1024,AB12345,AB12345-CHN-2-id-332,id-332,CHN-2,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,4.21852991899993,LOW,Y,Y,N,N,N,2019-10-08,2019-10-08 07:50:23.683,,2019-10-08 07:50:23.683,,,,2019-10-08 07:50:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,201.919943001121,DAYS,2019-11-01 07:50:23.683,24,0,Disease Progression,,
1025,AB12345,AB12345-CHN-2-id-332,id-332,CHN-2,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,4.21852991899993,LOW,Y,Y,N,N,N,2019-10-08,2019-10-08 07:50:23.683,,2019-10-08 07:50:23.683,,,,2019-10-08 07:50:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.05918020063289
1026,AB12345,AB12345-CHN-2-id-34,id-34,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,9.61601764164246,MEDIUM,Y,Y,Y,N,N,2019-07-17,2019-07-17 09:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-28,,,4,4,Duration of Confirmed Response,CRSD,186.809551622719,DAYS,2022-04-01 09:56:10.683,989,1,Last Tumor Assessment,Completion or Discontinuation,
1027,AB12345,AB12345-CHN-2-id-34,id-34,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,9.61601764164246,MEDIUM,Y,Y,Y,N,N,2019-07-17,2019-07-17 09:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-28,,,1,1,Event Free Survival,EFS,99.9045853980351,DAYS,2019-11-17 09:56:10.683,123,1,Last Tumor Assessment,Completion or Discontinuation,
1028,AB12345,AB12345-CHN-2-id-34,id-34,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,9.61601764164246,MEDIUM,Y,Y,Y,N,N,2019-07-17,2019-07-17 09:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-28,,,3,3,Overall Survival,OS,487.248356500641,DAYS,2021-05-30 09:56:10.683,683,1,Alive,Alive During Study,
1029,AB12345,AB12345-CHN-2-id-34,id-34,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,9.61601764164246,MEDIUM,Y,Y,Y,N,N,2019-07-17,2019-07-17 09:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-28,,,2,2,Progression Free Survival,PFS,239.691107487306,DAYS,2020-03-14 09:56:10.683,241,0,Disease Progression,,
1030,AB12345,AB12345-CHN-2-id-34,id-34,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,9.61601764164246,MEDIUM,Y,Y,Y,N,N,2019-07-17,2019-07-17 09:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,2019-07-17 09:56:10.683,2021-07-16 21:56:10.683,2021-07-16 21:56:10.683,2022-07-17 03:56:10.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-28,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-3.00805157143521
1031,AB12345,AB12345-CHN-2-id-342,id-342,CHN-2,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,6.05373964596125,HIGH,Y,Y,N,Y,N,2020-05-02,2020-05-04 23:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-27,,,3,3,Duration of Confirmed Response,CRSD,42.6056961610448,DAYS,2022-09-15 23:38:32.683,864,0,Death,,
1032,AB12345,AB12345-CHN-2-id-342,id-342,CHN-2,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,6.05373964596125,HIGH,Y,Y,N,Y,N,2020-05-02,2020-05-04 23:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-27,,,1,1,Event Free Survival,EFS,42.6056961610448,DAYS,2021-06-06 23:38:32.683,398,0,Death,,
1033,AB12345,AB12345-CHN-2-id-342,id-342,CHN-2,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,6.05373964596125,HIGH,Y,Y,N,Y,N,2020-05-02,2020-05-04 23:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-27,,,2,2,Overall Survival,OS,42.6056961610448,DAYS,2022-05-26 23:38:32.683,752,0,Death,,
1034,AB12345,AB12345-CHN-2-id-342,id-342,CHN-2,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,6.05373964596125,HIGH,Y,Y,N,Y,N,2020-05-02,2020-05-04 23:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-27,,,4,4,Progression Free Survival,PFS,42.6056961610448,DAYS,2023-03-15 23:38:32.683,1045,0,Death,,
1035,AB12345,AB12345-CHN-2-id-342,id-342,CHN-2,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,6.05373964596125,HIGH,Y,Y,N,Y,N,2020-05-02,2020-05-04 23:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,2020-05-04 23:38:32.683,2022-05-05 11:38:32.683,2022-05-05 11:38:32.683,2023-05-05 17:38:32.683,COMPLETED,COMPLETED,2023-05-05,1096,,,,,,,2023-05-27,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.67021214500741
1036,AB12345,AB12345-CHN-2-id-367,id-367,CHN-2,40,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,3.81440551166055,LOW,Y,Y,Y,N,N,2020-06-24,2020-06-27 18:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-26,,,4,4,Duration of Confirmed Response,CRSD,156.259845383465,DAYS,2023-05-12 18:42:56.683,1049,0,Disease Progression,,
1037,AB12345,AB12345-CHN-2-id-367,id-367,CHN-2,40,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,3.81440551166055,LOW,Y,Y,Y,N,N,2020-06-24,2020-06-27 18:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-26,,,1,1,Event Free Survival,EFS,97.6580427330919,DAYS,2020-07-09 18:42:56.683,12,0,Disease Progression,,
1038,AB12345,AB12345-CHN-2-id-367,id-367,CHN-2,40,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,3.81440551166055,LOW,Y,Y,Y,N,N,2020-06-24,2020-06-27 18:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-26,,,3,3,Overall Survival,OS,257.932903780602,DAYS,2022-02-09 18:42:56.683,592,0,Death,,
1039,AB12345,AB12345-CHN-2-id-367,id-367,CHN-2,40,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,3.81440551166055,LOW,Y,Y,Y,N,N,2020-06-24,2020-06-27 18:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-26,,,2,2,Progression Free Survival,PFS,257.932903780602,DAYS,2021-12-24 18:42:56.683,545,0,Death,,
1040,AB12345,AB12345-CHN-2-id-367,id-367,CHN-2,40,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,3.81440551166055,LOW,Y,Y,Y,N,N,2020-06-24,2020-06-27 18:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,2020-06-27 18:42:56.683,2022-06-28 06:42:56.683,2022-06-28 06:42:56.683,2023-06-28 12:42:56.683,COMPLETED,COMPLETED,2023-06-28,1096,,,,,,,2023-07-26,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,0,,,-0.848566552106981
1041,AB12345,AB12345-CHN-2-id-395,id-395,CHN-2,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,9.48239956494545,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-27 18:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,2,2,Duration of Confirmed Response,CRSD,119.84444775153,DAYS,2019-10-20 18:58:23.683,176,1,Adverse Event,Preferred Term,
1042,AB12345,AB12345-CHN-2-id-395,id-395,CHN-2,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,9.48239956494545,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-27 18:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,1,1,Event Free Survival,EFS,85.0986800552346,DAYS,2019-07-01 18:58:23.683,65,1,Last Tumor Assessment,Completion or Discontinuation,
1043,AB12345,AB12345-CHN-2-id-395,id-395,CHN-2,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,9.48239956494545,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-27 18:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,3,3,Overall Survival,OS,344.912922987714,DAYS,2020-04-14 18:58:23.683,353,1,Alive,Alive During Study,
1044,AB12345,AB12345-CHN-2-id-395,id-395,CHN-2,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,9.48239956494545,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-27 18:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,4,4,Progression Free Survival,PFS,261.898963502608,DAYS,2021-08-04 18:58:23.683,830,0,Disease Progression,,
1045,AB12345,AB12345-CHN-2-id-395,id-395,CHN-2,28,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S1,9.48239956494545,LOW,Y,Y,Y,N,N,2019-04-25,2019-04-27 18:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,2019-04-27 18:58:23.683,2021-04-27 06:58:23.683,2021-04-27 06:58:23.683,2022-04-27 12:58:23.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-16,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Preferred Term,-0.293490563928867
1046,AB12345,AB12345-CHN-2-id-398,id-398,CHN-2,46,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S1,3.34260143284233,MEDIUM,Y,Y,N,N,N,2019-10-16,2019-10-19 21:44:33.683,,2019-10-19 21:44:33.683,,,,2019-10-19 21:44:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,175.650512473658,DAYS,2020-12-25 21:44:33.683,433,1,Last Tumor Assessment,Completion or Discontinuation,
1047,AB12345,AB12345-CHN-2-id-398,id-398,CHN-2,46,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S1,3.34260143284233,MEDIUM,Y,Y,N,N,N,2019-10-16,2019-10-19 21:44:33.683,,2019-10-19 21:44:33.683,,,,2019-10-19 21:44:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,17.1440170612186,DAYS,2021-01-12 21:44:33.683,451,0,Disease Progression,,
1048,AB12345,AB12345-CHN-2-id-398,id-398,CHN-2,46,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S1,3.34260143284233,MEDIUM,Y,Y,N,N,N,2019-10-16,2019-10-19 21:44:33.683,,2019-10-19 21:44:33.683,,,,2019-10-19 21:44:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,311.573782609776,DAYS,2020-08-01 21:44:33.683,287,1,Alive,Alive During Study,
1049,AB12345,AB12345-CHN-2-id-398,id-398,CHN-2,46,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S1,3.34260143284233,MEDIUM,Y,Y,N,N,N,2019-10-16,2019-10-19 21:44:33.683,,2019-10-19 21:44:33.683,,,,2019-10-19 21:44:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,263.815694465302,DAYS,2019-11-23 21:44:33.683,35,1,Adverse Event,Preferred Term,
1050,AB12345,AB12345-CHN-2-id-398,id-398,CHN-2,46,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S1,3.34260143284233,MEDIUM,Y,Y,N,N,N,2019-10-16,2019-10-19 21:44:33.683,,2019-10-19 21:44:33.683,,,,2019-10-19 21:44:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.861261762445978
1051,AB12345,AB12345-CHN-2-id-98,id-98,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,5.05389654988776,HIGH,Y,Y,Y,N,N,2020-03-25,2020-03-27 03:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,COMPLETED,COMPLETED,2023-03-27,1096,,,,,,,2023-04-10,,,3,3,Duration of Confirmed Response,CRSD,169.15447707288,DAYS,2021-07-13 03:36:25.683,473,0,Death,,
1052,AB12345,AB12345-CHN-2-id-98,id-98,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,5.05389654988776,HIGH,Y,Y,Y,N,N,2020-03-25,2020-03-27 03:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,COMPLETED,COMPLETED,2023-03-27,1096,,,,,,,2023-04-10,,,1,1,Event Free Survival,EFS,72.2728141257539,DAYS,2021-03-03 03:36:25.683,341,0,Disease Progression,,
1053,AB12345,AB12345-CHN-2-id-98,id-98,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,5.05389654988776,HIGH,Y,Y,Y,N,N,2020-03-25,2020-03-27 03:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,COMPLETED,COMPLETED,2023-03-27,1096,,,,,,,2023-04-10,,,4,4,Overall Survival,OS,169.15447707288,DAYS,2022-06-22 03:36:25.683,817,0,Death,,
1054,AB12345,AB12345-CHN-2-id-98,id-98,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,5.05389654988776,HIGH,Y,Y,Y,N,N,2020-03-25,2020-03-27 03:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,COMPLETED,COMPLETED,2023-03-27,1096,,,,,,,2023-04-10,,,2,2,Progression Free Survival,PFS,169.15447707288,DAYS,2021-04-24 03:36:25.683,393,0,Death,,
1055,AB12345,AB12345-CHN-2-id-98,id-98,CHN-2,48,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-2,Dr. CHN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,B,S2,5.05389654988776,HIGH,Y,Y,Y,N,N,2020-03-25,2020-03-27 03:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,2020-03-27 03:36:25.683,2022-03-27 15:36:25.683,2022-03-27 15:36:25.683,2023-03-27 21:36:25.683,COMPLETED,COMPLETED,2023-03-27,1096,,,,,,,2023-04-10,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.766181737258488
1056,AB12345,AB12345-CHN-3-id-128,id-128,CHN-3,32,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,14.424933692778,MEDIUM,Y,Y,Y,Y,N,2019-02-22,2019-02-24 11:09:25.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,DISCONTINUED,DISCONTINUED,2022-02-12,1084,DEATH,2022-03-06,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-06,1105,Yes,2,2,Duration of Confirmed Response,CRSD,78.3444615756162,DAYS,2019-10-19 11:09:25.683,237,0,Death,,
1057,AB12345,AB12345-CHN-3-id-128,id-128,CHN-3,32,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,14.424933692778,MEDIUM,Y,Y,Y,Y,N,2019-02-22,2019-02-24 11:09:25.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,DISCONTINUED,DISCONTINUED,2022-02-12,1084,DEATH,2022-03-06,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-06,1105,Yes,4,4,Event Free Survival,EFS,78.3444615756162,DAYS,2021-12-22 11:09:25.683,1032,0,Death,,
1058,AB12345,AB12345-CHN-3-id-128,id-128,CHN-3,32,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,14.424933692778,MEDIUM,Y,Y,Y,Y,N,2019-02-22,2019-02-24 11:09:25.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,DISCONTINUED,DISCONTINUED,2022-02-12,1084,DEATH,2022-03-06,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-06,1105,Yes,1,1,Overall Survival,OS,78.3444615756162,DAYS,2019-03-25 11:09:25.683,29,0,Death,,
1059,AB12345,AB12345-CHN-3-id-128,id-128,CHN-3,32,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,14.424933692778,MEDIUM,Y,Y,Y,Y,N,2019-02-22,2019-02-24 11:09:25.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,DISCONTINUED,DISCONTINUED,2022-02-12,1084,DEATH,2022-03-06,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-06,1105,Yes,3,3,Progression Free Survival,PFS,78.3444615756162,DAYS,2021-08-08 11:09:25.683,896,0,Death,,
1060,AB12345,AB12345-CHN-3-id-128,id-128,CHN-3,32,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,Y,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,14.424933692778,MEDIUM,Y,Y,Y,Y,N,2019-02-22,2019-02-24 11:09:25.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,2019-02-24 11:09:25.683,2021-02-11 22:28:08.683,2021-02-11 22:28:08.683,2022-02-12 04:28:08.683,DISCONTINUED,DISCONTINUED,2022-02-12,1084,DEATH,2022-03-06,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-06,1105,Yes,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-1.88791156025967
1061,AB12345,AB12345-CHN-3-id-155,id-155,CHN-3,35,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,13.270866630102,MEDIUM,Y,Y,N,Y,N,2020-05-17,2020-05-20 13:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,COMPLETED,COMPLETED,2023-05-21,1096,,,,,,,2023-06-02,,,4,4,Duration of Confirmed Response,CRSD,115.117178671062,DAYS,2023-04-27 13:11:59.683,1072,0,Disease Progression,,
1062,AB12345,AB12345-CHN-3-id-155,id-155,CHN-3,35,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,13.270866630102,MEDIUM,Y,Y,N,Y,N,2020-05-17,2020-05-20 13:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,COMPLETED,COMPLETED,2023-05-21,1096,,,,,,,2023-06-02,,,3,3,Event Free Survival,EFS,25.545259002829,DAYS,2023-03-24 13:11:59.683,1038,1,Adverse Event,Preferred Term,
1063,AB12345,AB12345-CHN-3-id-155,id-155,CHN-3,35,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,13.270866630102,MEDIUM,Y,Y,N,Y,N,2020-05-17,2020-05-20 13:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,COMPLETED,COMPLETED,2023-05-21,1096,,,,,,,2023-06-02,,,1,1,Overall Survival,OS,217.743062530644,DAYS,2022-05-22 13:11:59.683,732,0,Death,,
1064,AB12345,AB12345-CHN-3-id-155,id-155,CHN-3,35,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,13.270866630102,MEDIUM,Y,Y,N,Y,N,2020-05-17,2020-05-20 13:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,COMPLETED,COMPLETED,2023-05-21,1096,,,,,,,2023-06-02,,,2,2,Progression Free Survival,PFS,217.743062530644,DAYS,2022-10-28 13:11:59.683,891,0,Death,,
1065,AB12345,AB12345-CHN-3-id-155,id-155,CHN-3,35,YEARS,F,WHITE,HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,13.270866630102,MEDIUM,Y,Y,N,Y,N,2020-05-17,2020-05-20 13:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,2020-05-20 13:11:59.683,2022-05-21 01:11:59.683,2022-05-21 01:11:59.683,2023-05-21 07:11:59.683,COMPLETED,COMPLETED,2023-05-21,1096,,,,,,,2023-06-02,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-0.306452520035999
1066,AB12345,AB12345-CHN-3-id-193,id-193,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,5.46044188011641,MEDIUM,Y,Y,Y,N,N,2021-01-24,2021-01-26 01:09:53.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,DISCONTINUED,DISCONTINUED,2022-02-13,384,PHYSICIAN DECISION,,,,,,2022-03-12,,,4,4,Duration of Confirmed Response,CRSD,163.378864317201,DAYS,2021-12-18 01:09:53.683,326,1,Adverse Event,Preferred Term,
1067,AB12345,AB12345-CHN-3-id-193,id-193,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,5.46044188011641,MEDIUM,Y,Y,Y,N,N,2021-01-24,2021-01-26 01:09:53.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,DISCONTINUED,DISCONTINUED,2022-02-13,384,PHYSICIAN DECISION,,,,,,2022-03-12,,,1,1,Event Free Survival,EFS,15.7539047603495,DAYS,2021-05-20 01:09:53.683,114,1,Last Tumor Assessment,Completion or Discontinuation,
1068,AB12345,AB12345-CHN-3-id-193,id-193,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,5.46044188011641,MEDIUM,Y,Y,Y,N,N,2021-01-24,2021-01-26 01:09:53.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,DISCONTINUED,DISCONTINUED,2022-02-13,384,PHYSICIAN DECISION,,,,,,2022-03-12,,,2,2,Overall Survival,OS,355.544009804726,DAYS,2021-06-19 01:09:53.683,144,1,Alive,Alive During Study,
1069,AB12345,AB12345-CHN-3-id-193,id-193,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,5.46044188011641,MEDIUM,Y,Y,Y,N,N,2021-01-24,2021-01-26 01:09:53.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,DISCONTINUED,DISCONTINUED,2022-02-13,384,PHYSICIAN DECISION,,,,,,2022-03-12,,,3,3,Progression Free Survival,PFS,237.275088508613,DAYS,2021-12-16 01:09:53.683,324,1,Adverse Event,Preferred Term,
1070,AB12345,AB12345-CHN-3-id-193,id-193,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,5.46044188011641,MEDIUM,Y,Y,Y,N,N,2021-01-24,2021-01-26 01:09:53.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,2021-01-26 01:09:53.683,2021-02-13 07:07:25.683,2021-02-13 07:07:25.683,2022-02-13 13:07:25.683,DISCONTINUED,DISCONTINUED,2022-02-13,384,PHYSICIAN DECISION,,,,,,2022-03-12,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-1.2506673813417
1071,AB12345,AB12345-CHN-3-id-204,id-204,CHN-3,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,4.6826362279958,LOW,Y,Y,Y,N,N,2019-08-06,2019-08-08 21:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,COMPLETED,COMPLETED,2022-08-08,1096,,,,,,,2022-08-29,,,2,2,Duration of Confirmed Response,CRSD,120.371114136651,DAYS,2021-03-18 21:00:24.683,588,0,Death,,
1072,AB12345,AB12345-CHN-3-id-204,id-204,CHN-3,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,4.6826362279958,LOW,Y,Y,Y,N,N,2019-08-06,2019-08-08 21:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,COMPLETED,COMPLETED,2022-08-08,1096,,,,,,,2022-08-29,,,4,4,Event Free Survival,EFS,29.6632225636858,DAYS,2022-03-15 21:00:24.683,950,0,Disease Progression,,
1073,AB12345,AB12345-CHN-3-id-204,id-204,CHN-3,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,4.6826362279958,LOW,Y,Y,Y,N,N,2019-08-06,2019-08-08 21:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,COMPLETED,COMPLETED,2022-08-08,1096,,,,,,,2022-08-29,,,1,1,Overall Survival,OS,120.371114136651,DAYS,2019-08-25 21:00:24.683,17,0,Death,,
1074,AB12345,AB12345-CHN-3-id-204,id-204,CHN-3,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,4.6826362279958,LOW,Y,Y,Y,N,N,2019-08-06,2019-08-08 21:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,COMPLETED,COMPLETED,2022-08-08,1096,,,,,,,2022-08-29,,,3,3,Progression Free Survival,PFS,120.371114136651,DAYS,2021-05-01 21:00:24.683,632,0,Death,,
1075,AB12345,AB12345-CHN-3-id-204,id-204,CHN-3,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S1,4.6826362279958,LOW,Y,Y,Y,N,N,2019-08-06,2019-08-08 21:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,2019-08-08 21:00:24.683,2021-08-08 09:00:24.683,2021-08-08 09:00:24.683,2022-08-08 15:00:24.683,COMPLETED,COMPLETED,2022-08-08,1096,,,,,,,2022-08-29,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.220376878064711
1076,AB12345,AB12345-CHN-3-id-259,id-259,CHN-3,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S1,3.33129512265211,MEDIUM,Y,Y,N,N,N,2019-08-04,2019-08-07 07:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,COMPLETED,COMPLETED,2022-08-07,1096,,,,,,,2022-08-18,,,2,2,Duration of Confirmed Response,CRSD,125.34315045923,DAYS,2021-07-08 07:18:48.683,701,1,Last Tumor Assessment,Completion or Discontinuation,
1077,AB12345,AB12345-CHN-3-id-259,id-259,CHN-3,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S1,3.33129512265211,MEDIUM,Y,Y,N,N,N,2019-08-04,2019-08-07 07:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,COMPLETED,COMPLETED,2022-08-07,1096,,,,,,,2022-08-18,,,4,4,Event Free Survival,EFS,33.859024947742,DAYS,2022-05-01 07:18:48.683,998,1,Last Tumor Assessment,Completion or Discontinuation,
1078,AB12345,AB12345-CHN-3-id-259,id-259,CHN-3,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S1,3.33129512265211,MEDIUM,Y,Y,N,N,N,2019-08-04,2019-08-07 07:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,COMPLETED,COMPLETED,2022-08-07,1096,,,,,,,2022-08-18,,,3,3,Overall Survival,OS,484.335352806374,DAYS,2021-08-21 07:18:48.683,745,1,Alive,Alive During Study,
1079,AB12345,AB12345-CHN-3-id-259,id-259,CHN-3,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S1,3.33129512265211,MEDIUM,Y,Y,N,N,N,2019-08-04,2019-08-07 07:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,COMPLETED,COMPLETED,2022-08-07,1096,,,,,,,2022-08-18,,,1,1,Progression Free Survival,PFS,217.009768937714,DAYS,2021-04-05 07:18:48.683,607,1,Adverse Event,Preferred Term,
1080,AB12345,AB12345-CHN-3-id-259,id-259,CHN-3,27,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S1,3.33129512265211,MEDIUM,Y,Y,N,N,N,2019-08-04,2019-08-07 07:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,2019-08-07 07:18:48.683,2021-08-06 19:18:48.683,2021-08-06 19:18:48.683,2022-08-07 01:18:48.683,COMPLETED,COMPLETED,2022-08-07,1096,,,,,,,2022-08-18,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.989743375112732
1081,AB12345,AB12345-CHN-3-id-271,id-271,CHN-3,24,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.80752342637141,LOW,Y,Y,N,N,N,2020-08-04,2020-08-06 02:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-09-04,,,1,1,Duration of Confirmed Response,CRSD,108.510920917615,DAYS,2021-02-21 02:22:10.683,199,0,Death,,
1082,AB12345,AB12345-CHN-3-id-271,id-271,CHN-3,24,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.80752342637141,LOW,Y,Y,N,N,N,2020-08-04,2020-08-06 02:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-09-04,,,4,4,Event Free Survival,EFS,44.3516439700034,DAYS,2023-06-01 02:22:10.683,1029,0,Disease Progression,,
1083,AB12345,AB12345-CHN-3-id-271,id-271,CHN-3,24,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.80752342637141,LOW,Y,Y,N,N,N,2020-08-04,2020-08-06 02:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-09-04,,,2,2,Overall Survival,OS,108.510920917615,DAYS,2021-06-28 02:22:10.683,326,0,Death,,
1084,AB12345,AB12345-CHN-3-id-271,id-271,CHN-3,24,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.80752342637141,LOW,Y,Y,N,N,N,2020-08-04,2020-08-06 02:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-09-04,,,3,3,Progression Free Survival,PFS,108.510920917615,DAYS,2021-12-06 02:22:10.683,487,0,Death,,
1085,AB12345,AB12345-CHN-3-id-271,id-271,CHN-3,24,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.80752342637141,LOW,Y,Y,N,N,N,2020-08-04,2020-08-06 02:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,2020-08-06 02:22:10.683,2022-08-06 14:22:10.683,2022-08-06 14:22:10.683,2023-08-06 20:22:10.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-09-04,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.420929612270356
1086,AB12345,AB12345-CHN-3-id-281,id-281,CHN-3,41,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.37455106872875,MEDIUM,Y,Y,N,Y,N,2020-08-31,2020-09-02 16:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,COMPLETED,COMPLETED,2023-09-03,1096,,,,,,,2023-09-16,,,4,4,Duration of Confirmed Response,CRSD,154.334351955913,DAYS,2023-05-27 16:09:58.683,997,0,Disease Progression,,
1087,AB12345,AB12345-CHN-3-id-281,id-281,CHN-3,41,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.37455106872875,MEDIUM,Y,Y,N,Y,N,2020-08-31,2020-09-02 16:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,COMPLETED,COMPLETED,2023-09-03,1096,,,,,,,2023-09-16,,,1,1,Event Free Survival,EFS,47.1145134384278,DAYS,2022-01-10 16:09:58.683,495,0,Disease Progression,,
1088,AB12345,AB12345-CHN-3-id-281,id-281,CHN-3,41,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.37455106872875,MEDIUM,Y,Y,N,Y,N,2020-08-31,2020-09-02 16:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,COMPLETED,COMPLETED,2023-09-03,1096,,,,,,,2023-09-16,,,2,2,Overall Survival,OS,364.062705542892,DAYS,2022-09-17 16:09:58.683,745,1,Alive,Alive During Study,
1089,AB12345,AB12345-CHN-3-id-281,id-281,CHN-3,41,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.37455106872875,MEDIUM,Y,Y,N,Y,N,2020-08-31,2020-09-02 16:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,COMPLETED,COMPLETED,2023-09-03,1096,,,,,,,2023-09-16,,,3,3,Progression Free Survival,PFS,278.701092605479,DAYS,2022-12-29 16:09:58.683,848,1,Adverse Event,Preferred Term,
1090,AB12345,AB12345-CHN-3-id-281,id-281,CHN-3,41,YEARS,M,BLACK OR AFRICAN AMERICAN,UNKNOWN,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.37455106872875,MEDIUM,Y,Y,N,Y,N,2020-08-31,2020-09-02 16:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,2020-09-02 16:09:58.683,2022-09-03 04:09:58.683,2022-09-03 04:09:58.683,2023-09-03 10:09:58.683,COMPLETED,COMPLETED,2023-09-03,1096,,,,,,,2023-09-16,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-0.524210654182241
1091,AB12345,AB12345-CHN-3-id-303,id-303,CHN-3,44,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,3.81708276470525,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-05 01:05:40.683,,2020-01-05 01:05:40.683,,,,2020-01-05 01:05:40.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,199.847048521042,DAYS,2020-10-23 01:05:40.683,292,0,Disease Progression,,
1092,AB12345,AB12345-CHN-3-id-303,id-303,CHN-3,44,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,3.81708276470525,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-05 01:05:40.683,,2020-01-05 01:05:40.683,,,,2020-01-05 01:05:40.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,86.2332740577403,DAYS,2021-04-08 01:05:40.683,459,1,Last Tumor Assessment,Completion or Discontinuation,
1093,AB12345,AB12345-CHN-3-id-303,id-303,CHN-3,44,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,3.81708276470525,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-05 01:05:40.683,,2020-01-05 01:05:40.683,,,,2020-01-05 01:05:40.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,387.459298269823,DAYS,2021-04-19 01:05:40.683,470,1,Alive,Alive During Study,
1094,AB12345,AB12345-CHN-3-id-303,id-303,CHN-3,44,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,3.81708276470525,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-05 01:05:40.683,,2020-01-05 01:05:40.683,,,,2020-01-05 01:05:40.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,221.3442992419,DAYS,2020-02-13 01:05:40.683,39,0,Disease Progression,,
1095,AB12345,AB12345-CHN-3-id-303,id-303,CHN-3,44,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,3.81708276470525,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-05 01:05:40.683,,2020-01-05 01:05:40.683,,,,2020-01-05 01:05:40.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,0,,,-1.89424742503575
1096,AB12345,AB12345-CHN-3-id-333,id-333,CHN-3,30,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,2.72885639511699,LOW,Y,Y,Y,Y,Y,2020-01-13,2020-01-13 07:01:27.683,,2020-01-13 07:01:27.683,,,,2020-01-13 07:01:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,196.557670854963,DAYS,2020-03-17 07:01:27.683,64,1,Adverse Event,Preferred Term,
1097,AB12345,AB12345-CHN-3-id-333,id-333,CHN-3,30,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,2.72885639511699,LOW,Y,Y,Y,Y,Y,2020-01-13,2020-01-13 07:01:27.683,,2020-01-13 07:01:27.683,,,,2020-01-13 07:01:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,47.1920496830717,DAYS,2020-06-21 07:01:27.683,160,1,Last Tumor Assessment,Completion or Discontinuation,
1098,AB12345,AB12345-CHN-3-id-333,id-333,CHN-3,30,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,2.72885639511699,LOW,Y,Y,Y,Y,Y,2020-01-13,2020-01-13 07:01:27.683,,2020-01-13 07:01:27.683,,,,2020-01-13 07:01:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,461.227066768333,DAYS,2021-10-15 07:01:27.683,641,1,Alive,Alive During Study,
1099,AB12345,AB12345-CHN-3-id-333,id-333,CHN-3,30,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,2.72885639511699,LOW,Y,Y,Y,Y,Y,2020-01-13,2020-01-13 07:01:27.683,,2020-01-13 07:01:27.683,,,,2020-01-13 07:01:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,264.111650222912,DAYS,2020-04-17 07:01:27.683,95,1,Last Tumor Assessment,Completion or Discontinuation,
1100,AB12345,AB12345-CHN-3-id-333,id-333,CHN-3,30,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,2.72885639511699,LOW,Y,Y,Y,Y,Y,2020-01-13,2020-01-13 07:01:27.683,,2020-01-13 07:01:27.683,,,,2020-01-13 07:01:27.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,0.0720657387840892
1101,AB12345,AB12345-CHN-3-id-361,id-361,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.32503378707655,HIGH,Y,Y,Y,N,N,2019-04-11,2019-04-11 18:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,COMPLETED,COMPLETED,2022-04-11,1096,,,,,,,2022-04-26,,,1,1,Duration of Confirmed Response,CRSD,105.862244800664,DAYS,2019-05-11 18:40:28.683,30,0,Disease Progression,,
1102,AB12345,AB12345-CHN-3-id-361,id-361,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.32503378707655,HIGH,Y,Y,Y,N,N,2019-04-11,2019-04-11 18:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,COMPLETED,COMPLETED,2022-04-11,1096,,,,,,,2022-04-26,,,4,4,Event Free Survival,EFS,93.1202860502526,DAYS,2021-03-25 18:40:28.683,714,0,Disease Progression,,
1103,AB12345,AB12345-CHN-3-id-361,id-361,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.32503378707655,HIGH,Y,Y,Y,N,N,2019-04-11,2019-04-11 18:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,COMPLETED,COMPLETED,2022-04-11,1096,,,,,,,2022-04-26,,,3,3,Overall Survival,OS,439.376557664946,DAYS,2019-09-30 18:40:28.683,172,1,Alive,Alive During Study,
1104,AB12345,AB12345-CHN-3-id-361,id-361,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.32503378707655,HIGH,Y,Y,Y,N,N,2019-04-11,2019-04-11 18:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,COMPLETED,COMPLETED,2022-04-11,1096,,,,,,,2022-04-26,,,2,2,Progression Free Survival,PFS,247.764285560697,DAYS,2019-09-01 18:40:28.683,143,1,Adverse Event,Preferred Term,
1105,AB12345,AB12345-CHN-3-id-361,id-361,CHN-3,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,6.32503378707655,HIGH,Y,Y,Y,N,N,2019-04-11,2019-04-11 18:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,2019-04-11 18:40:28.683,2021-04-11 06:40:28.683,2021-04-11 06:40:28.683,2022-04-11 12:40:28.683,COMPLETED,COMPLETED,2022-04-11,1096,,,,,,,2022-04-26,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.482692394351537
1106,AB12345,AB12345-CHN-3-id-81,id-81,CHN-3,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,9.81724361222271,MEDIUM,Y,Y,N,N,N,2020-09-07,2020-09-09 23:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-10-05,,,2,2,Duration of Confirmed Response,CRSD,175.685431691818,DAYS,2022-12-10 23:01:01.683,822,0,Disease Progression,,
1107,AB12345,AB12345-CHN-3-id-81,id-81,CHN-3,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,9.81724361222271,MEDIUM,Y,Y,N,N,N,2020-09-07,2020-09-09 23:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-10-05,,,1,1,Event Free Survival,EFS,18.7970783002675,DAYS,2022-02-09 23:01:01.683,518,1,Adverse Event,Preferred Term,
1108,AB12345,AB12345-CHN-3-id-81,id-81,CHN-3,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,9.81724361222271,MEDIUM,Y,Y,N,N,N,2020-09-07,2020-09-09 23:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-10-05,,,4,4,Overall Survival,OS,402.028092602268,DAYS,2023-04-26 23:01:01.683,959,1,Alive,Alive During Study,
1109,AB12345,AB12345-CHN-3-id-81,id-81,CHN-3,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,9.81724361222271,MEDIUM,Y,Y,N,N,N,2020-09-07,2020-09-09 23:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-10-05,,,3,3,Progression Free Survival,PFS,259.167372481897,DAYS,2023-03-18 23:01:01.683,920,1,Adverse Event,Preferred Term,
1110,AB12345,AB12345-CHN-3-id-81,id-81,CHN-3,35,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-3,Dr. CHN-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,9.81724361222271,MEDIUM,Y,Y,N,N,N,2020-09-07,2020-09-09 23:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,2020-09-09 23:01:01.683,2022-09-10 11:01:01.683,2022-09-10 11:01:01.683,2023-09-10 17:01:01.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-10-05,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-3.91984223900443
1111,AB12345,AB12345-CHN-4-id-114,id-114,CHN-4,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S2,5.10418549084273,MEDIUM,Y,Y,Y,Y,N,2019-08-16,2019-08-18 22:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,COMPLETED,COMPLETED,2022-08-18,1096,,,,,,,2022-09-07,,,2,2,Duration of Confirmed Response,CRSD,102.548196609132,DAYS,2019-10-02 22:39:14.683,45,0,Death,,
1112,AB12345,AB12345-CHN-4-id-114,id-114,CHN-4,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S2,5.10418549084273,MEDIUM,Y,Y,Y,Y,N,2019-08-16,2019-08-18 22:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,COMPLETED,COMPLETED,2022-08-18,1096,,,,,,,2022-09-07,,,1,1,Event Free Survival,EFS,53.4711501479615,DAYS,2019-08-30 22:39:14.683,12,0,Disease Progression,,
1113,AB12345,AB12345-CHN-4-id-114,id-114,CHN-4,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S2,5.10418549084273,MEDIUM,Y,Y,Y,Y,N,2019-08-16,2019-08-18 22:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,COMPLETED,COMPLETED,2022-08-18,1096,,,,,,,2022-09-07,,,4,4,Overall Survival,OS,102.548196609132,DAYS,2021-10-21 22:39:14.683,795,0,Death,,
1114,AB12345,AB12345-CHN-4-id-114,id-114,CHN-4,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S2,5.10418549084273,MEDIUM,Y,Y,Y,Y,N,2019-08-16,2019-08-18 22:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,COMPLETED,COMPLETED,2022-08-18,1096,,,,,,,2022-09-07,,,3,3,Progression Free Survival,PFS,102.548196609132,DAYS,2020-04-05 22:39:14.683,231,0,Death,,
1115,AB12345,AB12345-CHN-4-id-114,id-114,CHN-4,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,B,S2,5.10418549084273,MEDIUM,Y,Y,Y,Y,N,2019-08-16,2019-08-18 22:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,2019-08-18 22:39:14.683,2021-08-18 10:39:14.683,2021-08-18 10:39:14.683,2022-08-18 16:39:14.683,COMPLETED,COMPLETED,2022-08-18,1096,,,,,,,2022-09-07,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.25051106243668
1116,AB12345,AB12345-CHN-4-id-115,id-115,CHN-4,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S1,9.00518541690504,HIGH,Y,Y,N,N,N,2019-03-26,2019-03-28 09:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,COMPLETED,COMPLETED,2022-03-28,1096,,,,,,,2022-04-09,,,3,3,Duration of Confirmed Response,CRSD,198.762743966654,DAYS,2021-02-19 09:33:43.683,694,0,Disease Progression,,
1117,AB12345,AB12345-CHN-4-id-115,id-115,CHN-4,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S1,9.00518541690504,HIGH,Y,Y,N,N,N,2019-03-26,2019-03-28 09:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,COMPLETED,COMPLETED,2022-03-28,1096,,,,,,,2022-04-09,,,4,4,Event Free Survival,EFS,96.7567067942582,DAYS,2021-08-14 09:33:43.683,870,0,Disease Progression,,
1118,AB12345,AB12345-CHN-4-id-115,id-115,CHN-4,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S1,9.00518541690504,HIGH,Y,Y,N,N,N,2019-03-26,2019-03-28 09:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,COMPLETED,COMPLETED,2022-03-28,1096,,,,,,,2022-04-09,,,2,2,Overall Survival,OS,263.435955811292,DAYS,2020-09-10 09:33:43.683,532,0,Death,,
1119,AB12345,AB12345-CHN-4-id-115,id-115,CHN-4,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S1,9.00518541690504,HIGH,Y,Y,N,N,N,2019-03-26,2019-03-28 09:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,COMPLETED,COMPLETED,2022-03-28,1096,,,,,,,2022-04-09,,,1,1,Progression Free Survival,PFS,263.435955811292,DAYS,2019-09-08 09:33:43.683,164,0,Death,,
1120,AB12345,AB12345-CHN-4-id-115,id-115,CHN-4,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,A,S1,9.00518541690504,HIGH,Y,Y,N,N,N,2019-03-26,2019-03-28 09:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,2019-03-28 09:33:43.683,2021-03-27 21:33:43.683,2021-03-27 21:33:43.683,2022-03-28 03:33:43.683,COMPLETED,COMPLETED,2022-03-28,1096,,,,,,,2022-04-09,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.04912010778918
1121,AB12345,AB12345-CHN-4-id-122,id-122,CHN-4,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,5.85898877781203,LOW,Y,Y,N,Y,N,2019-12-21,2019-12-21 08:08:52.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,DISCONTINUED,DISCONTINUED,2022-02-15,788,LACK OF EFFICACY,,,,,,2022-03-05,,,2,2,Duration of Confirmed Response,CRSD,126.662590517662,DAYS,2020-07-17 08:08:52.683,209,1,Adverse Event,Preferred Term,
1122,AB12345,AB12345-CHN-4-id-122,id-122,CHN-4,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,5.85898877781203,LOW,Y,Y,N,Y,N,2019-12-21,2019-12-21 08:08:52.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,DISCONTINUED,DISCONTINUED,2022-02-15,788,LACK OF EFFICACY,,,,,,2022-03-05,,,3,3,Event Free Survival,EFS,51.1710144858807,DAYS,2021-08-01 08:08:52.683,589,0,Disease Progression,,
1123,AB12345,AB12345-CHN-4-id-122,id-122,CHN-4,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,5.85898877781203,LOW,Y,Y,N,Y,N,2019-12-21,2019-12-21 08:08:52.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,DISCONTINUED,DISCONTINUED,2022-02-15,788,LACK OF EFFICACY,,,,,,2022-03-05,,,1,1,Overall Survival,OS,366.028312686831,DAYS,2020-05-23 08:08:52.683,154,1,Alive,Alive During Study,
1124,AB12345,AB12345-CHN-4-id-122,id-122,CHN-4,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,5.85898877781203,LOW,Y,Y,N,Y,N,2019-12-21,2019-12-21 08:08:52.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,DISCONTINUED,DISCONTINUED,2022-02-15,788,LACK OF EFFICACY,,,,,,2022-03-05,,,4,4,Progression Free Survival,PFS,208.05694879964,DAYS,2021-08-09 08:08:52.683,597,1,Last Tumor Assessment,Completion or Discontinuation,
1125,AB12345,AB12345-CHN-4-id-122,id-122,CHN-4,23,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S2,5.85898877781203,LOW,Y,Y,N,Y,N,2019-12-21,2019-12-21 08:08:52.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,2019-12-21 08:08:52.683,2021-02-15 17:16:33.683,2021-02-15 17:16:33.683,2022-02-15 23:16:33.683,DISCONTINUED,DISCONTINUED,2022-02-15,788,LACK OF EFFICACY,,,,,,2022-03-05,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-0.698756559929011
1126,AB12345,AB12345-CHN-4-id-310,id-310,CHN-4,36,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,2.85139241358806,LOW,Y,Y,N,N,N,2019-07-20,2019-07-20 12:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-08,,,3,3,Duration of Confirmed Response,CRSD,130.667519848794,DAYS,2021-03-25 12:02:21.683,614,0,Death,,
1127,AB12345,AB12345-CHN-4-id-310,id-310,CHN-4,36,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,2.85139241358806,LOW,Y,Y,N,N,N,2019-07-20,2019-07-20 12:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-08,,,1,1,Event Free Survival,EFS,90.9942587476689,DAYS,2020-09-05 12:02:21.683,413,0,Disease Progression,,
1128,AB12345,AB12345-CHN-4-id-310,id-310,CHN-4,36,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,2.85139241358806,LOW,Y,Y,N,N,N,2019-07-20,2019-07-20 12:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-08,,,4,4,Overall Survival,OS,130.667519848794,DAYS,2022-03-17 12:02:21.683,971,0,Death,,
1129,AB12345,AB12345-CHN-4-id-310,id-310,CHN-4,36,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,2.85139241358806,LOW,Y,Y,N,N,N,2019-07-20,2019-07-20 12:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-08,,,2,2,Progression Free Survival,PFS,130.667519848794,DAYS,2020-11-27 12:02:21.683,496,0,Death,,
1130,AB12345,AB12345-CHN-4-id-310,id-310,CHN-4,36,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,2.85139241358806,LOW,Y,Y,N,N,N,2019-07-20,2019-07-20 12:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,2019-07-20 12:02:21.683,2021-07-20 00:02:21.683,2021-07-20 00:02:21.683,2022-07-20 06:02:21.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-08,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.847660136941146
1131,AB12345,AB12345-CHN-4-id-311,id-311,CHN-4,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S1,2.30046321219174,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-10 04:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,COMPLETED,COMPLETED,2023-08-10,1096,,,,,,,2023-08-29,,,1,1,Duration of Confirmed Response,CRSD,157.379139750265,DAYS,2020-10-23 04:39:48.683,74,1,Last Tumor Assessment,Completion or Discontinuation,
1132,AB12345,AB12345-CHN-4-id-311,id-311,CHN-4,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S1,2.30046321219174,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-10 04:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,COMPLETED,COMPLETED,2023-08-10,1096,,,,,,,2023-08-29,,,4,4,Event Free Survival,EFS,49.2060265003238,DAYS,2022-05-16 04:39:48.683,644,1,Adverse Event,Preferred Term,
1133,AB12345,AB12345-CHN-4-id-311,id-311,CHN-4,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S1,2.30046321219174,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-10 04:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,COMPLETED,COMPLETED,2023-08-10,1096,,,,,,,2023-08-29,,,3,3,Overall Survival,OS,414.003427512944,DAYS,2021-01-17 04:39:48.683,160,1,Alive,Alive During Study,
1134,AB12345,AB12345-CHN-4-id-311,id-311,CHN-4,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S1,2.30046321219174,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-10 04:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,COMPLETED,COMPLETED,2023-08-10,1096,,,,,,,2023-08-29,,,2,2,Progression Free Survival,PFS,259.698838437907,DAYS,2020-12-30 04:39:48.683,142,1,Adverse Event,Preferred Term,
1135,AB12345,AB12345-CHN-4-id-311,id-311,CHN-4,29,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S1,2.30046321219174,MEDIUM,Y,Y,Y,N,N,2020-08-06,2020-08-10 04:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,2020-08-10 04:39:48.683,2022-08-10 16:39:48.683,2022-08-10 16:39:48.683,2023-08-10 22:39:48.683,COMPLETED,COMPLETED,2023-08-10,1096,,,,,,,2023-08-29,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-0.263795728340593
1136,AB12345,AB12345-CHN-4-id-335,id-335,CHN-4,33,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,2.57018620453516,LOW,Y,Y,N,Y,N,2020-04-13,2020-04-17 12:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,COMPLETED,COMPLETED,2023-04-18,1096,,,,,,,2023-05-11,,,4,4,Duration of Confirmed Response,CRSD,182.012674445286,DAYS,2023-02-21 12:58:47.683,1040,0,Disease Progression,,
1137,AB12345,AB12345-CHN-4-id-335,id-335,CHN-4,33,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,2.57018620453516,LOW,Y,Y,N,Y,N,2020-04-13,2020-04-17 12:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,COMPLETED,COMPLETED,2023-04-18,1096,,,,,,,2023-05-11,,,2,2,Event Free Survival,EFS,33.5360594769008,DAYS,2022-11-15 12:58:47.683,942,0,Disease Progression,,
1138,AB12345,AB12345-CHN-4-id-335,id-335,CHN-4,33,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,2.57018620453516,LOW,Y,Y,N,Y,N,2020-04-13,2020-04-17 12:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,COMPLETED,COMPLETED,2023-04-18,1096,,,,,,,2023-05-11,,,1,1,Overall Survival,OS,425.116562983021,DAYS,2020-08-19 12:58:47.683,124,1,Alive,Alive During Study,
1139,AB12345,AB12345-CHN-4-id-335,id-335,CHN-4,33,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,2.57018620453516,LOW,Y,Y,N,Y,N,2020-04-13,2020-04-17 12:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,COMPLETED,COMPLETED,2023-04-18,1096,,,,,,,2023-05-11,,,3,3,Progression Free Survival,PFS,203.665578085929,DAYS,2022-12-25 12:58:47.683,982,0,Disease Progression,,
1140,AB12345,AB12345-CHN-4-id-335,id-335,CHN-4,33,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,B,S1,2.57018620453516,LOW,Y,Y,N,Y,N,2020-04-13,2020-04-17 12:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,2020-04-17 12:58:47.683,2022-04-18 00:58:47.683,2022-04-18 00:58:47.683,2023-04-18 06:58:47.683,COMPLETED,COMPLETED,2023-04-18,1096,,,,,,,2023-05-11,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.0929654781849032
1141,AB12345,AB12345-CHN-4-id-370,id-370,CHN-4,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.09845214575852,HIGH,Y,Y,N,N,N,2019-03-28,2019-03-29 19:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,COMPLETED,COMPLETED,2022-03-29,1096,,,,,,,2022-04-24,,,1,1,Duration of Confirmed Response,CRSD,135.692613851279,DAYS,2019-04-02 19:55:52.683,4,0,Disease Progression,,
1142,AB12345,AB12345-CHN-4-id-370,id-370,CHN-4,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.09845214575852,HIGH,Y,Y,N,N,N,2019-03-28,2019-03-29 19:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,COMPLETED,COMPLETED,2022-03-29,1096,,,,,,,2022-04-24,,,4,4,Event Free Survival,EFS,51.8457097455394,DAYS,2021-08-14 19:55:52.683,869,1,Last Tumor Assessment,Completion or Discontinuation,
1143,AB12345,AB12345-CHN-4-id-370,id-370,CHN-4,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.09845214575852,HIGH,Y,Y,N,N,N,2019-03-28,2019-03-29 19:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,COMPLETED,COMPLETED,2022-03-29,1096,,,,,,,2022-04-24,,,2,2,Overall Survival,OS,334.690409572795,DAYS,2020-10-04 19:55:52.683,555,1,Alive,Alive During Study,
1144,AB12345,AB12345-CHN-4-id-370,id-370,CHN-4,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.09845214575852,HIGH,Y,Y,N,N,N,2019-03-28,2019-03-29 19:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,COMPLETED,COMPLETED,2022-03-29,1096,,,,,,,2022-04-24,,,3,3,Progression Free Survival,PFS,277.366764005274,DAYS,2021-05-02 19:55:52.683,765,1,Adverse Event,Preferred Term,
1145,AB12345,AB12345-CHN-4-id-370,id-370,CHN-4,45,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,7.09845214575852,HIGH,Y,Y,N,N,N,2019-03-28,2019-03-29 19:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,2019-03-29 19:55:52.683,2021-03-29 07:55:52.683,2021-03-29 07:55:52.683,2022-03-29 13:55:52.683,COMPLETED,COMPLETED,2022-03-29,1096,,,,,,,2022-04-24,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.24957597970716
1146,AB12345,AB12345-CHN-4-id-67,id-67,CHN-4,26,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,3.89305019252383,HIGH,Y,Y,Y,N,N,2020-02-10,2020-02-11 04:11:36.683,,2020-02-11 04:11:36.683,,,,2020-02-11 04:11:36.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,56.9227627222426,DAYS,2021-05-19 04:11:36.683,463,0,Death,,
1147,AB12345,AB12345-CHN-4-id-67,id-67,CHN-4,26,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,3.89305019252383,HIGH,Y,Y,Y,N,N,2020-02-10,2020-02-11 04:11:36.683,,2020-02-11 04:11:36.683,,,,2020-02-11 04:11:36.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,56.9227627222426,DAYS,2020-08-25 04:11:36.683,196,0,Death,,
1148,AB12345,AB12345-CHN-4-id-67,id-67,CHN-4,26,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,3.89305019252383,HIGH,Y,Y,Y,N,N,2020-02-10,2020-02-11 04:11:36.683,,2020-02-11 04:11:36.683,,,,2020-02-11 04:11:36.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,56.9227627222426,DAYS,2021-02-13 04:11:36.683,368,0,Death,,
1149,AB12345,AB12345-CHN-4-id-67,id-67,CHN-4,26,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,3.89305019252383,HIGH,Y,Y,Y,N,N,2020-02-10,2020-02-11 04:11:36.683,,2020-02-11 04:11:36.683,,,,2020-02-11 04:11:36.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,56.9227627222426,DAYS,2022-02-08 04:11:36.683,728,0,Death,,
1150,AB12345,AB12345-CHN-4-id-67,id-67,CHN-4,26,YEARS,M,ASIAN,UNKNOWN,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,B,S1,3.89305019252383,HIGH,Y,Y,Y,N,N,2020-02-10,2020-02-11 04:11:36.683,,2020-02-11 04:11:36.683,,,,2020-02-11 04:11:36.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-0.471863903872017
1151,AB12345,AB12345-CHN-4-id-73,id-73,CHN-4,24,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,2.86312402599659,MEDIUM,Y,Y,Y,Y,N,2019-03-16,2019-03-17 14:18:17.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,DISCONTINUED,DISCONTINUED,2022-02-14,1066,LACK OF EFFICACY,,,,,,2022-03-07,,,1,1,Duration of Confirmed Response,CRSD,151.100102276541,DAYS,2019-10-06 14:18:17.683,203,1,Last Tumor Assessment,Completion or Discontinuation,
1152,AB12345,AB12345-CHN-4-id-73,id-73,CHN-4,24,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,2.86312402599659,MEDIUM,Y,Y,Y,Y,N,2019-03-16,2019-03-17 14:18:17.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,DISCONTINUED,DISCONTINUED,2022-02-14,1066,LACK OF EFFICACY,,,,,,2022-03-07,,,4,4,Event Free Survival,EFS,77.6610572228674,DAYS,2021-12-04 14:18:17.683,993,1,Last Tumor Assessment,Completion or Discontinuation,
1153,AB12345,AB12345-CHN-4-id-73,id-73,CHN-4,24,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,2.86312402599659,MEDIUM,Y,Y,Y,Y,N,2019-03-16,2019-03-17 14:18:17.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,DISCONTINUED,DISCONTINUED,2022-02-14,1066,LACK OF EFFICACY,,,,,,2022-03-07,,,3,3,Overall Survival,OS,417.579988110811,DAYS,2021-01-20 14:18:17.683,675,1,Alive,Alive During Study,
1154,AB12345,AB12345-CHN-4-id-73,id-73,CHN-4,24,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,2.86312402599659,MEDIUM,Y,Y,Y,Y,N,2019-03-16,2019-03-17 14:18:17.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,DISCONTINUED,DISCONTINUED,2022-02-14,1066,LACK OF EFFICACY,,,,,,2022-03-07,,,2,2,Progression Free Survival,PFS,247.508691600524,DAYS,2020-08-14 14:18:17.683,516,1,Adverse Event,Preferred Term,
1155,AB12345,AB12345-CHN-4-id-73,id-73,CHN-4,24,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-4,Dr. CHN-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,2.86312402599659,MEDIUM,Y,Y,Y,Y,N,2019-03-16,2019-03-17 14:18:17.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,2019-03-17 14:18:17.683,2021-02-14 13:35:43.683,2021-02-14 13:35:43.683,2022-02-14 19:35:43.683,DISCONTINUED,DISCONTINUED,2022-02-14,1066,LACK OF EFFICACY,,,,,,2022-03-07,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-1.16813619169409
1156,AB12345,AB12345-CHN-5-id-108,id-108,CHN-5,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S2,6.7472114567188,HIGH,Y,Y,Y,Y,N,2019-09-07,2019-09-11 06:10:06.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,DISCONTINUED,DISCONTINUED,2022-02-13,886,DEATH,2022-04-04,MISSING,OTHER,50,>30,2022-04-04,935,,2,2,Duration of Confirmed Response,CRSD,63.6656772438437,DAYS,2020-09-25 06:10:06.683,380,0,Death,,
1157,AB12345,AB12345-CHN-5-id-108,id-108,CHN-5,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S2,6.7472114567188,HIGH,Y,Y,Y,Y,N,2019-09-07,2019-09-11 06:10:06.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,DISCONTINUED,DISCONTINUED,2022-02-13,886,DEATH,2022-04-04,MISSING,OTHER,50,>30,2022-04-04,935,,1,1,Event Free Survival,EFS,63.6656772438437,DAYS,2020-03-08 06:10:06.683,179,0,Death,,
1158,AB12345,AB12345-CHN-5-id-108,id-108,CHN-5,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S2,6.7472114567188,HIGH,Y,Y,Y,Y,N,2019-09-07,2019-09-11 06:10:06.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,DISCONTINUED,DISCONTINUED,2022-02-13,886,DEATH,2022-04-04,MISSING,OTHER,50,>30,2022-04-04,935,,4,4,Overall Survival,OS,63.6656772438437,DAYS,2021-09-07 06:10:06.683,727,0,Death,,
1159,AB12345,AB12345-CHN-5-id-108,id-108,CHN-5,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S2,6.7472114567188,HIGH,Y,Y,Y,Y,N,2019-09-07,2019-09-11 06:10:06.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,DISCONTINUED,DISCONTINUED,2022-02-13,886,DEATH,2022-04-04,MISSING,OTHER,50,>30,2022-04-04,935,,3,3,Progression Free Survival,PFS,63.6656772438437,DAYS,2021-04-27 06:10:06.683,594,0,Death,,
1160,AB12345,AB12345-CHN-5-id-108,id-108,CHN-5,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,B,S2,6.7472114567188,HIGH,Y,Y,Y,Y,N,2019-09-07,2019-09-11 06:10:06.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,2019-09-11 06:10:06.683,2021-02-12 23:36:22.683,2021-02-12 23:36:22.683,2022-02-13 05:36:22.683,DISCONTINUED,DISCONTINUED,2022-02-13,886,DEATH,2022-04-04,MISSING,OTHER,50,>30,2022-04-04,935,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.422176706025756
1161,AB12345,AB12345-CHN-5-id-159,id-159,CHN-5,38,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.54626290173689,HIGH,Y,Y,N,Y,N,2019-05-26,2019-05-27 04:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,COMPLETED,COMPLETED,2022-05-26,1096,,,,,,,2022-06-11,,,3,3,Duration of Confirmed Response,CRSD,186.512555577792,DAYS,2021-04-03 04:18:29.683,677,0,Disease Progression,,
1162,AB12345,AB12345-CHN-5-id-159,id-159,CHN-5,38,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.54626290173689,HIGH,Y,Y,N,Y,N,2019-05-26,2019-05-27 04:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,COMPLETED,COMPLETED,2022-05-26,1096,,,,,,,2022-06-11,,,2,2,Event Free Survival,EFS,70.66800796194,DAYS,2020-06-22 04:18:29.683,392,1,Last Tumor Assessment,Completion or Discontinuation,
1163,AB12345,AB12345-CHN-5-id-159,id-159,CHN-5,38,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.54626290173689,HIGH,Y,Y,N,Y,N,2019-05-26,2019-05-27 04:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,COMPLETED,COMPLETED,2022-05-26,1096,,,,,,,2022-06-11,,,4,4,Overall Survival,OS,492.023231135681,DAYS,2021-08-31 04:18:29.683,827,1,Alive,Alive During Study,
1164,AB12345,AB12345-CHN-5-id-159,id-159,CHN-5,38,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.54626290173689,HIGH,Y,Y,N,Y,N,2019-05-26,2019-05-27 04:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,COMPLETED,COMPLETED,2022-05-26,1096,,,,,,,2022-06-11,,,1,1,Progression Free Survival,PFS,239.68463758938,DAYS,2020-06-10 04:18:29.683,380,1,Adverse Event,Preferred Term,
1165,AB12345,AB12345-CHN-5-id-159,id-159,CHN-5,38,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S2,3.54626290173689,HIGH,Y,Y,N,Y,N,2019-05-26,2019-05-27 04:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,2019-05-27 04:18:29.683,2021-05-26 16:18:29.683,2021-05-26 16:18:29.683,2022-05-26 22:18:29.683,COMPLETED,COMPLETED,2022-05-26,1096,,,,,,,2022-06-11,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-2.88179861846554
1166,AB12345,AB12345-CHN-5-id-160,id-160,CHN-5,21,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,0.165447463531243,LOW,Y,Y,Y,Y,N,2019-07-15,2019-07-17 21:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-27,,,3,3,Duration of Confirmed Response,CRSD,117.008827999234,DAYS,2021-06-03 21:28:31.683,687,1,Adverse Event,Preferred Term,
1167,AB12345,AB12345-CHN-5-id-160,id-160,CHN-5,21,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,0.165447463531243,LOW,Y,Y,Y,Y,N,2019-07-15,2019-07-17 21:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-27,,,2,2,Event Free Survival,EFS,47.3745666944887,DAYS,2021-03-27 21:28:31.683,619,1,Last Tumor Assessment,Completion or Discontinuation,
1168,AB12345,AB12345-CHN-5-id-160,id-160,CHN-5,21,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,0.165447463531243,LOW,Y,Y,Y,Y,N,2019-07-15,2019-07-17 21:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-27,,,4,4,Overall Survival,OS,489.984041871503,DAYS,2021-07-07 21:28:31.683,721,1,Alive,Alive During Study,
1169,AB12345,AB12345-CHN-5-id-160,id-160,CHN-5,21,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,0.165447463531243,LOW,Y,Y,Y,Y,N,2019-07-15,2019-07-17 21:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-27,,,1,1,Progression Free Survival,PFS,223.160487855785,DAYS,2020-09-18 21:28:31.683,429,0,Disease Progression,,
1170,AB12345,AB12345-CHN-5-id-160,id-160,CHN-5,21,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,0.165447463531243,LOW,Y,Y,Y,Y,N,2019-07-15,2019-07-17 21:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,2019-07-17 21:28:31.683,2021-07-17 09:28:31.683,2021-07-17 09:28:31.683,2022-07-17 15:28:31.683,COMPLETED,COMPLETED,2022-07-17,1096,,,,,,,2022-07-27,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-0.885538142544508
1171,AB12345,AB12345-CHN-5-id-175,id-175,CHN-5,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,4.9801709978259,LOW,Y,Y,Y,Y,N,2020-09-29,2020-10-03 06:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-26,,,4,4,Duration of Confirmed Response,CRSD,119.304401590489,DAYS,2023-01-31 06:43:58.683,850,1,Last Tumor Assessment,Completion or Discontinuation,
1172,AB12345,AB12345-CHN-5-id-175,id-175,CHN-5,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,4.9801709978259,LOW,Y,Y,Y,Y,N,2020-09-29,2020-10-03 06:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-26,,,2,2,Event Free Survival,EFS,22.0981933991425,DAYS,2022-10-21 06:43:58.683,748,0,Disease Progression,,
1173,AB12345,AB12345-CHN-5-id-175,id-175,CHN-5,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,4.9801709978259,LOW,Y,Y,Y,Y,N,2020-09-29,2020-10-03 06:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-26,,,1,1,Overall Survival,OS,421.003201603889,DAYS,2020-10-15 06:43:58.683,12,1,Alive,Alive During Study,
1174,AB12345,AB12345-CHN-5-id-175,id-175,CHN-5,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,4.9801709978259,LOW,Y,Y,Y,Y,N,2020-09-29,2020-10-03 06:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-26,,,3,3,Progression Free Survival,PFS,207.469529518858,DAYS,2023-01-22 06:43:58.683,841,1,Last Tumor Assessment,Completion or Discontinuation,
1175,AB12345,AB12345-CHN-5-id-175,id-175,CHN-5,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,4.9801709978259,LOW,Y,Y,Y,Y,N,2020-09-29,2020-10-03 06:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,2020-10-03 06:43:58.683,2022-10-03 18:43:58.683,2022-10-03 18:43:58.683,2023-10-04 00:43:58.683,COMPLETED,COMPLETED,2023-10-04,1096,,,,,,,2023-10-26,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-3.38205827353345
1176,AB12345,AB12345-CHN-5-id-195,id-195,CHN-5,29,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,1.79755760327361,MEDIUM,Y,Y,Y,N,N,2020-02-28,2020-03-03 05:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,3,3,Duration of Confirmed Response,CRSD,158.798726066016,DAYS,2022-04-05 05:58:06.683,763,0,Death,,
1177,AB12345,AB12345-CHN-5-id-195,id-195,CHN-5,29,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,1.79755760327361,MEDIUM,Y,Y,Y,N,N,2020-02-28,2020-03-03 05:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,2,2,Event Free Survival,EFS,33.3466461917851,DAYS,2020-11-10 05:58:06.683,252,0,Disease Progression,,
1178,AB12345,AB12345-CHN-5-id-195,id-195,CHN-5,29,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,1.79755760327361,MEDIUM,Y,Y,Y,N,N,2020-02-28,2020-03-03 05:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,1,1,Overall Survival,OS,158.798726066016,DAYS,2020-06-08 05:58:06.683,97,0,Death,,
1179,AB12345,AB12345-CHN-5-id-195,id-195,CHN-5,29,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,1.79755760327361,MEDIUM,Y,Y,Y,N,N,2020-02-28,2020-03-03 05:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,4,4,Progression Free Survival,PFS,158.798726066016,DAYS,2022-11-17 05:58:06.683,989,0,Death,,
1180,AB12345,AB12345-CHN-5-id-195,id-195,CHN-5,29,YEARS,F,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,1.79755760327361,MEDIUM,Y,Y,Y,N,N,2020-02-28,2020-03-03 05:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,2020-03-03 05:58:06.683,2022-03-03 17:58:06.683,2022-03-03 17:58:06.683,2023-03-03 23:58:06.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.93991522955389
1181,AB12345,AB12345-CHN-5-id-221,id-221,CHN-5,40,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,5.47576229697458,HIGH,Y,Y,Y,N,N,2020-10-24,2020-10-28 20:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,COMPLETED,COMPLETED,2023-10-29,1096,,,,,,,2023-11-16,,,1,1,Duration of Confirmed Response,CRSD,139.092517923564,DAYS,2022-10-01 20:35:29.683,703,1,Last Tumor Assessment,Completion or Discontinuation,
1182,AB12345,AB12345-CHN-5-id-221,id-221,CHN-5,40,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,5.47576229697458,HIGH,Y,Y,Y,N,N,2020-10-24,2020-10-28 20:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,COMPLETED,COMPLETED,2023-10-29,1096,,,,,,,2023-11-16,,,2,2,Event Free Survival,EFS,34.4562962744385,DAYS,2022-10-24 20:35:29.683,726,1,Last Tumor Assessment,Completion or Discontinuation,
1183,AB12345,AB12345-CHN-5-id-221,id-221,CHN-5,40,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,5.47576229697458,HIGH,Y,Y,Y,N,N,2020-10-24,2020-10-28 20:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,COMPLETED,COMPLETED,2023-10-29,1096,,,,,,,2023-11-16,,,3,3,Overall Survival,OS,234.790591336787,DAYS,2023-07-17 20:35:29.683,992,0,Death,,
1184,AB12345,AB12345-CHN-5-id-221,id-221,CHN-5,40,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,5.47576229697458,HIGH,Y,Y,Y,N,N,2020-10-24,2020-10-28 20:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,COMPLETED,COMPLETED,2023-10-29,1096,,,,,,,2023-11-16,,,4,4,Progression Free Survival,PFS,234.790591336787,DAYS,2023-08-17 20:35:29.683,1023,0,Death,,
1185,AB12345,AB12345-CHN-5-id-221,id-221,CHN-5,40,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S1,5.47576229697458,HIGH,Y,Y,Y,N,N,2020-10-24,2020-10-28 20:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,2020-10-28 20:35:29.683,2022-10-29 08:35:29.683,2022-10-29 08:35:29.683,2023-10-29 14:35:29.683,COMPLETED,COMPLETED,2023-10-29,1096,,,,,,,2023-11-16,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-4.16160022322596
1186,AB12345,AB12345-CHN-5-id-231,id-231,CHN-5,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.59692458666915,LOW,Y,Y,N,Y,N,2020-12-03,2020-12-07 16:13:10.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,DISCONTINUED,DISCONTINUED,2022-02-18,439,DEATH,2022-03-21,ADVERSE EVENT,ADVERSE EVENT,31,>30,2022-03-21,468,Yes,3,3,Duration of Confirmed Response,CRSD,111.203912366182,DAYS,2021-04-29 16:13:10.683,143,0,Death,,
1187,AB12345,AB12345-CHN-5-id-231,id-231,CHN-5,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.59692458666915,LOW,Y,Y,N,Y,N,2020-12-03,2020-12-07 16:13:10.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,DISCONTINUED,DISCONTINUED,2022-02-18,439,DEATH,2022-03-21,ADVERSE EVENT,ADVERSE EVENT,31,>30,2022-03-21,468,Yes,1,1,Event Free Survival,EFS,93.0622492113616,DAYS,2020-12-19 16:13:10.683,12,1,Adverse Event,Preferred Term,
1188,AB12345,AB12345-CHN-5-id-231,id-231,CHN-5,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.59692458666915,LOW,Y,Y,N,Y,N,2020-12-03,2020-12-07 16:13:10.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,DISCONTINUED,DISCONTINUED,2022-02-18,439,DEATH,2022-03-21,ADVERSE EVENT,ADVERSE EVENT,31,>30,2022-03-21,468,Yes,2,2,Overall Survival,OS,111.203912366182,DAYS,2021-03-08 16:13:10.683,91,0,Death,,
1189,AB12345,AB12345-CHN-5-id-231,id-231,CHN-5,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.59692458666915,LOW,Y,Y,N,Y,N,2020-12-03,2020-12-07 16:13:10.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,DISCONTINUED,DISCONTINUED,2022-02-18,439,DEATH,2022-03-21,ADVERSE EVENT,ADVERSE EVENT,31,>30,2022-03-21,468,Yes,4,4,Progression Free Survival,PFS,111.203912366182,DAYS,2021-12-21 16:13:10.683,379,0,Death,,
1190,AB12345,AB12345-CHN-5-id-231,id-231,CHN-5,37,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.59692458666915,LOW,Y,Y,N,Y,N,2020-12-03,2020-12-07 16:13:10.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,2020-12-07 16:13:10.683,2021-02-18 14:24:38.683,2021-02-18 14:24:38.683,2022-02-18 20:24:38.683,DISCONTINUED,DISCONTINUED,2022-02-18,439,DEATH,2022-03-21,ADVERSE EVENT,ADVERSE EVENT,31,>30,2022-03-21,468,Yes,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.38967004561286
1191,AB12345,AB12345-CHN-5-id-273,id-273,CHN-5,34,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,10.5363405630913,HIGH,Y,Y,N,N,N,2021-01-03,2021-01-03 11:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-02-01,,,1,1,Duration of Confirmed Response,CRSD,118.662406993099,DAYS,2022-05-28 11:47:16.683,510,0,Death,,
1192,AB12345,AB12345-CHN-5-id-273,id-273,CHN-5,34,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,10.5363405630913,HIGH,Y,Y,N,N,N,2021-01-03,2021-01-03 11:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-02-01,,,2,2,Event Free Survival,EFS,36.6729722055607,DAYS,2022-06-23 11:47:16.683,536,0,Disease Progression,,
1193,AB12345,AB12345-CHN-5-id-273,id-273,CHN-5,34,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,10.5363405630913,HIGH,Y,Y,N,N,N,2021-01-03,2021-01-03 11:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-02-01,,,4,4,Overall Survival,OS,118.662406993099,DAYS,2023-11-03 11:47:16.683,1034,0,Death,,
1194,AB12345,AB12345-CHN-5-id-273,id-273,CHN-5,34,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,10.5363405630913,HIGH,Y,Y,N,N,N,2021-01-03,2021-01-03 11:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-02-01,,,3,3,Progression Free Survival,PFS,118.662406993099,DAYS,2022-08-09 11:47:16.683,583,0,Death,,
1195,AB12345,AB12345-CHN-5-id-273,id-273,CHN-5,34,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,10.5363405630913,HIGH,Y,Y,N,N,N,2021-01-03,2021-01-03 11:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,2021-01-03 11:47:16.683,2023-01-03 23:47:16.683,2023-01-03 23:47:16.683,2024-01-04 05:47:16.683,COMPLETED,COMPLETED,2024-01-04,1096,,,,,,,2024-02-01,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-2.68775991981634
1196,AB12345,AB12345-CHN-5-id-338,id-338,CHN-5,37,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,1.37538132177818,MEDIUM,Y,Y,Y,N,N,2019-08-08,2019-08-09 23:27:53.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,DISCONTINUED,DISCONTINUED,2022-02-20,926,LACK OF EFFICACY,,,,,,2022-03-13,,,2,2,Duration of Confirmed Response,CRSD,193.296878226101,DAYS,2020-12-21 23:27:53.683,500,1,Last Tumor Assessment,Completion or Discontinuation,
1197,AB12345,AB12345-CHN-5-id-338,id-338,CHN-5,37,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,1.37538132177818,MEDIUM,Y,Y,Y,N,N,2019-08-08,2019-08-09 23:27:53.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,DISCONTINUED,DISCONTINUED,2022-02-20,926,LACK OF EFFICACY,,,,,,2022-03-13,,,1,1,Event Free Survival,EFS,78.3711994544137,DAYS,2020-12-17 23:27:53.683,496,1,Last Tumor Assessment,Completion or Discontinuation,
1198,AB12345,AB12345-CHN-5-id-338,id-338,CHN-5,37,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,1.37538132177818,MEDIUM,Y,Y,Y,N,N,2019-08-08,2019-08-09 23:27:53.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,DISCONTINUED,DISCONTINUED,2022-02-20,926,LACK OF EFFICACY,,,,,,2022-03-13,,,3,3,Overall Survival,OS,428.998736245558,DAYS,2021-01-07 23:27:53.683,517,1,Alive,Alive During Study,
1199,AB12345,AB12345-CHN-5-id-338,id-338,CHN-5,37,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,1.37538132177818,MEDIUM,Y,Y,Y,N,N,2019-08-08,2019-08-09 23:27:53.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,DISCONTINUED,DISCONTINUED,2022-02-20,926,LACK OF EFFICACY,,,,,,2022-03-13,,,4,4,Progression Free Survival,PFS,249.471189384349,DAYS,2021-03-22 23:27:53.683,591,0,Disease Progression,,
1200,AB12345,AB12345-CHN-5-id-338,id-338,CHN-5,37,YEARS,F,WHITE,NOT REPORTED,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Asia,A,S1,1.37538132177818,MEDIUM,Y,Y,Y,N,N,2019-08-08,2019-08-09 23:27:53.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,2019-08-09 23:27:53.683,2021-02-19 21:47:56.683,2021-02-19 21:47:56.683,2022-02-20 03:47:56.683,DISCONTINUED,DISCONTINUED,2022-02-20,926,LACK OF EFFICACY,,,,,,2022-03-13,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.438379517068245
1201,AB12345,AB12345-CHN-5-id-348,id-348,CHN-5,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,4.35489811558349,MEDIUM,Y,Y,N,N,N,2020-09-21,2020-09-23 08:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,COMPLETED,COMPLETED,2023-09-24,1096,,,,,,,2023-10-14,,,2,2,Duration of Confirmed Response,CRSD,160.299464617856,DAYS,2021-08-09 08:41:18.683,320,0,Disease Progression,,
1202,AB12345,AB12345-CHN-5-id-348,id-348,CHN-5,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,4.35489811558349,MEDIUM,Y,Y,N,N,N,2020-09-21,2020-09-23 08:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,COMPLETED,COMPLETED,2023-09-24,1096,,,,,,,2023-10-14,,,1,1,Event Free Survival,EFS,29.9432198808063,DAYS,2020-11-28 08:41:18.683,66,0,Disease Progression,,
1203,AB12345,AB12345-CHN-5-id-348,id-348,CHN-5,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,4.35489811558349,MEDIUM,Y,Y,N,N,N,2020-09-21,2020-09-23 08:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,COMPLETED,COMPLETED,2023-09-24,1096,,,,,,,2023-10-14,,,3,3,Overall Survival,OS,398.041880875826,DAYS,2021-08-16 08:41:18.683,327,1,Alive,Alive During Study,
1204,AB12345,AB12345-CHN-5-id-348,id-348,CHN-5,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,4.35489811558349,MEDIUM,Y,Y,N,N,N,2020-09-21,2020-09-23 08:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,COMPLETED,COMPLETED,2023-09-24,1096,,,,,,,2023-10-14,,,4,4,Progression Free Survival,PFS,288.775766594335,DAYS,2022-03-07 08:41:18.683,530,1,Adverse Event,Preferred Term,
1205,AB12345,AB12345-CHN-5-id-348,id-348,CHN-5,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,C,S2,4.35489811558349,MEDIUM,Y,Y,N,N,N,2020-09-21,2020-09-23 08:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,2020-09-23 08:41:18.683,2022-09-23 20:41:18.683,2022-09-23 20:41:18.683,2023-09-24 02:41:18.683,COMPLETED,COMPLETED,2023-09-24,1096,,,,,,,2023-10-14,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.67871798759607
1206,AB12345,AB12345-CHN-5-id-83,id-83,CHN-5,44,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S1,4.60955780094896,HIGH,Y,Y,N,N,N,2019-10-08,2019-10-08 10:03:25.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,ADVERSE EVENT,,,,,,2022-03-02,,,2,2,Duration of Confirmed Response,CRSD,117.939079226926,DAYS,2020-10-25 10:03:25.683,383,0,Disease Progression,,
1207,AB12345,AB12345-CHN-5-id-83,id-83,CHN-5,44,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S1,4.60955780094896,HIGH,Y,Y,N,N,N,2019-10-08,2019-10-08 10:03:25.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,ADVERSE EVENT,,,,,,2022-03-02,,,3,3,Event Free Survival,EFS,16.5626036690082,DAYS,2021-01-10 10:03:25.683,460,1,Adverse Event,Preferred Term,
1208,AB12345,AB12345-CHN-5-id-83,id-83,CHN-5,44,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S1,4.60955780094896,HIGH,Y,Y,N,N,N,2019-10-08,2019-10-08 10:03:25.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,ADVERSE EVENT,,,,,,2022-03-02,,,1,1,Overall Survival,OS,355.392812239006,DAYS,2019-11-25 10:03:25.683,48,1,Alive,Alive During Study,
1209,AB12345,AB12345-CHN-5-id-83,id-83,CHN-5,44,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S1,4.60955780094896,HIGH,Y,Y,N,N,N,2019-10-08,2019-10-08 10:03:25.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,ADVERSE EVENT,,,,,,2022-03-02,,,4,4,Progression Free Survival,PFS,229.939113836735,DAYS,2021-08-22 10:03:25.683,684,0,Disease Progression,,
1210,AB12345,AB12345-CHN-5-id-83,id-83,CHN-5,44,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-5,Dr. CHN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S1,4.60955780094896,HIGH,Y,Y,N,N,N,2019-10-08,2019-10-08 10:03:25.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,2019-10-08 10:03:25.683,2021-02-17 03:03:28.683,2021-02-17 03:03:28.683,2022-02-17 09:03:28.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,ADVERSE EVENT,,,,,,2022-03-02,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.50765946548486
1211,AB12345,AB12345-CHN-6-id-248,id-248,CHN-6,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S2,6.11272086741194,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 00:59:20.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,DISCONTINUED,DISCONTINUED,2022-02-18,459,DEATH,2022-03-21,Post-study reporting of death,OTHER,31,>30,2022-03-21,488,No,4,4,Duration of Confirmed Response,CRSD,135.532134771347,DAYS,2021-12-30 00:59:20.683,408,0,Disease Progression,,
1212,AB12345,AB12345-CHN-6-id-248,id-248,CHN-6,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S2,6.11272086741194,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 00:59:20.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,DISCONTINUED,DISCONTINUED,2022-02-18,459,DEATH,2022-03-21,Post-study reporting of death,OTHER,31,>30,2022-03-21,488,No,1,1,Event Free Survival,EFS,20.2368010755163,DAYS,2021-05-03 00:59:20.683,167,1,Adverse Event,Preferred Term,
1213,AB12345,AB12345-CHN-6-id-248,id-248,CHN-6,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S2,6.11272086741194,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 00:59:20.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,DISCONTINUED,DISCONTINUED,2022-02-18,459,DEATH,2022-03-21,Post-study reporting of death,OTHER,31,>30,2022-03-21,488,No,2,2,Overall Survival,OS,407.006311696023,DAYS,2021-05-04 00:59:20.683,168,1,Alive,Alive During Study,
1214,AB12345,AB12345-CHN-6-id-248,id-248,CHN-6,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S2,6.11272086741194,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 00:59:20.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,DISCONTINUED,DISCONTINUED,2022-02-18,459,DEATH,2022-03-21,Post-study reporting of death,OTHER,31,>30,2022-03-21,488,No,3,3,Progression Free Survival,PFS,257.703775400296,DAYS,2021-07-12 00:59:20.683,237,0,Disease Progression,,
1215,AB12345,AB12345-CHN-6-id-248,id-248,CHN-6,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,A,S2,6.11272086741194,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 00:59:20.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,2020-11-17 00:59:20.683,2021-02-18 07:27:57.683,2021-02-18 07:27:57.683,2022-02-18 13:27:57.683,DISCONTINUED,DISCONTINUED,2022-02-18,459,DEATH,2022-03-21,Post-study reporting of death,OTHER,31,>30,2022-03-21,488,No,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-3.23444618914347
1216,AB12345,AB12345-CHN-6-id-30,id-30,CHN-6,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,12.2207613947984,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-24 12:54:31.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,DISCONTINUED,DISCONTINUED,2022-02-14,539,DEATH,2022-03-26,Post-study reporting of death,OTHER,40,>30,2022-03-26,578,No,1,1,Duration of Confirmed Response,CRSD,148.614897835068,DAYS,2020-09-05 12:54:31.683,12,0,Death,,
1217,AB12345,AB12345-CHN-6-id-30,id-30,CHN-6,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,12.2207613947984,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-24 12:54:31.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,DISCONTINUED,DISCONTINUED,2022-02-14,539,DEATH,2022-03-26,Post-study reporting of death,OTHER,40,>30,2022-03-26,578,No,2,2,Event Free Survival,EFS,66.3631905755028,DAYS,2021-04-06 12:54:31.683,225,1,Last Tumor Assessment,Completion or Discontinuation,
1218,AB12345,AB12345-CHN-6-id-30,id-30,CHN-6,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,12.2207613947984,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-24 12:54:31.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,DISCONTINUED,DISCONTINUED,2022-02-14,539,DEATH,2022-03-26,Post-study reporting of death,OTHER,40,>30,2022-03-26,578,No,3,3,Overall Survival,OS,148.614897835068,DAYS,2021-05-16 12:54:31.683,265,0,Death,,
1219,AB12345,AB12345-CHN-6-id-30,id-30,CHN-6,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,12.2207613947984,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-24 12:54:31.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,DISCONTINUED,DISCONTINUED,2022-02-14,539,DEATH,2022-03-26,Post-study reporting of death,OTHER,40,>30,2022-03-26,578,No,4,4,Progression Free Survival,PFS,148.614897835068,DAYS,2021-07-08 12:54:31.683,318,0,Death,,
1220,AB12345,AB12345-CHN-6-id-30,id-30,CHN-6,29,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-6,Dr. CHN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Asia,A,S1,12.2207613947984,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-24 12:54:31.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,2020-08-24 12:54:31.683,2021-02-13 22:32:24.683,2021-02-13 22:32:24.683,2022-02-14 04:32:24.683,DISCONTINUED,DISCONTINUED,2022-02-14,539,DEATH,2022-03-26,Post-study reporting of death,OTHER,40,>30,2022-03-26,578,No,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.64926726572634
1221,AB12345,AB12345-CHN-6-id-385,id-385,CHN-6,40,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.68371966308082,LOW,Y,Y,N,N,N,2019-11-18,2019-11-21 17:46:54.683,,2019-11-21 17:46:54.683,,,,2019-11-21 17:46:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,196.457004873082,DAYS,2020-09-11 17:46:54.683,295,1,Last Tumor Assessment,Completion or Discontinuation,
1222,AB12345,AB12345-CHN-6-id-385,id-385,CHN-6,40,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.68371966308082,LOW,Y,Y,N,N,N,2019-11-18,2019-11-21 17:46:54.683,,2019-11-21 17:46:54.683,,,,2019-11-21 17:46:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,26.1882582830731,DAYS,2020-02-04 17:46:54.683,75,0,Disease Progression,,
1223,AB12345,AB12345-CHN-6-id-385,id-385,CHN-6,40,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.68371966308082,LOW,Y,Y,N,N,N,2019-11-18,2019-11-21 17:46:54.683,,2019-11-21 17:46:54.683,,,,2019-11-21 17:46:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,373.367876932025,DAYS,2019-12-17 17:46:54.683,26,1,Alive,Alive During Study,
1224,AB12345,AB12345-CHN-6-id-385,id-385,CHN-6,40,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.68371966308082,LOW,Y,Y,N,N,N,2019-11-18,2019-11-21 17:46:54.683,,2019-11-21 17:46:54.683,,,,2019-11-21 17:46:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,274.246157635935,DAYS,2019-12-29 17:46:54.683,38,1,Adverse Event,Preferred Term,
1225,AB12345,AB12345-CHN-6-id-385,id-385,CHN-6,40,YEARS,F,WHITE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,8.68371966308082,LOW,Y,Y,N,N,N,2019-11-18,2019-11-21 17:46:54.683,,2019-11-21 17:46:54.683,,,,2019-11-21 17:46:54.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.914586600029842
1226,AB12345,AB12345-CHN-6-id-89,id-89,CHN-6,39,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,10.3533519400184,MEDIUM,Y,Y,Y,Y,N,2021-01-23,2021-01-23 18:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,COMPLETED,COMPLETED,2024-01-24,1096,,,,,,,2024-02-16,,,4,4,Duration of Confirmed Response,CRSD,122.69396733027,DAYS,2024-01-01 18:55:06.683,1073,1,Adverse Event,Preferred Term,
1227,AB12345,AB12345-CHN-6-id-89,id-89,CHN-6,39,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,10.3533519400184,MEDIUM,Y,Y,Y,Y,N,2021-01-23,2021-01-23 18:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,COMPLETED,COMPLETED,2024-01-24,1096,,,,,,,2024-02-16,,,3,3,Event Free Survival,EFS,27.8201500663999,DAYS,2021-10-03 18:55:06.683,253,1,Last Tumor Assessment,Completion or Discontinuation,
1228,AB12345,AB12345-CHN-6-id-89,id-89,CHN-6,39,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,10.3533519400184,MEDIUM,Y,Y,Y,Y,N,2021-01-23,2021-01-23 18:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,COMPLETED,COMPLETED,2024-01-24,1096,,,,,,,2024-02-16,,,2,2,Overall Survival,OS,274.511680891737,DAYS,2021-06-16 18:55:06.683,144,0,Death,,
1229,AB12345,AB12345-CHN-6-id-89,id-89,CHN-6,39,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,10.3533519400184,MEDIUM,Y,Y,Y,Y,N,2021-01-23,2021-01-23 18:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,COMPLETED,COMPLETED,2024-01-24,1096,,,,,,,2024-02-16,,,1,1,Progression Free Survival,PFS,274.511680891737,DAYS,2021-03-14 18:55:06.683,50,0,Death,,
1230,AB12345,AB12345-CHN-6-id-89,id-89,CHN-6,39,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-6,Dr. CHN-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S2,10.3533519400184,MEDIUM,Y,Y,Y,Y,N,2021-01-23,2021-01-23 18:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,2021-01-23 18:55:06.683,2023-01-24 06:55:06.683,2023-01-24 06:55:06.683,2024-01-24 12:55:06.683,COMPLETED,COMPLETED,2024-01-24,1096,,,,,,,2024-02-16,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-1.64680845647624
1231,AB12345,AB12345-CHN-7-id-126,id-126,CHN-7,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,3.77454851866136,LOW,Y,Y,N,N,N,2019-05-02,2019-05-02 14:23:21.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,DISCONTINUED,DISCONTINUED,2022-02-20,1025,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,42,>30,2022-04-03,1066,Yes,1,1,Duration of Confirmed Response,CRSD,159.399329684675,DAYS,2019-07-31 14:23:21.683,90,0,Death,,
1232,AB12345,AB12345-CHN-7-id-126,id-126,CHN-7,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,3.77454851866136,LOW,Y,Y,N,N,N,2019-05-02,2019-05-02 14:23:21.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,DISCONTINUED,DISCONTINUED,2022-02-20,1025,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,42,>30,2022-04-03,1066,Yes,3,3,Event Free Survival,EFS,19.3003521114588,DAYS,2021-12-08 14:23:21.683,951,1,Adverse Event,Preferred Term,
1233,AB12345,AB12345-CHN-7-id-126,id-126,CHN-7,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,3.77454851866136,LOW,Y,Y,N,N,N,2019-05-02,2019-05-02 14:23:21.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,DISCONTINUED,DISCONTINUED,2022-02-20,1025,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,42,>30,2022-04-03,1066,Yes,2,2,Overall Survival,OS,159.399329684675,DAYS,2021-03-22 14:23:21.683,690,0,Death,,
1234,AB12345,AB12345-CHN-7-id-126,id-126,CHN-7,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,3.77454851866136,LOW,Y,Y,N,N,N,2019-05-02,2019-05-02 14:23:21.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,DISCONTINUED,DISCONTINUED,2022-02-20,1025,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,42,>30,2022-04-03,1066,Yes,4,4,Progression Free Survival,PFS,159.399329684675,DAYS,2021-12-23 14:23:21.683,966,0,Death,,
1235,AB12345,AB12345-CHN-7-id-126,id-126,CHN-7,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,CHN,Y,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S1,3.77454851866136,LOW,Y,Y,N,N,N,2019-05-02,2019-05-02 14:23:21.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,2019-05-02 14:23:21.683,2021-02-19 18:30:20.683,2021-02-19 18:30:20.683,2022-02-20 00:30:20.683,DISCONTINUED,DISCONTINUED,2022-02-20,1025,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,42,>30,2022-04-03,1066,Yes,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-1.26600028305937
1236,AB12345,AB12345-CHN-7-id-202,id-202,CHN-7,44,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.59829827683604,MEDIUM,Y,Y,N,Y,N,2019-11-05,2019-11-06 20:15:16.683,,2019-11-06 20:15:16.683,,,,2019-11-06 20:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,176.278072502464,DAYS,2021-07-17 20:15:16.683,619,1,Adverse Event,Preferred Term,
1237,AB12345,AB12345-CHN-7-id-202,id-202,CHN-7,44,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.59829827683604,MEDIUM,Y,Y,N,Y,N,2019-11-05,2019-11-06 20:15:16.683,,2019-11-06 20:15:16.683,,,,2019-11-06 20:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,28.0263051146176,DAYS,2019-11-08 20:15:16.683,2,1,Last Tumor Assessment,Completion or Discontinuation,
1238,AB12345,AB12345-CHN-7-id-202,id-202,CHN-7,44,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.59829827683604,MEDIUM,Y,Y,N,Y,N,2019-11-05,2019-11-06 20:15:16.683,,2019-11-06 20:15:16.683,,,,2019-11-06 20:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,334.799622138962,DAYS,2020-09-09 20:15:16.683,308,1,Alive,Alive During Study,
1239,AB12345,AB12345-CHN-7-id-202,id-202,CHN-7,44,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.59829827683604,MEDIUM,Y,Y,N,Y,N,2019-11-05,2019-11-06 20:15:16.683,,2019-11-06 20:15:16.683,,,,2019-11-06 20:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,299.528106488287,DAYS,2020-11-16 20:15:16.683,376,1,Last Tumor Assessment,Completion or Discontinuation,
1240,AB12345,AB12345-CHN-7-id-202,id-202,CHN-7,44,YEARS,F,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,C,S1,5.59829827683604,MEDIUM,Y,Y,N,Y,N,2019-11-05,2019-11-06 20:15:16.683,,2019-11-06 20:15:16.683,,,,2019-11-06 20:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,0.376690819420766
1241,AB12345,AB12345-CHN-7-id-267,id-267,CHN-7,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,6.2067627167943,LOW,Y,Y,N,N,N,2019-03-01,2019-03-02 00:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-15,,,3,3,Duration of Confirmed Response,CRSD,67.6261199207511,DAYS,2020-12-06 00:09:33.683,645,0,Death,,
1242,AB12345,AB12345-CHN-7-id-267,id-267,CHN-7,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,6.2067627167943,LOW,Y,Y,N,N,N,2019-03-01,2019-03-02 00:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-15,,,4,4,Event Free Survival,EFS,67.6261199207511,DAYS,2021-09-28 00:09:33.683,941,0,Death,,
1243,AB12345,AB12345-CHN-7-id-267,id-267,CHN-7,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,6.2067627167943,LOW,Y,Y,N,N,N,2019-03-01,2019-03-02 00:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-15,,,2,2,Overall Survival,OS,67.6261199207511,DAYS,2019-07-28 00:09:33.683,148,0,Death,,
1244,AB12345,AB12345-CHN-7-id-267,id-267,CHN-7,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,6.2067627167943,LOW,Y,Y,N,N,N,2019-03-01,2019-03-02 00:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-15,,,1,1,Progression Free Survival,PFS,67.6261199207511,DAYS,2019-05-10 00:09:33.683,69,0,Death,,
1245,AB12345,AB12345-CHN-7-id-267,id-267,CHN-7,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Asia,C,S1,6.2067627167943,LOW,Y,Y,N,N,N,2019-03-01,2019-03-02 00:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,2019-03-02 00:09:33.683,2021-03-01 12:09:33.683,2021-03-01 12:09:33.683,2022-03-01 18:09:33.683,COMPLETED,COMPLETED,2022-03-01,1096,,,,,,,2022-03-15,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.01051438495929
1246,AB12345,AB12345-CHN-7-id-28,id-28,CHN-7,40,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,11.1444469908374,MEDIUM,Y,Y,N,N,Y,2019-03-10,2019-03-11 09:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,COMPLETED,COMPLETED,2022-03-11,1096,,,,,,,2022-03-31,,,4,4,Duration of Confirmed Response,CRSD,181.82582622394,DAYS,2021-09-05 09:11:52.683,909,1,Adverse Event,Preferred Term,
1247,AB12345,AB12345-CHN-7-id-28,id-28,CHN-7,40,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,11.1444469908374,MEDIUM,Y,Y,N,N,Y,2019-03-10,2019-03-11 09:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,COMPLETED,COMPLETED,2022-03-11,1096,,,,,,,2022-03-31,,,2,2,Event Free Survival,EFS,60.7285697874613,DAYS,2020-06-03 09:11:52.683,450,0,Disease Progression,,
1248,AB12345,AB12345-CHN-7-id-28,id-28,CHN-7,40,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,11.1444469908374,MEDIUM,Y,Y,N,N,Y,2019-03-10,2019-03-11 09:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,COMPLETED,COMPLETED,2022-03-11,1096,,,,,,,2022-03-31,,,3,3,Overall Survival,OS,416.465387353674,DAYS,2021-01-21 09:11:52.683,682,1,Alive,Alive During Study,
1249,AB12345,AB12345-CHN-7-id-28,id-28,CHN-7,40,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,11.1444469908374,MEDIUM,Y,Y,N,N,Y,2019-03-10,2019-03-11 09:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,COMPLETED,COMPLETED,2022-03-11,1096,,,,,,,2022-03-31,,,1,1,Progression Free Survival,PFS,232.174690719694,DAYS,2020-05-08 09:11:52.683,424,0,Disease Progression,,
1250,AB12345,AB12345-CHN-7-id-28,id-28,CHN-7,40,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S2,11.1444469908374,MEDIUM,Y,Y,N,N,Y,2019-03-10,2019-03-11 09:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,2019-03-11 09:11:52.683,2021-03-10 21:11:52.683,2021-03-10 21:11:52.683,2022-03-11 03:11:52.683,COMPLETED,COMPLETED,2022-03-11,1096,,,,,,,2022-03-31,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-2.81602752095289
1251,AB12345,AB12345-CHN-7-id-290,id-290,CHN-7,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,2.23873239520595,HIGH,Y,Y,N,Y,N,2021-01-11,2021-01-15 03:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-01-27,,,1,1,Duration of Confirmed Response,CRSD,157.0644013118,DAYS,2022-08-29 03:12:48.683,591,1,Last Tumor Assessment,Completion or Discontinuation,
1252,AB12345,AB12345-CHN-7-id-290,id-290,CHN-7,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,2.23873239520595,HIGH,Y,Y,N,Y,N,2021-01-11,2021-01-15 03:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-01-27,,,3,3,Event Free Survival,EFS,21.0292522539385,DAYS,2022-11-08 03:12:48.683,662,1,Last Tumor Assessment,Completion or Discontinuation,
1253,AB12345,AB12345-CHN-7-id-290,id-290,CHN-7,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,2.23873239520595,HIGH,Y,Y,N,Y,N,2021-01-11,2021-01-15 03:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-01-27,,,4,4,Overall Survival,OS,256.067725061439,DAYS,2023-05-11 03:12:48.683,846,0,Death,,
1254,AB12345,AB12345-CHN-7-id-290,id-290,CHN-7,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,2.23873239520595,HIGH,Y,Y,N,Y,N,2021-01-11,2021-01-15 03:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-01-27,,,2,2,Progression Free Survival,PFS,256.067725061439,DAYS,2022-10-16 03:12:48.683,639,0,Death,,
1255,AB12345,AB12345-CHN-7-id-290,id-290,CHN-7,33,YEARS,M,ASIAN,HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,A,S2,2.23873239520595,HIGH,Y,Y,N,Y,N,2021-01-11,2021-01-15 03:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,2021-01-15 03:12:48.683,2023-01-15 15:12:48.683,2023-01-15 15:12:48.683,2024-01-15 21:12:48.683,COMPLETED,COMPLETED,2024-01-15,1096,,,,,,,2024-01-27,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-1.21537847744458
1256,AB12345,AB12345-CHN-7-id-40,id-40,CHN-7,33,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,13.1636595597587,HIGH,Y,Y,N,N,N,2020-11-27,2020-11-30 05:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,COMPLETED,COMPLETED,2023-11-30,1096,,,,,,,2023-12-13,,,3,3,Duration of Confirmed Response,CRSD,196.194878523238,DAYS,2023-06-08 05:49:22.683,920,1,Last Tumor Assessment,Completion or Discontinuation,
1257,AB12345,AB12345-CHN-7-id-40,id-40,CHN-7,33,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,13.1636595597587,HIGH,Y,Y,N,N,N,2020-11-27,2020-11-30 05:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,COMPLETED,COMPLETED,2023-11-30,1096,,,,,,,2023-12-13,,,2,2,Event Free Survival,EFS,51.9045298569836,DAYS,2023-01-03 05:49:22.683,764,1,Last Tumor Assessment,Completion or Discontinuation,
1258,AB12345,AB12345-CHN-7-id-40,id-40,CHN-7,33,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,13.1636595597587,HIGH,Y,Y,N,N,N,2020-11-27,2020-11-30 05:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,COMPLETED,COMPLETED,2023-11-30,1096,,,,,,,2023-12-13,,,1,1,Overall Survival,OS,351.693906402215,DAYS,2021-08-10 05:49:22.683,253,1,Alive,Alive During Study,
1259,AB12345,AB12345-CHN-7-id-40,id-40,CHN-7,33,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,13.1636595597587,HIGH,Y,Y,N,N,N,2020-11-27,2020-11-30 05:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,COMPLETED,COMPLETED,2023-11-30,1096,,,,,,,2023-12-13,,,4,4,Progression Free Survival,PFS,271.127168438397,DAYS,2023-11-05 05:49:22.683,1070,1,Adverse Event,Preferred Term,
1260,AB12345,AB12345-CHN-7-id-40,id-40,CHN-7,33,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-7,Dr. CHN-7 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,C,S2,13.1636595597587,HIGH,Y,Y,N,N,N,2020-11-27,2020-11-30 05:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,2020-11-30 05:49:22.683,2022-11-30 17:49:22.683,2022-11-30 17:49:22.683,2023-11-30 23:49:22.683,COMPLETED,COMPLETED,2023-11-30,1096,,,,,,,2023-12-13,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.495051668012805
1261,AB12345,AB12345-CHN-8-id-205,id-205,CHN-8,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,5.15911521510357,HIGH,Y,Y,N,Y,N,2021-01-14,2021-01-18 16:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,COMPLETED,COMPLETED,2024-01-19,1096,,,,,,,2024-02-13,,,3,3,Duration of Confirmed Response,CRSD,142.081166314892,DAYS,2023-02-07 16:23:39.683,750,0,Disease Progression,,
1262,AB12345,AB12345-CHN-8-id-205,id-205,CHN-8,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,5.15911521510357,HIGH,Y,Y,N,Y,N,2021-01-14,2021-01-18 16:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,COMPLETED,COMPLETED,2024-01-19,1096,,,,,,,2024-02-13,,,4,4,Event Free Survival,EFS,93.6825907032471,DAYS,2023-08-15 16:23:39.683,939,1,Adverse Event,Preferred Term,
1263,AB12345,AB12345-CHN-8-id-205,id-205,CHN-8,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,5.15911521510357,HIGH,Y,Y,N,Y,N,2021-01-14,2021-01-18 16:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,COMPLETED,COMPLETED,2024-01-19,1096,,,,,,,2024-02-13,,,1,1,Overall Survival,OS,450.933009525761,DAYS,2021-07-13 16:23:39.683,176,1,Alive,Alive During Study,
1264,AB12345,AB12345-CHN-8-id-205,id-205,CHN-8,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,5.15911521510357,HIGH,Y,Y,N,Y,N,2021-01-14,2021-01-18 16:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,COMPLETED,COMPLETED,2024-01-19,1096,,,,,,,2024-02-13,,,2,2,Progression Free Survival,PFS,281.63007455878,DAYS,2021-12-13 16:23:39.683,329,1,Adverse Event,Preferred Term,
1265,AB12345,AB12345-CHN-8-id-205,id-205,CHN-8,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,B,S1,5.15911521510357,HIGH,Y,Y,N,Y,N,2021-01-14,2021-01-18 16:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,2021-01-18 16:23:39.683,2023-01-19 04:23:39.683,2023-01-19 04:23:39.683,2024-01-19 10:23:39.683,COMPLETED,COMPLETED,2024-01-19,1096,,,,,,,2024-02-13,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-4.6588591108475
1266,AB12345,AB12345-CHN-8-id-299,id-299,CHN-8,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,3.15501827570869,MEDIUM,Y,Y,Y,N,N,2019-11-09,2019-11-09 02:49:13.683,,2019-11-09 02:49:13.683,,,,2019-11-09 02:49:13.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,151.441683201119,DAYS,2021-10-29 02:49:13.683,720,1,Last Tumor Assessment,Completion or Discontinuation,
1267,AB12345,AB12345-CHN-8-id-299,id-299,CHN-8,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,3.15501827570869,MEDIUM,Y,Y,Y,N,N,2019-11-09,2019-11-09 02:49:13.683,,2019-11-09 02:49:13.683,,,,2019-11-09 02:49:13.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,50.0321808806621,DAYS,2021-05-22 02:49:13.683,560,1,Last Tumor Assessment,Completion or Discontinuation,
1268,AB12345,AB12345-CHN-8-id-299,id-299,CHN-8,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,3.15501827570869,MEDIUM,Y,Y,Y,N,N,2019-11-09,2019-11-09 02:49:13.683,,2019-11-09 02:49:13.683,,,,2019-11-09 02:49:13.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,494.804860837758,DAYS,2021-03-16 02:49:13.683,493,1,Alive,Alive During Study,
1269,AB12345,AB12345-CHN-8-id-299,id-299,CHN-8,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,3.15501827570869,MEDIUM,Y,Y,Y,N,N,2019-11-09,2019-11-09 02:49:13.683,,2019-11-09 02:49:13.683,,,,2019-11-09 02:49:13.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,254.228471848182,DAYS,2021-07-27 02:49:13.683,626,0,Disease Progression,,
1270,AB12345,AB12345-CHN-8-id-299,id-299,CHN-8,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-8,Dr. CHN-8 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,3.15501827570869,MEDIUM,Y,Y,Y,N,N,2019-11-09,2019-11-09 02:49:13.683,,2019-11-09 02:49:13.683,,,,2019-11-09 02:49:13.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-0.533044596448766
1271,AB12345,AB12345-CHN-9-id-11,id-11,CHN-9,28,YEARS,F,NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER,HISPANIC OR LATINO,CHN,Y,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S1,4.26791563235003,MEDIUM,Y,Y,Y,Y,Y,2021-01-26,2021-01-27 02:18:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,DISCONTINUED,DISCONTINUED,2022-02-18,388,DEATH,2022-03-02,UNKNOWN,OTHER,12,<=30,2022-03-02,398,No,3,3,Duration of Confirmed Response,CRSD,176.950380532071,DAYS,2021-08-02 02:18:01.683,187,1,Adverse Event,Preferred Term,
1272,AB12345,AB12345-CHN-9-id-11,id-11,CHN-9,28,YEARS,F,NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER,HISPANIC OR LATINO,CHN,Y,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S1,4.26791563235003,MEDIUM,Y,Y,Y,Y,Y,2021-01-26,2021-01-27 02:18:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,DISCONTINUED,DISCONTINUED,2022-02-18,388,DEATH,2022-03-02,UNKNOWN,OTHER,12,<=30,2022-03-02,398,No,4,4,Event Free Survival,EFS,21.2592261657119,DAYS,2021-12-07 02:18:01.683,314,0,Disease Progression,,
1273,AB12345,AB12345-CHN-9-id-11,id-11,CHN-9,28,YEARS,F,NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER,HISPANIC OR LATINO,CHN,Y,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S1,4.26791563235003,MEDIUM,Y,Y,Y,Y,Y,2021-01-26,2021-01-27 02:18:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,DISCONTINUED,DISCONTINUED,2022-02-18,388,DEATH,2022-03-02,UNKNOWN,OTHER,12,<=30,2022-03-02,398,No,1,1,Overall Survival,OS,287.255490920506,DAYS,2021-05-27 02:18:01.683,120,0,Death,,
1274,AB12345,AB12345-CHN-9-id-11,id-11,CHN-9,28,YEARS,F,NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER,HISPANIC OR LATINO,CHN,Y,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S1,4.26791563235003,MEDIUM,Y,Y,Y,Y,Y,2021-01-26,2021-01-27 02:18:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,DISCONTINUED,DISCONTINUED,2022-02-18,388,DEATH,2022-03-02,UNKNOWN,OTHER,12,<=30,2022-03-02,398,No,2,2,Progression Free Survival,PFS,287.255490920506,DAYS,2021-07-24 02:18:01.683,178,0,Death,,
1275,AB12345,AB12345-CHN-9-id-11,id-11,CHN-9,28,YEARS,F,NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER,HISPANIC OR LATINO,CHN,Y,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Asia,C,S1,4.26791563235003,MEDIUM,Y,Y,Y,Y,Y,2021-01-26,2021-01-27 02:18:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,2021-01-27 02:18:01.683,2021-02-18 04:34:01.683,2021-02-18 04:34:01.683,2022-02-18 10:34:01.683,DISCONTINUED,DISCONTINUED,2022-02-18,388,DEATH,2022-03-02,UNKNOWN,OTHER,12,<=30,2022-03-02,398,No,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Preferred Term,-2.13790316450138
1276,AB12345,AB12345-CHN-9-id-147,id-147,CHN-9,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S2,2.5464709095177,MEDIUM,Y,Y,N,N,Y,2020-02-03,2020-02-06 16:03:48.683,,2020-02-06 16:03:48.683,,,,2020-02-06 16:03:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,196.514764404856,DAYS,2020-12-03 16:03:48.683,301,1,Last Tumor Assessment,Completion or Discontinuation,
1277,AB12345,AB12345-CHN-9-id-147,id-147,CHN-9,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S2,2.5464709095177,MEDIUM,Y,Y,N,N,Y,2020-02-03,2020-02-06 16:03:48.683,,2020-02-06 16:03:48.683,,,,2020-02-06 16:03:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,99.1385746852029,DAYS,2020-02-21 16:03:48.683,15,1,Last Tumor Assessment,Completion or Discontinuation,
1278,AB12345,AB12345-CHN-9-id-147,id-147,CHN-9,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S2,2.5464709095177,MEDIUM,Y,Y,N,N,Y,2020-02-03,2020-02-06 16:03:48.683,,2020-02-06 16:03:48.683,,,,2020-02-06 16:03:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,313.077858788893,DAYS,2020-05-14 16:03:48.683,98,1,Alive,Alive During Study,
1279,AB12345,AB12345-CHN-9-id-147,id-147,CHN-9,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S2,2.5464709095177,MEDIUM,Y,Y,N,N,Y,2020-02-03,2020-02-06 16:03:48.683,,2020-02-06 16:03:48.683,,,,2020-02-06 16:03:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,263.642131863162,DAYS,2022-01-21 16:03:48.683,715,1,Adverse Event,Preferred Term,
1280,AB12345,AB12345-CHN-9-id-147,id-147,CHN-9,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S2,2.5464709095177,MEDIUM,Y,Y,N,N,Y,2020-02-03,2020-02-06 16:03:48.683,,2020-02-06 16:03:48.683,,,,2020-02-06 16:03:48.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.816690613908374
1281,AB12345,AB12345-CHN-9-id-374,id-374,CHN-9,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,14.7580255033029,HIGH,Y,Y,N,N,N,2020-11-14,2020-11-17 12:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-13,,,1,1,Duration of Confirmed Response,CRSD,149.278478045017,DAYS,2022-06-15 12:08:20.683,575,1,Adverse Event,Preferred Term,
1282,AB12345,AB12345-CHN-9-id-374,id-374,CHN-9,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,14.7580255033029,HIGH,Y,Y,N,N,N,2020-11-14,2020-11-17 12:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-13,,,3,3,Event Free Survival,EFS,25.9152541740332,DAYS,2023-01-26 12:08:20.683,800,0,Disease Progression,,
1283,AB12345,AB12345-CHN-9-id-374,id-374,CHN-9,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,14.7580255033029,HIGH,Y,Y,N,N,N,2020-11-14,2020-11-17 12:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-13,,,2,2,Overall Survival,OS,337.875742744654,DAYS,2023-01-15 12:08:20.683,789,1,Alive,Alive During Study,
1284,AB12345,AB12345-CHN-9-id-374,id-374,CHN-9,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,14.7580255033029,HIGH,Y,Y,N,N,N,2020-11-14,2020-11-17 12:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-13,,,4,4,Progression Free Survival,PFS,266.324486024678,DAYS,2023-10-06 12:08:20.683,1053,1,Last Tumor Assessment,Completion or Discontinuation,
1285,AB12345,AB12345-CHN-9-id-374,id-374,CHN-9,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,CHN,N,INV ID CHN-9,Dr. CHN-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,14.7580255033029,HIGH,Y,Y,N,N,N,2020-11-14,2020-11-17 12:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,2020-11-17 12:08:20.683,2022-11-18 00:08:20.683,2022-11-18 00:08:20.683,2023-11-18 06:08:20.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-13,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-4.31972694360654
1286,AB12345,AB12345-GBR-1-id-319,id-319,GBR-1,36,YEARS,F,ASIAN,NOT REPORTED,GBR,Y,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Europe,C,S1,1.8307675934904,HIGH,Y,Y,Y,Y,N,2020-10-02,2020-10-02 12:20:27.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,DISCONTINUED,DISCONTINUED,2022-02-12,499,DEATH,2022-03-18,ADVERSE EVENT,ADVERSE EVENT,34,>30,2022-03-18,531,Yes,2,2,Duration of Confirmed Response,CRSD,111.556032556109,DAYS,2021-03-02 12:20:27.683,151,0,Disease Progression,,
1287,AB12345,AB12345-GBR-1-id-319,id-319,GBR-1,36,YEARS,F,ASIAN,NOT REPORTED,GBR,Y,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Europe,C,S1,1.8307675934904,HIGH,Y,Y,Y,Y,N,2020-10-02,2020-10-02 12:20:27.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,DISCONTINUED,DISCONTINUED,2022-02-12,499,DEATH,2022-03-18,ADVERSE EVENT,ADVERSE EVENT,34,>30,2022-03-18,531,Yes,4,4,Event Free Survival,EFS,30.0958634295966,DAYS,2021-12-29 12:20:27.683,453,0,Disease Progression,,
1288,AB12345,AB12345-GBR-1-id-319,id-319,GBR-1,36,YEARS,F,ASIAN,NOT REPORTED,GBR,Y,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Europe,C,S1,1.8307675934904,HIGH,Y,Y,Y,Y,N,2020-10-02,2020-10-02 12:20:27.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,DISCONTINUED,DISCONTINUED,2022-02-12,499,DEATH,2022-03-18,ADVERSE EVENT,ADVERSE EVENT,34,>30,2022-03-18,531,Yes,1,1,Overall Survival,OS,471.48216990754,DAYS,2021-01-13 12:20:27.683,103,1,Alive,Alive During Study,
1289,AB12345,AB12345-GBR-1-id-319,id-319,GBR-1,36,YEARS,F,ASIAN,NOT REPORTED,GBR,Y,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Europe,C,S1,1.8307675934904,HIGH,Y,Y,Y,Y,N,2020-10-02,2020-10-02 12:20:27.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,DISCONTINUED,DISCONTINUED,2022-02-12,499,DEATH,2022-03-18,ADVERSE EVENT,ADVERSE EVENT,34,>30,2022-03-18,531,Yes,3,3,Progression Free Survival,PFS,215.695240022615,DAYS,2021-08-11 12:20:27.683,313,0,Disease Progression,,
1290,AB12345,AB12345-GBR-1-id-319,id-319,GBR-1,36,YEARS,F,ASIAN,NOT REPORTED,GBR,Y,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Europe,C,S1,1.8307675934904,HIGH,Y,Y,Y,Y,N,2020-10-02,2020-10-02 12:20:27.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,2020-10-02 12:20:27.683,2021-02-12 17:41:46.683,2021-02-12 17:41:46.683,2022-02-12 23:41:46.683,DISCONTINUED,DISCONTINUED,2022-02-12,499,DEATH,2022-03-18,ADVERSE EVENT,ADVERSE EVENT,34,>30,2022-03-18,531,Yes,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-2.47205428933093
1291,AB12345,AB12345-GBR-1-id-355,id-355,GBR-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Europe,A,S1,10.627957771122,HIGH,Y,Y,N,Y,N,2020-04-02,2020-04-02 12:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,COMPLETED,COMPLETED,2023-04-03,1096,,,,,,,2023-05-01,,,1,1,Duration of Confirmed Response,CRSD,187.83416710794,DAYS,2020-05-28 12:54:17.683,56,0,Disease Progression,,
1292,AB12345,AB12345-GBR-1-id-355,id-355,GBR-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Europe,A,S1,10.627957771122,HIGH,Y,Y,N,Y,N,2020-04-02,2020-04-02 12:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,COMPLETED,COMPLETED,2023-04-03,1096,,,,,,,2023-05-01,,,4,4,Event Free Survival,EFS,51.1131451942492,DAYS,2022-10-21 12:54:17.683,932,1,Last Tumor Assessment,Completion or Discontinuation,
1293,AB12345,AB12345-GBR-1-id-355,id-355,GBR-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Europe,A,S1,10.627957771122,HIGH,Y,Y,N,Y,N,2020-04-02,2020-04-02 12:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,COMPLETED,COMPLETED,2023-04-03,1096,,,,,,,2023-05-01,,,2,2,Overall Survival,OS,495.763923367485,DAYS,2022-05-25 12:54:17.683,783,1,Alive,Alive During Study,
1294,AB12345,AB12345-GBR-1-id-355,id-355,GBR-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Europe,A,S1,10.627957771122,HIGH,Y,Y,N,Y,N,2020-04-02,2020-04-02 12:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,COMPLETED,COMPLETED,2023-04-03,1096,,,,,,,2023-05-01,,,3,3,Progression Free Survival,PFS,282.482656394131,DAYS,2022-07-17 12:54:17.683,836,0,Disease Progression,,
1295,AB12345,AB12345-GBR-1-id-355,id-355,GBR-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Europe,A,S1,10.627957771122,HIGH,Y,Y,N,Y,N,2020-04-02,2020-04-02 12:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,2020-04-02 12:54:17.683,2022-04-03 00:54:17.683,2022-04-03 00:54:17.683,2023-04-03 06:54:17.683,COMPLETED,COMPLETED,2023-04-03,1096,,,,,,,2023-05-01,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-1.78982651407872
1296,AB12345,AB12345-GBR-1-id-384,id-384,GBR-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Europe,B,S2,2.64399665783162,HIGH,Y,Y,N,Y,N,2020-01-16,2020-01-19 06:57:47.683,,2020-01-19 06:57:47.683,,,,2020-01-19 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,169.152327603661,DAYS,2021-04-23 06:57:47.683,460,1,Adverse Event,Preferred Term,
1297,AB12345,AB12345-GBR-1-id-384,id-384,GBR-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Europe,B,S2,2.64399665783162,HIGH,Y,Y,N,Y,N,2020-01-16,2020-01-19 06:57:47.683,,2020-01-19 06:57:47.683,,,,2020-01-19 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,68.9361563476268,DAYS,2021-08-01 06:57:47.683,560,1,Adverse Event,Preferred Term,
1298,AB12345,AB12345-GBR-1-id-384,id-384,GBR-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Europe,B,S2,2.64399665783162,HIGH,Y,Y,N,Y,N,2020-01-16,2020-01-19 06:57:47.683,,2020-01-19 06:57:47.683,,,,2020-01-19 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,279.218333936296,DAYS,2020-11-17 06:57:47.683,303,0,Death,,
1299,AB12345,AB12345-GBR-1-id-384,id-384,GBR-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Europe,B,S2,2.64399665783162,HIGH,Y,Y,N,Y,N,2020-01-16,2020-01-19 06:57:47.683,,2020-01-19 06:57:47.683,,,,2020-01-19 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,279.218333936296,DAYS,2021-09-06 06:57:47.683,596,0,Death,,
1300,AB12345,AB12345-GBR-1-id-384,id-384,GBR-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-1,Dr. GBR-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Europe,B,S2,2.64399665783162,HIGH,Y,Y,N,Y,N,2020-01-16,2020-01-19 06:57:47.683,,2020-01-19 06:57:47.683,,,,2020-01-19 06:57:47.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-0.737268029724188
1301,AB12345,AB12345-GBR-11-id-340,id-340,GBR-11,26,YEARS,F,WHITE,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Europe,B,S2,4.11634079346403,MEDIUM,Y,Y,N,Y,N,2020-05-13,2020-05-17 10:28:18.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,DISCONTINUED,DISCONTINUED,2022-02-18,643,ADVERSE EVENT,,,,,,2022-02-28,,,2,2,Duration of Confirmed Response,CRSD,181.999368104152,DAYS,2020-11-19 10:28:18.683,186,1,Last Tumor Assessment,Completion or Discontinuation,
1302,AB12345,AB12345-GBR-11-id-340,id-340,GBR-11,26,YEARS,F,WHITE,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Europe,B,S2,4.11634079346403,MEDIUM,Y,Y,N,Y,N,2020-05-13,2020-05-17 10:28:18.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,DISCONTINUED,DISCONTINUED,2022-02-18,643,ADVERSE EVENT,,,,,,2022-02-28,,,4,4,Event Free Survival,EFS,17.9045048693661,DAYS,2022-01-09 10:28:18.683,602,0,Disease Progression,,
1303,AB12345,AB12345-GBR-11-id-340,id-340,GBR-11,26,YEARS,F,WHITE,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Europe,B,S2,4.11634079346403,MEDIUM,Y,Y,N,Y,N,2020-05-13,2020-05-17 10:28:18.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,DISCONTINUED,DISCONTINUED,2022-02-18,643,ADVERSE EVENT,,,,,,2022-02-28,,,3,3,Overall Survival,OS,386.355378385633,DAYS,2021-06-07 10:28:18.683,386,1,Alive,Alive During Study,
1304,AB12345,AB12345-GBR-11-id-340,id-340,GBR-11,26,YEARS,F,WHITE,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Europe,B,S2,4.11634079346403,MEDIUM,Y,Y,N,Y,N,2020-05-13,2020-05-17 10:28:18.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,DISCONTINUED,DISCONTINUED,2022-02-18,643,ADVERSE EVENT,,,,,,2022-02-28,,,1,1,Progression Free Survival,PFS,268.763616262004,DAYS,2020-07-29 10:28:18.683,73,1,Last Tumor Assessment,Completion or Discontinuation,
1305,AB12345,AB12345-GBR-11-id-340,id-340,GBR-11,26,YEARS,F,WHITE,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Europe,B,S2,4.11634079346403,MEDIUM,Y,Y,N,Y,N,2020-05-13,2020-05-17 10:28:18.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,2020-05-17 10:28:18.683,2021-02-18 14:19:14.683,2021-02-18 14:19:14.683,2022-02-18 20:19:14.683,DISCONTINUED,DISCONTINUED,2022-02-18,643,ADVERSE EVENT,,,,,,2022-02-28,,,,,Total Number of Exacerbations,TNE,9,COUNT,,,1,,Completion or Discontinuation,0.794952329529247
1306,AB12345,AB12345-GBR-11-id-390,id-390,GBR-11,69,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Europe,C,S1,2.05012267173994,HIGH,Y,Y,N,Y,N,2019-12-27,2019-12-31 19:28:12.683,,2019-12-31 19:28:12.683,,,,2019-12-31 19:28:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,100.814770301804,DAYS,2020-03-01 19:28:12.683,61,0,Disease Progression,,
1307,AB12345,AB12345-GBR-11-id-390,id-390,GBR-11,69,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Europe,C,S1,2.05012267173994,HIGH,Y,Y,N,Y,N,2019-12-27,2019-12-31 19:28:12.683,,2019-12-31 19:28:12.683,,,,2019-12-31 19:28:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,35.7294418860693,DAYS,2020-01-18 19:28:12.683,18,1,Last Tumor Assessment,Completion or Discontinuation,
1308,AB12345,AB12345-GBR-11-id-390,id-390,GBR-11,69,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Europe,C,S1,2.05012267173994,HIGH,Y,Y,N,Y,N,2019-12-27,2019-12-31 19:28:12.683,,2019-12-31 19:28:12.683,,,,2019-12-31 19:28:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,242.11061433889,DAYS,2020-02-20 19:28:12.683,51,0,Death,,
1309,AB12345,AB12345-GBR-11-id-390,id-390,GBR-11,69,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Europe,C,S1,2.05012267173994,HIGH,Y,Y,N,Y,N,2019-12-27,2019-12-31 19:28:12.683,,2019-12-31 19:28:12.683,,,,2019-12-31 19:28:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,242.11061433889,DAYS,2020-08-30 19:28:12.683,243,0,Death,,
1310,AB12345,AB12345-GBR-11-id-390,id-390,GBR-11,69,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-11,Dr. GBR-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Europe,C,S1,2.05012267173994,HIGH,Y,Y,N,Y,N,2019-12-27,2019-12-31 19:28:12.683,,2019-12-31 19:28:12.683,,,,2019-12-31 19:28:12.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.38498898234323
1311,AB12345,AB12345-GBR-13-id-80,id-80,GBR-13,28,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,GBR,N,INV ID GBR-13,Dr. GBR-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Europe,C,S1,7.74987392947792,LOW,Y,Y,Y,Y,N,2020-10-21,2020-10-24 19:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,COMPLETED,COMPLETED,2023-10-25,1096,,,,,,,2023-11-14,,,1,1,Duration of Confirmed Response,CRSD,81.8913371756207,DAYS,2021-01-13 19:46:20.683,81,0,Death,,
1312,AB12345,AB12345-GBR-13-id-80,id-80,GBR-13,28,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,GBR,N,INV ID GBR-13,Dr. GBR-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Europe,C,S1,7.74987392947792,LOW,Y,Y,Y,Y,N,2020-10-21,2020-10-24 19:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,COMPLETED,COMPLETED,2023-10-25,1096,,,,,,,2023-11-14,,,4,4,Event Free Survival,EFS,81.8913371756207,DAYS,2022-12-05 19:46:20.683,772,0,Death,,
1313,AB12345,AB12345-GBR-13-id-80,id-80,GBR-13,28,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,GBR,N,INV ID GBR-13,Dr. GBR-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Europe,C,S1,7.74987392947792,LOW,Y,Y,Y,Y,N,2020-10-21,2020-10-24 19:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,COMPLETED,COMPLETED,2023-10-25,1096,,,,,,,2023-11-14,,,3,3,Overall Survival,OS,81.8913371756207,DAYS,2021-11-21 19:46:20.683,393,0,Death,,
1314,AB12345,AB12345-GBR-13-id-80,id-80,GBR-13,28,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,GBR,N,INV ID GBR-13,Dr. GBR-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Europe,C,S1,7.74987392947792,LOW,Y,Y,Y,Y,N,2020-10-21,2020-10-24 19:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,COMPLETED,COMPLETED,2023-10-25,1096,,,,,,,2023-11-14,,,2,2,Progression Free Survival,PFS,81.8913371756207,DAYS,2021-10-15 19:46:20.683,356,0,Death,,
1315,AB12345,AB12345-GBR-13-id-80,id-80,GBR-13,28,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,GBR,N,INV ID GBR-13,Dr. GBR-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Europe,C,S1,7.74987392947792,LOW,Y,Y,Y,Y,N,2020-10-21,2020-10-24 19:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,2020-10-24 19:46:20.683,2022-10-25 07:46:20.683,2022-10-25 07:46:20.683,2023-10-25 13:46:20.683,COMPLETED,COMPLETED,2023-10-25,1096,,,,,,,2023-11-14,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-3.60905826183311
1316,AB12345,AB12345-GBR-15-id-293,id-293,GBR-15,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-15,Dr. GBR-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Europe,B,S1,1.56299043336672,HIGH,Y,Y,N,N,N,2020-05-18,2020-05-21 08:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,COMPLETED,COMPLETED,2023-05-22,1096,,,,,,,2023-06-02,,,4,4,Duration of Confirmed Response,CRSD,198.496305872686,DAYS,2022-09-28 08:57:46.683,860,1,Last Tumor Assessment,Completion or Discontinuation,
1317,AB12345,AB12345-GBR-15-id-293,id-293,GBR-15,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-15,Dr. GBR-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Europe,B,S1,1.56299043336672,HIGH,Y,Y,N,N,N,2020-05-18,2020-05-21 08:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,COMPLETED,COMPLETED,2023-05-22,1096,,,,,,,2023-06-02,,,1,1,Event Free Survival,EFS,65.6253304344136,DAYS,2021-07-20 08:57:46.683,425,1,Last Tumor Assessment,Completion or Discontinuation,
1318,AB12345,AB12345-GBR-15-id-293,id-293,GBR-15,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-15,Dr. GBR-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Europe,B,S1,1.56299043336672,HIGH,Y,Y,N,N,N,2020-05-18,2020-05-21 08:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,COMPLETED,COMPLETED,2023-05-22,1096,,,,,,,2023-06-02,,,3,3,Overall Survival,OS,404.655683552846,DAYS,2022-09-03 08:57:46.683,835,1,Alive,Alive During Study,
1319,AB12345,AB12345-GBR-15-id-293,id-293,GBR-15,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-15,Dr. GBR-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Europe,B,S1,1.56299043336672,HIGH,Y,Y,N,N,N,2020-05-18,2020-05-21 08:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,COMPLETED,COMPLETED,2023-05-22,1096,,,,,,,2023-06-02,,,2,2,Progression Free Survival,PFS,252.804345590994,DAYS,2022-03-14 08:57:46.683,662,1,Adverse Event,Preferred Term,
1320,AB12345,AB12345-GBR-15-id-293,id-293,GBR-15,27,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-15,Dr. GBR-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Europe,B,S1,1.56299043336672,HIGH,Y,Y,N,N,N,2020-05-18,2020-05-21 08:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,2020-05-21 08:57:46.683,2022-05-21 20:57:46.683,2022-05-21 20:57:46.683,2023-05-22 02:57:46.683,COMPLETED,COMPLETED,2023-05-22,1096,,,,,,,2023-06-02,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-1.62266939411636
1321,AB12345,AB12345-GBR-17-id-211,id-211,GBR-17,62,YEARS,M,ASIAN,HISPANIC OR LATINO,GBR,Y,INV ID GBR-17,Dr. GBR-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Europe,A,S1,3.72544818037091,MEDIUM,Y,Y,N,Y,N,2020-12-20,2020-12-23 03:12:22.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,DISCONTINUED,DISCONTINUED,2022-02-19,424,DEATH,2022-03-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,33,>30,2022-03-24,455,Yes,2,2,Duration of Confirmed Response,CRSD,108.772240928374,DAYS,2021-04-22 03:12:22.683,120,0,Disease Progression,,
1322,AB12345,AB12345-GBR-17-id-211,id-211,GBR-17,62,YEARS,M,ASIAN,HISPANIC OR LATINO,GBR,Y,INV ID GBR-17,Dr. GBR-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Europe,A,S1,3.72544818037091,MEDIUM,Y,Y,N,Y,N,2020-12-20,2020-12-23 03:12:22.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,DISCONTINUED,DISCONTINUED,2022-02-19,424,DEATH,2022-03-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,33,>30,2022-03-24,455,Yes,1,1,Event Free Survival,EFS,81.8478084134404,DAYS,2021-04-01 03:12:22.683,99,0,Disease Progression,,
1323,AB12345,AB12345-GBR-17-id-211,id-211,GBR-17,62,YEARS,M,ASIAN,HISPANIC OR LATINO,GBR,Y,INV ID GBR-17,Dr. GBR-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Europe,A,S1,3.72544818037091,MEDIUM,Y,Y,N,Y,N,2020-12-20,2020-12-23 03:12:22.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,DISCONTINUED,DISCONTINUED,2022-02-19,424,DEATH,2022-03-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,33,>30,2022-03-24,455,Yes,4,4,Overall Survival,OS,371.320824045688,DAYS,2022-01-16 03:12:22.683,389,1,Alive,Alive During Study,
1324,AB12345,AB12345-GBR-17-id-211,id-211,GBR-17,62,YEARS,M,ASIAN,HISPANIC OR LATINO,GBR,Y,INV ID GBR-17,Dr. GBR-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Europe,A,S1,3.72544818037091,MEDIUM,Y,Y,N,Y,N,2020-12-20,2020-12-23 03:12:22.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,DISCONTINUED,DISCONTINUED,2022-02-19,424,DEATH,2022-03-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,33,>30,2022-03-24,455,Yes,3,3,Progression Free Survival,PFS,225.611198064871,DAYS,2021-05-06 03:12:22.683,134,1,Last Tumor Assessment,Completion or Discontinuation,
1325,AB12345,AB12345-GBR-17-id-211,id-211,GBR-17,62,YEARS,M,ASIAN,HISPANIC OR LATINO,GBR,Y,INV ID GBR-17,Dr. GBR-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Europe,A,S1,3.72544818037091,MEDIUM,Y,Y,N,Y,N,2020-12-20,2020-12-23 03:12:22.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,2020-12-23 03:12:22.683,2021-02-18 22:06:37.683,2021-02-18 22:06:37.683,2022-02-19 04:06:37.683,DISCONTINUED,DISCONTINUED,2022-02-19,424,DEATH,2022-03-24,DISEASE PROGRESSION,PROGRESSIVE DISEASE,33,>30,2022-03-24,455,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.90770872436136
1326,AB12345,AB12345-GBR-6-id-111,id-111,GBR-6,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-6,Dr. GBR-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Europe,B,S2,4.67011436688164,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 00:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-12,,,1,1,Duration of Confirmed Response,CRSD,117.501848773099,DAYS,2019-12-13 00:29:19.683,137,0,Death,,
1327,AB12345,AB12345-GBR-6-id-111,id-111,GBR-6,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-6,Dr. GBR-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Europe,B,S2,4.67011436688164,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 00:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-12,,,4,4,Event Free Survival,EFS,36.169713929994,DAYS,2020-12-03 00:29:19.683,493,1,Adverse Event,Preferred Term,
1328,AB12345,AB12345-GBR-6-id-111,id-111,GBR-6,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-6,Dr. GBR-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Europe,B,S2,4.67011436688164,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 00:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-12,,,3,3,Overall Survival,OS,117.501848773099,DAYS,2020-07-03 00:29:19.683,340,0,Death,,
1329,AB12345,AB12345-GBR-6-id-111,id-111,GBR-6,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-6,Dr. GBR-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Europe,B,S2,4.67011436688164,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 00:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-12,,,2,2,Progression Free Survival,PFS,117.501848773099,DAYS,2020-01-02 00:29:19.683,157,0,Death,,
1330,AB12345,AB12345-GBR-6-id-111,id-111,GBR-6,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,GBR,N,INV ID GBR-6,Dr. GBR-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Europe,B,S2,4.67011436688164,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 00:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,2019-07-29 00:29:19.683,2021-07-28 12:29:19.683,2021-07-28 12:29:19.683,2022-07-28 18:29:19.683,COMPLETED,COMPLETED,2022-07-28,1096,,,,,,,2022-08-12,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.778100285207779
1331,AB12345,AB12345-JPN-1-id-21,id-21,JPN-1,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,13.2986854871951,MEDIUM,Y,Y,N,N,N,2020-11-15,2020-11-17 23:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-11-30,,,2,2,Duration of Confirmed Response,CRSD,63.6983768641949,DAYS,2021-07-29 23:27:24.683,254,0,Death,,
1332,AB12345,AB12345-JPN-1-id-21,id-21,JPN-1,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,13.2986854871951,MEDIUM,Y,Y,N,N,N,2020-11-15,2020-11-17 23:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-11-30,,,4,4,Event Free Survival,EFS,63.6983768641949,DAYS,2023-10-21 23:27:24.683,1068,0,Death,,
1333,AB12345,AB12345-JPN-1-id-21,id-21,JPN-1,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,13.2986854871951,MEDIUM,Y,Y,N,N,N,2020-11-15,2020-11-17 23:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-11-30,,,3,3,Overall Survival,OS,63.6983768641949,DAYS,2022-07-27 23:27:24.683,617,0,Death,,
1334,AB12345,AB12345-JPN-1-id-21,id-21,JPN-1,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,13.2986854871951,MEDIUM,Y,Y,N,N,N,2020-11-15,2020-11-17 23:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-11-30,,,1,1,Progression Free Survival,PFS,63.6983768641949,DAYS,2020-12-28 23:27:24.683,41,0,Death,,
1335,AB12345,AB12345-JPN-1-id-21,id-21,JPN-1,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S1,13.2986854871951,MEDIUM,Y,Y,N,N,N,2020-11-15,2020-11-17 23:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,2020-11-17 23:27:24.683,2022-11-18 11:27:24.683,2022-11-18 11:27:24.683,2023-11-18 17:27:24.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-11-30,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.26951079866671
1336,AB12345,AB12345-JPN-1-id-218,id-218,JPN-1,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S2,5.81330109583102,HIGH,Y,Y,Y,N,N,2019-10-05,2019-10-09 16:25:26.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,PROTOCOL VIOLATION,,,,,,2022-03-12,,,2,2,Duration of Confirmed Response,CRSD,180.994896916673,DAYS,2019-11-12 16:25:26.683,34,1,Adverse Event,Preferred Term,
1337,AB12345,AB12345-JPN-1-id-218,id-218,JPN-1,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S2,5.81330109583102,HIGH,Y,Y,Y,N,N,2019-10-05,2019-10-09 16:25:26.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,PROTOCOL VIOLATION,,,,,,2022-03-12,,,3,3,Event Free Survival,EFS,56.0884176043328,DAYS,2021-09-13 16:25:26.683,705,0,Disease Progression,,
1338,AB12345,AB12345-JPN-1-id-218,id-218,JPN-1,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S2,5.81330109583102,HIGH,Y,Y,Y,N,N,2019-10-05,2019-10-09 16:25:26.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,PROTOCOL VIOLATION,,,,,,2022-03-12,,,4,4,Overall Survival,OS,369.48875952512,DAYS,2021-11-07 16:25:26.683,760,1,Alive,Alive During Study,
1339,AB12345,AB12345-JPN-1-id-218,id-218,JPN-1,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S2,5.81330109583102,HIGH,Y,Y,Y,N,N,2019-10-05,2019-10-09 16:25:26.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,PROTOCOL VIOLATION,,,,,,2022-03-12,,,1,1,Progression Free Survival,PFS,275.051523395814,DAYS,2019-11-03 16:25:26.683,25,1,Adverse Event,Preferred Term,
1340,AB12345,AB12345-JPN-1-id-218,id-218,JPN-1,35,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S2,5.81330109583102,HIGH,Y,Y,Y,N,N,2019-10-05,2019-10-09 16:25:26.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,2019-10-09 16:25:26.683,2021-02-17 17:03:29.683,2021-02-17 17:03:29.683,2022-02-17 23:03:29.683,DISCONTINUED,DISCONTINUED,2022-02-17,863,PROTOCOL VIOLATION,,,,,,2022-03-12,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Preferred Term,-1.95690066407311
1341,AB12345,AB12345-JPN-1-id-225,id-225,JPN-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,1.86373376035954,HIGH,Y,Y,N,N,N,2019-12-04,2019-12-07 03:36:02.683,,2019-12-07 03:36:02.683,,,,2019-12-07 03:36:02.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,125.176422810182,DAYS,2021-09-13 03:36:02.683,646,1,Last Tumor Assessment,Completion or Discontinuation,
1342,AB12345,AB12345-JPN-1-id-225,id-225,JPN-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,1.86373376035954,HIGH,Y,Y,N,N,N,2019-12-04,2019-12-07 03:36:02.683,,2019-12-07 03:36:02.683,,,,2019-12-07 03:36:02.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,83.5843311646022,DAYS,2020-02-15 03:36:02.683,70,1,Adverse Event,Preferred Term,
1343,AB12345,AB12345-JPN-1-id-225,id-225,JPN-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,1.86373376035954,HIGH,Y,Y,N,N,N,2019-12-04,2019-12-07 03:36:02.683,,2019-12-07 03:36:02.683,,,,2019-12-07 03:36:02.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,331.24314667657,DAYS,2021-08-08 03:36:02.683,610,1,Alive,Alive During Study,
1344,AB12345,AB12345-JPN-1-id-225,id-225,JPN-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,1.86373376035954,HIGH,Y,Y,N,N,N,2019-12-04,2019-12-07 03:36:02.683,,2019-12-07 03:36:02.683,,,,2019-12-07 03:36:02.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,259.296355396509,DAYS,2021-09-09 03:36:02.683,642,1,Last Tumor Assessment,Completion or Discontinuation,
1345,AB12345,AB12345-JPN-1-id-225,id-225,JPN-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S1,1.86373376035954,HIGH,Y,Y,N,N,N,2019-12-04,2019-12-07 03:36:02.683,,2019-12-07 03:36:02.683,,,,2019-12-07 03:36:02.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.368172206482317
1346,AB12345,AB12345-JPN-1-id-300,id-300,JPN-1,35,YEARS,M,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,6.97286724134903,HIGH,Y,Y,Y,N,N,2020-05-04,2020-05-07 07:48:41.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,DISCONTINUED,DISCONTINUED,2022-02-19,654,PROTOCOL VIOLATION,,,,,,2022-03-02,,,1,1,Duration of Confirmed Response,CRSD,122.63773009181,DAYS,2021-03-08 07:48:41.683,305,0,Disease Progression,,
1347,AB12345,AB12345-JPN-1-id-300,id-300,JPN-1,35,YEARS,M,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,6.97286724134903,HIGH,Y,Y,Y,N,N,2020-05-04,2020-05-07 07:48:41.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,DISCONTINUED,DISCONTINUED,2022-02-19,654,PROTOCOL VIOLATION,,,,,,2022-03-02,,,2,2,Event Free Survival,EFS,29.888570382027,DAYS,2021-05-05 07:48:41.683,363,1,Last Tumor Assessment,Completion or Discontinuation,
1348,AB12345,AB12345-JPN-1-id-300,id-300,JPN-1,35,YEARS,M,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,6.97286724134903,HIGH,Y,Y,Y,N,N,2020-05-04,2020-05-07 07:48:41.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,DISCONTINUED,DISCONTINUED,2022-02-19,654,PROTOCOL VIOLATION,,,,,,2022-03-02,,,4,4,Overall Survival,OS,377.67529594712,DAYS,2021-11-30 07:48:41.683,572,1,Alive,Alive During Study,
1349,AB12345,AB12345-JPN-1-id-300,id-300,JPN-1,35,YEARS,M,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,6.97286724134903,HIGH,Y,Y,Y,N,N,2020-05-04,2020-05-07 07:48:41.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,DISCONTINUED,DISCONTINUED,2022-02-19,654,PROTOCOL VIOLATION,,,,,,2022-03-02,,,3,3,Progression Free Survival,PFS,279.19632520061,DAYS,2021-09-17 07:48:41.683,498,1,Last Tumor Assessment,Completion or Discontinuation,
1350,AB12345,AB12345-JPN-1-id-300,id-300,JPN-1,35,YEARS,M,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,B,S2,6.97286724134903,HIGH,Y,Y,Y,N,N,2020-05-04,2020-05-07 07:48:41.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,2020-05-07 07:48:41.683,2021-02-19 13:46:51.683,2021-02-19 13:46:51.683,2022-02-19 19:46:51.683,DISCONTINUED,DISCONTINUED,2022-02-19,654,PROTOCOL VIOLATION,,,,,,2022-03-02,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.599358305911312
1351,AB12345,AB12345-JPN-1-id-7,id-7,JPN-1,54,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,4.08724279665752,MEDIUM,Y,Y,N,Y,N,2019-10-09,2019-10-10 08:49:00.683,,2019-10-10 08:49:00.683,,,,2019-10-10 08:49:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,92.4538727628533,DAYS,2021-02-22 08:49:00.683,501,0,Death,,
1352,AB12345,AB12345-JPN-1-id-7,id-7,JPN-1,54,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,4.08724279665752,MEDIUM,Y,Y,N,Y,N,2019-10-09,2019-10-10 08:49:00.683,,2019-10-10 08:49:00.683,,,,2019-10-10 08:49:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,92.4538727628533,DAYS,2021-03-05 08:49:00.683,512,0,Death,,
1353,AB12345,AB12345-JPN-1-id-7,id-7,JPN-1,54,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,4.08724279665752,MEDIUM,Y,Y,N,Y,N,2019-10-09,2019-10-10 08:49:00.683,,2019-10-10 08:49:00.683,,,,2019-10-10 08:49:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,92.4538727628533,DAYS,2021-06-07 08:49:00.683,606,0,Death,,
1354,AB12345,AB12345-JPN-1-id-7,id-7,JPN-1,54,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,4.08724279665752,MEDIUM,Y,Y,N,Y,N,2019-10-09,2019-10-10 08:49:00.683,,2019-10-10 08:49:00.683,,,,2019-10-10 08:49:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,92.4538727628533,DAYS,2021-01-16 08:49:00.683,464,0,Death,,
1355,AB12345,AB12345-JPN-1-id-7,id-7,JPN-1,54,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-1,Dr. JPN-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,B,S2,4.08724279665752,MEDIUM,Y,Y,N,Y,N,2019-10-09,2019-10-10 08:49:00.683,,2019-10-10 08:49:00.683,,,,2019-10-10 08:49:00.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.04435688436945
1356,AB12345,AB12345-JPN-11-id-135,id-135,JPN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.12702675819534,LOW,Y,Y,N,Y,N,2019-10-09,2019-10-12 13:29:09.683,,2019-10-12 13:29:09.683,,,,2019-10-12 13:29:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,198.783515696414,DAYS,2020-12-01 13:29:09.683,416,1,Last Tumor Assessment,Completion or Discontinuation,
1357,AB12345,AB12345-JPN-11-id-135,id-135,JPN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.12702675819534,LOW,Y,Y,N,Y,N,2019-10-09,2019-10-12 13:29:09.683,,2019-10-12 13:29:09.683,,,,2019-10-12 13:29:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,25.356999351643,DAYS,2020-07-04 13:29:09.683,266,1,Adverse Event,Preferred Term,
1358,AB12345,AB12345-JPN-11-id-135,id-135,JPN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.12702675819534,LOW,Y,Y,N,Y,N,2019-10-09,2019-10-12 13:29:09.683,,2019-10-12 13:29:09.683,,,,2019-10-12 13:29:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,362.155166780576,DAYS,2021-01-02 13:29:09.683,448,1,Alive,Alive During Study,
1359,AB12345,AB12345-JPN-11-id-135,id-135,JPN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.12702675819534,LOW,Y,Y,N,Y,N,2019-10-09,2019-10-12 13:29:09.683,,2019-10-12 13:29:09.683,,,,2019-10-12 13:29:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,275.528792059049,DAYS,2021-01-14 13:29:09.683,460,0,Disease Progression,,
1360,AB12345,AB12345-JPN-11-id-135,id-135,JPN-11,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,A,S2,2.12702675819534,LOW,Y,Y,N,Y,N,2019-10-09,2019-10-12 13:29:09.683,,2019-10-12 13:29:09.683,,,,2019-10-12 13:29:09.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-1.18197928759216
1361,AB12345,AB12345-JPN-11-id-373,id-373,JPN-11,45,YEARS,M,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,5.03423535745455,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-25 07:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,COMPLETED,COMPLETED,2023-08-26,1096,,,,,,,2023-09-19,,,1,1,Duration of Confirmed Response,CRSD,168.228306132369,DAYS,2020-09-12 07:10:45.683,18,1,Adverse Event,Preferred Term,
1362,AB12345,AB12345-JPN-11-id-373,id-373,JPN-11,45,YEARS,M,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,5.03423535745455,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-25 07:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,COMPLETED,COMPLETED,2023-08-26,1096,,,,,,,2023-09-19,,,2,2,Event Free Survival,EFS,16.6885554313194,DAYS,2020-10-04 07:10:45.683,40,1,Last Tumor Assessment,Completion or Discontinuation,
1363,AB12345,AB12345-JPN-11-id-373,id-373,JPN-11,45,YEARS,M,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,5.03423535745455,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-25 07:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,COMPLETED,COMPLETED,2023-08-26,1096,,,,,,,2023-09-19,,,4,4,Overall Survival,OS,476.740141073242,DAYS,2021-07-14 07:10:45.683,323,1,Alive,Alive During Study,
1364,AB12345,AB12345-JPN-11-id-373,id-373,JPN-11,45,YEARS,M,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,5.03423535745455,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-25 07:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,COMPLETED,COMPLETED,2023-08-26,1096,,,,,,,2023-09-19,,,3,3,Progression Free Survival,PFS,243.873606668785,DAYS,2020-11-07 07:10:45.683,74,0,Disease Progression,,
1365,AB12345,AB12345-JPN-11-id-373,id-373,JPN-11,45,YEARS,M,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,5.03423535745455,MEDIUM,Y,Y,N,N,N,2020-08-22,2020-08-25 07:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,2020-08-25 07:10:45.683,2022-08-25 19:10:45.683,2022-08-25 19:10:45.683,2023-08-26 01:10:45.683,COMPLETED,COMPLETED,2023-08-26,1096,,,,,,,2023-09-19,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Preferred Term,-2.57101314876654
1366,AB12345,AB12345-JPN-11-id-61,id-61,JPN-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,14.0086948162122,LOW,Y,Y,N,Y,N,2020-12-18,2020-12-22 00:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-14,,,4,4,Duration of Confirmed Response,CRSD,145.366955595091,DAYS,2023-07-04 00:39:24.683,924,0,Death,,
1367,AB12345,AB12345-JPN-11-id-61,id-61,JPN-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,14.0086948162122,LOW,Y,Y,N,Y,N,2020-12-18,2020-12-22 00:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-14,,,1,1,Event Free Survival,EFS,21.3107217743527,DAYS,2021-05-09 00:39:24.683,138,0,Disease Progression,,
1368,AB12345,AB12345-JPN-11-id-61,id-61,JPN-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,14.0086948162122,LOW,Y,Y,N,Y,N,2020-12-18,2020-12-22 00:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-14,,,2,2,Overall Survival,OS,145.366955595091,DAYS,2022-08-05 00:39:24.683,591,0,Death,,
1369,AB12345,AB12345-JPN-11-id-61,id-61,JPN-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,14.0086948162122,LOW,Y,Y,N,Y,N,2020-12-18,2020-12-22 00:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-14,,,3,3,Progression Free Survival,PFS,145.366955595091,DAYS,2022-09-21 00:39:24.683,638,0,Death,,
1370,AB12345,AB12345-JPN-11-id-61,id-61,JPN-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,JPN,N,INV ID JPN-11,Dr. JPN-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,14.0086948162122,LOW,Y,Y,N,Y,N,2020-12-18,2020-12-22 00:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,2020-12-22 00:39:24.683,2022-12-22 12:39:24.683,2022-12-22 12:39:24.683,2023-12-22 18:39:24.683,COMPLETED,COMPLETED,2023-12-22,1096,,,,,,,2024-01-14,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.185111577113064
1371,AB12345,AB12345-JPN-12-id-219,id-219,JPN-12,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-12,Dr. JPN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,2.39188157775348,HIGH,Y,Y,N,N,N,2020-04-30,2020-05-03 05:02:53.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,DISCONTINUED,DISCONTINUED,2022-02-13,652,PROTOCOL VIOLATION,,,,,,2022-03-12,,,1,1,Duration of Confirmed Response,CRSD,170.015924167819,DAYS,2020-07-14 05:02:53.683,72,0,Disease Progression,,
1372,AB12345,AB12345-JPN-12-id-219,id-219,JPN-12,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-12,Dr. JPN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,2.39188157775348,HIGH,Y,Y,N,N,N,2020-04-30,2020-05-03 05:02:53.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,DISCONTINUED,DISCONTINUED,2022-02-13,652,PROTOCOL VIOLATION,,,,,,2022-03-12,,,4,4,Event Free Survival,EFS,90.4830830032006,DAYS,2021-05-05 05:02:53.683,367,1,Last Tumor Assessment,Completion or Discontinuation,
1373,AB12345,AB12345-JPN-12-id-219,id-219,JPN-12,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-12,Dr. JPN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,2.39188157775348,HIGH,Y,Y,N,N,N,2020-04-30,2020-05-03 05:02:53.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,DISCONTINUED,DISCONTINUED,2022-02-13,652,PROTOCOL VIOLATION,,,,,,2022-03-12,,,2,2,Overall Survival,OS,416.978160478175,DAYS,2020-08-20 05:02:53.683,109,1,Alive,Alive During Study,
1374,AB12345,AB12345-JPN-12-id-219,id-219,JPN-12,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-12,Dr. JPN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,2.39188157775348,HIGH,Y,Y,N,N,N,2020-04-30,2020-05-03 05:02:53.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,DISCONTINUED,DISCONTINUED,2022-02-13,652,PROTOCOL VIOLATION,,,,,,2022-03-12,,,3,3,Progression Free Survival,PFS,230.461561121047,DAYS,2021-03-26 05:02:53.683,327,1,Adverse Event,Preferred Term,
1375,AB12345,AB12345-JPN-12-id-219,id-219,JPN-12,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-12,Dr. JPN-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,C,S2,2.39188157775348,HIGH,Y,Y,N,N,N,2020-04-30,2020-05-03 05:02:53.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,2020-05-03 05:02:53.683,2021-02-13 05:00:51.683,2021-02-13 05:00:51.683,2022-02-13 11:00:51.683,DISCONTINUED,DISCONTINUED,2022-02-13,652,PROTOCOL VIOLATION,,,,,,2022-03-12,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-3.8178380570532
1376,AB12345,AB12345-JPN-14-id-194,id-194,JPN-14,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-14,Dr. JPN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,3.44685758761002,LOW,Y,Y,Y,N,N,2019-10-31,2019-11-01 00:14:23.683,,2019-11-01 00:14:23.683,,,,2019-11-01 00:14:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,144.652355927974,DAYS,2020-05-30 00:14:23.683,211,1,Last Tumor Assessment,Completion or Discontinuation,
1377,AB12345,AB12345-JPN-14-id-194,id-194,JPN-14,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-14,Dr. JPN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,3.44685758761002,LOW,Y,Y,Y,N,N,2019-10-31,2019-11-01 00:14:23.683,,2019-11-01 00:14:23.683,,,,2019-11-01 00:14:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,88.9885704533663,DAYS,2020-06-29 00:14:23.683,241,1,Last Tumor Assessment,Completion or Discontinuation,
1378,AB12345,AB12345-JPN-14-id-194,id-194,JPN-14,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-14,Dr. JPN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,3.44685758761002,LOW,Y,Y,Y,N,N,2019-10-31,2019-11-01 00:14:23.683,,2019-11-01 00:14:23.683,,,,2019-11-01 00:14:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,413.381721731275,DAYS,2021-10-18 00:14:23.683,717,1,Alive,Alive During Study,
1379,AB12345,AB12345-JPN-14-id-194,id-194,JPN-14,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-14,Dr. JPN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,3.44685758761002,LOW,Y,Y,Y,N,N,2019-10-31,2019-11-01 00:14:23.683,,2019-11-01 00:14:23.683,,,,2019-11-01 00:14:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,233.737303968519,DAYS,2021-07-29 00:14:23.683,636,1,Adverse Event,Preferred Term,
1380,AB12345,AB12345-JPN-14-id-194,id-194,JPN-14,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-14,Dr. JPN-14 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,3.44685758761002,LOW,Y,Y,Y,N,N,2019-10-31,2019-11-01 00:14:23.683,,2019-11-01 00:14:23.683,,,,2019-11-01 00:14:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Completion or Discontinuation,-3.74474257615674
1381,AB12345,AB12345-JPN-17-id-250,id-250,JPN-17,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,5.45957766731765,LOW,Y,Y,Y,N,N,2020-02-17,2020-02-17 09:49:22.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-17,732,DEATH,2022-03-02,MISSING,OTHER,13,<=30,2022-03-02,743,,3,3,Duration of Confirmed Response,CRSD,183.266066480428,DAYS,2020-12-26 09:49:22.683,313,0,Disease Progression,,
1382,AB12345,AB12345-JPN-17-id-250,id-250,JPN-17,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,5.45957766731765,LOW,Y,Y,Y,N,N,2020-02-17,2020-02-17 09:49:22.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-17,732,DEATH,2022-03-02,MISSING,OTHER,13,<=30,2022-03-02,743,,4,4,Event Free Survival,EFS,50.340023440076,DAYS,2021-01-10 09:49:22.683,328,1,Adverse Event,Preferred Term,
1383,AB12345,AB12345-JPN-17-id-250,id-250,JPN-17,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,5.45957766731765,LOW,Y,Y,Y,N,N,2020-02-17,2020-02-17 09:49:22.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-17,732,DEATH,2022-03-02,MISSING,OTHER,13,<=30,2022-03-02,743,,1,1,Overall Survival,OS,431.72980863601,DAYS,2020-08-24 09:49:22.683,189,1,Alive,Alive During Study,
1384,AB12345,AB12345-JPN-17-id-250,id-250,JPN-17,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,5.45957766731765,LOW,Y,Y,Y,N,N,2020-02-17,2020-02-17 09:49:22.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-17,732,DEATH,2022-03-02,MISSING,OTHER,13,<=30,2022-03-02,743,,2,2,Progression Free Survival,PFS,215.370758809149,DAYS,2020-09-22 09:49:22.683,218,1,Adverse Event,Preferred Term,
1385,AB12345,AB12345-JPN-17-id-250,id-250,JPN-17,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,A,S1,5.45957766731765,LOW,Y,Y,Y,N,N,2020-02-17,2020-02-17 09:49:22.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,2020-02-17 09:49:22.683,2021-02-17 14:00:41.683,2021-02-17 14:00:41.683,2022-02-17 20:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-17,732,DEATH,2022-03-02,MISSING,OTHER,13,<=30,2022-03-02,743,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-1.37516274198652
1386,AB12345,AB12345-JPN-17-id-393,id-393,JPN-17,26,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,5.65964828340265,MEDIUM,Y,Y,N,Y,N,2020-06-07,2020-06-08 23:44:46.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,DISCONTINUED,DISCONTINUED,2022-02-12,614,DEATH,2022-03-23,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-23,652,Yes,1,1,Duration of Confirmed Response,CRSD,132.045092852786,DAYS,2020-06-19 23:44:46.683,11,1,Last Tumor Assessment,Completion or Discontinuation,
1387,AB12345,AB12345-JPN-17-id-393,id-393,JPN-17,26,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,5.65964828340265,MEDIUM,Y,Y,N,Y,N,2020-06-07,2020-06-08 23:44:46.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,DISCONTINUED,DISCONTINUED,2022-02-12,614,DEATH,2022-03-23,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-23,652,Yes,4,4,Event Free Survival,EFS,15.0872796145268,DAYS,2021-10-08 23:44:46.683,487,1,Last Tumor Assessment,Completion or Discontinuation,
1388,AB12345,AB12345-JPN-17-id-393,id-393,JPN-17,26,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,5.65964828340265,MEDIUM,Y,Y,N,Y,N,2020-06-07,2020-06-08 23:44:46.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,DISCONTINUED,DISCONTINUED,2022-02-12,614,DEATH,2022-03-23,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-23,652,Yes,2,2,Overall Survival,OS,302.510501910001,DAYS,2020-06-25 23:44:46.683,17,1,Alive,Alive During Study,
1389,AB12345,AB12345-JPN-17-id-393,id-393,JPN-17,26,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,5.65964828340265,MEDIUM,Y,Y,N,Y,N,2020-06-07,2020-06-08 23:44:46.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,DISCONTINUED,DISCONTINUED,2022-02-12,614,DEATH,2022-03-23,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-23,652,Yes,3,3,Progression Free Survival,PFS,295.013288059272,DAYS,2020-06-29 23:44:46.683,21,0,Disease Progression,,
1390,AB12345,AB12345-JPN-17-id-393,id-393,JPN-17,26,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,Y,INV ID JPN-17,Dr. JPN-17 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Asia,C,S2,5.65964828340265,MEDIUM,Y,Y,N,Y,N,2020-06-07,2020-06-08 23:44:46.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,2020-06-08 23:44:46.683,2021-02-12 01:11:49.683,2021-02-12 01:11:49.683,2022-02-12 07:11:49.683,DISCONTINUED,DISCONTINUED,2022-02-12,614,DEATH,2022-03-23,ADVERSE EVENT,ADVERSE EVENT,39,>30,2022-03-23,652,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-3.0109901103888
1391,AB12345,AB12345-JPN-18-id-189,id-189,JPN-18,48,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-18,Dr. JPN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,8.84644011350322,HIGH,Y,Y,N,N,N,2020-09-07,2020-09-09 19:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-30,,,4,4,Duration of Confirmed Response,CRSD,121.328837051988,DAYS,2023-05-11 19:54:53.683,974,1,Last Tumor Assessment,Completion or Discontinuation,
1392,AB12345,AB12345-JPN-18-id-189,id-189,JPN-18,48,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-18,Dr. JPN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,8.84644011350322,HIGH,Y,Y,N,N,N,2020-09-07,2020-09-09 19:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-30,,,3,3,Event Free Survival,EFS,21.7227150627878,DAYS,2022-05-24 19:54:53.683,622,1,Last Tumor Assessment,Completion or Discontinuation,
1393,AB12345,AB12345-JPN-18-id-189,id-189,JPN-18,48,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-18,Dr. JPN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,8.84644011350322,HIGH,Y,Y,N,N,N,2020-09-07,2020-09-09 19:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-30,,,1,1,Overall Survival,OS,398.407917516306,DAYS,2021-04-13 19:54:53.683,216,1,Alive,Alive During Study,
1394,AB12345,AB12345-JPN-18-id-189,id-189,JPN-18,48,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-18,Dr. JPN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,8.84644011350322,HIGH,Y,Y,N,N,N,2020-09-07,2020-09-09 19:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-30,,,2,2,Progression Free Survival,PFS,299.484325898811,DAYS,2022-05-10 19:54:53.683,608,1,Last Tumor Assessment,Completion or Discontinuation,
1395,AB12345,AB12345-JPN-18-id-189,id-189,JPN-18,48,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-18,Dr. JPN-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,8.84644011350322,HIGH,Y,Y,N,N,N,2020-09-07,2020-09-09 19:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,2020-09-09 19:54:53.683,2022-09-10 07:54:53.683,2022-09-10 07:54:53.683,2023-09-10 13:54:53.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-30,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-2.0916099237501
1396,AB12345,AB12345-JPN-2-id-214,id-214,JPN-2,41,YEARS,F,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-2,Dr. JPN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,8.13204948132353,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-28 08:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-27,,,4,4,Duration of Confirmed Response,CRSD,100.596133503132,DAYS,2023-01-30 08:32:27.683,1038,0,Death,,
1397,AB12345,AB12345-JPN-2-id-214,id-214,JPN-2,41,YEARS,F,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-2,Dr. JPN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,8.13204948132353,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-28 08:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-27,,,3,3,Event Free Survival,EFS,68.3489000366535,DAYS,2022-08-13 08:32:27.683,868,1,Adverse Event,Preferred Term,
1398,AB12345,AB12345-JPN-2-id-214,id-214,JPN-2,41,YEARS,F,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-2,Dr. JPN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,8.13204948132353,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-28 08:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-27,,,2,2,Overall Survival,OS,100.596133503132,DAYS,2021-05-08 08:32:27.683,406,0,Death,,
1399,AB12345,AB12345-JPN-2-id-214,id-214,JPN-2,41,YEARS,F,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-2,Dr. JPN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,8.13204948132353,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-28 08:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-27,,,1,1,Progression Free Survival,PFS,100.596133503132,DAYS,2020-06-14 08:32:27.683,78,0,Death,,
1400,AB12345,AB12345-JPN-2-id-214,id-214,JPN-2,41,YEARS,F,ASIAN,NOT REPORTED,JPN,N,INV ID JPN-2,Dr. JPN-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,8.13204948132353,LOW,Y,Y,Y,Y,N,2020-03-26,2020-03-28 08:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,2020-03-28 08:32:27.683,2022-03-28 20:32:27.683,2022-03-28 20:32:27.683,2023-03-29 02:32:27.683,COMPLETED,COMPLETED,2023-03-29,1096,,,,,,,2023-04-27,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-3.5380136227625
1401,AB12345,AB12345-JPN-3-id-109,id-109,JPN-3,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-3,Dr. JPN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,9.2038738985764,HIGH,Y,Y,Y,N,N,2019-10-16,2019-10-17 05:30:19.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,DISCONTINUED,DISCONTINUED,2022-02-16,853,WITHDRAWAL BY SUBJECT,,,,,,2022-03-08,,,1,1,Duration of Confirmed Response,CRSD,198.648041719571,DAYS,2019-10-25 05:30:19.683,8,0,Disease Progression,,
1402,AB12345,AB12345-JPN-3-id-109,id-109,JPN-3,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-3,Dr. JPN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,9.2038738985764,HIGH,Y,Y,Y,N,N,2019-10-16,2019-10-17 05:30:19.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,DISCONTINUED,DISCONTINUED,2022-02-16,853,WITHDRAWAL BY SUBJECT,,,,,,2022-03-08,,,2,2,Event Free Survival,EFS,39.2975898925215,DAYS,2021-05-10 05:30:19.683,571,1,Adverse Event,Preferred Term,
1403,AB12345,AB12345-JPN-3-id-109,id-109,JPN-3,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-3,Dr. JPN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,9.2038738985764,HIGH,Y,Y,Y,N,N,2019-10-16,2019-10-17 05:30:19.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,DISCONTINUED,DISCONTINUED,2022-02-16,853,WITHDRAWAL BY SUBJECT,,,,,,2022-03-08,,,4,4,Overall Survival,OS,313.654998177662,DAYS,2022-02-03 05:30:19.683,840,1,Alive,Alive During Study,
1404,AB12345,AB12345-JPN-3-id-109,id-109,JPN-3,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-3,Dr. JPN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,9.2038738985764,HIGH,Y,Y,Y,N,N,2019-10-16,2019-10-17 05:30:19.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,DISCONTINUED,DISCONTINUED,2022-02-16,853,WITHDRAWAL BY SUBJECT,,,,,,2022-03-08,,,3,3,Progression Free Survival,PFS,275.769232492894,DAYS,2021-07-17 05:30:19.683,639,0,Disease Progression,,
1405,AB12345,AB12345-JPN-3-id-109,id-109,JPN-3,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-3,Dr. JPN-3 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,B,S2,9.2038738985764,HIGH,Y,Y,Y,N,N,2019-10-16,2019-10-17 05:30:19.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,2019-10-17 05:30:19.683,2021-02-15 19:43:40.683,2021-02-15 19:43:40.683,2022-02-16 01:43:40.683,DISCONTINUED,DISCONTINUED,2022-02-16,853,WITHDRAWAL BY SUBJECT,,,,,,2022-03-08,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.538178223340895
1406,AB12345,AB12345-JPN-5-id-252,id-252,JPN-5,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.5431902668676,LOW,Y,Y,Y,N,N,2020-10-16,2020-10-16 05:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,COMPLETED,COMPLETED,2023-10-16,1096,,,,,,,2023-10-26,,,1,1,Duration of Confirmed Response,CRSD,112.287140707485,DAYS,2021-03-17 05:04:34.683,152,0,Death,,
1407,AB12345,AB12345-JPN-5-id-252,id-252,JPN-5,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.5431902668676,LOW,Y,Y,Y,N,N,2020-10-16,2020-10-16 05:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,COMPLETED,COMPLETED,2023-10-16,1096,,,,,,,2023-10-26,,,2,2,Event Free Survival,EFS,83.9149381837342,DAYS,2021-08-11 05:04:34.683,299,1,Adverse Event,Preferred Term,
1408,AB12345,AB12345-JPN-5-id-252,id-252,JPN-5,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.5431902668676,LOW,Y,Y,Y,N,N,2020-10-16,2020-10-16 05:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,COMPLETED,COMPLETED,2023-10-16,1096,,,,,,,2023-10-26,,,3,3,Overall Survival,OS,112.287140707485,DAYS,2021-09-16 05:04:34.683,335,0,Death,,
1409,AB12345,AB12345-JPN-5-id-252,id-252,JPN-5,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.5431902668676,LOW,Y,Y,Y,N,N,2020-10-16,2020-10-16 05:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,COMPLETED,COMPLETED,2023-10-16,1096,,,,,,,2023-10-26,,,4,4,Progression Free Survival,PFS,112.287140707485,DAYS,2023-09-20 05:04:34.683,1069,0,Death,,
1410,AB12345,AB12345-JPN-5-id-252,id-252,JPN-5,31,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,Asia,C,S1,3.5431902668676,LOW,Y,Y,Y,N,N,2020-10-16,2020-10-16 05:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,2020-10-16 05:04:34.683,2022-10-16 17:04:34.683,2022-10-16 17:04:34.683,2023-10-16 23:04:34.683,COMPLETED,COMPLETED,2023-10-16,1096,,,,,,,2023-10-26,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-1.99121061654014
1411,AB12345,AB12345-JPN-5-id-326,id-326,JPN-5,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,8.09448588982289,HIGH,Y,Y,Y,Y,N,2019-11-03,2019-11-03 13:10:25.683,,2019-11-03 13:10:25.683,,,,2019-11-03 13:10:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,192.754364525899,DAYS,2020-11-29 13:10:25.683,392,0,Disease Progression,,
1412,AB12345,AB12345-JPN-5-id-326,id-326,JPN-5,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,8.09448588982289,HIGH,Y,Y,Y,Y,N,2019-11-03,2019-11-03 13:10:25.683,,2019-11-03 13:10:25.683,,,,2019-11-03 13:10:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,49.8430606548209,DAYS,2020-12-22 13:10:25.683,415,1,Last Tumor Assessment,Completion or Discontinuation,
1413,AB12345,AB12345-JPN-5-id-326,id-326,JPN-5,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,8.09448588982289,HIGH,Y,Y,Y,Y,N,2019-11-03,2019-11-03 13:10:25.683,,2019-11-03 13:10:25.683,,,,2019-11-03 13:10:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,302.853322867304,DAYS,2020-09-28 13:10:25.683,330,1,Alive,Alive During Study,
1414,AB12345,AB12345-JPN-5-id-326,id-326,JPN-5,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,8.09448588982289,HIGH,Y,Y,Y,Y,N,2019-11-03,2019-11-03 13:10:25.683,,2019-11-03 13:10:25.683,,,,2019-11-03 13:10:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,255.420823930763,DAYS,2021-10-04 13:10:25.683,701,1,Last Tumor Assessment,Completion or Discontinuation,
1415,AB12345,AB12345-JPN-5-id-326,id-326,JPN-5,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-5,Dr. JPN-5 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,B,S2,8.09448588982289,HIGH,Y,Y,Y,Y,N,2019-11-03,2019-11-03 13:10:25.683,,2019-11-03 13:10:25.683,,,,2019-11-03 13:10:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-2.05938118838285
1416,AB12345,AB12345-JPN-6-id-260,id-260,JPN-6,29,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-6,Dr. JPN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S2,2.71335111030137,HIGH,Y,Y,Y,Y,N,2021-01-03,2021-01-06 23:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-17,,,1,1,Duration of Confirmed Response,CRSD,177.006553253159,DAYS,2021-03-17 23:20:36.683,70,0,Disease Progression,,
1417,AB12345,AB12345-JPN-6-id-260,id-260,JPN-6,29,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-6,Dr. JPN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S2,2.71335111030137,HIGH,Y,Y,Y,Y,N,2021-01-03,2021-01-06 23:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-17,,,3,3,Event Free Survival,EFS,97.2260489012115,DAYS,2022-02-25 23:20:36.683,415,0,Disease Progression,,
1418,AB12345,AB12345-JPN-6-id-260,id-260,JPN-6,29,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-6,Dr. JPN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S2,2.71335111030137,HIGH,Y,Y,Y,Y,N,2021-01-03,2021-01-06 23:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-17,,,2,2,Overall Survival,OS,207.995241321623,DAYS,2021-03-18 23:20:36.683,71,0,Death,,
1419,AB12345,AB12345-JPN-6-id-260,id-260,JPN-6,29,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-6,Dr. JPN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S2,2.71335111030137,HIGH,Y,Y,Y,Y,N,2021-01-03,2021-01-06 23:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-17,,,4,4,Progression Free Survival,PFS,207.995241321623,DAYS,2023-01-11 23:20:36.683,735,0,Death,,
1420,AB12345,AB12345-JPN-6-id-260,id-260,JPN-6,29,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,JPN,N,INV ID JPN-6,Dr. JPN-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S2,2.71335111030137,HIGH,Y,Y,Y,Y,N,2021-01-03,2021-01-06 23:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,2021-01-06 23:20:36.683,2023-01-07 11:20:36.683,2023-01-07 11:20:36.683,2024-01-07 17:20:36.683,COMPLETED,COMPLETED,2024-01-07,1096,,,,,,,2024-01-17,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-3.88601068158123
1421,AB12345,AB12345-NGA-1-id-172,id-172,NGA-1,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Africa,B,S2,2.61988342063317,MEDIUM,Y,Y,Y,N,N,2020-03-02,2020-03-06 08:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,COMPLETED,COMPLETED,2023-03-07,1096,,,,,,,2023-03-22,,,3,3,Duration of Confirmed Response,CRSD,148.042654525489,DAYS,2022-12-07 08:29:56.683,1006,0,Disease Progression,,
1422,AB12345,AB12345-NGA-1-id-172,id-172,NGA-1,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Africa,B,S2,2.61988342063317,MEDIUM,Y,Y,Y,N,N,2020-03-02,2020-03-06 08:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,COMPLETED,COMPLETED,2023-03-07,1096,,,,,,,2023-03-22,,,1,1,Event Free Survival,EFS,46.0606871102937,DAYS,2020-10-13 08:29:56.683,221,1,Last Tumor Assessment,Completion or Discontinuation,
1423,AB12345,AB12345-NGA-1-id-172,id-172,NGA-1,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Africa,B,S2,2.61988342063317,MEDIUM,Y,Y,Y,N,N,2020-03-02,2020-03-06 08:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,COMPLETED,COMPLETED,2023-03-07,1096,,,,,,,2023-03-22,,,2,2,Overall Survival,OS,457.289450149983,DAYS,2020-11-23 08:29:56.683,262,1,Alive,Alive During Study,
1424,AB12345,AB12345-NGA-1-id-172,id-172,NGA-1,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Africa,B,S2,2.61988342063317,MEDIUM,Y,Y,Y,N,N,2020-03-02,2020-03-06 08:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,COMPLETED,COMPLETED,2023-03-07,1096,,,,,,,2023-03-22,,,4,4,Progression Free Survival,PFS,267.576069198549,DAYS,2023-01-18 08:29:56.683,1048,1,Adverse Event,Preferred Term,
1425,AB12345,AB12345-NGA-1-id-172,id-172,NGA-1,37,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Africa,B,S2,2.61988342063317,MEDIUM,Y,Y,Y,N,N,2020-03-02,2020-03-06 08:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,2020-03-06 08:29:56.683,2022-03-06 20:29:56.683,2022-03-06 20:29:56.683,2023-03-07 02:29:56.683,COMPLETED,COMPLETED,2023-03-07,1096,,,,,,,2023-03-22,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-2.59798467096713
1426,AB12345,AB12345-NGA-1-id-198,id-198,NGA-1,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,8.96000147848601,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-26 17:34:20.683,,2019-12-26 17:34:20.683,,,,2019-12-26 17:34:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,107.867750362493,DAYS,2021-07-29 17:34:20.683,581,1,Last Tumor Assessment,Completion or Discontinuation,
1427,AB12345,AB12345-NGA-1-id-198,id-198,NGA-1,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,8.96000147848601,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-26 17:34:20.683,,2019-12-26 17:34:20.683,,,,2019-12-26 17:34:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,83.8549348711967,DAYS,2020-10-18 17:34:20.683,297,1,Last Tumor Assessment,Completion or Discontinuation,
1428,AB12345,AB12345-NGA-1-id-198,id-198,NGA-1,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,8.96000147848601,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-26 17:34:20.683,,2019-12-26 17:34:20.683,,,,2019-12-26 17:34:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,307.346558803692,DAYS,2021-11-22 17:34:20.683,697,1,Alive,Alive During Study,
1429,AB12345,AB12345-NGA-1-id-198,id-198,NGA-1,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,8.96000147848601,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-26 17:34:20.683,,2019-12-26 17:34:20.683,,,,2019-12-26 17:34:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,216.89144410193,DAYS,2021-09-28 17:34:20.683,642,0,Disease Progression,,
1430,AB12345,AB12345-NGA-1-id-198,id-198,NGA-1,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,8.96000147848601,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-26 17:34:20.683,,2019-12-26 17:34:20.683,,,,2019-12-26 17:34:20.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-1.6850222111317
1431,AB12345,AB12345-NGA-1-id-200,id-200,NGA-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Africa,B,S1,3.92477081330047,LOW,Y,Y,Y,N,N,2019-08-30,2019-09-01 00:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,COMPLETED,COMPLETED,2022-08-31,1096,,,,,,,2022-09-28,,,1,1,Duration of Confirmed Response,CRSD,35.4120962542947,DAYS,2020-04-26 00:38:52.683,238,0,Death,,
1432,AB12345,AB12345-NGA-1-id-200,id-200,NGA-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Africa,B,S1,3.92477081330047,LOW,Y,Y,Y,N,N,2019-08-30,2019-09-01 00:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,COMPLETED,COMPLETED,2022-08-31,1096,,,,,,,2022-09-28,,,4,4,Event Free Survival,EFS,35.4120962542947,DAYS,2021-07-18 00:38:52.683,686,0,Death,,
1433,AB12345,AB12345-NGA-1-id-200,id-200,NGA-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Africa,B,S1,3.92477081330047,LOW,Y,Y,Y,N,N,2019-08-30,2019-09-01 00:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,COMPLETED,COMPLETED,2022-08-31,1096,,,,,,,2022-09-28,,,2,2,Overall Survival,OS,35.4120962542947,DAYS,2020-05-20 00:38:52.683,262,0,Death,,
1434,AB12345,AB12345-NGA-1-id-200,id-200,NGA-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Africa,B,S1,3.92477081330047,LOW,Y,Y,Y,N,N,2019-08-30,2019-09-01 00:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,COMPLETED,COMPLETED,2022-08-31,1096,,,,,,,2022-09-28,,,3,3,Progression Free Survival,PFS,35.4120962542947,DAYS,2021-03-29 00:38:52.683,575,0,Death,,
1435,AB12345,AB12345-NGA-1-id-200,id-200,NGA-1,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Africa,B,S1,3.92477081330047,LOW,Y,Y,Y,N,N,2019-08-30,2019-09-01 00:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,2019-09-01 00:38:52.683,2021-08-31 12:38:52.683,2021-08-31 12:38:52.683,2022-08-31 18:38:52.683,COMPLETED,COMPLETED,2022-08-31,1096,,,,,,,2022-09-28,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.162170598589214
1436,AB12345,AB12345-NGA-1-id-325,id-325,NGA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Africa,C,S2,7.97282016980075,HIGH,Y,Y,N,N,N,2019-09-07,2019-09-08 13:23:00.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,892,DEATH,2022-04-01,DISEASE PROGRESSION,PROGRESSIVE DISEASE,45,>30,2022-04-01,935,Yes,1,1,Duration of Confirmed Response,CRSD,100.136347976513,DAYS,2019-09-28 13:23:00.683,20,0,Death,,
1437,AB12345,AB12345-NGA-1-id-325,id-325,NGA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Africa,C,S2,7.97282016980075,HIGH,Y,Y,N,N,N,2019-09-07,2019-09-08 13:23:00.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,892,DEATH,2022-04-01,DISEASE PROGRESSION,PROGRESSIVE DISEASE,45,>30,2022-04-01,935,Yes,3,3,Event Free Survival,EFS,92.5365904648788,DAYS,2021-12-24 13:23:00.683,838,0,Disease Progression,,
1438,AB12345,AB12345-NGA-1-id-325,id-325,NGA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Africa,C,S2,7.97282016980075,HIGH,Y,Y,N,N,N,2019-09-07,2019-09-08 13:23:00.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,892,DEATH,2022-04-01,DISEASE PROGRESSION,PROGRESSIVE DISEASE,45,>30,2022-04-01,935,Yes,4,4,Overall Survival,OS,100.136347976513,DAYS,2022-01-20 13:23:00.683,865,0,Death,,
1439,AB12345,AB12345-NGA-1-id-325,id-325,NGA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Africa,C,S2,7.97282016980075,HIGH,Y,Y,N,N,N,2019-09-07,2019-09-08 13:23:00.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,892,DEATH,2022-04-01,DISEASE PROGRESSION,PROGRESSIVE DISEASE,45,>30,2022-04-01,935,Yes,2,2,Progression Free Survival,PFS,100.136347976513,DAYS,2021-03-26 13:23:00.683,565,0,Death,,
1440,AB12345,AB12345-NGA-1-id-325,id-325,NGA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Africa,C,S2,7.97282016980075,HIGH,Y,Y,N,N,N,2019-09-07,2019-09-08 13:23:00.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,2019-09-08 13:23:00.683,2021-02-15 12:16:55.683,2021-02-15 12:16:55.683,2022-02-15 18:16:55.683,DISCONTINUED,DISCONTINUED,2022-02-15,892,DEATH,2022-04-01,DISEASE PROGRESSION,PROGRESSIVE DISEASE,45,>30,2022-04-01,935,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-2.06203046220121
1441,AB12345,AB12345-NGA-1-id-327,id-327,NGA-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Africa,C,S2,6.09908166843484,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-01 08:23:21.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,DISCONTINUED,DISCONTINUED,2022-02-18,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-16,,,3,3,Duration of Confirmed Response,CRSD,116.826293175109,DAYS,2020-06-24 08:23:21.683,175,0,Death,,
1442,AB12345,AB12345-NGA-1-id-327,id-327,NGA-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Africa,C,S2,6.09908166843484,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-01 08:23:21.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,DISCONTINUED,DISCONTINUED,2022-02-18,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-16,,,1,1,Event Free Survival,EFS,34.3205380893778,DAYS,2020-03-24 08:23:21.683,83,0,Disease Progression,,
1443,AB12345,AB12345-NGA-1-id-327,id-327,NGA-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Africa,C,S2,6.09908166843484,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-01 08:23:21.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,DISCONTINUED,DISCONTINUED,2022-02-18,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-16,,,4,4,Overall Survival,OS,116.826293175109,DAYS,2020-10-01 08:23:21.683,274,0,Death,,
1444,AB12345,AB12345-NGA-1-id-327,id-327,NGA-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Africa,C,S2,6.09908166843484,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-01 08:23:21.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,DISCONTINUED,DISCONTINUED,2022-02-18,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-16,,,2,2,Progression Free Survival,PFS,116.826293175109,DAYS,2020-04-23 08:23:21.683,113,0,Death,,
1445,AB12345,AB12345-NGA-1-id-327,id-327,NGA-1,36,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Africa,C,S2,6.09908166843484,LOW,Y,Y,Y,N,N,2020-01-01,2020-01-01 08:23:21.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,2020-01-01 08:23:21.683,2021-02-18 10:58:58.683,2021-02-18 10:58:58.683,2022-02-18 16:58:58.683,DISCONTINUED,DISCONTINUED,2022-02-18,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-16,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-5.9380888344481
1446,AB12345,AB12345-NGA-1-id-357,id-357,NGA-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S2,3.82877200478878,MEDIUM,Y,Y,N,N,N,2020-01-17,2020-01-21 03:04:29.683,,2020-01-21 03:04:29.683,,,,2020-01-21 03:04:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,164.809716120362,DAYS,2020-03-23 03:04:29.683,62,0,Death,,
1447,AB12345,AB12345-NGA-1-id-357,id-357,NGA-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S2,3.82877200478878,MEDIUM,Y,Y,N,N,N,2020-01-17,2020-01-21 03:04:29.683,,2020-01-21 03:04:29.683,,,,2020-01-21 03:04:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,27.729813773185,DAYS,2020-09-20 03:04:29.683,243,0,Disease Progression,,
1448,AB12345,AB12345-NGA-1-id-357,id-357,NGA-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S2,3.82877200478878,MEDIUM,Y,Y,N,N,N,2020-01-17,2020-01-21 03:04:29.683,,2020-01-21 03:04:29.683,,,,2020-01-21 03:04:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,164.809716120362,DAYS,2021-08-05 03:04:29.683,562,0,Death,,
1449,AB12345,AB12345-NGA-1-id-357,id-357,NGA-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S2,3.82877200478878,MEDIUM,Y,Y,N,N,N,2020-01-17,2020-01-21 03:04:29.683,,2020-01-21 03:04:29.683,,,,2020-01-21 03:04:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,164.809716120362,DAYS,2021-12-29 03:04:29.683,708,0,Death,,
1450,AB12345,AB12345-NGA-1-id-357,id-357,NGA-1,41,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT REPORTED,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S2,3.82877200478878,MEDIUM,Y,Y,N,N,N,2020-01-17,2020-01-21 03:04:29.683,,2020-01-21 03:04:29.683,,,,2020-01-21 03:04:29.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.96940844078881
1451,AB12345,AB12345-NGA-1-id-388,id-388,NGA-1,39,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.19788868158086,HIGH,Y,Y,Y,N,N,2019-05-17,2019-05-17 15:03:20.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,DISCONTINUED,DISCONTINUED,2022-02-15,1005,LACK OF EFFICACY,,,,,,2022-03-11,,,4,4,Duration of Confirmed Response,CRSD,56.2736666889396,DAYS,2021-12-23 15:03:20.683,951,0,Death,,
1452,AB12345,AB12345-NGA-1-id-388,id-388,NGA-1,39,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.19788868158086,HIGH,Y,Y,Y,N,N,2019-05-17,2019-05-17 15:03:20.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,DISCONTINUED,DISCONTINUED,2022-02-15,1005,LACK OF EFFICACY,,,,,,2022-03-11,,,1,1,Event Free Survival,EFS,56.2736666889396,DAYS,2019-06-16 15:03:20.683,30,0,Death,,
1453,AB12345,AB12345-NGA-1-id-388,id-388,NGA-1,39,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.19788868158086,HIGH,Y,Y,Y,N,N,2019-05-17,2019-05-17 15:03:20.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,DISCONTINUED,DISCONTINUED,2022-02-15,1005,LACK OF EFFICACY,,,,,,2022-03-11,,,3,3,Overall Survival,OS,56.2736666889396,DAYS,2020-12-29 15:03:20.683,592,0,Death,,
1454,AB12345,AB12345-NGA-1-id-388,id-388,NGA-1,39,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.19788868158086,HIGH,Y,Y,Y,N,N,2019-05-17,2019-05-17 15:03:20.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,DISCONTINUED,DISCONTINUED,2022-02-15,1005,LACK OF EFFICACY,,,,,,2022-03-11,,,2,2,Progression Free Survival,PFS,56.2736666889396,DAYS,2020-09-01 15:03:20.683,473,0,Death,,
1455,AB12345,AB12345-NGA-1-id-388,id-388,NGA-1,39,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.19788868158086,HIGH,Y,Y,Y,N,N,2019-05-17,2019-05-17 15:03:20.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,2019-05-17 15:03:20.683,2021-02-15 01:04:01.683,2021-02-15 01:04:01.683,2022-02-15 07:04:01.683,DISCONTINUED,DISCONTINUED,2022-02-15,1005,LACK OF EFFICACY,,,,,,2022-03-11,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.55350750603291
1456,AB12345,AB12345-NGA-1-id-43,id-43,NGA-1,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Africa,A,S1,5.08773598375667,HIGH,Y,Y,N,Y,N,2020-09-08,2020-09-10 03:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-22,,,2,2,Duration of Confirmed Response,CRSD,128.966945665888,DAYS,2021-09-22 03:20:32.683,377,1,Adverse Event,Preferred Term,
1457,AB12345,AB12345-NGA-1-id-43,id-43,NGA-1,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Africa,A,S1,5.08773598375667,HIGH,Y,Y,N,Y,N,2020-09-08,2020-09-10 03:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-22,,,4,4,Event Free Survival,EFS,73.9257671497762,DAYS,2023-08-27 03:20:32.683,1081,0,Disease Progression,,
1458,AB12345,AB12345-NGA-1-id-43,id-43,NGA-1,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Africa,A,S1,5.08773598375667,HIGH,Y,Y,N,Y,N,2020-09-08,2020-09-10 03:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-22,,,1,1,Overall Survival,OS,297.867165971547,DAYS,2020-11-01 03:20:32.683,52,0,Death,,
1459,AB12345,AB12345-NGA-1-id-43,id-43,NGA-1,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Africa,A,S1,5.08773598375667,HIGH,Y,Y,N,Y,N,2020-09-08,2020-09-10 03:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-22,,,3,3,Progression Free Survival,PFS,297.867165971547,DAYS,2022-09-04 03:20:32.683,724,0,Death,,
1460,AB12345,AB12345-NGA-1-id-43,id-43,NGA-1,37,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Africa,A,S1,5.08773598375667,HIGH,Y,Y,N,Y,N,2020-09-08,2020-09-10 03:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,2020-09-10 03:20:32.683,2022-09-10 15:20:32.683,2022-09-10 15:20:32.683,2023-09-10 21:20:32.683,COMPLETED,COMPLETED,2023-09-10,1096,,,,,,,2023-09-22,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-0.232986845900793
1461,AB12345,AB12345-NGA-1-id-46,id-46,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,A,S2,3.84648297282627,HIGH,Y,Y,N,Y,N,2020-03-29,2020-04-01 20:05:10.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,689,DEATH,2022-02-28,DISEASE PROGRESSION,PROGRESSIVE DISEASE,10,<=30,2022-02-28,697,Yes,3,3,Duration of Confirmed Response,CRSD,152.576452121139,DAYS,2022-01-02 20:05:10.683,641,0,Death,,
1462,AB12345,AB12345-NGA-1-id-46,id-46,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,A,S2,3.84648297282627,HIGH,Y,Y,N,Y,N,2020-03-29,2020-04-01 20:05:10.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,689,DEATH,2022-02-28,DISEASE PROGRESSION,PROGRESSIVE DISEASE,10,<=30,2022-02-28,697,Yes,2,2,Event Free Survival,EFS,39.4907380011864,DAYS,2021-11-28 20:05:10.683,606,1,Adverse Event,Preferred Term,
1463,AB12345,AB12345-NGA-1-id-46,id-46,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,A,S2,3.84648297282627,HIGH,Y,Y,N,Y,N,2020-03-29,2020-04-01 20:05:10.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,689,DEATH,2022-02-28,DISEASE PROGRESSION,PROGRESSIVE DISEASE,10,<=30,2022-02-28,697,Yes,1,1,Overall Survival,OS,152.576452121139,DAYS,2021-09-02 20:05:10.683,519,0,Death,,
1464,AB12345,AB12345-NGA-1-id-46,id-46,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,A,S2,3.84648297282627,HIGH,Y,Y,N,Y,N,2020-03-29,2020-04-01 20:05:10.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,689,DEATH,2022-02-28,DISEASE PROGRESSION,PROGRESSIVE DISEASE,10,<=30,2022-02-28,697,Yes,4,4,Progression Free Survival,PFS,152.576452121139,DAYS,2022-01-17 20:05:10.683,656,0,Death,,
1465,AB12345,AB12345-NGA-1-id-46,id-46,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-1,Dr. NGA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,A,S2,3.84648297282627,HIGH,Y,Y,N,Y,N,2020-03-29,2020-04-01 20:05:10.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,2020-04-01 20:05:10.683,2021-02-18 15:52:40.683,2021-02-18 15:52:40.683,2022-02-18 21:52:40.683,DISCONTINUED,DISCONTINUED,2022-02-18,689,DEATH,2022-02-28,DISEASE PROGRESSION,PROGRESSIVE DISEASE,10,<=30,2022-02-28,697,Yes,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.141079222162897
1466,AB12345,AB12345-NGA-1-id-96,id-96,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,C,S2,12.9234760447228,MEDIUM,Y,Y,N,Y,N,2019-07-17,2019-07-21 22:20:59.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,DISCONTINUED,DISCONTINUED,2022-02-16,941,LACK OF EFFICACY,,,,,,2022-02-28,,,1,1,Duration of Confirmed Response,CRSD,167.855383525603,DAYS,2020-10-18 22:20:59.683,455,0,Death,,
1467,AB12345,AB12345-NGA-1-id-96,id-96,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,C,S2,12.9234760447228,MEDIUM,Y,Y,N,Y,N,2019-07-17,2019-07-21 22:20:59.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,DISCONTINUED,DISCONTINUED,2022-02-16,941,LACK OF EFFICACY,,,,,,2022-02-28,,,3,3,Event Free Survival,EFS,21.614892919315,DAYS,2021-09-07 22:20:59.683,779,1,Last Tumor Assessment,Completion or Discontinuation,
1468,AB12345,AB12345-NGA-1-id-96,id-96,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,C,S2,12.9234760447228,MEDIUM,Y,Y,N,Y,N,2019-07-17,2019-07-21 22:20:59.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,DISCONTINUED,DISCONTINUED,2022-02-16,941,LACK OF EFFICACY,,,,,,2022-02-28,,,4,4,Overall Survival,OS,167.855383525603,DAYS,2021-10-31 22:20:59.683,833,0,Death,,
1469,AB12345,AB12345-NGA-1-id-96,id-96,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,C,S2,12.9234760447228,MEDIUM,Y,Y,N,Y,N,2019-07-17,2019-07-21 22:20:59.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,DISCONTINUED,DISCONTINUED,2022-02-16,941,LACK OF EFFICACY,,,,,,2022-02-28,,,2,2,Progression Free Survival,PFS,167.855383525603,DAYS,2021-06-02 22:20:59.683,682,0,Death,,
1470,AB12345,AB12345-NGA-1-id-96,id-96,NGA-1,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-1,Dr. NGA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,C,S2,12.9234760447228,MEDIUM,Y,Y,N,Y,N,2019-07-17,2019-07-21 22:20:59.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,2019-07-21 22:20:59.683,2021-02-16 01:42:06.683,2021-02-16 01:42:06.683,2022-02-16 07:42:06.683,DISCONTINUED,DISCONTINUED,2022-02-16,941,LACK OF EFFICACY,,,,,,2022-02-28,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.220412794316981
1471,AB12345,AB12345-NGA-11-id-173,id-173,NGA-11,24,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.99722573047567,LOW,Y,Y,Y,Y,Y,2019-03-08,2019-03-10 09:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,COMPLETED,COMPLETED,2022-03-10,1096,,,,,,,2022-03-30,,,4,4,Duration of Confirmed Response,CRSD,152.980445511639,DAYS,2021-11-23 09:35:30.683,989,1,Last Tumor Assessment,Completion or Discontinuation,
1472,AB12345,AB12345-NGA-11-id-173,id-173,NGA-11,24,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.99722573047567,LOW,Y,Y,Y,Y,Y,2019-03-08,2019-03-10 09:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,COMPLETED,COMPLETED,2022-03-10,1096,,,,,,,2022-03-30,,,2,2,Event Free Survival,EFS,30.4657259047963,DAYS,2019-05-17 09:35:30.683,68,0,Disease Progression,,
1473,AB12345,AB12345-NGA-11-id-173,id-173,NGA-11,24,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.99722573047567,LOW,Y,Y,Y,Y,Y,2019-03-08,2019-03-10 09:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,COMPLETED,COMPLETED,2022-03-10,1096,,,,,,,2022-03-30,,,3,3,Overall Survival,OS,362.637439183891,DAYS,2020-02-25 09:35:30.683,352,1,Alive,Alive During Study,
1474,AB12345,AB12345-NGA-11-id-173,id-173,NGA-11,24,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.99722573047567,LOW,Y,Y,Y,Y,Y,2019-03-08,2019-03-10 09:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,COMPLETED,COMPLETED,2022-03-10,1096,,,,,,,2022-03-30,,,1,1,Progression Free Survival,PFS,280.167882889509,DAYS,2019-04-09 09:35:30.683,30,1,Adverse Event,Preferred Term,
1475,AB12345,AB12345-NGA-11-id-173,id-173,NGA-11,24,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.99722573047567,LOW,Y,Y,Y,Y,Y,2019-03-08,2019-03-10 09:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,2019-03-10 09:35:30.683,2021-03-09 21:35:30.683,2021-03-09 21:35:30.683,2022-03-10 03:35:30.683,COMPLETED,COMPLETED,2022-03-10,1096,,,,,,,2022-03-30,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-0.947324028597651
1476,AB12345,AB12345-NGA-11-id-313,id-313,NGA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Africa,B,S2,2.91107616235718,MEDIUM,Y,Y,N,N,N,2019-05-09,2019-05-12 18:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,COMPLETED,COMPLETED,2022-05-12,1096,,,,,,,2022-05-24,,,1,1,Duration of Confirmed Response,CRSD,177.304452261887,DAYS,2019-09-09 18:44:09.683,120,0,Disease Progression,,
1477,AB12345,AB12345-NGA-11-id-313,id-313,NGA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Africa,B,S2,2.91107616235718,MEDIUM,Y,Y,N,N,N,2019-05-09,2019-05-12 18:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,COMPLETED,COMPLETED,2022-05-12,1096,,,,,,,2022-05-24,,,2,2,Event Free Survival,EFS,73.7582399975508,DAYS,2019-09-29 18:44:09.683,140,1,Adverse Event,Preferred Term,
1478,AB12345,AB12345-NGA-11-id-313,id-313,NGA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Africa,B,S2,2.91107616235718,MEDIUM,Y,Y,N,N,N,2019-05-09,2019-05-12 18:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,COMPLETED,COMPLETED,2022-05-12,1096,,,,,,,2022-05-24,,,4,4,Overall Survival,OS,435.752030601725,DAYS,2021-11-09 18:44:09.683,912,1,Alive,Alive During Study,
1479,AB12345,AB12345-NGA-11-id-313,id-313,NGA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Africa,B,S2,2.91107616235718,MEDIUM,Y,Y,N,N,N,2019-05-09,2019-05-12 18:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,COMPLETED,COMPLETED,2022-05-12,1096,,,,,,,2022-05-24,,,3,3,Progression Free Survival,PFS,226.179363252595,DAYS,2020-11-24 18:44:09.683,562,1,Adverse Event,Preferred Term,
1480,AB12345,AB12345-NGA-11-id-313,id-313,NGA-11,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Africa,B,S2,2.91107616235718,MEDIUM,Y,Y,N,N,N,2019-05-09,2019-05-12 18:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,2019-05-12 18:44:09.683,2021-05-12 06:44:09.683,2021-05-12 06:44:09.683,2022-05-12 12:44:09.683,COMPLETED,COMPLETED,2022-05-12,1096,,,,,,,2022-05-24,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-4.11081978093996
1481,AB12345,AB12345-NGA-11-id-334,id-334,NGA-11,20,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,A,S1,2.90931699435785,LOW,Y,Y,N,N,N,2021-01-16,2021-01-16 09:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,COMPLETED,COMPLETED,2024-01-17,1096,,,,,,,2024-02-04,,,3,3,Duration of Confirmed Response,CRSD,155.148751987144,DAYS,2023-04-24 09:01:10.683,828,1,Adverse Event,Preferred Term,
1482,AB12345,AB12345-NGA-11-id-334,id-334,NGA-11,20,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,A,S1,2.90931699435785,LOW,Y,Y,N,N,N,2021-01-16,2021-01-16 09:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,COMPLETED,COMPLETED,2024-01-17,1096,,,,,,,2024-02-04,,,2,2,Event Free Survival,EFS,99.3321801547427,DAYS,2022-05-19 09:01:10.683,488,1,Last Tumor Assessment,Completion or Discontinuation,
1483,AB12345,AB12345-NGA-11-id-334,id-334,NGA-11,20,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,A,S1,2.90931699435785,LOW,Y,Y,N,N,N,2021-01-16,2021-01-16 09:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,COMPLETED,COMPLETED,2024-01-17,1096,,,,,,,2024-02-04,,,1,1,Overall Survival,OS,341.480868961662,DAYS,2021-12-19 09:01:10.683,337,1,Alive,Alive During Study,
1484,AB12345,AB12345-NGA-11-id-334,id-334,NGA-11,20,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,A,S1,2.90931699435785,LOW,Y,Y,N,N,N,2021-01-16,2021-01-16 09:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,COMPLETED,COMPLETED,2024-01-17,1096,,,,,,,2024-02-04,,,4,4,Progression Free Survival,PFS,293.068447359838,DAYS,2023-09-29 09:01:10.683,986,1,Last Tumor Assessment,Completion or Discontinuation,
1485,AB12345,AB12345-NGA-11-id-334,id-334,NGA-11,20,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,A,S1,2.90931699435785,LOW,Y,Y,N,N,N,2021-01-16,2021-01-16 09:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,2021-01-16 09:01:10.683,2023-01-16 21:01:10.683,2023-01-16 21:01:10.683,2024-01-17 03:01:10.683,COMPLETED,COMPLETED,2024-01-17,1096,,,,,,,2024-02-04,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-3.61838656267968
1486,AB12345,AB12345-NGA-11-id-35,id-35,NGA-11,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,B,S2,9.0284053711661,MEDIUM,Y,Y,Y,Y,N,2019-08-24,2019-08-26 05:10:30.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,DISCONTINUED,DISCONTINUED,2022-02-13,903,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-07,923,Yes,4,4,Duration of Confirmed Response,CRSD,148.398658935912,DAYS,2022-02-12 05:10:30.683,901,0,Death,,
1487,AB12345,AB12345-NGA-11-id-35,id-35,NGA-11,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,B,S2,9.0284053711661,MEDIUM,Y,Y,Y,Y,N,2019-08-24,2019-08-26 05:10:30.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,DISCONTINUED,DISCONTINUED,2022-02-13,903,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-07,923,Yes,3,3,Event Free Survival,EFS,34.5465183560736,DAYS,2021-01-09 05:10:30.683,502,0,Disease Progression,,
1488,AB12345,AB12345-NGA-11-id-35,id-35,NGA-11,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,B,S2,9.0284053711661,MEDIUM,Y,Y,Y,Y,N,2019-08-24,2019-08-26 05:10:30.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,DISCONTINUED,DISCONTINUED,2022-02-13,903,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-07,923,Yes,1,1,Overall Survival,OS,148.398658935912,DAYS,2019-08-30 05:10:30.683,4,0,Death,,
1489,AB12345,AB12345-NGA-11-id-35,id-35,NGA-11,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,B,S2,9.0284053711661,MEDIUM,Y,Y,Y,Y,N,2019-08-24,2019-08-26 05:10:30.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,DISCONTINUED,DISCONTINUED,2022-02-13,903,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-07,923,Yes,2,2,Progression Free Survival,PFS,148.398658935912,DAYS,2020-02-24 05:10:30.683,182,0,Death,,
1490,AB12345,AB12345-NGA-11-id-35,id-35,NGA-11,32,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-11,Dr. NGA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,B,S2,9.0284053711661,MEDIUM,Y,Y,Y,Y,N,2019-08-24,2019-08-26 05:10:30.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,2019-08-26 05:10:30.683,2021-02-13 13:35:42.683,2021-02-13 13:35:42.683,2022-02-13 19:35:42.683,DISCONTINUED,DISCONTINUED,2022-02-13,903,DEATH,2022-03-07,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-07,923,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.87040955618466
1491,AB12345,AB12345-NGA-11-id-366,id-366,NGA-11,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Africa,A,S1,3.3162417351018,MEDIUM,Y,Y,Y,N,N,2020-10-04,2020-10-05 21:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,COMPLETED,COMPLETED,2023-10-06,1096,,,,,,,2023-10-30,,,3,3,Duration of Confirmed Response,CRSD,178.272135695443,DAYS,2022-04-02 21:21:07.683,544,0,Death,,
1492,AB12345,AB12345-NGA-11-id-366,id-366,NGA-11,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Africa,A,S1,3.3162417351018,MEDIUM,Y,Y,Y,N,N,2020-10-04,2020-10-05 21:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,COMPLETED,COMPLETED,2023-10-06,1096,,,,,,,2023-10-30,,,2,2,Event Free Survival,EFS,54.1900484752841,DAYS,2021-09-03 21:21:07.683,333,1,Adverse Event,Preferred Term,
1493,AB12345,AB12345-NGA-11-id-366,id-366,NGA-11,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Africa,A,S1,3.3162417351018,MEDIUM,Y,Y,Y,N,N,2020-10-04,2020-10-05 21:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,COMPLETED,COMPLETED,2023-10-06,1096,,,,,,,2023-10-30,,,4,4,Overall Survival,OS,178.272135695443,DAYS,2023-05-19 21:21:07.683,956,0,Death,,
1494,AB12345,AB12345-NGA-11-id-366,id-366,NGA-11,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Africa,A,S1,3.3162417351018,MEDIUM,Y,Y,Y,N,N,2020-10-04,2020-10-05 21:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,COMPLETED,COMPLETED,2023-10-06,1096,,,,,,,2023-10-30,,,1,1,Progression Free Survival,PFS,178.272135695443,DAYS,2020-11-05 21:21:07.683,31,0,Death,,
1495,AB12345,AB12345-NGA-11-id-366,id-366,NGA-11,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Africa,A,S1,3.3162417351018,MEDIUM,Y,Y,Y,N,N,2020-10-04,2020-10-05 21:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,2020-10-05 21:21:07.683,2022-10-06 09:21:07.683,2022-10-06 09:21:07.683,2023-10-06 15:21:07.683,COMPLETED,COMPLETED,2023-10-06,1096,,,,,,,2023-10-30,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.571996353969133
1496,AB12345,AB12345-NGA-11-id-41,id-41,NGA-11,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Africa,B,S2,7.20651120555002,LOW,Y,Y,Y,N,N,2020-07-28,2020-08-01 00:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-19,,,3,3,Duration of Confirmed Response,CRSD,15.0514476164244,DAYS,2023-05-17 00:52:12.683,1019,0,Death,,
1497,AB12345,AB12345-NGA-11-id-41,id-41,NGA-11,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Africa,B,S2,7.20651120555002,LOW,Y,Y,Y,N,N,2020-07-28,2020-08-01 00:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-19,,,4,4,Event Free Survival,EFS,15.0514476164244,DAYS,2023-05-20 00:52:12.683,1022,0,Death,,
1498,AB12345,AB12345-NGA-11-id-41,id-41,NGA-11,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Africa,B,S2,7.20651120555002,LOW,Y,Y,Y,N,N,2020-07-28,2020-08-01 00:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-19,,,2,2,Overall Survival,OS,15.0514476164244,DAYS,2023-02-01 00:52:12.683,914,0,Death,,
1499,AB12345,AB12345-NGA-11-id-41,id-41,NGA-11,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Africa,B,S2,7.20651120555002,LOW,Y,Y,Y,N,N,2020-07-28,2020-08-01 00:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-19,,,1,1,Progression Free Survival,PFS,15.0514476164244,DAYS,2020-09-20 00:52:12.683,50,0,Death,,
1500,AB12345,AB12345-NGA-11-id-41,id-41,NGA-11,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-11,Dr. NGA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Africa,B,S2,7.20651120555002,LOW,Y,Y,Y,N,N,2020-07-28,2020-08-01 00:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,2020-08-01 00:52:12.683,2022-08-01 12:52:12.683,2022-08-01 12:52:12.683,2023-08-01 18:52:12.683,COMPLETED,COMPLETED,2023-08-01,1096,,,,,,,2023-08-19,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.10972588772592
1501,AB12345,AB12345-NGA-12-id-264,id-264,NGA-12,24,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-12,Dr. NGA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Africa,C,S1,4.82763768491632,HIGH,Y,Y,N,N,N,2020-04-06,2020-04-09 06:10:35.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,DISCONTINUED,DISCONTINUED,2022-02-14,677,DEATH,2022-03-09,DISEASE PROGRESSION,PROGRESSIVE DISEASE,23,<=30,2022-03-09,698,Yes,1,1,Duration of Confirmed Response,CRSD,78.8029873056803,DAYS,2021-04-21 06:10:35.683,377,0,Death,,
1502,AB12345,AB12345-NGA-12-id-264,id-264,NGA-12,24,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-12,Dr. NGA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Africa,C,S1,4.82763768491632,HIGH,Y,Y,N,N,N,2020-04-06,2020-04-09 06:10:35.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,DISCONTINUED,DISCONTINUED,2022-02-14,677,DEATH,2022-03-09,DISEASE PROGRESSION,PROGRESSIVE DISEASE,23,<=30,2022-03-09,698,Yes,3,3,Event Free Survival,EFS,78.8029873056803,DAYS,2021-10-26 06:10:35.683,565,0,Death,,
1503,AB12345,AB12345-NGA-12-id-264,id-264,NGA-12,24,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-12,Dr. NGA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Africa,C,S1,4.82763768491632,HIGH,Y,Y,N,N,N,2020-04-06,2020-04-09 06:10:35.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,DISCONTINUED,DISCONTINUED,2022-02-14,677,DEATH,2022-03-09,DISEASE PROGRESSION,PROGRESSIVE DISEASE,23,<=30,2022-03-09,698,Yes,2,2,Overall Survival,OS,78.8029873056803,DAYS,2021-09-21 06:10:35.683,530,0,Death,,
1504,AB12345,AB12345-NGA-12-id-264,id-264,NGA-12,24,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-12,Dr. NGA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Africa,C,S1,4.82763768491632,HIGH,Y,Y,N,N,N,2020-04-06,2020-04-09 06:10:35.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,DISCONTINUED,DISCONTINUED,2022-02-14,677,DEATH,2022-03-09,DISEASE PROGRESSION,PROGRESSIVE DISEASE,23,<=30,2022-03-09,698,Yes,4,4,Progression Free Survival,PFS,78.8029873056803,DAYS,2021-11-25 06:10:35.683,595,0,Death,,
1505,AB12345,AB12345-NGA-12-id-264,id-264,NGA-12,24,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-12,Dr. NGA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Africa,C,S1,4.82763768491632,HIGH,Y,Y,N,N,N,2020-04-06,2020-04-09 06:10:35.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,2020-04-09 06:10:35.683,2021-02-14 06:41:56.683,2021-02-14 06:41:56.683,2022-02-14 12:41:56.683,DISCONTINUED,DISCONTINUED,2022-02-14,677,DEATH,2022-03-09,DISEASE PROGRESSION,PROGRESSIVE DISEASE,23,<=30,2022-03-09,698,Yes,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.45827293922276
1506,AB12345,AB12345-NGA-12-id-387,id-387,NGA-12,25,YEARS,F,ASIAN,UNKNOWN,NGA,N,INV ID NGA-12,Dr. NGA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,4.36860516152138,HIGH,Y,Y,Y,N,N,2020-01-05,2020-01-07 17:07:38.683,,2020-01-07 17:07:38.683,,,,2020-01-07 17:07:38.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,131.467123632319,DAYS,2021-06-09 17:07:38.683,519,1,Last Tumor Assessment,Completion or Discontinuation,
1507,AB12345,AB12345-NGA-12-id-387,id-387,NGA-12,25,YEARS,F,ASIAN,UNKNOWN,NGA,N,INV ID NGA-12,Dr. NGA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,4.36860516152138,HIGH,Y,Y,Y,N,N,2020-01-05,2020-01-07 17:07:38.683,,2020-01-07 17:07:38.683,,,,2020-01-07 17:07:38.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,85.6122571916785,DAYS,2021-10-28 17:07:38.683,660,1,Adverse Event,Preferred Term,
1508,AB12345,AB12345-NGA-12-id-387,id-387,NGA-12,25,YEARS,F,ASIAN,UNKNOWN,NGA,N,INV ID NGA-12,Dr. NGA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,4.36860516152138,HIGH,Y,Y,Y,N,N,2020-01-05,2020-01-07 17:07:38.683,,2020-01-07 17:07:38.683,,,,2020-01-07 17:07:38.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,350.342309847474,DAYS,2020-12-29 17:07:38.683,357,1,Alive,Alive During Study,
1509,AB12345,AB12345-NGA-12-id-387,id-387,NGA-12,25,YEARS,F,ASIAN,UNKNOWN,NGA,N,INV ID NGA-12,Dr. NGA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,4.36860516152138,HIGH,Y,Y,Y,N,N,2020-01-05,2020-01-07 17:07:38.683,,2020-01-07 17:07:38.683,,,,2020-01-07 17:07:38.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,271.203316003084,DAYS,2021-03-02 17:07:38.683,420,0,Disease Progression,,
1510,AB12345,AB12345-NGA-12-id-387,id-387,NGA-12,25,YEARS,F,ASIAN,UNKNOWN,NGA,N,INV ID NGA-12,Dr. NGA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Africa,C,S1,4.36860516152138,HIGH,Y,Y,Y,N,N,2020-01-05,2020-01-07 17:07:38.683,,2020-01-07 17:07:38.683,,,,2020-01-07 17:07:38.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-2.50335815387321
1511,AB12345,AB12345-NGA-17-id-230,id-230,NGA-17,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Africa,A,S2,17.6723385130354,HIGH,Y,Y,N,N,N,2020-05-05,2020-05-05 16:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,COMPLETED,COMPLETED,2023-05-06,1096,,,,,,,2023-05-25,,,1,1,Duration of Confirmed Response,CRSD,169.595484714955,DAYS,2020-11-29 16:01:31.683,208,0,Death,,
1512,AB12345,AB12345-NGA-17-id-230,id-230,NGA-17,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Africa,A,S2,17.6723385130354,HIGH,Y,Y,N,N,N,2020-05-05,2020-05-05 16:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,COMPLETED,COMPLETED,2023-05-06,1096,,,,,,,2023-05-25,,,2,2,Event Free Survival,EFS,41.2945373496041,DAYS,2020-12-14 16:01:31.683,223,1,Adverse Event,Preferred Term,
1513,AB12345,AB12345-NGA-17-id-230,id-230,NGA-17,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Africa,A,S2,17.6723385130354,HIGH,Y,Y,N,N,N,2020-05-05,2020-05-05 16:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,COMPLETED,COMPLETED,2023-05-06,1096,,,,,,,2023-05-25,,,4,4,Overall Survival,OS,169.595484714955,DAYS,2023-01-03 16:01:31.683,973,0,Death,,
1514,AB12345,AB12345-NGA-17-id-230,id-230,NGA-17,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Africa,A,S2,17.6723385130354,HIGH,Y,Y,N,N,N,2020-05-05,2020-05-05 16:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,COMPLETED,COMPLETED,2023-05-06,1096,,,,,,,2023-05-25,,,3,3,Progression Free Survival,PFS,169.595484714955,DAYS,2022-11-09 16:01:31.683,918,0,Death,,
1515,AB12345,AB12345-NGA-17-id-230,id-230,NGA-17,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Africa,A,S2,17.6723385130354,HIGH,Y,Y,N,N,N,2020-05-05,2020-05-05 16:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,2020-05-05 16:01:31.683,2022-05-06 04:01:31.683,2022-05-06 04:01:31.683,2023-05-06 10:01:31.683,COMPLETED,COMPLETED,2023-05-06,1096,,,,,,,2023-05-25,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.48363410267935
1516,AB12345,AB12345-NGA-17-id-72,id-72,NGA-17,50,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,C,S2,6.402541361626,LOW,Y,Y,Y,Y,N,2019-09-09,2019-09-11 13:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-10-10,,,2,2,Duration of Confirmed Response,CRSD,185.289021302015,DAYS,2020-10-12 13:31:34.683,397,0,Disease Progression,,
1517,AB12345,AB12345-NGA-17-id-72,id-72,NGA-17,50,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,C,S2,6.402541361626,LOW,Y,Y,Y,Y,N,2019-09-09,2019-09-11 13:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-10-10,,,4,4,Event Free Survival,EFS,50.9631299960893,DAYS,2021-05-25 13:31:34.683,622,0,Disease Progression,,
1518,AB12345,AB12345-NGA-17-id-72,id-72,NGA-17,50,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,C,S2,6.402541361626,LOW,Y,Y,Y,Y,N,2019-09-09,2019-09-11 13:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-10-10,,,3,3,Overall Survival,OS,409.635503264144,DAYS,2020-11-05 13:31:34.683,421,1,Alive,Alive During Study,
1519,AB12345,AB12345-NGA-17-id-72,id-72,NGA-17,50,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,C,S2,6.402541361626,LOW,Y,Y,Y,Y,N,2019-09-09,2019-09-11 13:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-10-10,,,1,1,Progression Free Survival,PFS,253.439991665073,DAYS,2020-05-21 13:31:34.683,253,0,Disease Progression,,
1520,AB12345,AB12345-NGA-17-id-72,id-72,NGA-17,50,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-17,Dr. NGA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Africa,C,S2,6.402541361626,LOW,Y,Y,Y,Y,N,2019-09-09,2019-09-11 13:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,2019-09-11 13:31:34.683,2021-09-11 01:31:34.683,2021-09-11 01:31:34.683,2022-09-11 07:31:34.683,COMPLETED,COMPLETED,2022-09-11,1096,,,,,,,2022-10-10,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.720018130682314
1521,AB12345,AB12345-NGA-2-id-308,id-308,NGA-2,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Africa,A,S2,4.82400485469849,MEDIUM,Y,Y,N,Y,N,2019-09-22,2019-09-25 10:44:03.683,,2019-09-25 10:44:03.683,,,,2019-09-25 10:44:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,137.70290799439,DAYS,2020-12-05 10:44:03.683,437,0,Death,,
1522,AB12345,AB12345-NGA-2-id-308,id-308,NGA-2,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Africa,A,S2,4.82400485469849,MEDIUM,Y,Y,N,Y,N,2019-09-22,2019-09-25 10:44:03.683,,2019-09-25 10:44:03.683,,,,2019-09-25 10:44:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,86.8712381727528,DAYS,2020-11-15 10:44:03.683,417,1,Last Tumor Assessment,Completion or Discontinuation,
1523,AB12345,AB12345-NGA-2-id-308,id-308,NGA-2,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Africa,A,S2,4.82400485469849,MEDIUM,Y,Y,N,Y,N,2019-09-22,2019-09-25 10:44:03.683,,2019-09-25 10:44:03.683,,,,2019-09-25 10:44:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,137.70290799439,DAYS,2020-09-27 10:44:03.683,368,0,Death,,
1524,AB12345,AB12345-NGA-2-id-308,id-308,NGA-2,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Africa,A,S2,4.82400485469849,MEDIUM,Y,Y,N,Y,N,2019-09-22,2019-09-25 10:44:03.683,,2019-09-25 10:44:03.683,,,,2019-09-25 10:44:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,137.70290799439,DAYS,2021-04-26 10:44:03.683,579,0,Death,,
1525,AB12345,AB12345-NGA-2-id-308,id-308,NGA-2,26,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Africa,A,S2,4.82400485469849,MEDIUM,Y,Y,N,Y,N,2019-09-22,2019-09-25 10:44:03.683,,2019-09-25 10:44:03.683,,,,2019-09-25 10:44:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-3.60751784594257
1526,AB12345,AB12345-NGA-2-id-353,id-353,NGA-2,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Africa,B,S1,3.94481499255935,LOW,Y,Y,Y,N,N,2020-02-28,2020-03-02 21:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,1,1,Duration of Confirmed Response,CRSD,118.924802867696,DAYS,2020-03-28 21:26:47.683,26,1,Adverse Event,Preferred Term,
1527,AB12345,AB12345-NGA-2-id-353,id-353,NGA-2,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Africa,B,S1,3.94481499255935,LOW,Y,Y,Y,N,N,2020-02-28,2020-03-02 21:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,3,3,Event Free Survival,EFS,29.113712675171,DAYS,2021-10-15 21:26:47.683,592,1,Last Tumor Assessment,Completion or Discontinuation,
1528,AB12345,AB12345-NGA-2-id-353,id-353,NGA-2,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Africa,B,S1,3.94481499255935,LOW,Y,Y,Y,N,N,2020-02-28,2020-03-02 21:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,2,2,Overall Survival,OS,367.5006469246,DAYS,2021-03-04 21:26:47.683,367,1,Alive,Alive During Study,
1529,AB12345,AB12345-NGA-2-id-353,id-353,NGA-2,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Africa,B,S1,3.94481499255935,LOW,Y,Y,Y,N,N,2020-02-28,2020-03-02 21:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,4,4,Progression Free Survival,PFS,285.686781606637,DAYS,2022-07-01 21:26:47.683,851,0,Disease Progression,,
1530,AB12345,AB12345-NGA-2-id-353,id-353,NGA-2,28,YEARS,M,WHITE,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-2,Dr. NGA-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Africa,B,S1,3.94481499255935,LOW,Y,Y,Y,N,N,2020-02-28,2020-03-02 21:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,2020-03-02 21:26:47.683,2022-03-03 09:26:47.683,2022-03-03 09:26:47.683,2023-03-03 15:26:47.683,COMPLETED,COMPLETED,2023-03-03,1096,,,,,,,2023-04-01,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-4.58891966719024
1531,AB12345,AB12345-NGA-4-id-215,id-215,NGA-4,40,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-4,Dr. NGA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S1,10.4977304928482,MEDIUM,Y,Y,Y,Y,N,2020-05-15,2020-05-19 00:04:12.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,DISCONTINUED,DISCONTINUED,2022-02-18,641,DEATH,2022-02-26,ADVERSE EVENT,ADVERSE EVENT,8,<=30,2022-02-26,647,Yes,2,2,Duration of Confirmed Response,CRSD,106.907020206563,DAYS,2021-08-29 00:04:12.683,467,1,Last Tumor Assessment,Completion or Discontinuation,
1532,AB12345,AB12345-NGA-4-id-215,id-215,NGA-4,40,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-4,Dr. NGA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S1,10.4977304928482,MEDIUM,Y,Y,Y,Y,N,2020-05-15,2020-05-19 00:04:12.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,DISCONTINUED,DISCONTINUED,2022-02-18,641,DEATH,2022-02-26,ADVERSE EVENT,ADVERSE EVENT,8,<=30,2022-02-26,647,Yes,1,1,Event Free Survival,EFS,80.8773999789264,DAYS,2021-03-14 00:04:12.683,299,0,Disease Progression,,
1533,AB12345,AB12345-NGA-4-id-215,id-215,NGA-4,40,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-4,Dr. NGA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S1,10.4977304928482,MEDIUM,Y,Y,Y,Y,N,2020-05-15,2020-05-19 00:04:12.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,DISCONTINUED,DISCONTINUED,2022-02-18,641,DEATH,2022-02-26,ADVERSE EVENT,ADVERSE EVENT,8,<=30,2022-02-26,647,Yes,4,4,Overall Survival,OS,224.094926565886,DAYS,2021-12-10 00:04:12.683,570,0,Death,,
1534,AB12345,AB12345-NGA-4-id-215,id-215,NGA-4,40,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-4,Dr. NGA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S1,10.4977304928482,MEDIUM,Y,Y,Y,Y,N,2020-05-15,2020-05-19 00:04:12.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,DISCONTINUED,DISCONTINUED,2022-02-18,641,DEATH,2022-02-26,ADVERSE EVENT,ADVERSE EVENT,8,<=30,2022-02-26,647,Yes,3,3,Progression Free Survival,PFS,224.094926565886,DAYS,2021-09-07 00:04:12.683,476,0,Death,,
1535,AB12345,AB12345-NGA-4-id-215,id-215,NGA-4,40,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,NGA,Y,INV ID NGA-4,Dr. NGA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Africa,A,S1,10.4977304928482,MEDIUM,Y,Y,Y,Y,N,2020-05-15,2020-05-19 00:04:12.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,2020-05-19 00:04:12.683,2021-02-18 04:40:54.683,2021-02-18 04:40:54.683,2022-02-18 10:40:54.683,DISCONTINUED,DISCONTINUED,2022-02-18,641,DEATH,2022-02-26,ADVERSE EVENT,ADVERSE EVENT,8,<=30,2022-02-26,647,Yes,,,Total Number of Exacerbations,TNE,0,COUNT,,,1,,Completion or Discontinuation,-1.80441376956769
1536,AB12345,AB12345-NGA-4-id-37,id-37,NGA-4,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-4,Dr. NGA-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.57225381469043,LOW,Y,Y,Y,N,N,2020-08-14,2020-08-17 20:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-03,,,1,1,Duration of Confirmed Response,CRSD,138.711298909038,DAYS,2020-12-06 20:10:19.683,111,1,Adverse Event,Preferred Term,
1537,AB12345,AB12345-NGA-4-id-37,id-37,NGA-4,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-4,Dr. NGA-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.57225381469043,LOW,Y,Y,Y,N,N,2020-08-14,2020-08-17 20:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-03,,,4,4,Event Free Survival,EFS,35.6381562177557,DAYS,2021-07-12 20:10:19.683,329,0,Disease Progression,,
1538,AB12345,AB12345-NGA-4-id-37,id-37,NGA-4,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-4,Dr. NGA-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.57225381469043,LOW,Y,Y,Y,N,N,2020-08-14,2020-08-17 20:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-03,,,3,3,Overall Survival,OS,493.439409695566,DAYS,2021-05-26 20:10:19.683,282,1,Alive,Alive During Study,
1539,AB12345,AB12345-NGA-4-id-37,id-37,NGA-4,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-4,Dr. NGA-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.57225381469043,LOW,Y,Y,Y,N,N,2020-08-14,2020-08-17 20:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-03,,,2,2,Progression Free Survival,PFS,287.180502107367,DAYS,2021-03-13 20:10:19.683,208,0,Disease Progression,,
1540,AB12345,AB12345-NGA-4-id-37,id-37,NGA-4,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-4,Dr. NGA-4 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Africa,C,S1,4.57225381469043,LOW,Y,Y,Y,N,N,2020-08-14,2020-08-17 20:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,2020-08-17 20:10:19.683,2022-08-18 08:10:19.683,2022-08-18 08:10:19.683,2023-08-18 14:10:19.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-03,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-0.251225805743165
1541,AB12345,AB12345-NGA-5-id-99,id-99,NGA-5,31,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-5,Dr. NGA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,A,S2,5.48616279828362,LOW,Y,Y,Y,N,N,2020-11-30,2020-12-04 03:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,COMPLETED,COMPLETED,2023-12-04,1096,,,,,,,2024-01-02,,,1,1,Duration of Confirmed Response,CRSD,143.771530152299,DAYS,2020-12-11 03:19:40.683,7,0,Death,,
1542,AB12345,AB12345-NGA-5-id-99,id-99,NGA-5,31,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-5,Dr. NGA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,A,S2,5.48616279828362,LOW,Y,Y,Y,N,N,2020-11-30,2020-12-04 03:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,COMPLETED,COMPLETED,2023-12-04,1096,,,,,,,2024-01-02,,,2,2,Event Free Survival,EFS,88.6878830287606,DAYS,2021-09-28 03:19:40.683,298,1,Adverse Event,Preferred Term,
1543,AB12345,AB12345-NGA-5-id-99,id-99,NGA-5,31,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-5,Dr. NGA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,A,S2,5.48616279828362,LOW,Y,Y,Y,N,N,2020-11-30,2020-12-04 03:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,COMPLETED,COMPLETED,2023-12-04,1096,,,,,,,2024-01-02,,,3,3,Overall Survival,OS,143.771530152299,DAYS,2023-06-12 03:19:40.683,920,0,Death,,
1544,AB12345,AB12345-NGA-5-id-99,id-99,NGA-5,31,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-5,Dr. NGA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,A,S2,5.48616279828362,LOW,Y,Y,Y,N,N,2020-11-30,2020-12-04 03:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,COMPLETED,COMPLETED,2023-12-04,1096,,,,,,,2024-01-02,,,4,4,Progression Free Survival,PFS,143.771530152299,DAYS,2023-09-05 03:19:40.683,1005,0,Death,,
1545,AB12345,AB12345-NGA-5-id-99,id-99,NGA-5,31,YEARS,F,WHITE,HISPANIC OR LATINO,NGA,N,INV ID NGA-5,Dr. NGA-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Africa,A,S2,5.48616279828362,LOW,Y,Y,Y,N,N,2020-11-30,2020-12-04 03:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,2020-12-04 03:19:40.683,2022-12-04 15:19:40.683,2022-12-04 15:19:40.683,2023-12-04 21:19:40.683,COMPLETED,COMPLETED,2023-12-04,1096,,,,,,,2024-01-02,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-3.27653857475722
1546,AB12345,AB12345-NGA-6-id-363,id-363,NGA-6,50,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-6,Dr. NGA-6 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.17936675641175,HIGH,Y,Y,Y,Y,N,2020-04-07,2020-04-08 16:56:00.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,DISCONTINUED,DISCONTINUED,2022-02-18,681,PROTOCOL VIOLATION,,,,,,2022-03-16,,,3,3,Duration of Confirmed Response,CRSD,31.3147123297676,DAYS,2021-03-15 16:56:00.683,341,0,Death,,
1547,AB12345,AB12345-NGA-6-id-363,id-363,NGA-6,50,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-6,Dr. NGA-6 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.17936675641175,HIGH,Y,Y,Y,Y,N,2020-04-07,2020-04-08 16:56:00.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,DISCONTINUED,DISCONTINUED,2022-02-18,681,PROTOCOL VIOLATION,,,,,,2022-03-16,,,2,2,Event Free Survival,EFS,31.3147123297676,DAYS,2020-12-20 16:56:00.683,256,0,Death,,
1548,AB12345,AB12345-NGA-6-id-363,id-363,NGA-6,50,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-6,Dr. NGA-6 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.17936675641175,HIGH,Y,Y,Y,Y,N,2020-04-07,2020-04-08 16:56:00.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,DISCONTINUED,DISCONTINUED,2022-02-18,681,PROTOCOL VIOLATION,,,,,,2022-03-16,,,4,4,Overall Survival,OS,31.3147123297676,DAYS,2021-09-24 16:56:00.683,534,0,Death,,
1549,AB12345,AB12345-NGA-6-id-363,id-363,NGA-6,50,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-6,Dr. NGA-6 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.17936675641175,HIGH,Y,Y,Y,Y,N,2020-04-07,2020-04-08 16:56:00.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,DISCONTINUED,DISCONTINUED,2022-02-18,681,PROTOCOL VIOLATION,,,,,,2022-03-16,,,1,1,Progression Free Survival,PFS,31.3147123297676,DAYS,2020-11-20 16:56:00.683,226,0,Death,,
1550,AB12345,AB12345-NGA-6-id-363,id-363,NGA-6,50,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,NGA,N,INV ID NGA-6,Dr. NGA-6 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Africa,C,S2,4.17936675641175,HIGH,Y,Y,Y,Y,N,2020-04-07,2020-04-08 16:56:00.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,2020-04-08 16:56:00.683,2021-02-17 21:34:30.683,2021-02-17 21:34:30.683,2022-02-18 03:34:30.683,DISCONTINUED,DISCONTINUED,2022-02-18,681,PROTOCOL VIOLATION,,,,,,2022-03-16,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-0.39484011717694
1551,AB12345,AB12345-PAK-1-id-112,id-112,PAK-1,44,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S2,14.2374091968138,MEDIUM,Y,Y,N,N,N,2019-12-24,2019-12-26 06:22:25.683,,2019-12-26 06:22:25.683,,,,2019-12-26 06:22:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,158.345163753256,DAYS,2020-07-22 06:22:25.683,209,0,Disease Progression,,
1552,AB12345,AB12345-PAK-1-id-112,id-112,PAK-1,44,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S2,14.2374091968138,MEDIUM,Y,Y,N,N,N,2019-12-24,2019-12-26 06:22:25.683,,2019-12-26 06:22:25.683,,,,2019-12-26 06:22:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,21.9950243830681,DAYS,2021-07-18 06:22:25.683,570,1,Adverse Event,Preferred Term,
1553,AB12345,AB12345-PAK-1-id-112,id-112,PAK-1,44,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S2,14.2374091968138,MEDIUM,Y,Y,N,N,N,2019-12-24,2019-12-26 06:22:25.683,,2019-12-26 06:22:25.683,,,,2019-12-26 06:22:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,405.532531160861,DAYS,2021-02-24 06:22:25.683,426,1,Alive,Alive During Study,
1554,AB12345,AB12345-PAK-1-id-112,id-112,PAK-1,44,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S2,14.2374091968138,MEDIUM,Y,Y,N,N,N,2019-12-24,2019-12-26 06:22:25.683,,2019-12-26 06:22:25.683,,,,2019-12-26 06:22:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,207.036149548367,DAYS,2020-10-03 06:22:25.683,282,1,Last Tumor Assessment,Completion or Discontinuation,
1555,AB12345,AB12345-PAK-1-id-112,id-112,PAK-1,44,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,A,S2,14.2374091968138,MEDIUM,Y,Y,N,N,N,2019-12-24,2019-12-26 06:22:25.683,,2019-12-26 06:22:25.683,,,,2019-12-26 06:22:25.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.82479086924125
1556,AB12345,AB12345-PAK-1-id-125,id-125,PAK-1,49,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,6.63963208831141,LOW,Y,Y,Y,Y,N,2020-11-09,2020-11-11 10:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,COMPLETED,COMPLETED,2023-11-12,1096,,,,,,,2023-12-04,,,3,3,Duration of Confirmed Response,CRSD,104.819137067534,DAYS,2023-05-15 10:40:21.683,915,1,Adverse Event,Preferred Term,
1557,AB12345,AB12345-PAK-1-id-125,id-125,PAK-1,49,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,6.63963208831141,LOW,Y,Y,Y,Y,N,2020-11-09,2020-11-11 10:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,COMPLETED,COMPLETED,2023-11-12,1096,,,,,,,2023-12-04,,,4,4,Event Free Survival,EFS,55.1445042574778,DAYS,2023-11-05 10:40:21.683,1089,1,Last Tumor Assessment,Completion or Discontinuation,
1558,AB12345,AB12345-PAK-1-id-125,id-125,PAK-1,49,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,6.63963208831141,LOW,Y,Y,Y,Y,N,2020-11-09,2020-11-11 10:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,COMPLETED,COMPLETED,2023-11-12,1096,,,,,,,2023-12-04,,,1,1,Overall Survival,OS,458.25424301438,DAYS,2022-01-31 10:40:21.683,446,1,Alive,Alive During Study,
1559,AB12345,AB12345-PAK-1-id-125,id-125,PAK-1,49,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,6.63963208831141,LOW,Y,Y,Y,Y,N,2020-11-09,2020-11-11 10:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,COMPLETED,COMPLETED,2023-11-12,1096,,,,,,,2023-12-04,,,2,2,Progression Free Survival,PFS,259.454080765136,DAYS,2023-01-16 10:40:21.683,796,0,Disease Progression,,
1560,AB12345,AB12345-PAK-1-id-125,id-125,PAK-1,49,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,C,S1,6.63963208831141,LOW,Y,Y,Y,Y,N,2020-11-09,2020-11-11 10:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,2020-11-11 10:40:21.683,2022-11-11 22:40:21.683,2022-11-11 22:40:21.683,2023-11-12 04:40:21.683,COMPLETED,COMPLETED,2023-11-12,1096,,,,,,,2023-12-04,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,1,,Preferred Term,-1.28130486532871
1561,AB12345,AB12345-PAK-1-id-148,id-148,PAK-1,46,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,5.39562629989155,HIGH,Y,Y,N,N,N,2019-06-16,2019-06-17 13:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,COMPLETED,COMPLETED,2022-06-17,1096,,,,,,,2022-07-01,,,3,3,Duration of Confirmed Response,CRSD,102.79159292113,DAYS,2021-11-11 13:39:24.683,878,0,Disease Progression,,
1562,AB12345,AB12345-PAK-1-id-148,id-148,PAK-1,46,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,5.39562629989155,HIGH,Y,Y,N,N,N,2019-06-16,2019-06-17 13:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,COMPLETED,COMPLETED,2022-06-17,1096,,,,,,,2022-07-01,,,4,4,Event Free Survival,EFS,65.9038381127175,DAYS,2022-05-02 13:39:24.683,1050,1,Last Tumor Assessment,Completion or Discontinuation,
1563,AB12345,AB12345-PAK-1-id-148,id-148,PAK-1,46,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,5.39562629989155,HIGH,Y,Y,N,N,N,2019-06-16,2019-06-17 13:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,COMPLETED,COMPLETED,2022-06-17,1096,,,,,,,2022-07-01,,,2,2,Overall Survival,OS,321.248792903498,DAYS,2021-09-08 13:39:24.683,814,1,Alive,Alive During Study,
1564,AB12345,AB12345-PAK-1-id-148,id-148,PAK-1,46,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,5.39562629989155,HIGH,Y,Y,N,N,N,2019-06-16,2019-06-17 13:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,COMPLETED,COMPLETED,2022-06-17,1096,,,,,,,2022-07-01,,,1,1,Progression Free Survival,PFS,239.572663186118,DAYS,2021-07-28 13:39:24.683,772,0,Disease Progression,,
1565,AB12345,AB12345-PAK-1-id-148,id-148,PAK-1,46,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,A,S2,5.39562629989155,HIGH,Y,Y,N,N,N,2019-06-16,2019-06-17 13:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,2019-06-17 13:39:24.683,2021-06-17 01:39:24.683,2021-06-17 01:39:24.683,2022-06-17 07:39:24.683,COMPLETED,COMPLETED,2022-06-17,1096,,,,,,,2022-07-01,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.77002989455184
1566,AB12345,AB12345-PAK-1-id-169,id-169,PAK-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S1,12.8744427423884,HIGH,Y,Y,N,N,N,2019-11-12,2019-11-15 13:39:58.683,,2019-11-15 13:39:58.683,,,,2019-11-15 13:39:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,184.089776780456,DAYS,2019-12-25 13:39:58.683,40,1,Adverse Event,Preferred Term,
1567,AB12345,AB12345-PAK-1-id-169,id-169,PAK-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S1,12.8744427423884,HIGH,Y,Y,N,N,N,2019-11-12,2019-11-15 13:39:58.683,,2019-11-15 13:39:58.683,,,,2019-11-15 13:39:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,17.0494679815602,DAYS,2019-12-15 13:39:58.683,30,1,Last Tumor Assessment,Completion or Discontinuation,
1568,AB12345,AB12345-PAK-1-id-169,id-169,PAK-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S1,12.8744427423884,HIGH,Y,Y,N,N,N,2019-11-12,2019-11-15 13:39:58.683,,2019-11-15 13:39:58.683,,,,2019-11-15 13:39:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,358.85952943936,DAYS,2021-02-10 13:39:58.683,453,1,Alive,Alive During Study,
1569,AB12345,AB12345-PAK-1-id-169,id-169,PAK-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S1,12.8744427423884,HIGH,Y,Y,N,N,N,2019-11-12,2019-11-15 13:39:58.683,,2019-11-15 13:39:58.683,,,,2019-11-15 13:39:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,232.639992586337,DAYS,2021-08-30 13:39:58.683,654,0,Disease Progression,,
1570,AB12345,AB12345-PAK-1-id-169,id-169,PAK-1,29,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Asia,B,S1,12.8744427423884,HIGH,Y,Y,N,N,N,2019-11-12,2019-11-15 13:39:58.683,,2019-11-15 13:39:58.683,,,,2019-11-15 13:39:58.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-2.13617255586868
1571,AB12345,AB12345-PAK-1-id-17,id-17,PAK-1,33,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,9.27194708626264,MEDIUM,Y,Y,N,Y,N,2019-07-08,2019-07-12 01:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,COMPLETED,COMPLETED,2022-07-11,1096,,,,,,,2022-07-30,,,1,1,Duration of Confirmed Response,CRSD,141.434742463753,DAYS,2019-07-19 01:03:24.683,7,1,Adverse Event,Preferred Term,
1572,AB12345,AB12345-PAK-1-id-17,id-17,PAK-1,33,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,9.27194708626264,MEDIUM,Y,Y,N,Y,N,2019-07-08,2019-07-12 01:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,COMPLETED,COMPLETED,2022-07-11,1096,,,,,,,2022-07-30,,,4,4,Event Free Survival,EFS,84.9463282793295,DAYS,2021-09-02 01:03:24.683,783,0,Disease Progression,,
1573,AB12345,AB12345-PAK-1-id-17,id-17,PAK-1,33,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,9.27194708626264,MEDIUM,Y,Y,N,Y,N,2019-07-08,2019-07-12 01:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,COMPLETED,COMPLETED,2022-07-11,1096,,,,,,,2022-07-30,,,3,3,Overall Survival,OS,310.481677716598,DAYS,2020-09-11 01:03:24.683,427,1,Alive,Alive During Study,
1574,AB12345,AB12345-PAK-1-id-17,id-17,PAK-1,33,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,9.27194708626264,MEDIUM,Y,Y,N,Y,N,2019-07-08,2019-07-12 01:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,COMPLETED,COMPLETED,2022-07-11,1096,,,,,,,2022-07-30,,,2,2,Progression Free Survival,PFS,201.017122296616,DAYS,2019-12-24 01:03:24.683,165,1,Adverse Event,Preferred Term,
1575,AB12345,AB12345-PAK-1-id-17,id-17,PAK-1,33,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Asia,C,S1,9.27194708626264,MEDIUM,Y,Y,N,Y,N,2019-07-08,2019-07-12 01:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,2019-07-12 01:03:24.683,2021-07-11 13:03:24.683,2021-07-11 13:03:24.683,2022-07-11 19:03:24.683,COMPLETED,COMPLETED,2022-07-11,1096,,,,,,,2022-07-30,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,1,,Preferred Term,-1.25369480808595
1576,AB12345,AB12345-PAK-1-id-178,id-178,PAK-1,46,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,5.32131184681401,HIGH,Y,Y,N,Y,N,2019-06-06,2019-06-06 02:47:09.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-20,990,DEATH,2022-03-30,DISEASE PROGRESSION,PROGRESSIVE DISEASE,38,>30,2022-03-30,1027,Yes,1,1,Duration of Confirmed Response,CRSD,107.339494698681,DAYS,2020-03-19 02:47:09.683,287,1,Last Tumor Assessment,Completion or Discontinuation,
1577,AB12345,AB12345-PAK-1-id-178,id-178,PAK-1,46,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,5.32131184681401,HIGH,Y,Y,N,Y,N,2019-06-06,2019-06-06 02:47:09.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-20,990,DEATH,2022-03-30,DISEASE PROGRESSION,PROGRESSIVE DISEASE,38,>30,2022-03-30,1027,Yes,2,2,Event Free Survival,EFS,77.0814824174158,DAYS,2021-05-13 02:47:09.683,707,1,Last Tumor Assessment,Completion or Discontinuation,
1578,AB12345,AB12345-PAK-1-id-178,id-178,PAK-1,46,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,5.32131184681401,HIGH,Y,Y,N,Y,N,2019-06-06,2019-06-06 02:47:09.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-20,990,DEATH,2022-03-30,DISEASE PROGRESSION,PROGRESSIVE DISEASE,38,>30,2022-03-30,1027,Yes,3,3,Overall Survival,OS,427.434393437579,DAYS,2021-08-15 02:47:09.683,801,1,Alive,Alive During Study,
1579,AB12345,AB12345-PAK-1-id-178,id-178,PAK-1,46,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,5.32131184681401,HIGH,Y,Y,N,Y,N,2019-06-06,2019-06-06 02:47:09.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-20,990,DEATH,2022-03-30,DISEASE PROGRESSION,PROGRESSIVE DISEASE,38,>30,2022-03-30,1027,Yes,4,4,Progression Free Survival,PFS,207.035662652925,DAYS,2021-09-11 02:47:09.683,828,0,Disease Progression,,
1580,AB12345,AB12345-PAK-1-id-178,id-178,PAK-1,46,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,Asia,B,S1,5.32131184681401,HIGH,Y,Y,N,Y,N,2019-06-06,2019-06-06 02:47:09.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,2019-06-06 02:47:09.683,2021-02-19 20:00:41.683,2021-02-19 20:00:41.683,2022-02-20 02:00:41.683,DISCONTINUED,DISCONTINUED,2022-02-20,990,DEATH,2022-03-30,DISEASE PROGRESSION,PROGRESSIVE DISEASE,38,>30,2022-03-30,1027,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-0.97929583986536
1581,AB12345,AB12345-PAK-1-id-280,id-280,PAK-1,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S2,2.96261376922728,LOW,Y,Y,Y,Y,N,2019-05-26,2019-05-28 21:30:08.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,DISCONTINUED,DISCONTINUED,2022-02-14,993,ADVERSE EVENT,,,,,,2022-03-14,,,4,4,Duration of Confirmed Response,CRSD,143.071783077903,DAYS,2021-01-28 21:30:08.683,611,1,Last Tumor Assessment,Completion or Discontinuation,
1582,AB12345,AB12345-PAK-1-id-280,id-280,PAK-1,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S2,2.96261376922728,LOW,Y,Y,Y,Y,N,2019-05-26,2019-05-28 21:30:08.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,DISCONTINUED,DISCONTINUED,2022-02-14,993,ADVERSE EVENT,,,,,,2022-03-14,,,2,2,Event Free Survival,EFS,50.1309990312438,DAYS,2019-11-24 21:30:08.683,180,0,Disease Progression,,
1583,AB12345,AB12345-PAK-1-id-280,id-280,PAK-1,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S2,2.96261376922728,LOW,Y,Y,Y,Y,N,2019-05-26,2019-05-28 21:30:08.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,DISCONTINUED,DISCONTINUED,2022-02-14,993,ADVERSE EVENT,,,,,,2022-03-14,,,3,3,Overall Survival,OS,355.42333573103,DAYS,2020-02-25 21:30:08.683,273,1,Alive,Alive During Study,
1584,AB12345,AB12345-PAK-1-id-280,id-280,PAK-1,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S2,2.96261376922728,LOW,Y,Y,Y,Y,N,2019-05-26,2019-05-28 21:30:08.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,DISCONTINUED,DISCONTINUED,2022-02-14,993,ADVERSE EVENT,,,,,,2022-03-14,,,1,1,Progression Free Survival,PFS,208.024637051858,DAYS,2019-09-02 21:30:08.683,97,1,Adverse Event,Preferred Term,
1585,AB12345,AB12345-PAK-1-id-280,id-280,PAK-1,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,B,S2,2.96261376922728,LOW,Y,Y,Y,Y,N,2019-05-26,2019-05-28 21:30:08.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,2019-05-28 21:30:08.683,2021-02-14 12:11:59.683,2021-02-14 12:11:59.683,2022-02-14 18:11:59.683,DISCONTINUED,DISCONTINUED,2022-02-14,993,ADVERSE EVENT,,,,,,2022-03-14,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-0.113295886349995
1586,AB12345,AB12345-PAK-1-id-39,id-39,PAK-1,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT REPORTED,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,4.5618343436434,LOW,Y,Y,Y,Y,N,2020-08-01,2020-08-05 06:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-08-28,,,2,2,Duration of Confirmed Response,CRSD,109.10974657163,DAYS,2021-11-27 06:55:43.683,479,0,Death,,
1587,AB12345,AB12345-PAK-1-id-39,id-39,PAK-1,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT REPORTED,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,4.5618343436434,LOW,Y,Y,Y,Y,N,2020-08-01,2020-08-05 06:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-08-28,,,4,4,Event Free Survival,EFS,82.4960366089363,DAYS,2022-12-08 06:55:43.683,855,1,Adverse Event,Preferred Term,
1588,AB12345,AB12345-PAK-1-id-39,id-39,PAK-1,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT REPORTED,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,4.5618343436434,LOW,Y,Y,Y,Y,N,2020-08-01,2020-08-05 06:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-08-28,,,3,3,Overall Survival,OS,109.10974657163,DAYS,2022-04-25 06:55:43.683,628,0,Death,,
1589,AB12345,AB12345-PAK-1-id-39,id-39,PAK-1,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT REPORTED,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,4.5618343436434,LOW,Y,Y,Y,Y,N,2020-08-01,2020-08-05 06:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-08-28,,,1,1,Progression Free Survival,PFS,109.10974657163,DAYS,2021-04-05 06:55:43.683,243,0,Death,,
1590,AB12345,AB12345-PAK-1-id-39,id-39,PAK-1,36,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT REPORTED,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,4.5618343436434,LOW,Y,Y,Y,Y,N,2020-08-01,2020-08-05 06:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,2020-08-05 06:55:43.683,2022-08-05 18:55:43.683,2022-08-05 18:55:43.683,2023-08-06 00:55:43.683,COMPLETED,COMPLETED,2023-08-06,1096,,,,,,,2023-08-28,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.388544925965556
1591,AB12345,AB12345-PAK-1-id-79,id-79,PAK-1,37,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,4.72170491490622,LOW,Y,Y,N,N,N,2019-11-18,2019-11-22 03:05:33.683,,2019-11-22 03:05:33.683,,,,2019-11-22 03:05:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,113.625545823015,DAYS,2020-03-14 03:05:33.683,113,0,Disease Progression,,
1592,AB12345,AB12345-PAK-1-id-79,id-79,PAK-1,37,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,4.72170491490622,LOW,Y,Y,N,N,N,2019-11-18,2019-11-22 03:05:33.683,,2019-11-22 03:05:33.683,,,,2019-11-22 03:05:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,38.517985092476,DAYS,2021-06-13 03:05:33.683,569,1,Last Tumor Assessment,Completion or Discontinuation,
1593,AB12345,AB12345-PAK-1-id-79,id-79,PAK-1,37,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,4.72170491490622,LOW,Y,Y,N,N,N,2019-11-18,2019-11-22 03:05:33.683,,2019-11-22 03:05:33.683,,,,2019-11-22 03:05:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,495.826004492119,DAYS,2020-05-21 03:05:33.683,181,1,Alive,Alive During Study,
1594,AB12345,AB12345-PAK-1-id-79,id-79,PAK-1,37,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,4.72170491490622,LOW,Y,Y,N,N,N,2019-11-18,2019-11-22 03:05:33.683,,2019-11-22 03:05:33.683,,,,2019-11-22 03:05:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,266.34760950692,DAYS,2021-08-01 03:05:33.683,618,0,Disease Progression,,
1595,AB12345,AB12345-PAK-1-id-79,id-79,PAK-1,37,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-1,Dr. PAK-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,B,S1,4.72170491490622,LOW,Y,Y,N,N,N,2019-11-18,2019-11-22 03:05:33.683,,2019-11-22 03:05:33.683,,,,2019-11-22 03:05:33.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.805604285314275
1596,AB12345,AB12345-PAK-1-id-95,id-95,PAK-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,2.88672878790842,MEDIUM,Y,Y,N,N,N,2019-05-01,2019-05-01 02:20:10.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-18,1025,DEATH,2022-02-22,Post-study reporting of death,OTHER,4,<=30,2022-02-22,1027,No,2,2,Duration of Confirmed Response,CRSD,137.202698434703,DAYS,2019-08-18 02:20:10.683,109,1,Last Tumor Assessment,Completion or Discontinuation,
1597,AB12345,AB12345-PAK-1-id-95,id-95,PAK-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,2.88672878790842,MEDIUM,Y,Y,N,N,N,2019-05-01,2019-05-01 02:20:10.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-18,1025,DEATH,2022-02-22,Post-study reporting of death,OTHER,4,<=30,2022-02-22,1027,No,4,4,Event Free Survival,EFS,33.0039634206332,DAYS,2021-07-30 02:20:10.683,821,1,Adverse Event,Preferred Term,
1598,AB12345,AB12345-PAK-1-id-95,id-95,PAK-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,2.88672878790842,MEDIUM,Y,Y,N,N,N,2019-05-01,2019-05-01 02:20:10.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-18,1025,DEATH,2022-02-22,Post-study reporting of death,OTHER,4,<=30,2022-02-22,1027,No,1,1,Overall Survival,OS,456.107229460031,DAYS,2019-07-03 02:20:10.683,63,1,Alive,Alive During Study,
1599,AB12345,AB12345-PAK-1-id-95,id-95,PAK-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,2.88672878790842,MEDIUM,Y,Y,N,N,N,2019-05-01,2019-05-01 02:20:10.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-18,1025,DEATH,2022-02-22,Post-study reporting of death,OTHER,4,<=30,2022-02-22,1027,No,3,3,Progression Free Survival,PFS,211.836471664719,DAYS,2020-12-13 02:20:10.683,592,1,Adverse Event,Preferred Term,
1600,AB12345,AB12345-PAK-1-id-95,id-95,PAK-1,28,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-1,Dr. PAK-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,A,S1,2.88672878790842,MEDIUM,Y,Y,N,N,N,2019-05-01,2019-05-01 02:20:10.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,2019-05-01 02:20:10.683,2021-02-18 01:22:15.683,2021-02-18 01:22:15.683,2022-02-18 07:22:15.683,DISCONTINUED,DISCONTINUED,2022-02-18,1025,DEATH,2022-02-22,Post-study reporting of death,OTHER,4,<=30,2022-02-22,1027,No,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-3.36073796831603
1601,AB12345,AB12345-PAK-11-id-145,id-145,PAK-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S1,8.20278855748974,LOW,Y,Y,Y,Y,N,2020-01-17,2020-01-17 15:15:16.683,,2020-01-17 15:15:16.683,,,,2020-01-17 15:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,178.377509233542,DAYS,2020-08-22 15:15:16.683,218,1,Adverse Event,Preferred Term,
1602,AB12345,AB12345-PAK-11-id-145,id-145,PAK-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S1,8.20278855748974,LOW,Y,Y,Y,Y,N,2020-01-17,2020-01-17 15:15:16.683,,2020-01-17 15:15:16.683,,,,2020-01-17 15:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,20.5741481611039,DAYS,2020-03-23 15:15:16.683,66,1,Adverse Event,Preferred Term,
1603,AB12345,AB12345-PAK-11-id-145,id-145,PAK-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S1,8.20278855748974,LOW,Y,Y,Y,Y,N,2020-01-17,2020-01-17 15:15:16.683,,2020-01-17 15:15:16.683,,,,2020-01-17 15:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,455.468334490433,DAYS,2021-01-10 15:15:16.683,359,1,Alive,Alive During Study,
1604,AB12345,AB12345-PAK-11-id-145,id-145,PAK-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S1,8.20278855748974,LOW,Y,Y,Y,Y,N,2020-01-17,2020-01-17 15:15:16.683,,2020-01-17 15:15:16.683,,,,2020-01-17 15:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,212.385221198201,DAYS,2021-04-28 15:15:16.683,467,0,Disease Progression,,
1605,AB12345,AB12345-PAK-11-id-145,id-145,PAK-11,32,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,Asia,A,S1,8.20278855748974,LOW,Y,Y,Y,Y,N,2020-01-17,2020-01-17 15:15:16.683,,2020-01-17 15:15:16.683,,,,2020-01-17 15:15:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-4.92470882006031
1606,AB12345,AB12345-PAK-11-id-187,id-187,PAK-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S1,3.37729718582607,MEDIUM,Y,Y,Y,N,N,2019-12-21,2019-12-24 02:15:24.683,,2019-12-24 02:15:24.683,,,,2019-12-24 02:15:24.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,161.593001079746,DAYS,2020-02-04 02:15:24.683,42,0,Death,,
1607,AB12345,AB12345-PAK-11-id-187,id-187,PAK-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S1,3.37729718582607,MEDIUM,Y,Y,Y,N,N,2019-12-21,2019-12-24 02:15:24.683,,2019-12-24 02:15:24.683,,,,2019-12-24 02:15:24.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,45.7146711857058,DAYS,2021-02-01 02:15:24.683,405,0,Disease Progression,,
1608,AB12345,AB12345-PAK-11-id-187,id-187,PAK-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S1,3.37729718582607,MEDIUM,Y,Y,Y,N,N,2019-12-21,2019-12-24 02:15:24.683,,2019-12-24 02:15:24.683,,,,2019-12-24 02:15:24.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,161.593001079746,DAYS,2021-05-03 02:15:24.683,496,0,Death,,
1609,AB12345,AB12345-PAK-11-id-187,id-187,PAK-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S1,3.37729718582607,MEDIUM,Y,Y,Y,N,N,2019-12-21,2019-12-24 02:15:24.683,,2019-12-24 02:15:24.683,,,,2019-12-24 02:15:24.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,161.593001079746,DAYS,2020-08-30 02:15:24.683,250,0,Death,,
1610,AB12345,AB12345-PAK-11-id-187,id-187,PAK-11,32,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,C,S1,3.37729718582607,MEDIUM,Y,Y,Y,N,N,2019-12-21,2019-12-24 02:15:24.683,,2019-12-24 02:15:24.683,,,,2019-12-24 02:15:24.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,0,,,-2.87112661996625
1611,AB12345,AB12345-PAK-11-id-210,id-210,PAK-11,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,13.6415989082734,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:53:23.683,,2019-09-25 15:53:23.683,,,,2019-09-25 15:53:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,110.522009991109,DAYS,2020-03-27 15:53:23.683,184,1,Adverse Event,Preferred Term,
1612,AB12345,AB12345-PAK-11-id-210,id-210,PAK-11,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,13.6415989082734,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:53:23.683,,2019-09-25 15:53:23.683,,,,2019-09-25 15:53:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,92.9486319830175,DAYS,2020-08-07 15:53:23.683,317,1,Adverse Event,Preferred Term,
1613,AB12345,AB12345-PAK-11-id-210,id-210,PAK-11,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,13.6415989082734,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:53:23.683,,2019-09-25 15:53:23.683,,,,2019-09-25 15:53:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,331.273311097175,DAYS,2020-12-22 15:53:23.683,454,1,Alive,Alive During Study,
1614,AB12345,AB12345-PAK-11-id-210,id-210,PAK-11,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,13.6415989082734,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:53:23.683,,2019-09-25 15:53:23.683,,,,2019-09-25 15:53:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,271.554579399526,DAYS,2020-01-09 15:53:23.683,106,1,Last Tumor Assessment,Completion or Discontinuation,
1615,AB12345,AB12345-PAK-11-id-210,id-210,PAK-11,23,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,A,S2,13.6415989082734,HIGH,Y,Y,Y,N,N,2019-09-25,2019-09-25 15:53:23.683,,2019-09-25 15:53:23.683,,,,2019-09-25 15:53:23.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-1.83917481647952
1616,AB12345,AB12345-PAK-11-id-268,id-268,PAK-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,2.82014082273392,MEDIUM,Y,Y,N,N,N,2019-03-21,2019-03-21 23:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,COMPLETED,COMPLETED,2022-03-21,1096,,,,,,,2022-04-02,,,3,3,Duration of Confirmed Response,CRSD,37.2339363023639,DAYS,2020-11-20 23:53:53.683,610,0,Death,,
1617,AB12345,AB12345-PAK-11-id-268,id-268,PAK-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,2.82014082273392,MEDIUM,Y,Y,N,N,N,2019-03-21,2019-03-21 23:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,COMPLETED,COMPLETED,2022-03-21,1096,,,,,,,2022-04-02,,,4,4,Event Free Survival,EFS,37.2339363023639,DAYS,2020-12-15 23:53:53.683,635,0,Death,,
1618,AB12345,AB12345-PAK-11-id-268,id-268,PAK-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,2.82014082273392,MEDIUM,Y,Y,N,N,N,2019-03-21,2019-03-21 23:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,COMPLETED,COMPLETED,2022-03-21,1096,,,,,,,2022-04-02,,,2,2,Overall Survival,OS,37.2339363023639,DAYS,2020-04-12 23:53:53.683,388,0,Death,,
1619,AB12345,AB12345-PAK-11-id-268,id-268,PAK-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,2.82014082273392,MEDIUM,Y,Y,N,N,N,2019-03-21,2019-03-21 23:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,COMPLETED,COMPLETED,2022-03-21,1096,,,,,,,2022-04-02,,,1,1,Progression Free Survival,PFS,37.2339363023639,DAYS,2019-04-16 23:53:53.683,26,0,Death,,
1620,AB12345,AB12345-PAK-11-id-268,id-268,PAK-11,28,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Asia,C,S2,2.82014082273392,MEDIUM,Y,Y,N,N,N,2019-03-21,2019-03-21 23:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,2019-03-21 23:53:53.683,2021-03-21 11:53:53.683,2021-03-21 11:53:53.683,2022-03-21 17:53:53.683,COMPLETED,COMPLETED,2022-03-21,1096,,,,,,,2022-04-02,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-2.01956276204936
1621,AB12345,AB12345-PAK-11-id-330,id-330,PAK-11,32,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,6.69531244545059,HIGH,Y,Y,N,N,N,2020-01-13,2020-01-15 09:04:51.683,,2020-01-15 09:04:51.683,,,,2020-01-15 09:04:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,159.47590705473,DAYS,2020-02-02 09:04:51.683,18,0,Death,,
1622,AB12345,AB12345-PAK-11-id-330,id-330,PAK-11,32,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,6.69531244545059,HIGH,Y,Y,N,N,N,2020-01-13,2020-01-15 09:04:51.683,,2020-01-15 09:04:51.683,,,,2020-01-15 09:04:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,80.7722662505694,DAYS,2020-10-16 09:04:51.683,275,1,Last Tumor Assessment,Completion or Discontinuation,
1623,AB12345,AB12345-PAK-11-id-330,id-330,PAK-11,32,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,6.69531244545059,HIGH,Y,Y,N,N,N,2020-01-13,2020-01-15 09:04:51.683,,2020-01-15 09:04:51.683,,,,2020-01-15 09:04:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,159.47590705473,DAYS,2020-02-24 09:04:51.683,40,0,Death,,
1624,AB12345,AB12345-PAK-11-id-330,id-330,PAK-11,32,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,6.69531244545059,HIGH,Y,Y,N,N,N,2020-01-13,2020-01-15 09:04:51.683,,2020-01-15 09:04:51.683,,,,2020-01-15 09:04:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,159.47590705473,DAYS,2021-05-22 09:04:51.683,493,0,Death,,
1625,AB12345,AB12345-PAK-11-id-330,id-330,PAK-11,32,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Asia,C,S2,6.69531244545059,HIGH,Y,Y,N,N,N,2020-01-13,2020-01-15 09:04:51.683,,2020-01-15 09:04:51.683,,,,2020-01-15 09:04:51.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.970780100348092
1626,AB12345,AB12345-PAK-11-id-49,id-49,PAK-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,3.14572844925099,MEDIUM,Y,Y,Y,N,N,2019-12-24,2019-12-25 10:00:18.683,,2019-12-25 10:00:18.683,,,,2019-12-25 10:00:18.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,115.846793376841,DAYS,2019-12-29 10:00:18.683,4,0,Disease Progression,,
1627,AB12345,AB12345-PAK-11-id-49,id-49,PAK-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,3.14572844925099,MEDIUM,Y,Y,Y,N,N,2019-12-24,2019-12-25 10:00:18.683,,2019-12-25 10:00:18.683,,,,2019-12-25 10:00:18.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,23.1070209189784,DAYS,2020-01-25 10:00:18.683,31,0,Disease Progression,,
1628,AB12345,AB12345-PAK-11-id-49,id-49,PAK-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,3.14572844925099,MEDIUM,Y,Y,Y,N,N,2019-12-24,2019-12-25 10:00:18.683,,2019-12-25 10:00:18.683,,,,2019-12-25 10:00:18.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,353.836545255035,DAYS,2021-10-21 10:00:18.683,666,1,Alive,Alive During Study,
1629,AB12345,AB12345-PAK-11-id-49,id-49,PAK-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,3.14572844925099,MEDIUM,Y,Y,Y,N,N,2019-12-24,2019-12-25 10:00:18.683,,2019-12-25 10:00:18.683,,,,2019-12-25 10:00:18.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,270.109071489424,DAYS,2020-05-23 10:00:18.683,150,0,Disease Progression,,
1630,AB12345,AB12345-PAK-11-id-49,id-49,PAK-11,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,Asia,C,S1,3.14572844925099,MEDIUM,Y,Y,Y,N,N,2019-12-24,2019-12-25 10:00:18.683,,2019-12-25 10:00:18.683,,,,2019-12-25 10:00:18.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.82996386150576
1631,AB12345,AB12345-PAK-11-id-68,id-68,PAK-11,37,YEARS,F,ASIAN,UNKNOWN,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.24086210177526,HIGH,Y,Y,Y,Y,N,2019-06-02,2019-06-03 16:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,COMPLETED,COMPLETED,2022-06-03,1096,,,,,,,2022-06-19,,,2,2,Duration of Confirmed Response,CRSD,156.26652922947,DAYS,2020-06-30 16:33:00.683,393,1,Last Tumor Assessment,Completion or Discontinuation,
1632,AB12345,AB12345-PAK-11-id-68,id-68,PAK-11,37,YEARS,F,ASIAN,UNKNOWN,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.24086210177526,HIGH,Y,Y,Y,Y,N,2019-06-02,2019-06-03 16:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,COMPLETED,COMPLETED,2022-06-03,1096,,,,,,,2022-06-19,,,1,1,Event Free Survival,EFS,40.2305554132909,DAYS,2020-06-10 16:33:00.683,373,1,Last Tumor Assessment,Completion or Discontinuation,
1633,AB12345,AB12345-PAK-11-id-68,id-68,PAK-11,37,YEARS,F,ASIAN,UNKNOWN,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.24086210177526,HIGH,Y,Y,Y,Y,N,2019-06-02,2019-06-03 16:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,COMPLETED,COMPLETED,2022-06-03,1096,,,,,,,2022-06-19,,,4,4,Overall Survival,OS,499.272662168369,DAYS,2022-05-05 16:33:00.683,1067,1,Alive,Alive During Study,
1634,AB12345,AB12345-PAK-11-id-68,id-68,PAK-11,37,YEARS,F,ASIAN,UNKNOWN,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.24086210177526,HIGH,Y,Y,Y,Y,N,2019-06-02,2019-06-03 16:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,COMPLETED,COMPLETED,2022-06-03,1096,,,,,,,2022-06-19,,,3,3,Progression Free Survival,PFS,234.517651237547,DAYS,2022-01-07 16:33:00.683,949,1,Last Tumor Assessment,Completion or Discontinuation,
1635,AB12345,AB12345-PAK-11-id-68,id-68,PAK-11,37,YEARS,F,ASIAN,UNKNOWN,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,C,S1,5.24086210177526,HIGH,Y,Y,Y,Y,N,2019-06-02,2019-06-03 16:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,2019-06-03 16:33:00.683,2021-06-03 04:33:00.683,2021-06-03 04:33:00.683,2022-06-03 10:33:00.683,COMPLETED,COMPLETED,2022-06-03,1096,,,,,,,2022-06-19,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Completion or Discontinuation,-0.694895260303346
1636,AB12345,AB12345-PAK-11-id-82,id-82,PAK-11,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,5.98363415756435,LOW,Y,Y,Y,Y,N,2020-10-16,2020-10-18 15:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,COMPLETED,COMPLETED,2023-10-19,1096,,,,,,,2023-10-30,,,1,1,Duration of Confirmed Response,CRSD,159.07471976243,DAYS,2021-01-05 15:55:14.683,79,1,Adverse Event,Preferred Term,
1637,AB12345,AB12345-PAK-11-id-82,id-82,PAK-11,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,5.98363415756435,LOW,Y,Y,Y,Y,N,2020-10-16,2020-10-18 15:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,COMPLETED,COMPLETED,2023-10-19,1096,,,,,,,2023-10-30,,,4,4,Event Free Survival,EFS,33.2656183897052,DAYS,2023-09-27 15:55:14.683,1074,1,Last Tumor Assessment,Completion or Discontinuation,
1638,AB12345,AB12345-PAK-11-id-82,id-82,PAK-11,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,5.98363415756435,LOW,Y,Y,Y,Y,N,2020-10-16,2020-10-18 15:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,COMPLETED,COMPLETED,2023-10-19,1096,,,,,,,2023-10-30,,,3,3,Overall Survival,OS,407.985785510391,DAYS,2023-08-04 15:55:14.683,1020,1,Alive,Alive During Study,
1639,AB12345,AB12345-PAK-11-id-82,id-82,PAK-11,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,5.98363415756435,LOW,Y,Y,Y,Y,N,2020-10-16,2020-10-18 15:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,COMPLETED,COMPLETED,2023-10-19,1096,,,,,,,2023-10-30,,,2,2,Progression Free Survival,PFS,240.899104741402,DAYS,2022-03-08 15:55:14.683,506,1,Last Tumor Assessment,Completion or Discontinuation,
1640,AB12345,AB12345-PAK-11-id-82,id-82,PAK-11,32,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,Asia,A,S2,5.98363415756435,LOW,Y,Y,Y,Y,N,2020-10-16,2020-10-18 15:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,2020-10-18 15:55:14.683,2022-10-19 03:55:14.683,2022-10-19 03:55:14.683,2023-10-19 09:55:14.683,COMPLETED,COMPLETED,2023-10-19,1096,,,,,,,2023-10-30,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-0.278621009430971
1641,AB12345,AB12345-PAK-11-id-87,id-87,PAK-11,32,YEARS,F,ASIAN,NOT REPORTED,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,13.4762114359431,LOW,Y,Y,Y,N,N,2019-07-19,2019-07-21 00:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-12,,,4,4,Duration of Confirmed Response,CRSD,101.065314328298,DAYS,2022-02-15 00:20:16.683,940,1,Adverse Event,Preferred Term,
1642,AB12345,AB12345-PAK-11-id-87,id-87,PAK-11,32,YEARS,F,ASIAN,NOT REPORTED,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,13.4762114359431,LOW,Y,Y,Y,N,N,2019-07-19,2019-07-21 00:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-12,,,1,1,Event Free Survival,EFS,83.8335845887195,DAYS,2019-12-10 00:20:16.683,142,1,Last Tumor Assessment,Completion or Discontinuation,
1643,AB12345,AB12345-PAK-11-id-87,id-87,PAK-11,32,YEARS,F,ASIAN,NOT REPORTED,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,13.4762114359431,LOW,Y,Y,Y,N,N,2019-07-19,2019-07-21 00:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-12,,,2,2,Overall Survival,OS,267.498955619521,DAYS,2020-03-22 00:20:16.683,245,0,Death,,
1644,AB12345,AB12345-PAK-11-id-87,id-87,PAK-11,32,YEARS,F,ASIAN,NOT REPORTED,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,13.4762114359431,LOW,Y,Y,Y,N,N,2019-07-19,2019-07-21 00:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-12,,,3,3,Progression Free Survival,PFS,267.498955619521,DAYS,2021-02-09 00:20:16.683,569,0,Death,,
1645,AB12345,AB12345-PAK-11-id-87,id-87,PAK-11,32,YEARS,F,ASIAN,NOT REPORTED,PAK,N,INV ID PAK-11,Dr. PAK-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,Asia,A,S2,13.4762114359431,LOW,Y,Y,Y,N,N,2019-07-19,2019-07-21 00:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,2019-07-21 00:20:16.683,2021-07-20 12:20:16.683,2021-07-20 12:20:16.683,2022-07-20 18:20:16.683,COMPLETED,COMPLETED,2022-07-20,1096,,,,,,,2022-08-12,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Preferred Term,-2.11223405429022
1646,AB12345,AB12345-PAK-12-id-328,id-328,PAK-12,21,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S2,9.04077290992881,MEDIUM,Y,Y,Y,Y,N,2019-09-10,2019-09-10 10:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,COMPLETED,COMPLETED,2022-09-10,1096,,,,,,,2022-10-01,,,4,4,Duration of Confirmed Response,CRSD,140.808876580559,DAYS,2021-12-23 10:48:40.683,835,0,Disease Progression,,
1647,AB12345,AB12345-PAK-12-id-328,id-328,PAK-12,21,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S2,9.04077290992881,MEDIUM,Y,Y,Y,Y,N,2019-09-10,2019-09-10 10:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,COMPLETED,COMPLETED,2022-09-10,1096,,,,,,,2022-10-01,,,1,1,Event Free Survival,EFS,89.8154320905451,DAYS,2020-12-21 10:48:40.683,468,1,Last Tumor Assessment,Completion or Discontinuation,
1648,AB12345,AB12345-PAK-12-id-328,id-328,PAK-12,21,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S2,9.04077290992881,MEDIUM,Y,Y,Y,Y,N,2019-09-10,2019-09-10 10:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,COMPLETED,COMPLETED,2022-09-10,1096,,,,,,,2022-10-01,,,3,3,Overall Survival,OS,461.570262769237,DAYS,2021-11-06 10:48:40.683,788,1,Alive,Alive During Study,
1649,AB12345,AB12345-PAK-12-id-328,id-328,PAK-12,21,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S2,9.04077290992881,MEDIUM,Y,Y,Y,Y,N,2019-09-10,2019-09-10 10:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,COMPLETED,COMPLETED,2022-09-10,1096,,,,,,,2022-10-01,,,2,2,Progression Free Survival,PFS,289.405213459395,DAYS,2021-06-21 10:48:40.683,650,1,Last Tumor Assessment,Completion or Discontinuation,
1650,AB12345,AB12345-PAK-12-id-328,id-328,PAK-12,21,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,B: Placebo,Asia,C,S2,9.04077290992881,MEDIUM,Y,Y,Y,Y,N,2019-09-10,2019-09-10 10:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,2019-09-10 10:48:40.683,2021-09-09 22:48:40.683,2021-09-09 22:48:40.683,2022-09-10 04:48:40.683,COMPLETED,COMPLETED,2022-09-10,1096,,,,,,,2022-10-01,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,0,,,-4.5704127756119
1651,AB12345,AB12345-PAK-12-id-85,id-85,PAK-12,31,YEARS,M,ASIAN,UNKNOWN,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.69780174846346,HIGH,Y,Y,Y,N,N,2020-09-06,2020-09-09 04:06:54.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,DISCONTINUED,DISCONTINUED,2022-02-14,524,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-06,,,2,2,Duration of Confirmed Response,CRSD,195.113946939819,DAYS,2021-04-27 04:06:54.683,230,0,Death,,
1652,AB12345,AB12345-PAK-12-id-85,id-85,PAK-12,31,YEARS,M,ASIAN,UNKNOWN,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.69780174846346,HIGH,Y,Y,Y,N,N,2020-09-06,2020-09-09 04:06:54.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,DISCONTINUED,DISCONTINUED,2022-02-14,524,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-06,,,1,1,Event Free Survival,EFS,19.442815927323,DAYS,2021-02-04 04:06:54.683,148,1,Last Tumor Assessment,Completion or Discontinuation,
1653,AB12345,AB12345-PAK-12-id-85,id-85,PAK-12,31,YEARS,M,ASIAN,UNKNOWN,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.69780174846346,HIGH,Y,Y,Y,N,N,2020-09-06,2020-09-09 04:06:54.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,DISCONTINUED,DISCONTINUED,2022-02-14,524,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-06,,,4,4,Overall Survival,OS,195.113946939819,DAYS,2022-01-10 04:06:54.683,488,0,Death,,
1654,AB12345,AB12345-PAK-12-id-85,id-85,PAK-12,31,YEARS,M,ASIAN,UNKNOWN,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.69780174846346,HIGH,Y,Y,Y,N,N,2020-09-06,2020-09-09 04:06:54.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,DISCONTINUED,DISCONTINUED,2022-02-14,524,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-06,,,3,3,Progression Free Survival,PFS,195.113946939819,DAYS,2021-10-06 04:06:54.683,392,0,Death,,
1655,AB12345,AB12345-PAK-12-id-85,id-85,PAK-12,31,YEARS,M,ASIAN,UNKNOWN,PAK,N,INV ID PAK-12,Dr. PAK-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,C: Combination,Asia,C,S2,3.69780174846346,HIGH,Y,Y,Y,N,N,2020-09-06,2020-09-09 04:06:54.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,2020-09-09 04:06:54.683,2021-02-14 02:34:04.683,2021-02-14 02:34:04.683,2022-02-14 08:34:04.683,DISCONTINUED,DISCONTINUED,2022-02-14,524,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-06,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-2.86840568905623
1656,AB12345,AB12345-PAK-13-id-251,id-251,PAK-13,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S2,5.6604043084358,LOW,Y,Y,Y,N,N,2020-03-18,2020-03-19 10:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,COMPLETED,COMPLETED,2023-03-20,1096,,,,,,,2023-04-09,,,3,3,Duration of Confirmed Response,CRSD,149.745918367989,DAYS,2021-05-20 10:52:36.683,427,0,Disease Progression,,
1657,AB12345,AB12345-PAK-13-id-251,id-251,PAK-13,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S2,5.6604043084358,LOW,Y,Y,Y,N,N,2020-03-18,2020-03-19 10:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,COMPLETED,COMPLETED,2023-03-20,1096,,,,,,,2023-04-09,,,1,1,Event Free Survival,EFS,57.4099298904184,DAYS,2020-06-05 10:52:36.683,78,1,Last Tumor Assessment,Completion or Discontinuation,
1658,AB12345,AB12345-PAK-13-id-251,id-251,PAK-13,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S2,5.6604043084358,LOW,Y,Y,Y,N,N,2020-03-18,2020-03-19 10:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,COMPLETED,COMPLETED,2023-03-20,1096,,,,,,,2023-04-09,,,4,4,Overall Survival,OS,436.199463857338,DAYS,2023-02-24 10:52:36.683,1072,1,Alive,Alive During Study,
1659,AB12345,AB12345-PAK-13-id-251,id-251,PAK-13,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S2,5.6604043084358,LOW,Y,Y,Y,N,N,2020-03-18,2020-03-19 10:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,COMPLETED,COMPLETED,2023-03-20,1096,,,,,,,2023-04-09,,,2,2,Progression Free Survival,PFS,220.12220104225,DAYS,2020-08-05 10:52:36.683,139,1,Last Tumor Assessment,Completion or Discontinuation,
1660,AB12345,AB12345-PAK-13-id-251,id-251,PAK-13,32,YEARS,M,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Asia,A,S2,5.6604043084358,LOW,Y,Y,Y,N,N,2020-03-18,2020-03-19 10:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,2020-03-19 10:52:36.683,2022-03-19 22:52:36.683,2022-03-19 22:52:36.683,2023-03-20 04:52:36.683,COMPLETED,COMPLETED,2023-03-20,1096,,,,,,,2023-04-09,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.941570221146268
1661,AB12345,AB12345-PAK-13-id-350,id-350,PAK-13,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S2,5.7137749086158,MEDIUM,Y,Y,Y,Y,N,2020-11-21,2020-11-24 07:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,COMPLETED,COMPLETED,2023-11-25,1096,,,,,,,2023-12-06,,,1,1,Duration of Confirmed Response,CRSD,160.957774030976,DAYS,2021-03-31 07:06:07.683,127,0,Death,,
1662,AB12345,AB12345-PAK-13-id-350,id-350,PAK-13,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S2,5.7137749086158,MEDIUM,Y,Y,Y,Y,N,2020-11-21,2020-11-24 07:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,COMPLETED,COMPLETED,2023-11-25,1096,,,,,,,2023-12-06,,,2,2,Event Free Survival,EFS,61.5208556153812,DAYS,2021-05-19 07:06:07.683,176,1,Last Tumor Assessment,Completion or Discontinuation,
1663,AB12345,AB12345-PAK-13-id-350,id-350,PAK-13,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S2,5.7137749086158,MEDIUM,Y,Y,Y,Y,N,2020-11-21,2020-11-24 07:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,COMPLETED,COMPLETED,2023-11-25,1096,,,,,,,2023-12-06,,,4,4,Overall Survival,OS,160.957774030976,DAYS,2023-08-13 07:06:07.683,992,0,Death,,
1664,AB12345,AB12345-PAK-13-id-350,id-350,PAK-13,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S2,5.7137749086158,MEDIUM,Y,Y,Y,Y,N,2020-11-21,2020-11-24 07:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,COMPLETED,COMPLETED,2023-11-25,1096,,,,,,,2023-12-06,,,3,3,Progression Free Survival,PFS,160.957774030976,DAYS,2023-04-04 07:06:07.683,861,0,Death,,
1665,AB12345,AB12345-PAK-13-id-350,id-350,PAK-13,39,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-13,Dr. PAK-13 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Asia,A,S2,5.7137749086158,MEDIUM,Y,Y,Y,Y,N,2020-11-21,2020-11-24 07:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,2020-11-24 07:06:07.683,2022-11-24 19:06:07.683,2022-11-24 19:06:07.683,2023-11-25 01:06:07.683,COMPLETED,COMPLETED,2023-11-25,1096,,,,,,,2023-12-06,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.0352165550295185
1666,AB12345,AB12345-PAK-14-id-117,id-117,PAK-14,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-14,Dr. PAK-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.26523211998877,HIGH,Y,Y,Y,N,N,2019-07-11,2019-07-15 04:23:49.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,DISCONTINUED,DISCONTINUED,2022-02-20,951,PROTOCOL VIOLATION,,,,,,2022-03-21,,,2,2,Duration of Confirmed Response,CRSD,116.406116471626,DAYS,2020-04-25 04:23:49.683,285,0,Disease Progression,,
1667,AB12345,AB12345-PAK-14-id-117,id-117,PAK-14,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-14,Dr. PAK-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.26523211998877,HIGH,Y,Y,Y,N,N,2019-07-11,2019-07-15 04:23:49.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,DISCONTINUED,DISCONTINUED,2022-02-20,951,PROTOCOL VIOLATION,,,,,,2022-03-21,,,3,3,Event Free Survival,EFS,41.1955546995159,DAYS,2021-02-04 04:23:49.683,570,1,Last Tumor Assessment,Completion or Discontinuation,
1668,AB12345,AB12345-PAK-14-id-117,id-117,PAK-14,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-14,Dr. PAK-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.26523211998877,HIGH,Y,Y,Y,N,N,2019-07-11,2019-07-15 04:23:49.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,DISCONTINUED,DISCONTINUED,2022-02-20,951,PROTOCOL VIOLATION,,,,,,2022-03-21,,,4,4,Overall Survival,OS,335.414145002142,DAYS,2021-03-13 04:23:49.683,607,1,Alive,Alive During Study,
1669,AB12345,AB12345-PAK-14-id-117,id-117,PAK-14,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-14,Dr. PAK-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.26523211998877,HIGH,Y,Y,Y,N,N,2019-07-11,2019-07-15 04:23:49.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,DISCONTINUED,DISCONTINUED,2022-02-20,951,PROTOCOL VIOLATION,,,,,,2022-03-21,,,1,1,Progression Free Survival,PFS,284.739972627722,DAYS,2020-02-14 04:23:49.683,214,1,Last Tumor Assessment,Completion or Discontinuation,
1670,AB12345,AB12345-PAK-14-id-117,id-117,PAK-14,25,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-14,Dr. PAK-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,Asia,A,S2,6.26523211998877,HIGH,Y,Y,Y,N,N,2019-07-11,2019-07-15 04:23:49.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,2019-07-15 04:23:49.683,2021-02-19 19:27:23.683,2021-02-19 19:27:23.683,2022-02-20 01:27:23.683,DISCONTINUED,DISCONTINUED,2022-02-20,951,PROTOCOL VIOLATION,,,,,,2022-03-21,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-3.70015010609705
1671,AB12345,AB12345-PAK-15-id-314,id-314,PAK-15,27,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-15,Dr. PAK-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,3.51130999725565,LOW,Y,Y,N,N,N,2019-09-13,2019-09-17 23:08:16.683,,2019-09-17 23:08:16.683,,,,2019-09-17 23:08:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,197.255654959008,DAYS,2020-08-26 23:08:16.683,344,0,Death,,
1672,AB12345,AB12345-PAK-15-id-314,id-314,PAK-15,27,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-15,Dr. PAK-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,3.51130999725565,LOW,Y,Y,N,N,N,2019-09-13,2019-09-17 23:08:16.683,,2019-09-17 23:08:16.683,,,,2019-09-17 23:08:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,64.8279116954654,DAYS,2020-04-07 23:08:16.683,203,1,Adverse Event,Preferred Term,
1673,AB12345,AB12345-PAK-15-id-314,id-314,PAK-15,27,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-15,Dr. PAK-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,3.51130999725565,LOW,Y,Y,N,N,N,2019-09-13,2019-09-17 23:08:16.683,,2019-09-17 23:08:16.683,,,,2019-09-17 23:08:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,197.255654959008,DAYS,2020-08-08 23:08:16.683,326,0,Death,,
1674,AB12345,AB12345-PAK-15-id-314,id-314,PAK-15,27,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-15,Dr. PAK-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,3.51130999725565,LOW,Y,Y,N,N,N,2019-09-13,2019-09-17 23:08:16.683,,2019-09-17 23:08:16.683,,,,2019-09-17 23:08:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Progression Free Survival,PFS,197.255654959008,DAYS,2021-07-21 23:08:16.683,673,0,Death,,
1675,AB12345,AB12345-PAK-15-id-314,id-314,PAK-15,27,YEARS,F,ASIAN,HISPANIC OR LATINO,PAK,N,INV ID PAK-15,Dr. PAK-15 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Asia,A,S1,3.51130999725565,LOW,Y,Y,N,N,N,2019-09-13,2019-09-17 23:08:16.683,,2019-09-17 23:08:16.683,,,,2019-09-17 23:08:16.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,0.294110378118356
1676,AB12345,AB12345-PAK-2-id-188,id-188,PAK-2,23,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,16.4876657397025,LOW,Y,Y,N,Y,N,2020-03-11,2020-03-12 10:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,COMPLETED,COMPLETED,2023-03-13,1096,,,,,,,2023-04-09,,,2,2,Duration of Confirmed Response,CRSD,181.091625452973,DAYS,2021-08-03 10:44:07.683,509,1,Adverse Event,Preferred Term,
1677,AB12345,AB12345-PAK-2-id-188,id-188,PAK-2,23,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,16.4876657397025,LOW,Y,Y,N,Y,N,2020-03-11,2020-03-12 10:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,COMPLETED,COMPLETED,2023-03-13,1096,,,,,,,2023-04-09,,,1,1,Event Free Survival,EFS,60.3984416811727,DAYS,2020-09-21 10:44:07.683,193,0,Disease Progression,,
1678,AB12345,AB12345-PAK-2-id-188,id-188,PAK-2,23,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,16.4876657397025,LOW,Y,Y,N,Y,N,2020-03-11,2020-03-12 10:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,COMPLETED,COMPLETED,2023-03-13,1096,,,,,,,2023-04-09,,,3,3,Overall Survival,OS,454.196221427992,DAYS,2022-08-28 10:44:07.683,899,1,Alive,Alive During Study,
1679,AB12345,AB12345-PAK-2-id-188,id-188,PAK-2,23,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,16.4876657397025,LOW,Y,Y,N,Y,N,2020-03-11,2020-03-12 10:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,COMPLETED,COMPLETED,2023-03-13,1096,,,,,,,2023-04-09,,,4,4,Progression Free Survival,PFS,265.090651111677,DAYS,2022-10-18 10:44:07.683,950,1,Adverse Event,Preferred Term,
1680,AB12345,AB12345-PAK-2-id-188,id-188,PAK-2,23,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Asia,B,S1,16.4876657397025,LOW,Y,Y,N,Y,N,2020-03-11,2020-03-12 10:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,2020-03-12 10:44:07.683,2022-03-12 22:44:07.683,2022-03-12 22:44:07.683,2023-03-13 04:44:07.683,COMPLETED,COMPLETED,2023-03-13,1096,,,,,,,2023-04-09,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-1.17432391805002
1681,AB12345,AB12345-PAK-2-id-191,id-191,PAK-2,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,3.14368544614065,HIGH,Y,Y,N,N,Y,2019-04-03,2019-04-07 17:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,COMPLETED,COMPLETED,2022-04-07,1096,,,,,,,2022-04-27,,,2,2,Duration of Confirmed Response,CRSD,155.866028112359,DAYS,2020-10-19 17:15:55.683,561,0,Disease Progression,,
1682,AB12345,AB12345-PAK-2-id-191,id-191,PAK-2,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,3.14368544614065,HIGH,Y,Y,N,N,Y,2019-04-03,2019-04-07 17:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,COMPLETED,COMPLETED,2022-04-07,1096,,,,,,,2022-04-27,,,4,4,Event Free Survival,EFS,17.9374568001367,DAYS,2022-02-06 17:15:55.683,1036,1,Last Tumor Assessment,Completion or Discontinuation,
1683,AB12345,AB12345-PAK-2-id-191,id-191,PAK-2,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,3.14368544614065,HIGH,Y,Y,N,N,Y,2019-04-03,2019-04-07 17:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,COMPLETED,COMPLETED,2022-04-07,1096,,,,,,,2022-04-27,,,3,3,Overall Survival,OS,212.008736701682,DAYS,2022-01-01 17:15:55.683,1000,0,Death,,
1684,AB12345,AB12345-PAK-2-id-191,id-191,PAK-2,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,3.14368544614065,HIGH,Y,Y,N,N,Y,2019-04-03,2019-04-07 17:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,COMPLETED,COMPLETED,2022-04-07,1096,,,,,,,2022-04-27,,,1,1,Progression Free Survival,PFS,212.008736701682,DAYS,2019-07-31 17:15:55.683,115,0,Death,,
1685,AB12345,AB12345-PAK-2-id-191,id-191,PAK-2,38,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Asia,A,S2,3.14368544614065,HIGH,Y,Y,N,N,Y,2019-04-03,2019-04-07 17:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,2019-04-07 17:15:55.683,2021-04-07 05:15:55.683,2021-04-07 05:15:55.683,2022-04-07 11:15:55.683,COMPLETED,COMPLETED,2022-04-07,1096,,,,,,,2022-04-27,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.62440815100718
1686,AB12345,AB12345-PAK-2-id-213,id-213,PAK-2,38,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,B,S1,1.81794398603702,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-16 13:35:03.683,,2020-01-16 13:35:03.683,,,,2020-01-16 13:35:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,191.412566113286,DAYS,2021-02-16 13:35:03.683,397,0,Disease Progression,,
1687,AB12345,AB12345-PAK-2-id-213,id-213,PAK-2,38,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,B,S1,1.81794398603702,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-16 13:35:03.683,,2020-01-16 13:35:03.683,,,,2020-01-16 13:35:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,73.3354683895595,DAYS,2022-01-07 13:35:03.683,722,1,Last Tumor Assessment,Completion or Discontinuation,
1688,AB12345,AB12345-PAK-2-id-213,id-213,PAK-2,38,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,B,S1,1.81794398603702,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-16 13:35:03.683,,2020-01-16 13:35:03.683,,,,2020-01-16 13:35:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Overall Survival,OS,415.115208970383,DAYS,2021-03-06 13:35:03.683,415,1,Alive,Alive During Study,
1689,AB12345,AB12345-PAK-2-id-213,id-213,PAK-2,38,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,B,S1,1.81794398603702,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-16 13:35:03.683,,2020-01-16 13:35:03.683,,,,2020-01-16 13:35:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,256.034976034425,DAYS,2020-11-11 13:35:03.683,300,1,Last Tumor Assessment,Completion or Discontinuation,
1690,AB12345,AB12345-PAK-2-id-213,id-213,PAK-2,38,YEARS,F,WHITE,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-2,Dr. PAK-2 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,Asia,B,S1,1.81794398603702,MEDIUM,Y,Y,N,Y,N,2020-01-13,2020-01-16 13:35:03.683,,2020-01-16 13:35:03.683,,,,2020-01-16 13:35:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.0914687518203686
1691,AB12345,AB12345-PAK-4-id-15,id-15,PAK-4,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-4,Dr. PAK-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,8.81158907284128,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-27 05:43:17.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,DISCONTINUED,DISCONTINUED,2022-02-14,781,DEATH,2022-03-18,LOST TO FOLLOW UP,OTHER,32,>30,2022-03-18,811,,3,3,Duration of Confirmed Response,CRSD,58.9237631764263,DAYS,2021-01-03 05:43:17.683,373,0,Death,,
1692,AB12345,AB12345-PAK-4-id-15,id-15,PAK-4,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-4,Dr. PAK-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,8.81158907284128,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-27 05:43:17.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,DISCONTINUED,DISCONTINUED,2022-02-14,781,DEATH,2022-03-18,LOST TO FOLLOW UP,OTHER,32,>30,2022-03-18,811,,4,4,Event Free Survival,EFS,58.9237631764263,DAYS,2021-12-25 05:43:17.683,729,0,Death,,
1693,AB12345,AB12345-PAK-4-id-15,id-15,PAK-4,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-4,Dr. PAK-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,8.81158907284128,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-27 05:43:17.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,DISCONTINUED,DISCONTINUED,2022-02-14,781,DEATH,2022-03-18,LOST TO FOLLOW UP,OTHER,32,>30,2022-03-18,811,,1,1,Overall Survival,OS,58.9237631764263,DAYS,2020-09-13 05:43:17.683,261,0,Death,,
1694,AB12345,AB12345-PAK-4-id-15,id-15,PAK-4,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-4,Dr. PAK-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,8.81158907284128,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-27 05:43:17.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,DISCONTINUED,DISCONTINUED,2022-02-14,781,DEATH,2022-03-18,LOST TO FOLLOW UP,OTHER,32,>30,2022-03-18,811,,2,2,Progression Free Survival,PFS,58.9237631764263,DAYS,2020-12-07 05:43:17.683,346,0,Death,,
1695,AB12345,AB12345-PAK-4-id-15,id-15,PAK-4,30,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,Y,INV ID PAK-4,Dr. PAK-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,A: Drug X,Asia,B,S1,8.81158907284128,LOW,Y,Y,N,Y,N,2019-12-25,2019-12-27 05:43:17.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,2019-12-27 05:43:17.683,2021-02-14 04:25:12.683,2021-02-14 04:25:12.683,2022-02-14 10:25:12.683,DISCONTINUED,DISCONTINUED,2022-02-14,781,DEATH,2022-03-18,LOST TO FOLLOW UP,OTHER,32,>30,2022-03-18,811,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.27061069389274
1696,AB12345,AB12345-PAK-4-id-164,id-164,PAK-4,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-4,Dr. PAK-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,1.83050175976707,MEDIUM,Y,Y,N,Y,N,2019-11-27,2019-11-30 22:27:22.683,,2019-11-30 22:27:22.683,,,,2019-11-30 22:27:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,158.839658019133,DAYS,2021-01-28 22:27:22.683,425,1,Adverse Event,Preferred Term,
1697,AB12345,AB12345-PAK-4-id-164,id-164,PAK-4,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-4,Dr. PAK-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,1.83050175976707,MEDIUM,Y,Y,N,Y,N,2019-11-27,2019-11-30 22:27:22.683,,2019-11-30 22:27:22.683,,,,2019-11-30 22:27:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,70.9341294923797,DAYS,2020-01-14 22:27:22.683,45,1,Last Tumor Assessment,Completion or Discontinuation,
1698,AB12345,AB12345-PAK-4-id-164,id-164,PAK-4,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-4,Dr. PAK-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,1.83050175976707,MEDIUM,Y,Y,N,Y,N,2019-11-27,2019-11-30 22:27:22.683,,2019-11-30 22:27:22.683,,,,2019-11-30 22:27:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,331.227250676602,DAYS,2021-08-03 22:27:22.683,612,1,Alive,Alive During Study,
1699,AB12345,AB12345-PAK-4-id-164,id-164,PAK-4,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-4,Dr. PAK-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,1.83050175976707,MEDIUM,Y,Y,N,Y,N,2019-11-27,2019-11-30 22:27:22.683,,2019-11-30 22:27:22.683,,,,2019-11-30 22:27:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,207.99245799426,DAYS,2020-04-03 22:27:22.683,125,1,Adverse Event,Preferred Term,
1700,AB12345,AB12345-PAK-4-id-164,id-164,PAK-4,28,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-4,Dr. PAK-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,Asia,B,S1,1.83050175976707,MEDIUM,Y,Y,N,Y,N,2019-11-27,2019-11-30 22:27:22.683,,2019-11-30 22:27:22.683,,,,2019-11-30 22:27:22.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Preferred Term,-3.7874591088228
1701,AB12345,AB12345-PAK-5-id-20,id-20,PAK-5,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-5,Dr. PAK-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S2,5.84789495060854,HIGH,Y,Y,N,N,N,2020-09-20,2020-09-21 06:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,COMPLETED,COMPLETED,2023-09-22,1096,,,,,,,2023-10-11,,,3,3,Duration of Confirmed Response,CRSD,199.182979739271,DAYS,2023-02-06 06:37:27.683,868,0,Disease Progression,,
1702,AB12345,AB12345-PAK-5-id-20,id-20,PAK-5,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-5,Dr. PAK-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S2,5.84789495060854,HIGH,Y,Y,N,N,N,2020-09-20,2020-09-21 06:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,COMPLETED,COMPLETED,2023-09-22,1096,,,,,,,2023-10-11,,,1,1,Event Free Survival,EFS,98.7319162313361,DAYS,2021-07-26 06:37:27.683,308,1,Adverse Event,Preferred Term,
1703,AB12345,AB12345-PAK-5-id-20,id-20,PAK-5,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-5,Dr. PAK-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S2,5.84789495060854,HIGH,Y,Y,N,N,N,2020-09-20,2020-09-21 06:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,COMPLETED,COMPLETED,2023-09-22,1096,,,,,,,2023-10-11,,,4,4,Overall Survival,OS,457.742492901161,DAYS,2023-03-31 06:37:27.683,921,1,Alive,Alive During Study,
1704,AB12345,AB12345-PAK-5-id-20,id-20,PAK-5,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-5,Dr. PAK-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S2,5.84789495060854,HIGH,Y,Y,N,N,N,2020-09-20,2020-09-21 06:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,COMPLETED,COMPLETED,2023-09-22,1096,,,,,,,2023-10-11,,,2,2,Progression Free Survival,PFS,229.47561906185,DAYS,2022-11-29 06:37:27.683,799,1,Adverse Event,Preferred Term,
1705,AB12345,AB12345-PAK-5-id-20,id-20,PAK-5,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,PAK,N,INV ID PAK-5,Dr. PAK-5 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Asia,A,S2,5.84789495060854,HIGH,Y,Y,N,N,N,2020-09-20,2020-09-21 06:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,2020-09-21 06:37:27.683,2022-09-21 18:37:27.683,2022-09-21 18:37:27.683,2023-09-22 00:37:27.683,COMPLETED,COMPLETED,2023-09-22,1096,,,,,,,2023-10-11,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-0.25040632413427
1706,AB12345,AB12345-RUS-1-id-52,id-52,RUS-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-1,Dr. RUS-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Eurasia,C,S2,7.20634823208459,HIGH,Y,Y,N,N,N,2019-03-17,2019-03-18 09:38:55.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,DISCONTINUED,DISCONTINUED,2022-02-13,1064,DEATH,2022-02-20,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-20,1069,Yes,4,4,Duration of Confirmed Response,CRSD,140.082666347735,DAYS,2021-12-30 09:38:55.683,1018,1,Last Tumor Assessment,Completion or Discontinuation,
1707,AB12345,AB12345-RUS-1-id-52,id-52,RUS-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-1,Dr. RUS-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Eurasia,C,S2,7.20634823208459,HIGH,Y,Y,N,N,N,2019-03-17,2019-03-18 09:38:55.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,DISCONTINUED,DISCONTINUED,2022-02-13,1064,DEATH,2022-02-20,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-20,1069,Yes,2,2,Event Free Survival,EFS,73.3806405437645,DAYS,2020-08-24 09:38:55.683,525,1,Adverse Event,Preferred Term,
1708,AB12345,AB12345-RUS-1-id-52,id-52,RUS-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-1,Dr. RUS-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Eurasia,C,S2,7.20634823208459,HIGH,Y,Y,N,N,N,2019-03-17,2019-03-18 09:38:55.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,DISCONTINUED,DISCONTINUED,2022-02-13,1064,DEATH,2022-02-20,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-20,1069,Yes,3,3,Overall Survival,OS,477.482788125053,DAYS,2021-01-25 09:38:55.683,679,1,Alive,Alive During Study,
1709,AB12345,AB12345-RUS-1-id-52,id-52,RUS-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-1,Dr. RUS-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Eurasia,C,S2,7.20634823208459,HIGH,Y,Y,N,N,N,2019-03-17,2019-03-18 09:38:55.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,DISCONTINUED,DISCONTINUED,2022-02-13,1064,DEATH,2022-02-20,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-20,1069,Yes,1,1,Progression Free Survival,PFS,239.684113604017,DAYS,2019-06-07 09:38:55.683,81,1,Last Tumor Assessment,Completion or Discontinuation,
1710,AB12345,AB12345-RUS-1-id-52,id-52,RUS-1,40,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-1,Dr. RUS-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,Eurasia,C,S2,7.20634823208459,HIGH,Y,Y,N,N,N,2019-03-17,2019-03-18 09:38:55.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,2019-03-18 09:38:55.683,2021-02-13 06:30:28.683,2021-02-13 06:30:28.683,2022-02-13 12:30:28.683,DISCONTINUED,DISCONTINUED,2022-02-13,1064,DEATH,2022-02-20,DISEASE PROGRESSION,PROGRESSIVE DISEASE,7,<=30,2022-02-20,1069,Yes,,,Total Number of Exacerbations,TNE,5,COUNT,,,1,,Completion or Discontinuation,-3.88589251338133
1711,AB12345,AB12345-RUS-11-id-162,id-162,RUS-11,37,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Eurasia,C,S1,8.34704733480695,MEDIUM,Y,Y,N,Y,N,2020-03-30,2020-03-30 21:19:53.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,DISCONTINUED,DISCONTINUED,2022-02-13,685,DEATH,2022-03-29,LOST TO FOLLOW UP,OTHER,44,>30,2022-03-29,728,,1,1,Duration of Confirmed Response,CRSD,126.52450397145,DAYS,2021-04-18 21:19:53.683,384,0,Death,,
1712,AB12345,AB12345-RUS-11-id-162,id-162,RUS-11,37,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Eurasia,C,S1,8.34704733480695,MEDIUM,Y,Y,N,Y,N,2020-03-30,2020-03-30 21:19:53.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,DISCONTINUED,DISCONTINUED,2022-02-13,685,DEATH,2022-03-29,LOST TO FOLLOW UP,OTHER,44,>30,2022-03-29,728,,3,3,Event Free Survival,EFS,84.8766381188761,DAYS,2021-10-31 21:19:53.683,580,1,Last Tumor Assessment,Completion or Discontinuation,
1713,AB12345,AB12345-RUS-11-id-162,id-162,RUS-11,37,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Eurasia,C,S1,8.34704733480695,MEDIUM,Y,Y,N,Y,N,2020-03-30,2020-03-30 21:19:53.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,DISCONTINUED,DISCONTINUED,2022-02-13,685,DEATH,2022-03-29,LOST TO FOLLOW UP,OTHER,44,>30,2022-03-29,728,,4,4,Overall Survival,OS,126.52450397145,DAYS,2022-01-02 21:19:53.683,643,0,Death,,
1714,AB12345,AB12345-RUS-11-id-162,id-162,RUS-11,37,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Eurasia,C,S1,8.34704733480695,MEDIUM,Y,Y,N,Y,N,2020-03-30,2020-03-30 21:19:53.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,DISCONTINUED,DISCONTINUED,2022-02-13,685,DEATH,2022-03-29,LOST TO FOLLOW UP,OTHER,44,>30,2022-03-29,728,,2,2,Progression Free Survival,PFS,126.52450397145,DAYS,2021-05-03 21:19:53.683,399,0,Death,,
1715,AB12345,AB12345-RUS-11-id-162,id-162,RUS-11,37,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,Eurasia,C,S1,8.34704733480695,MEDIUM,Y,Y,N,Y,N,2020-03-30,2020-03-30 21:19:53.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,2020-03-30 21:19:53.683,2021-02-13 08:07:21.683,2021-02-13 08:07:21.683,2022-02-13 14:07:21.683,DISCONTINUED,DISCONTINUED,2022-02-13,685,DEATH,2022-03-29,LOST TO FOLLOW UP,OTHER,44,>30,2022-03-29,728,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.77138053212835
1716,AB12345,AB12345-RUS-11-id-283,id-283,RUS-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Eurasia,B,S2,2.78881133860389,LOW,Y,Y,Y,N,N,2020-07-19,2020-07-23 11:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-12,,,3,3,Duration of Confirmed Response,CRSD,195.647406741045,DAYS,2021-12-25 11:49:14.683,520,0,Death,,
1717,AB12345,AB12345-RUS-11-id-283,id-283,RUS-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Eurasia,B,S2,2.78881133860389,LOW,Y,Y,Y,N,N,2020-07-19,2020-07-23 11:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-12,,,2,2,Event Free Survival,EFS,30.3995242936071,DAYS,2021-06-21 11:49:14.683,333,1,Last Tumor Assessment,Completion or Discontinuation,
1718,AB12345,AB12345-RUS-11-id-283,id-283,RUS-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Eurasia,B,S2,2.78881133860389,LOW,Y,Y,Y,N,N,2020-07-19,2020-07-23 11:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-12,,,1,1,Overall Survival,OS,195.647406741045,DAYS,2021-01-10 11:49:14.683,171,0,Death,,
1719,AB12345,AB12345-RUS-11-id-283,id-283,RUS-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Eurasia,B,S2,2.78881133860389,LOW,Y,Y,Y,N,N,2020-07-19,2020-07-23 11:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-12,,,4,4,Progression Free Survival,PFS,195.647406741045,DAYS,2023-01-18 11:49:14.683,909,0,Death,,
1720,AB12345,AB12345-RUS-11-id-283,id-283,RUS-11,37,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,Eurasia,B,S2,2.78881133860389,LOW,Y,Y,Y,N,N,2020-07-19,2020-07-23 11:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,2020-07-23 11:49:14.683,2022-07-23 23:49:14.683,2022-07-23 23:49:14.683,2023-07-24 05:49:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-12,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-2.2211330647472
1721,AB12345,AB12345-RUS-11-id-76,id-76,RUS-11,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Eurasia,C,S2,3.74484239532288,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-11 14:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,COMPLETED,COMPLETED,2022-08-11,1096,,,,,,,2022-08-21,,,1,1,Duration of Confirmed Response,CRSD,134.665263188072,DAYS,2020-03-01 14:39:28.683,203,0,Disease Progression,,
1722,AB12345,AB12345-RUS-11-id-76,id-76,RUS-11,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Eurasia,C,S2,3.74484239532288,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-11 14:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,COMPLETED,COMPLETED,2022-08-11,1096,,,,,,,2022-08-21,,,4,4,Event Free Survival,EFS,86.178986588493,DAYS,2022-05-28 14:39:28.683,1021,1,Last Tumor Assessment,Completion or Discontinuation,
1723,AB12345,AB12345-RUS-11-id-76,id-76,RUS-11,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Eurasia,C,S2,3.74484239532288,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-11 14:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,COMPLETED,COMPLETED,2022-08-11,1096,,,,,,,2022-08-21,,,2,2,Overall Survival,OS,284.20864418149,DAYS,2020-05-18 14:39:28.683,281,0,Death,,
1724,AB12345,AB12345-RUS-11-id-76,id-76,RUS-11,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Eurasia,C,S2,3.74484239532288,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-11 14:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,COMPLETED,COMPLETED,2022-08-11,1096,,,,,,,2022-08-21,,,3,3,Progression Free Survival,PFS,284.20864418149,DAYS,2020-06-26 14:39:28.683,320,0,Death,,
1725,AB12345,AB12345-RUS-11-id-76,id-76,RUS-11,25,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-11,Dr. RUS-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,Eurasia,C,S2,3.74484239532288,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-11 14:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,2019-08-11 14:39:28.683,2021-08-11 02:39:28.683,2021-08-11 02:39:28.683,2022-08-11 08:39:28.683,COMPLETED,COMPLETED,2022-08-11,1096,,,,,,,2022-08-21,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.70114644349925
1726,AB12345,AB12345-RUS-11-id-94,id-94,RUS-11,36,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Eurasia,A,S1,9.31688061509297,LOW,Y,Y,Y,Y,N,2019-08-19,2019-08-23 21:17:59.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,DISCONTINUED,DISCONTINUED,2022-02-12,904,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,953,Yes,2,2,Duration of Confirmed Response,CRSD,121.454192395322,DAYS,2019-10-30 21:17:59.683,68,0,Death,,
1727,AB12345,AB12345-RUS-11-id-94,id-94,RUS-11,36,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Eurasia,A,S1,9.31688061509297,LOW,Y,Y,Y,Y,N,2019-08-19,2019-08-23 21:17:59.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,DISCONTINUED,DISCONTINUED,2022-02-12,904,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,953,Yes,3,3,Event Free Survival,EFS,15.8610655413941,DAYS,2019-11-30 21:17:59.683,99,0,Disease Progression,,
1728,AB12345,AB12345-RUS-11-id-94,id-94,RUS-11,36,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Eurasia,A,S1,9.31688061509297,LOW,Y,Y,Y,Y,N,2019-08-19,2019-08-23 21:17:59.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,DISCONTINUED,DISCONTINUED,2022-02-12,904,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,953,Yes,4,4,Overall Survival,OS,121.454192395322,DAYS,2021-12-03 21:17:59.683,833,0,Death,,
1729,AB12345,AB12345-RUS-11-id-94,id-94,RUS-11,36,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Eurasia,A,S1,9.31688061509297,LOW,Y,Y,Y,Y,N,2019-08-19,2019-08-23 21:17:59.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,DISCONTINUED,DISCONTINUED,2022-02-12,904,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,953,Yes,1,1,Progression Free Survival,PFS,121.454192395322,DAYS,2019-09-26 21:17:59.683,34,0,Death,,
1730,AB12345,AB12345-RUS-11-id-94,id-94,RUS-11,36,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,Y,INV ID RUS-11,Dr. RUS-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,Eurasia,A,S1,9.31688061509297,LOW,Y,Y,Y,Y,N,2019-08-19,2019-08-23 21:17:59.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,2019-08-23 21:17:59.683,2021-02-12 01:49:07.683,2021-02-12 01:49:07.683,2022-02-12 07:49:07.683,DISCONTINUED,DISCONTINUED,2022-02-12,904,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,953,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-3.05537579982153
1731,AB12345,AB12345-RUS-12-id-185,id-185,RUS-12,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-12,Dr. RUS-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,A,S2,7.67624716209496,MEDIUM,Y,Y,N,N,N,2019-12-04,2019-12-08 11:19:06.683,,2019-12-08 11:19:06.683,,,,2019-12-08 11:19:06.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,104.865534510463,DAYS,2020-06-26 11:19:06.683,201,0,Death,,
1732,AB12345,AB12345-RUS-12-id-185,id-185,RUS-12,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-12,Dr. RUS-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,A,S2,7.67624716209496,MEDIUM,Y,Y,N,N,N,2019-12-04,2019-12-08 11:19:06.683,,2019-12-08 11:19:06.683,,,,2019-12-08 11:19:06.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,92.6674732344691,DAYS,2021-05-27 11:19:06.683,536,1,Last Tumor Assessment,Completion or Discontinuation,
1733,AB12345,AB12345-RUS-12-id-185,id-185,RUS-12,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-12,Dr. RUS-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,A,S2,7.67624716209496,MEDIUM,Y,Y,N,N,N,2019-12-04,2019-12-08 11:19:06.683,,2019-12-08 11:19:06.683,,,,2019-12-08 11:19:06.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,104.865534510463,DAYS,2021-09-01 11:19:06.683,633,0,Death,,
1734,AB12345,AB12345-RUS-12-id-185,id-185,RUS-12,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-12,Dr. RUS-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,A,S2,7.67624716209496,MEDIUM,Y,Y,N,N,N,2019-12-04,2019-12-08 11:19:06.683,,2019-12-08 11:19:06.683,,,,2019-12-08 11:19:06.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,104.865534510463,DAYS,2020-08-20 11:19:06.683,256,0,Death,,
1735,AB12345,AB12345-RUS-12-id-185,id-185,RUS-12,31,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-12,Dr. RUS-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,A,S2,7.67624716209496,MEDIUM,Y,Y,N,N,N,2019-12-04,2019-12-08 11:19:06.683,,2019-12-08 11:19:06.683,,,,2019-12-08 11:19:06.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-2.07485678063298
1736,AB12345,AB12345-RUS-13-id-70,id-70,RUS-13,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-13,Dr. RUS-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,C,S2,3.48731937682499,HIGH,Y,Y,Y,N,N,2019-04-15,2019-04-15 01:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,COMPLETED,COMPLETED,2022-04-14,1096,,,,,,,2022-05-05,,,4,4,Duration of Confirmed Response,CRSD,165.578800602816,DAYS,2022-04-04 01:39:32.683,1085,1,Adverse Event,Preferred Term,
1737,AB12345,AB12345-RUS-13-id-70,id-70,RUS-13,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-13,Dr. RUS-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,C,S2,3.48731937682499,HIGH,Y,Y,Y,N,N,2019-04-15,2019-04-15 01:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,COMPLETED,COMPLETED,2022-04-14,1096,,,,,,,2022-05-05,,,2,2,Event Free Survival,EFS,89.0546302648727,DAYS,2021-08-05 01:39:32.683,843,1,Adverse Event,Preferred Term,
1738,AB12345,AB12345-RUS-13-id-70,id-70,RUS-13,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-13,Dr. RUS-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,C,S2,3.48731937682499,HIGH,Y,Y,Y,N,N,2019-04-15,2019-04-15 01:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,COMPLETED,COMPLETED,2022-04-14,1096,,,,,,,2022-05-05,,,1,1,Overall Survival,OS,301.887428667396,DAYS,2020-04-24 01:39:32.683,375,1,Alive,Alive During Study,
1739,AB12345,AB12345-RUS-13-id-70,id-70,RUS-13,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-13,Dr. RUS-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,C,S2,3.48731937682499,HIGH,Y,Y,Y,N,N,2019-04-15,2019-04-15 01:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,COMPLETED,COMPLETED,2022-04-14,1096,,,,,,,2022-05-05,,,3,3,Progression Free Survival,PFS,221.937187830918,DAYS,2022-03-20 01:39:32.683,1070,0,Disease Progression,,
1740,AB12345,AB12345-RUS-13-id-70,id-70,RUS-13,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-13,Dr. RUS-13 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,C,S2,3.48731937682499,HIGH,Y,Y,Y,N,N,2019-04-15,2019-04-15 01:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,2019-04-15 01:39:32.683,2021-04-14 13:39:32.683,2021-04-14 13:39:32.683,2022-04-14 19:39:32.683,COMPLETED,COMPLETED,2022-04-14,1096,,,,,,,2022-05-05,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-1.67819822801916
1741,AB12345,AB12345-RUS-14-id-183,id-183,RUS-14,28,YEARS,M,ASIAN,NOT REPORTED,RUS,N,INV ID RUS-14,Dr. RUS-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S1,4.1960504899445,HIGH,Y,Y,Y,Y,N,2019-08-23,2019-08-27 23:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,COMPLETED,COMPLETED,2022-08-27,1096,,,,,,,2022-09-12,,,3,3,Duration of Confirmed Response,CRSD,176.745085162111,DAYS,2021-08-02 23:04:32.683,706,0,Death,,
1742,AB12345,AB12345-RUS-14-id-183,id-183,RUS-14,28,YEARS,M,ASIAN,NOT REPORTED,RUS,N,INV ID RUS-14,Dr. RUS-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S1,4.1960504899445,HIGH,Y,Y,Y,Y,N,2019-08-23,2019-08-27 23:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,COMPLETED,COMPLETED,2022-08-27,1096,,,,,,,2022-09-12,,,4,4,Event Free Survival,EFS,21.7332321067806,DAYS,2022-05-02 23:04:32.683,979,1,Last Tumor Assessment,Completion or Discontinuation,
1743,AB12345,AB12345-RUS-14-id-183,id-183,RUS-14,28,YEARS,M,ASIAN,NOT REPORTED,RUS,N,INV ID RUS-14,Dr. RUS-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S1,4.1960504899445,HIGH,Y,Y,Y,Y,N,2019-08-23,2019-08-27 23:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,COMPLETED,COMPLETED,2022-08-27,1096,,,,,,,2022-09-12,,,1,1,Overall Survival,OS,176.745085162111,DAYS,2020-07-01 23:04:32.683,309,0,Death,,
1744,AB12345,AB12345-RUS-14-id-183,id-183,RUS-14,28,YEARS,M,ASIAN,NOT REPORTED,RUS,N,INV ID RUS-14,Dr. RUS-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S1,4.1960504899445,HIGH,Y,Y,Y,Y,N,2019-08-23,2019-08-27 23:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,COMPLETED,COMPLETED,2022-08-27,1096,,,,,,,2022-09-12,,,2,2,Progression Free Survival,PFS,176.745085162111,DAYS,2020-07-14 23:04:32.683,322,0,Death,,
1745,AB12345,AB12345-RUS-14-id-183,id-183,RUS-14,28,YEARS,M,ASIAN,NOT REPORTED,RUS,N,INV ID RUS-14,Dr. RUS-14 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S1,4.1960504899445,HIGH,Y,Y,Y,Y,N,2019-08-23,2019-08-27 23:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,2019-08-27 23:04:32.683,2021-08-27 11:04:32.683,2021-08-27 11:04:32.683,2022-08-27 17:04:32.683,COMPLETED,COMPLETED,2022-08-27,1096,,,,,,,2022-09-12,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-5.31029360463215
1746,AB12345,AB12345-RUS-16-id-165,id-165,RUS-16,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-16,Dr. RUS-16 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Eurasia,A,S2,3.49284215498154,MEDIUM,Y,Y,Y,Y,N,2020-07-04,2020-07-06 15:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,COMPLETED,COMPLETED,2023-07-07,1096,,,,,,,2023-07-21,,,4,4,Duration of Confirmed Response,CRSD,177.495206426829,DAYS,2023-07-05 15:51:46.683,1094,0,Death,,
1747,AB12345,AB12345-RUS-16-id-165,id-165,RUS-16,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-16,Dr. RUS-16 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Eurasia,A,S2,3.49284215498154,MEDIUM,Y,Y,Y,Y,N,2020-07-04,2020-07-06 15:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,COMPLETED,COMPLETED,2023-07-07,1096,,,,,,,2023-07-21,,,1,1,Event Free Survival,EFS,17.8294677624945,DAYS,2020-09-04 15:51:46.683,60,1,Last Tumor Assessment,Completion or Discontinuation,
1748,AB12345,AB12345-RUS-16-id-165,id-165,RUS-16,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-16,Dr. RUS-16 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Eurasia,A,S2,3.49284215498154,MEDIUM,Y,Y,Y,Y,N,2020-07-04,2020-07-06 15:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,COMPLETED,COMPLETED,2023-07-07,1096,,,,,,,2023-07-21,,,2,2,Overall Survival,OS,177.495206426829,DAYS,2020-12-06 15:51:46.683,153,0,Death,,
1749,AB12345,AB12345-RUS-16-id-165,id-165,RUS-16,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-16,Dr. RUS-16 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Eurasia,A,S2,3.49284215498154,MEDIUM,Y,Y,Y,Y,N,2020-07-04,2020-07-06 15:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,COMPLETED,COMPLETED,2023-07-07,1096,,,,,,,2023-07-21,,,3,3,Progression Free Survival,PFS,177.495206426829,DAYS,2023-05-24 15:51:46.683,1052,0,Death,,
1750,AB12345,AB12345-RUS-16-id-165,id-165,RUS-16,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-16,Dr. RUS-16 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,Eurasia,A,S2,3.49284215498154,MEDIUM,Y,Y,Y,Y,N,2020-07-04,2020-07-06 15:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,2020-07-06 15:51:46.683,2022-07-07 03:51:46.683,2022-07-07 03:51:46.683,2023-07-07 09:51:46.683,COMPLETED,COMPLETED,2023-07-07,1096,,,,,,,2023-07-21,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-0.924770429974617
1751,AB12345,AB12345-RUS-16-id-4,id-4,RUS-16,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-16,Dr. RUS-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Eurasia,B,S1,12.7693973120077,MEDIUM,Y,Y,Y,N,N,2020-03-25,2020-03-28 04:01:15.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,DISCONTINUED,DISCONTINUED,2022-02-14,689,DEATH,2022-02-26,MISSING,OTHER,12,<=30,2022-02-26,699,,3,3,Duration of Confirmed Response,CRSD,178.481725859456,DAYS,2021-11-23 04:01:15.683,605,0,Death,,
1752,AB12345,AB12345-RUS-16-id-4,id-4,RUS-16,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-16,Dr. RUS-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Eurasia,B,S1,12.7693973120077,MEDIUM,Y,Y,Y,N,N,2020-03-25,2020-03-28 04:01:15.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,DISCONTINUED,DISCONTINUED,2022-02-14,689,DEATH,2022-02-26,MISSING,OTHER,12,<=30,2022-02-26,699,,4,4,Event Free Survival,EFS,48.4865685540717,DAYS,2022-01-15 04:01:15.683,658,1,Last Tumor Assessment,Completion or Discontinuation,
1753,AB12345,AB12345-RUS-16-id-4,id-4,RUS-16,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-16,Dr. RUS-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Eurasia,B,S1,12.7693973120077,MEDIUM,Y,Y,Y,N,N,2020-03-25,2020-03-28 04:01:15.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,DISCONTINUED,DISCONTINUED,2022-02-14,689,DEATH,2022-02-26,MISSING,OTHER,12,<=30,2022-02-26,699,,2,2,Overall Survival,OS,178.481725859456,DAYS,2021-10-04 04:01:15.683,555,0,Death,,
1754,AB12345,AB12345-RUS-16-id-4,id-4,RUS-16,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-16,Dr. RUS-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Eurasia,B,S1,12.7693973120077,MEDIUM,Y,Y,Y,N,N,2020-03-25,2020-03-28 04:01:15.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,DISCONTINUED,DISCONTINUED,2022-02-14,689,DEATH,2022-02-26,MISSING,OTHER,12,<=30,2022-02-26,699,,1,1,Progression Free Survival,PFS,178.481725859456,DAYS,2020-09-04 04:01:15.683,160,0,Death,,
1755,AB12345,AB12345-RUS-16-id-4,id-4,RUS-16,36,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-16,Dr. RUS-16 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,C: Combination,Eurasia,B,S1,12.7693973120077,MEDIUM,Y,Y,Y,N,N,2020-03-25,2020-03-28 04:01:15.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,2020-03-28 04:01:15.683,2021-02-14 06:31:55.683,2021-02-14 06:31:55.683,2022-02-14 12:31:55.683,DISCONTINUED,DISCONTINUED,2022-02-14,689,DEATH,2022-02-26,MISSING,OTHER,12,<=30,2022-02-26,699,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.65886265599418
1756,AB12345,AB12345-RUS-18-id-359,id-359,RUS-18,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-18,Dr. RUS-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Eurasia,B,S1,4.42015902700297,HIGH,Y,Y,N,Y,Y,2019-06-06,2019-06-08 15:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,COMPLETED,COMPLETED,2022-06-08,1096,,,,,,,2022-06-25,,,1,1,Duration of Confirmed Response,CRSD,136.615157802589,DAYS,2021-11-27 15:04:44.683,903,1,Last Tumor Assessment,Completion or Discontinuation,
1757,AB12345,AB12345-RUS-18-id-359,id-359,RUS-18,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-18,Dr. RUS-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Eurasia,B,S1,4.42015902700297,HIGH,Y,Y,N,Y,Y,2019-06-06,2019-06-08 15:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,COMPLETED,COMPLETED,2022-06-08,1096,,,,,,,2022-06-25,,,4,4,Event Free Survival,EFS,17.8332451358438,DAYS,2022-03-20 15:04:44.683,1016,1,Last Tumor Assessment,Completion or Discontinuation,
1758,AB12345,AB12345-RUS-18-id-359,id-359,RUS-18,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-18,Dr. RUS-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Eurasia,B,S1,4.42015902700297,HIGH,Y,Y,N,Y,Y,2019-06-06,2019-06-08 15:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,COMPLETED,COMPLETED,2022-06-08,1096,,,,,,,2022-06-25,,,2,2,Overall Survival,OS,493.182507529855,DAYS,2021-12-22 15:04:44.683,928,1,Alive,Alive During Study,
1759,AB12345,AB12345-RUS-18-id-359,id-359,RUS-18,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-18,Dr. RUS-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Eurasia,B,S1,4.42015902700297,HIGH,Y,Y,N,Y,Y,2019-06-06,2019-06-08 15:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,COMPLETED,COMPLETED,2022-06-08,1096,,,,,,,2022-06-25,,,3,3,Progression Free Survival,PFS,220.768843987025,DAYS,2021-12-28 15:04:44.683,934,1,Adverse Event,Preferred Term,
1760,AB12345,AB12345-RUS-18-id-359,id-359,RUS-18,47,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-18,Dr. RUS-18 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,Eurasia,B,S1,4.42015902700297,HIGH,Y,Y,N,Y,Y,2019-06-06,2019-06-08 15:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,2019-06-08 15:04:44.683,2021-06-08 03:04:44.683,2021-06-08 03:04:44.683,2022-06-08 09:04:44.683,COMPLETED,COMPLETED,2022-06-08,1096,,,,,,,2022-06-25,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.413202390191355
1761,AB12345,AB12345-RUS-2-id-176,id-176,RUS-2,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-2,Dr. RUS-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,C,S2,5.65962488479405,LOW,Y,Y,N,N,N,2020-04-12,2020-04-12 13:48:53.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,DISCONTINUED,DISCONTINUED,2022-02-15,674,DEATH,2022-02-27,MISSING,OTHER,12,<=30,2022-02-27,685,,3,3,Duration of Confirmed Response,CRSD,144.111595186405,DAYS,2021-08-17 13:48:53.683,492,0,Death,,
1762,AB12345,AB12345-RUS-2-id-176,id-176,RUS-2,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-2,Dr. RUS-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,C,S2,5.65962488479405,LOW,Y,Y,N,N,N,2020-04-12,2020-04-12 13:48:53.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,DISCONTINUED,DISCONTINUED,2022-02-15,674,DEATH,2022-02-27,MISSING,OTHER,12,<=30,2022-02-27,685,,4,4,Event Free Survival,EFS,63.0221106263343,DAYS,2021-09-25 13:48:53.683,531,0,Disease Progression,,
1763,AB12345,AB12345-RUS-2-id-176,id-176,RUS-2,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-2,Dr. RUS-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,C,S2,5.65962488479405,LOW,Y,Y,N,N,N,2020-04-12,2020-04-12 13:48:53.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,DISCONTINUED,DISCONTINUED,2022-02-15,674,DEATH,2022-02-27,MISSING,OTHER,12,<=30,2022-02-27,685,,2,2,Overall Survival,OS,144.111595186405,DAYS,2021-08-15 13:48:53.683,490,0,Death,,
1764,AB12345,AB12345-RUS-2-id-176,id-176,RUS-2,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-2,Dr. RUS-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,C,S2,5.65962488479405,LOW,Y,Y,N,N,N,2020-04-12,2020-04-12 13:48:53.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,DISCONTINUED,DISCONTINUED,2022-02-15,674,DEATH,2022-02-27,MISSING,OTHER,12,<=30,2022-02-27,685,,1,1,Progression Free Survival,PFS,144.111595186405,DAYS,2020-10-22 13:48:53.683,193,0,Death,,
1765,AB12345,AB12345-RUS-2-id-176,id-176,RUS-2,42,YEARS,F,WHITE,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-2,Dr. RUS-2 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,B: Placebo,Eurasia,C,S2,5.65962488479405,LOW,Y,Y,N,N,N,2020-04-12,2020-04-12 13:48:53.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,2020-04-12 13:48:53.683,2021-02-15 04:07:51.683,2021-02-15 04:07:51.683,2022-02-15 10:07:51.683,DISCONTINUED,DISCONTINUED,2022-02-15,674,DEATH,2022-02-27,MISSING,OTHER,12,<=30,2022-02-27,685,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-2.42749818409123
1766,AB12345,AB12345-RUS-3-id-378,id-378,RUS-3,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-3,Dr. RUS-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Eurasia,A,S1,2.80323956920649,HIGH,Y,Y,Y,N,N,2019-02-24,2019-02-28 03:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,COMPLETED,COMPLETED,2022-02-27,1096,,,,,,,2022-03-11,,,1,1,Duration of Confirmed Response,CRSD,116.563327750191,DAYS,2019-09-19 03:19:22.683,203,0,Disease Progression,,
1767,AB12345,AB12345-RUS-3-id-378,id-378,RUS-3,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-3,Dr. RUS-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Eurasia,A,S1,2.80323956920649,HIGH,Y,Y,Y,N,N,2019-02-24,2019-02-28 03:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,COMPLETED,COMPLETED,2022-02-27,1096,,,,,,,2022-03-11,,,3,3,Event Free Survival,EFS,83.3287899091374,DAYS,2020-10-19 03:19:22.683,599,1,Last Tumor Assessment,Completion or Discontinuation,
1768,AB12345,AB12345-RUS-3-id-378,id-378,RUS-3,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-3,Dr. RUS-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Eurasia,A,S1,2.80323956920649,HIGH,Y,Y,Y,N,N,2019-02-24,2019-02-28 03:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,COMPLETED,COMPLETED,2022-02-27,1096,,,,,,,2022-03-11,,,4,4,Overall Survival,OS,220.611856225878,DAYS,2021-03-07 03:19:22.683,738,0,Death,,
1769,AB12345,AB12345-RUS-3-id-378,id-378,RUS-3,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-3,Dr. RUS-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Eurasia,A,S1,2.80323956920649,HIGH,Y,Y,Y,N,N,2019-02-24,2019-02-28 03:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,COMPLETED,COMPLETED,2022-02-27,1096,,,,,,,2022-03-11,,,2,2,Progression Free Survival,PFS,220.611856225878,DAYS,2020-03-20 03:19:22.683,386,0,Death,,
1770,AB12345,AB12345-RUS-3-id-378,id-378,RUS-3,30,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-3,Dr. RUS-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,Eurasia,A,S1,2.80323956920649,HIGH,Y,Y,Y,N,N,2019-02-24,2019-02-28 03:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,2019-02-28 03:19:22.683,2021-02-27 15:19:22.683,2021-02-27 15:19:22.683,2022-02-27 21:19:22.683,COMPLETED,COMPLETED,2022-02-27,1096,,,,,,,2022-03-11,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.62537781078303
1771,AB12345,AB12345-RUS-4-id-150,id-150,RUS-4,29,YEARS,M,WHITE,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,C,S1,3.31455199584702,LOW,Y,Y,N,Y,N,2020-03-09,2020-03-09 04:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,1,1,Duration of Confirmed Response,CRSD,145.081490767188,DAYS,2021-03-31 04:49:56.683,387,1,Last Tumor Assessment,Completion or Discontinuation,
1772,AB12345,AB12345-RUS-4-id-150,id-150,RUS-4,29,YEARS,M,WHITE,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,C,S1,3.31455199584702,LOW,Y,Y,N,Y,N,2020-03-09,2020-03-09 04:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,3,3,Event Free Survival,EFS,44.6298675937578,DAYS,2022-08-24 04:49:56.683,898,1,Adverse Event,Preferred Term,
1773,AB12345,AB12345-RUS-4-id-150,id-150,RUS-4,29,YEARS,M,WHITE,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,C,S1,3.31455199584702,LOW,Y,Y,N,Y,N,2020-03-09,2020-03-09 04:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,4,4,Overall Survival,OS,420.123692369089,DAYS,2023-03-06 04:49:56.683,1092,1,Alive,Alive During Study,
1774,AB12345,AB12345-RUS-4-id-150,id-150,RUS-4,29,YEARS,M,WHITE,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,C,S1,3.31455199584702,LOW,Y,Y,N,Y,N,2020-03-09,2020-03-09 04:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,2,2,Progression Free Survival,PFS,210.317673278041,DAYS,2021-06-06 04:49:56.683,454,1,Adverse Event,Preferred Term,
1775,AB12345,AB12345-RUS-4-id-150,id-150,RUS-4,29,YEARS,M,WHITE,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,C,S1,3.31455199584702,LOW,Y,Y,N,Y,N,2020-03-09,2020-03-09 04:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,2020-03-09 04:49:56.683,2022-03-09 16:49:56.683,2022-03-09 16:49:56.683,2023-03-09 22:49:56.683,COMPLETED,COMPLETED,2023-03-09,1096,,,,,,,2023-03-31,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-1.74915393952617
1776,AB12345,AB12345-RUS-4-id-180,id-180,RUS-4,31,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,A,S1,1.62271793424187,HIGH,Y,Y,Y,Y,N,2019-06-17,2019-06-21 02:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,COMPLETED,COMPLETED,2022-06-20,1096,,,,,,,2022-07-05,,,2,2,Duration of Confirmed Response,CRSD,195.718610915355,DAYS,2021-10-08 02:08:16.683,840,1,Adverse Event,Preferred Term,
1777,AB12345,AB12345-RUS-4-id-180,id-180,RUS-4,31,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,A,S1,1.62271793424187,HIGH,Y,Y,Y,Y,N,2019-06-17,2019-06-21 02:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,COMPLETED,COMPLETED,2022-06-20,1096,,,,,,,2022-07-05,,,4,4,Event Free Survival,EFS,23.5491221689153,DAYS,2022-01-26 02:08:16.683,950,1,Last Tumor Assessment,Completion or Discontinuation,
1778,AB12345,AB12345-RUS-4-id-180,id-180,RUS-4,31,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,A,S1,1.62271793424187,HIGH,Y,Y,Y,Y,N,2019-06-17,2019-06-21 02:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,COMPLETED,COMPLETED,2022-06-20,1096,,,,,,,2022-07-05,,,3,3,Overall Survival,OS,333.778876019642,DAYS,2021-11-12 02:08:16.683,875,1,Alive,Alive During Study,
1779,AB12345,AB12345-RUS-4-id-180,id-180,RUS-4,31,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,A,S1,1.62271793424187,HIGH,Y,Y,Y,Y,N,2019-06-17,2019-06-21 02:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,COMPLETED,COMPLETED,2022-06-20,1096,,,,,,,2022-07-05,,,1,1,Progression Free Survival,PFS,258.097443939187,DAYS,2020-12-26 02:08:16.683,554,1,Adverse Event,Preferred Term,
1780,AB12345,AB12345-RUS-4-id-180,id-180,RUS-4,31,YEARS,F,ASIAN,HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,Eurasia,A,S1,1.62271793424187,HIGH,Y,Y,Y,Y,N,2019-06-17,2019-06-21 02:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,2019-06-21 02:08:16.683,2021-06-20 14:08:16.683,2021-06-20 14:08:16.683,2022-06-20 20:08:16.683,COMPLETED,COMPLETED,2022-06-20,1096,,,,,,,2022-07-05,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,0.628712538240142
1781,AB12345,AB12345-RUS-4-id-6,id-6,RUS-4,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Eurasia,B,S2,4.94419512919253,MEDIUM,Y,Y,Y,N,N,2019-03-31,2019-04-03 01:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,COMPLETED,COMPLETED,2022-04-02,1096,,,,,,,2022-04-13,,,1,1,Duration of Confirmed Response,CRSD,105.432283971459,DAYS,2019-04-17 01:01:46.683,14,1,Adverse Event,Preferred Term,
1782,AB12345,AB12345-RUS-4-id-6,id-6,RUS-4,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Eurasia,B,S2,4.94419512919253,MEDIUM,Y,Y,Y,N,N,2019-03-31,2019-04-03 01:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,COMPLETED,COMPLETED,2022-04-02,1096,,,,,,,2022-04-13,,,3,3,Event Free Survival,EFS,59.0785463270731,DAYS,2019-08-19 01:01:46.683,138,1,Last Tumor Assessment,Completion or Discontinuation,
1783,AB12345,AB12345-RUS-4-id-6,id-6,RUS-4,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Eurasia,B,S2,4.94419512919253,MEDIUM,Y,Y,Y,N,N,2019-03-31,2019-04-03 01:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,COMPLETED,COMPLETED,2022-04-02,1096,,,,,,,2022-04-13,,,2,2,Overall Survival,OS,306.494894064963,DAYS,2019-07-12 01:01:46.683,100,1,Alive,Alive During Study,
1784,AB12345,AB12345-RUS-4-id-6,id-6,RUS-4,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Eurasia,B,S2,4.94419512919253,MEDIUM,Y,Y,Y,N,N,2019-03-31,2019-04-03 01:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,COMPLETED,COMPLETED,2022-04-02,1096,,,,,,,2022-04-13,,,4,4,Progression Free Survival,PFS,218.187462771311,DAYS,2021-10-28 01:01:46.683,939,1,Adverse Event,Preferred Term,
1785,AB12345,AB12345-RUS-4-id-6,id-6,RUS-4,44,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-4,Dr. RUS-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,Eurasia,B,S2,4.94419512919253,MEDIUM,Y,Y,Y,N,N,2019-03-31,2019-04-03 01:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,2019-04-03 01:01:46.683,2021-04-02 13:01:46.683,2021-04-02 13:01:46.683,2022-04-02 19:01:46.683,COMPLETED,COMPLETED,2022-04-02,1096,,,,,,,2022-04-13,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Preferred Term,-0.100259569464743
1786,AB12345,AB12345-RUS-5-id-29,id-29,RUS-5,58,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-5,Dr. RUS-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Eurasia,B,S2,2.11507688662117,HIGH,Y,Y,N,N,N,2020-12-05,2020-12-08 01:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,COMPLETED,COMPLETED,2023-12-08,1096,,,,,,,2023-12-25,,,1,1,Duration of Confirmed Response,CRSD,171.080473158509,DAYS,2021-06-05 01:10:31.683,179,0,Disease Progression,,
1787,AB12345,AB12345-RUS-5-id-29,id-29,RUS-5,58,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-5,Dr. RUS-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Eurasia,B,S2,2.11507688662117,HIGH,Y,Y,N,N,N,2020-12-05,2020-12-08 01:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,COMPLETED,COMPLETED,2023-12-08,1096,,,,,,,2023-12-25,,,4,4,Event Free Survival,EFS,50.1431144040544,DAYS,2022-10-25 01:10:31.683,686,1,Adverse Event,Preferred Term,
1788,AB12345,AB12345-RUS-5-id-29,id-29,RUS-5,58,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-5,Dr. RUS-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Eurasia,B,S2,2.11507688662117,HIGH,Y,Y,N,N,N,2020-12-05,2020-12-08 01:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,COMPLETED,COMPLETED,2023-12-08,1096,,,,,,,2023-12-25,,,3,3,Overall Survival,OS,395.20607017912,DAYS,2021-10-09 01:10:31.683,305,1,Alive,Alive During Study,
1789,AB12345,AB12345-RUS-5-id-29,id-29,RUS-5,58,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-5,Dr. RUS-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Eurasia,B,S2,2.11507688662117,HIGH,Y,Y,N,N,N,2020-12-05,2020-12-08 01:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,COMPLETED,COMPLETED,2023-12-08,1096,,,,,,,2023-12-25,,,2,2,Progression Free Survival,PFS,243.829421675764,DAYS,2021-09-14 01:10:31.683,280,1,Last Tumor Assessment,Completion or Discontinuation,
1790,AB12345,AB12345-RUS-5-id-29,id-29,RUS-5,58,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-5,Dr. RUS-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,Eurasia,B,S2,2.11507688662117,HIGH,Y,Y,N,N,N,2020-12-05,2020-12-08 01:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,2020-12-08 01:10:31.683,2022-12-08 13:10:31.683,2022-12-08 13:10:31.683,2023-12-08 19:10:31.683,COMPLETED,COMPLETED,2023-12-08,1096,,,,,,,2023-12-25,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.7758402347148
1791,AB12345,AB12345-RUS-6-id-77,id-77,RUS-6,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-6,Dr. RUS-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,B,S2,5.81259383017409,LOW,Y,Y,Y,Y,N,2020-11-23,2020-11-24 21:11:00.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,DISCONTINUED,DISCONTINUED,2022-02-14,447,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-04,495,Yes,3,3,Duration of Confirmed Response,CRSD,177.996834251098,DAYS,2021-03-31 21:11:00.683,127,1,Last Tumor Assessment,Completion or Discontinuation,
1792,AB12345,AB12345-RUS-6-id-77,id-77,RUS-6,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-6,Dr. RUS-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,B,S2,5.81259383017409,LOW,Y,Y,Y,Y,N,2020-11-23,2020-11-24 21:11:00.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,DISCONTINUED,DISCONTINUED,2022-02-14,447,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-04,495,Yes,2,2,Event Free Survival,EFS,47.2749013279099,DAYS,2021-03-01 21:11:00.683,97,0,Disease Progression,,
1793,AB12345,AB12345-RUS-6-id-77,id-77,RUS-6,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-6,Dr. RUS-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,B,S2,5.81259383017409,LOW,Y,Y,Y,Y,N,2020-11-23,2020-11-24 21:11:00.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,DISCONTINUED,DISCONTINUED,2022-02-14,447,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-04,495,Yes,4,4,Overall Survival,OS,388.799682818353,DAYS,2021-10-20 21:11:00.683,330,1,Alive,Alive During Study,
1794,AB12345,AB12345-RUS-6-id-77,id-77,RUS-6,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-6,Dr. RUS-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,B,S2,5.81259383017409,LOW,Y,Y,Y,Y,N,2020-11-23,2020-11-24 21:11:00.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,DISCONTINUED,DISCONTINUED,2022-02-14,447,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-04,495,Yes,1,1,Progression Free Survival,PFS,296.157720312476,DAYS,2021-02-08 21:11:00.683,76,1,Adverse Event,Preferred Term,
1795,AB12345,AB12345-RUS-6-id-77,id-77,RUS-6,26,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,RUS,Y,INV ID RUS-6,Dr. RUS-6 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,Eurasia,B,S2,5.81259383017409,LOW,Y,Y,Y,Y,N,2020-11-23,2020-11-24 21:11:00.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,2020-11-24 21:11:00.683,2021-02-14 09:19:45.683,2021-02-14 09:19:45.683,2022-02-14 15:19:45.683,DISCONTINUED,DISCONTINUED,2022-02-14,447,DEATH,2022-04-04,ADVERSE EVENT,ADVERSE EVENT,49,>30,2022-04-04,495,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-0.515579545574125
1796,AB12345,AB12345-RUS-7-id-243,id-243,RUS-7,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-7,Dr. RUS-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S2,3.03180044557785,LOW,Y,Y,N,Y,N,2021-01-22,2021-01-23 08:04:50.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,DISCONTINUED,DISCONTINUED,2022-02-13,387,ADVERSE EVENT,,,,,,2022-02-24,,,2,2,Duration of Confirmed Response,CRSD,165.287494170479,DAYS,2021-06-28 08:04:50.683,156,0,Disease Progression,,
1797,AB12345,AB12345-RUS-7-id-243,id-243,RUS-7,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-7,Dr. RUS-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S2,3.03180044557785,LOW,Y,Y,N,Y,N,2021-01-22,2021-01-23 08:04:50.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,DISCONTINUED,DISCONTINUED,2022-02-13,387,ADVERSE EVENT,,,,,,2022-02-24,,,3,3,Event Free Survival,EFS,38.5090041160583,DAYS,2021-07-31 08:04:50.683,189,1,Last Tumor Assessment,Completion or Discontinuation,
1798,AB12345,AB12345-RUS-7-id-243,id-243,RUS-7,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-7,Dr. RUS-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S2,3.03180044557785,LOW,Y,Y,N,Y,N,2021-01-22,2021-01-23 08:04:50.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,DISCONTINUED,DISCONTINUED,2022-02-13,387,ADVERSE EVENT,,,,,,2022-02-24,,,1,1,Overall Survival,OS,417.741276370361,DAYS,2021-06-19 08:04:50.683,147,1,Alive,Alive During Study,
1799,AB12345,AB12345-RUS-7-id-243,id-243,RUS-7,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-7,Dr. RUS-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S2,3.03180044557785,LOW,Y,Y,N,Y,N,2021-01-22,2021-01-23 08:04:50.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,DISCONTINUED,DISCONTINUED,2022-02-13,387,ADVERSE EVENT,,,,,,2022-02-24,,,4,4,Progression Free Survival,PFS,275.472403527237,DAYS,2021-12-30 08:04:50.683,341,1,Last Tumor Assessment,Completion or Discontinuation,
1800,AB12345,AB12345-RUS-7-id-243,id-243,RUS-7,27,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,RUS,N,INV ID RUS-7,Dr. RUS-7 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,A: Drug X,Eurasia,C,S2,3.03180044557785,LOW,Y,Y,N,Y,N,2021-01-22,2021-01-23 08:04:50.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,2021-01-23 08:04:50.683,2021-02-13 08:12:56.683,2021-02-13 08:12:56.683,2022-02-13 14:12:56.683,DISCONTINUED,DISCONTINUED,2022-02-13,387,ADVERSE EVENT,,,,,,2022-02-24,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-1.59515754495851
1801,AB12345,AB12345-USA-1-id-137,id-137,USA-1,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,C,S2,3.40697206354116,HIGH,Y,Y,Y,N,N,2019-05-01,2019-05-03 19:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-19,,,4,4,Duration of Confirmed Response,CRSD,150.939102610573,DAYS,2021-12-25 19:18:43.683,967,1,Adverse Event,Preferred Term,
1802,AB12345,AB12345-USA-1-id-137,id-137,USA-1,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,C,S2,3.40697206354116,HIGH,Y,Y,Y,N,N,2019-05-01,2019-05-03 19:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-19,,,3,3,Event Free Survival,EFS,46.1863359971903,DAYS,2021-08-15 19:18:43.683,835,1,Adverse Event,Preferred Term,
1803,AB12345,AB12345-USA-1-id-137,id-137,USA-1,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,C,S2,3.40697206354116,HIGH,Y,Y,Y,N,N,2019-05-01,2019-05-03 19:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-19,,,1,1,Overall Survival,OS,353.330907132477,DAYS,2019-05-22 19:18:43.683,19,1,Alive,Alive During Study,
1804,AB12345,AB12345-USA-1-id-137,id-137,USA-1,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,C,S2,3.40697206354116,HIGH,Y,Y,Y,N,N,2019-05-01,2019-05-03 19:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-19,,,2,2,Progression Free Survival,PFS,214.422911358997,DAYS,2020-04-30 19:18:43.683,363,0,Disease Progression,,
1805,AB12345,AB12345-USA-1-id-137,id-137,USA-1,29,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,C,S2,3.40697206354116,HIGH,Y,Y,Y,N,N,2019-05-01,2019-05-03 19:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,2019-05-03 19:18:43.683,2021-05-03 07:18:43.683,2021-05-03 07:18:43.683,2022-05-03 13:18:43.683,COMPLETED,COMPLETED,2022-05-03,1096,,,,,,,2022-05-19,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Preferred Term,-2.76529333756997
1806,AB12345,AB12345-USA-1-id-138,id-138,USA-1,36,YEARS,M,ASIAN,UNKNOWN,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,A,S1,2.96585672819946,MEDIUM,Y,Y,N,N,N,2020-08-14,2020-08-15 03:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,COMPLETED,COMPLETED,2023-08-15,1096,,,,,,,2023-09-04,,,2,2,Duration of Confirmed Response,CRSD,189.652729523368,DAYS,2022-01-12 03:09:56.683,515,0,Disease Progression,,
1807,AB12345,AB12345-USA-1-id-138,id-138,USA-1,36,YEARS,M,ASIAN,UNKNOWN,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,A,S1,2.96585672819946,MEDIUM,Y,Y,N,N,N,2020-08-14,2020-08-15 03:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,COMPLETED,COMPLETED,2023-08-15,1096,,,,,,,2023-09-04,,,3,3,Event Free Survival,EFS,29.7747775714379,DAYS,2022-12-18 03:09:56.683,855,1,Adverse Event,Preferred Term,
1808,AB12345,AB12345-USA-1-id-138,id-138,USA-1,36,YEARS,M,ASIAN,UNKNOWN,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,A,S1,2.96585672819946,MEDIUM,Y,Y,N,N,N,2020-08-14,2020-08-15 03:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,COMPLETED,COMPLETED,2023-08-15,1096,,,,,,,2023-09-04,,,4,4,Overall Survival,OS,256.234313268214,DAYS,2023-01-14 03:09:56.683,882,0,Death,,
1809,AB12345,AB12345-USA-1-id-138,id-138,USA-1,36,YEARS,M,ASIAN,UNKNOWN,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,A,S1,2.96585672819946,MEDIUM,Y,Y,N,N,N,2020-08-14,2020-08-15 03:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,COMPLETED,COMPLETED,2023-08-15,1096,,,,,,,2023-09-04,,,1,1,Progression Free Survival,PFS,256.234313268214,DAYS,2020-10-09 03:09:56.683,55,0,Death,,
1810,AB12345,AB12345-USA-1-id-138,id-138,USA-1,36,YEARS,M,ASIAN,UNKNOWN,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,A,S1,2.96585672819946,MEDIUM,Y,Y,N,N,N,2020-08-14,2020-08-15 03:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,2020-08-15 03:09:56.683,2022-08-15 15:09:56.683,2022-08-15 15:09:56.683,2023-08-15 21:09:56.683,COMPLETED,COMPLETED,2023-08-15,1096,,,,,,,2023-09-04,,,,,Total Number of Exacerbations,TNE,8,COUNT,,,0,,,-2.92567631583475
1811,AB12345,AB12345-USA-1-id-207,id-207,USA-1,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,A,S2,5.30656153475866,MEDIUM,Y,Y,N,N,N,2021-01-13,2021-01-14 21:27:58.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,DISCONTINUED,DISCONTINUED,2022-02-17,400,DEATH,2022-03-04,DISEASE PROGRESSION,PROGRESSIVE DISEASE,15,<=30,2022-03-04,413,Yes,3,3,Duration of Confirmed Response,CRSD,44.1086170263588,DAYS,2021-12-22 21:27:58.683,342,0,Death,,
1812,AB12345,AB12345-USA-1-id-207,id-207,USA-1,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,A,S2,5.30656153475866,MEDIUM,Y,Y,N,N,N,2021-01-13,2021-01-14 21:27:58.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,DISCONTINUED,DISCONTINUED,2022-02-17,400,DEATH,2022-03-04,DISEASE PROGRESSION,PROGRESSIVE DISEASE,15,<=30,2022-03-04,413,Yes,2,2,Event Free Survival,EFS,44.1086170263588,DAYS,2021-11-09 21:27:58.683,299,0,Death,,
1813,AB12345,AB12345-USA-1-id-207,id-207,USA-1,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,A,S2,5.30656153475866,MEDIUM,Y,Y,N,N,N,2021-01-13,2021-01-14 21:27:58.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,DISCONTINUED,DISCONTINUED,2022-02-17,400,DEATH,2022-03-04,DISEASE PROGRESSION,PROGRESSIVE DISEASE,15,<=30,2022-03-04,413,Yes,1,1,Overall Survival,OS,44.1086170263588,DAYS,2021-06-29 21:27:58.683,166,0,Death,,
1814,AB12345,AB12345-USA-1-id-207,id-207,USA-1,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,A,S2,5.30656153475866,MEDIUM,Y,Y,N,N,N,2021-01-13,2021-01-14 21:27:58.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,DISCONTINUED,DISCONTINUED,2022-02-17,400,DEATH,2022-03-04,DISEASE PROGRESSION,PROGRESSIVE DISEASE,15,<=30,2022-03-04,413,Yes,4,4,Progression Free Survival,PFS,44.1086170263588,DAYS,2022-01-14 21:27:58.683,365,0,Death,,
1815,AB12345,AB12345-USA-1-id-207,id-207,USA-1,38,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,A,S2,5.30656153475866,MEDIUM,Y,Y,N,N,N,2021-01-13,2021-01-14 21:27:58.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,2021-01-14 21:27:58.683,2021-02-17 17:02:32.683,2021-02-17 17:02:32.683,2022-02-17 23:02:32.683,DISCONTINUED,DISCONTINUED,2022-02-17,400,DEATH,2022-03-04,DISEASE PROGRESSION,PROGRESSIVE DISEASE,15,<=30,2022-03-04,413,Yes,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-1.76992300041862
1816,AB12345,AB12345-USA-1-id-242,id-242,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,13.8785901006382,HIGH,Y,Y,Y,N,N,2019-04-25,2019-04-27 19:55:31.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,DISCONTINUED,DISCONTINUED,2022-02-15,1025,ADVERSE EVENT,,,,,,2022-03-01,,,2,2,Duration of Confirmed Response,CRSD,174.753848323599,DAYS,2020-04-01 19:55:31.683,340,0,Disease Progression,,
1817,AB12345,AB12345-USA-1-id-242,id-242,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,13.8785901006382,HIGH,Y,Y,Y,N,N,2019-04-25,2019-04-27 19:55:31.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,DISCONTINUED,DISCONTINUED,2022-02-15,1025,ADVERSE EVENT,,,,,,2022-03-01,,,4,4,Event Free Survival,EFS,39.117022829596,DAYS,2021-09-12 19:55:31.683,869,1,Last Tumor Assessment,Completion or Discontinuation,
1818,AB12345,AB12345-USA-1-id-242,id-242,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,13.8785901006382,HIGH,Y,Y,Y,N,N,2019-04-25,2019-04-27 19:55:31.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,DISCONTINUED,DISCONTINUED,2022-02-15,1025,ADVERSE EVENT,,,,,,2022-03-01,,,3,3,Overall Survival,OS,413.077199086547,DAYS,2020-07-08 19:55:31.683,438,1,Alive,Alive During Study,
1819,AB12345,AB12345-USA-1-id-242,id-242,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,13.8785901006382,HIGH,Y,Y,Y,N,N,2019-04-25,2019-04-27 19:55:31.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,DISCONTINUED,DISCONTINUED,2022-02-15,1025,ADVERSE EVENT,,,,,,2022-03-01,,,1,1,Progression Free Survival,PFS,256.285019475035,DAYS,2019-09-23 19:55:31.683,149,0,Disease Progression,,
1820,AB12345,AB12345-USA-1-id-242,id-242,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,B,S2,13.8785901006382,HIGH,Y,Y,Y,N,N,2019-04-25,2019-04-27 19:55:31.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,2019-04-27 19:55:31.683,2021-02-14 19:01:53.683,2021-02-14 19:01:53.683,2022-02-15 01:01:53.683,DISCONTINUED,DISCONTINUED,2022-02-15,1025,ADVERSE EVENT,,,,,,2022-03-01,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-2.35598765359714
1821,AB12345,AB12345-USA-1-id-254,id-254,USA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,2.65998328430932,MEDIUM,Y,Y,Y,N,N,2020-09-13,2020-09-15 15:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-14,,,2,2,Duration of Confirmed Response,CRSD,196.258659195155,DAYS,2021-09-15 15:02:29.683,365,1,Last Tumor Assessment,Completion or Discontinuation,
1822,AB12345,AB12345-USA-1-id-254,id-254,USA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,2.65998328430932,MEDIUM,Y,Y,Y,N,N,2020-09-13,2020-09-15 15:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-14,,,1,1,Event Free Survival,EFS,68.8332054635976,DAYS,2021-07-29 15:02:29.683,317,0,Disease Progression,,
1823,AB12345,AB12345-USA-1-id-254,id-254,USA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,2.65998328430932,MEDIUM,Y,Y,Y,N,N,2020-09-13,2020-09-15 15:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-14,,,3,3,Overall Survival,OS,452.304835338145,DAYS,2021-09-17 15:02:29.683,367,1,Alive,Alive During Study,
1824,AB12345,AB12345-USA-1-id-254,id-254,USA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,2.65998328430932,MEDIUM,Y,Y,Y,N,N,2020-09-13,2020-09-15 15:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-14,,,4,4,Progression Free Survival,PFS,276.894120406359,DAYS,2021-11-15 15:02:29.683,426,1,Adverse Event,Preferred Term,
1825,AB12345,AB12345-USA-1-id-254,id-254,USA-1,28,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,2.65998328430932,MEDIUM,Y,Y,Y,N,N,2020-09-13,2020-09-15 15:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,2020-09-15 15:02:29.683,2022-09-16 03:02:29.683,2022-09-16 03:02:29.683,2023-09-16 09:02:29.683,COMPLETED,COMPLETED,2023-09-16,1096,,,,,,,2023-10-14,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,1,,Completion or Discontinuation,-0.677937735101378
1826,AB12345,AB12345-USA-1-id-261,id-261,USA-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S1,2.85516419937308,HIGH,Y,Y,Y,N,N,2019-03-02,2019-03-06 17:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,1,1,Duration of Confirmed Response,CRSD,27.9813825397287,DAYS,2019-06-10 17:21:21.683,96,0,Death,,
1827,AB12345,AB12345-USA-1-id-261,id-261,USA-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S1,2.85516419937308,HIGH,Y,Y,Y,N,N,2019-03-02,2019-03-06 17:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,2,2,Event Free Survival,EFS,27.9813825397287,DAYS,2019-07-03 17:21:21.683,119,0,Death,,
1828,AB12345,AB12345-USA-1-id-261,id-261,USA-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S1,2.85516419937308,HIGH,Y,Y,Y,N,N,2019-03-02,2019-03-06 17:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,3,3,Overall Survival,OS,27.9813825397287,DAYS,2020-06-10 17:21:21.683,462,0,Death,,
1829,AB12345,AB12345-USA-1-id-261,id-261,USA-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S1,2.85516419937308,HIGH,Y,Y,Y,N,N,2019-03-02,2019-03-06 17:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,4,4,Progression Free Survival,PFS,27.9813825397287,DAYS,2021-11-21 17:21:21.683,991,0,Death,,
1830,AB12345,AB12345-USA-1-id-261,id-261,USA-1,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S1,2.85516419937308,HIGH,Y,Y,Y,N,N,2019-03-02,2019-03-06 17:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,2019-03-06 17:21:21.683,2021-03-06 05:21:21.683,2021-03-06 05:21:21.683,2022-03-06 11:21:21.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.37231922266116
1831,AB12345,AB12345-USA-1-id-269,id-269,USA-1,35,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,C,S1,3.54766984034304,MEDIUM,Y,Y,N,N,N,2019-05-16,2019-05-17 11:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,COMPLETED,COMPLETED,2022-05-17,1096,,,,,,,2022-06-09,,,4,4,Duration of Confirmed Response,CRSD,191.361579415388,DAYS,2021-02-24 11:14:23.683,649,0,Death,,
1832,AB12345,AB12345-USA-1-id-269,id-269,USA-1,35,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,C,S1,3.54766984034304,MEDIUM,Y,Y,N,N,N,2019-05-16,2019-05-17 11:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,COMPLETED,COMPLETED,2022-05-17,1096,,,,,,,2022-06-09,,,1,1,Event Free Survival,EFS,46.2628272781149,DAYS,2019-06-19 11:14:23.683,33,1,Adverse Event,Preferred Term,
1833,AB12345,AB12345-USA-1-id-269,id-269,USA-1,35,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,C,S1,3.54766984034304,MEDIUM,Y,Y,N,N,N,2019-05-16,2019-05-17 11:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,COMPLETED,COMPLETED,2022-05-17,1096,,,,,,,2022-06-09,,,2,2,Overall Survival,OS,191.361579415388,DAYS,2020-03-28 11:14:23.683,316,0,Death,,
1834,AB12345,AB12345-USA-1-id-269,id-269,USA-1,35,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,C,S1,3.54766984034304,MEDIUM,Y,Y,N,N,N,2019-05-16,2019-05-17 11:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,COMPLETED,COMPLETED,2022-05-17,1096,,,,,,,2022-06-09,,,3,3,Progression Free Survival,PFS,191.361579415388,DAYS,2020-09-10 11:14:23.683,482,0,Death,,
1835,AB12345,AB12345-USA-1-id-269,id-269,USA-1,35,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,C,S1,3.54766984034304,MEDIUM,Y,Y,N,N,N,2019-05-16,2019-05-17 11:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,2019-05-17 11:14:23.683,2021-05-16 23:14:23.683,2021-05-16 23:14:23.683,2022-05-17 05:14:23.683,COMPLETED,COMPLETED,2022-05-17,1096,,,,,,,2022-06-09,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.55284378506974
1836,AB12345,AB12345-USA-1-id-295,id-295,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,B,S1,1.68619278274214,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-09 23:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,COMPLETED,COMPLETED,2022-08-09,1096,,,,,,,2022-08-28,,,2,2,Duration of Confirmed Response,CRSD,102.773472690023,DAYS,2020-01-01 23:49:26.683,145,1,Last Tumor Assessment,Completion or Discontinuation,
1837,AB12345,AB12345-USA-1-id-295,id-295,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,B,S1,1.68619278274214,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-09 23:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,COMPLETED,COMPLETED,2022-08-09,1096,,,,,,,2022-08-28,,,3,3,Event Free Survival,EFS,57.189762480557,DAYS,2020-11-19 23:49:26.683,468,1,Last Tumor Assessment,Completion or Discontinuation,
1838,AB12345,AB12345-USA-1-id-295,id-295,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,B,S1,1.68619278274214,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-09 23:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,COMPLETED,COMPLETED,2022-08-09,1096,,,,,,,2022-08-28,,,1,1,Overall Survival,OS,305.437543615699,DAYS,2019-10-04 23:49:26.683,56,1,Alive,Alive During Study,
1839,AB12345,AB12345-USA-1-id-295,id-295,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,B,S1,1.68619278274214,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-09 23:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,COMPLETED,COMPLETED,2022-08-09,1096,,,,,,,2022-08-28,,,4,4,Progression Free Survival,PFS,245.013938541524,DAYS,2021-01-03 23:49:26.683,513,1,Adverse Event,Preferred Term,
1840,AB12345,AB12345-USA-1-id-295,id-295,USA-1,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,B,S1,1.68619278274214,MEDIUM,Y,Y,Y,N,N,2019-08-07,2019-08-09 23:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,2019-08-09 23:49:26.683,2021-08-09 11:49:26.683,2021-08-09 11:49:26.683,2022-08-09 17:49:26.683,COMPLETED,COMPLETED,2022-08-09,1096,,,,,,,2022-08-28,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Completion or Discontinuation,-2.9899236178293
1841,AB12345,AB12345-USA-1-id-394,id-394,USA-1,46,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,A,S1,6.14556299638028,LOW,Y,Y,Y,Y,N,2019-12-14,2019-12-18 19:22:55.683,,2019-12-18 19:22:55.683,,,,2019-12-18 19:22:55.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,187.196247885004,DAYS,2020-08-28 19:22:55.683,254,0,Disease Progression,,
1842,AB12345,AB12345-USA-1-id-394,id-394,USA-1,46,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,A,S1,6.14556299638028,LOW,Y,Y,Y,Y,N,2019-12-14,2019-12-18 19:22:55.683,,2019-12-18 19:22:55.683,,,,2019-12-18 19:22:55.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Event Free Survival,EFS,16.5530290140305,DAYS,2020-12-04 19:22:55.683,352,0,Disease Progression,,
1843,AB12345,AB12345-USA-1-id-394,id-394,USA-1,46,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,A,S1,6.14556299638028,LOW,Y,Y,Y,Y,N,2019-12-14,2019-12-18 19:22:55.683,,2019-12-18 19:22:55.683,,,,2019-12-18 19:22:55.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,478.547683823854,DAYS,2021-11-15 19:22:55.683,698,1,Alive,Alive During Study,
1844,AB12345,AB12345-USA-1-id-394,id-394,USA-1,46,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,A,S1,6.14556299638028,LOW,Y,Y,Y,Y,N,2019-12-14,2019-12-18 19:22:55.683,,2019-12-18 19:22:55.683,,,,2019-12-18 19:22:55.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,295.518888928927,DAYS,2021-09-18 19:22:55.683,640,1,Adverse Event,Preferred Term,
1845,AB12345,AB12345-USA-1-id-394,id-394,USA-1,46,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,A: Drug X,North America,A,S1,6.14556299638028,LOW,Y,Y,Y,Y,N,2019-12-14,2019-12-18 19:22:55.683,,2019-12-18 19:22:55.683,,,,2019-12-18 19:22:55.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-0.578970927694302
1846,AB12345,AB12345-USA-1-id-45,id-45,USA-1,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S1,0.463560441314472,LOW,Y,Y,N,N,N,2019-03-04,2019-03-06 06:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,2,2,Duration of Confirmed Response,CRSD,112.353307544254,DAYS,2020-01-15 06:32:29.683,315,0,Disease Progression,,
1847,AB12345,AB12345-USA-1-id-45,id-45,USA-1,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S1,0.463560441314472,LOW,Y,Y,N,N,N,2019-03-04,2019-03-06 06:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,3,3,Event Free Survival,EFS,87.7862419781741,DAYS,2020-02-27 06:32:29.683,358,1,Last Tumor Assessment,Completion or Discontinuation,
1848,AB12345,AB12345-USA-1-id-45,id-45,USA-1,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S1,0.463560441314472,LOW,Y,Y,N,N,N,2019-03-04,2019-03-06 06:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,1,1,Overall Survival,OS,222.165473876521,DAYS,2019-12-18 06:32:29.683,287,0,Death,,
1849,AB12345,AB12345-USA-1-id-45,id-45,USA-1,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S1,0.463560441314472,LOW,Y,Y,N,N,N,2019-03-04,2019-03-06 06:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,4,4,Progression Free Survival,PFS,222.165473876521,DAYS,2022-02-06 06:32:29.683,1068,0,Death,,
1850,AB12345,AB12345-USA-1-id-45,id-45,USA-1,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-1,Dr. USA-1 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S1,0.463560441314472,LOW,Y,Y,N,N,N,2019-03-04,2019-03-06 06:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,2019-03-06 06:32:29.683,2021-03-05 18:32:29.683,2021-03-05 18:32:29.683,2022-03-06 00:32:29.683,COMPLETED,COMPLETED,2022-03-06,1096,,,,,,,2022-03-30,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,1.09407821563517
1851,AB12345,AB12345-USA-11-id-100,id-100,USA-11,40,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,6.64371306186804,HIGH,Y,Y,N,Y,Y,2020-03-08,2020-03-10 18:02:56.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,DISCONTINUED,DISCONTINUED,2022-02-13,705,LACK OF EFFICACY,,,,,,2022-03-10,,,4,4,Duration of Confirmed Response,CRSD,164.877212583087,DAYS,2022-02-11 18:02:56.683,703,0,Disease Progression,,
1852,AB12345,AB12345-USA-11-id-100,id-100,USA-11,40,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,6.64371306186804,HIGH,Y,Y,N,Y,Y,2020-03-08,2020-03-10 18:02:56.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,DISCONTINUED,DISCONTINUED,2022-02-13,705,LACK OF EFFICACY,,,,,,2022-03-10,,,2,2,Event Free Survival,EFS,73.6731350934133,DAYS,2021-09-29 18:02:56.683,568,1,Last Tumor Assessment,Completion or Discontinuation,
1853,AB12345,AB12345-USA-11-id-100,id-100,USA-11,40,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,6.64371306186804,HIGH,Y,Y,N,Y,Y,2020-03-08,2020-03-10 18:02:56.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,DISCONTINUED,DISCONTINUED,2022-02-13,705,LACK OF EFFICACY,,,,,,2022-03-10,,,1,1,Overall Survival,OS,209.1445192229,DAYS,2020-03-27 18:02:56.683,17,0,Death,,
1854,AB12345,AB12345-USA-11-id-100,id-100,USA-11,40,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,6.64371306186804,HIGH,Y,Y,N,Y,Y,2020-03-08,2020-03-10 18:02:56.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,DISCONTINUED,DISCONTINUED,2022-02-13,705,LACK OF EFFICACY,,,,,,2022-03-10,,,3,3,Progression Free Survival,PFS,209.1445192229,DAYS,2021-11-04 18:02:56.683,604,0,Death,,
1855,AB12345,AB12345-USA-11-id-100,id-100,USA-11,40,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,6.64371306186804,HIGH,Y,Y,N,Y,Y,2020-03-08,2020-03-10 18:02:56.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,2020-03-10 18:02:56.683,2021-02-13 05:12:36.683,2021-02-13 05:12:36.683,2022-02-13 11:12:36.683,DISCONTINUED,DISCONTINUED,2022-02-13,705,LACK OF EFFICACY,,,,,,2022-03-10,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-0.434773217933134
1856,AB12345,AB12345-USA-11-id-136,id-136,USA-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S1,3.57954535642375,HIGH,Y,Y,N,N,Y,2019-09-28,2019-10-02 05:04:53.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,DISCONTINUED,DISCONTINUED,2022-02-12,865,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,913,Yes,3,3,Duration of Confirmed Response,CRSD,194.437823793851,DAYS,2021-01-24 05:04:53.683,480,0,Disease Progression,,
1857,AB12345,AB12345-USA-11-id-136,id-136,USA-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S1,3.57954535642375,HIGH,Y,Y,N,N,Y,2019-09-28,2019-10-02 05:04:53.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,DISCONTINUED,DISCONTINUED,2022-02-12,865,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,913,Yes,1,1,Event Free Survival,EFS,65.6234147038776,DAYS,2019-11-04 05:04:53.683,33,0,Disease Progression,,
1858,AB12345,AB12345-USA-11-id-136,id-136,USA-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S1,3.57954535642375,HIGH,Y,Y,N,N,Y,2019-09-28,2019-10-02 05:04:53.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,DISCONTINUED,DISCONTINUED,2022-02-12,865,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,913,Yes,4,4,Overall Survival,OS,212.865765299648,DAYS,2021-07-08 05:04:53.683,645,0,Death,,
1859,AB12345,AB12345-USA-11-id-136,id-136,USA-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S1,3.57954535642375,HIGH,Y,Y,N,N,Y,2019-09-28,2019-10-02 05:04:53.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,DISCONTINUED,DISCONTINUED,2022-02-12,865,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,913,Yes,2,2,Progression Free Survival,PFS,212.865765299648,DAYS,2020-04-08 05:04:53.683,189,0,Death,,
1860,AB12345,AB12345-USA-11-id-136,id-136,USA-11,38,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S1,3.57954535642375,HIGH,Y,Y,N,N,Y,2019-09-28,2019-10-02 05:04:53.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,2019-10-02 05:04:53.683,2021-02-12 05:48:41.683,2021-02-12 05:48:41.683,2022-02-12 11:48:41.683,DISCONTINUED,DISCONTINUED,2022-02-12,865,DEATH,2022-04-03,ADVERSE EVENT,ADVERSE EVENT,50,>30,2022-04-03,913,Yes,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-2.57325790374933
1861,AB12345,AB12345-USA-11-id-157,id-157,USA-11,50,YEARS,M,WHITE,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,A,S2,6.18034839141255,LOW,Y,Y,Y,N,Y,2020-06-14,2020-06-14 21:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,COMPLETED,COMPLETED,2023-06-15,1096,,,,,,,2023-07-14,,,2,2,Duration of Confirmed Response,CRSD,193.18757080473,DAYS,2021-05-26 21:16:44.683,346,1,Adverse Event,Preferred Term,
1862,AB12345,AB12345-USA-11-id-157,id-157,USA-11,50,YEARS,M,WHITE,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,A,S2,6.18034839141255,LOW,Y,Y,Y,N,Y,2020-06-14,2020-06-14 21:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,COMPLETED,COMPLETED,2023-06-15,1096,,,,,,,2023-07-14,,,3,3,Event Free Survival,EFS,59.5996605569962,DAYS,2022-02-05 21:16:44.683,601,1,Last Tumor Assessment,Completion or Discontinuation,
1863,AB12345,AB12345-USA-11-id-157,id-157,USA-11,50,YEARS,M,WHITE,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,A,S2,6.18034839141255,LOW,Y,Y,Y,N,Y,2020-06-14,2020-06-14 21:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,COMPLETED,COMPLETED,2023-06-15,1096,,,,,,,2023-07-14,,,4,4,Overall Survival,OS,380.394322657958,DAYS,2023-02-05 21:16:44.683,966,1,Alive,Alive During Study,
1864,AB12345,AB12345-USA-11-id-157,id-157,USA-11,50,YEARS,M,WHITE,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,A,S2,6.18034839141255,LOW,Y,Y,Y,N,Y,2020-06-14,2020-06-14 21:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,COMPLETED,COMPLETED,2023-06-15,1096,,,,,,,2023-07-14,,,1,1,Progression Free Survival,PFS,244.198206625879,DAYS,2021-01-17 21:16:44.683,217,1,Adverse Event,Preferred Term,
1865,AB12345,AB12345-USA-11-id-157,id-157,USA-11,50,YEARS,M,WHITE,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,A,S2,6.18034839141255,LOW,Y,Y,Y,N,Y,2020-06-14,2020-06-14 21:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,2020-06-14 21:16:44.683,2022-06-15 09:16:44.683,2022-06-15 09:16:44.683,2023-06-15 15:16:44.683,COMPLETED,COMPLETED,2023-06-15,1096,,,,,,,2023-07-14,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-1.6400578364926
1866,AB12345,AB12345-USA-11-id-203,id-203,USA-11,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,North America,B,S2,5.60082179689868,LOW,Y,Y,Y,N,N,2019-12-26,2019-12-29 09:35:30.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-10,,,3,3,Duration of Confirmed Response,CRSD,157.282997737639,DAYS,2021-09-04 09:35:30.683,615,1,Adverse Event,Preferred Term,
1867,AB12345,AB12345-USA-11-id-203,id-203,USA-11,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,North America,B,S2,5.60082179689868,LOW,Y,Y,Y,N,N,2019-12-26,2019-12-29 09:35:30.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-10,,,1,1,Event Free Survival,EFS,46.0694125306327,DAYS,2020-05-02 09:35:30.683,125,1,Adverse Event,Preferred Term,
1868,AB12345,AB12345-USA-11-id-203,id-203,USA-11,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,North America,B,S2,5.60082179689868,LOW,Y,Y,Y,N,N,2019-12-26,2019-12-29 09:35:30.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-10,,,2,2,Overall Survival,OS,431.442766403779,DAYS,2021-02-07 09:35:30.683,406,1,Alive,Alive During Study,
1869,AB12345,AB12345-USA-11-id-203,id-203,USA-11,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,North America,B,S2,5.60082179689868,LOW,Y,Y,Y,N,N,2019-12-26,2019-12-29 09:35:30.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-10,,,4,4,Progression Free Survival,PFS,210.616740095429,DAYS,2021-12-16 09:35:30.683,718,1,Last Tumor Assessment,Completion or Discontinuation,
1870,AB12345,AB12345-USA-11-id-203,id-203,USA-11,41,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,A: Drug X,North America,B,S2,5.60082179689868,LOW,Y,Y,Y,N,N,2019-12-26,2019-12-29 09:35:30.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,2019-12-29 09:35:30.683,2021-02-15 16:34:47.683,2021-02-15 16:34:47.683,2022-02-15 22:34:47.683,DISCONTINUED,DISCONTINUED,2022-02-15,780,WITHDRAWAL BY PARENT/GUARDIAN,,,,,,2022-03-10,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Preferred Term,-1.63510359653348
1871,AB12345,AB12345-USA-11-id-224,id-224,USA-11,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S2,6.42716837782529,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 21:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-14,,,2,2,Duration of Confirmed Response,CRSD,116.008113906719,DAYS,2021-03-30 21:27:55.683,133,1,Adverse Event,Preferred Term,
1872,AB12345,AB12345-USA-11-id-224,id-224,USA-11,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S2,6.42716837782529,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 21:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-14,,,1,1,Event Free Survival,EFS,83.0407284153625,DAYS,2020-12-09 21:27:55.683,22,0,Disease Progression,,
1873,AB12345,AB12345-USA-11-id-224,id-224,USA-11,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S2,6.42716837782529,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 21:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-14,,,4,4,Overall Survival,OS,249.914980633184,DAYS,2022-10-04 21:27:55.683,686,0,Death,,
1874,AB12345,AB12345-USA-11-id-224,id-224,USA-11,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S2,6.42716837782529,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 21:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-14,,,3,3,Progression Free Survival,PFS,249.914980633184,DAYS,2021-07-16 21:27:55.683,241,0,Death,,
1875,AB12345,AB12345-USA-11-id-224,id-224,USA-11,36,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,A: Drug X,North America,C,S2,6.42716837782529,HIGH,Y,Y,N,Y,N,2020-11-13,2020-11-17 21:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,2020-11-17 21:27:55.683,2022-11-18 09:27:55.683,2022-11-18 09:27:55.683,2023-11-18 15:27:55.683,COMPLETED,COMPLETED,2023-11-18,1096,,,,,,,2023-12-14,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Preferred Term,-3.63035438318491
1876,AB12345,AB12345-USA-11-id-238,id-238,USA-11,35,YEARS,F,ASIAN,UNKNOWN,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,C,S2,8.03919840675427,HIGH,Y,Y,Y,Y,N,2019-12-15,2019-12-17 16:17:31.683,,2019-12-17 16:17:31.683,,,,2019-12-17 16:17:31.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Duration of Confirmed Response,CRSD,168.859821022488,DAYS,2020-09-15 16:17:31.683,273,0,Death,,
1877,AB12345,AB12345-USA-11-id-238,id-238,USA-11,35,YEARS,F,ASIAN,UNKNOWN,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,C,S2,8.03919840675427,HIGH,Y,Y,Y,Y,N,2019-12-15,2019-12-17 16:17:31.683,,2019-12-17 16:17:31.683,,,,2019-12-17 16:17:31.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,26.8035906937439,DAYS,2021-05-23 16:17:31.683,523,1,Last Tumor Assessment,Completion or Discontinuation,
1878,AB12345,AB12345-USA-11-id-238,id-238,USA-11,35,YEARS,F,ASIAN,UNKNOWN,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,C,S2,8.03919840675427,HIGH,Y,Y,Y,Y,N,2019-12-15,2019-12-17 16:17:31.683,,2019-12-17 16:17:31.683,,,,2019-12-17 16:17:31.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Overall Survival,OS,168.859821022488,DAYS,2020-05-02 16:17:31.683,137,0,Death,,
1879,AB12345,AB12345-USA-11-id-238,id-238,USA-11,35,YEARS,F,ASIAN,UNKNOWN,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,C,S2,8.03919840675427,HIGH,Y,Y,Y,Y,N,2019-12-15,2019-12-17 16:17:31.683,,2019-12-17 16:17:31.683,,,,2019-12-17 16:17:31.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,168.859821022488,DAYS,2020-10-25 16:17:31.683,313,0,Death,,
1880,AB12345,AB12345-USA-11-id-238,id-238,USA-11,35,YEARS,F,ASIAN,UNKNOWN,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,B: Placebo,North America,C,S2,8.03919840675427,HIGH,Y,Y,Y,Y,N,2019-12-15,2019-12-17 16:17:31.683,,2019-12-17 16:17:31.683,,,,2019-12-17 16:17:31.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,6,COUNT,,,0,,,-0.805014272921908
1881,AB12345,AB12345-USA-11-id-32,id-32,USA-11,24,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,8.45456312994187,MEDIUM,Y,Y,N,Y,N,2020-03-09,2020-03-13 22:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,COMPLETED,COMPLETED,2023-03-14,1096,,,,,,,2023-04-05,,,2,2,Duration of Confirmed Response,CRSD,120.781287481077,DAYS,2021-11-16 22:38:04.683,613,1,Last Tumor Assessment,Completion or Discontinuation,
1882,AB12345,AB12345-USA-11-id-32,id-32,USA-11,24,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,8.45456312994187,MEDIUM,Y,Y,N,Y,N,2020-03-09,2020-03-13 22:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,COMPLETED,COMPLETED,2023-03-14,1096,,,,,,,2023-04-05,,,1,1,Event Free Survival,EFS,55.8545637445059,DAYS,2020-09-16 22:38:04.683,187,0,Disease Progression,,
1883,AB12345,AB12345-USA-11-id-32,id-32,USA-11,24,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,8.45456312994187,MEDIUM,Y,Y,N,Y,N,2020-03-09,2020-03-13 22:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,COMPLETED,COMPLETED,2023-03-14,1096,,,,,,,2023-04-05,,,3,3,Overall Survival,OS,366.684214258566,DAYS,2022-05-09 22:38:04.683,787,1,Alive,Alive During Study,
1884,AB12345,AB12345-USA-11-id-32,id-32,USA-11,24,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,8.45456312994187,MEDIUM,Y,Y,N,Y,N,2020-03-09,2020-03-13 22:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,COMPLETED,COMPLETED,2023-03-14,1096,,,,,,,2023-04-05,,,4,4,Progression Free Survival,PFS,271.772133558989,DAYS,2023-01-20 22:38:04.683,1043,1,Adverse Event,Preferred Term,
1885,AB12345,AB12345-USA-11-id-32,id-32,USA-11,24,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,8.45456312994187,MEDIUM,Y,Y,N,Y,N,2020-03-09,2020-03-13 22:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,2020-03-13 22:38:04.683,2022-03-14 10:38:04.683,2022-03-14 10:38:04.683,2023-03-14 16:38:04.683,COMPLETED,COMPLETED,2023-03-14,1096,,,,,,,2023-04-05,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-1.77457606063698
1886,AB12345,AB12345-USA-11-id-339,id-339,USA-11,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,17.212126555217,MEDIUM,Y,Y,Y,Y,N,2019-10-17,2019-10-19 19:45:27.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,854,DEATH,2022-03-16,UNKNOWN,OTHER,25,<=30,2022-03-16,878,No,2,2,Duration of Confirmed Response,CRSD,159.349874872714,DAYS,2020-11-22 19:45:27.683,400,0,Death,,
1887,AB12345,AB12345-USA-11-id-339,id-339,USA-11,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,17.212126555217,MEDIUM,Y,Y,Y,Y,N,2019-10-17,2019-10-19 19:45:27.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,854,DEATH,2022-03-16,UNKNOWN,OTHER,25,<=30,2022-03-16,878,No,3,3,Event Free Survival,EFS,60.0013276422396,DAYS,2021-03-23 19:45:27.683,521,1,Last Tumor Assessment,Completion or Discontinuation,
1888,AB12345,AB12345-USA-11-id-339,id-339,USA-11,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,17.212126555217,MEDIUM,Y,Y,Y,Y,N,2019-10-17,2019-10-19 19:45:27.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,854,DEATH,2022-03-16,UNKNOWN,OTHER,25,<=30,2022-03-16,878,No,4,4,Overall Survival,OS,159.349874872714,DAYS,2021-09-02 19:45:27.683,684,0,Death,,
1889,AB12345,AB12345-USA-11-id-339,id-339,USA-11,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,17.212126555217,MEDIUM,Y,Y,Y,Y,N,2019-10-17,2019-10-19 19:45:27.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,854,DEATH,2022-03-16,UNKNOWN,OTHER,25,<=30,2022-03-16,878,No,1,1,Progression Free Survival,PFS,159.349874872714,DAYS,2019-11-10 19:45:27.683,22,0,Death,,
1890,AB12345,AB12345-USA-11-id-339,id-339,USA-11,39,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,17.212126555217,MEDIUM,Y,Y,Y,Y,N,2019-10-17,2019-10-19 19:45:27.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,2019-10-19 19:45:27.683,2021-02-19 06:30:11.683,2021-02-19 06:30:11.683,2022-02-19 12:30:11.683,DISCONTINUED,DISCONTINUED,2022-02-19,854,DEATH,2022-03-16,UNKNOWN,OTHER,25,<=30,2022-03-16,878,No,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.16019206606905
1891,AB12345,AB12345-USA-11-id-365,id-365,USA-11,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,B,S1,1.90915276592905,MEDIUM,Y,Y,Y,Y,N,2019-06-09,2019-06-09 18:23:33.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,DISCONTINUED,DISCONTINUED,2022-02-14,981,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-08,1002,Yes,1,1,Duration of Confirmed Response,CRSD,79.5905660174321,DAYS,2019-06-14 18:23:33.683,5,0,Death,,
1892,AB12345,AB12345-USA-11-id-365,id-365,USA-11,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,B,S1,1.90915276592905,MEDIUM,Y,Y,Y,Y,N,2019-06-09,2019-06-09 18:23:33.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,DISCONTINUED,DISCONTINUED,2022-02-14,981,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-08,1002,Yes,2,2,Event Free Survival,EFS,79.5905660174321,DAYS,2020-04-27 18:23:33.683,323,0,Death,,
1893,AB12345,AB12345-USA-11-id-365,id-365,USA-11,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,B,S1,1.90915276592905,MEDIUM,Y,Y,Y,Y,N,2019-06-09,2019-06-09 18:23:33.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,DISCONTINUED,DISCONTINUED,2022-02-14,981,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-08,1002,Yes,3,3,Overall Survival,OS,79.5905660174321,DAYS,2021-07-03 18:23:33.683,755,0,Death,,
1894,AB12345,AB12345-USA-11-id-365,id-365,USA-11,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,B,S1,1.90915276592905,MEDIUM,Y,Y,Y,Y,N,2019-06-09,2019-06-09 18:23:33.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,DISCONTINUED,DISCONTINUED,2022-02-14,981,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-08,1002,Yes,4,4,Progression Free Survival,PFS,79.5905660174321,DAYS,2021-12-19 18:23:33.683,924,0,Death,,
1895,AB12345,AB12345-USA-11-id-365,id-365,USA-11,34,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-11,Dr. USA-11 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,B: Placebo,North America,B,S1,1.90915276592905,MEDIUM,Y,Y,Y,Y,N,2019-06-09,2019-06-09 18:23:33.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,2019-06-09 18:23:33.683,2021-02-13 19:28:19.683,2021-02-13 19:28:19.683,2022-02-14 01:28:19.683,DISCONTINUED,DISCONTINUED,2022-02-14,981,DEATH,2022-03-08,ADVERSE EVENT,ADVERSE EVENT,22,<=30,2022-03-08,1002,Yes,,,Total Number of Exacerbations,TNE,4,COUNT,,,0,,,-0.693558993823833
1896,AB12345,AB12345-USA-12-id-131,id-131,USA-12,44,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,3.72693508002419,LOW,Y,Y,Y,N,N,2021-02-14,2021-02-17 15:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,COMPLETED,COMPLETED,2024-02-18,1096,,,,,,,2024-03-07,,,1,1,Duration of Confirmed Response,CRSD,163.11799522955,DAYS,2021-12-25 15:03:58.683,311,0,Death,,
1897,AB12345,AB12345-USA-12-id-131,id-131,USA-12,44,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,3.72693508002419,LOW,Y,Y,Y,N,N,2021-02-14,2021-02-17 15:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,COMPLETED,COMPLETED,2024-02-18,1096,,,,,,,2024-03-07,,,4,4,Event Free Survival,EFS,18.3741523057688,DAYS,2024-01-22 15:03:58.683,1069,1,Last Tumor Assessment,Completion or Discontinuation,
1898,AB12345,AB12345-USA-12-id-131,id-131,USA-12,44,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,3.72693508002419,LOW,Y,Y,Y,N,N,2021-02-14,2021-02-17 15:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,COMPLETED,COMPLETED,2024-02-18,1096,,,,,,,2024-03-07,,,2,2,Overall Survival,OS,163.11799522955,DAYS,2022-12-20 15:03:58.683,671,0,Death,,
1899,AB12345,AB12345-USA-12-id-131,id-131,USA-12,44,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,3.72693508002419,LOW,Y,Y,Y,N,N,2021-02-14,2021-02-17 15:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,COMPLETED,COMPLETED,2024-02-18,1096,,,,,,,2024-03-07,,,3,3,Progression Free Survival,PFS,163.11799522955,DAYS,2023-05-18 15:03:58.683,820,0,Death,,
1900,AB12345,AB12345-USA-12-id-131,id-131,USA-12,44,YEARS,F,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,A: Drug X,North America,B,S1,3.72693508002419,LOW,Y,Y,Y,N,N,2021-02-14,2021-02-17 15:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,2021-02-17 15:03:58.683,2023-02-18 03:03:58.683,2023-02-18 03:03:58.683,2024-02-18 09:03:58.683,COMPLETED,COMPLETED,2024-02-18,1096,,,,,,,2024-03-07,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-1.44611052981905
1901,AB12345,AB12345-USA-12-id-140,id-140,USA-12,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S2,14.2299270302934,MEDIUM,Y,Y,N,Y,N,2020-07-03,2020-07-05 21:31:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,591,PROTOCOL VIOLATION,,,,,,2022-03-05,,,4,4,Duration of Confirmed Response,CRSD,170.725658582523,DAYS,2021-12-03 21:31:45.683,516,1,Last Tumor Assessment,Completion or Discontinuation,
1902,AB12345,AB12345-USA-12-id-140,id-140,USA-12,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S2,14.2299270302934,MEDIUM,Y,Y,N,Y,N,2020-07-03,2020-07-05 21:31:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,591,PROTOCOL VIOLATION,,,,,,2022-03-05,,,2,2,Event Free Survival,EFS,29.479733457556,DAYS,2021-05-04 21:31:45.683,303,0,Disease Progression,,
1903,AB12345,AB12345-USA-12-id-140,id-140,USA-12,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S2,14.2299270302934,MEDIUM,Y,Y,N,Y,N,2020-07-03,2020-07-05 21:31:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,591,PROTOCOL VIOLATION,,,,,,2022-03-05,,,3,3,Overall Survival,OS,316.064489120618,DAYS,2021-05-29 21:31:45.683,328,1,Alive,Alive During Study,
1904,AB12345,AB12345-USA-12-id-140,id-140,USA-12,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S2,14.2299270302934,MEDIUM,Y,Y,N,Y,N,2020-07-03,2020-07-05 21:31:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,591,PROTOCOL VIOLATION,,,,,,2022-03-05,,,1,1,Progression Free Survival,PFS,226.472227461636,DAYS,2020-07-12 21:31:45.683,7,0,Disease Progression,,
1905,AB12345,AB12345-USA-12-id-140,id-140,USA-12,32,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,C: Combination,North America,C,S2,14.2299270302934,MEDIUM,Y,Y,N,Y,N,2020-07-03,2020-07-05 21:31:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,2020-07-05 21:31:45.683,2021-02-16 09:46:45.683,2021-02-16 09:46:45.683,2022-02-16 15:46:45.683,DISCONTINUED,DISCONTINUED,2022-02-16,591,PROTOCOL VIOLATION,,,,,,2022-03-05,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,0.0458733067627359
1906,AB12345,AB12345-USA-12-id-152,id-152,USA-12,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,B,S1,6.72989743666522,LOW,Y,Y,Y,Y,N,2020-08-14,2020-08-17 08:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-14,,,3,3,Duration of Confirmed Response,CRSD,75.6226179120131,DAYS,2022-03-26 08:35:43.683,586,0,Death,,
1907,AB12345,AB12345-USA-12-id-152,id-152,USA-12,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,B,S1,6.72989743666522,LOW,Y,Y,Y,Y,N,2020-08-14,2020-08-17 08:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-14,,,4,4,Event Free Survival,EFS,75.6226179120131,DAYS,2023-05-26 08:35:43.683,1012,0,Death,,
1908,AB12345,AB12345-USA-12-id-152,id-152,USA-12,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,B,S1,6.72989743666522,LOW,Y,Y,Y,Y,N,2020-08-14,2020-08-17 08:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-14,,,1,1,Overall Survival,OS,75.6226179120131,DAYS,2020-08-21 08:35:43.683,4,0,Death,,
1909,AB12345,AB12345-USA-12-id-152,id-152,USA-12,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,B,S1,6.72989743666522,LOW,Y,Y,Y,Y,N,2020-08-14,2020-08-17 08:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-14,,,2,2,Progression Free Survival,PFS,75.6226179120131,DAYS,2021-04-23 08:35:43.683,249,0,Death,,
1910,AB12345,AB12345-USA-12-id-152,id-152,USA-12,29,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,B,S1,6.72989743666522,LOW,Y,Y,Y,Y,N,2020-08-14,2020-08-17 08:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,2020-08-17 08:35:43.683,2022-08-17 20:35:43.683,2022-08-17 20:35:43.683,2023-08-18 02:35:43.683,COMPLETED,COMPLETED,2023-08-18,1096,,,,,,,2023-09-14,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-0.281203501280291
1911,AB12345,AB12345-USA-12-id-226,id-226,USA-12,30,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,North America,A,S1,4.21438697153769,LOW,Y,Y,N,Y,Y,2020-01-25,2020-01-29 18:22:03.683,,2020-01-29 18:22:03.683,,,,2020-01-29 18:22:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,117.02255255077,DAYS,2020-04-19 18:22:03.683,81,0,Death,,
1912,AB12345,AB12345-USA-12-id-226,id-226,USA-12,30,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,North America,A,S1,4.21438697153769,LOW,Y,Y,N,Y,Y,2020-01-25,2020-01-29 18:22:03.683,,2020-01-29 18:22:03.683,,,,2020-01-29 18:22:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Event Free Survival,EFS,78.8192003825679,DAYS,2021-06-04 18:22:03.683,492,0,Disease Progression,,
1913,AB12345,AB12345-USA-12-id-226,id-226,USA-12,30,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,North America,A,S1,4.21438697153769,LOW,Y,Y,N,Y,Y,2020-01-25,2020-01-29 18:22:03.683,,2020-01-29 18:22:03.683,,,,2020-01-29 18:22:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Overall Survival,OS,117.02255255077,DAYS,2021-08-15 18:22:03.683,564,0,Death,,
1914,AB12345,AB12345-USA-12-id-226,id-226,USA-12,30,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,North America,A,S1,4.21438697153769,LOW,Y,Y,N,Y,Y,2020-01-25,2020-01-29 18:22:03.683,,2020-01-29 18:22:03.683,,,,2020-01-29 18:22:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Progression Free Survival,PFS,117.02255255077,DAYS,2020-04-21 18:22:03.683,83,0,Death,,
1915,AB12345,AB12345-USA-12-id-226,id-226,USA-12,30,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,B: Placebo,North America,A,S1,4.21438697153769,LOW,Y,Y,N,Y,Y,2020-01-25,2020-01-29 18:22:03.683,,2020-01-29 18:22:03.683,,,,2020-01-29 18:22:03.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-1.21640629940804
1916,AB12345,AB12345-USA-12-id-343,id-343,USA-12,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,3.75539130796289,HIGH,Y,Y,Y,N,N,2020-03-15,2020-03-18 17:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,COMPLETED,COMPLETED,2023-03-19,1096,,,,,,,2023-04-17,,,2,2,Duration of Confirmed Response,CRSD,113.685529003851,DAYS,2020-06-11 17:13:25.683,85,1,Last Tumor Assessment,Completion or Discontinuation,
1917,AB12345,AB12345-USA-12-id-343,id-343,USA-12,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,3.75539130796289,HIGH,Y,Y,Y,N,N,2020-03-15,2020-03-18 17:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,COMPLETED,COMPLETED,2023-03-19,1096,,,,,,,2023-04-17,,,4,4,Event Free Survival,EFS,33.2598835672252,DAYS,2022-05-22 17:13:25.683,795,0,Disease Progression,,
1918,AB12345,AB12345-USA-12-id-343,id-343,USA-12,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,3.75539130796289,HIGH,Y,Y,Y,N,N,2020-03-15,2020-03-18 17:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,COMPLETED,COMPLETED,2023-03-19,1096,,,,,,,2023-04-17,,,3,3,Overall Survival,OS,232.070478703827,DAYS,2021-07-29 17:13:25.683,498,0,Death,,
1919,AB12345,AB12345-USA-12-id-343,id-343,USA-12,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,3.75539130796289,HIGH,Y,Y,Y,N,N,2020-03-15,2020-03-18 17:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,COMPLETED,COMPLETED,2023-03-19,1096,,,,,,,2023-04-17,,,1,1,Progression Free Survival,PFS,232.070478703827,DAYS,2020-03-23 17:13:25.683,5,0,Death,,
1920,AB12345,AB12345-USA-12-id-343,id-343,USA-12,38,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,B,S2,3.75539130796289,HIGH,Y,Y,Y,N,N,2020-03-15,2020-03-18 17:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,2020-03-18 17:13:25.683,2022-03-19 05:13:25.683,2022-03-19 05:13:25.683,2023-03-19 11:13:25.683,COMPLETED,COMPLETED,2023-03-19,1096,,,,,,,2023-04-17,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-0.741875686808616
1921,AB12345,AB12345-USA-12-id-44,id-44,USA-12,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S2,8.53652555557173,MEDIUM,Y,Y,Y,N,N,2019-04-28,2019-04-28 00:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-20,,,3,3,Duration of Confirmed Response,CRSD,145.82466033753,DAYS,2021-03-06 00:35:06.683,678,1,Adverse Event,Preferred Term,
1922,AB12345,AB12345-USA-12-id-44,id-44,USA-12,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S2,8.53652555557173,MEDIUM,Y,Y,Y,N,N,2019-04-28,2019-04-28 00:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-20,,,4,4,Event Free Survival,EFS,71.0705316241365,DAYS,2022-04-14 00:35:06.683,1082,1,Last Tumor Assessment,Completion or Discontinuation,
1923,AB12345,AB12345-USA-12-id-44,id-44,USA-12,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S2,8.53652555557173,MEDIUM,Y,Y,Y,N,N,2019-04-28,2019-04-28 00:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-20,,,2,2,Overall Survival,OS,309.938323125243,DAYS,2020-05-28 00:35:06.683,396,1,Alive,Alive During Study,
1924,AB12345,AB12345-USA-12-id-44,id-44,USA-12,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S2,8.53652555557173,MEDIUM,Y,Y,Y,N,N,2019-04-28,2019-04-28 00:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-20,,,1,1,Progression Free Survival,PFS,222.1783839399,DAYS,2020-01-12 00:35:06.683,259,1,Last Tumor Assessment,Completion or Discontinuation,
1925,AB12345,AB12345-USA-12-id-44,id-44,USA-12,34,YEARS,F,BLACK OR AFRICAN AMERICAN,NOT REPORTED,USA,N,INV ID USA-12,Dr. USA-12 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S2,8.53652555557173,MEDIUM,Y,Y,Y,N,N,2019-04-28,2019-04-28 00:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,2019-04-28 00:35:06.683,2021-04-27 12:35:06.683,2021-04-27 12:35:06.683,2022-04-27 18:35:06.683,COMPLETED,COMPLETED,2022-04-27,1096,,,,,,,2022-05-20,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,1,,Preferred Term,-1.29026927019446
1926,AB12345,AB12345-USA-14-id-196,id-196,USA-14,31,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-14,Dr. USA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,North America,B,S2,3.92637318135674,LOW,Y,Y,N,N,N,2020-01-22,2020-01-25 11:41:32.683,,2020-01-25 11:41:32.683,,,,2020-01-25 11:41:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,146.035597682931,DAYS,2020-06-17 11:41:32.683,144,0,Death,,
1927,AB12345,AB12345-USA-14-id-196,id-196,USA-14,31,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-14,Dr. USA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,North America,B,S2,3.92637318135674,LOW,Y,Y,N,N,N,2020-01-22,2020-01-25 11:41:32.683,,2020-01-25 11:41:32.683,,,,2020-01-25 11:41:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,86.6522371023893,DAYS,2021-07-20 11:41:32.683,542,1,Last Tumor Assessment,Completion or Discontinuation,
1928,AB12345,AB12345-USA-14-id-196,id-196,USA-14,31,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-14,Dr. USA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,North America,B,S2,3.92637318135674,LOW,Y,Y,N,N,N,2020-01-22,2020-01-25 11:41:32.683,,2020-01-25 11:41:32.683,,,,2020-01-25 11:41:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,146.035597682931,DAYS,2020-03-17 11:41:32.683,52,0,Death,,
1929,AB12345,AB12345-USA-14-id-196,id-196,USA-14,31,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-14,Dr. USA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,North America,B,S2,3.92637318135674,LOW,Y,Y,N,N,N,2020-01-22,2020-01-25 11:41:32.683,,2020-01-25 11:41:32.683,,,,2020-01-25 11:41:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,146.035597682931,DAYS,2020-02-13 11:41:32.683,19,0,Death,,
1930,AB12345,AB12345-USA-14-id-196,id-196,USA-14,31,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-14,Dr. USA-14 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,A: Drug X,North America,B,S2,3.92637318135674,LOW,Y,Y,N,N,N,2020-01-22,2020-01-25 11:41:32.683,,2020-01-25 11:41:32.683,,,,2020-01-25 11:41:32.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,7,COUNT,,,0,,,-3.72772693825493
1931,AB12345,AB12345-USA-15-id-127,id-127,USA-15,57,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,B,S1,3.37225353336814,HIGH,Y,Y,N,N,N,2019-05-09,2019-05-12 00:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,COMPLETED,COMPLETED,2022-05-11,1096,,,,,,,2022-05-25,,,3,3,Duration of Confirmed Response,CRSD,133.002010989003,DAYS,2021-03-03 00:32:46.683,661,1,Last Tumor Assessment,Completion or Discontinuation,
1932,AB12345,AB12345-USA-15-id-127,id-127,USA-15,57,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,B,S1,3.37225353336814,HIGH,Y,Y,N,N,N,2019-05-09,2019-05-12 00:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,COMPLETED,COMPLETED,2022-05-11,1096,,,,,,,2022-05-25,,,2,2,Event Free Survival,EFS,18.7968704395462,DAYS,2021-02-07 00:32:46.683,637,1,Last Tumor Assessment,Completion or Discontinuation,
1933,AB12345,AB12345-USA-15-id-127,id-127,USA-15,57,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,B,S1,3.37225353336814,HIGH,Y,Y,N,N,N,2019-05-09,2019-05-12 00:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,COMPLETED,COMPLETED,2022-05-11,1096,,,,,,,2022-05-25,,,1,1,Overall Survival,OS,347.244199737906,DAYS,2019-06-11 00:32:46.683,30,1,Alive,Alive During Study,
1934,AB12345,AB12345-USA-15-id-127,id-127,USA-15,57,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,B,S1,3.37225353336814,HIGH,Y,Y,N,N,N,2019-05-09,2019-05-12 00:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,COMPLETED,COMPLETED,2022-05-11,1096,,,,,,,2022-05-25,,,4,4,Progression Free Survival,PFS,235.048202332109,DAYS,2022-04-21 00:32:46.683,1075,1,Last Tumor Assessment,Completion or Discontinuation,
1935,AB12345,AB12345-USA-15-id-127,id-127,USA-15,57,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,A: Drug X,A: Drug X,North America,B,S1,3.37225353336814,HIGH,Y,Y,N,N,N,2019-05-09,2019-05-12 00:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,2019-05-12 00:32:46.683,2021-05-11 12:32:46.683,2021-05-11 12:32:46.683,2022-05-11 18:32:46.683,COMPLETED,COMPLETED,2022-05-11,1096,,,,,,,2022-05-25,,,,,Total Number of Exacerbations,TNE,4,COUNT,,,1,,Completion or Discontinuation,-2.03302374172004
1936,AB12345,AB12345-USA-15-id-372,id-372,USA-15,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S1,3.44809977448492,LOW,Y,Y,Y,Y,N,2020-01-20,2020-01-22 12:25:28.683,,2020-01-22 12:25:28.683,,,,2020-01-22 12:25:28.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Duration of Confirmed Response,CRSD,128.958496893756,DAYS,2020-05-30 12:25:28.683,129,1,Adverse Event,Preferred Term,
1937,AB12345,AB12345-USA-15-id-372,id-372,USA-15,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S1,3.44809977448492,LOW,Y,Y,Y,Y,N,2020-01-20,2020-01-22 12:25:28.683,,2020-01-22 12:25:28.683,,,,2020-01-22 12:25:28.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,32.7924402302597,DAYS,2021-10-12 12:25:28.683,629,1,Last Tumor Assessment,Completion or Discontinuation,
1938,AB12345,AB12345-USA-15-id-372,id-372,USA-15,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S1,3.44809977448492,LOW,Y,Y,Y,Y,N,2020-01-20,2020-01-22 12:25:28.683,,2020-01-22 12:25:28.683,,,,2020-01-22 12:25:28.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,229.983004322276,DAYS,2020-12-19 12:25:28.683,332,0,Death,,
1939,AB12345,AB12345-USA-15-id-372,id-372,USA-15,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S1,3.44809977448492,LOW,Y,Y,Y,Y,N,2020-01-20,2020-01-22 12:25:28.683,,2020-01-22 12:25:28.683,,,,2020-01-22 12:25:28.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,229.983004322276,DAYS,2021-05-17 12:25:28.683,481,0,Death,,
1940,AB12345,AB12345-USA-15-id-372,id-372,USA-15,27,YEARS,M,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-15,Dr. USA-15 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,C: Combination,A: Drug X,North America,C,S1,3.44809977448492,LOW,Y,Y,Y,Y,N,2020-01-20,2020-01-22 12:25:28.683,,2020-01-22 12:25:28.683,,,,2020-01-22 12:25:28.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-1.02693836960017
1941,AB12345,AB12345-USA-17-id-142,id-142,USA-17,31,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-17,Dr. USA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,North America,B,S2,8.81869901971081,MEDIUM,Y,Y,Y,N,N,2019-05-13,2019-05-14 12:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,COMPLETED,COMPLETED,2022-05-14,1096,,,,,,,2022-06-12,,,1,1,Duration of Confirmed Response,CRSD,176.2660629116,DAYS,2019-11-13 12:56:10.683,183,1,Last Tumor Assessment,Completion or Discontinuation,
1942,AB12345,AB12345-USA-17-id-142,id-142,USA-17,31,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-17,Dr. USA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,North America,B,S2,8.81869901971081,MEDIUM,Y,Y,Y,N,N,2019-05-13,2019-05-14 12:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,COMPLETED,COMPLETED,2022-05-14,1096,,,,,,,2022-06-12,,,2,2,Event Free Survival,EFS,90.9495403326582,DAYS,2020-04-24 12:56:10.683,346,1,Last Tumor Assessment,Completion or Discontinuation,
1943,AB12345,AB12345-USA-17-id-142,id-142,USA-17,31,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-17,Dr. USA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,North America,B,S2,8.81869901971081,MEDIUM,Y,Y,Y,N,N,2019-05-13,2019-05-14 12:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,COMPLETED,COMPLETED,2022-05-14,1096,,,,,,,2022-06-12,,,4,4,Overall Survival,OS,451.733909687027,DAYS,2020-09-02 12:56:10.683,477,1,Alive,Alive During Study,
1944,AB12345,AB12345-USA-17-id-142,id-142,USA-17,31,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-17,Dr. USA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,North America,B,S2,8.81869901971081,MEDIUM,Y,Y,Y,N,N,2019-05-13,2019-05-14 12:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,COMPLETED,COMPLETED,2022-05-14,1096,,,,,,,2022-06-12,,,3,3,Progression Free Survival,PFS,210.402936860919,DAYS,2020-08-27 12:56:10.683,471,1,Last Tumor Assessment,Completion or Discontinuation,
1945,AB12345,AB12345-USA-17-id-142,id-142,USA-17,31,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-17,Dr. USA-17 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,B: Placebo,C: Combination,North America,B,S2,8.81869901971081,MEDIUM,Y,Y,Y,N,N,2019-05-13,2019-05-14 12:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,2019-05-14 12:56:10.683,2021-05-14 00:56:10.683,2021-05-14 00:56:10.683,2022-05-14 06:56:10.683,COMPLETED,COMPLETED,2022-05-14,1096,,,,,,,2022-06-12,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,-0.00246009716897302
1946,AB12345,AB12345-USA-17-id-3,id-3,USA-17,36,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-17,Dr. USA-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S1,5.39748255878243,MEDIUM,Y,Y,Y,Y,N,2020-01-25,2020-01-26 15:30:59.683,,2020-01-26 15:30:59.683,,,,2020-01-26 15:30:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Duration of Confirmed Response,CRSD,122.103567654267,DAYS,2021-09-04 15:30:59.683,587,1,Last Tumor Assessment,Completion or Discontinuation,
1947,AB12345,AB12345-USA-17-id-3,id-3,USA-17,36,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-17,Dr. USA-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S1,5.39748255878243,MEDIUM,Y,Y,Y,Y,N,2020-01-25,2020-01-26 15:30:59.683,,2020-01-26 15:30:59.683,,,,2020-01-26 15:30:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Event Free Survival,EFS,50.2523717819713,DAYS,2022-01-24 15:30:59.683,729,1,Adverse Event,Preferred Term,
1948,AB12345,AB12345-USA-17-id-3,id-3,USA-17,36,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-17,Dr. USA-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S1,5.39748255878243,MEDIUM,Y,Y,Y,Y,N,2020-01-25,2020-01-26 15:30:59.683,,2020-01-26 15:30:59.683,,,,2020-01-26 15:30:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,306.050108512864,DAYS,2021-01-30 15:30:59.683,370,1,Alive,Alive During Study,
1949,AB12345,AB12345-USA-17-id-3,id-3,USA-17,36,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-17,Dr. USA-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S1,5.39748255878243,MEDIUM,Y,Y,Y,Y,N,2020-01-25,2020-01-26 15:30:59.683,,2020-01-26 15:30:59.683,,,,2020-01-26 15:30:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Progression Free Survival,PFS,200.671869982034,DAYS,2020-09-27 15:30:59.683,245,1,Adverse Event,Preferred Term,
1950,AB12345,AB12345-USA-17-id-3,id-3,USA-17,36,YEARS,F,ASIAN,NOT REPORTED,USA,N,INV ID USA-17,Dr. USA-17 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,B,S1,5.39748255878243,MEDIUM,Y,Y,Y,Y,N,2020-01-25,2020-01-26 15:30:59.683,,2020-01-26 15:30:59.683,,,,2020-01-26 15:30:59.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,1,,Completion or Discontinuation,0.0772168099841009
1951,AB12345,AB12345-USA-19-id-58,id-58,USA-19,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-19,Dr. USA-19 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,A,S1,2.54604550725415,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 20:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-17,,,3,3,Duration of Confirmed Response,CRSD,122.049497929402,DAYS,2022-06-30 20:26:34.683,607,0,Death,,
1952,AB12345,AB12345-USA-19-id-58,id-58,USA-19,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-19,Dr. USA-19 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,A,S1,2.54604550725415,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 20:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-17,,,2,2,Event Free Survival,EFS,36.2586561334319,DAYS,2021-09-14 20:26:34.683,318,0,Disease Progression,,
1953,AB12345,AB12345-USA-19-id-58,id-58,USA-19,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-19,Dr. USA-19 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,A,S1,2.54604550725415,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 20:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-17,,,4,4,Overall Survival,OS,122.049497929402,DAYS,2023-09-01 20:26:34.683,1035,0,Death,,
1954,AB12345,AB12345-USA-19-id-58,id-58,USA-19,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-19,Dr. USA-19 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,A,S1,2.54604550725415,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 20:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-17,,,1,1,Progression Free Survival,PFS,122.049497929402,DAYS,2021-08-18 20:26:34.683,291,0,Death,,
1955,AB12345,AB12345-USA-19-id-58,id-58,USA-19,47,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-19,Dr. USA-19 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,B: Placebo,North America,A,S1,2.54604550725415,LOW,Y,Y,Y,Y,N,2020-10-29,2020-10-31 20:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,2020-10-31 20:26:34.683,2022-11-01 08:26:34.683,2022-11-01 08:26:34.683,2023-11-01 14:26:34.683,COMPLETED,COMPLETED,2023-11-01,1096,,,,,,,2023-11-17,,,,,Total Number of Exacerbations,TNE,5,COUNT,,,0,,,-1.55341427603626
1956,AB12345,AB12345-USA-2-id-110,id-110,USA-2,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-2,Dr. USA-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,A,S2,9.67482040493121,LOW,Y,Y,N,Y,N,2020-07-23,2020-07-23 14:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-04,,,2,2,Duration of Confirmed Response,CRSD,41.186884297058,DAYS,2021-12-04 14:26:14.683,499,0,Death,,
1957,AB12345,AB12345-USA-2-id-110,id-110,USA-2,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-2,Dr. USA-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,A,S2,9.67482040493121,LOW,Y,Y,N,Y,N,2020-07-23,2020-07-23 14:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-04,,,1,1,Event Free Survival,EFS,41.186884297058,DAYS,2020-12-08 14:26:14.683,138,0,Death,,
1958,AB12345,AB12345-USA-2-id-110,id-110,USA-2,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-2,Dr. USA-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,A,S2,9.67482040493121,LOW,Y,Y,N,Y,N,2020-07-23,2020-07-23 14:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-04,,,3,3,Overall Survival,OS,41.186884297058,DAYS,2022-05-25 14:26:14.683,671,0,Death,,
1959,AB12345,AB12345-USA-2-id-110,id-110,USA-2,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-2,Dr. USA-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,A,S2,9.67482040493121,LOW,Y,Y,N,Y,N,2020-07-23,2020-07-23 14:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-04,,,4,4,Progression Free Survival,PFS,41.186884297058,DAYS,2022-07-10 14:26:14.683,717,0,Death,,
1960,AB12345,AB12345-USA-2-id-110,id-110,USA-2,35,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-2,Dr. USA-2 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,A,S2,9.67482040493121,LOW,Y,Y,N,Y,N,2020-07-23,2020-07-23 14:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,2020-07-23 14:26:14.683,2022-07-24 02:26:14.683,2022-07-24 02:26:14.683,2023-07-24 08:26:14.683,COMPLETED,COMPLETED,2023-07-24,1096,,,,,,,2023-08-04,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,0,,,-2.83669695863869
1961,AB12345,AB12345-USA-3-id-282,id-282,USA-3,38,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S1,3.35943552055686,LOW,Y,Y,N,Y,N,2020-07-19,2020-07-20 03:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-08-13,,,1,1,Duration of Confirmed Response,CRSD,193.850277364254,DAYS,2020-08-14 03:57:30.683,25,1,Adverse Event,Preferred Term,
1962,AB12345,AB12345-USA-3-id-282,id-282,USA-3,38,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S1,3.35943552055686,LOW,Y,Y,N,Y,N,2020-07-19,2020-07-20 03:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-08-13,,,3,3,Event Free Survival,EFS,92.2558696230408,DAYS,2022-04-03 03:57:30.683,622,0,Disease Progression,,
1963,AB12345,AB12345-USA-3-id-282,id-282,USA-3,38,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S1,3.35943552055686,LOW,Y,Y,N,Y,N,2020-07-19,2020-07-20 03:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-08-13,,,2,2,Overall Survival,OS,333.604053268209,DAYS,2022-01-31 03:57:30.683,560,1,Alive,Alive During Study,
1964,AB12345,AB12345-USA-3-id-282,id-282,USA-3,38,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S1,3.35943552055686,LOW,Y,Y,N,Y,N,2020-07-19,2020-07-20 03:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-08-13,,,4,4,Progression Free Survival,PFS,249.190460494719,DAYS,2023-03-14 03:57:30.683,967,1,Adverse Event,Preferred Term,
1965,AB12345,AB12345-USA-3-id-282,id-282,USA-3,38,YEARS,M,AMERICAN INDIAN OR ALASKA NATIVE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,A: Drug X,B: Placebo,North America,B,S1,3.35943552055686,LOW,Y,Y,N,Y,N,2020-07-19,2020-07-20 03:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,2020-07-20 03:57:30.683,2022-07-20 15:57:30.683,2022-07-20 15:57:30.683,2023-07-20 21:57:30.683,COMPLETED,COMPLETED,2023-07-20,1096,,,,,,,2023-08-13,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,1,,Preferred Term,-1.200261966578
1966,AB12345,AB12345-USA-3-id-320,id-320,USA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,B,S1,4.73444722667449,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 11:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-26,,,3,3,Duration of Confirmed Response,CRSD,119.155522156507,DAYS,2020-03-30 11:44:23.683,245,0,Death,,
1967,AB12345,AB12345-USA-3-id-320,id-320,USA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,B,S1,4.73444722667449,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 11:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-26,,,4,4,Event Free Survival,EFS,31.0560370143503,DAYS,2021-08-02 11:44:23.683,735,1,Last Tumor Assessment,Completion or Discontinuation,
1968,AB12345,AB12345-USA-3-id-320,id-320,USA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,B,S1,4.73444722667449,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 11:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-26,,,2,2,Overall Survival,OS,119.155522156507,DAYS,2019-11-27 11:44:23.683,121,0,Death,,
1969,AB12345,AB12345-USA-3-id-320,id-320,USA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,B,S1,4.73444722667449,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 11:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-26,,,1,1,Progression Free Survival,PFS,119.155522156507,DAYS,2019-11-18 11:44:23.683,112,0,Death,,
1970,AB12345,AB12345-USA-3-id-320,id-320,USA-3,42,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-3,Dr. USA-3 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,B: Placebo,North America,B,S1,4.73444722667449,MEDIUM,Y,Y,N,N,N,2019-07-26,2019-07-29 11:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,2019-07-29 11:44:23.683,2021-07-28 23:44:23.683,2021-07-28 23:44:23.683,2022-07-29 05:44:23.683,COMPLETED,COMPLETED,2022-07-29,1096,,,,,,,2022-08-26,,,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-1.28797969481448
1971,AB12345,AB12345-USA-4-id-190,id-190,USA-4,53,YEARS,M,MULTIPLE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-4,Dr. USA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,B,S2,1.14955857546294,LOW,Y,Y,Y,Y,N,2019-10-29,2019-10-29 14:54:10.683,,2019-10-29 14:54:10.683,,,,2019-10-29 14:54:10.683,,,,ONGOING,ONGOING,,,,,,,,,,,,4,4,Duration of Confirmed Response,CRSD,108.111215382814,DAYS,2021-07-04 14:54:10.683,614,0,Death,,
1972,AB12345,AB12345-USA-4-id-190,id-190,USA-4,53,YEARS,M,MULTIPLE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-4,Dr. USA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,B,S2,1.14955857546294,LOW,Y,Y,Y,Y,N,2019-10-29,2019-10-29 14:54:10.683,,2019-10-29 14:54:10.683,,,,2019-10-29 14:54:10.683,,,,ONGOING,ONGOING,,,,,,,,,,,,1,1,Event Free Survival,EFS,57.7959647332318,DAYS,2020-07-29 14:54:10.683,274,1,Last Tumor Assessment,Completion or Discontinuation,
1973,AB12345,AB12345-USA-4-id-190,id-190,USA-4,53,YEARS,M,MULTIPLE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-4,Dr. USA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,B,S2,1.14955857546294,LOW,Y,Y,Y,Y,N,2019-10-29,2019-10-29 14:54:10.683,,2019-10-29 14:54:10.683,,,,2019-10-29 14:54:10.683,,,,ONGOING,ONGOING,,,,,,,,,,,,2,2,Overall Survival,OS,108.111215382814,DAYS,2020-10-21 14:54:10.683,358,0,Death,,
1974,AB12345,AB12345-USA-4-id-190,id-190,USA-4,53,YEARS,M,MULTIPLE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-4,Dr. USA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,B,S2,1.14955857546294,LOW,Y,Y,Y,Y,N,2019-10-29,2019-10-29 14:54:10.683,,2019-10-29 14:54:10.683,,,,2019-10-29 14:54:10.683,,,,ONGOING,ONGOING,,,,,,,,,,,,3,3,Progression Free Survival,PFS,108.111215382814,DAYS,2020-11-25 14:54:10.683,393,0,Death,,
1975,AB12345,AB12345-USA-4-id-190,id-190,USA-4,53,YEARS,M,MULTIPLE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-4,Dr. USA-4 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,C: Combination,North America,B,S2,1.14955857546294,LOW,Y,Y,Y,Y,N,2019-10-29,2019-10-29 14:54:10.683,,2019-10-29 14:54:10.683,,,,2019-10-29 14:54:10.683,,,,ONGOING,ONGOING,,,,,,,,,,,,,,Total Number of Exacerbations,TNE,3,COUNT,,,0,,,-2.60026251507962
1976,AB12345,AB12345-USA-4-id-382,id-382,USA-4,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-4,Dr. USA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,7.94870710745563,HIGH,Y,Y,N,N,N,2019-09-01,2019-09-03 10:47:51.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,DISCONTINUED,DISCONTINUED,2022-02-17,899,DEATH,2022-03-01,ADVERSE EVENT,ADVERSE EVENT,12,<=30,2022-03-01,909,Yes,3,3,Duration of Confirmed Response,CRSD,157.134723011404,DAYS,2021-09-15 10:47:51.683,743,0,Death,,
1977,AB12345,AB12345-USA-4-id-382,id-382,USA-4,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-4,Dr. USA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,7.94870710745563,HIGH,Y,Y,N,N,N,2019-09-01,2019-09-03 10:47:51.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,DISCONTINUED,DISCONTINUED,2022-02-17,899,DEATH,2022-03-01,ADVERSE EVENT,ADVERSE EVENT,12,<=30,2022-03-01,909,Yes,4,4,Event Free Survival,EFS,82.5492067995947,DAYS,2022-02-06 10:47:51.683,887,1,Adverse Event,Preferred Term,
1978,AB12345,AB12345-USA-4-id-382,id-382,USA-4,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-4,Dr. USA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,7.94870710745563,HIGH,Y,Y,N,N,N,2019-09-01,2019-09-03 10:47:51.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,DISCONTINUED,DISCONTINUED,2022-02-17,899,DEATH,2022-03-01,ADVERSE EVENT,ADVERSE EVENT,12,<=30,2022-03-01,909,Yes,2,2,Overall Survival,OS,157.134723011404,DAYS,2020-02-13 10:47:51.683,163,0,Death,,
1979,AB12345,AB12345-USA-4-id-382,id-382,USA-4,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-4,Dr. USA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,7.94870710745563,HIGH,Y,Y,N,N,N,2019-09-01,2019-09-03 10:47:51.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,DISCONTINUED,DISCONTINUED,2022-02-17,899,DEATH,2022-03-01,ADVERSE EVENT,ADVERSE EVENT,12,<=30,2022-03-01,909,Yes,1,1,Progression Free Survival,PFS,157.134723011404,DAYS,2020-01-12 10:47:51.683,131,0,Death,,
1980,AB12345,AB12345-USA-4-id-382,id-382,USA-4,31,YEARS,M,BLACK OR AFRICAN AMERICAN,NOT HISPANIC OR LATINO,USA,Y,INV ID USA-4,Dr. USA-4 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,A: Drug X,C: Combination,North America,C,S1,7.94870710745563,HIGH,Y,Y,N,N,N,2019-09-01,2019-09-03 10:47:51.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,2019-09-03 10:47:51.683,2021-02-17 12:00:34.683,2021-02-17 12:00:34.683,2022-02-17 18:00:34.683,DISCONTINUED,DISCONTINUED,2022-02-17,899,DEATH,2022-03-01,ADVERSE EVENT,ADVERSE EVENT,12,<=30,2022-03-01,909,Yes,,,Total Number of Exacerbations,TNE,1,COUNT,,,0,,,-2.50214051025874
1981,AB12345,AB12345-USA-5-id-179,id-179,USA-5,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,USA,N,INV ID USA-5,Dr. USA-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,C,S1,4.67743474587652,LOW,Y,Y,Y,N,N,2020-09-07,2020-09-08 02:16:02.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,DISCONTINUED,DISCONTINUED,2022-02-14,525,PHYSICIAN DECISION,,,,,,2022-02-25,,,1,1,Duration of Confirmed Response,CRSD,187.576876883395,DAYS,2020-09-12 02:16:02.683,4,0,Death,,
1982,AB12345,AB12345-USA-5-id-179,id-179,USA-5,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,USA,N,INV ID USA-5,Dr. USA-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,C,S1,4.67743474587652,LOW,Y,Y,Y,N,N,2020-09-07,2020-09-08 02:16:02.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,DISCONTINUED,DISCONTINUED,2022-02-14,525,PHYSICIAN DECISION,,,,,,2022-02-25,,,2,2,Event Free Survival,EFS,97.359016611008,DAYS,2021-04-09 02:16:02.683,213,1,Adverse Event,Preferred Term,
1983,AB12345,AB12345-USA-5-id-179,id-179,USA-5,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,USA,N,INV ID USA-5,Dr. USA-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,C,S1,4.67743474587652,LOW,Y,Y,Y,N,N,2020-09-07,2020-09-08 02:16:02.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,DISCONTINUED,DISCONTINUED,2022-02-14,525,PHYSICIAN DECISION,,,,,,2022-02-25,,,3,3,Overall Survival,OS,187.576876883395,DAYS,2021-06-30 02:16:02.683,295,0,Death,,
1984,AB12345,AB12345-USA-5-id-179,id-179,USA-5,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,USA,N,INV ID USA-5,Dr. USA-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,C,S1,4.67743474587652,LOW,Y,Y,Y,N,N,2020-09-07,2020-09-08 02:16:02.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,DISCONTINUED,DISCONTINUED,2022-02-14,525,PHYSICIAN DECISION,,,,,,2022-02-25,,,4,4,Progression Free Survival,PFS,187.576876883395,DAYS,2021-10-25 02:16:02.683,412,0,Death,,
1985,AB12345,AB12345-USA-5-id-179,id-179,USA-5,30,YEARS,M,BLACK OR AFRICAN AMERICAN,HISPANIC OR LATINO,USA,N,INV ID USA-5,Dr. USA-5 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,C: Combination,C: Combination,North America,C,S1,4.67743474587652,LOW,Y,Y,Y,N,N,2020-09-07,2020-09-08 02:16:02.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,2020-09-08 02:16:02.683,2021-02-14 02:20:34.683,2021-02-14 02:20:34.683,2022-02-14 08:20:34.683,DISCONTINUED,DISCONTINUED,2022-02-14,525,PHYSICIAN DECISION,,,,,,2022-02-25,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-1.46985099379001
1986,AB12345,AB12345-USA-6-id-151,id-151,USA-6,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-6,Dr. USA-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S2,2.04531429284571,MEDIUM,Y,Y,Y,N,N,2020-04-07,2020-04-11 21:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,COMPLETED,COMPLETED,2023-04-12,1096,,,,,,,2023-04-26,,,3,3,Duration of Confirmed Response,CRSD,111.535467766225,DAYS,2022-10-04 21:05:28.683,906,1,Last Tumor Assessment,Completion or Discontinuation,
1987,AB12345,AB12345-USA-6-id-151,id-151,USA-6,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-6,Dr. USA-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S2,2.04531429284571,MEDIUM,Y,Y,Y,N,N,2020-04-07,2020-04-11 21:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,COMPLETED,COMPLETED,2023-04-12,1096,,,,,,,2023-04-26,,,1,1,Event Free Survival,EFS,74.9975186004303,DAYS,2021-01-26 21:05:28.683,290,1,Adverse Event,Preferred Term,
1988,AB12345,AB12345-USA-6-id-151,id-151,USA-6,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-6,Dr. USA-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S2,2.04531429284571,MEDIUM,Y,Y,Y,N,N,2020-04-07,2020-04-11 21:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,COMPLETED,COMPLETED,2023-04-12,1096,,,,,,,2023-04-26,,,4,4,Overall Survival,OS,367.030866909772,DAYS,2023-04-06 21:05:28.683,1090,1,Alive,Alive During Study,
1989,AB12345,AB12345-USA-6-id-151,id-151,USA-6,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-6,Dr. USA-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S2,2.04531429284571,MEDIUM,Y,Y,Y,N,N,2020-04-07,2020-04-11 21:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,COMPLETED,COMPLETED,2023-04-12,1096,,,,,,,2023-04-26,,,2,2,Progression Free Survival,PFS,216.09923474025,DAYS,2021-04-01 21:05:28.683,355,0,Disease Progression,,
1990,AB12345,AB12345-USA-6-id-151,id-151,USA-6,30,YEARS,F,WHITE,NOT HISPANIC OR LATINO,USA,N,INV ID USA-6,Dr. USA-6 Doe,B: Placebo,ARM B,B: Placebo,ARM B,B: Placebo,B: Placebo,B: Placebo,B: Placebo,North America,C,S2,2.04531429284571,MEDIUM,Y,Y,Y,N,N,2020-04-07,2020-04-11 21:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,2020-04-11 21:05:28.683,2022-04-12 09:05:28.683,2022-04-12 09:05:28.683,2023-04-12 15:05:28.683,COMPLETED,COMPLETED,2023-04-12,1096,,,,,,,2023-04-26,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,-2.45763859792309
1991,AB12345,AB12345-USA-8-id-206,id-206,USA-8,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-8,Dr. USA-8 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,B,S1,14.4780570691081,HIGH,Y,Y,Y,Y,N,2019-07-19,2019-07-22 10:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,COMPLETED,COMPLETED,2022-07-22,1096,,,,,,,2022-08-07,,,3,3,Duration of Confirmed Response,CRSD,191.407894250005,DAYS,2021-12-28 10:23:30.683,890,1,Last Tumor Assessment,Completion or Discontinuation,
1992,AB12345,AB12345-USA-8-id-206,id-206,USA-8,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-8,Dr. USA-8 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,B,S1,14.4780570691081,HIGH,Y,Y,Y,Y,N,2019-07-19,2019-07-22 10:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,COMPLETED,COMPLETED,2022-07-22,1096,,,,,,,2022-08-07,,,2,2,Event Free Survival,EFS,99.0317807625979,DAYS,2020-04-09 10:23:30.683,262,1,Last Tumor Assessment,Completion or Discontinuation,
1993,AB12345,AB12345-USA-8-id-206,id-206,USA-8,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-8,Dr. USA-8 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,B,S1,14.4780570691081,HIGH,Y,Y,Y,Y,N,2019-07-19,2019-07-22 10:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,COMPLETED,COMPLETED,2022-07-22,1096,,,,,,,2022-08-07,,,4,4,Overall Survival,OS,349.378738505766,DAYS,2022-02-13 10:23:30.683,937,1,Alive,Alive During Study,
1994,AB12345,AB12345-USA-8-id-206,id-206,USA-8,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-8,Dr. USA-8 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,B,S1,14.4780570691081,HIGH,Y,Y,Y,Y,N,2019-07-19,2019-07-22 10:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,COMPLETED,COMPLETED,2022-07-22,1096,,,,,,,2022-08-07,,,1,1,Progression Free Survival,PFS,253.509718016721,DAYS,2019-08-31 10:23:30.683,40,1,Last Tumor Assessment,Completion or Discontinuation,
1995,AB12345,AB12345-USA-8-id-206,id-206,USA-8,34,YEARS,F,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-8,Dr. USA-8 Doe,C: Combination,ARM C,C: Combination,ARM C,C: Combination,C: Combination,B: Placebo,C: Combination,North America,B,S1,14.4780570691081,HIGH,Y,Y,Y,Y,N,2019-07-19,2019-07-22 10:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,2019-07-22 10:23:30.683,2021-07-21 22:23:30.683,2021-07-21 22:23:30.683,2022-07-22 04:23:30.683,COMPLETED,COMPLETED,2022-07-22,1096,,,,,,,2022-08-07,,,,,Total Number of Exacerbations,TNE,2,COUNT,,,1,,Completion or Discontinuation,0.31791575877547
1996,AB12345,AB12345-USA-9-id-130,id-130,USA-9,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-9,Dr. USA-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,1.28052500745343,MEDIUM,Y,Y,N,N,N,2020-07-17,2020-07-18 19:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,COMPLETED,COMPLETED,2023-07-19,1096,,,,,,,2023-08-09,,,2,2,Duration of Confirmed Response,CRSD,175.348961702548,DAYS,2021-05-08 19:43:32.683,294,0,Disease Progression,,
1997,AB12345,AB12345-USA-9-id-130,id-130,USA-9,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-9,Dr. USA-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,1.28052500745343,MEDIUM,Y,Y,N,N,N,2020-07-17,2020-07-18 19:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,COMPLETED,COMPLETED,2023-07-19,1096,,,,,,,2023-08-09,,,1,1,Event Free Survival,EFS,93.3994795323815,DAYS,2020-07-19 19:43:32.683,1,0,Disease Progression,,
1998,AB12345,AB12345-USA-9-id-130,id-130,USA-9,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-9,Dr. USA-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,1.28052500745343,MEDIUM,Y,Y,N,N,N,2020-07-17,2020-07-18 19:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,COMPLETED,COMPLETED,2023-07-19,1096,,,,,,,2023-08-09,,,4,4,Overall Survival,OS,430.309631209821,DAYS,2022-06-17 19:43:32.683,699,1,Alive,Alive During Study,
1999,AB12345,AB12345-USA-9-id-130,id-130,USA-9,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-9,Dr. USA-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,1.28052500745343,MEDIUM,Y,Y,N,N,N,2020-07-17,2020-07-18 19:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,COMPLETED,COMPLETED,2023-07-19,1096,,,,,,,2023-08-09,,,3,3,Progression Free Survival,PFS,290.350731345825,DAYS,2021-12-05 19:43:32.683,505,1,Adverse Event,Preferred Term,
2000,AB12345,AB12345-USA-9-id-130,id-130,USA-9,40,YEARS,M,ASIAN,NOT HISPANIC OR LATINO,USA,N,INV ID USA-9,Dr. USA-9 Doe,A: Drug X,ARM A,A: Drug X,ARM A,A: Drug X,A: Drug X,C: Combination,C: Combination,North America,A,S1,1.28052500745343,MEDIUM,Y,Y,N,N,N,2020-07-17,2020-07-18 19:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,2020-07-18 19:43:32.683,2022-07-19 07:43:32.683,2022-07-19 07:43:32.683,2023-07-19 13:43:32.683,COMPLETED,COMPLETED,2023-07-19,1096,,,,,,,2023-08-09,,,,,Total Number of Exacerbations,TNE,0,COUNT,,,0,,,-2.46109754035844
